<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Expert Opin Drug Discov
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Expert Opin Drug Discov
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       IEDC
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       iedc20
      </journal-id>
      <journal-title-group>
       <journal-title>
        Expert Opinion on Drug Discovery
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1746-0441
      </issn>
      <issn pub-type="epub">
       1746-045X
      </issn>
      <publisher>
       <publisher-name>
        Taylor &amp; Francis
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30849247
      </article-id>
      <article-id pub-id-type="pmc">
       7103675
      </article-id>
      <article-id pub-id-type="publisher-id">
       1581171
      </article-id>
      <article-id pub-id-type="doi">
       10.1080/17460441.2019.1581171
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Broad-spectrum coronavirus antiviral drug discovery
       </article-title>
       <alt-title alt-title-type="running-authors">
        A. L. TOTURA AND S. BAVARI
       </alt-title>
       <alt-title alt-title-type="running-title">
        EXPERT OPINION ON DRUG DISCOVERY
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0001-6827-0523
        </contrib-id>
        <name>
         <surname>
          Totura
         </surname>
         <given-names>
          Allison L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="AFF0001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bavari
         </surname>
         <given-names>
          Sina
         </given-names>
        </name>
        <xref ref-type="corresp" rid="AN0001">
        </xref>
        <xref ref-type="aff" rid="AFF0001">
        </xref>
       </contrib>
       <aff id="AFF0001">
        <institution>
         Division of Molecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases
        </institution>
        , Fort Detrick, MD,
        <country>
         USA
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="AN0001">
        CONTACT Sina Bavari
        <email xlink:href="sina.bavari.civ@mail.mil">
         sina.bavari.civ@mail.mil
        </email>
        <institution>
         Division of Molecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases
        </institution>
        , Fort Detrick, MD 21702,
        <country>
         USA
        </country>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        08
       </day>
       <month>
        3
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       4
      </issue>
      <fpage seq="9">
       397
      </fpage>
      <lpage>
       412
      </lpage>
      <history>
       <date date-type="received">
        <day>
         16
        </day>
        <month>
         8
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         07
        </day>
        <month>
         2
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 Informa UK Limited, trading as Taylor &amp; Francis Group
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <copyright-holder>
        Informa UK Limited, trading as Taylor &amp; Francis Group
       </copyright-holder>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="IEDC_14_1581171.pdf">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        <bold>
         Introduction
        </bold>
        : The highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are lethal zoonotic viruses that have emerged into human populations these past 15 years. These coronaviruses are associated with novel respiratory syndromes that spread from person-to-person via close contact, resulting in high morbidity and mortality caused by the progression to Acute Respiratory Distress Syndrome (ARDS).
       </p>
       <p>
        <bold>
         Areas covered
        </bold>
        : The risks of re-emergence of SARS-CoV from bat reservoir hosts, the persistence of MERS-CoV circulation, and the potential for future emergence of novel coronaviruses indicate antiviral drug discovery will require activity against multiple coronaviruses. In this review, approaches that antagonize viral nonstructural proteins, neutralize structural proteins, or modulate essential host elements of viral infection with varying levels of efficacy in models of highly pathogenic coronavirus disease are discussed.
       </p>
       <p>
        <bold>
         Expert opinion
        </bold>
        : Treatment of SARS and MERS in outbreak settings has focused on therapeutics with general antiviral activity and good safety profiles rather than efficacy data provided by cellular, rodent, or nonhuman primate models of highly pathogenic coronavirus infection. Based on lessons learned from SARS and MERS outbreaks, lack of drugs capable of pan-coronavirus antiviral activity increases the vulnerability of public health systems to a highly pathogenic coronavirus pandemic.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        KEYWORDS
       </title>
       <kwd>
        Antiviral
       </kwd>
       <kwd>
        ARDS
       </kwd>
       <kwd>
        acute respiratory distress syndrome
       </kwd>
       <kwd>
        bat
       </kwd>
       <kwd>
        broad-spectrum
       </kwd>
       <kwd>
        camel
       </kwd>
       <kwd>
        civet
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        emerging virus
       </kwd>
       <kwd>
        highly pathogenic virus
       </kwd>
       <kwd>
        human cases
       </kwd>
       <kwd>
        interferon
       </kwd>
       <kwd>
        in vitro model
       </kwd>
       <kwd>
        lopinavir
       </kwd>
       <kwd>
        MERS
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        pneumonia
       </kwd>
       <kwd>
        primate model
       </kwd>
       <kwd>
        respiratory
       </kwd>
       <kwd>
        ribavirin
       </kwd>
       <kwd>
        rodent model
       </kwd>
       <kwd>
        SARS
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        severe acute respiratory syndrome
       </kwd>
       <kwd>
        therapeutic
       </kwd>
       <kwd>
        zoonosis
       </kwd>
       <kwd>
        zoonotic
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <named-content content-type="funder-name">
          not funded
         </named-content>
        </funding-source>
       </award-group>
       <funding-statement>
        This research was supported in part by an appointment to the Postgraduate Research Participation Program at the US Army Medical Research Institute of Infectious Diseases administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the US Army Medical Research and Materiel Command (USAMRMC).
       </funding-statement>
      </funding-group>
      <counts>
       <fig-count count="3">
       </fig-count>
       <table-count count="3">
       </table-count>
       <ref-count count="127">
       </ref-count>
       <page-count count="16">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <sec id="S0001" sec-type="intro">
     <label>
      1.
     </label>
     <title>
      Introduction
     </title>
     <p>
      Outbreaks of severe acute respiratory syndrome (SARS, 2002–2004 [
      <xref rid="CIT0001">
       1
      </xref>
      ,
      <xref rid="CIT0002">
       2
      </xref>
      ]) and Middle East respiratory syndrome (MERS, 2012-current [
      <xref rid="CIT0003">
       3
      </xref>
      ]) in the last two decades are a significant threat to global public health. SARS and MERS represent a new class of public health concern that may continue to emerge into human populations: respiratory syndromes caused by coronaviruses (CoVs) that are transmitted from person-to-person via close contact, resulting in high morbidity and mortality in infected individuals. Although SARS and MERS initially present as mild, influenza-like illnesses with fever, dyspnea, and cough, progression to more severe symptoms is characterized by an atypical interstitial pneumonia and diffuse alveolar damage. Both SARS-CoV and MERS-CoV are capable of causing acute respiratory distress syndrome (ARDS), the most severe form of acute lung injury where alveolar inflammation, pneumonia, and hypoxic lung conditions lead to respiratory failure, multiple organ disease, and death in 50% of ARDS patients [
      <xref rid="CIT0004">
       4
      </xref>
      ]. The total confirmed number of patients infected with highly pathogenic CoVs is relatively low (approximately 10,000 cases of both SARS and MERS since 2002), but CoVs are of particular concern due to high case fatality rates, lack of proven therapeutics, as well as the demonstrated ability of these pathogens to seed outbreaks that rapidly cross geographic and geopolitical borders into other countries and continents [
      <xref rid="CIT0005">
       5
      </xref>
      ,
      <xref rid="CIT0006">
       6
      </xref>
      ].
     </p>
     <sec id="S0001-S2001">
      <label>
       1.1.
      </label>
      <title>
       Coronaviridae phylogeny and emergence
      </title>
      <p>
       Highly pathogenic coronaviruses SARS-CoV and MERS-CoV recently emerged into human populations, but other human coronaviruses (HCoVs) including HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1 are estimated to have circulated in human populations for hundreds of years, causing mild respiratory illness to which approximately 5–30% of ‘common colds’ are attributed [
       <xref rid="CIT0007">
        7
       </xref>
       ,
       <xref rid="CIT0008">
        8
       </xref>
       ]. Within the
       <italic>
        Coronaviridae
       </italic>
       family (order Nidovirales) four genera are recognized: alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus. The six HCoVs (
       <xref rid="T0001">
        Table 1
       </xref>
       ) currently identified belong to the genera alphacoronavirus (HCoV-229E and HCoV-NL63) and betacoronavirus (SARS-CoV, MERS-CoV, HCoV-OC43, and HCoV-HKU1). Gammacoronaviruses and deltacoronaviruses have no known viruses that infect humans, but contain important agricultural pathogens of livestock. Epizootic coronaviruses in animals cause a wide range of disease signs resulting from respiratory, enteric, and neurological tissue tropism. Although HCoVs cause primarily respiratory symptoms, the potential for a wide range of severe disease symptoms in humans caused by infection by future emergent coronaviruses cannot be excluded. Despite the severity and diversity of coronavirus disease signs and symptoms affecting a large number of important livestock species as well as humans, there are no proven therapies that specifically target CoVs.
       <table-wrap id="T0001" orientation="landscape" position="float">
        <object-id pub-id-type="doi">
         10.1080/17460441.2019.1581171-T0001
        </object-id>
        <label>
         Table 1.
        </label>
        <caption>
         <p>
          Human coronavirus
          <italic>
           in vitro
          </italic>
          properties.
         </p>
        </caption>
        <!--OASIS TABLE HERE-->
        <table frame="hsides" rules="groups">
         <colgroup>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="center" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
         </colgroup>
         <thead>
          <tr>
           <th align="left">
            Human Coronavirus
           </th>
           <th align="center">
            Genus
           </th>
           <th align="center">
            Genogroup
           </th>
           <th align="center">
            Receptor
           </th>
           <th align="center">
            Protease
           </th>
           <th align="center">
            Human Target Cells
           </th>
           <th align="center">
            Cell Lines
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            HCoV-OC43
           </td>
           <td align="left">
            betacoronavirus
           </td>
           <td align="center">
            2A
           </td>
           <td align="left">
            O-acetylated Sialic Aicd (Protein Receptor Unknown)
           </td>
           <td align="left">
            Cathepsin L, TMPRSS2
           </td>
           <td align="left">
            Upper Respiratory Tract
           </td>
           <td align="left">
            BS-C-1, RD, HRT-18, Huh-7
           </td>
          </tr>
          <tr>
           <td align="left">
            HCoV-229E
           </td>
           <td align="left">
            alphacoronavirus
           </td>
           <td align="center">
            1B
           </td>
           <td align="left">
            APN
           </td>
           <td align="left">
            Cathepsin L, TMPRSS2
           </td>
           <td align="left">
            Upper Respiratory Tract
           </td>
           <td align="left">
            WI-38, MRC-5, L-132, Huh-7
           </td>
          </tr>
          <tr>
           <td align="left">
            HCoV-HKU1
           </td>
           <td align="left">
            betacoronavirus
           </td>
           <td align="center">
            2A
           </td>
           <td align="left">
            O-acetylated Sialic Aicd (Protein Receptor Unknown)
           </td>
           <td align="left">
            Cathepsin L, TMPRSS2
           </td>
           <td align="left">
            Upper Respiratory Tract
           </td>
           <td align="left">
            NR*
           </td>
          </tr>
          <tr>
           <td align="left">
            HCoV-NL63
           </td>
           <td align="left">
            alphacoronavirus
           </td>
           <td align="center">
            1B
           </td>
           <td align="left">
            ACE2
           </td>
           <td align="left">
            NR
           </td>
           <td align="left">
            Upper Respiratory Tract
           </td>
           <td align="left">
            tMK, Vero, LLC-MK2, CaCo-2
           </td>
          </tr>
          <tr>
           <td align="left">
            SARS-CoV
           </td>
           <td align="left">
            betacoronavirus
           </td>
           <td align="center">
            2B
           </td>
           <td align="left">
            ACE2
           </td>
           <td align="left">
            Cathepsin L, Elastase, TMPRSS2, TMPRSS11a, HAT, Trypsin
           </td>
           <td align="left">
            Lower Respiratory Tract
           </td>
           <td align="left">
            BGM, COS, CV-1, FRhK, LLC-MK2, MA-104, MEK, pCMK, Vero, Vero E6, HEK-293, HepG2, Huh-7, RK-13
           </td>
          </tr>
          <tr>
           <td align="left">
            MERS-CoV
           </td>
           <td align="left">
            betacoronavirus
           </td>
           <td align="center">
            2C
           </td>
           <td align="left">
            DPP4
           </td>
           <td align="left">
            Cathepsins, TMPRSS2, Furin
           </td>
           <td align="left">
            Lower Respiratory Tract
           </td>
           <td align="left">
            Caco-2, Calu-3, HFL, Huh-7, HEK, His-1, LLC-MK2, Vero, Vero-E6, CL-1, PK-15
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           *NR – not reported
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       In addition to CoVs known to cause disease in humans and livestock, a large number of highly diverse coronaviruses have been identified based on sequences collected from sampling bat species. Bat coronavirus (BatCoV) sequences recovered from sampling sites on different continents (Asia, Europe, Africa, North America) over the last decade contain putative BatCoVs from diverse branches of the betacoronavirus and alphacoronavirus phylogenetic tree [
       <xref rid="CIT0009">
        9
       </xref>
       –
       <xref rid="CIT0012">
        12
       </xref>
       ]. Importantly, the two coronaviruses that cause the most severe disease in humans, SARS-CoV and MERS-CoV, emerged from BatCoVs that were not previously recognized to infect humans or animals other than bats [
       <xref rid="CIT0012">
        12
       </xref>
       –
       <xref rid="CIT0014">
        14
       </xref>
       ]. Recent studies suggest that BatCoV-SHC014 and BatCoV-WIV1 are genetically similar to SARS-CoV and enter cells using human receptors [
       <xref rid="CIT0010">
        10
       </xref>
       ,
       <xref rid="CIT0015">
        15
       </xref>
       ,
       <xref rid="CIT0016">
        16
       </xref>
       ]. Similarly, BatCoV-HKU4 and BatCoV-HKU5 are MERS-like BatCoVs that may also be circulating in bat populations, and some MERS-like BatCoVs may also be able to recognize human host cell receptors [
       <xref rid="CIT0017">
        17
       </xref>
       –
       <xref rid="CIT0019">
        19
       </xref>
       ]. Such BatCoVs are now called ‘pre-emergent’, because they may have the potential to emerge into human populations. Importantly, therapeutics that rely on host memory responses to target CoV infection are often not effective against pre-emergent BatCoVs that differ antigenically from known HCoVs, highlighting the need for pan-coronavirus therapeutics that target conserved mechanisms utilized by HCoVs and BatCoVs [
       <xref rid="CIT0015">
        15
       </xref>
       ].
      </p>
      <p>
       SARS-CoV and MERS-CoV likely evolved from BatCoVs that infected other intermediate host animals in closer proximity to humans, resulting in SARS and MERS outbreaks (
       <xref rid="F0001">
        Figure 1
       </xref>
       ) [
       <xref rid="CIT0020">
        20
       </xref>
       ,
       <xref rid="CIT0021">
        21
       </xref>
       ]. SARS-CoV was detected in small animals like civets and raccoon dogs that were present in live-animal markets [
       <xref rid="CIT0020">
        20
       </xref>
       ]. Evolution of SARS-CoV evidenced by genomic sequence differences between zoonotic SARS-CoV strains infecting civets and epidemic SARS-CoV isolates likely resulted from viral adaptation, which is thought to be required for emergent CoVs to become transmissible from person-to-person [
       <xref rid="CIT0022">
        22
       </xref>
       ,
       <xref rid="CIT0023">
        23
       </xref>
       ]. MERS-CoV has been identified in dromedary camels, and is now known to be endemic in camel populations in the Middle East and Sub-Saharan Africa.
       <fig fig-type="figure" id="F0001" orientation="portrait" position="float">
        <object-id pub-id-type="doi">
         10.1080/17460441.2019.1581171-F0001
        </object-id>
        <label>
         Figure 1.
        </label>
        <caption>
         <p>
          Coronavirus emergence from zoonotic reservoirs.
         </p>
         <p specific-use="attrib">
          Emergence of coronaviruses into human populations, including highly pathogenic viruses like SARS-CoV and MERS-CoV, has occurred by spillover from bat reservoir hosts into intermediate hosts. The intermediate hosts during the 2003 SARS-CoV epidemic included civets and other small carnivore species located in wet animal markets. MERS-CoV has been identified in dromedary camels, and is particularly associated with active infection of juvenile camels. Novel emerging CoVs may occur in the future via infection from bat populations into other intermediate animal hosts. Additional evidence from BatCoVs indicates that pre-emergent CoVs with the ability to directly infect human cells may be poised for emergence into human populations. Based on prior research from SARS and MERS outbreaks, animal workers that have contact with intermediate animal host species and health-care workers that are exposed to nosocomial CoV infections are at increased risk of highly pathogenic coronavirus transmission. More severe disease in SARS and MERS cases resulted in patients that were over the age of 65 or had comorbidities such as obesity, heart disease, diabetes, renal disease, or hypertension.
         </p>
        </caption>
        <graphic content-type="black-white" xlink:href="IEDC_A_1581171_F0001_B">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="S0001-S2002">
      <label>
       1.2.
      </label>
      <title>
       Epidemiological features of CoV outbreaks
      </title>
      <p>
       Research on coronavirus-specific antiviral drugs has focused primarily on highly pathogenic coronaviruses SARS-CoV and MERS-CoV due to the major potential consequences of pandemics resulting from these pathogens. SARS-CoV and MERS-CoV did not transmit as efficiently from person-to-person compared to other respiratory pathogens like seasonal influenza, but mortality in patients of SARS (approximately 10%) and MERS (approximately 35%) greatly exceeded typical seasonal influenza case-fatality rates (2.4 deaths per 100,000 cases) [
       <xref rid="CIT0024">
        24
       </xref>
       ]. Air travel facilitated these CoVs in seeding outbreaks in regions distant from initial localized viral spread: SARS-CoV emerged in the Guangdong province of southeastern China in late 2002, and then spread rapidly to other parts of the world, with outbreaks in major cities including Beijing, Hong Kong, Singapore, and Toronto, resulting in one of the first pandemics of the twenty-first century [
       <xref rid="CIT0005">
        5
       </xref>
       ]. Since MERS-CoV emerged in 2012, MERS cases have been exported from the Middle East to Europe, North America, Africa, and South East Asia, including a major outbreak of 186 people in the Republic of Korea in 2015 [
       <xref rid="CIT0025">
        25
       </xref>
       ]. Superspreaders (individuals that transmit SARS-CoV or MERS-CoV to a large number of people) played an important role in initiating and perpetuating CoV outbreaks: the 2015 MERS-CoV outbreak in the Republic of Korea started from a single traveler case, and just five cases were responsible for more than 80% of the transmission events [
       <xref rid="CIT0025">
        25
       </xref>
       ]. SARS-CoV and MERS-CoV were transmitted by close contact, with known outbreaks occurring in hotels, apartment buildings, and hospitals or health-care centers. Health-care workers, in particular, were at risk for infection by SARS-CoV and MERS-CoV at high rates [
       <xref rid="CIT0005">
        5
       </xref>
       ,
       <xref rid="CIT0026">
        26
       </xref>
       ]. In addition, animal workers were more likely to come into contact with CoV infected animals, and a large percentage of MERS patients had contact with intermediate host camels [
       <xref rid="CIT0026">
        26
       </xref>
       ,
       <xref rid="CIT0027">
        27
       </xref>
       ]. Analysis of severe SARS or MERS disease identified disproportionately high case-fatality rates in elderly patients (age &gt; 65 years) and patients with pre-existing comorbidities including diabetes, heart disease, hypertension, and renal disease [
       <xref rid="CIT0004">
        4
       </xref>
       ,
       <xref rid="CIT0026">
        26
       </xref>
       ,
       <xref rid="CIT0028">
        28
       </xref>
       ]. Based on these epidemiological considerations, pan-coronavirus therapeutics are needed to i) protect populations with occupational risk for transmission of CoVs, ii) protect populations with susceptibility to severe disease from CoVs, iii) work in concert with public health measures like quarantine and contact tracing, and iv) be rapidly deployable to geographically distant regions from local HCoV epidemics.
      </p>
     </sec>
    </sec>
    <sec id="S0002">
     <label>
      2.
     </label>
     <title>
      <italic>
       In vitro
      </italic>
      systems for pan-coronavirus drug discovery
     </title>
     <sec id="S0002-S2001">
      <label>
       2.1.
      </label>
      <title>
       Reverse genetics systems
      </title>
      <p>
       Advances in the study of highly pathogenic coronaviruses and potential pan-coronavirus drug candidates partially depend on the technology to genetically manipulate CoVs to probe mechanisms of viral pathogenesis and antiviral drug activity. Reverse genetics systems synthetically generate viruses from known viral sequences [
       <xref rid="CIT0029">
        29
       </xref>
       ]. In situations where clinical isolates of infectious material are unavailable due to restriction for collecting patient samples, shipping infectious materials, or availability of containment laboratories, reverse genetics systems provide essential research materials for studies on viral pathogenesis and model development. Prior to the SARS pandemic, robust reverse genetics systems to manipulate the genomes of CoVs had already been developed by systematic assembly of cDNA cassettes into full-length infectious clones, allowing precise and targeted genetic manipulation of viral genes [
       <xref rid="CIT0030">
        30
       </xref>
       ,
       <xref rid="CIT0031">
        31
       </xref>
       ]. Infectious clones allow the creation of near-homogenous viral stocks, whereas traditional viral stocks are prepared by amplification of infectious material in cell culture over many passages. Strategies to build reverse genetics systems were rapidly applied to both SARS-CoV and MERS-CoV within the first year of identification of these viruses [
       <xref rid="CIT0032">
        32
       </xref>
       ,
       <xref rid="CIT0033">
        33
       </xref>
       ].
      </p>
      <p>
       In addition to reconstructing epidemic strains of CoVs, reverse genetic systems allow targeting of mutations to specific viral genes and assembly of viruses when infectious material is not available. As an example, the ability to isolate mutations in particular genes was applied to studies of the spike (S) glycoprotein of SARS-CoV, while maintaining the isogenic background of the viral replicase and other structural proteins. Mutations from zoonotic, early, middle, and late epidemic strains of the SARS-CoV outbreak were inserted into the S glycoprotein of the epidemic strain of SARS-CoV (Urbani) to determine the effect of evolution on viral entry into human cells as well as viral pathogenesis in rodent and primate models of disease [
       <xref rid="CIT0034">
        34
       </xref>
       –
       <xref rid="CIT0036">
        36
       </xref>
       ]. By targeting mutations to a specific viral gene, reverse genetics systems allow researchers to probe cause-and-effect relationships of host pathogenic responses to viral genetic changes. In addition, reverse genetics techniques were utilized to study pre-emergent BatCoV strains: recombinant versions of BatCoV-HKU3, BatCoV-WIV1, and BatCoV-SHC014 (SARS-CoV-like), as well as BatCoV-HKU5 (MERS-CoV-like) viruses, were generated and used for
       <italic>
        in vitro
       </italic>
       and
       <italic>
        in vivo
       </italic>
       models of emerging coronavirus disease [
       <xref rid="CIT0015">
        15
       </xref>
       ,
       <xref rid="CIT0016">
        16
       </xref>
       ,
       <xref rid="CIT0037">
        37
       </xref>
       ,
       <xref rid="CIT0038">
        38
       </xref>
       ]. Panels of zoonotic, epidemic, and pre-emergent viruses synthesized by reverse genetics techniques encompass a diverse array for use in high-throughput platforms for the discovery of countermeasures that are effective against the broadest range of CoVs without being reliant on procuring clinical isolates.
      </p>
     </sec>
     <sec id="S0002-S2002">
      <label>
       2.2.
      </label>
      <title>
       Cell-based systems
      </title>
      <p>
       Like all other viruses, coronaviruses require host cell machinery to replicate their genomes, produce progeny virions, and cause disease. Cell lines require expression of the host cell receptor as well as expression of necessary proteases to facilitate viral entry, although additional host factors may also be important for infection. The S glycoprotein of coronaviruses, the main determinant of host cell attachment and viral entry, is not well conserved between HCoVs. Most human coronaviruses use different host cell receptors for viral entry, and may also require different host cell proteases that allow fusion of viral and cellular membranes (
       <xref rid="T0001">
        Table 1
       </xref>
       ) [
       <xref rid="CIT0039">
        39
       </xref>
       ]. Although all known HCoVs have viral tropism targeted at the human respiratory tract, lung cell lines infected by a broad range of HCoVs have not been defined. A key feature of SARS-CoV and MERS-CoV is that highly pathogenic coronaviruses grow to higher viral titer on a wider range of cell lines than the other mildly pathogenic coronaviruses HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1 [
       <xref rid="CIT0040">
        40
       </xref>
       –
       <xref rid="CIT0044">
        44
       </xref>
       ]. High throughput approaches to screen compound libraries for targeted activity against coronaviruses have been underdeveloped and limited in the number of viral strains used [
       <xref rid="CIT0045">
        45
       </xref>
       –
       <xref rid="CIT0052">
        52
       </xref>
       ]. Infection of panels of cell lines from various animal species with HCoVs and BatCoVs informs on the potential host range of the pathogen, and may help to identify susceptible mammalian host involved in viral spread. However, productive infection of cell lines does not always translate to recapitulation of pathogenesis in the same animal model that the cell lines are derived from, which may be due to receptor availability in live animals or other biological and immunological factors during infection.
      </p>
      <p>
       Infection of pseudostratified airway epithelium cultures from primary cells of the lung provides a cell culture model that simulates infection of cells in a more complex environment more closely resembling the human respiratory tract. Known as Human Airway Epithelia (HAE) or Normal Human Bronchial Epithelia (NHBE) cells, these cultures can be infected with all of the HCoVs identified thus far, including SARS-CoV and MERS-CoV, providing a potential platform to screen novel CoVs for emergence into human populations [
       <xref rid="CIT0042">
        42
       </xref>
       ,
       <xref rid="CIT0053">
        53
       </xref>
       –
       <xref rid="CIT0056">
        56
       </xref>
       ]. However, several limitations are associated with HAEs including difficulty in collection due to the scarcity of donors and difficulty in maintenance because of limited capacity for cell divisions. HAEs may be sourced from donors with a preexisting disease state, which could influence viral pathogenesis. In addition, because of the genetic variability of donors, HAEs cultures often differ in expression levels of genes crucial to infectivity, including the various host receptors for HCoVs, which leads to high variability in the infectivity of these cultures. Importantly, these
       <italic>
        in vitro
       </italic>
       methods fail to capture more complex viral interactions that occur with an intact immune system including infiltration of proinflammatory cells that may promote and contribute to ARDS in the most severe forms of SARS and MERS. Organ-on-a-chip models in development may provide the next generation of
       <italic>
        in vitro
       </italic>
       models that could capture these critical interactions between respiratory cells and immune cells, but infection of these novel culture systems has not been reported with coronaviruses [
       <xref rid="CIT0057">
        57
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="S0003">
     <label>
      3.
     </label>
     <title>
      <italic>
       In vivo
      </italic>
      systems for pan-coronavirus drug discovery
     </title>
     <p>
      Based on the results from
      <italic>
       in vitro
      </italic>
      screening methods, potential new pan-coronavirus drugs that successfully target HCoVs require additional evaluation in animal species that model viral infection on an organismal scale. Due to urgent public health need for effective treatments against SARS-CoV and MERS-CoV, development of animal models of CoV infection emphasized these pathogens [
      <xref rid="CIT0058">
       58
      </xref>
      ,
      <xref rid="CIT0059">
       59
      </xref>
      ]. Reproducible models of highly pathogenic coronavirus infection in common laboratory animal species have utility not only in development and testing of pan-coronavirus drugs, but also in elucidating mechanisms of viral replication or disease pathogenesis. Desirable qualities for animal models of SARS-CoV and MERS-CoV include recapitulation of severe disease symptoms seen in SARS and MERS patients, and lethality caused by fulminant viral infection of the lung as indicated by high viral titers, inflammatory infiltrates, and aberrant cell signaling programs. Although therapeutic efficacy against viral transmission is essential to disrupting SARS or MERS outbreaks, current animal model development has focused on disease resulting from relevant infection routes (i.e. intranasal) over directly developing models of CoVs transmission.
     </p>
     <sec id="S0003-S2001">
      <label>
       3.1.
      </label>
      <title>
       Small animal models for pan-coronavirus drug discovery
      </title>
      <p>
       Following the emergence of SARS-CoV in 2003, small animal model development was initiated by inoculating animals with human epidemic isolates of SARS-CoV that replicated in mice, hamsters, guinea pigs, and ferrets, but only ferrets exhibited disease signs resulting from infection (
       <xref rid="T0002">
        Table 2
       </xref>
       ) [
       <xref rid="CIT0060">
        60
       </xref>
       –
       <xref rid="CIT0063">
        63
       </xref>
       ]. SARS-CoV replicated in laboratory strains of mice, but did not cause disease signs, and virus was rapidly cleared from the lung in these models [
       <xref rid="CIT0060">
        60
       </xref>
       ]. Serial passage of SARS-CoV in the lungs of mice by multiple research groups resulted in mouse-adapted SARS-CoV strains that caused lethal lung disease in wild-type mouse intranasal (IN) infection models [
       <xref rid="CIT0064">
        64
       </xref>
       ,
       <xref rid="CIT0065">
        65
       </xref>
       ]. Mouse-adapted SARS-CoV MA15 is the best characterized small animal model of CoV infection, and has been used to test several pan-coronavirus drug candidates [
       <xref rid="CIT0066">
        66
       </xref>
       ,
       <xref rid="CIT0067">
        67
       </xref>
       ]. The benefit of mouse-adapted models of SARS-CoV in wild-type inbred mouse strains includes reproducible susceptibility to disease assayed by survival, weight loss, and whole body plethysmography of individual mice as well as quantification of infiltrating cells, viral titers, histopathology, and transcriptomics and proteomics changes in target organs. To evaluate pathogenesis of emergent viruses
       <italic>
        in vivo
       </italic>
       , zoonotic SARS-CoV and pre-emergent BatCoV mutations have been incorporated into the SARS-CoV MA15 backbone, providing novel animal models for viruses that have the potential to emerge into humans [
       <xref rid="CIT0015">
        15
       </xref>
       ,
       <xref rid="CIT0035">
        35
       </xref>
       ]. Additional valuable avenues of research on variables known to impact severe CoV disease in the MA15 models of SARS-CoV include age, dose, and host genetic contributions to disease phenotypes [
       <xref rid="CIT0068">
        68
       </xref>
       ,
       <xref rid="CIT0069">
        69
       </xref>
       ]. The greatest limitations of SARS-CoV mouse-adapted models for drug discovery are the incorporation of mutations in the SARS-CoV genome (particularly for testing antiviral drugs that target viral genes with mutations) and acknowledged differences between mouse and human immune responses.
       <table-wrap id="T0002" orientation="landscape" position="float">
        <object-id pub-id-type="doi">
         10.1080/17460441.2019.1581171-T0002
        </object-id>
        <label>
         Table 2.
        </label>
        <caption>
         <p>
          <italic>
           In vivo
          </italic>
          models of SARS-CoV.
         </p>
        </caption>
        <!--OASIS TABLE HERE-->
        <table frame="hsides" rules="groups">
         <colgroup>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="center" width="1*"/>
          <col align="center" width="1*"/>
          <col align="left" width="1*"/>
          <col align="center" width="1*"/>
         </colgroup>
         <thead>
          <tr>
           <th align="left" colspan="7">
            Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            <bold>
             Human Clinical Disease
            </bold>
            <hr/>
           </td>
           <td align="left">
            <hr/>
           </td>
           <td align="left" colspan="5">
            SARS manifests in humans as a severe atypical pneumonia associated with diffuse alveolar damage. SARS-CoV incubation period is 2–10 days. Initial flu-like symptoms of fever, cough, and shortness of breath may progress to pneumonia, and in severe cases infection may lead to Acute Respiratory Distress Syndrome (ARDS), the most severe form of acute lung injury. Pathological findings include the deposition of alveolar exudates and formation of hyalin membranes in severe cases. Overall mortality rate for SARS-CoV in reported cases was approximately 10%, with more severe disease in patients over age 65.
            <hr/>
           </td>
          </tr>
          <tr>
           <td align="left">
            <hr/>
           </td>
           <td align="left">
            <hr/>
           </td>
           <td align="center">
            Viral Strain
            <hr/>
           </td>
           <td align="center">
            Route of Infection
            <hr/>
           </td>
           <td align="center">
            Replication
            <hr/>
           </td>
           <td align="center">
            Disease signs, severity, and other comments
            <hr/>
           </td>
           <td align="center">
            Reference
            <hr/>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Non Human Primate Models
            </bold>
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
           <td align="center">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            African Green Monkey
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IN/IT
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No clinical disease signs. Higher viral replication in lungs than Rhesus or Cynomolgus Macaques. Interstitial pneumonitis observed. No lethal disease observed.
           </td>
           <td align="center">
            [
            <xref rid="CIT0083">
             83
            </xref>
            ,
            <xref rid="CIT0086">
             86
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Rhesus Macaque
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IN/IT
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No clinical disease signs. Alveolar pneumonitis observed, but less pathology and viral replication when directly compared to African Green Monkeys.
           </td>
           <td align="center">
            [
            <xref rid="CIT0083">
             83
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Cynomolgus Macaque
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IN/IT
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No clinical disease signs. Alveolar pneumonia observed, but less pathology and viral replication when directly compared to African Green Monkeys.
           </td>
           <td align="center">
            [
            <xref rid="CIT0083">
             83
            </xref>
            ,
            <xref rid="CIT0085">
             85
            </xref>
            ,
            <xref rid="CIT0086">
             86
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Common Marmoset
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IT
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No clinical disease signs. Mild/moderate pathology: Interstitial pneumonitis, bronchiolitis, and occasion edema.
           </td>
           <td align="center">
            [
            <xref rid="CIT0084">
             84
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Small Animal Models
            </bold>
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
           <td align="center">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Mouse Wild Type
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IN
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            Viral replication in the lungs, but no clinical disease signs.
           </td>
           <td align="center">
            [
            <xref rid="CIT0060">
             60
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Mouse Adapted Virus
           </td>
           <td align="left">
            MA15*
           </td>
           <td align="center">
            IN
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            Lethal disease is dependent on genetic background of mice and age. BALB/c: &gt;20% weight loss, mortality in young and old mice C57BL6J: ~15% weight loss and recovery in 10 week old animals, increasing weight loss and mortality in older mice; Age dependent and dose dependent responses; Other laboratory and wild-derived mouse strains evaluated include: 129, A/J, NOD, NZO, CAST, PWK, and WSB
           </td>
           <td align="center">
            [
            <xref rid="CIT0064">
             64
            </xref>
            ,
            <xref rid="CIT0068">
             68
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Hamster
           </td>
           <td align="left">
            Urbani
           </td>
           <td align="center">
            IN
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No weight loss, no clinical disease signs, no mortality
           </td>
           <td align="center">
            [
            <xref rid="CIT0061">
             61
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Ferret
           </td>
           <td align="left">
            HKU39849
           </td>
           <td align="center">
            IN
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No lethal disease, but disease signs observed include fever and sneezing. Observed lung pathology is consistent with interstitial pneumonia and replicates severe lung disease. SARS-CoV infected ferrets transmit virus to co-housed naïve ferrets.
           </td>
           <td align="center">
            [
            <xref rid="CIT0063">
             63
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Guinea Pig
           </td>
           <td align="left">
            Frankfurt
           </td>
           <td align="center">
            IP
           </td>
           <td align="center">
            Yes
           </td>
           <td align="left">
            No clinical disease signs; minor replication and pathological changes in lungs. Route of infection is not relevant to human SARS-CoV transmission.
           </td>
           <td align="center">
            [
            <xref rid="CIT0062">
             62
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           NR, not reported; IN, intranasal; IT, intratracheal; IP intraperitoneal;
          </p>
         </fn>
         <fn>
          <p>
           *Other mouse-adapted SARS-CoV strains exist, with similar published phenotypes [
           <xref rid="CIT0055">
            55
           </xref>
           ]
          </p>
         </fn>
         <fn>
          <p>
           Urbani (GenBank Accession AY278741)
          </p>
         </fn>
         <fn>
          <p>
           BJ01 (GenBank Accession AY278488)
          </p>
         </fn>
         <fn>
          <p>
           GZ01 (GenBank Accession AY278489)
          </p>
         </fn>
         <fn>
          <p>
           MA15 (GenBank Accession DQ497008)
          </p>
         </fn>
         <fn>
          <p>
           HKU39849 (GenBank Accession AY278491)
          </p>
         </fn>
         <fn>
          <p>
           Frankfurt (GenBank Accession AY291315)
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       Unlike SARS-CoV, human clinical strains of MERS-CoV (
       <xref rid="T0003">
        Table 3
       </xref>
       ) did not replicate in mice, hamsters, or ferrets, and further studies of the host receptor identified critical amino acid residue differences between the MERS-CoV receptor, DPP4, in laboratory animal model species that prevented entry into cells compared to human DPP4 [
       <xref rid="CIT0070">
        70
       </xref>
       –
       <xref rid="CIT0072">
        72
       </xref>
       ]. MERS-CoV infection of rabbits resulted in viral replication in the upper respiratory tract, but no clinical disease signs that reflect more severe MERS-CoV disease symptoms were reported, although the model has been used for limited testing of MERS-CoV antiviral therapeutics [
       <xref rid="CIT0073">
        73
       </xref>
       ,
       <xref rid="CIT0074">
        74
       </xref>
       ]. However, due to the utility of the mouse-adapted SARS-CoV model, a mouse model continued to be pursued, and adenovirus-vectored transient expression of the human DPP4 receptor in mice and subsequent replication of MERS-CoV in these mice determined that MERS-CoV replication was dependent on human DPP4 expression in rodents [
       <xref rid="CIT0075">
        75
       </xref>
       ]. Transgenic expression of human DPP4 in mice allowed MERS-CoV replication in mice, but resulted in lethal brain disease not representative of MERS-CoV infection in humans [
       <xref rid="CIT0076">
        76
       </xref>
       ,
       <xref rid="CIT0077">
        77
       </xref>
       ]. Replacing mouse DPP4 with the expression of human DPP4 in mice resulted in a humanized DPP4 mouse model that allows MERS-CoV replication within the lung and some MERS-associated lung pathology, but no lethal disease [
       <xref rid="CIT0078">
        78
       </xref>
       ]. Similarly, knock-in expression of the human DPP4 exons 10–12 in mice allowed viral replication but no overt MERS disease signs [
       <xref rid="CIT0079">
        79
       </xref>
       ]. Serial passage of MERS-CoV in the lungs of these mice resulted in a MERS-MA virus that caused lethal disease in mice, including weight loss and severe lung pathology [
       <xref rid="CIT0079">
        79
       </xref>
       ]. Identification of amino acids in mouse DPP4 that prevent entry of MERS-CoV into mouse cells led to the rational design of the mouse DPP4 gene edited by CRISPR/Cas9 to express two human DPP4 mutations (288/330 DPP4) [
       <xref rid="CIT0080">
        80
       </xref>
       ]. 288/330 DPP4 mice supported viral replication without severe disease or lethality, but serial passage of MERS-CoV (generating a mouse-adapted virus called MERS-15) produced lethal disease in the 288/330 DPP4 mice [
       <xref rid="CIT0080">
        80
       </xref>
       ]. Although many of the same metrics of disease to MA15-SARS-CoV are available in the MERS-15 or MERS-MA models for drug discovery of coronavirus antivirals, an additional drawback is the requirement for both mouse-adapted virus and a modified rodent host. Despite these limitations, mouse models of adapted SARS-CoV and MERS-CoV are currently the best-developed models of highly pathogenic coronavirus infection available for pan-coronavirus drug discovery.
       <table-wrap id="T0003" orientation="landscape" position="float">
        <object-id pub-id-type="doi">
         10.1080/17460441.2019.1581171-T0003
        </object-id>
        <label>
         Table 3.
        </label>
        <caption>
         <p>
          <italic>
           In vivo
          </italic>
          models of MERS-CoV.
         </p>
        </caption>
        <!--OASIS TABLE HERE-->
        <table frame="hsides" rules="groups">
         <colgroup>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="left" width="1*"/>
          <col align="center" width="1*"/>
         </colgroup>
         <thead>
          <tr>
           <th align="left" colspan="7">
            Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            <bold>
             Human Clinical Disease
            </bold>
            <hr/>
           </td>
           <td align="left">
            <hr/>
           </td>
           <td align="left" colspan="5">
            MERS-CoV manifests in humans as a severe atypical pneumonia associated with diffuse alveolar damage. This is likely to include the deposition of alveolar exudates and formation of hyalin membranes in severe cases. Incubation period of MERS-CoV is 2–14 days. Initial symptoms may include fever and influenza-like illness followed by a progression to lower respiratory symptoms including dyspnea, cough, and pneumonia. MERS-CoV infection may lead to Acute Respiratory Distress Syndrome (ARDS), the most severe form of acute lung injury. Clinical MERS symptoms may occur for weeks following infection, including persistence of viral RNA in the lower respiratory tract. Healthcare workers and animal workers (particularly handlers of camels) are at increased occupational risk of exposure. Overall mortality rate for MERS-CoV in reported cases is approximately 30–40%, with more severe disease in patients over age 65 or with preexisting co-morbidities. Asymptomatic or subclinical MERS-CoV infection, particularly among healthy individuals may occur.
            <hr/>
           </td>
          </tr>
          <tr>
           <td align="left">
            <hr/>
           </td>
           <td align="left">
            <hr/>
           </td>
           <td align="center">
            Viral Strain
            <hr/>
           </td>
           <td align="center">
            Route of Infection
            <hr/>
           </td>
           <td align="center">
            Replication
            <hr/>
           </td>
           <td align="center">
            Disease signs, severity, and other comments
            <hr/>
           </td>
           <td align="center">
            Reference
            <hr/>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Non Human Primate Models
            </bold>
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Rhesus Macaque
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            Multiple Routes*
           </td>
           <td align="left">
            Yes
           </td>
           <td align="left">
            Disease signs include elevated temperature, loss of appetite, hunched posture, cough lasting for several days. Pathology indicates interstitial pneumonia. No lethal disease.
           </td>
           <td align="center">
            [
            <xref rid="CIT0088">
             88
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Rhesus Macaque
           </td>
           <td align="left">
            JOR/2012
           </td>
           <td align="left">
            IT
           </td>
           <td align="left">
            ND
           </td>
           <td align="left">
            Few clinical disease signs observed. Mild pathology of interstitial pneumonia. No lethal disease.
           </td>
           <td align="center">
            [
            <xref rid="CIT0089">
             89
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Common Marmoset
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            Multiple Routes*
           </td>
           <td align="left">
            Yes
           </td>
           <td align="left">
            Moderate to severe disease with disease signs including loss appetite and lethargy. High viral load in the lung of all animals, some with viremia. Interstitial pneumonia observed.
           </td>
           <td align="center">
            [
            <xref rid="CIT0090">
             90
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Common Marmoset
           </td>
           <td align="left">
            EMC/2012, JOR/2012
           </td>
           <td align="left">
            IT
           </td>
           <td align="left">
            ND
           </td>
           <td align="left">
            Mild to moderate non-lethal disease with few clinical signs. Viral replication in lungs and interstitial pneumonia observed. Similar phenotypes with EMC and Jordan isolates
           </td>
           <td align="center">
            [
            <xref rid="CIT0091">
             91
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Small Animal Models
            </bold>
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="left">
           </td>
           <td align="center">
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Mouse Wild Type
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            IN
           </td>
           <td align="left">
            No
           </td>
           <td align="left">
            No viral replication or disease signs were observed in BALB/c, 129Sv/Ev or STAT-/- mice. Other immune deficient mice are not susceptible to MERS-CoV (RAG-/-, SCID-/-, Myd88-/-). The mouse DPP4 receptor does not allow viral replication.
           </td>
           <td align="center">
            [
            <xref rid="CIT0071">
             71
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Mouse hDPP4 Transgenic
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            IN
           </td>
           <td align="left">
            Yes
           </td>
           <td align="left">
            Transient expression of the human DPP4 (hDPP4) receptor in mice by Ad5-hDPP4 allows vial replication in C57Bl6/J and BALB/c mice, but only minor clinical disease signs. Global constitutive expression of hDPP4 in transgenic mice results in lethal disease with minor lung pathology, but high viral replication in the CNS and lethal neuropathology not associated with human disease. Expression of hDPP4 in place of the mouse DPP4 ORF results in non-lethal disease characterized by viral replication and lung pathology.
           </td>
           <td align="center">
            [
            <xref rid="CIT0075">
             75
            </xref>
            –
            <xref rid="CIT0078">
             78
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Mouse Adapted Virus
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            IN
           </td>
           <td align="left">
            Yes
           </td>
           <td align="left">
            Editing of mouse DPP4 by CRISPR/Cas9 generated 288/330 hDPP4 mice resulting in viral replication in the lungs of mice. Serial passage of MERS-CoV 15 times in the lung of 288/330 hDPP4 mice resulted in MERS-15 virus that was lethal in about 40% of mice infected. Knock In (KI) expression of hDPP4 exons 10–12 in mice resulted in viral replication with no clinical disease signs following MERS-CoV infection. Serial passage of MERS-CoV 30 times in the lung of KI DPP4 mice resulted in a lethal mouse adapted strain, MERS-MA.
           </td>
           <td align="center">
            [
            <xref rid="CIT0079">
             79
            </xref>
            ,
            <xref rid="CIT0080">
             80
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Hamster
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            IT
           </td>
           <td align="left">
            No
           </td>
           <td align="left">
            No disease signs or viral replication observed, the hamster DPP4 receptor does not allow viral replication
           </td>
           <td align="center">
            [
            <xref rid="CIT0070">
             70
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Ferret
           </td>
           <td align="left">
            EMC/2012
           </td>
           <td align="left">
            IN/IT
           </td>
           <td align="left">
            No
           </td>
           <td align="left">
            No disease signs or viral replication observed, the ferret DPP4 receptor does not allow viral replication
           </td>
           <td align="center">
            [
            <xref rid="CIT0072">
             72
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td align="left">
           </td>
           <td align="left">
            Rabbit
           </td>
           <td align="left">
            EMC/2012, England-2
           </td>
           <td align="left">
            IN/IT
           </td>
           <td align="left">
            Yes
           </td>
           <td align="left">
            Viral replication observed from nasal swabs, MERS-CoV detected in lungs by RT-qPCR, ISH, and IHC. Similar phenotypes with EMC and England isolates
           </td>
           <td align="center">
            [
            <xref rid="CIT0073">
             73
            </xref>
            ,
            <xref rid="CIT0074">
             74
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           NR, not reported; ND, not detected; IN, intranasal; IT, intratracheal;
          </p>
         </fn>
         <fn>
          <p>
           * Multiple Routes indicates combined Ocular, Oral, IN and IT inoculation
          </p>
         </fn>
         <fn>
          <p>
           EMC/2012 (GenBank Accession JX869059)
          </p>
         </fn>
         <fn>
          <p>
           JOR/2012 (GenBank Accession KC776174)
          </p>
         </fn>
         <fn>
          <p>
           England-2 (GenBank Accession KM015348)
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="S0003-S2002">
      <label>
       3.2.
      </label>
      <title>
       Primate models for pan-coronavirus discovery
      </title>
      <p>
       Small animal models have been more thoroughly developed as models of SARS-CoV and MERS-CoV infection, due to ease of manipulation with rodents and increased costs and ethical concerns associated with nonhuman primates (NHPs). However, NHP model development of highly pathogenic coronavirus infections is pivotal in the evaluation of pan-coronavirus therapeutics, because host immune responses from NHPs share greater homology with humans compared to rodents, and may more accurately indicate immunological biomarkers of severe disease needed to evaluate pan-coronavirus therapeutics. Disease signs are observed in NHP models of infection without adaptation of CoVs required in rodent models of SARS-CoV and MERS-CoV. Both SARS-CoV and MERS-CoV isolates from humans replicate in NHPs, indicating conservation of important aspects to coronavirus-induced diseases including respiratory tract biology, receptor homology, and pattern of expression of host receptor and proteases.
      </p>
      <p>
       SARS-CoV infection of common laboratory primate species by the IT route including African green monkeys, rhesus macaques, cynomolgus macaques, and common marmosets, resulted in disease signs with differing degrees of severity, but none were reflective of the lethal SARS disease seen in humans (
       <xref rid="T0002">
        Table 2
       </xref>
       ) [
       <xref rid="CIT0081">
        81
       </xref>
       –
       <xref rid="CIT0085">
        85
       </xref>
       ]. Commonly reported disease signs included lethargy and increased respiratory rates following SARS-CoV infection in multiple NHP models of infection, but other acute signs of illness including fever or dyspnea were infrequently reported. The most severe disease phenotypes were observed in the histopathology of the lungs at acute times post-infection (3–6 days) with typical findings of pulmonary lesions and pneumonitis and occasional observations of diffuse alveolar damage [
       <xref rid="CIT0086">
        86
       </xref>
       ]. Although none of the NHP species that were infected with SARS-CoV developed lethal respiratory disease reflective of SARS patients, NHP models did recapitulate enhanced disease in aged NHPs, including aberrant innate immune signaling programs [
       <xref rid="CIT0087">
        87
       </xref>
       ]. However, lack of emulation of human SARS disease was never resolved in an NHP model that could be used for consistent evaluation of therapeutic candidates against SARS-CoV.
      </p>
      <p>
       MERS-CoV infection of nonhuman primate models was reported, with the best characterized NHP models of MERS-CoV infection in rhesus macaques and common marmosets (
       <xref rid="T0003">
        Table 3
       </xref>
       ) [
       <xref rid="CIT0088">
        88
       </xref>
       –
       <xref rid="CIT0091">
        91
       </xref>
       ]. Administering MERS-CoV via the IT route to either rhesus macaques or common marmosets resulted in mild disease with very few observable disease phenotypes [
       <xref rid="CIT0089">
        89
       </xref>
       ,
       <xref rid="CIT0091">
        91
       </xref>
       ]. However, infecting rhesus macaques or common marmosets by multiple concurrent routes (IN, IT, oral, and ocular) resulted in moderate disease in rhesus macaques, but more severe disease in marmosets [
       <xref rid="CIT0088">
        88
       </xref>
       ,
       <xref rid="CIT0090">
        90
       </xref>
       ]. Infecting NHPs by multiple routes likely caused a systemic infection potentially not representative of human MERS-CoV infection. Although the marmoset is currently the best developed NHP model of MERS-CoV disease, discrepancies in disease severity of marmosets infected by multiple routes and marmosets infected by the IT route illuminate potential difficulties with using this model for drug development studies. Small size and fragility of marmosets precluded serial blood draws on multiple days following infection, and may confound experimental outcomes resulting from MERS-CoV infection or treatment [
       <xref rid="CIT0092">
        92
       </xref>
       ]. Absence of reproducible clinical disease signs like fever, respiratory distress, or lethality that recapitulated human symptoms of SARS or MERS indicates that currently developed models present significant challenges to testing of pan-coronavirus antivirals in NHP models of infection.
      </p>
     </sec>
    </sec>
    <sec id="S0004">
     <label>
      4.
     </label>
     <title>
      Pan-coronavirus antivirals
     </title>
     <p>
      Pan-coronavirus antivirals must target viral or host factors that are i) highly conserved among known CoVs, ii) essential to viral replication or viral pathogenesis by known CoVs, and iii) likely to be conserved and essential in emerging CoVs. Inhibiting highly conserved mechanisms involved in the coronavirus lifecycle is likely to result in a reduction of viral titers, alteration of host responses, and/or amelioration of disease signs. SARS-CoV and MERS-CoV are known threats to global health, but other novel coronaviruses may emerge in the future complicating drug design if antiviral targets are too specific to known viral strains. Unlike with influenza viruses, specific antiviral drugs like oseltamivir and zanamivir targeting coronaviruses are not yet available, but several promising candidates have been recently described in the literature. The most conserved proteins among CoVs are nonstructural proteins (nsps) involved in essential functions of the viral lifecycle. The structural proteins that make up the virion are less conserved than nsps, and accessory proteins are only functionally conserved among very closely related viruses (
      <xref rid="F0002">
       Figure 2
      </xref>
      ). In addition to potential lack of conservation between known and emerging HCoVs, targeting viral proteins can be problematic for drug discovery due to viral escape by mutation. Alternatively, antivirals that target conserved host factors utilized during the viral life cycle may also be potential pan-coronavirus antiviral therapeutics, but have the disadvantage of potential off-target effects.
      <fig fig-type="figure" id="F0002" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1080/17460441.2019.1581171-F0002
       </object-id>
       <label>
        Figure 2.
       </label>
       <caption>
        <p>
         Coronavirus virion structure and genomic organization.
        </p>
        <p specific-use="attrib">
         As an example of coronavirus virion (A) and genome (B) structure, a schematic of MERS-CoV (GenBank JX869059) is provided. Virions exist as enveloped viral particles, with the Spike (S), Membrane (M), and Envelope (E) proteins decorating the outside of the membrane. Coronaviruses in genogroup 2a have an additional structural protein hemagglutinin esterase (HE), which has been omitted from this discussion. Inside of the virion, the Nucleocapsid (N) protein encapsidates the viral genome. The viral genome is composed of + sense, single-stranded RNA. At the 5ʹ end of the genome, a single polyprotein open reading frame encodes the more highly conserved nonstructural proteins (ORF1a, ORF1b). At the 3ʹ end of the genome, the functionally conserved structural proteins that make up the virion are interspersed with virus-specific accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF 8b). Accessory proteins are conserved between very closely related viruses like BatCoV-HKU4, BatCoV-HKU5, and MERS-CoV. There is no conservation of accessory proteins between known HCoVs.
        </p>
       </caption>
       <graphic xlink:href="IEDC_A_1581171_F0002_OC">
       </graphic>
      </fig>
     </p>
     <sec id="S0004-S2001">
      <label>
       4.1.
      </label>
      <title>
       Targeting CoV nonstructural proteins
      </title>
      <p>
       Coronavirus nsps are highly conserved components of the coronavirus lifecycle that mediate viral replication including 3C-like protease (3CLpro), papain-like Protease (PLpro), and RNA-dependent RNA polymerase (RdRp). The CoV RdRp replicates the viral RNA genome and generates viral RNA transcripts, essential functions that cannot be performed by cellular polymerases. Another essential element of the CoV lifecycle is proteolytic processing of viral polyproteins into functional nsps by two viral proteases, the 3CLpro and PLpro. In addition to polymerase and protease functions, other essential functions performed by the nsps of CoVs include immune antagonism, double membrane vesicle organization, scaffolding for replication complex formation, nucleic acid binding, helicase activity, and viral RNA proofreading which may be future targets of coronavirus specific antiviral drug discovery [
       <xref rid="CIT0093">
        93
       </xref>
       ].
      </p>
      <sec id="S0004-S2001-S3001">
       <label>
        4.1.1.
       </label>
       <title>
        GS-5734
       </title>
       <p>
        GS-5734 is a small molecule nucleoside analog that has demonstrated antiviral activity
        <italic>
         in vitro
        </italic>
        against several viral families of emerging infectious diseases including
        <italic>
         Filoviridae, Pneumoviridae, Paramyxoviridae
        </italic>
        , and
        <italic>
         Coronaviridae
        </italic>
        [
        <xref rid="CIT0045">
         45
        </xref>
        ,
        <xref rid="CIT0066">
         66
        </xref>
        ,
        <xref rid="CIT0094">
         94
        </xref>
        ]. Efficacy of GS-5734 in post-exposure treatment of Ebola virus-infected nonhuman primates led to GS-5734 inclusion in an experimental therapy for an infant survivor of Ebola virus disease [
        <xref rid="CIT0045">
         45
        </xref>
        ,
        <xref rid="CIT0095">
         95
        </xref>
        ]. These encouraging results demonstrated that GS-5734 may be an acceptable therapeutic intervention to lethal viral disease, even days after viral exposure, and tolerated by patients with viral diseases that were previously treated primarily with supportive care. Based on activity against MERS-CoV within a larger panel targeting lethal viruses from multiple viral families, additional studies demonstrated that GS-5734 decreased viral titers and viral RNA in
        <italic>
         in vitro
        </italic>
        models of both SARS-CoV and MERS-CoV infection of HAEs [
        <xref rid="CIT0066">
         66
        </xref>
        ]. Additionally, GS-5734 had similar effects against other diverse CoVs including HCoV-NL63 and Mouse Hepatitis Virus (MHV, betacoronavirus group 2a) [
        <xref rid="CIT0066">
         66
        </xref>
        ,
        <xref rid="CIT0096">
         96
        </xref>
        ]. Importantly, GS-5734 inhibited replication of pre-emergent BatCoVs including BatCoV-HKU5, BatCoV-HKU3, BatCoV-SHC014, and BatCoV-WIV1 [
        <xref rid="CIT0066">
         66
        </xref>
        ]. Activity
        <italic>
         in vivo
        </italic>
        against CoVs was supported by ameliorated disease signs (weight loss, lung viral titers) in MA15 SARS-CoV infected mice treated prophylactically or therapeutically with GS-5734 [
        <xref rid="CIT0066">
         66
        </xref>
        ]. Although viral resistance to GS-5734 was shown experimentally
        <italic>
         in vitro
        </italic>
        , mutations to conserved motifs in SARS-CoV and MHV resulted in decreased viral fitness
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        [
        <xref rid="CIT0096">
         96
        </xref>
        ]. Altogether,
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        data support GS-5734 development as a potential pan-coronavirus antiviral based on results against several CoVs, including highly pathogenic CoVs and potentially emergent BatCoVs.
       </p>
      </sec>
      <sec id="S0004-S2001-S3002">
       <label>
        4.1.2.
       </label>
       <title>
        Lopinavir–Ritonavir
       </title>
       <p>
        Lopinavir–ritonavir was initially developed as an HIV-1 protease inhibitor but
        <italic>
         in vitro
        </italic>
        activity also targeted SARS-CoV nonstructural protein 3CLpro [
        <xref rid="CIT0097">
         97
        </xref>
        ]. During the SARS-CoV epidemic, lopinavir–ritonavir combination therapy with ribavirin in SARS patients was associated with decreased viral load and decreased adverse clinical outcomes of death or ARDS when compared with historical control cases [
        <xref rid="CIT0098">
         98
        </xref>
        ]. Shortly after the emergence of MERS, high throughput screening approaches of known antiviral compounds identified lopinavir activity against MERS-CoV
        <italic>
         in vitro
        </italic>
        [
        <xref rid="CIT0051">
         51
        </xref>
        ]. Oral treatment with lopinavir-ritonavir in the marmoset model of MERS-CoV infection resulted in modest improvements in MERS disease signs, including decreased pulmonary infiltrates identified by chest x-ray, decreased interstitial pneumonia, and decreased weight loss [
        <xref rid="CIT0092">
         92
        </xref>
        ]. MERS patient case reports of treatment regimens including lopinavir-ritonavir were associated with positive disease outcomes including defervescence, viral clearance from serum and sputum, and survival [
        <xref rid="CIT0099">
         99
        </xref>
        ,
        <xref rid="CIT0100">
         100
        </xref>
        ]. Based on
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        activity against MERS-CoV, a clinical trial has been designed using combination of lopinavir-ritonavir and IFN-β1b therapies in hospitalized MERS patients in Saudi Arabia [
        <xref rid="CIT0101">
         101
        </xref>
        ].
       </p>
      </sec>
      <sec id="S0004-S2001-S3003">
       <label>
        4.1.3.
       </label>
       <title>
        Ribavirin
       </title>
       <p>
        Ribavirin is a guanosine analog with
        <italic>
         in vitro
        </italic>
        activity against a large number of highly lethal emerging viruses. Mechanistically, ribavirin inhibits RNA synthesis by viral RdRp as well as inhibits mRNA capping. However, studies demonstrated that while SARS-CoV, MERS-CoV, and HCoV-OC43 were sensitive to ribavirin
        <italic>
         in vitro
        </italic>
        , doses that significantly inhibited CoV replication exceeded ribavirin concentrations attainable by typical human regimens [
        <xref rid="CIT0046">
         46
        </xref>
        ,
        <xref rid="CIT0102">
         102
        </xref>
        –
        <xref rid="CIT0104">
         104
        </xref>
        ]. Recently, it was demonstrated that excision of ribavirin nucleoside analogs by conserved coronavirus proofreading mechanisms likely accounted for decreased
        <italic>
         in vitro
        </italic>
        efficacy of ribavirin than expected [
        <xref rid="CIT0105">
         105
        </xref>
        ]. Additional
        <italic>
         in vivo
        </italic>
        testing of ribavirin in mouse models found limited activity against MA15 SARS-CoV by ribavirin alone, and suggested that ribavirin treatment enhanced SARS disease signs [
        <xref rid="CIT0065">
         65
        </xref>
        ,
        <xref rid="CIT0106">
         106
        </xref>
        ]. However, combination treatment of ribavirin and type I Interferons in primate models improved MERS disease signs [
        <xref rid="CIT0107">
         107
        </xref>
        ]. Ribavirin has been given as part of treatment regimens for SARS and MERS patients, but meta-analyses of case studies have found limited (if any) efficacy of ribavirin in treating patients with highly pathogenic coronavirus respiratory syndromes [
        <xref rid="CIT0108">
         108
        </xref>
        ,
        <xref rid="CIT0109">
         109
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="S0004-S2002">
      <label>
       4.2.
      </label>
      <title>
       Targeting CoV structural and accessory proteins
      </title>
      <p>
       Coronavirus structural proteins compose the virion, including the Spike (S) glycoprotein, Envelope (E) protein, Membrane (M) protein, and the Nucleopcapsid (N) protein (
       <xref rid="F0002">
        Figure 2
       </xref>
       ). These proteins also perform important functions in the viral life cycle: S is the main determinant of cell tropism, host range, and viral entry; E facilitates viral assembly and release, and has viroporin activity; M maintains the membrane structure of the virion; and N encapsidates the viral RNA genome. Although most of these functions are essential to viral infection, CoVs tolerated E deletion and remained replication competent, but viral fitness was impaired [
       <xref rid="CIT0110">
        110
       </xref>
       ]. Unfortunately, while structural protein functions are similar between CoVs, protein identity is less conserved than with nsps, making the development of pan-coronavirus therapeutics directly targeting structural proteins problematic. Genes encoding structural and accessory proteins are interspersed at the 3ʹ end of the coronavirus RNA genome (
       <xref rid="F0002">
        Figure 2
       </xref>
       ). Deletion of accessory protein genes using reverse genetics systems demonstrated that these proteins were not essential for viral replication, but impacted viral replication or viral fitness
       <italic>
        in vitro
       </italic>
       and
       <italic>
        in vivo
       </italic>
       [
       <xref rid="CIT0111">
        111
       </xref>
       ,
       <xref rid="CIT0112">
        112
       </xref>
       ]. However, unlike nonstructural proteins or structural proteins, significant variation in number, function, and sequence of accessory proteins between closely related viruses makes accessory proteins poor targets for pan-coronavirus therapeutic approaches.
      </p>
      <sec id="S0004-S2002-S3001">
       <label>
        4.2.1.
       </label>
       <title>
        Monoclonal antibody therapeutics
       </title>
       <p>
        Monoclonal antibodies (mAbs) have potential utility in combating highly pathogenic viral diseases, by prophylactic and therapeutic neutralization of structural proteins on virions.
        <italic>
         In vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        approaches by multiple groups identified mAbs targeting either SARS-CoV or MERS-CoV that inhibited viral replication and ameliorated SARS and MERS disease in animal models [
        <xref rid="CIT0074">
         74
        </xref>
        ,
        <xref rid="CIT0078">
         78
        </xref>
        ,
        <xref rid="CIT0089">
         89
        </xref>
        ,
        <xref rid="CIT0113">
         113
        </xref>
        ]. As an example, antibodies generated against the S glycoprotein of MERS-CoV inhibited viral replication when administered 24 h prior to infection, as well as 24 h postinfection in a humanized DPP4 mouse model [
        <xref rid="CIT0078">
         78
        </xref>
        ]. In general, mAbs that were effective against CoV infection in animal models targeted the highly variable S glycoprotein, but these mAbs lack cross-protection against other related CoVs [
        <xref rid="CIT0114">
         114
        </xref>
        ]. Monoclonal antibodies developed against SARS-CoV, MERS-CoV, or other emerging CoVs may require separate formulations for each virus due to differences in the targeted antigen. For example, mAbs targeted against S from 2003 SARS-CoV isolates failed to neutralize closely related BatCoV-SHC014 and only some mAbs neutralized BatCoV-WIV1 [
        <xref rid="CIT0015">
         15
        </xref>
        ,
        <xref rid="CIT0016">
         16
        </xref>
        ]. In general, mAbs target specific epitopes, and viruses avoid neutralization by accruing mutations in the targeted epitope that allow viral escape from mAb therapy. Pre-clinical and clinical mAb formulations may include a cocktail of multiple mAbs that target different epitopes to ensure that viruses cannot escape neutralization. However, SARS-CoV S tolerated mutations in multiple epitopes allowing escape from neutralization from multiple mAbs, and the introduction of mAb escape mutations enhanced pathogenesis of the virus in some animal models [
        <xref rid="CIT0115">
         115
        </xref>
        ]. In sum, efficacious monoclonal antibody therapy against highly pathogenic coronaviruses may require several mAbs targeting conserved epitopes and rigorous testing is required to demonstrate that viral evasion of mAbs does not result in enhanced virulence.
       </p>
      </sec>
      <sec id="S0004-S2002-S3002">
       <label>
        4.2.2.
       </label>
       <title>
        Coronavirus vaccines
       </title>
       <p>
        Vaccines have long been considered the gold standard for infectious disease prevention and eradication targeted at human populations as well as conferring the benefits of long-lived immune protection for the individual. Zoonotic pathogens like coronaviruses emerge from animal reservoir species, thus vaccination strategies are unlikely to lead to eradication while the virus continues to circulate in reservoir hosts. One Health approaches to solving the problems of emerging infectious diseases consider the environment and animal health, as well as human health [
        <xref rid="CIT0116">
         116
        </xref>
        ]. For example, vaccination strategies targeting the camel intermediate host of MERS-CoV have been developed, which may work to repress viral replication in camels, preventing MERS-CoV transmission to humans [
        <xref rid="CIT0117">
         117
        </xref>
        ].
       </p>
       <p>
        In human infections of highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the most vulnerable populations are patients over the age of 65 and patients with comorbidities, and design of efficacious vaccines for patients in these groups is difficult. Vaccine formulations that have been developed against SARS-CoV not only fail to protect animal models of aged populations, but also result in immunopathology in younger populations, where SARS disease is enhanced in vaccinated groups that are subsequently challenged with SARS-CoV [
        <xref rid="CIT0118">
         118
        </xref>
        ,
        <xref rid="CIT0119">
         119
        </xref>
        ]. In addition, vaccines generate memory immune responses to specific pathogens, and no vaccine formulations have been developed that are effective against multiple CoVs. Due to the diversity of BatCoVs, it seems unlikely that current therapeutic strategies targeting specific SARS-CoV or MERS-CoV antigens will be efficacious against future coronaviruses that emerge into the human population. Vaccines formulated against the SARS-CoV epidemic antigens do not offer effective protection against SARS-like BatCoVs that are currently circulating in bat populations [
        <xref rid="CIT0015">
         15
        </xref>
        ]. Rather, a modular vaccine platform that can be rapidly adjusted for newly emergent viral antigens in potentially pandemic CoVs may be able to provide emergency vaccine coverage against emergent viral strains.
       </p>
      </sec>
     </sec>
     <sec id="S0004-S2003">
      <label>
       4.3.
      </label>
      <title>
       Targeting host factors essential for CoV infection
      </title>
      <sec id="S0004-S2003-S3001">
       <label>
        4.3.1.
       </label>
       <title>
        Host factor modulation
       </title>
       <p>
        Antiviral compounds that specifically target viral proteins may result in viral escape by mutation in the targeted viral proteins, as has been described with monoclonal antibodies and GS-5734 [
        <xref rid="CIT0096">
         96
        </xref>
        ,
        <xref rid="CIT0115">
         115
        </xref>
        ]. However, targeting conserved host mechanisms utilized by multiple coronavirus as an essential part of the viral life cycle is an approach to pan-coronavirus drug development where viral escape by mutation is less likely. Several groups have attempted to inhibit host proteases (including furin, cathepsins, and TMPRSS2) that process viral S glycoproteins at the cell surface during viral entry [
        <xref rid="CIT0050">
         50
        </xref>
        ,
        <xref rid="CIT0120">
         120
        </xref>
        –
        <xref rid="CIT0122">
         122
        </xref>
        ]. However, due to variation in viral S glycoproteins among different CoVs and variation in the host proteases required for viral entry (
        <xref rid="T0001">
         Table 1
        </xref>
        ), combinations of protease inhibitors would be required for pan-coronavirus treatment regimens, particularly for emergent novel CoVs where host protease requirements have not been evaluated. Additional host targets with less established mechanisms of activity include Cyclosporins, a class of cyclophilin inhibitors with antiviral activity against coronaviruses in addition to immunosuppressive properties [
        <xref rid="CIT0123">
         123
        </xref>
        ]. Non-immunosuppressive derivatives of cyclosporins like alisporivir retained antiviral properties
        <italic>
         in vitro
        </italic>
        against coronaviruses including SARS-CoV, MERS-CoV, but were not effective against SARS-CoV in mouse models of infection [
        <xref rid="CIT0124">
         124
        </xref>
        ].
       </p>
      </sec>
      <sec id="S0004-S2003-S3002">
       <label>
        4.3.2.
       </label>
       <title>
        Host immune modulation
       </title>
       <p>
        Interferons (IFNs) are a class of immunomodulatory compounds produced by host cells in response to detection of pathogen-specific motifs, resulting in IFN secretion that affects not only the stimulated cell, but also neighboring cells. Early in infection, IFN stimulation results in altered cellular transcriptional programs, leading to an antiviral state characterized by the activation of a large set of host genes with partially defined antiviral functions [
        <xref rid="CIT0125">
         125
        </xref>
        ]. Based on these potentially beneficial immunomodulatory properties in the context of infections, IFNs have been used for the treatment of emerging viral infections where no specific antiviral drugs yet exist, with the greatest benefits resulting from administration very early following infection. For SARS-CoV and MERS-CoV, Type I IFNs were effective at decreasing viral replication
        <italic>
         in vitro
        </italic>
        and showed additional benefits in
        <italic>
         in vivo
        </italic>
        primate models of infection [
        <xref rid="CIT0103">
         103
        </xref>
        ,
        <xref rid="CIT0104">
         104
        </xref>
        ,
        <xref rid="CIT0107">
         107
        </xref>
        ,
        <xref rid="CIT0126">
         126
        </xref>
        ,
        <xref rid="CIT0127">
         127
        </xref>
        ]. IFNs used in the treatment of SARS and MERS patients often occurred in combinatory therapies with other drugs including ribavirin and lopinavir-ritonavir, although potential beneficial effects of therapies were limited, potentially due to administration at later times postinfection [
        <xref rid="CIT0108">
         108
        </xref>
        ]. Upstream stimulants of IFN induction, including polyI:C resulted in IFN signaling cascade activation, with demonstrated effectivity
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        against SARS-CoV and MERS-CoV [
        <xref rid="CIT0067">
         67
        </xref>
        ,
        <xref rid="CIT0075">
         75
        </xref>
        ]. Additional immunomodulatory compounds that regulate the expression of innate immune genes have been suggested as potential therapeutics for highly pathogenic coronaviruses; however, compounds that modulate the host response require significant testing in the most rigorous animal models before therapeutic applications could be pursued. For example, corticosteroids (methylprednisolone) were given as treatment during the SARS and MERS epidemics due to immunomodulatory effects that suppress inflammatory responses with no perceived benefit and possible deleterious effects [
        <xref rid="CIT0108">
         108
        </xref>
        ,
        <xref rid="CIT0109">
         109
        </xref>
        ].
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="S0005">
     <label>
      5.
     </label>
     <title>
      Expert opinion
     </title>
     <p>
      In response to outbreaks of previously unrecognized respiratory syndromes characterized by atypical pneumonia in 2003 and 2012, collaborative new research programs were quickly established that identified the etiologic agents involved as highly pathogenic coronaviruses SARS-CoV and MERS-CoV. These coronaviruses may have the potential to cause devastating pandemics due to unique features in virus biology including rapid viral replication, broad host range, cross-species transmission, person-to-person transmission, and lack of herd immunity in human populations. SARS-CoV and MERS-CoV were contained by diligent enforcement of public health measures that limited viral spread to approximately 10,000 cases total for both SARS and MERS since 2003. However, the threat of SARS-CoV, MERS-CoV, or an as-yet unknown BatCoV that causes severe disease in humans makes antiviral therapeutics that broadly target coronaviruses a highly desirable commodity to ensure global public health. The current challenge is to produce medical countermeasures that can protect vulnerable populations against known coronaviruses like SARS-CoV and MERS-CoV, but that are also effective against novel highly pathogenic coronaviruses that may emerge from animal reservoir hosts.
     </p>
     <p>
      While SARS-CoV and MERS-CoV were rapidly identified following clinical reports of novel atypical pneumonia, progress in developing effective antivirals for SARS-CoV and MERS-CoV has been impeded by several factors. A key finding from our review of the literature is that current animal models for highly pathogenic coronaviruses SARS-CoV and MERS-CoV are not adequate to support advanced development of antiviral therapeutics. MERS-CoV continues to circulate on the Arabian Peninsula, providing the opportunity to investigate some treatments of MERS in clinical trials. However, future emerging coronaviruses may require use of the FDA Animal Efficacy Rule for Investigational New Drugs (INDs). INDs must fulfill the Animal Efficacy Rule criteria of i) reasonable safety for initial use in humans, ii) pharmacological data that support reasonably well-understood mechanism of activity against the pathogen, and iii) efficacy in animal models with disease signs representative of clinical illness in humans (including one non-rodent model). While the vigorous pursuit of small animal models has been successful in generating rodent models that recapitulate severe SARS and MERS disease signs (including morbidity and mortality), progress in generating additional animal models has lagged, particularly in primate models of SARS-CoV or MERS-CoV infection. Past strategies for experimental treatment regimens primarily relied on combination therapies with approved drugs known to have acceptable safety profiles and broad-spectrum antiviral activity including IFNs, ribavirin, and corticosteroids. However, analyses of data returned from these treatments indicated that most regimens were not effective in treating SARS and MERS patients. With sufficient investment in the development of drug discovery pipeline model systems, pan-coronavirus targets based on supportive
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      evidence for effective treatments during the current MERS outbreaks and future outbreaks of emergent CoVs (
      <xref rid="F0003">
       Figure 3
      </xref>
      ).
      <fig fig-type="figure" id="F0003" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1080/17460441.2019.1581171-F0003
       </object-id>
       <label>
        Figure 3.
       </label>
       <caption>
        <p>
         Pan-coronavirus drug discovery.
        </p>
        <p specific-use="attrib">
         Currently, the state of pan-coronavirus drug discovery is not structured to provide adequate pre-clinical therapeutics to combat emerging CoV pathogens. A diverse array of coronaviruses is needed that includes epidemic isolates of SARS-CoV and MERS-CoV, zoonotic viruses isolated from intermediate reservoir hosts, pre-emergent CoVs from bats, and clinical isolates of mildly pathogenic HCoVs.
         <italic>
          In vitro
         </italic>
         testing in compatible cell lines uses high throughput screening to identify novel targets that mitigate replication of coronaviruses. Targets identified by
         <italic>
          in vitro
         </italic>
         methods can be confirmed using human airway epithelial cultures. Based on these results, lead targets will be tested in small animal models and nonhuman primate models of highly pathogenic coronavirus infections that recapitulate signs of human SARS or MERS patients. Our analysis identified several key weaknesses in both
         <italic>
          in vitro
         </italic>
         and
         <italic>
          in vivo
         </italic>
         models of highly pathogenic coronavirus virus infection impeding the identification of pan-coronavirus antiviral drugs.
        </p>
       </caption>
       <graphic xlink:href="IEDC_A_1581171_F0003_OC">
       </graphic>
      </fig>
     </p>
     <p>
      In addition, logistical challenges to drug development have hindered discovery of pan-coronavirus therapeutics. Availability of diverse coronavirus clinical isolates for building
      <italic>
       in vitro
      </italic>
      and
      <italic>
       in vivo
      </italic>
      systems of drug discovery is limited. Most of the emphasis of the discovery of coronavirus antivirals has been targeted toward the genus betacoronavirus, which includes SARS-CoV and MERS-CoV. However, while therapeutics that target known coronavirus threats to public health are of paramount importance, it is critical to note that future outbreaks of emerging highly pathogenic coronaviruses in humans could result from other coronavirus genera with unique tropism to different tissues, different clinical signs and symptoms, and altered transmission profiles that cannot be captured by limiting drug discovery studies to the very few viral strains of SARS-CoV and MERS-CoV currently available to researchers. Currently, Biodefense and Emerging Infections Research Resources Repository (BEI Resources) is a source for a limited number of strains of SARS-CoV, MERS-CoV, and HCoV-NL63. Laboratory strains of HCoV-OC43 and HCoV-229E are available through the American Type Culture Collection, but strains of HCoV-HKU1 are not available through either resource. High throughput surrogate systems at biosafety level 2 are not well-developed and do not yet capture the phylogenetic diversity within the family
      <italic>
       Coronaviridae
      </italic>
      . Biosafety level 3 conditions are required for working with SARS-CoV, MERS-CoV, or pre-emergent zoonotic strains due to the severe disease these viruses cause, which restricts the number of laboratories that can safely perform screening for pan-coronavirus therapeutics.
     </p>
     <p>
      In the last 15 years, two outbreaks of previously unknown highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have demonstrated that CoVs will continue to spill over into human populations, likely facilitated by interaction between infected animals and humans. Reverse genetics approaches have generated pre-emergent BatCoVs from sequence, especially those related to SARS-CoV and MERS-CoV. These particularly novel avenues of research have identified that BatCoV strains with similar pathogenic profiles to SARS-CoV or MERS-CoV continue to circulate within bat populations, indicating a continued vulnerability to highly pathogenic coronavirus emergence. While the next emerging coronavirus may be symptomatically or antigenically similar to SARS-CoV or MERS-CoV, the possibility exists that novel highly pathogenic coronaviruses may be poised for spillover into human populations, with potentially disastrous consequences. Currently, public health measures have been adequate to stymie the spread of SARS-CoV and MERS-CoV primarily due to disease surveillance coupled with viruses with limited person-to-person transmission. However, biological factors that increase cross-species transmission or facilitate person-to-person spread may lead to future coronavirus strains not capable of being contained by timely quarantine of infected individuals. Any increase in highly pathogenic CoV virulence, pathogenesis, or transmission would likely require a targeted medical countermeasure. Without strategic research programs that fill the gaps identified in our literature review, medical countermeasures that target highly pathogenic coronaviruses cannot be brought to market, leaving global public health vulnerable to this emerging threat.
     </p>
    </sec>
    <back>
     <sec id="S0006">
      <title>
       Article Highlights
      </title>
      <p>
       <list list-type="bullet">
        <list-item>
         <p>
          Broad-spectrum drugs targeting coronaviruses must have efficacy against known highly pathogenic human coronaviruses SARS-CoV and MERS-CoV, but also have activity against additional novel coronaviruses that may emerge in the future.
         </p>
        </list-item>
        <list-item>
         <p>
          Conventional approaches identifying adaptive-based therapeutics like vaccines and monoclonal antibodies against coronaviruses target antigens that are not conserved and are unlikely to retain therapeutic efficacy against diverse coronavirus pathogens.
         </p>
        </list-item>
        <list-item>
         <p>
          Reverse genetics approaches that generate novel coronaviruses currently circulating in bats are an innovative but under-utilized resource to provide additional zoonotic and pre-emergent virus diversity to
          <italic>
           in vitro
          </italic>
          and
          <italic>
           in vivo
          </italic>
          drug discovery platforms.
         </p>
        </list-item>
        <list-item>
         <p>
          Many of the treatments used in SARS or MERS patients in outbreak situations were not based on clear
          <italic>
           in vitro
          </italic>
          and
          <italic>
           in vivo
          </italic>
          model evidence of efficacy, and meta-analyses of treatments failed to show effective therapeutic regimens.
         </p>
        </list-item>
        <list-item>
         <p>
          Development of a drug discovery pipeline consisting of
          <italic>
           in vitro
          </italic>
          and
          <italic>
           in vivo
          </italic>
          models of coronavirus infection is needed to identify antivirals targeting essential mechanisms of infection.
         </p>
        </list-item>
       </list>
      </p>
      <p>
       This box summarizes key points contained in the article.
      </p>
     </sec>
     <sec id="S0007">
      <title>
       Declaration of interest
      </title>
      <p>
       The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
      </p>
     </sec>
     <sec id="S0008">
      <title>
       Reviewer Disclosures
      </title>
      <p>
       Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
      </p>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <p>
       Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
      </p>
      <ref id="CIT0001">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Erdman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Goldsmith
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        (
        <issue>
         20
        </issue>
        ):
        <fpage>
         1953
        </fpage>
        –
        <lpage>
         1966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Günther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Preiser
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        (
        <issue>
         20
        </issue>
        ):
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         1976
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        (
        <issue>
         19
        </issue>
        ):
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lew
          </surname>
          <given-names>
           TWK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kwek
          </surname>
          <given-names>
           T-K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tai
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Acute respiratory distress syndrome in critically Ill patients with severe acute respiratory syndrome
        </article-title>
        .
        <source>
         JAMA
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         290
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         374
        </fpage>
        –
        <lpage>
         380
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jama.ama-assn.org/cgi/content/abstract/290/3/374">
         http://jama.ama-assn.org/cgi/content/abstract/290/3/374
        </ext-link>
        <pub-id pub-id-type="pmid">
         12865379
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <label>
        5.
       </label>
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003
        </article-title>
        .
        <date-in-citation>
         [cited 2019
         <month>
          1
         </month>
         <day>
          25
         </day>
         ]
        </date-in-citation>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2004_04_21/en/index.html">
         http://www.who.int/csr/sars/country/table2004_04_21/en/index.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <label>
        6.
       </label>
       <mixed-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         MERS situation update
        </article-title>
        .
        <month>
         12
        </month>
        <year>
         2018
        </year>
        <date-in-citation>
         [cited 2019
         <month>
          1
         </month>
         <day>
          25
         </day>
         ]
        </date-in-citation>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" xlink:href="http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-december-2018.html">
         http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-december-2018.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <label>
        7.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         , et al
        </person-group>
        <chapter-title>
         Chapter eight - hosts and sources of endemic human coronaviruses
        </chapter-title>
        In:
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Kielian
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mettenleiter
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Roossinck
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        , editors.
        <source>
         Advances in virus research
        </source>
        . Vol.
        <volume>
         100
        </volume>
        Cambridge, MA:
        <publisher-name>
         Academic Press
        </publisher-name>
        ;
        <year>
         2018
        </year>
        p.
        <fpage>
         163
        </fpage>
        –
        <lpage>
         188
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Davis
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Foxman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Monto
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding
        </article-title>
        .
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         12
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         582
        </fpage>
        –
        <lpage>
         590
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29660826
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         45
        </fpage>
        –
        <lpage>
         56
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0166354213003161">
         http://www.sciencedirect.com/science/article/pii/S0166354213003161
        </ext-link>
        <pub-id pub-id-type="pmid">
         24184128
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ge
          </surname>
          <given-names>
           X-Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           J-L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           X-L
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. [Letter]
        </article-title>
        .
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         503
        </volume>
        (
        <issue>
         7477
        </issue>
        ):
        <fpage>
         535
        </fpage>
        –
        <lpage>
         538
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ziad
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nischay
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kevin
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        .
        <source>
         Emerg Infect Dis J
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         1819
        </fpage>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://wwwnc.cdc.gov/eid/article/19/11/13-1172">
         http://wwwnc.cdc.gov/eid/article/19/11/13-1172
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Comparative analysis of twelve genomes of three novel Group 2c and Group 2d coronaviruses reveals unique group and subgroup features
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         1574
        </fpage>
        –
        <lpage>
         1585
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/81/4/1574.abstract">
         http://jvi.asm.org/content/81/4/1574.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         17121802
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KSM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        (
        <issue>
         39
        </issue>
        ):
        <fpage>
         14040
        </fpage>
        –
        <lpage>
         14045
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/102/39/14040.abstract">
         http://www.pnas.org/content/102/39/14040.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Anthony
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gilardi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         8
        </volume>
        (
        <issue>
         2
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00373-17
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         ,
         <name name-style="western">
          <surname>
           Debbink
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        .
        <source>
         Nat Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <page-range>
         1508–1513
        </page-range>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         SARS-like WIV1-CoV poised for human emergence
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         3048
        </fpage>
        –
        <lpage>
         3053
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/113/11/3048.abstract">
         http://www.pnas.org/content/113/11/3048.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         26976607
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KSM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Molecular diversity of coronaviruses in bats
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         351
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         180
        </fpage>
        –
        <lpage>
         187
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682206001425">
         http://www.sciencedirect.com/science/article/pii/S0042682206001425
        </ext-link>
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        (
        <issue>
         34
        </issue>
        ):
        <fpage>
         12516
        </fpage>
        –
        <lpage>
         12521
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/111/34/12516.abstract">
         http://www.pnas.org/content/111/34/12516.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         25114257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        .
        <source>
         Cell Host Microbe
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         16
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         328
        </fpage>
        –
        <lpage>
         337
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1931312814003011">
         http://www.sciencedirect.com/science/article/pii/S1931312814003011
        </ext-link>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           He
          </surname>
          <given-names>
           YQ
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China
        </article-title>
        .
        <source>
         Science
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         302
        </volume>
        (
        <issue>
         5643
        </issue>
        ):
        <fpage>
         276
        </fpage>
        –
        <lpage>
         278
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencemag.org/content/302/5643/276.abstract">
         http://www.sciencemag.org/content/302/5643/276.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Alagaili
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mishra
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        (
        <issue>
         2
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00884-14
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           H-D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tu
          </surname>
          <given-names>
           -C-C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           G-W
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         2430
        </fpage>
        –
        <lpage>
         2435
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/102/7/2430.abstract">
         http://www.pnas.org/content/102/7/2430.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         15695582
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rockx
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Donaldson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         82
        </volume>
        (
        <issue>
         17
        </issue>
        ):
        <fpage>
         8721
        </fpage>
        –
        <lpage>
         8732
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/82/17/8721.abstract">
         http://jvi.asm.org/content/82/17/8721.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         18579604
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Thompson
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shay
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Estimates of deaths associated with seasonal influenza - United States, 1976–2007
        </article-title>
        .
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         59
        </volume>
        (
        <issue>
         33
        </issue>
        ):
        <fpage>
         1057
        </fpage>
        –
        <lpage>
         1062
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20798667
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Korea Centers for Disease, C., &amp; Prevention
         </collab>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015
        </article-title>
        .
        <source>
         Osong Public Health Res Perspect
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         269
        </fpage>
        –
        <lpage>
         278
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S221090991530045X">
         http://www.sciencedirect.com/science/article/pii/S221090991530045X
        </ext-link>
        <pub-id pub-id-type="pmid">
         26473095
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Arden
          </surname>
          <given-names>
           KE.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus: diagnostics, epidemiology and transmission
        </article-title>
        .
        <source>
         Virol J
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         222
        </fpage>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687373/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687373/
        </ext-link>
        <pub-id pub-id-type="pmid">
         26695637
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0027">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         559
        </fpage>
        –
        <lpage>
         564
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1473309915700903">
         http://www.sciencedirect.com/science/article/pii/S1473309915700903
        </ext-link>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0028">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ng
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)
        </article-title>
        .
        <source>
         Thorax
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         58
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         686
        </fpage>
        –
        <lpage>
         689
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746764/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746764/
        </ext-link>
        <pub-id pub-id-type="pmid">
         12885985
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0029">
       <label>
        29.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Beall
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         , et al
        </person-group>
        <chapter-title>
         Efficient reverse genetic systems for rapid genetic manipulation of emergent and preemergent infectious coronaviruses
        </chapter-title>
        In:
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Perez
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        , editor.
        <source>
         Reverse genetics of RNA viruses: methods and Protocols
        </source>
        .
        <publisher-loc>
         New York
        </publisher-loc>
        :
        <publisher-name>
         Springer New York
        </publisher-name>
        ;
        <year>
         2017
        </year>
        p.
        <fpage>
         59
        </fpage>
        –
        <lpage>
         81
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0030">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Curtis
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2000
        </year>
        ;
        <volume>
         74
        </volume>
        (
        <issue>
         22
        </issue>
        ):
        <fpage>
         10600
        </fpage>
        –
        <lpage>
         10611
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/74/22/10600.abstract">
         http://jvi.asm.org/content/74/22/10600.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         11044104
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0031">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Denison
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         76
        </volume>
        (
        <issue>
         21
        </issue>
        ):
        <fpage>
         11065
        </fpage>
        –
        <lpage>
         11078
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/76/21/11065.abstract">
         http://jvi.asm.org/content/76/21/11065.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         12368349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0032">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Curtis
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fritz
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         100
        </volume>
        (
        <issue>
         22
        </issue>
        ):
        <fpage>
         12995
        </fpage>
        –
        <lpage>
         13000
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/100/22/12995.abstract">
         http://www.pnas.org/content/100/22/12995.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         14569023
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0033">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Scobey
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         110
        </volume>
        (
        <issue>
         40
        </issue>
        ):
        <fpage>
         16157
        </fpage>
        –
        <lpage>
         16162
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/110/40/16157.abstract">
         http://www.pnas.org/content/110/40/16157.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24043791
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0034">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rockx
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Donaldson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        (
        <issue>
         14
        </issue>
        ):
        <fpage>
         7410
        </fpage>
        –
        <lpage>
         7423
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/81/14/7410.abstract">
         http://jvi.asm.org/content/81/14/7410.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         17507479
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0035">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rockx
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Donaldson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         82
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         2274
        </fpage>
        –
        <lpage>
         2285
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/82/5/2274.abstract">
         http://jvi.asm.org/content/82/5/2274.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         18094188
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0036">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rockx
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Feldmann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Brining
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         6
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         e18558
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21533129
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0037">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Becker
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         105
        </volume>
        (
        <issue>
         50
        </issue>
        ):
        <fpage>
         19944
        </fpage>
        –
        <lpage>
         19949
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/105/50/19944.abstract">
         http://www.pnas.org/content/105/50/19944.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         19036930
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0038">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A mouse model for betacoronavirus Subgroup 2c Using a Bat coronavirus strain HKU5 variant
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        (
        <issue>
         2
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00047-14
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0039">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Millet
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Whittaker
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell proteases: critical determinants of coronavirus tropism and pathogenesis
        </article-title>
        .
        <source>
         Virus Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         202
        </volume>
        :
        <fpage>
         120
        </fpage>
        –
        <lpage>
         134
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168170214004961">
         http://www.sciencedirect.com/science/article/pii/S0168170214004961
        </ext-link>
        <pub-id pub-id-type="pmid">
         25445340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0040">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           JF-W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Choi
          </surname>
          <given-names>
           GK-Y
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         207
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         1743
        </fpage>
        –
        <lpage>
         1752
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/content/207/11/1743.abstract">
         http://jid.oxfordjournals.org/content/207/11/1743.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0041">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Identification of a new human coronavirus
        </article-title>
        .
        <source>
         Nat Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         368
        </fpage>
        –
        <lpage>
         373
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/nm/journal/v10/n4/suppinfo/nm1024_S1.html">
         http://www.nature.com/nm/journal/v10/n4/suppinfo/nm1024_S1.html
        </ext-link>
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0042">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        (
        <issue>
         21
        </issue>
        ):
        <fpage>
         11255
        </fpage>
        –
        <lpage>
         11263
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/84/21/11255.abstract">
         http://jvi.asm.org/content/84/21/11255.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         20719951
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0043">
       <label>
        43.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lambert
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jacomy
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Marceau
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         , et al
        </person-group>
        <chapter-title>
         Titration of human coronaviruses, HCoV-229E and HCoV-OC43, by an indirect immunoperoxidase assay
        </chapter-title>
        In:
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        , editor.
        <source>
         SARS- and other coronaviruses
        </source>
        . Vol.
        <volume>
         454
        </volume>
        Totowa, NJ:
        <publisher-name>
         Humana Press
        </publisher-name>
        ;
        <year>
         2008
        </year>
        p.
        <fpage>
         93
        </fpage>
        –
        <lpage>
         102
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0044">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kaye
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Druce
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tran
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         SARS–associated coronavirus replication in cell lines
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         12
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         128
        </fpage>
        –
        <lpage>
         133
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291385/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291385/
        </ext-link>
        <pub-id pub-id-type="pmid">
         16494729
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0045">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Warren
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jordan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lo
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
        </article-title>
        .
        <source>
         Nature
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         531
        </volume>
        :
        <fpage>
         381
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26934220
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0046">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         60
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         5492
        </fpage>
        –
        <lpage>
         5503
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://aac.asm.org/content/60/9/5492.abstract">
         http://aac.asm.org/content/60/9/5492.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         27381385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0047">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Severson
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shindo
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sosa
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library
        </article-title>
        .
        <source>
         J Biomol Screen
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         12
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         33
        </fpage>
        –
        <lpage>
         40
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17200104
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0048">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ge
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xiong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           F-S
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         80
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         107
        </fpage>
        –
        <lpage>
         113
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0166354208003112">
         http://www.sciencedirect.com/science/article/pii/S0166354208003112
        </ext-link>
        <pub-id pub-id-type="pmid">
         18584889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0049">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ghosh
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Takayama
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rao
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation
        </article-title>
        .
        <source>
         J Med Chem
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         53
        </volume>
        (
        <issue>
         13
        </issue>
        ):
        <fpage>
         4968
        </fpage>
        –
        <lpage>
         4979
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/PMC2918394/">
         https://www.ncbi.nlm.nih.gov/pmc/PMC2918394/
        </ext-link>
        <pub-id pub-id-type="pmid">
         20527968
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0050">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         4885
        </fpage>
        –
        <lpage>
         4893
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://aac.asm.org/content/58/8/4885.abstract">
         http://aac.asm.org/content/58/8/4885.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24841273
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0051">
       <label>
        51.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jochmans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Posthuma
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture
        </article-title>
        .
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        (
        <issue>
         8
        </issue>
        ):p
        <fpage>
         4875
        </fpage>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://aac.asm.org/content/58/8/4875.abstract">
         http://aac.asm.org/content/58/8/4875.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0052">
       <label>
        52.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Elshabrawy
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haddad
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <page-range>
         4353–4365
        </page-range>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/88/8/4353.abstract">
         http://jvi.asm.org/content/88/8/4353.abstract
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0053">
       <label>
        53.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        (
        <issue>
         24
        </issue>
        ):
        <fpage>
         15511
        </fpage>
        –
        <lpage>
         15524
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/79/24/15511.abstract">
         http://jvi.asm.org/content/79/24/15511.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         16306622
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0054">
       <label>
        54.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Banach
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Orenstein
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fox
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Human airway epithelial cell culture to identify new respiratory viruses: coronavirus NL63 as a model
        </article-title>
        .
        <source>
         J Virol Methods
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         156
        </volume>
        (
        <issue>
         1–2
        </issue>
        ):
        <fpage>
         19
        </fpage>
        –
        <lpage>
         26
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0166093408003807">
         http://www.sciencedirect.com/science/article/pii/S0166093408003807
        </ext-link>
        <pub-id pub-id-type="pmid">
         19027037
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0055">
       <label>
        55.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Koekkoek
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         6081
        </fpage>
        –
        <lpage>
         6090
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/87/11/6081.abstract">
         http://jvi.asm.org/content/87/11/6081.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         23427150
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0056">
       <label>
        56.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           RWY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study
        </article-title>
        .
        <source>
         Lancet Respir Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         813
        </fpage>
        –
        <lpage>
         822
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S2213260014701584">
         http://www.sciencedirect.com/science/article/pii/S2213260014701584
        </ext-link>
        <pub-id pub-id-type="pmid">
         25174549
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0057">
       <label>
        57.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Niemeyer
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tuder
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Advanced microengineered lung models for translational drug discovery
        </article-title>
        .
        <source>
         SLAS Discov
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         23
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         777
        </fpage>
        –
        <lpage>
         789
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29447055
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0058">
       <label>
        58.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leist
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Douglas
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice
        </article-title>
        .
        <source>
         Mamm Genome
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         29
        </volume>
        (
        <issue>
         7–8
        </issue>
        ):
        <fpage>
         367
        </fpage>
        –
        <lpage>
         383
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/PMC6132729/">
         https://www.ncbi.nlm.nih.gov/pmc/PMC6132729/
        </ext-link>
        <pub-id pub-id-type="pmid">
         30043100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0059">
       <label>
        59.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sutton
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Subbarao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         479–480
        </volume>
        :
        <fpage>
         247
        </fpage>
        –
        <lpage>
         258
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682215000768">
         http://www.sciencedirect.com/science/article/pii/S0042682215000768
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0060">
       <label>
        60.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Glass
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Subbarao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Murphy
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice
        </article-title>
        .
        <source>
         J Immunol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         173
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         4030
        </fpage>
        –
        <lpage>
         4039
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jimmunol.org/content/173/6/4030.abstract">
         http://jimmunol.org/content/173/6/4030.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         15356152
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0061">
       <label>
        61.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vogel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guarner
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         503
        </fpage>
        –
        <lpage>
         511
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/79/1/503.abstract">
         http://jvi.asm.org/content/79/1/503.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         15596843
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0062">
       <label>
        62.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chepurnov
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dadaeva
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Malkova
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. [Journal article]
        </article-title>
        .
        <source>
         Dokl Biol Sci
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         397
        </volume>
        (
        <issue>
         1–6
        </issue>
        ):
        <fpage>
         310
        </fpage>
        –
        <lpage>
         313
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15508583
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0063">
       <label>
        63.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Martina
          </surname>
          <given-names>
           BEE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kuiken
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Virology: SARS virus infection of cats and ferrets
        </article-title>
        .
        <source>
         Nature
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         425
        </volume>
        (
        <issue>
         6961
        </issue>
        ):
        <fpage>
         915
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         14586458
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0064">
       <label>
        64.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Deming
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paddock
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         3
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         e5
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         17222058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0065">
       <label>
        65.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cai
          </surname>
          <given-names>
           SX
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         395
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         210
        </fpage>
        –
        <lpage>
         222
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682209005832">
         http://www.sciencedirect.com/science/article/pii/S0042682209005832
        </ext-link>
        <pub-id pub-id-type="pmid">
         19853271
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0066">
       <label>
        66.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
        </article-title>
        .
        <source>
         Sci Transl Med
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         9
        </volume>
        (
        <issue>
         396
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1126/scitranslmed.aal3653
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          •• Describes GS-5734 antiviral activity against a range of coronaviruses in vitro and in vivo.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0067">
       <label>
        67.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Intranasal treatment with poly(I·C) protects aged mice from lethal respiratory virus infections
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        (
        <issue>
         21
        </issue>
        ):
        <fpage>
         11416
        </fpage>
        –
        <lpage>
         11424
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/86/21/11416.abstract">
         http://jvi.asm.org/content/86/21/11416.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         22915814
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0068">
       <label>
        68.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bankhead
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jeng
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         4
        </volume>
        (
        <issue>
         4
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00271-13
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0069">
       <label>
        69.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ferris
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Aylor
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross
        </article-title>
        .
        <source>
         PLoS Genet
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         11
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         e1005504
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26452100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0070">
       <label>
        70.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Prescott
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baseler
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         8
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         e69127
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23844250
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0071">
       <label>
        71.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Matthews
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Goicochea
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         95
        </volume>
        (
        <issue>
         Pt 2
        </issue>
        ):
        <fpage>
         408
        </fpage>
        –
        <lpage>
         412
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24197535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0072">
       <label>
        72.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Provacia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         1834
        </fpage>
        –
        <lpage>
         1838
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/88/3/1834.abstract">
         http://jvi.asm.org/content/88/3/1834.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0073">
       <label>
        73.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Den Brand
          </surname>
          <given-names>
           JMA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Provacia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Asymptomatic Middle East Respiratory syndrome coronavirus infection in rabbits
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        (
        <issue>
         11
        </issue>
        ):
        <fpage>
         6131
        </fpage>
        –
        <lpage>
         6135
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/89/11/6131.abstract">
         http://jvi.asm.org/content/89/11/6131.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0074">
       <label>
        74.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Houser
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gretebeck
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)–specific human monoclonal antibody protects rabbits from MERS-CoV infection
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         213
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         1557
        </fpage>
        –
        <lpage>
         1561
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/jid/article/213/10/1557/2459422">
         https://academic.oup.com/jid/article/213/10/1557/2459422
        </ext-link>
        <pub-id pub-id-type="pmid">
         26941283
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0075">
       <label>
        75.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        (
        <issue>
         13
        </issue>
        ):
        <fpage>
         4970
        </fpage>
        –
        <lpage>
         4975
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/111/13/4970.abstract">
         http://www.pnas.org/content/111/13/4970.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          • First mouse model of MERS-CoV, utilizing adenovirus vectors to transduce expression of DPP4.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0076">
       <label>
        76.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Garron
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         3659
        </fpage>
        –
        <lpage>
         3670
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/89/7/3659.abstract">
         http://jvi.asm.org/content/89/7/3659.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         25589660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0077">
       <label>
        77.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         213
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         712
        </fpage>
        –
        <lpage>
         722
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/PMC4747621/">
         https://www.ncbi.nlm.nih.gov/pmc/PMC4747621/
        </ext-link>
        <pub-id pub-id-type="pmid">
         26486634
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0078">
       <label>
        78.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pascal
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mujica
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <page-range>
         8738–8743
        </page-range>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/early/2015/06/24/1510830112.abstract">
         http://www.pnas.org/content/early/2015/06/24/1510830112.abstract
        </ext-link>
       </mixed-citation>
       <note>
        <p>
         <bold>
          •• Demonstrates viral replication in a humanized mouse as a potential path towards a MERS-CoV mouse model.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0079">
       <label>
        79.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
        </article-title>
        .
        <source>
         J Proc National Acad Sci
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         114
        </volume>
        (
        <issue>
         15
        </issue>
        ):
        <fpage>
         E3119
        </fpage>
        –
        <lpage>
         E3128
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/content/pnas/114/15/E3119.full.pdf">
         https://www.pnas.org/content/pnas/114/15/E3119.full.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0080">
       <label>
        80.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Scobey
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. [Article]
        </article-title>
        .
        <source>
         Nat Microbiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         16226
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          • First Mouse Adapted MERS-CoV strain combined with a CRISPR/Cas approach to generating a mouse model.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0081">
       <label>
        81.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kuiken
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fouchier
          </surname>
          <given-names>
           RAM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schutten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        (
        <issue>
         9380
        </issue>
        ):
        <fpage>
         263
        </fpage>
        –
        <lpage>
         270
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12892955
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0082">
       <label>
        82.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Rowe
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hogan
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Macaque model for severe acute respiratory syndrome
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         78
        </volume>
        (
        <issue>
         20
        </issue>
        ):
        <fpage>
         11401
        </fpage>
        –
        <lpage>
         11404
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/78/20/11401.abstract">
         http://jvi.asm.org/content/78/20/11401.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         15452262
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0083">
       <label>
        83.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           McAuliffe
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vogel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         330
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         8
        </fpage>
        –
        <lpage>
         15
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682204006087">
         http://www.sciencedirect.com/science/article/pii/S0042682204006087
        </ext-link>
        <pub-id pub-id-type="pmid">
         15527829
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0084">
       <label>
        84.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Greenough
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Carville
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Coderre
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) Infected with the severe acute respiratory syndrome-associated coronavirus
        </article-title>
        .
        <source>
         Am J Pathol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         167
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         455
        </fpage>
        –
        <lpage>
         463
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16049331
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0085">
       <label>
        85.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lawler
          </surname>
          <given-names>
           JV
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Endy
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hensley
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Cynomolgus macaque as an animal model for severe acute respiratory syndrome
        </article-title>
        .
        <source>
         PLoS Med
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        (
        <issue>
         5
        </issue>
        ):
        <fpage>
         e149
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16605302
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0086">
       <label>
        86.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Den Brand
          </surname>
          <given-names>
           JMA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Lang
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different Nonhuman primate species
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         85
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         4234
        </fpage>
        –
        <lpage>
         4245
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/85/9/4234.abstract">
         http://jvi.asm.org/content/85/9/4234.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         21325418
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0087">
       <label>
        87.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Lang
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Den Brand
          </surname>
          <given-names>
           JMA
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Exacerbated innate host response to SARS-CoV in aged non-human primates
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         6
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         e1000756
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         20140198
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0088">
       <label>
        88.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rasmussen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         110
        </volume>
        (
        <issue>
         41
        </issue>
        ):
        <fpage>
         16598
        </fpage>
        –
        <lpage>
         16603
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/110/41/16598.abstract">
         http://www.pnas.org/content/110/41/16598.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24062443
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0089">
       <label>
        89.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bagci
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Keith
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         490
        </volume>
        :
        <fpage>
         49
        </fpage>
        –
        <lpage>
         58
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682216000076">
         http://www.sciencedirect.com/science/article/pii/S0042682216000076
        </ext-link>
        <pub-id pub-id-type="pmid">
         26828465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0090">
       <label>
        90.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Feldmann
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        (
        <issue>
         8
        </issue>
        ):
        <fpage>
         e1004250
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          •• First Description of Severe Coronavirus Disease in a Primate Model.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0091">
       <label>
        91.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Via
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kumar
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
        </article-title>
        .
        <source>
         Virology
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         485
        </volume>
        :
        <fpage>
         422
        </fpage>
        –
        <lpage>
         430
        </lpage>
        .
        <comment>
         Available from
        </comment>
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0042682215003323">
         http://www.sciencedirect.com/science/article/pii/S0042682215003323
        </ext-link>
        <pub-id pub-id-type="pmid">
         26342468
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          • Demonstrates the variability in primate models, indicating the need for additional development.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0092">
       <label>
        92.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           JF-W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeung
          </surname>
          <given-names>
           M-L
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a Nonhuman primate model of common marmoset
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        (
        <issue>
         12
        </issue>
        ):
        <fpage>
         1904
        </fpage>
        –
        <lpage>
         1913
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/content/212/12/1904.abstract">
         http://jid.oxfordjournals.org/content/212/12/1904.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0093">
       <label>
        93.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Neuman
          </surname>
          <given-names>
           BW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chamberlain
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bowden
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Atlas of coronavirus replicase structure
        </article-title>
        .
        <source>
         Virus Res
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         194
        </volume>
        :
        <fpage>
         49
        </fpage>
        –
        <lpage>
         66
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168170213004334">
         http://www.sciencedirect.com/science/article/pii/S0168170213004334
        </ext-link>
        <pub-id pub-id-type="pmid">
         24355834
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0094">
       <label>
        94.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lo
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jordan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Arvey
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and paramyxoviruses. [Article]
        </article-title>
        .
        <source>
         Sci Rep
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         43395
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         28262699
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0095">
       <label>
        95.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Dörnemann
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Burzio
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ronsse
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         First newborn baby to receive experimental therapies survives ebola virus disease
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         215
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         171
        </fpage>
        –
        <lpage>
         174
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583641/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583641/
        </ext-link>
        <pub-id pub-id-type="pmid">
         28073857
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0096">
       <label>
        96.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agostini
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Andres
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         9
        </volume>
        (
        <issue>
         2
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00221-18
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0097">
       <label>
        97.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           C-Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jan
          </surname>
          <given-names>
           J-T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ma
          </surname>
          <given-names>
           S-H
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Small molecules targeting severe acute respiratory syndrome human coronavirus
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         101
        </volume>
        (
        <issue>
         27
        </issue>
        ):
        <fpage>
         10012
        </fpage>
        –
        <lpage>
         10017
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/pnas/101/27/10012.full.pdf">
         http://www.pnas.org/content/pnas/101/27/10012.full.pdf
        </ext-link>
        <pub-id pub-id-type="pmid">
         15226499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0098">
       <label>
        98.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hung
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
        </article-title>
        .
        <source>
         Thorax
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         59
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         252
        </fpage>
        –
        <lpage>
         256
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/
        </ext-link>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0099">
       <label>
        99.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           UJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Won
          </surname>
          <given-names>
           E-J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kee
          </surname>
          <given-names>
           S-J
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome
        </article-title>
        .
        <source>
         Antivir Ther
        </source>
        .
        <year>
         2016
        </year>
        ;(
        <issue>
         21
        </issue>
        ):
        <fpage>
         455
        </fpage>
        –
        <lpage>
         459
        </lpage>
        . DOI:
        <pub-id pub-id-type="doi">
         10.3851/IMP3002
        </pub-id>
        <pub-id pub-id-type="pmid">
         26492219
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0100">
       <label>
        100.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bin
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heo
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           M-S
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea
        </article-title>
        .
        <source>
         Clinl Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         62
        </volume>
        (
        <issue>
         6
        </issue>
        ):
        <fpage>
         755
        </fpage>
        –
        <lpage>
         760
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/content/early/2016/01/06/cid.civ1020.abstract">
         http://cid.oxfordjournals.org/content/early/2016/01/06/cid.civ1020.abstract
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0101">
       <label>
        101.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Arabi
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alothman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Balkhy
          </surname>
          <given-names>
           HH
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
        </article-title>
        .
        <source>
         Trials
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         19
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         81
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29382391
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0102">
       <label>
        102.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         95
        </volume>
        (
        <issue>
         Pt 3
        </issue>
        ):
        <fpage>
         571
        </fpage>
        –
        <lpage>
         577
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://vir.sgmjournals.org/content/95/Pt_3/571.abstract">
         http://vir.sgmjournals.org/content/95/Pt_3/571.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0103">
       <label>
        103.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ströher
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           DiCaro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         189
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         1164
        </fpage>
        –
        <lpage>
         1167
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jid.oxfordjournals.org/content/189/7/1164.abstract">
         http://jid.oxfordjournals.org/content/189/7/1164.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         15031783
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0104">
       <label>
        104.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Martellaro
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. [Article]
        </article-title>
        .
        <source>
         Sci Rep
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         1686
        </fpage>
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/srep01686">
         https://www.nature.com/articles/srep01686
        </ext-link>
        <pub-id pub-id-type="pmid">
         23594967
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0105">
       <label>
        105.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ferron
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Subissi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Silveira De Morais
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         115
        </volume>
        (
        <issue>
         2
        </issue>
        ):
        <fpage>
         E162
        </fpage>
        –
        <lpage>
         E171
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/pnas/115/2/E162.full.pdf">
         http://www.pnas.org/content/pnas/115/2/E162.full.pdf
        </ext-link>
        <pub-id pub-id-type="pmid">
         29279395
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0106">
       <label>
        106.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         71
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         53
        </fpage>
        –
        <lpage>
         63
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0166354206000660">
         http://www.sciencedirect.com/science/article/pii/S0166354206000660
        </ext-link>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0107">
       <label>
        107.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rasmussen
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        .
        <source>
         Nat Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         19
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         1313
        </fpage>
        –
        <lpage>
         1317
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093902/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093902/
        </ext-link>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0108">
       <label>
        108.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Stockman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bellamy
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Garner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        .
        <source>
         PLoS Med
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        (
        <issue>
         9
        </issue>
        ):
        <fpage>
         e343
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0109">
       <label>
        109.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Morra
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Van Thanh
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kamel
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis
        </article-title>
        .
        <source>
         Rev Med Virol
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         28
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         e1977
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29664167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0110">
       <label>
        110.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Álvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        (
        <issue>
         4
        </issue>
        ):
        <fpage>
         1701
        </fpage>
        –
        <lpage>
         1713
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/81/4/1701.abstract">
         http://jvi.asm.org/content/81/4/1701.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0111">
       <label>
        111.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mitchell
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cockrell
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         MERS-CoV accessory ORFs play key role for infection and pathogenesis
        </article-title>
        .
        <source>
         mBio
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         8
        </volume>
        (
        <issue>
         4
        </issue>
        ). DOI:
        <pub-id pub-id-type="doi">
         10.1128/mBio.00665-17
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0112">
       <label>
        112.
       </label>
       <mixed-citation publication-type="book">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         , et al
        </person-group>
        <chapter-title>
         SARS coronavirus accessory ORFs encode luxury functions
        </chapter-title>
        In:
        <person-group person-group-type="editor">
         <name name-style="western">
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Holmes
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        , editors.
        <source>
         The Nidoviruses
        </source>
        . Vol.
        <volume>
         581
        </volume>
        New York, NY:
        <publisher-name>
         Springer US
        </publisher-name>
        ;
        <year>
         2006
        </year>
        p.
        <fpage>
         149
        </fpage>
        –
        <lpage>
         152
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0113">
       <label>
        113.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chakraborti
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
        </article-title>
        .
        <source>
         Proc Nat Acad Sci
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         104
        </volume>
        (
        <issue>
         29
        </issue>
        ):
        <fpage>
         12123
        </fpage>
        –
        <lpage>
         12128
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/104/29/12123.abstract">
         http://www.pnas.org/content/104/29/12123.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         17620608
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0114">
       <label>
        114.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gopal
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Evaluation of serologic and antigenic relationships between Middle Eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        (
        <issue>
         7
        </issue>
        ):
        <fpage>
         995
        </fpage>
        –
        <lpage>
         1006
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952667/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952667/
        </ext-link>
        <pub-id pub-id-type="pmid">
         24253287
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0115">
       <label>
        115.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Deming
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rockx
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        (
        <issue>
         23
        </issue>
        ):
        <fpage>
         13769
        </fpage>
        –
        <lpage>
         13780
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/88/23/13769.abstract">
         http://jvi.asm.org/content/88/23/13769.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         25231316
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0116">
       <label>
        116.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dar
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kock
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Taking forward a ‘One Health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential
        </article-title>
        .
        <source>
         Inter J Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         47
        </volume>
        :
        <fpage>
         5
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1201971216310967">
         http://www.sciencedirect.com/science/article/pii/S1201971216310967
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="CIT0117">
       <label>
        117.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Den Brand
          </surname>
          <given-names>
           JMA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        .
        <source>
         Science
        </source>
        .
        <year>
         2015
        </year>
        DOI:
        <pub-id pub-id-type="doi">
         10.1126/science.aad1283
        </pub-id>
       </mixed-citation>
       <note>
        <p>
         <bold>
          •• Demonstrates MERS-CoV infection of camels and potential vaccine therapeutic.
         </bold>
        </p>
       </note>
      </ref>
      <ref id="CIT0118">
       <label>
        118.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Bolles
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Deming
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Long
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         85
        </volume>
        (
        <issue>
         23
        </issue>
        ):
        <fpage>
         12201
        </fpage>
        –
        <lpage>
         12215
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/85/23/12201.abstract">
         http://jvi.asm.org/content/85/23/12201.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         21937658
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0119">
       <label>
        119.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Whitmore
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Long
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         85
        </volume>
        (
        <issue>
         1
        </issue>
        ):
        <fpage>
         217
        </fpage>
        –
        <lpage>
         230
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://jvi.asm.org/content/85/1/217.abstract">
         http://jvi.asm.org/content/85/1/217.abstract
        </ext-link>
        <pub-id pub-id-type="pmid">
         20980507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0120">
       <label>
        120.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Simmons
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gosalia
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rennekamp
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
        </article-title>
        .
        <source>
         Proc Natl Acad Sci USA
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        (
        <issue>
         33
        </issue>
        ):
        <fpage>
         11876
        </fpage>
        –
        <lpage>
         11881
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/content/pnas/102/33/11876.full.pdf">
         http://www.pnas.org/content/pnas/102/33/11876.full.pdf
        </ext-link>
        <pub-id pub-id-type="pmid">
         16081529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0121">
       <label>
        121.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vedantham
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry
        </article-title>
        .
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         116
        </volume>
        :
        <fpage>
         76
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/
        </ext-link>
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0122">
       <label>
        122.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         291
        </volume>
        (
        <issue>
         17
        </issue>
        ):
        <fpage>
         9218
        </fpage>
        –
        <lpage>
         9232
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861487/">
         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861487/
        </ext-link>
        <pub-id pub-id-type="pmid">
         26953343
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0123">
       <label>
        123.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schöpf
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kögl
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         7
        </volume>
        (
        <issue>
         10
        </issue>
        ):
        <fpage>
         e1002331
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         22046132
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0124">
       <label>
        124.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model
        </article-title>
        .
        <source>
         Virus Res
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         228
        </volume>
        :
        <fpage>
         7
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168170216305524">
         http://www.sciencedirect.com/science/article/pii/S0168170216305524
        </ext-link>
        <pub-id pub-id-type="pmid">
         27840112
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0125">
       <label>
        125.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schoggins
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wilson
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Panis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         A diverse range of gene products are effectors of the type I interferon antiviral response
        </article-title>
        .
        <source>
         Nature
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         472
        </volume>
        (
        <issue>
         7344
        </issue>
        ):
        <fpage>
         481
        </fpage>
        –
        <lpage>
         485
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21478870
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0126">
       <label>
        126.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bauer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        .
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        (
        <issue>
         9380
        </issue>
        ):
        <fpage>
         293
        </fpage>
        –
        <lpage>
         294
        </lpage>
        .
        <comment>
         Available from
        </comment>
        :
        <ext-link ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0140673603139736">
         http://www.sciencedirect.com/science/article/pii/S0140673603139736
        </ext-link>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0127">
       <label>
        127.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kuiken
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Martina
          </surname>
          <given-names>
           BE
          </given-names>
         </name>
         , et al
        </person-group>
        <article-title>
         Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
        </article-title>
        .
        <source>
         Nat Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        (
        <issue>
         3
        </issue>
        ):
        <fpage>
         290
        </fpage>
        –
        <lpage>
         293
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14981511
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ecancermedicalscience
      </journal-id>
      <journal-title-group>
       <journal-title>
        ecancermedicalscience
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1754-6605
      </issn>
      <publisher>
       <publisher-name>
        Cancer Intelligence
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32256705
      </article-id>
      <article-id pub-id-type="pmc">
       7105343
      </article-id>
      <article-id pub-id-type="doi">
       10.3332/ecancer.2020.1022
      </article-id>
      <article-id pub-id-type="publisher-id">
       can-14-1022
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Russell
         </surname>
         <given-names>
          Beth
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Moss
         </surname>
         <given-names>
          Charlotte
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          George
         </surname>
         <given-names>
          Gincy
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Santaolalla
         </surname>
         <given-names>
          Aida
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cope
         </surname>
         <given-names>
          Andrew
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Papa
         </surname>
         <given-names>
          Sophie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Van Hemelrijck
         </surname>
         <given-names>
          Mieke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        Translational Oncology and Urology Research, King’s College London, London, UK
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Guy’s and St. Thomas NHS Foundation Trust, London, UK
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        Centre for Rheumatic Diseases, King’s College London, London, UK
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK
       </aff>
       <aff id="aff5">
        <label>
         *
        </label>
        All authors contributed equally.
       </aff>
       <aff id="aff6">
        <label>
         **
        </label>
        Both senior authors contributed equally.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1-can-14-1022">
        <bold>
         Correspondence to:
        </bold>
        Mieke Van Hemelrijck
        <email>
         mieke.vanhemelrijck@kcl.ac.uk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <elocation-id>
       1022
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © the authors; licensee
        <italic>
         e
        </italic>
        cancermedicalscience.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
        <license-p>
         <!--CREATIVE COMMONS-->
         This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">
          http://creativecommons.org/licenses/by/3.0
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <sec>
        <title>
         Background
        </title>
        <p>
         Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.
        </p>
       </sec>
       <sec sec-type="methods">
        <title>
         Methods
        </title>
        <p>
         Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
        </p>
       </sec>
      </abstract>
      <kwd-group>
       <kwd>
        immune modulation
       </kwd>
       <kwd>
        immune suppression
       </kwd>
       <kwd>
        cancer
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        adverse events
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <title>
      Introduction
     </title>
     <p>
      Since the outbreak of severe acute respiratory syndrome (SARS)-CoV-2 or COVID-19 coronavirus started in China in December 2019, there is increasing evidence that those with existing comorbidities, older age or a compromised immune system are at higher risk of developing severe and even fatal respiratory diseases [
      <xref ref-type="bibr" rid="ref1">
       1
      </xref>
      ]. Cancer and transplant patients are also considered to be in this risk group [
      <xref ref-type="bibr" rid="ref2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="ref3">
       3
      </xref>
      ], especially as they may be treated with immune-suppressive or immune-stimulating drugs.
     </p>
     <p>
      The current review focuses on the effects of immune-suppressive or immune-stimulating drugs on the host immunity against COVID-19. Here, we report a short introduction to each drug, followed by a summary of the results from the identified studies for each relative drug.
     </p>
     <p>
      We hypothesise that the drugs selected will likely be categorised into one of two groups: 1) those that may be harmful for patients and put them at risk of increased morbidity/mortality associated with COVID-19 infection and 2) those that may be used to treat the immunopathology associated with severe persistent viral infection. The clinical impact of this review is, thus, twofold. It aims to identify which drugs clinicians should be thinking about taking patients off to protect them from increased harm from COVID-19 and also which drugs could be potentially beneficial in the fight against the disease.
     </p>
     <p>
      This review covers the information available today. As the COVID-19 pandemic progresses, there is an opportunity and responsibility to collect prospective data using established randomised controlled trial involving drugs of interest and cohort-based translational studies.
      <list list-type="order">
       <list-item>
        <p>
         All cytotoxic chemotherapy
        </p>
       </list-item>
       <list-item>
        <p>
         Low-dose steroids and non-steroidal anti-inflammatory drugs (NSAIDs)
        </p>
       </list-item>
       <list-item>
        <p>
         Any tumour necrosis factor (TNF) blocker
        </p>
       </list-item>
       <list-item>
        <p>
         interlukin-6 (IL-6) blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Janus kinase (JAK) inhibitors
        </p>
       </list-item>
       <list-item>
        <p>
         IL-1 blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Mycophenolate
        </p>
       </list-item>
       <list-item>
        <p>
         Tacrolimus
        </p>
       </list-item>
       <list-item>
        <p>
         Anti-CD20
        </p>
       </list-item>
       <list-item>
        <p>
         CTLA4-Ig
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <p>
      A search was conducted using Ovid MEDLINE and a total of 89 studies were included in this review for 10 different types of immune-suppressing or immune-stimulating drug groups.
      <xref ref-type="table" rid="table1">
       Table 1
      </xref>
      shows the search terms and the number of studies included in the review.
     </p>
    </sec>
    <sec>
     <title>
      Results
     </title>
     <sec>
      <title>
       All cytotoxic chemotherapy
      </title>
      <p>
       Cytotoxic chemotherapy inhibits cell division through multiple mechanisms. It may have therapeutic activity as compounds against corona viral strains. Moreover, cancer patients who have undergone chemotherapy may be at increased risk of developing symptoms of SARS.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        The search yielded 24 results, of which 18 were included (
        <xref ref-type="table" rid="Stable1">
         Supplementary Table 1
        </xref>
        ). Below are key case-reports of interest to highlight:
        <list list-type="bullet">
         <list-item>
          <p>
           Coronavirus was one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy, second to human rhinovirus [
           <xref ref-type="bibr" rid="ref4">
            4
           </xref>
           ]. Viral co-detection was frequent in patients with cancer and acute respiratory infections.
          </p>
         </list-item>
         <list-item>
          <p>
           A brain biopsy was HCoV-OC43-positive by metagenomic next-generation sequencing in the case of a 1-year-old child with pre-B acute lymphoblastic leukaemia [
           <xref ref-type="bibr" rid="ref5">
            5
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           A case of a young woman with stage IIIA breast cancer from 1999 reported that diagnosis of coronavirus following treatment for cancer using a high-dose chemotherapy regimen and autologous bone marrow and stem cell transplantation. The electron microscopy revealed coronavirus pneumonia [
           <xref ref-type="bibr" rid="ref6">
            6
           </xref>
           ]. Coronavirus should be potentially considered in the differential diagnoses of respiratory failure in patients who have undergone high-dose chemotherapy and autologous bone marrow transplantation.
          </p>
         </list-item>
        </list>
       </p>
       <p>
        In addition, some further observations have been made in relation to specific treatments:
        <list list-type="bullet">
         <list-item>
          <p>
           Although HIV protease inhibitors such as lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV, the different mechanistic classes that HIV and coronavirus fall under meant that there was low affinity for coronavirus strains compared to HIV [
           <xref ref-type="bibr" rid="ref7">
            7
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The following compounds have been shown to be active
           <italic>
            in vitro
           </italic>
           against the SARS-CoV virus: TNFα-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanized monoclonal antibody (a neutralising antibody specific for SARS-CoV), recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic); therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system [
           <xref ref-type="bibr" rid="ref8">
            8
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus [
           <xref ref-type="bibr" rid="ref9">
            9
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs [
           <xref ref-type="bibr" rid="ref10">
            10
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The genome of SARS-CoV encodes five major proteins: the spike protein (S), the envelope protein (E), the membrane glycoprotein (M), and the nucleocapsid protein (N). M and E may help host cells to induce the production of protective IFN-α to fight against the virus. Bananin 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol acts as zinc (Zn
           <sup>
            2+
           </sup>
           ) chelator and is therefore of interest to target and inhibit immunodeficiency virus type 1 (HIV-1) zinc finger HIV-1 RNA-binding nucleocapsid protein p7 (NCp7). Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation. Targets of BNP and B6RA has shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates [
           <xref ref-type="bibr" rid="ref11">
            11
           </xref>
           ].
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Coronavirus strains were one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy. Patients with pre-B acute lymphoblastic leukaemia and breast cancer who have undergone chemotherapy have reported cases of coronavirus infection. Cytotoxic therapies used in cancer chemotherapy such as 6MP and 6TG have shown to be specific inhibitors for SARS coronavirus in
        <italic>
         in vitro
        </italic>
        studies. However, further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies are required to confirm this, especially in COVID-19. Currently, there is no scientific evidence of the interaction between methotrexate and COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Low-dose steroids and NSAIDs
      </title>
      <p>
       Since the outbreak of the novel COVID-19 infection, various contradictory information has been circulated regarding the potentially negative effect of treating patients with NSAIDs, non-NSAIDs and corticosteroids. NSAIDs work through inhibition of the cyclooxygenase enzymes (COX-1/COX-2), which are involved in the synthesis of key biological mediators. These mediators in turn control inflammation. Corticosteroids are involved in a number of key physiological processes including the immune response and inflammation and low-dose steroids are often prescribed to cancer patients with suppressed immune systems to prevent the development of related auto-immune diseases.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 58 studies were identified from the search terms, of which 13 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable2">
         Supplementary Table 2
        </xref>
        ). Our search did not identify any strong evidence for or against the use of ibuprofen for treatment of COVID-19 specifically. One study did however link SARS-CoV to the downregulation of angiotensin converting enzyme-2 (ACE2) which is upregulated by ibuprofen [
        <xref ref-type="bibr" rid="ref12">
         12
        </xref>
        ]. The authors of this study were investigating the link between the severity of COVID-19 symptoms in patients with asthma and hypertension.
       </p>
       <p>
        The only other study to investigate a non-steroidal anti-inflammatory drug was one which looked at indomethacin [
        <xref ref-type="bibr" rid="ref13">
         13
        </xref>
        ]. This study suggested that indomethacin exhibited potent antiviral activity against canine coronavirus (dramatically inhibiting virus replication and protecting the host cell from virus-induced damage). This activity was also observed against human SARS-CoV at a concentration dose of 1 mg/kg.
       </p>
       <p>
        In general, there appeared to be a few positive results for the use of corticosteroids in viral infections such as SARS-CoV [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        -
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Corticosteroids were widely used during the SARS-CoV outbreak due to their known ability to modulate a variety of involved cytokines (including IL-1, IL-6, IL-8, IL-12 and TNFα) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="ref16">
         16
        </xref>
        ]. Various studies in humans noted that corticosteroids appeared effective in reducing immunopathological damage but concerns centred around the promotion of viral rebound and association with adverse events (including acute respiratory distress syndrome) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ]. One laboratory study which treated porcine respiratory coronavirus infected pigs with dexamethasone suggested that one or two doses of the corticosteroid in the acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged administration may play a role in enhancing viral replication [
        <xref ref-type="bibr" rid="ref18">
         18
        </xref>
        ]. A separate Chinese study, which separated SARS-CoV patients into 4 treatment groups, identified early high-dose steroids in combination with a quinolone as producing the best patient outcomes [
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Nevertheless, one review stated that the WHO does not currently recommend corticosteroids in other viral diseases such as Dengue as the ‘glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition’ [
        <xref ref-type="bibr" rid="ref20">
         20
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        The current literature does not give conclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients, though there appears to be some evidence that corticosteroids may be beneficial in the treatment of SARS-CoV. However, it is important to note this is not specific to COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       TNFa blocker
      </title>
      <p>
       TNF family of receptors and cytokines is very large and are often the targets for drugs. One example are TNFa inhibitors, which act by supressing the physiologic response to TNFa. TNFa is a pro-inflammatory cytokine involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma. Inhibitors of TNFa may be used in their treatment.
      </p>
      <p>
       Inhibition of TNFa can be achieved with a monoclonal antibody, such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), or with the receptor fusion protein etanercept (Enbrel).
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of three studies were identified, of which two were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable3">
         Supplementary Table 3
        </xref>
        ). The first study was a research letter that suggested that TNFa has been implicated in the severe immune-based pulmonary injury caused by SARS coronavirus, suggesting that TNFa inhibitors could be a potential treatment for the acute respiratory disease syndrome caused by coronavirus [
        <xref ref-type="bibr" rid="ref21">
         21
        </xref>
        ]
       </p>
       <p>
        The second study utilised 22 piglets to assess the efficacy of an anti-TNFa)therapy for endotoxin respiratory diseases and observed that TNFa blockade was not associated with decrease in disease severity [
        <xref ref-type="bibr" rid="ref22">
         22
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Currently, there is no evidence indicating that TNFa blockade is harmful to patients in the context of COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-6 blockade
      </title>
      <p>
       IL-6, promptly and transiently produced in response to infections and tissue injuries, contributes to host defence through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity [
       <xref ref-type="bibr" rid="ref23">
        23
       </xref>
       ]. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Other approved anti IL-6 drugs are siltuximab (Sylvant) and sarilumab. Several agents are in clinical trials:olokizumab (CDP6038), elsilimomab, BMS945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ALX-0061, clazakizumab, olokizumab, sarilumab, sirukumab, ARGX-109, FE301 and FM101
       <sup>
        .
       </sup>
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 108 studies were identified from the second search strategy, 23 were suitable for inclusion (
        <xref ref-type="table" rid="Stable4">
         Supplementary Table 4
        </xref>
        ). The first search strategy found no hits.
       </p>
      </sec>
      <sec>
       <title>
        IL6 an actor in the pathogenetic mechanisms of the coronavirus infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          COVID-19 induces a pro-inflammatory generation and secretion of cytokines including IL-1b and IL-6 via the toll like receptors (TLR) that causes the production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Anti-inflammatory cytokines, such as IL1-Ra, IL-37 or IL-38 could potentially provide relief in both systemic inflammation and fever occurring after infection [
          <xref ref-type="bibr" rid="ref24">
           24
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Cytokine profiles in patients diagnosed with SARS showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine interferon-gamma (IFN-γ), inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset. Children however presented a much milder cytokine and chemokine storm [
          <xref ref-type="bibr" rid="ref16">
           16
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The high levels of IL-6 in the acute stage associated with lung lesions found in SARS patients are activated by the viral nucleocapsid SARS-CoV N protein [
          <xref ref-type="bibr" rid="ref25">
           25
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Over induction of inflammatory cytokine and dysregulation of cytokine signalling has been observed in patients with SARS in comparison with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2). SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2 [
          <xref ref-type="bibr" rid="ref26">
           26
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The N-protein of SARS-CoV induces pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV [
          <xref ref-type="bibr" rid="ref15">
           15
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV does not productively infect human macrophages (Mphi) or dentritic cells (DCs), however it modulates a massive release of IL-6 and IL-12 and compromises the endocytic capacity (e.g., antigen capture capture) of Mphi was significantly compromised [
          <xref ref-type="bibr" rid="ref27">
           27
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed. The elevation of Th1 cytokine IFN-γ, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyper-innate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils [
          <xref ref-type="bibr" rid="ref17">
           17
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        IL-6 as a potential marker of disease severity in coronavirus infected patients
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          IL-6 blood measurements seem useful to diagnose severe COVID-19 cases. The findings suggest that IL-6 and D-Dimer level can be used to estimate the severity of COVID-19. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia [
          <xref ref-type="bibr" rid="ref28">
           28
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The increased expression of IL-2R and IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients [
          <xref ref-type="bibr" rid="ref29">
           29
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The serum levels of IL-6 and CXCL-10 were significantly elevated in MERS-CoV patients who developed severe diseases [
          <xref ref-type="bibr" rid="ref30">
           30
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A new lethal animal model was characterised for SARS-CoV. Strain v2163 had nine mutations that increased levels of IL-1alpha and IL-6 in mice. The high IL-6 expression was correlated with mortality [
          <xref ref-type="bibr" rid="ref31">
           31
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS vaccination was tested in a murine SARS model. A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity [
          <xref ref-type="bibr" rid="ref32">
           32
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          Interleukin-6 (IL-6) and IL-8 are key SARS-CoV-induced epithelial cytokines capable of inhibiting the T-cell-priming ability of dendritic cells, a cellular element of the host innate defenses against respiratory infections, leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients [
          <xref ref-type="bibr" rid="ref33">
           33
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          In patients with a diagnosis of SARS-associated coronavirus infection, there were no significant differences in peak levels of IL-6, IL-8 and TNF
          <bold>
           α
          </bold>
          between patients with and without acute respiratory distress syndrome. However , CRP and TNFα were associated with worse outcomes and might be used as prognostic markers of SARS [
          <xref ref-type="bibr" rid="ref34">
           34
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG were highly elevated in the acute phase sera of Taiwan SARS patients, being IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group. It suggests that an interferon-gamma-related cytokine storm was induced post SARS coronavirus infection [
          <xref ref-type="bibr" rid="ref35">
           35
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Eight patients with SARS [
          <xref ref-type="bibr" rid="ref36">
           36
          </xref>
          ] were treated with ribavirin, which was not effective in reducing the SARS coronavirus load in three of eight. Elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in eight and six cases [
          <xref ref-type="bibr" rid="ref37">
           37
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A cytokine profiling was performed for 110 serum from healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence. IL6 concentrations were significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects which suggested that IL6 is associated with SARS severity [
          <xref ref-type="bibr" rid="ref38">
           38
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations’ key proinflammatory cytokines, including IL-6, were not substantially increased in any of the patients throughout the course of illness. From this, the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients [
          <xref ref-type="bibr" rid="ref39">
           39
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential targets for therapeutic intervention related to IL6 regulation during infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          ADAM-17 regulates IL-6 class switching as a mediator between pro- and anti-inflammatory responses to viral antigenic stimuli in Ebola, SARS-CoV and dengue infections in humans. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery for infections, such as SARS-CoV [
          <xref ref-type="bibr" rid="ref20">
           20
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV ssRNA is a new therapeutic target given its capacity to cause acute lung injury in mice with a high mortality rate
          <italic>
           in vivo
          </italic>
          experiment suggesting that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity [
          <xref ref-type="bibr" rid="ref40">
           40
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          DUSP1 and p38 MAPK are potential therapeutic targets for coronavirus infectious bronchitis virus, given their capability to reduce the production of an excessive amount of IL-6 and IL-8 in the infected cells [
          <xref ref-type="bibr" rid="ref41">
           41
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential therapeutic agents that inhibit the infection-induced production of IL6
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          Pretreatment of primary cultures of human nasal and tracheal epithelial cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E and the infection-induced production of cytokines, including IL-6, IL-8 and IFN-beta. Treatment of the cells with the CD13 inhibitor 2’2’-dipyridyl decreased viral titers. Pretreatment of the cells with a combination of three drugs (glycopyrronium, formoterol and budesonide) exerted additive inhibitory effects on viral titers and cytokine production [
          <xref ref-type="bibr" rid="ref42">
           42
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        It has been suggested that the pathogenesis of SARS-CoV is mediated by disproportional immune responses and the ability of the virus to circumvent innate immunity. The COVID-19 infection has also been observed to induce pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, which dysregulates the local inflammatory responses that have been suggested as partially responsible for the devastating acute respiratory distress syndrome.
       </p>
       <p>
        Moreover, it has been observed that COVID-19 induces high levels of IL-6 for at least 2 weeks after disease onset. Children presented lower levels of cytokine production. IL-6 has been suggested as a potential prognostic marker of COVID-19 disease severity. Different molecules related with the IL6 pathway have been suggested as potential therapeutic targets such as ADAM-17, SARS-CoV ssRNA, DUSP1 and p38 MAPK.
       </p>
       <p>
        Currently, there is no scientific evidence of the beneficial impact of IL-6 inhibitors in the modulation of the COVID-19 infection. Further understanding of the role of IL-6 reduction will be forthcoming as the pandemic progresses and further clinical data becomes available.
        <italic>
         In vitro
        </italic>
        treatment with glycopyrronium, formoterol and budesonide exerted additive inhibitory effects on viral titers and cytokine production human nasal and tracheal epithelial cells.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       JAK inhibitors
      </title>
      <p>
       JAK inhibitors work by inhibiting the activity of one or more of the JAK family of enzymes, including, JAK1, JAK2, JAK3 and TYK3. JAKs interact with signal transducer and activator of transcription proteins (STATs) and the JAK-STAT pathway is central to cellular response to exogenous signals in the immune system. The JAK family of enzymes are responsible for signal transduction and JAK inhibitors play a major role in inhibiting and blocking cytokine release that can contribute to growth of malignant cells in cancer. JAK inhibitors are used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref43">
        43
       </xref>
       ].
      </p>
      <p>
       This review focuses on how the JAK-STAT pathway can be manipulated to reduce viral entry and inflammation in patients with coronavirus. The main targets that the review highlighted were baricitinib (JAK inhibitor), IRE1α (an endoplasmic reticulum stress sensor, leading to an increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3) and combination therapies using tylophorine-based compounds with JAK2 inhibitors.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Fifteen studies were yielded from the search of which 4 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable5">
         Supplementary Table 5
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        Baricitinib
       </title>
       <p>
        Baricitinib (Olumiant) is a JAK inhibitor that was approved by the European Medicines Agency in February 2017 for the treatment of moderate-to-severe active rheumatoid arthritis in adults with an inadequate response to one or more disease-modifying anti-rheumatic drugs [
        <xref ref-type="bibr" rid="ref44">
         44
        </xref>
        ]. One study suggested the use of Baricitinib to reduce the viral entry and inflammation caused by 2019-nCoV. Most viruses enter cells through receptor-mediated endocytosis. ACE2, a cell-surface protein expressed on cells in the kidney, blood vessels, heart, and alveola type 2 (AT2) cells in the pulmonary epithelia, may be the receptor that 2019-nCoV uses to infect lung cells. The authors of Richardson
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref45">
         45
        </xref>
        ] suggest that by inhibiting adaptor associated protein kinase 1 (AAK1) receptor that promotes endocytosis involved in ACE2, Baricitinib may reduce both the viral entry and the inflammation in 2019-nCoV patients.
       </p>
      </sec>
      <sec>
       <title>
        IRE1α
       </title>
       <p>
        Inositol-requiring transmembrane kinase/endoribonuclease 1α (IRE1α) is an endoplasmic reticulum stress sensor that leads to increased expression of negative regulators of JAK-STAT, suppressor of cytokine signalling (SOCS)-1 and SOCS-3 [
        <xref ref-type="bibr" rid="ref46">
         46
        </xref>
        ]. Therefore, IRE1α may be a novel target against coronavirus infection requiring further exploration.
       </p>
      </sec>
      <sec>
       <title>
        Tylophorine-based compounds
       </title>
       <p>
        Tylophorine-based compounds are isolated from plants and exert potent anti-coronaviral activities against SARS-CoV and MERS-CoV [
        <xref ref-type="bibr" rid="ref47">
         47
        </xref>
        ]. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation is a common pro-inflammatory response of host cells to viral infection. Following
        <italic>
         in vitro
        </italic>
        analysis, Yang
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref48">
         48
        </xref>
        ] suggests the use of a combination therapy for SARS-CoV or MERS-CoV, wherein a tylophorine compound known to target transmissible gastroenteritis virus and a JAK2 inhibitor synergise to block the alternative dominant NF-κB activation mediated by JAK2. Therefore, the combination treatment for the inhibition of coronavirus per se, e.g. viral genome replication, and blocking cellular NF-κB activation by coronaviruses, is a promising approach for the development of anti-coronavirals.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Current studies suggest that although there are potential targets in the JAK-STAT pathway that can be manipulated in the treatment for coronaviruses, they are all in early stages and require further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies to confirm their therapeutic effects.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-1 blockade
      </title>
      <p>
       IL-1 is a pro-inflammatory cytokine and an important mediator of local and systemic inflammation. Excessive IL-1 release during viral infections can cause lung and tissue inflammation, fever and fibrosis. IL-1 suppression has found to be effective in many inflammatory diseases including rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ].
      </p>
      <p>
       It is well established that an over-expression of interleukin-1 is a hallmark of SARS-CoV infection, probably through activation of transcription factor nuclear factor, activator protein 1 and activating factor 2. In COVID-19 specifically, the virus is thought to bind to TLRs which activate the formation of pro-IL-1 and activation of the inflammasome [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ]. This inflammasome activation is important for the regulation of cells of both the innate and adaptive immune system paving the way for specific immune responses. As part of the inflammasome activation, IL1-b is subsequently produced which mediates the inflammation of the lungs, fever and fibrosis thus causing respiratory complications in the infected host.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 37 studies were identified from the search of which 9 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable6">
         Supplementary Table 6
        </xref>
        ). Many of the studies were
        <italic>
         in vitro
        </italic>
        studies and repeatedly demonstrated increased IL-1 levels in patients infected with a coronavirus. One study investigated the levels of various inflammatory cytokines in 29, COVID-19 patients in China and compared the levels between general, severe and critically ill groups [
        <xref ref-type="bibr" rid="ref49">
         49
        </xref>
        ]. The authors reported no significant differences in IL-1b levels between the three groups of patients. Another study involving 20 consecutive SARS patients admitted to a Hong Kong hospital identified significantly elevated levels of IL-1β within the first 12, 7 and 5 days following onset of infection [
        <xref ref-type="bibr" rid="ref17">
         17
        </xref>
        ]. Those patients with more severe disease were treated with pulsed methylprednisolone and IL-1β levels returned to normal after 7 days. The seven patients with less severe disease did not receive any dosage of corticosteroids and their cytokine levels returned to normal range levels over the same 7-day time period.
       </p>
       <p>
        A further Chinese study also identified reduced levels of IL-1β following administration of corticosteroids- suggesting inhibition of pro-inflammatory cytokines such as IL-1 may be a beneficial treatment strategy for treatment of SARS [
        <xref ref-type="bibr" rid="ref50">
         50
        </xref>
        ]. A third study, which measured serum cytokine levels in four patient groups including controls, patients with SARS, patients with severe SARS and convalescent SARS patients suggested that longer term treatment (over a period of 7-10 days) with low-dose steroids can alter serum cytokine levels, including IL-1α [
        <xref ref-type="bibr" rid="ref38">
         38
        </xref>
        ].
       </p>
       <p>
        One rat model showed promising results for an IL-1 receptor antagonist which reduced the chemokine expression in infected animals [
        <xref ref-type="bibr" rid="ref51">
         51
        </xref>
        ]. However, this result cannot be generalised for humans. Unfortunately, one study, in which the authors state the ‘demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family’, was only available as an abstract [
        <xref ref-type="bibr" rid="ref52">
         52
        </xref>
        ]. Therefore, further evidence or information to back this claim up is not available.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall, this review demonstrated that although it is evident that IL-1 is elevated in patients infected with a coronavirus, there is not at present evidence for an established role for IL-1 blockers in the treatment of COVID-19 in humans. The literature did, however, suggest a potential role for low-dose corticosteroids to reduce levels of pro-inflammatory markers, such as IL-1, which are elevated as part of the immune response and may have a role in the severe lung damage associated with human coronaviruses.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Mycophenolate
      </title>
      <p>
       Mycophenolate mofetil (which is a derivative of mycophenolic acid (MPA)) is an immune suppressant, antineoplastic and antiviral mediation. According to the British National Formulary, mycophenolate mofetil is used for the prophylaxis of acute rejection in renal transplantation and is usually used in combination with a corticosteroid and ciclosporin.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Almost all of the studies investigated MPA as a potential therapy for MERS-CoV due to its anti-viral properties. Six of the 13 selected studies were
        <italic>
         in vitro
        </italic>
        studies, two were
        <italic>
         in vivo,
        </italic>
        one was a clinical example and four were reviews (therefore there was some overlapping of results) (
        <xref ref-type="table" rid="Stable7">
         Supplementary Table 7
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        In-vitro studies
       </title>
       <p>
        In general, the
        <italic>
         in vitro
        </italic>
        studies looked positive with MPA targeting the papain like proteases of both MERS-CoV and SARS-CoV [
        <xref ref-type="bibr" rid="ref53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="ref54">
         54
        </xref>
        ]. The studies found that MPA showed strong inhibition of the virus with a very low IC50 [
        <xref ref-type="bibr" rid="ref55">
         55
        </xref>
        -
        <xref ref-type="bibr" rid="ref57">
         57
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        In vivo study
       </title>
       <p>
        MPA can been used in combination with interferon-beta (IFN-b). One study, which applied this regime in marmosets exhibiting a severe disease resembling human MERS, reported high viral loads with more severe or even fatal disease [
        <xref ref-type="bibr" rid="ref28">
         28
        </xref>
        ]. The authors of this study state that MPA is likely to cause more harm than benefit to MERS patients.
       </p>
      </sec>
      <sec>
       <title>
        Clinical studies
       </title>
       <p>
        According to the review by Mo and Fisher [
        <xref ref-type="bibr" rid="ref58">
         58
        </xref>
        ], MPA monotherapy had not been tested in a clinical setting for the treatment of MERS-CoV. Al Ghamdi
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref59">
         59
        </xref>
        ], presented an example where eight patients were treated with MPA for MERS-CoV, seven in combination with IFN-β. All eight of these patients survived, however the review by Mo and Fisher stated that this group of patients had lower Acute Physiology and Chronic Health Evaluation II scores compared with others in the cohort who received a variety of antiviral agents including ribavirin and IFN-a, steroids and antibiotics. Therefore, the results must be interpreted with caution.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Whilst the
        <italic>
         in vitro
        </italic>
        studies showed promising results for MPA against MERS, the
        <italic>
         in vivo
        </italic>
        studies suggest that its use is likely to cause more harm than benefit and hence is not likely to be useful against coronavirus infections. The clinical studies are too small to confirm or deny any beneficial use for MERS-CoV patients.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Tacrolimus
      </title>
      <p>
       Tacroliumus, also known as fujimycin, envarsus or FK506, is an immunosuppressive drug which is mainly administered after allogeneic organ transplant to lower risk of organ rejection. It’s mechanism of action focusses on inhibition of calcineurin which is involved in the production of IL-2. IL-2 is a cytokine which promotes the development and proliferation of T cells which form a vital component of the human adaptive immune response.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 18 studies were identified from the search terms, of which three were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable8">
         Supplementary Table 8
        </xref>
        ).
       </p>
       <p>
        Overall, the literature appeared to suggest a potential role for tacrolimus in the treatment of human coronaviruses. In a case study of two renal transplant recipients who tested positive for MERS CoV, a patient who was being treated with an immunosuppressive regimen of tacrolimus underwent full recovery whilst the other patient (who was not on this treatment regimen) succumbed to the infection [
        <xref ref-type="bibr" rid="ref60">
         60
        </xref>
        ]. The patient who eventually made a full recovery was also treated with antibacterial therapy and a reduced dose of mycophenolate mofetil and it is therefore not possible to conclude that patient recovery due to tacrolimus.
       </p>
       <p>
        The two other included studies were both laboratory studies involving cell line culture. The first investigated pathways of coronavirus viral replication as potential antiviral therapeutic targets [
        <xref ref-type="bibr" rid="ref61">
         61
        </xref>
        ]. Genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identified FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1. Subsequently, the authors investigated whether tacrolimus inhibits viral replication of human coronaviruses. VeroFM cells infected with SARS-CoV and other human coronaviruses were treated with FK506. Results showed that FK506 effectively inhibited viral replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with a reduction in viral titers to undetectable levels. The second study further confirmed this inhibition using novel non-immunosuppressive derivatives of FK506 in the context of HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture [
        <xref ref-type="bibr" rid="ref62">
         62
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall the small amount of literature available suggests a potential role of FK506 (tacrolimus) as a potent antiviral in the treatment of human coronaviruses. It is important to note, however, that COVID-19 is a novel disease and may have different aetiology and mechanistic action compared to existing strains and to date, this immunosuppressive drug and its derivatives has not been tested in humans. Further study is warranted, both in the clinical setting and laboratory.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Anti-CD20
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
     <sec>
      <title>
       CTLA-4 Ig
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Overall conclusion
     </title>
     <p>
      The rapidly progressing SARS-CoV-2 pandemic has led to challenging decision-making about the treatment of critically unwell patients with the novel viral infection. In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune-suppressive medication. This systematic review looks to provide guidance from the current available literature.
     </p>
     <p>
      As the COVID-19 pandemic progresses, collective effort to capture data from prospective trials is required. Sponsors of randomized controlled trials recruiting patients randomized to receive immune modulatory drugs that may be affected by COVID-19 should collect data about the disease outcomes and consider interim analysis of potential advantages and disadvantages associated with using one of these medications.
     </p>
     <p>
      Low-dose prednisolone and tacrolimus therapy may have beneficial impacts on the course of SARS-CoV-2. This observation requires further validation. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFa biological agents are contraindicated. There is evidence that IL-6 peak levels are associated with severity of pulmonary complications. Ongoing studies of blockade of the IL-6 pathway are rational and will hopefully inform practice as the pandemic progresses.
     </p>
    </sec>
    <sec>
     <title>
      Funding declaration
     </title>
     <p>
      We would like to thank our various funders: Guy’s and St Thomas’ Charity, Cancer Research UK (C45074/A26553), and the CRUK King’s Health Partner Centre.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Conflicts of interest
     </title>
     <p>
      The authors have no conflicts of interest to declare.
     </p>
    </sec>
    <back>
     <sec>
      <title>
       Supplementary tables of summarised literature
      </title>
      <table-wrap id="Stable1" position="anchor">
       <label>
        Supplementary Table 1.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19 and cytotoxic chemotherapy.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS1">
            1
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           COVID-19 complicates the clinical scenario of pulmonary infiltrates in cancer patients. Active treatment against the infection and patient surveillance should be initiated if infectious disease is considered.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS2">
            2
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recommendations based on stage of cancer:
           <list list-type="bullet">
            <list-item>
             <p>
              Recurrent metastatic colorectal cancer: low-intensity maintenance therapy
             </p>
            </list-item>
            <list-item>
             <p>
              Patients with tumour changes or higher malignancy still need to receive combined chemotherapy.
             </p>
            </list-item>
            <list-item>
             <p>
              After radical surgery, given the relatively limited benefits of adjuvant chemotherapy, the intensity and duration of treatment can be reduced.
             </p>
            </list-item>
            <list-item>
             <p>
              In the face of patients with febrile tumour chemotherapy, it is necessary to analyse the cause of the fever of the patient.
             </p>
            </list-item>
            <list-item>
             <p>
              Stable disease and good general condition: elect to delay the time of imaging evaluation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS3">
            3
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nilsson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A one-year-old child with pre-B acute lymphoblastic leukaemia (ALL) developed fatal encephalitis associated with human coronavirus OC43 (HCoV-OC43). During chemotherapy the child had a persistent HCoV-OC43 respiratory infection and later developed progressive encephalitis. Cerebrospinal fluid was negative for pathogens including HCoV-OC43, but a brain biopsy was HCoV-OC43-positive.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS4">
            4
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard and Kumaki
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-SARS-CoV therapies recently published from 2007 to 2010 reviewed in this paper and the following compounds have been shown to be active in vitro against the virus:
           <break>
           </break>
           TNF-α-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanised monoclonal antibody, recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic);
           <break>
           </break>
           therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS5">
            5
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A 3-Year Retrospective Study of the Epidemiology of Acute Respiratory Viral Infections in Pediatric Patients With Cancer Undergoing Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Aydin Köker et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Turkey
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were analysed in patients younger than 21 years with acute respiratory infections.
             </p>
            </list-item>
            <list-item>
             <p>
              Coinfection with 2 viruses was present in 20.5% (45/219) of the episodes.
             </p>
            </list-item>
            <list-item>
             <p>
              Most frequent coinfections of respiratory viruses: 6 cases of HRV+hBoV, 5 of HRV, +AdRV, 4 of PI3+CoV 43, 3 of HRV+CoV 43, 3 of HRV, +IF A/H1N1, 3 of HRV+RSV A/B, and 2 of HRV+EV
             </p>
            </list-item>
            <list-item>
             <p>
              Detected more often in the months of January (16%) and October (15%) than in the other months
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: no increase in mortality of cancer patients but cause for significant delays to chemotherapy, which might have an indirect impact on patient survival rates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS6">
            6
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Söderman
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were collected during 87 episodes of febrile neutropenia in children age 0-18 years
             </p>
            </list-item>
            <list-item>
             <p>
              No symptoms were apparent in four episodes involving RV and one episode involving HCoV
             </p>
            </list-item>
            <list-item>
             <p>
              Persistent HCoV with a median follow-up time of 31 days
             </p>
            </list-item>
            <list-item>
             <p>
              High viral loads were correlated to more symptoms
             </p>
            </list-item>
            <list-item>
             <p>
              Respiratory viruses play an etiologic role in febrile neutropenia in children receiving treatment for a malignancy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS7">
            7
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pillaiyar
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The paper focuses on on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003−2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening.
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: No coronavirus protease inhibitor has yet successfully completed a preclinical development program
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS8">
            8
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hijano
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Switzerland
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical manifestations vary significantly depending on the type of virus and the type and degree of immunosuppression.
             </p>
            </list-item>
            <list-item>
             <p>
              Risk factors associated with prolonged viral shedding can include viral load, use of steroids, and myeloablative conditioning.
             </p>
            </list-item>
            <list-item>
             <p>
              Mortality associated with coronavirus in HCT recipients was inconclusive. While some studies [
              <xref ref-type="bibr" rid="refS9">
               9
              </xref>
              ] reported no associations, other studies [
              <xref ref-type="bibr" rid="refS10">
               10
              </xref>
              ] reported similar mortality rates in HCT recipients to those observed with other viruses such as RSV, influenza virus, and PIV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS11">
            11
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ghosh et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV proteases are attractive targets for the development of antiviral drugs to reduce viral replication and pathogenicity.
             </p>
            </list-item>
            <list-item>
             <p>
              Glycyrrhizin showed inhibitory activity for SARS-CoV replication but it has high cytotoxicity.
             </p>
            </list-item>
            <list-item>
             <p>
              HIV protease inhibitor nelfinavir, antihelminthic drug niclosamide and antimalarial agent chloroquine have also showed strong inhibitory activity against SARS-CoV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              A human lgG1 form of 80R was found to bind the S1 domain of the SARS-CoV S protein (with a higher affinity comparable to that of ACE2 suggesting that the 80R human monoclonal antibody is a useful viral entry inhibitor for SARS treatment.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS12">
            12
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LaFemina, RL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Lopinavir is an HIV protease inhibitor.
             </p>
            </list-item>
            <list-item>
             <p>
              Lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV.
             </p>
            </list-item>
            <list-item>
             <p>
              However, proteases of HIV and coronaviruses fall into different mechanistic classes of proteases.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS13">
            13
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Acute respiratory viral infections in paediatric cancer patients undergoing chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Benites
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Brazil
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Paediatric patients with cancer and acute respiratory infection [
              <xref ref-type="bibr" rid="refS14">
               14
              </xref>
              ] and/or fever.
             </p>
            </list-item>
            <list-item>
             <p>
              Coronavirus was identified in 6.8% in the 50 samples of respiratory cases.
             </p>
            </list-item>
            <list-item>
             <p>
              Human rhinovirus (HRV) was the most common viral pathogen, followed by coronavirus, respiratory syncytial virus (RSV), and metapneumovirus, demonstrating the importance of these pathogens in the studied population.
             </p>
            </list-item>
            <list-item>
             <p>
              The prevalence of respiratory viruses was relevant in the infectious episode, with no increase in morbidity and mortality. Viral co-detection was frequent in patients with cancer and ARIs.
             </p>
            </list-item>
            <list-item>
             <p>
              The link of whether severe acute infection was directly related to the type of cancer or viral pathogen was not identified in the study.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS15">
            15
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS14">
            14
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Balzarini, J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Belgium
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs.
             </p>
            </list-item>
            <list-item>
             <p>
              In HIV, glycan deletions in gp120 delays the spread of virus.
             </p>
            </list-item>
            <list-item>
             <p>
              CBA administration may bring the viral infection under control before glycan deletions occur and the immune system can get involved in the further clearance of the virus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS16">
            16
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chebotkevich et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Russia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Only abstract available, article in Russian and not accessible.
           <list list-type="bullet">
            <list-item>
             <p>
              Communicable respiratory viruses were investigated in 51 patients as a causative factor of infectious complication in hemoblastosis and myelodepression
             </p>
            </list-item>
            <list-item>
             <p>
              Coronaviruses detected in 13.7%
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS17">
            17
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ]. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kesel AJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           United Arab Emirates
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              25 test materials including interferon-inducer
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin (BN) was an effective inhibitor of SARS-CoV in cell culture.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS19">
            19
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huali
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The M and E are play a role in coronaviral particle assembling. Targeting these agents may lead to immune responses by inducing the production of protective IFN-α.
             </p>
            </list-item>
            <list-item>
             <p>
              N, M, and E genes may be used as the targets to prevent SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS20">
            20
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Keseal AJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Bananin acts as zinc (Zn2+) chelator
             </p>
            </list-item>
            <list-item>
             <p>
              Targets and inhibits zinc finger of HIV-1 RNA-binding nucleocapsid protein p7 (NCp7).
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation.
             </p>
            </list-item>
            <list-item>
             <p>
              Targets of BNP and B6RA have shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS21">
            21
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronavirus Pneumonia
           <break>
           </break>
           Following Autologous Bone
           <break>
           </break>
           Marrow Transplantation for
           <break>
           </break>
           Breast Cancer
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Folz and Elkordy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1999
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Case report: coronavirus in woman with stage III breast cancer following treatment with hig-dose chemotherapy and autologous bone marrow and stem cell transplant.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable2" position="anchor">
       <label>
        Supplementary Table 2.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and low-dose steroids.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS22">
            22
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fu, Cheng and Wu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review suggests that:
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV S protein can downregulate ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              Loss of pulmonary ACE2 function has been suggested to be associated with acute lung injury; the reduction in ACE2 function can cause dysfunction of the renin-angiotensin system [
              <xref ref-type="bibr" rid="refS23">
               23
              </xref>
              ] and enhance inflammation and vascular permeability.
             </p>
            </list-item>
            <list-item>
             <p>
              ACE2-associated lung injury has been suggested in SARS- CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              From reading this article the following article was then discovered…
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS24">
            24
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fang, Karakiulakis and Roth
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The expression of ACE2 is substantially increased in patients with type 1 or type 2 diabetes, who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs). Hypertension is also treated with ACE inhibitors and ARBs, which results in an upregulation of ACE2
           <break>
           </break>
           ACE2 can be increased by thiazolidinediones and ibuprofen. These data suggest that ACE2 expression is increased in diabetes and treatment with ACE inhibitors and ARBs increases ACE2 expression. Consequently, the increased expression of ACE2 would facilitate infection with COVID-19.
           <break>
           </break>
           The authors therefore hypothesise that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS25">
            25
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Drug treatment options for the 2019-new coronavirus (2019- nCoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           No evidence given for or against using ibuprofen only that ‘anti-inflammatory drugs (such as hormones and other molecules)’ are potential therapeutic options for 2019-nCoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Chan, Wong
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Corticosteroid treatment reduced interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and IFN-γ-inducible protein-10 (IP-10) concentrations from 5 - 8 days after treatment in SARS patients. These were all inflammatory markers which were remarkably increased in SARS patients. NB. This study is not specifically looking at SARS-CoV2 only at SARS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Bangladesh, Germany, Canada, UK and Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review article aimed to look at multiple diseases caused by various viruses including Dengue, Ebola and SARS-CoV. They stated that ribavirin (an antiviral) is the most frequently used drug to combat SARS-CoV, and is administered together with corticosteroids.
           <break>
           </break>
           Although immunosuppressive corticosteroid drugs are commonly used in an attempt to reduce fatality rates, the results of clinical trials are not sufficiently satisfactory to approve as an effective class of therapeutic
           <break>
           </break>
           Glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition. (Please note this is not specific for SARS-CoV-19 and is referring to the 3 viral diseases mentioned).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS28">
            28
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The management of coronavirus infections with particular reference to SARS.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong SS, Yuen KY
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HCoV-OC43 and HCoV-229E initial principal pathogens discovered in 1960’s; acute respiratory diseases of less severity and mortality than SARS-CoV which promoted rapid search for effective antiviral treatments.
           <break>
           </break>
           Immunomodulatory agents (primarily corticosteroids) widely used during SARS to avoid excessive tissue damage by cytokine dysregulation but benefit of use not conclusively demonstrated.
           <break>
           </break>
           Multiple studies demonstrated increased plasma viral load with use of corticosteroids (RCT measured plasma viral load at regular intervals in non-intubated cases found higher concentrations of SARS-CoV RNA in week 2/3 of illness compared to patients who received placebo).
           <break>
           </break>
           9.9% of patients in Hong Kong cohort study also suffered opportunitistic infections such as aspergillosis and late sequelae (including avascular osteonecrosis) with corticosteroid use.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS29">
            29
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Laboratory study which treated porcine respiratory coronavirus infected pigs with corticosteroid dexamethasone as a model for SARS.
           <break>
           </break>
           Goal to define whether corticosteroid treatment altered immunity and lung inflammatory response at cytokine level and how changes correlated with pig lung lesions.
           <break>
           </break>
           Confirmed infection model applicable and resembled SARS.
           <break>
           </break>
           Treatment with dexamethasone suppressed early local IL-6 levels but increased later on in disease. Suggests may decrease inflammation at early infection stage but not later.
           <break>
           </break>
           Results also suggest that dexamethasone induced reduction of IL-6 might play a role in delayed onset of lung lesions but increases of IL-6 at later infection stage may contribute to severity of lung lesions (mimicking delayed onset of disease severity as seen in SARS patients treated with corticosteroids).
           <break>
           </break>
           <bold>
            Overall findings suggest that 1 or 2 doses of dexamethasone in acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged DEX administration may play role in enhancing viral replication.
           </bold>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS30">
            30
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Indomethacin has a potent antiviral activity against SARS coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Amici C,
           <break>
           </break>
           Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Utilised observation that cyclopentenone cyclooxygenase (COX) metabolites are active against several RNA viruses to investigate effect of COX inhibitor indomethacin on coronavirus replication.
           <break>
           </break>
           Indomethacin is common NSAID.
           <break>
           </break>
           Report describes how indomethacin was unexpectedly found to possess potent antiviral activity against canine coronavirus (dramatically inhibit virus replication and protect the host cell from virus-induced damage).
           <break>
           </break>
           Activity also observed in vivo and against human SARS-CoV.
           <break>
           </break>
           Oral administration of concentration 1mg/kg found to be effective.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D, He LX, Qu JM, Pan J, Hu BJ, Zhang J, Li ZZ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China (full article only available in Chinese but informative abstract)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Studied pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on inflammatory reaction.
           <break>
           </break>
           Mice treated with dexamethasone.
           <break>
           </break>
           N-protein of SARS-CoV shown to have pathogenicity inducing pulmonary inflammatory reaction and acute lung injury which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines.
           <break>
           </break>
           Glucocorticoids (dexamethasone) demonstrated effectively alleviate pulmonary inflammatory reaction.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS32">
            32
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chihrin S, Loutfy MR
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Canada
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-inflammatory agents heavily utilised during SARS outbreak as it was believed that the development and worsening of the pulmonary disease had inflammatory aetiology and pathogenesis.
           <break>
           </break>
           Immunopathological analysis of 20 SARS patients demonstrated increased Th1 cytokine interferon y and inflammatory cytokines IL-1, IL-6 and IL-12 for &gt; 2 weeks following onset of symptoms.
           <break>
           </break>
           Also observed decrease in viral activity and IgG seroconversion during 2nd week of illness despite general progression of respiratory disease- suggesting respiratory damage is secondary to immune-mediated inflammatory response.
           <break>
           </break>
           Corticosteroids used during SARS outbreak for their ability to module variety of involved cytokines.
           <break>
           </break>
           Numerous papers published outcomes of patients administered corticosteroids (mostly IV hydrocortisone or methylprednisolone) in either early low-dose or pulsed-dose strategies. Most concluded corticosteroids appeared to be effective in reducing immunopathological damage (resulting in improved and rapid resolution of symptoms).
           <break>
           </break>
           Opposition to corticosteroid use centred around use of corticosteroid use in treatment of acute respiratory distress syndrome- concern that corticosteroid treatment may weaken immune response and promote viral rebound. Reports also add evidence to theory.
           <break>
           </break>
           Further opposition includes association with adverse events such as hyperglycaemia, hypokalaemia, hypertension, gastrointestinal haemorrhage and avascular necrosis (AVN).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS33">
            33
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl J Jr, Michaelis M, Morgenstern B, Doerr HW
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany (needs to be purchased)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Investigated influence of SARS-CoV infection on CXCL8 and CXCL10 in human intestinal epithelial cells.
           <break>
           </break>
           High concentrations of hydrocortisone prevented DNA binding activity of AP-1 and NF-kappabeta and inhibited upregulation of CXCL8 and CXCL10 but did not reduce chemokine expression to basal.
           <break>
           </break>
           Results suggest corticosteroid may be of limited benefit in suppression of chemokine production by SARS-CoV infected cells.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overproduction of TNF-alpha, IL-1, IL-6 and IL-10 hallmark of viral infection.
           <break>
           </break>
           Investigated inflammatory profiles of patients infected with SARS in Hong Kong hospital.
           <break>
           </break>
           Use of corticosteroids significantly reduced IL-8, MCP-1 and IP-10 concentrations from 5-8 days after treatment.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS35">
            35
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Description and clinical treatment of an early outbreak of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ] in Guangzhou, PR China.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Patients treated in different methods. 2 groups of 4 received steroids (in form of methyl prednisolone).
           <break>
           </break>
           Early use of high-dose steroids appeared to help recovery from SARS.
           <break>
           </break>
           Early use of high-dose steroids in combination with a quinolone plus azithromycin gave the best outcome with improvement of clinical signs and symptoms, decreased incidence of ARDs and mechanical ventilation as well as mortality.
           <break>
           </break>
           Hypothesised that steroids may help by reducing the damaging effect of the local inflammatory response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable3" position="anchor">
       <label>
        Supplementary Table 3.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/other coronavirus strains and TNF blockers.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS36">
            36
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tobinick E.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical and experimental evidence implicate TNF as a possible mediator of the severe immune-based pulmonary injury which can follow infection with H5N1 influenza and SARS coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              In humans, anti-TNF therapy utilising etanercept has been reported to be beneficial for treatment of the non-infectious idiopathic pneumonia syndrome which can follow stem-cell transplantation, a pulmonary syndrome that resembles SARS pneumonia in some respect.
             </p>
            </list-item>
            <list-item>
             <p>
              If the SARS coronavirus does indeed lead to massive release of TNF-αf rom alveolar macrophages, then early inhibition of TNF-α might be able to prevent TNF-αmediated immune activation and therefore reduce pulmonary injury in these patients.
             </p>
            </list-item>
            <list-item>
             <p>
              Compared with the use of corticosteroids, the use of biologic TNF inhibitors, including etanercept, has the potential to be a more specific and more effective method of ameliorating the severe alveolar damage which can occur following infection with these agents.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS37">
            37
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-TNF alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Atanasova K; Van Gucht S; Van Reeth K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2010
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           22 piglets were assessed to to elucidate the role of TNF-α in the development of virus-endotoxin-induced respiratory disease.
           <break>
           </break>
           The study demonstrates that after intratracheal administration etanercept is able to successfully block TNF-α activity in vivo in the lungs of PRCV-LPS inoculated pigs during the first 4–8 HPI.
           <break>
           </break>
           TNF-α reduction, however, was not associated with decrease in disease severity, bronchoalveolar neutrophil infiltration, or altered virus replication and induction of IL-1, IL-6, IL-12/IL-23 or IFN-α in the lungs.
           <break>
           </break>
           There was no obvious difference in macroscopic lung lesions and histopathological findings in the lungs. This data confirms the generally accepted belief that TNF-α, though very important, is not the sole culprit in development of respiratory disease and pathology, and possibly other, yet unidentified, components and mechanisms of the immune system are involved.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable4" position="anchor">
       <label>
        Supplementary Table 4.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-6.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS38">
            38
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Gao Y; Li T; Han M; Li X; Wu D; Xu Y; Zhu Y; Liu Y; Wang X; Wang L.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They investigated forty‐three adult patients with COVID‐19. The patients were classified into mild group (28 patients) and severe group (15 patients).
             </p>
            </list-item>
            <list-item>
             <p>
              Comparison of the haematological parameters between the mild and severe groups showed significant differences in IL‐6, D‐Dimer, GLU, TT, FIB and CRP (
              <italic>
               p
              </italic>
              &lt;0.05).
             </p>
            </list-item>
            <list-item>
             <p>
              Infection-related biomarkers appeared to differ between the two groups (IL-6).However, the proportion of IL-6 above normal was [36.10(23.00,59.20) pg/mL]in the severe group, which was significantly higher than that in the mild group [10.60(5.13,24.18) pg/mL].
             </p>
            </list-item>
            <list-item>
             <p>
              The AUC of IL-6 which was used to predict the severity of COVID-19 was 0.795 (P&lt;0.0001), which could better predict whetherrCOVID-19 was complicated by severe pneumonia. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia.
             </p>
            </list-item>
            <list-item>
             <p>
              IL‐6 and D‐Dimer were closely related to the occurrence of severe COVID‐19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID‐19 patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS39">
            39
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Conti, P; Ronconi, G; Caraffa, A; Gallenga, C; Ross, R; Frydas, I; Kritas, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis.
             </p>
            </list-item>
            <list-item>
             <p>
              Proinflammatory cytokines levels are correlated with COVID-19 replication and disease.
             </p>
            </list-item>
            <list-item>
             <p>
              Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS40">
            40
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Primary human nasal (HNE) and tracheal (HTE) epithelial cell cultures were infected with HCoV-229E coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              Pretreatment of HNE and HTE cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E receptor CD13, the number and fluorescence intensity of acidic endosomes where HCoV-229E RNA enters the cytoplasm, and the infection-induced production of cytokines, including IL-6, IL-8, and IFN-beta.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-6 and IL-8 are related to airway inflammation in COPD and bronchial asthma exacerbation induced by viral infection. The decreased production of IL-6 and IL-8 in cells pretreated with glycopyrronium, formoterol, and budesonide, as well as the increased inhibitory effects of GFB observed in the present study, may be associated with the inhibitory effects of these drugs on COPD and bronchial asthma exacerbation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS41">
            41
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel
           <bold>
            coronavirus
           </bold>
           pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen, L; Liu, H G; Liu, W; Liu, J; Liu, K; Shang, J; Deng, Y; Wei, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              29 patients with 2019-ncov admitted to the isolation ward of Tongji hospital ( mild (15 cases), severe (9 cases) and critical (5 cases).
             </p>
            </list-item>
            <list-item>
             <p>
              The expression levels of inflammatory cytokines and other markers in the serum of each group were detected.
             </p>
            </list-item>
            <list-item>
             <p>
              There were statistically significant differences in the expression levels of interleukin-2 receptor (IL-2R) and IL-6
              <bold>
               in the serum of the three groups (
              </bold>
              <italic>
               p
              </italic>
              &lt; 0.05), among which the critical group was higher than the severe group and the severe group was higher than the mild group.
             </p>
            </list-item>
            <list-item>
             <p>
              However, there were no statistically significant differences in serum levels of tumor necrosis factor-alpha (TNF-alpha), IL-1, IL-8, IL-10, hs-CRP, lymphocyte count and LDH among the three groups (P&gt;0.05).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Christopher W K; Chan, Michael H M; Wong, Chun K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They have investigated daily changes in plasma inflammatory cytokines and chemokines in 20 adult SARS patients [19 men and 1 woman, mean (SD) age 33 (12) years, range 21–58] for 19 consecutive days upon hospital admission (from ≤ 2 days after disease onset).
             </p>
            </list-item>
            <list-item>
             <p>
              The cytokine profile showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine IFN-γ, inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset, but there was no significant increase in inflammatory cytokine TNF-α, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2, and T-helper lymphocyte type 2 (Th2) cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              We have also performed serial studies of plasma cytokine and chemokine profiles of 8 children with SARS (5 boys and 3 girls, age 0.3 – 6.2 years) and found that these patients had a much milder cytokine and chemokine storm, rendering the use of corticosteroids more controversial if not unjustified.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS42">
            42
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection.
           <break>
           </break>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kim ES; Choe PG; Park WB; Oh HS; Kim EJ; Nam EY; Na SH; Kim M; Song KH; Bang JH; Park SW; Kim HB; Kim NJ; Oh MD.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Korea (South)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              17 patients with laboratory-confirmed MERS-CoV during the 2015 outbreak in Korea were studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The severe group had higher neutrophil counts during week 1 than the mild group (4,500 versus 2,200/muL, P = 0.026). In the second week of illness, the severe group had higher serum levels of IL-6 (54 versus 4 pg/ml,
              <italic>
               p
              </italic>
              = 0.006) and CXCL-10 (2,642 versus 382 pg/ml,
              <italic>
               p
              </italic>
              &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat A; Majumder A; Taufiqur Rahman KM; Mahedi Hasan AM; Didarul Islam KM; Taylor-Robinson AW; Billah MM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              IL-6 Interleukin acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signalling, which might relate to the cytokine storm that is triggered by excessive pro-inflammatory responses to Ebola, SARS-CoV and dengue infections in humans.
             </p>
            </list-item>
            <list-item>
             <p>
              Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling
             </p>
            </list-item>
            <list-item>
             <p>
              The tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli.
             </p>
            </list-item>
            <list-item>
             <p>
              ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS43">
            43
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li Y; Chen M; Cao H; Zhu Y; Zheng J; Zhou H.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           France
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They identified a set of SARS-CoV specific GU-rich ssRNA fragments with a high-density distribution in the genome.
             </p>
            </list-item>
            <list-item>
             <p>
              In vitro experiments, the result showed the representative SARS-CoV ssRNAs had powerful immunostimulatory activities to induce considerable level of pro-inflammatory cytokine TNF-a, IL-6 and IL-12 release via the TLR7 and TLR8, almost 2-fold higher than the strong stimulatory ssRNA40 that was found previously from other virus.
             </p>
            </list-item>
            <list-item>
             <p>
              Moreover, SARS-CoV ssRNA was able to cause acute lung injury in mice with a high mortality rate in vivo experiment. It suggests that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity and could open a new therapeutic strategy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS44">
            44
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Liao Y; Wang X; Huang M; Tam JP; Liu DX
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Characterised cellular mechanisms exploited by coronavirus infectious bronchitis virus (IBV) to regulate the induction of two pro-inflammatory cytokines, interleukin (IL)-6 and IL-8, at the transcriptional level.
             </p>
            </list-item>
            <list-item>
             <p>
              IBV modulates the infection by inducing the expression of dual-specificity phosphatase 1 (DUSP1), a negative regulator of the p38 MAPK, in order to limit the production of an excessive amount of IL-6 and IL-8 in the infected cells.
             </p>
            </list-item>
            <list-item>
             <p>
              DUSP1 and p38 MAPK are possible therapeutic targets for IBV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS45">
            45
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Day CW; Baric R; Cai SX; Frieman M; Kumaki Y; Morrey JD; Smee DF; Barnard DL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              A new strain of SARS-CoV (strain v2163) was characterised and it was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues.
             </p>
            </list-item>
            <list-item>
             <p>
              Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS46">
            46
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutralising antibody against severe acute respiratory syndrome -coronavirus spike is highly effective for the protection of mice in the murine SARS model.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The efficacy of three SARS vaccine candidates was tested in a murine SARS model utilising low-virulence Pp and SARS-CoV coinfection.
             </p>
            </list-item>
            <list-item>
             <p>
              Vaccinated mice were protected from severe respiratory disease.
             </p>
            </list-item>
            <list-item>
             <p>
              A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS47">
            47
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome (18) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yoshikawa T; Hill T; Li K; Peters CJ; Tseng CT.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              In highly polarised human lung epithelial Calu-3 cells modelled the cellular bases of the host antiviral innate immunity within the lungs.
             </p>
            </list-item>
            <list-item>
             <p>
              Role of IL-6 as a key SARS-CoV-induced epithelial cytokine capable of inhibiting the T-cell-priming ability of Denditric cells leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS48">
            48
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X; Wu K; Wang D; Yue X; Song D; Zhu Y; Wu J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              High levels of IL6 High levels of interleukin-6 (IL-6) in the acute stage associated with lung lesions were found in SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              The viral nucleocapsid SARS-CoV N protein
              <bold>
               activate
              </bold>
              IL-6 expression in the lung cells.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS49">
            49
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Okabayashi T; Kariwa H; Yokota S; Iki S; Indoh T; Yokosawa N; Takashima I; Tsutsumi H; Fujii N.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They compared the cytokine profile in Caco2 cells after infection of SARS coronavirus (SARS-CoV) with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2).
             </p>
            </list-item>
            <list-item>
             <p>
              Interferon (IFN) system (production and response) was not suppressed by SARS-CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2.
             </p>
            </list-item>
            <list-item>
             <p>
              Induction level of suppressor of cytokine signaling-3 (SOCS3) by SARS-CoV was significantly lower than that by RSV in spite of the significant production of IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              Collectively, overinduction of inflammatory cytokine and dysregulation of cytokine signaling may contribute to the immunopathology associated with “severe” inflammation in SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D; He LX; Qu JM; Pan J; Hu BJ; Zhang J; Li ZZ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The pulmonary inflammatory reaction in rat models were induced by intratracheal instillation of N-protein of SARS-CoV and glucocorticoids were administrated to one of the groups.
             </p>
            </list-item>
            <list-item>
             <p>
              The N-protein of SARS-CoV presented pathogenicity and could induce pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS50">
            50
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sheng WH; Chiang BL; Chang SC; Ho HN; Wang JT; Chen YC; Hsiao CH; Hseuh PR; Chie WC; Yang PC.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen hospitalised patients with a diagnosis of SARS-associated coronavirus infection.
             </p>
            </list-item>
            <list-item>
             <p>
              There were no significant differences in peak levels of IL-6, IL-8 and TNF-alpha between patients with and without acute respiratory distress syndrome.
             </p>
            </list-item>
            <list-item>
             <p>
              CRP and TNF-alpha are associated with worse outcomes and might be used as prognostic markers of SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS51">
            51
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tseng CT; Perrone LA; Zhu H; Makino S; Peters CJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV does not productively infect human macrophages or Dentritic cells, it appears to exert differential effects on Mphi and DC maturation and functions, which might contribute to SARS pathogenesis.
             </p>
            </list-item>
            <list-item>
             <p>
              It modulates a massive release of IL-6 and IL-12. However, the endocytic capacity (e.g., Ag capture) of Mphi was significantly compromised upon exposure to infectious SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS52">
            52
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An interferon-gamma-related cytokine storm in SARS patients.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huang KJ; Su IJ; Theron M; Wu YC; Lai SK; Liu CC; Lei HY.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen cytokines or chemokines were analysed on 88 RT-PCR-confirmed severe acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ] patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG, and IL-8, but not of TNF-alpha, IL-2, IL-4, IL-10, IL-13, or TNFRI, were highly elevated in the acute phase sera of Taiwan SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group
             </p>
            </list-item>
            <list-item>
             <p>
              An interferon-gamma-related cytokine storm was induced post SARS coronavirus infection, and this cytokine storm might be involved in the immunopathological damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS53">
            53
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang WK; Chen SY; Liu IJ; Kao CL; Chen HL; Chiang BL; Wang JT; Sheng WH; Hsueh PR; Yang CF; Yang PC; Chang SC;
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              8 patients with acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ], were included to study the link between viral load, ribavirin, proinflammatory cytokines, and clinical progression.
             </p>
            </list-item>
            <list-item>
             <p>
              ribavirin was not effective in reducing the SARS coronavirus load in 3 of 8 probable cases studied
             </p>
            </list-item>
            <list-item>
             <p>
              elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in 8 and 6 cases, respectively.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y; Li J; Zhan Y; Wu L; Yu X; Zhang W; Ye L; Xu S; Sun R; Wang Y; Lou J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Serum from 110 individuals (healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence) was collected and cytokine profile was studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The IL-6 concentration was increased in SARS patients and was significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects, suggesting that there was a positive relationship between the serum IL-6 concentration and
             </p>
            </list-item>
            <list-item>
             <p>
              SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-8 and TGF-beta were decreased in SARS patients and significantly reduced in severe SARS patients, but they were comparable in convalescent SARS patients and control subjects, suggesting that there was a negative relationship between the IL-8 and TGF-beta concentrations and SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-1 and TNF-alpha were not significantly different in different groups.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK; Lam CW; Wu AK; Ip WK; Lee NL; Chan IH; Lit LC; Hui DS; Chan MH; Chung SS; Sung JJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed.
             </p>
            </list-item>
            <list-item>
             <p>
              Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 was elevated for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10).
             </p>
            </list-item>
            <list-item>
             <p>
              Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all p &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS55">
            55
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang and Pang
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              (Abstract only)
             </p>
            </list-item>
            <list-item>
             <p>
              This study observed changed in various serum IL levels in patients with SARS. The authors stated that the mean concentration of serum IL-6 in SARS patients did not differ from the control group in 3-7-day group and 8-14-day group, but became significantly higher in over 14-day group as compared to the control group, 3-7-day group and 8-14-day group (
              <italic>
               p
              </italic>
              &lt; 0.01). The results of the study led the authors to conclude that the immune state of SARS was abnormal. However, as only the abstract was available it is hard to draw upon any more conclusions from this study in relation in IL-6 specifically.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS56">
            56
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inflammatory Cytokine Profile in Children With Severe Acute Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ng
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations key proinflammatory cytokines, including IL-6 were not substantially increased in any of the patients throughout the course of illness. From this the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients, as the host immunologic response did not seem to be as severe as initially anticipated.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable5" position="anchor">
       <label>
        Supplementary Table 5.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and JAK inhibitors
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS57">
            57
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Richardson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              ACE2 is a cell-surface protein on lung cells in corona viral infected patients
             </p>
            </list-item>
            <list-item>
             <p>
              AAK1 receptor promoted endocytosis involved in ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              The study suggests the use of Baricitinib to inhibit AAK1 in patients with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia [
              <xref ref-type="bibr" rid="refS58">
               58
              </xref>
              ].
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS59">
            59
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response through IRE1α-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ma
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              JAK-signal transducer and activator of transcription (STAT), the suppressor of cytokine signaling protein 1 (SOCS1), and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-I are major antiviral molecules, and coronaviruses have evolved diverse strategies to counter the IFN-I response during infection.
             </p>
            </list-item>
            <list-item>
             <p>
              This study uses endoplasmic reticulum stress and IFN-I production after infection with transmissible gastroenteritis virus (TGEV) to understand how coronavirus-elicited ER stress is actively involved in viral replication and manipulates the host IFN-I response.
             </p>
            </list-item>
            <list-item>
             <p>
              Increased SOCS1 or SOCS3 expression impaired the IFN-I antiviral response, promoting TGEV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              IRE1α is an endoplasmic reticulum stress sensor, which led to the increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              Therefore, IRE1α may be a novel target against coronavirus infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS60">
            60
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-kappaB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yang
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses.
             </p>
            </list-item>
            <list-item>
             <p>
              NF-
              <bold>
               κB
              </bold>
              activation is a common pro-inflammatory response of host cells to viral infection.
             </p>
            </list-item>
            <list-item>
             <p>
              The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-
              <bold>
               κB
              </bold>
              activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS61">
            61
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wathelet
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Expression of non-structural protein 1 (nsp1) significantly inhibited the activation of SARS-Cov signaling pathways.
             </p>
            </list-item>
            <list-item>
             <p>
              However, the study results show that SARS-CoV nsp1 does not inhibit JAK phosphorylation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable6" position="anchor">
       <label>
        Supplementary Table 6.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-1 blockade.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS62">
            62
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The levels of several inflammatory markers were
           <break>
           </break>
           measured in 29 COVID-19 patients and were compared between general, severe and critically ill groups. The authors reported no significant differences in IL-1b levels between the three groups of patients.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS63">
            63
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Miura
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used two rat coronaviruses on alveolar epithelial cells taken from 6-8 weeks old rats. Infection with the viruses caused the increase in expressed of both IL-1a and IL-1b. The authors concluded that the virus-induced chemokine expression was subsequently reduced by the IL-1 receptor antagonist, suggesting that IL-1 produced by infected cells induces uninfected cells to express chemokines.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS64">
            64
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zalinger, Elliott and Weiss
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used several infectious agents including murine coronavirus to assess the role of the inflammasome and its related cytokines on pathogenesis and host defence during viral infection. The authors concluded that mice lacking IL-1 signalling experienced elevated viral replication but similar survival compared to wild-type controls.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS65">
            65
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory
           <break>
           </break>
           Syndrome Coronavirus Viroporin 3a Activates the NLRP3
           <break>
           </break>
           Inflammasome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Japan and Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors provide evidence that SARS-CoV 3a protein activates the NLRP3 inflammasome in lipopolysaccharide-primed macrophages and that the ion channel activity of the 3a protein was essential for 3a-mediated IL-1β secretion. The macrophages obtained in this study were from 6-week-old female mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS66">
            66
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kritas
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece, Italy and USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Abstract Only)
           <break>
           </break>
           Infection with coronavirus activates mast cells which in turn causes the generation of pro-inflammatory IL-1 family members. The authors state that they demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family. However, as this is only an abstract there is no further information to support this statement.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS67">
            67
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS Immunity and Vaccination.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu M
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS-CoV binds to host cells via a specific SARS receptor, angiotensin converting enzyme 2 (ACE-2).
           <break>
           </break>
           Following entry into the cell, the virus uncoats, nucleic acid is released and transcription occurs for production of viral proteins. During this course, the host immune system is activated (B and T-cells).
           <break>
           </break>
           Specifically, CD4+ T helper cells recognise antigenic peptides produced by antigen presenting cells and produce cytokines that promote cell mediated and/or humoral immunity.
           <break>
           </break>
           Similarly to avian flu, SARS infection induced similar pro-inflammatory cytokine pattern and might contribute to the severe nature of the virus.
           <break>
           </break>
           Clinical evidence of SARS treatment by corticosteroids where levels of IL-1beta reduced after administration- thus inhibition of inflammatory cytokines such as IL-1 may be beneficial strategy for treatment of SARS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, Ye L, Xu S, Sun R, Wang Y, Lou J
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Following the discovery of SARS-CoV, no specific or efficient clinical treatments were available since pathogenesis was not well understood.
           <break>
           </break>
           Acute lung injury associated with SARS can be attributed to complex and multifactorial pathophysiological process involving cytokines. Demonstrated that IL-1 play key role in pathogenesis of acute lung injury. WHO inferred that severe immune response kills SARS patients and that some cytokines may play important role in the process.
           <break>
           </break>
           IL-1 cytokine promotes inflammation by inducing cell injury.
           <break>
           </break>
           Study measured levels of IL-1 in 4 patient groups: controls, patients with SARS, patients with severe SARS and convalescent SARS patients.
           <break>
           </break>
           Study showed that levels of IL-1alpha did not differ between 3 SARS groups or controls.
           <break>
           </break>
           Suggests that host immune response to novel coronavirus may be different from the immune reaction to other pathogens.
           <break>
           </break>
           Overall results suggest that acute lung injury associated with SARS may not be induced by circulating cytokines. HOWEVER some patients had accepted corticosteroids and therefore results consistent with reports that only long term treatment (7-10 days) with a steroid can alter serum cytokine levels.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Known that over-expression of IL-1beta hallmark of SARS infection probably through activation of transcription factor nuclear factor, activator protein AP1 and activating factor 2. Therefore lung damage associated with SARS postulated to occur through cytokine and chemokine dysregulation.
           <break>
           </break>
           Study involved measurement of cytokines and chemokines including IL-1beta in 20 consecutive patients admitted to Hong Kong hospital.
           <break>
           </break>
           IL-1beta was significantly elevated above normal range within first 12, 7 and 5 days after disease onset.
           <break>
           </break>
           Those patients with more severe disease treated with pulsed methylprednisolone. IL-1beta levels higher in this patient group particularly 3-10 days after onset but returned to normal levels 1 week after disease onset in both sets of patients.
           <break>
           </break>
           IL-1beta can act as early response cytokine to viral infection. IL-1 elevation in SARS can induce hyperinnate inflammatory response leading to recruitment and accumulation of alveolar macrophages and PMN.
           <break>
           </break>
           Higher disease severity associated with more elevated plasma IL-1beta and addition of pulsed steroid controlled rapidly deteriorating clinical condition and attenuated otherwise exaggerated immunological response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable7" position="anchor">
       <label>
        Supplementary Table 7.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Mycophenolate.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS68">
            68
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Interferon-β and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hart
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           only)
           <break>
           </break>
           MPA showed strong inhibition, with an IC50 of 2.87 mM. This drug may provide an alternative to ribavirin for treatment of MERS-CoV. In conclusion, IFN-b, MPA or a combination of the two may be beneficial in the treatment of MERS-CoV or as a post-exposure intervention in high-risk patients with known exposures to MERS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS69">
            69
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lin
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           Note. (PLpros)= Papain-like proteases MERS-CoV and SARS-CoV – act as a potential anti-viral target for drugs
           <break>
           </break>
           Multiple inhibition assays also support a kinetic mechanism by which disulfiram together with 6TG and/or MPA can synergistically inhibit MERS-CoV PLpro, but not, due to its competitive mode of inhibition, SARS-CoV PLpro.
           <break>
           </break>
           Synergistic inhibition of MERS-CoV PLpro by disulfiram and 6-thioguanine or
           <bold>
            mycophenolic acid
           </bold>
           implies the potential for combination treatments using these three clinically available drugs.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS70">
            70
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cheng et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           At the time of the study, there were no potent inhibitors that target MERS-CoV PLpro. The authors report that the immunosuppressive drug mycophenolic acid, was able to inhibit MERS-CoV PLpro.
           <break>
           </break>
           MPA is a non-competitive inhibitor of MERS-CoV PLpro.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS71">
            71
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           )
           <break>
           </break>
           The authors assessed the anti-MERS-CoV activities of several compounds. Only mycophenolic acid exhibited low EC50 and high selectivity index.
           <break>
           </break>
           They found that a combination of mycophenolic acid and IFN-b1b lowered the EC50 of each drug by 1-3 times.
           <break>
           </break>
           Mycophenolic acid exhibits a number of attributes that support its practical use in MERS-CoV infection. It is commonly available in two forms, the prodrug mycophenolate mofetil and the salt mycophenolate sodium, and could be given orally.
           <break>
           </break>
           Interferon-b1b with mycophenolic acid should be considered in treatment trials of MERS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS72">
            72
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Shen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <italic>
            (In vitro)
           </italic>
           <break>
           </break>
           The authors sought to identify potent broad-spectrum inhibitors of corona viruses. They concluded that they had identified seven compounds (lycorine, emetine, monensin sodium,
           <bold>
            mycophenolate mofetil, mycophenolic acid
           </bold>
           , phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to their strong inhibition of replication by four CoVs in vitro at low-micromolar concentrations. They all inhibited the replication of all CoVs with EC50 values of 5μm.
           <break>
           </break>
           Mycophenolate mofetil and mycophenolic acid, showed a similar antiviral effect on the four CoVs suggesting that the two drugs might harbour similar core structures and antiviral mechanisms.
           <break>
           </break>
           In vivo antiviral activity is unknown from this study.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS73">
            73
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro but using clinical samples - Abstract only)
           <break>
           </break>
           The authors assessed the antiviral activities of ribavirin, 6-azauridine, pyrazofurin,
           <bold>
            mycophenolic acid
           </bold>
           , and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany.
           <break>
           </break>
           Mycophenolic acid did not affect replication of the SARS-associated coronaviruses.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS74">
            74
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Clinical example)
           <break>
           </break>
           Eight patients (15.7%) received mycophenolate mofetil, seven of these patients received it in combination with interferon beta. All patients who received mycophenolate mofetil survived. The authors concluded that whilst treatment with beta interferon and mycophenolate mofetil predicted survival (in univariate analysis only), the greatest predictor of survival was the severity of illness on presentation.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS75">
            75
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vivo)
           <break>
           </break>
           The authors assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil, lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans.
           <break>
           </break>
           all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads.
           <break>
           </break>
           The authors concluded that MMF alone may worsen MERS and should not be used.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS76">
            76
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           In vivo study in BALB/c mice (a replication model for SARS infections)
           <break>
           </break>
           In mycophenolic acid-treated mice, the lung virus titers (aka viral load) increased with increasing dosage, although these increases in lung virus titers were not quite significantly different from the lung virus titers in placebo-treated, infected mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS77">
            77
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of treatment modalities for Middle East Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mo and Fisher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Mycophenolic acid also inhibits purine nucleotide synthesis in lymphocytes. This makes it a popular immunosuppressant in solid-organ transplants and autoimmune diseases such as systemic lupus erythematosus.
           <break>
           </break>
           The use of mycophenolic acid monotherapy has not been reported in MERS. IFN-b and mycophenolic acid combination therapy was described in a retrospective observational study in Saudi Arabia involving 51 patients; all of the 8 patients who received IFN-b and mycophenolic acid survived.
           <break>
           </break>
           Corticosteroids, ribavirin monotherapy and mycophenolic acid are likely to cause more harm than benefit.
           <break>
           </break>
           There are no clinical data on the efficacy of mycophenolic acid in SARS or MERS. However, it led to severe and/or fatal disease with higher mean viral loads in an animal model.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS78">
            78
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al-Tawfiq and Memish
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           MPA mechanism of action - Direct and indirect antiviral activity by modulation of IFN response
           <break>
           </break>
           The use of mycophenolate in the common marmoset animal model resulted in higher mortality than untreated animals: Mortality rate was 67% (untreated and MMF treated) at 36 h post inoculation versus 0%–33% (lopinavir/ ritonavir-treated and interferon-β1b- treated
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS79">
            79
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Middle East Respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           The combination of mycophenolic acid and interferon beta 1b shows synergistic activity against MERS-CoV in Vero cells. The desirable pharmacokinetics of mycophenolic acid compared to ribavirin warrants further evaluation, although the potential inhibitory effect on the immune system and therefore neutralising antibody production should be fully assessed in animal models before use in humans.
           <break>
           </break>
           A fatal case of MERS was reported in a renal transplant recipient who was receiving antirejection therapy consisting of prednisone, mycophenolate mofetil, and cyclosporine, but the dosage, serum drug level of mycophenolate mofetil, and resulting lymphocyte count were not reported
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS80">
            80
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rabaan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Reiteration of the promising results of MPA in an in vitro setting, however, the marmoset animal model resulted in fatal disease and high viral loads. The authors therefore state that MPA should be used with caution for treatment of MERS-CoV.
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          The EC50 is the concentration of a drug that gives half-maximal response. The IC50 is the concentration of an inhibitor where the response (or binding) is reduced by half. These terms are referred to a few times within the summary table.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="Stable8" position="anchor">
       <label>
        Supplementary Table 8.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Tacrolimus.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS81">
            81
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
           .
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany/Switzerland
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2012
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronaviruses represent the group of RNA viruses with the largest RNA genome to date therefore the development of resistant mutants to targeted drugs remains a concern.
           <break>
           </break>
           Viral replication represents potential antiviral targets.
           <break>
           </break>
           Study performed genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identifying FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1 (Nsp1).
           <break>
           </break>
           FK506-binding proteins bind the immunosuppressive drug FK506 (tacrolimus).
           <break>
           </break>
           Since Nsp1 interacts with FK506-binding proteins, investigated whether FK506 inhibits replication of human coronaviruses.
           <break>
           </break>
           VeroFM cells infected with SARS-CoV and other human coronaviruses and treated with FK506.
           <break>
           </break>
           Study found that FK506 inhibits the replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with reduction in viral titers to undetectable levels.
           <break>
           </break>
           All human coronaviruses sensitive to FK506 indicating the involvement of FK506-binding proteins in viral replication.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS82">
            82
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           MERS CoV infection in two renal transplant recipients: Case report
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pneumonia caused by MERS-CoV associated with severe morbidity and mortality in immunocompromised patients.
           <break>
           </break>
           Data on clinical picture in solid organ transplant recipients and effect of anti-rejection immunosuppressive regimens unclear.
           <break>
           </break>
           30-year old patient with renal transplant on immunosuppressive regimen of tacrolimus.
           <break>
           </break>
           Tested positive for MERS CoV through nasopharyngeal swab.
           <break>
           </break>
           Received antibacterial therapy and mycophenolate mofetil dose reduced and underwent full recovery.
           <break>
           </break>
           Difficult to pinpoint why made full recovery compared to other case study (not on tacrolimus) who died.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS83">
            83
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Human coronavirus NL63 replication is cyclophilin
           <break>
           </break>
           A-dependent and inhibited by non-immunosuppressive
           <break>
           </break>
           cyclosporine A-derivatives
           <break>
           </break>
           including Alisporivir
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Previous study shown that FK506 inhibit coronavirus replication.
           <break>
           </break>
           This study further shows that novel non-immunosuppressive derivatives of CsA and FK506 strongly inhibit the growth of human coronavirus HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture.
           <break>
           </break>
           HCoV-NL63 and HCoV-HKU1 discovered in 2004 and 2005 causing more severe lower respiratory tract
           <break>
           </break>
           infections in younger children.
           <break>
           </break>
           PPIase-independent activities of CsA and FK506 exerted by gain-of-function, result from binary complexes formed by binding of the drugs to FKBPs. Based on inhibition of the protein phosphatase activity of calcineurin, these complexes block the cellular calcineurin/NFAT pathway
           <break>
           </break>
           thereby interfering with T-cell activation and IL-2 production.
           <break>
           </break>
           FK506 analogues (altered by side chain modification)
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <ref id="ref1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref2">
       <label>
        2.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of COVID-19 for patients with cancer
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30149-2
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk of COVID-19 for cancer patients
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30150-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         32142622
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref5">
       <label>
        5.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref12">
       <label>
        12.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir therapy
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Narazaki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kishimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         IL-6 in inflammation, immunity, and disease
        </article-title>
        <source>
         Cold Spring Harb Perspect Biol
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         a016295
        </fpage>
        <pub-id pub-id-type="doi">
         10.1101/cshperspect.a016295
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4176007</pub-id>-->
        <pub-id pub-id-type="pmid">
         25190079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <comment>
         pii:1
        </comment>
        <pub-id pub-id-type="pmid">
         32171193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         203
        </fpage>
        <lpage>
         208
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref42">
       <label>
        42.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kontzias
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kotlyar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Laurence
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
        </article-title>
        <source>
         Curr Opin Pharmacol
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         464
        </fpage>
        <lpage>
         470
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coph.2012.06.008
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3419278</pub-id>-->
        <pub-id pub-id-type="pmid">
         22819198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref44">
       <label>
        44.
       </label>
       <element-citation publication-type="webpage">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agency
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Olumiant (baricitinib)
        </article-title>
        <year>
         2019
        </year>
        <comment>
         [
         <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant">
          https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant
         </ext-link>
         ]
        </comment>
       </element-citation>
      </ref>
      <ref id="ref45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           YZ
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Antivir Res
        </source>
        <year>
         2010
        </year>
        <volume>
         88
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         160
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2010.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         20727913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="ref50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="ref53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.02.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ref-list>
      <title>
       References
      </title>
      <ref id="refS1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           XH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease]
        </article-title>
        <source>
         Zhonghua Zhong Liu Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         42
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E008
        </fpage>
        <pub-id pub-id-type="pmid">
         32133833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Wei Chang Wai Ke Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         23
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E004
        </fpage>
        <pub-id pub-id-type="pmid">
         32100980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aydin Köker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Demirag
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Tahta
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A 3-year retrospective study of the epidemiology of acute respiratory viral infections in pediatric patients with cancer undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr Hematol Oncol
        </source>
        <year>
         2019
        </year>
        <volume>
         41
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e242
        </fpage>
        <lpage>
         e246
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/MPH.0000000000001418
        </pub-id>
        <pub-id pub-id-type="pmid">
         30688827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soderman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rhedin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tolfvenstam
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Frequent respiratory viral infections in children with febrile neutropenia—a prospective follow-up study
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         e0157398
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0157398
        </pub-id>
        <pub-id pub-id-type="pmid">
         27309354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pillaiyar
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Manickam
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Namasivayam
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy
        </article-title>
        <source>
         J Med Chem
        </source>
        <year>
         2016
        </year>
        <volume>
         59
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         6595
        </fpage>
        <lpage>
         6628
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acs.jmedchem.5b01461
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7075650</pub-id>-->
        <pub-id pub-id-type="pmid">
         26878082
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijano
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Maron
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         3097
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2018.03097
        </pub-id>
        <pub-id pub-id-type="pmid">
         30619176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Guthrie
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2010
        </year>
        <volume>
         115
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         2088
        </fpage>
        <lpage>
         2094
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2009-09-244152
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2837322</pub-id>-->
        <pub-id pub-id-type="pmid">
         20042728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ogimi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Waghmare
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1532
        </fpage>
        <lpage>
         1539
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/cix160
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5434339</pub-id>-->
        <pub-id pub-id-type="pmid">
         28329354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghosh
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Xi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
        </article-title>
        <source>
         Annu Rep Med Chem
        </source>
        <year>
         2007
        </year>
        <volume>
         41
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         196
        </lpage>
        <!--<pub-id pub-id-type="pmcid">2718771</pub-id>-->
        <pub-id pub-id-type="pmid">
         19649165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chebotkevich
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <name>
          <surname>
           Bessmel'tsev
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Volkov
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression]
        </article-title>
        <source>
         Vopr Onkol
        </source>
        <year>
         2006
        </year>
        <volume>
         52
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         421
        </fpage>
        <lpage>
         426
        </lpage>
        <pub-id pub-id-type="pmid">
         17024815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <issue>
         18
        </issue>
        <fpage>
         2095
        </fpage>
        <lpage>
         2162
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/0929867054637644
        </pub-id>
        <pub-id pub-id-type="pmid">
         16101496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2005
        </year>
        <volume>
         328
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         979
        </fpage>
        <lpage>
         986
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2005.01.048
        </pub-id>
        <pub-id pub-id-type="pmid">
         15707974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS22">
       <label>
        22.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools
        </article-title>
        <source>
         Virol Sin
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1007/s12250-020-00207-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7035235</pub-id>-->
        <pub-id pub-id-type="pmid">
         32125642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Acland
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Gunson
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Gillette
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ulcerative duodenitis in foals
        </article-title>
        <source>
         Vet Pathol
        </source>
        <year>
         1983
        </year>
        <volume>
         20
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         653
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/030098588302000601
        </pub-id>
        <pub-id pub-id-type="pmid">
         6649336
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS24">
       <label>
        24.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS25">
       <label>
        25.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SSY
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K-Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         The management of coronavirus infections with particular reference to SARS
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2008
        </year>
        <volume>
         62
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         437
        </fpage>
        <lpage>
         441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkn243
        </pub-id>
        <pub-id pub-id-type="pmid">
         18565970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir Ther
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
        <pub-id pub-id-type="pmid">
         17302372
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti-infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells
        </article-title>
        <source>
         Int J Mol Med
        </source>
        <year>
         2005
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         323
        </fpage>
        <lpage>
         327
        </lpage>
        <pub-id pub-id-type="pmid">
         15647850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS38">
       <label>
        38.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25770
        </pub-id>
        <pub-id pub-id-type="pmid">
         32181911
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         pii:1
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS40">
       <label>
        40.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           SX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2009
        </year>
        <volume>
         395
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         210
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2009.09.023
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2787736</pub-id>-->
        <pub-id pub-id-type="pmid">
         19853271
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wathelet
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Orr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         11620
        </fpage>
        <lpage>
         11633
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00702-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2168762</pub-id>-->
        <pub-id pub-id-type="pmid">
         17715225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zalinger
          </surname>
          <given-names>
           ZB
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus
        </article-title>
        <source>
         J Neurovirol
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         845
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s13365-017-0574-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5726909</pub-id>-->
        <pub-id pub-id-type="pmid">
         28895072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           IY
          </given-names>
         </name>
         <name>
          <surname>
           Moriyama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           M-F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus viroporin 3a activates the nlrp3 inflammasome
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2019.00050
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">6361828</pub-id>-->
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeostat Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="refS67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <issue>
         9374
        </issue>
        <fpage>
         2045
        </fpage>
        <lpage>
         2046
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13615-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         12814717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2017
        </year>
        <volume>
         15
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         269
        </fpage>
        <lpage>
         275
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14787210.2017.1271712
        </pub-id>
        <pub-id pub-id-type="pmid">
         27937060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2015
        </year>
        <volume>
         28
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4402954</pub-id>-->
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Alahmed
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2017
        </year>
        <volume>
         66
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         1261
        </fpage>
        <lpage>
         1274
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.000565
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7079582</pub-id>-->
        <pub-id pub-id-type="pmid">
         28855003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS83">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <table-wrap id="table1" position="float">
      <label>
       Table 1.
      </label>
      <caption>
       <title>
        Search terms and the number of studies included for each investigated drug group.
       </title>
      </caption>
      <table frame="border" rules="all">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Drug group
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Search terms
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Number of studies included
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          All cytotoxic
          <break>
          </break>
          chemotherapy
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or SARS-CoV AND
          <break>
          </break>
          chemotherapy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          24/30
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Low-dose steroids/NSAIDs
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-inflammatory or ibuprofen or isobutylphenylpropionic acid or cortisone or non-steroidal anti-inflammatory)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/58
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Any TNF blocker
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (TNF blocker or Anti-TNF therapy or TNFα inhibitor or infliximab or etanercept or Certolizumab or Golimumab or adalimumab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/3
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-6 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Two different search strategies were explored due to the number of agents that block the IL-6:
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Anti-IL-6 therapy or anti-interleukin-6 receptor antibody or anti-interlukin-6 therapy or interlukin 6 blockage or interlukin-6 blockage or IL 6 blockage or IL-6 blockage or tocilizumab or siltuximab or Sylvant or sarilumab or olokizumab or CDP6038 or elsilimomab or BMS-945429 or ALD518 or sirukumab or CNTO 136 or CPSI-2364 or ALX-0061 or clazakizumab or olokizumab or sarilumab or sirukumab or ARGX-109 or FE301 or FM101))
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (IL-6 or interlukin 6 or Anti-IL-6 therapy or IL-6 blockage or tocilizumab or siltuximab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
          <break>
          </break>
          23/108
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          JAK inhibitors
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (JAK or JAK1 or JAK2 or TYK3 or tofacitinib or baricitinib or filgotinib or peficitinib or ABT494 or decernotinib))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          4/15
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-1 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Interleukin-1 or IL-1 or IL-1RA or canakinumab or anti-IL-1 or IL-1 antagonists or IL-1 blockers or rilonacept or IL-1 trap or ACZ885 or anakinra)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          9/37
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Mycophenylate
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (mycophenolate mofetil OR mycophenolate OR myfortic)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/29
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Tacrolimus
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (envarsus or tacni or tacrolimus or prograf or FK506)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3/18
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Anti-CD20
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-cd20 monoclonal antibodies or anti-cd20 or rituximab or truxima or zevalin or ruxience or rituxan or arzerra or gazyva)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          CTLA4-Ig
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (CTLA-4 Ig or CTLA4 or CTLA-4 or Ipilimumab or yervoy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30646565
      </article-id>
      <article-id pub-id-type="pmc">
       6357155
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v11010059
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-11-00059
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        From SARS to MERS, Thrusting Coronaviruses into the Spotlight
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          Zhiqi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Yanfeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bao
         </surname>
         <given-names>
          Linlin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Ling
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yu
         </surname>
         <given-names>
          Pin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Qu
         </surname>
         <given-names>
          Yajin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Hua
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Wenjie
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Yunlin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Qin
         </surname>
         <given-names>
          Chuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-11-00059">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-11-00059">
       <label>
        1
       </label>
       Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC), Beijing 100021, China;
       <email>
        songzhiqi1989@foxmail.com
       </email>
       (Z.S.);
       <email>
        xuyanf2009@163.com
       </email>
       (Y.X.);
       <email>
        bllmsl@aliyun.com
       </email>
       (L.B.);
       <email>
        zhangling@cnilas.org
       </email>
       (L.Z.);
       <email>
        pinyucau@gmail.com
       </email>
       (P.Y.);
       <email>
        quyj@cnilas.org
       </email>
       (Y.Q.);
       <email>
        zhuh@cnilas.org
       </email>
       (H.Z.);
       <email>
        hnndwenjiezhao@163.com
       </email>
       (W.Z.);
       <email>
        18510165683@163.com
       </email>
       (Y.H.)
      </aff>
      <aff id="af2-viruses-11-00059">
       <label>
        2
       </label>
       NHC Key Laboratory of Human Disease Comparative Medicine, the Institute of Laboratory Animal Sciences, CAMS&amp;PUMC, Beijing 100021, China
      </aff>
      <aff id="af3-viruses-11-00059">
       <label>
        3
       </label>
       Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, Beijing 100021, China
      </aff>
      <author-notes>
       <corresp id="c1-viruses-11-00059">
        <label>
         *
        </label>
        Correspondence:
        <email>
         qinchuan@pumc.edu.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        14
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       1
      </issue>
      <elocation-id>
       59
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         16
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         1
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 by the authors.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused high pathogenicity and mortality rates in human populations. This brought CoVs global attention and highlighted the importance of controlling infectious pathogens at international borders. In this review, we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable animal models, we compare the current animal models recapitulating pathogenesis and summarize the potential role of host receptors contributing to diverse host affinity in various species. We outline the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV and MERS-CoV, but also these emerging coronaviral diseases.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        coronaviruses
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        spike proteins
       </kwd>
       <kwd>
        animal model
       </kwd>
       <kwd>
        prevention and treatment
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-11-00059">
     <title>
      1. Introduction
     </title>
     <p>
      Before the first outbreak of severe acute respiratory syndrome (SARS), a limited number of coronaviruses were known to be circulating in humans, causing only mild illnesses, such as the common cold [
      <xref ref-type="bibr" rid="B1-viruses-11-00059">
       1
      </xref>
      ]. Following the 2003 SARS pandemic [
      <xref ref-type="bibr" rid="B2-viruses-11-00059">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3-viruses-11-00059">
       3
      </xref>
      ], it became apparent that coronaviruses could cross the species barrier and cause life-threatening infections in humans. Therefore, further attention needs to be paid to these new coronaviruses.
     </p>
     <p>
      The 21st century has seen the worldwide spread of two previously unrecognized coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) [
      <xref ref-type="bibr" rid="B4-viruses-11-00059">
       4
      </xref>
      ] and Middle East respiratory syndrome coronavirus (MERS-CoV), both of which are highly pathogenic. Starting from November 2002 in China [
      <xref ref-type="bibr" rid="B5-viruses-11-00059">
       5
      </xref>
      ], there have been unprecedented nosocomial transmissions from person to person of SARS-CoV, accompanied by high fatality rates. A united global effort led to the rapid identification of the SARS coronavirus and remarkable scientific advancements in epidemic prevention. Additionally, the zoonotic transmission of SARS from December 2003 to January 2004 [
      <xref ref-type="bibr" rid="B6-viruses-11-00059">
       6
      </xref>
      ] provided insight for researchers into the origin of this novel coronavirus. Notably, the SARS pandemic was declared to be over in 2004 when no more infections in patients were being detected. Subsequently, certain SARS-CoV-like viruses found in bats demonstrated the ability to infect human cells without prior adaptation [
      <xref ref-type="bibr" rid="B7-viruses-11-00059">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-viruses-11-00059">
       8
      </xref>
      ] which indicates the possibility of the re-emergence of SARS-CoV or SARS-CoV-like viruses.
     </p>
     <p>
      A decade later in June 2012, another highly pathogenic and novel coronavirus, MERS-CoV, was isolated from the sputum of a male patient who died from acute pneumonia and renal failure in Saudi Arabia [
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ]. Nosocomial infections were reported, and international travel led to the transmission of MERS-CoV to countries outside of the Arabian Peninsula, causing it to become a global pathophoresis. In May 2015, an outbreak of MERS occurred in South Korea due to an individual returning from the Middle East [
      <xref ref-type="bibr" rid="B10-viruses-11-00059">
       10
      </xref>
      ]. Based on the lessons learned from managing SARS-CoV prevalence over the last decade, tremendous progress toward unraveling the biological characteristics of MERS-CoV has been achieved at an unprecedented speed. Scientific advancements have allowed for rapid and systemic progress in our understanding of the epidemiology and pathogenesis of MERS-CoV.
     </p>
     <p>
      SARS-CoV and MERS-CoV share several important common features that contribute to nosocomial transmission, preferential viral replication in the lower respiratory tract, and viral immunopathology. This review highlights the epidemiology and pathogenesis of these viruses, including our current understanding of their biological characteristics, their transmission, and their replication in the host. The spike proteins (S proteins) of CoVs play pivotal roles in viral infection and pathogenesis. As critical surface-located trimeric glycoproteins of CoVs, they guide entry into host cells. In this review, we summarize the structure and function of the S proteins and therapeutics designed to target them. Moreover, we will explore how CoV–host interactions cause pathogenic outcomes and discuss potential treatment options, as well as describe recent mammalian models that closely recapitulate the pathogenic process and have contributed to the development of prevention and treatment strategies for SARS-CoV and MERS-CoV. Although several potential therapies have been identified with SARS and MERS in animal and in vitro models, human clinical trials remain lacking, hindering the advancement of these potential countermeasures.
     </p>
    </sec>
    <sec id="sec2-viruses-11-00059">
     <title>
      2. Epidemiology of SARS-CoV and MERS-CoV
     </title>
     <p>
      Prior to the outbreaks of SARS and MERS [
      <xref ref-type="bibr" rid="B2-viruses-11-00059">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ], the clinical importance and epidemic possibility of CoVs had been recognized by researchers, (
      <xref ref-type="table" rid="viruses-11-00059-t001">
       Table 1
      </xref>
      ). In 2002, a SARS epidemic that originated in Guangdong Province in China resulted in 916 deaths among more than 8098 patients in 29 countries [
      <xref ref-type="bibr" rid="B11-viruses-11-00059">
       11
      </xref>
      ], identifying SARS as the first new infectious disease of the 21st century. Ten years later, the World Health Organization (WHO) published 2254 laboratory-confirmed cases of MERS-CoV that occurred from 2012 to 16 September 2018, with at least 800 deaths in 27 countries. Remarkably, more than 80% of recent research into the virology and genetics of this infection indicated that bats could be the possible natural reservoirs of both SARS and MERS-CoV. Palm civets [
      <xref ref-type="bibr" rid="B12-viruses-11-00059">
       12
      </xref>
      ] and dromedary camels [
      <xref ref-type="bibr" rid="B13-viruses-11-00059">
       13
      </xref>
      ] are also possible intermediary hosts of SARS and MERS, respectively, before dissemination to humans [
      <xref ref-type="bibr" rid="B14-viruses-11-00059">
       14
      </xref>
      ].
     </p>
     <p>
      The transmission mechanism of SARS-CoV and MERS-CoV has yet to be fully understood. For transmission from animals to humans, direct contact with the intermediary host might be one route. Recent reports demonstrated that camel workers in Saudi Arabia with high prevalence of MERS-CoV infection may contribute to the transmission of MERS [
      <xref ref-type="bibr" rid="B15-viruses-11-00059">
       15
      </xref>
      ]. Some customs and habits may also be conducive to transmission, such as the consumption of milk, urine, or uncooked meat. In this way, MERS-CoV was transmitted from dromedary camels directly to humans, principally in the Arabian Peninsula, and this is considered to be the main route of transmission from animals to humans, causing significant morbidity and mortality [
      <xref ref-type="bibr" rid="B16-viruses-11-00059">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17-viruses-11-00059">
       17
      </xref>
      ]. Human-to-human spread has also been detected, especially through nosocomial transmission. Delays in diagnosis in hospitals might lead to secondary cases among healthcare workers, family members, or other patients sharing rooms [
      <xref ref-type="bibr" rid="B18-viruses-11-00059">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B19-viruses-11-00059">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-viruses-11-00059">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-11-00059">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-11-00059">
       22
      </xref>
      ]. Among the reported cases of SARS, 22% were healthcare workers in China and more than 40% were healthcare workers in Canada [
      <xref ref-type="bibr" rid="B23-viruses-11-00059">
       23
      </xref>
      ]. Nosocomial transmission for MERS has similarly been seen in the Middle East [
      <xref ref-type="bibr" rid="B16-viruses-11-00059">
       16
      </xref>
      ] and in the Republic of Korea [
      <xref ref-type="bibr" rid="B22-viruses-11-00059">
       22
      </xref>
      ]. Outbreaks in other countries all resulted from the reported cases in the Middle East or North Africa, and transmission was the result of international travel. Both SARS and MERS caused large outbreaks with significant public health and economic consequences.
     </p>
    </sec>
    <sec id="sec3-viruses-11-00059">
     <title>
      3. Pathogenesis of SARS-CoV and MERS-CoV
     </title>
     <p>
      Although our current understanding of the pathogenesis of the SARS-CoV and MERS-CoV infection remains unclear, we summarize what is presently known (
      <xref ref-type="table" rid="viruses-11-00059-t002">
       Table 2
      </xref>
      ).
     </p>
     <p>
      Coronaviruses are the largest kind of positive-strand RNA viruses (26–32 kb) as they are about 125 nm in diameter [
      <xref ref-type="bibr" rid="B24-viruses-11-00059">
       24
      </xref>
      ], and comprise four genera (alpha-, beta-, gamma-, and delta-coronavirus) [
      <xref ref-type="bibr" rid="B25-viruses-11-00059">
       25
      </xref>
      ]. Currently, six human CoVs (HCoVs) have been confirmed: HCoV-NL63 and HCoV-229E, which belong to the alpha-coronavirus genus; and HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV, which belong to the beta-coronavirus genus. SARS-CoV and MERS-CoV are the two major causes of severe pneumonia in humans and share some common coronavirus structural characteristics. Similarly, their genomic organization is typical of coronaviruses, having an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins 3–5, that follow the characteristic gene order [5′-replicase (
      <italic>
       rep
      </italic>
      gene), spike (S), envelope (E), membrane (M), nucleocapsid (N)-3′] with short untranslated regions at both termini (
      <xref ref-type="fig" rid="viruses-11-00059-f001">
       Figure 1
      </xref>
      ). The viral membrane contains S, E, and M proteins, and the spike protein plays a vital functional role in viral entry. The
      <italic>
       rep
      </italic>
      gene encodes the non-structural protein and constitutes approximately two-thirds of the genome at the 5′ end. In detail, the S protein is in charge of receptor-binding and subsequent viral entry into host cells, and is therefore a major therapeutic target [
      <xref ref-type="bibr" rid="B26-viruses-11-00059">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="B27-viruses-11-00059">
       27
      </xref>
      ]. The M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis.
     </p>
     <p>
      The SARS-CoV genome has 29,727 nucleotides in length, including 11 open reading frames (ORFs). The SARS-CoV
      <italic>
       rep
      </italic>
      gene, containing about two-thirds of the genome, encodes at least two polyproteins (encoded by ORF1a and ORF1b) that undergo the process of cotranslational proteolysis. Between ORF1b and S of group 2 and some group 3 coronaviruses, there is a gene that encodes hemagglutinin-esterase [
      <xref ref-type="bibr" rid="B4-viruses-11-00059">
       4
      </xref>
      ], while this was not detected in SARS-CoV. This virus is significantly different from previously reported coronaviruses for many reasons, such as the short anchor of the S protein, the specific number and location of small ORFs, and the presence of only one copy of PLP
      <sup>
       pro
      </sup>
      .
     </p>
     <p>
      The MERS-CoV genome is larger than that of SARS-CoV at 30,119 nucleotides in length, and comprises a 5′ terminal cap structure, along with a poly (A) tail at the 3′ end, as well as the
      <italic>
       rep
      </italic>
      gene containing 16 non-structural proteins (nsp1–16) at the 5′ end of the genome. Four structural proteins (S, E, M, and N) and five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF8) constitute about 10 kb at the 3′ end of the genome. Unlike some other beta-coronaviruses, the MERS-CoV genome does not encode a hemagglutinin-esterase (HE) protein [
      <xref ref-type="bibr" rid="B1-viruses-11-00059">
       1
      </xref>
      ]. Genomic analysis of MERS-CoV implies the potential for genetic recombination during a MERS-CoV outbreak [
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ]. MERS-CoV and SARS-CoV possess five and eight accessory proteins, respectively, which might help the virus evade the immune system by being harmful to the innate immune response. These differences might lead to greater sensitivity to the effects of induction and signaling of type 1 interferons (IFNs) in MERS-CoV than SARS-CoV.
     </p>
    </sec>
    <sec id="sec4-viruses-11-00059">
     <title>
      4. Comparative Pathology and Life Cycles of SARS-CoV and MERS-CoV
     </title>
     <p>
      Both SARS and MERS cause severe pneumonia resulting from these novel coronaviruses, sharing some similarities in their pathogenesis (
      <xref ref-type="fig" rid="viruses-11-00059-f002">
       Figure 2
      </xref>
      ) [
      <xref ref-type="bibr" rid="B28-viruses-11-00059">
       28
      </xref>
      ].
     </p>
     <p>
      SARS is an emerging infectious viral disease characterized by severe clinical manifestations of the lower respiratory tract, resulting in diffuse alveolar damage. SARS-CoV spreads through respiratory secretions, such as droplets, via direct person-to-person contact. Upon exposure of the host to the virus, the virus binds to cells expressing the virus receptors, of which the angiotensin-converting enzyme 2 (ACE2) is one of the main receptors, and CD209L is an alternative receptor with a much lower affinity [
      <xref ref-type="bibr" rid="B29-viruses-11-00059">
       29
      </xref>
      ]. In the respiratory tract, ACE2 is widely expressed on the epithelial cells of alveoli, trachea, bronchi, bronchial serous glands [
      <xref ref-type="bibr" rid="B30-viruses-11-00059">
       30
      </xref>
      ], and alveolar monocytes and macrophages [
      <xref ref-type="bibr" rid="B31-viruses-11-00059">
       31
      </xref>
      ]. The virus enters and replicates in these target cells. The mature virions are then released from primary cells and infect new target cells [
      <xref ref-type="bibr" rid="B32-viruses-11-00059">
       32
      </xref>
      ]. Furthermore, as a surface molecule, ACE2 is also diffusely localized on the endothelial cells of arteries and veins, the mucosal cells of the intestines, tubular epithelial cells of the kidneys, epithelial cells of the renal tubules, and cerebral neurons and immune cells, providing a variety of susceptible cells to SARS-CoV [
      <xref ref-type="bibr" rid="B33-viruses-11-00059">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="B34-viruses-11-00059">
       34
      </xref>
      ]. Respiratory secretions, urine, stools, and sweat from patients with SARS contain infective viral particles, which may be excreted into and contaminate the environment. Atypical pneumonia with rapid respiratory deterioration and failure can be induced by SARS-CoV infection because of increased levels of activated proinflammatory chemokines and cytokines [
      <xref ref-type="bibr" rid="B35-viruses-11-00059">
       35
      </xref>
      ].
     </p>
     <p>
      For MERS-CoV infection of humans, the primary receptor is a multifunctional cell surface protein, dipeptidyl peptidase 4 (DPP4, also known as CD26) [
      <xref ref-type="bibr" rid="B36-viruses-11-00059">
       36
      </xref>
      ], which is widely expressed on epithelial cells in the kidney, alveoli, small intestine, liver, and prostate, and on activated leukocytes [
      <xref ref-type="bibr" rid="B37-viruses-11-00059">
       37
      </xref>
      ]. Consistent with this, MERS-CoV can infect several human cell lines, including lower respiratory, kidney, intestinal, and liver cells, as well as histiocytes, as shown by a cell-line susceptibility study [
      <xref ref-type="bibr" rid="B38-viruses-11-00059">
       38
      </xref>
      ], indicating that the range of MERS-CoV tissue tropism in vitro was broader than that of any other CoV. MERS-CoV causes acute, highly lethal pneumonia and renal dysfunction with various clinical symptoms, including—but not restricted to—fever, cough, sore throat, myalgia, chest pain, diarrhea, vomiting, and abdominal pain [
      <xref ref-type="bibr" rid="B39-viruses-11-00059">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-viruses-11-00059">
       40
      </xref>
      ]. Lung infection in the MERS animal model demonstrated infiltration of neutrophils and macrophages and alveolar edema [
      <xref ref-type="bibr" rid="B41-viruses-11-00059">
       41
      </xref>
      ]. The entry receptor (DPP4) for MERS-CoV is also highly expressed in the kidney, causing renal dysfunctions by either hypoxic damage or direct infection of the epithelia [
      <xref ref-type="bibr" rid="B42-viruses-11-00059">
       42
      </xref>
      ]. Remarkably, unlike SARS-CoV, MERS-CoV has the ability to infect human dendritic cells [
      <xref ref-type="bibr" rid="B43-viruses-11-00059">
       43
      </xref>
      ] and macrophages [
      <xref ref-type="bibr" rid="B44-viruses-11-00059">
       44
      </xref>
      ] in vitro, thus helping the virus to disrupt the immune system. T cells are another target for MERS-CoV because of their high amounts of CD26 [
      <xref ref-type="bibr" rid="B45-viruses-11-00059">
       45
      </xref>
      ]. This virus might deregulate antiviral T-cell responses due to the stimulation of T-cell apoptosis [
      <xref ref-type="bibr" rid="B45-viruses-11-00059">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="B46-viruses-11-00059">
       46
      </xref>
      ]. MERS-CoV might also lead to immune dysregulation [
      <xref ref-type="bibr" rid="B47-viruses-11-00059">
       47
      </xref>
      ] by stimulating attenuated innate immune responses, with delayed proinflammatory cytokine induction in vitro and in vivo [
      <xref ref-type="bibr" rid="B44-viruses-11-00059">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="B48-viruses-11-00059">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="B49-viruses-11-00059">
       49
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec5-viruses-11-00059">
     <title>
      5. SARS and MERS-CoV Spike Protein: A Key Target for Antivirals
     </title>
     <sec id="sec5dot1-viruses-11-00059">
      <title>
       5.1. Structure of the SARS-CoV and MERS-CoV Spike Protein
      </title>
      <p>
       Trimers of the S protein make up the spikes of SARS-CoV and provide the formation of a 1255-amino-acids-length surface glycoprotein precursor. Most of the protein and the amino terminus are situated on the outside of the virus particle or the cell surface [
       <xref ref-type="bibr" rid="B50-viruses-11-00059">
        50
       </xref>
       ]. The expected structure of the S protein comprises four parts: a signal peptide located at the N terminus from amino acids 1 to 12, an extracellular domain from amino acids 13 to 1195, a transmembrane domain from amino acids 1196 to 1215, and an intracellular domain from amino acids 1216 to 1255. Proteases such as factor Xa, trypsin, and cathepsin L cleave the SARS-CoV S protein into two subunits, the S1 and S2 subunits. A minimal receptor-binding domain (RBD) located in the S1 subunit (amino acids 318–510) can combine with the host cell receptor, ACE2. The RBD displays a concave surface during interaction with the receptor. The entire receptor-binding loop, known as the receptor-binding motif (RBM) (amino acids 424–494), is located on the RBD and is responsible for complete contact with ACE2. Importantly, two residues in the RBM at positions 479 and 487 determine the progression of the SARS disease and the tropism of SARS-CoV [
       <xref ref-type="bibr" rid="B51-viruses-11-00059">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="B52-viruses-11-00059">
        52
       </xref>
       ]. Recent studies using civets, mice, and rats demonstrated that any change in these two residues might improve animal-to-human or human-to-human transmission and facilitate efficient cross-species infection [
       <xref ref-type="bibr" rid="B53-viruses-11-00059">
        53
       </xref>
       ]. The S2 subunit mediates the fusion between SARS-CoV and target cells, and includes the heptad repeat 1 (HR1) and HR2 domains, whose HR1 region is longer than the HR2 region.
      </p>
      <p>
       Similar to SARS-CoV, during the infection process, the S protein of MERS-CoV is cleaved into a receptor-binding subunit S1 and a membrane-fusion subunit S2 [
       <xref ref-type="bibr" rid="B54-viruses-11-00059">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="B55-viruses-11-00059">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ]. The MERS-CoV S1 subunit also includes an RBD, mediating the attachment between virus and target cells [
       <xref ref-type="bibr" rid="B54-viruses-11-00059">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="B55-viruses-11-00059">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B58-viruses-11-00059">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="B59-viruses-11-00059">
        59
       </xref>
       ]. Unlike SARS-CoV, MERS-CoV requires DPP4 (also known as CD26) as its cellular receptor [
       <xref ref-type="bibr" rid="B60-viruses-11-00059">
        60
       </xref>
       ,
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ] but not ACE2. The RBDs of MERS-CoV and SARS-CoV differ, although they share a high degree of structural similarity in their core subdomains, explaining the different critical receptors noted above [
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B62-viruses-11-00059">
        62
       </xref>
       ]. The core subdomain of RBD is stabilized by three disulfide bonds, and includes a five-stranded antiparallel β-sheet and several connecting helices. The RBM comprises a four-stranded antiparallel β-sheet for connecting to the core via loops [
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B62-viruses-11-00059">
        62
       </xref>
       ]. Two N-linked glycans, N410 and N487, are seated in the core and RBM, respectively. Particularly, the residues 484–567 of RBM take charge of interacting with the extracellular β-propeller domain of DPP4. The fusion core formation of MERS-CoV resembles that of SARS-CoV; however, it is different from that of other coronaviruses, such as the mouse hepatitis virus (MHV) and HCoV-NL63 [
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="B64-viruses-11-00059">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="B65-viruses-11-00059">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="B66-viruses-11-00059">
        66
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot2-viruses-11-00059">
      <title>
       5.2. Functions of the SARS-CoV and MERS-CoV S Protein
      </title>
      <p>
       The SARS-CoV S protein plays pivotal roles in viral infection and pathogenesis [
       <xref ref-type="bibr" rid="B67-viruses-11-00059">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="B68-viruses-11-00059">
        68
       </xref>
       ]. The S1 subunit recognizes and binds to host receptors, and the subsequent conformational changes in the S2 subunit mediate fusion between the viral envelope and the host cell membrane [
       <xref ref-type="bibr" rid="B69-viruses-11-00059">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="B71-viruses-11-00059">
        71
       </xref>
       ]. ACE2 is a functional receptor for SARS-CoV that makes contact with 14 amino acids in the RBD of SARS-CoV among its 18 residues [
       <xref ref-type="bibr" rid="B53-viruses-11-00059">
        53
       </xref>
       ]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="B71-viruses-11-00059">
        71
       </xref>
       ]. Position R453 in the RBD and position K341 in ACE2 play indispensable roles in complex formation [
       <xref ref-type="bibr" rid="B72-viruses-11-00059">
        72
       </xref>
       ]. Furthermore, the N479 and T487 in the RBD of the S protein are pivotal positions for the affinity with ACE2 [
       <xref ref-type="bibr" rid="B52-viruses-11-00059">
        52
       </xref>
       ], and R441 or D454 in the RBD influences the antigenic structure and binding activity between RBD and ACE2 [
       <xref ref-type="bibr" rid="B73-viruses-11-00059">
        73
       </xref>
       ]. From a pre-fusion structure to a post-fusion structure, binding of the RBD in the S1 subunit to the receptor ACE2 stimulates a conformational change in S2. Accordingly, the supposed fusion peptide (amino acids 770–788) [
       <xref ref-type="bibr" rid="B74-viruses-11-00059">
        74
       </xref>
       ] builds in the target cell membrane of the host. Meanwhile, a six-helix bundle fusion core structure is made up by the HR1 and HR2 domains for bringing the viral envelope and the target cell membrane into close proximity and contributing to fusion [
       <xref ref-type="bibr" rid="B74-viruses-11-00059">
        74
       </xref>
       ]. Resembling the S2 subunit of SARS-CoV, the MERS-CoV S2 subunit is in charge of membrane fusion. The HR1 and HR2 regions in S2 play essential and complementary roles [
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ]. Furthermore, SARS-CoV displays an alternative method of binding to the host cell via other potential receptors. Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and/or liver/lymph node-SIGN (L-SIGN) are two examples of such receptors [
       <xref ref-type="bibr" rid="B29-viruses-11-00059">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="B75-viruses-11-00059">
        75
       </xref>
       ]. Seven residue sites, at positions 109, 118, 119, 158, 227, 589, and 699 of the S protein displaying asparagine-linked glycosylation are crucial for DC-SIGN or L-SIGN-mediated virus entry. These residues, unlike those of the ACE2-binding domain, function independently of ACE2 [
       <xref ref-type="bibr" rid="B76-viruses-11-00059">
        76
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot3-viruses-11-00059">
      <title>
       5.3. Vaccines Based on the SARS-CoV and MERS-CoV S Protein
      </title>
      <p>
       In order to control the outbreak of viruses, vaccinations were developed against SARS-CoV and MERS-CoV. There are various approaches of different vaccines, and the development and advantages/disadvantages of these are listed in
       <xref ref-type="table" rid="viruses-11-00059-t003">
        Table 3
       </xref>
       (this table includes updates about SARS-CoV and MERS-CoV since 2013; SARS-CoV-related parts were modified by Graham et al. in Nature Reviews Microbiology, 2013 [
       <xref ref-type="bibr" rid="B77-viruses-11-00059">
        77
       </xref>
       ]).
      </p>
      <p>
       Importantly, among all the functional/non-functional structural proteins of SARS-CoV and MERS-CoV, the S protein is the principal antigenic component that induces antibodies to block virus-binding, stimulate host immune responses, fuse or neutralize antibodies and/or protect the immune system against virus infection. Therefore, the S protein has been selected as a significant target for the development of vaccines. It has been noted that antibodies raised against subunit S1 (amino acids 485–625) or S2 (amino acids 1029–1192) neutralize infection by SARS-CoV strains in Vero E6 cells [
       <xref ref-type="bibr" rid="B78-viruses-11-00059">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="B79-viruses-11-00059">
        79
       </xref>
       ]. Researchers have constructed an attenuated parainfluenza virus encoding the full-length S protein of the SARS-CoV Urbani strain for the vaccination of African green monkeys. This vaccine could protect monkeys from subsequent homologous SARS-CoV infection, demonstrating highly effective immunization with the S protein [
       <xref ref-type="bibr" rid="B80-viruses-11-00059">
        80
       </xref>
       ]. Other studies in a mouse model structured a DNA vaccine encoding the full-length S protein of the SARS-CoV Urbani strain that not only induced T-cell and neutralizing-antibody responses, but also stimulated protective immunity [
       <xref ref-type="bibr" rid="B81-viruses-11-00059">
        81
       </xref>
       ]. Furthermore, monkeys or mice were vaccinated with a highly attenuated, modified vaccine virus, Ankara, encoding the full-length S protein of the SARS-CoV strain HKU39849 or Urbani [
       <xref ref-type="bibr" rid="B82-viruses-11-00059">
        82
       </xref>
       ]. However, full-length S protein-based SARS vaccines may induce harmful immune responses, causing liver damage in the vaccinated animals or enhancing infection after being challenged with homologous SARS-CoV [
       <xref ref-type="bibr" rid="B83-viruses-11-00059">
        83
       </xref>
       ,
       <xref ref-type="bibr" rid="B84-viruses-11-00059">
        84
       </xref>
       ]. Researchers are thus concerned about the safety and ultimate protective efficacy of vaccines that include the full-length SARS-CoV S protein.
      </p>
      <p>
       There are still no commercial vaccines available against MERS-CoV [
       <xref ref-type="bibr" rid="B26-viruses-11-00059">
        26
       </xref>
       ]. Multiple vaccine candidates targeting the S protein, which is responsible for viral entry, have been developed, including subunit vaccines [
       <xref ref-type="bibr" rid="B85-viruses-11-00059">
        85
       </xref>
       ,
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ], recombinant vector vaccines [
       <xref ref-type="bibr" rid="B87-viruses-11-00059">
        87
       </xref>
       ,
       <xref ref-type="bibr" rid="B88-viruses-11-00059">
        88
       </xref>
       ], and DNA vaccines [
       <xref ref-type="bibr" rid="B89-viruses-11-00059">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="B90-viruses-11-00059">
        90
       </xref>
       ]. Importantly, compared with other regions of the S protein, the RBD fragment induced the highest-titer IgG antibodies in mice [
       <xref ref-type="bibr" rid="B85-viruses-11-00059">
        85
       </xref>
       ]. Modified vaccines, including recombinant vectors of Ankara and adenoviruses expressing the MERS-CoV S glycoprotein, showed immunogenicity in mice [
       <xref ref-type="bibr" rid="B25-viruses-11-00059">
        25
       </xref>
       ]. Attenuated live vaccines also showed a protective function, but there were concerns regarding the degree of attenuation [
       <xref ref-type="bibr" rid="B91-viruses-11-00059">
        91
       </xref>
       ]. After intranasal vaccination with the CoV N protein, airway memory CD4 T cells were generated and mediated the protection following a CoV challenge [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. These cells could induce anti-viral innate responses at an early stage of infection, and facilitated CD8 T-cell responses by stimulating recombinant dendritic cell migration and CD8 T-cell mobilization [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. The stimulation of airway memory CD4 T cells should be regarded as an essential part of any HCoV vaccine strategy, because these CD4 T cells target a conserved epitope within the N protein that cross-reacts with several other CoVs [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. Furthermore, DNA vaccines expressing the MERS-CoV S1 gene produced antigen-specific humoral and cellular immune responses in mice [
       <xref ref-type="bibr" rid="B89-viruses-11-00059">
        89
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot4-viruses-11-00059">
      <title>
       5.4. S Protein-Based Therapeutics for SARS-CoV and MERS-CoV
      </title>
      <p>
       Despite the presence of extensive research reporting on SARS-CoV and MERS-CoV therapies, it was not possible to establish whether treatments benefited patients during their outbreak. In the absence of fundamental, clinically proven, effective antiviral therapy against SARS-CoV and MERS-CoV, patients mainly receive supportive care supplemented by diverse combinations of drugs. Several approaches are being considered to treat infections of SARS-CoV [
       <xref ref-type="bibr" rid="B113-viruses-11-00059">
        113
       </xref>
       ] and MERS-CoV (
       <xref ref-type="table" rid="viruses-11-00059-t004">
        Table 4
       </xref>
       , MERS-CoV-related table previously reviewed by de Wit et al. in Nature Reviews Microbiology, 2016 [
       <xref ref-type="bibr" rid="B10-viruses-11-00059">
        10
       </xref>
       ]), including the use of antibodies, IFNs, and inhibitors of viral and host proteases.
      </p>
      <p>
       The vital role of the S protein of SARS-CoV makes this protein an important therapeutic target, and numerous studies have explored potential therapeutics. Firstly, peptides that block RBD–ACE2-binding derived from both RBD [
       <xref ref-type="bibr" rid="B114-viruses-11-00059">
        114
       </xref>
       ] and ACE2 [
       <xref ref-type="bibr" rid="B76-viruses-11-00059">
        76
       </xref>
       ] could be developed as novel therapeutics against SARS-CoV infection. Secondly, peptides binding to the S protein interfere with the cleavage of S1 and S2. This step inhibits the production of functional S1 and S2 subunits and the consequent fusion of the viral envelope with the host cell membrane. Thirdly, anti-SARS-CoV peptides blocking the HR1–HR2 interaction by forming a fusion-active core have viral fusion inhibitory activity at the micromolar level [
       <xref ref-type="bibr" rid="B115-viruses-11-00059">
        115
       </xref>
       ,
       <xref ref-type="bibr" rid="B116-viruses-11-00059">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B117-viruses-11-00059">
        117
       </xref>
       ]. However, the potential selection of escape mutants with altered host range phenotypes is one of the disadvantages of this strategy that needs further modification [
       <xref ref-type="bibr" rid="B118-viruses-11-00059">
        118
       </xref>
       ]. Furthermore, mouse monoclonal antibodies (mAbs) targeting assorted fragments of the SARS-CoV S protein have effectively inhibited SARS-CoV infection [
       <xref ref-type="bibr" rid="B79-viruses-11-00059">
        79
       </xref>
       ,
       <xref ref-type="bibr" rid="B119-viruses-11-00059">
        119
       </xref>
       ,
       <xref ref-type="bibr" rid="B120-viruses-11-00059">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="B121-viruses-11-00059">
        121
       </xref>
       ,
       <xref ref-type="bibr" rid="B122-viruses-11-00059">
        122
       </xref>
       ]. A series of neutralizing human mAbs were generated from the B cells of patients infected with SARS-CoV [
       <xref ref-type="bibr" rid="B123-viruses-11-00059">
        123
       </xref>
       ,
       <xref ref-type="bibr" rid="B124-viruses-11-00059">
        124
       </xref>
       ]. Another strategy used human immunoglobulin transgenic mice immunized with full-length SARS-CoV S proteins [
       <xref ref-type="bibr" rid="B125-viruses-11-00059">
        125
       </xref>
       ,
       <xref ref-type="bibr" rid="B126-viruses-11-00059">
        126
       </xref>
       ,
       <xref ref-type="bibr" rid="B127-viruses-11-00059">
        127
       </xref>
       ]. 80R and CR3014 binding to the ACE2 receptor are examples of S-specific mAbs [
       <xref ref-type="bibr" rid="B128-viruses-11-00059">
        128
       </xref>
       ,
       <xref ref-type="bibr" rid="B129-viruses-11-00059">
        129
       </xref>
       ].
      </p>
      <p>
       Similarly, the therapeutic agents that have been developed against MERS-CoV are based on the S protein and basically restrain the binding of receptors or the fusion of membrane proteins, thereby leading to the inhibition of MERS-CoV infection. These methods mainly involve peptidic fusion inhibitors [
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="B116-viruses-11-00059">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B130-viruses-11-00059">
        130
       </xref>
       ], anti-MERS-CoV neutralizing mAbs [
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ,
       <xref ref-type="bibr" rid="B131-viruses-11-00059">
        131
       </xref>
       ], anti-DPP4 mAbs [
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ,
       <xref ref-type="bibr" rid="B132-viruses-11-00059">
        132
       </xref>
       ,
       <xref ref-type="bibr" rid="B133-viruses-11-00059">
        133
       </xref>
       ], DPP4 antagonists [
       <xref ref-type="bibr" rid="B134-viruses-11-00059">
        134
       </xref>
       ], and protease inhibitors [
       <xref ref-type="bibr" rid="B135-viruses-11-00059">
        135
       </xref>
       ,
       <xref ref-type="bibr" rid="B136-viruses-11-00059">
        136
       </xref>
       ,
       <xref ref-type="bibr" rid="B137-viruses-11-00059">
        137
       </xref>
       ]. However, none of these anti-MERS-CoV curative agents are approved for commercial use in humans.
      </p>
     </sec>
    </sec>
    <sec id="sec6-viruses-11-00059">
     <title>
      6. The Animal Models of SARS and MERS-CoV
     </title>
     <p>
      International coordination and cooperation led to the rapid identification of SARS-CoV and MERS-CoV. Emergency control measures and laboratory detection systems which were put in place in response to SARS-CoV and MERS-CoV outbreaks were both exemplary. To establish optimal prevention and control strategies for SARS and MERS, numerous efforts to develop animal models were undertaken in several laboratories, despite the fact that some conflicting results have been reported. It is therefore necessary to compare and document the features and disadvantages of different animal models to better understand viral replication, transmission, pathogenesis, prevention, and treatment. Notably, several animal species were suggested as suitable disease models of SARS-CoV, but most laboratory animals are refractory or only semi-permissive to MERS-CoV infection.
     </p>
     <sec id="sec6dot1-viruses-11-00059">
      <title>
       6.1. Animal Models of SARS-CoV
      </title>
      <p>
       SARS-CoV replication has been studied in mice, Syrian golden and Chinese hamsters, civet cats, and non-human primates. The most severe symptoms of SARS were observed in aged animals. To develop epidemiological symptoms that advanced age resulted in increased mortality, aged mouse model of SARS-CoV has been generated. Transgenic mice expressing human ACE2 were also developed to closely mimic SARS-CoV infection in humans. Some animal models have been tested and analyzed on the genomic and proteomics level to study the pathogenesis of SARS.
      </p>
      <sec id="sec6dot1dot1-viruses-11-00059">
       <title>
        6.1.1. Mouse Models
       </title>
       <p>
        Mouse species that have been used as SARS-CoV-infected animal models include BALB/c [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B150-viruses-11-00059">
         150
        </xref>
        ], C57BL6 (B6) [
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ], and 129SvEv-lineage mice. The most relevant transgenic and knockout lines are accessible based on these susceptible animals [
        <xref ref-type="bibr" rid="B152-viruses-11-00059">
         152
        </xref>
        ]. Signal transducers and activators of transcription 1 (STAT1)-knockout and myeloid differentiation primary response 88 (MYD88)-knockout mice [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ,
        <xref ref-type="bibr" rid="B153-viruses-11-00059">
         153
        </xref>
        ,
        <xref ref-type="bibr" rid="B154-viruses-11-00059">
         154
        </xref>
        ] are examples of mouse models with innate immune deficiency, and such animals display severe effects of the disease, such as pneumonitis, bronchiolitis, and weight loss, and often die within 9 days of infection. Notably, young mice require more mutations and passages than aged mice to produce SARS-CoV mouse-adapted strains. More severe pathological lesions and increased mortality were observed in one-year-old animals, along with fewer mutations at miscellaneous locations throughout the genome [
        <xref ref-type="bibr" rid="B98-viruses-11-00059">
         98
        </xref>
        ,
        <xref ref-type="bibr" rid="B155-viruses-11-00059">
         155
        </xref>
        ,
        <xref ref-type="bibr" rid="B156-viruses-11-00059">
         156
        </xref>
        ,
        <xref ref-type="bibr" rid="B157-viruses-11-00059">
         157
        </xref>
        ,
        <xref ref-type="bibr" rid="B158-viruses-11-00059">
         158
        </xref>
        ,
        <xref ref-type="bibr" rid="B159-viruses-11-00059">
         159
        </xref>
        ]. Intranasal inoculation of four- to eight-week-old BALB/c or B6 mice with SARS-CoV resulted in nasal turbinate in the upper respiratory tract and a high titer of virus replication in the lungs of the lower respiratory tract, and this model was highly reproducible without any signs of morbidity or mortality [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ]. Neutralizing antibody responses could be generated in sub-lethally infected mice protecting recipients from subsequent lethal challenges, which probably reflected the situation in infected humans during an epidemic [
        <xref ref-type="bibr" rid="B160-viruses-11-00059">
         160
        </xref>
        ]. However, on day 2–3 post-infection (pi), virus replication in the respiratory tract peaked but was not accompanied by massive pulmonary inflammation or pneumonitis. By day 5–7 pi, the virus had been eliminated from the lungs [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ]. It was obvious that viremia is common and long-lasting in patients, while it is rare and transient in mouse models [
        <xref ref-type="bibr" rid="B161-viruses-11-00059">
         161
        </xref>
        ]. Mice could therefore be used as a stable and reproducible animal model for the evaluation of vaccines, immune-prophylaxis, and antiviral drugs against SARS-CoV [
        <xref ref-type="bibr" rid="B81-viruses-11-00059">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="B96-viruses-11-00059">
         96
        </xref>
        ,
        <xref ref-type="bibr" rid="B109-viruses-11-00059">
         109
        </xref>
        ,
        <xref ref-type="bibr" rid="B124-viruses-11-00059">
         124
        </xref>
        ,
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B162-viruses-11-00059">
         162
        </xref>
        ,
        <xref ref-type="bibr" rid="B163-viruses-11-00059">
         163
        </xref>
        ,
        <xref ref-type="bibr" rid="B164-viruses-11-00059">
         164
        </xref>
        ,
        <xref ref-type="bibr" rid="B165-viruses-11-00059">
         165
        </xref>
        ,
        <xref ref-type="bibr" rid="B166-viruses-11-00059">
         166
        </xref>
        ].
       </p>
      </sec>
      <sec id="sec6dot1dot2-viruses-11-00059">
       <title>
        6.1.2. Hamster Model
       </title>
       <p>
        Golden Syrian and Chinese hamsters have also been evaluated and shown to be excellent models of SARS-CoV infection, owing to their high titer of virus replication in the respiratory tract, associated with diffuse alveolar damage, interstitial pneumonitis, and pulmonary consolidation [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B167-viruses-11-00059">
         167
        </xref>
        ,
        <xref ref-type="bibr" rid="B168-viruses-11-00059">
         168
        </xref>
        ,
        <xref ref-type="bibr" rid="B169-viruses-11-00059">
         169
        </xref>
        ]. On day 2 pi, peak levels of viral replication were detected in the lower respiratory tract, and the virus was cleared without obvious clinical illness 7–10 days after infection. Similarly to mice, infected hamsters also produced a protective neutralizing-antibody response to subsequent SARS-CoV challenges [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B170-viruses-11-00059">
         170
        </xref>
        ]. Resulting from the extremely high titers and reproducible pulmonary pathological lesions in SARS-CoV-infected hamsters, this animal model is ideal for studies on the immunoprophylaxis and treatment of SARS [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B170-viruses-11-00059">
         170
        </xref>
        ]. However, there are still limited resources in terms of genetically established animal lines and accurate immunological and cellular biomarkers for hamster models.
       </p>
      </sec>
      <sec id="sec6dot1dot3-viruses-11-00059">
       <title>
        6.1.3. Ferret Model
       </title>
       <p>
        Ferrets were found to be susceptible to SARS-CoV infection [
        <xref ref-type="bibr" rid="B171-viruses-11-00059">
         171
        </xref>
        ] but could also transmit the virus at low levels by direct contact [
        <xref ref-type="bibr" rid="B84-viruses-11-00059">
         84
        </xref>
        ,
        <xref ref-type="bibr" rid="B172-viruses-11-00059">
         172
        </xref>
        ,
        <xref ref-type="bibr" rid="B173-viruses-11-00059">
         173
        </xref>
        ,
        <xref ref-type="bibr" rid="B174-viruses-11-00059">
         174
        </xref>
        ]. They showed diverse clinical symptoms in different studies [
        <xref ref-type="bibr" rid="B171-viruses-11-00059">
         171
        </xref>
        ,
        <xref ref-type="bibr" rid="B174-viruses-11-00059">
         174
        </xref>
        ]. Importantly, ferrets could develop fever, which is a characteristic clinical symptom of SARS-CoV-infected patients [
        <xref ref-type="bibr" rid="B93-viruses-11-00059">
         93
        </xref>
        ,
        <xref ref-type="bibr" rid="B175-viruses-11-00059">
         175
        </xref>
        ]. Similar to rodent models, infection of ferrets with SARS-CoV did not result in significant mortality. However, there are still some conflicting reports regarding the histopathological lesions and severity of clinical observations in the ferret model that require further investigation.
       </p>
      </sec>
      <sec id="sec6dot1dot4-viruses-11-00059">
       <title>
        6.1.4. Non-Human Primate Models
       </title>
       <p>
        Several species of non-human primates (NHP) were evaluated as animal models for SARS. At least six NHP species were tested including three Old World monkeys: rhesus macaques [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B179-viruses-11-00059">
         179
        </xref>
        ,
        <xref ref-type="bibr" rid="B180-viruses-11-00059">
         180
        </xref>
        ], cynomolgus macaques [
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B181-viruses-11-00059">
         181
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ], and African green monkeys [
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ]; and three New World monkeys: the common marmoset [
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ], squirrel monkeys, and mustached tamarins [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B181-viruses-11-00059">
         181
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ,
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ,
        <xref ref-type="bibr" rid="B184-viruses-11-00059">
         184
        </xref>
        ]. Except for squirrel monkeys and mustached tamarins [
        <xref ref-type="bibr" rid="B185-viruses-11-00059">
         185
        </xref>
        ], all of the evaluated NHP species facilitated the replication of SARS-CoV [
        <xref ref-type="bibr" rid="B186-viruses-11-00059">
         186
        </xref>
        ]. Virus replication was detected in the respiratory tract of rhesus macaques, cynomolgus macaques, and African green monkeys. Pneumonitis was observed in each of these species in different studies [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ]. SARS-infected common marmosets displayed a fever, watery diarrhea, pneumonitis, and hepatitis [
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ]. Unfortunately, research into the clinical signs of disease in cynomolgus and rhesus macaques gave conflicting results and therefore needs further investigation. The main reason for the lack of reproducibility in such studies may be the limited sample size.
       </p>
      </sec>
     </sec>
     <sec id="sec6dot2-viruses-11-00059">
      <title>
       6.2. Animal Models of MERS-CoV
      </title>
      <p>
       Small animal models of MERS infection are urgently needed to elucidate MERS pathogenesis and explore potential vaccines and antiviral drugs. Previous studies have demonstrated the difficulties in developing such a model, such as that mice [
       <xref ref-type="bibr" rid="B187-viruses-11-00059">
        187
       </xref>
       ,
       <xref ref-type="bibr" rid="B188-viruses-11-00059">
        188
       </xref>
       ], ferrets [
       <xref ref-type="bibr" rid="B134-viruses-11-00059">
        134
       </xref>
       ], guinea pigs [
       <xref ref-type="bibr" rid="B189-viruses-11-00059">
        189
       </xref>
       ], and hamsters [
       <xref ref-type="bibr" rid="B189-viruses-11-00059">
        189
       </xref>
       ] are not susceptible to experimental MERS-CoV infection mainly because their homologous DPP4 molecules do not function as receptors for MERS-CoV entry. After administering a high dose of MERS-CoV, no viral replication could be detected in these animals [
       <xref ref-type="bibr" rid="B190-viruses-11-00059">
        190
       </xref>
       ]. In an animal model using New Zealand white rabbits, regardless of the fact that detectable viral RNA existed in the respiratory tract and moderate necrosis was observed in nasal turbinates, the animals showed no clinical symptoms of disease [
       <xref ref-type="bibr" rid="B191-viruses-11-00059">
        191
       </xref>
       ]. In another study, attempts to infect hamsters with MERS-CoV were not successful [
       <xref ref-type="bibr" rid="B192-viruses-11-00059">
        192
       </xref>
       ]. However, despite this, MERS-CoV is a broad host-range virus in vitro [
       <xref ref-type="bibr" rid="B25-viruses-11-00059">
        25
       </xref>
       ], and there is hope that a reproducible and stable animal model for human MERS-CoV infection can be improved in the near future.
      </p>
      <sec id="sec6dot2dot1-viruses-11-00059">
       <title>
        6.2.1. Mouse Model for MERS Infection
       </title>
       <p>
        Despite the fact that wild-type rodents are not susceptible to MERS-CoV infection [
        <xref ref-type="bibr" rid="B188-viruses-11-00059">
         188
        </xref>
        ], researchers have developed several models in which mice are susceptible to MERS-CoV infection [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ,
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ,
        <xref ref-type="bibr" rid="B195-viruses-11-00059">
         195
        </xref>
        ]. The first mouse model of MERS infection reported in 2014 involved transducing animals with recombinant adenovirus 5 encoding human DPP4 (hDPP4) molecules intranasally, and this resulted in replication of MERS-CoV in the lungs. This mouse model also showed clinical symptoms of interstitial pneumonia, including inflammatory cell infiltration, and thickened alveolar and mild edema [
        <xref ref-type="bibr" rid="B195-viruses-11-00059">
         195
        </xref>
        ]. However, there are certain limitations to this model, such as the uncontrolled expression and distribution of hDPP4. In 2015, the establishment of hDPP4 transgenic mice was reported [
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ]. MERS-CoV could infect this mouse model effectively. However, similarly to SARS-CoV-infected ACE2 transgenic mice [
        <xref ref-type="bibr" rid="B196-viruses-11-00059">
         196
        </xref>
        ], systemic expressions led to multiple organ lesions [
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ], resulting in the death of the animals. Most recently, the homologous hDPP4 gene was used in several MERS transgenic mouse models [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ,
        <xref ref-type="bibr" rid="B197-viruses-11-00059">
         197
        </xref>
        ]. Remarkably, hDPP4 knockin (KI) mice, where mouse DPP4 gene fragments had been displaced by homologous human DPP4 fragments, showed effective receptor binding. Furthermore, a mouse-adapted MERS-CoV strain (MERS
        <sub>
         MA
        </sub>
        ) including 13–22 mutations was produced in the lungs of hDPP4-KI mice after 30 serial passages, causing effective weight loss and mortality in this mouse model [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ]. Both this hDPP4-KI mouse and the MERS
        <sub>
         MA
        </sub>
        strain provide better tools to explore the pathogenesis of MERS and potential novel treatments.
       </p>
      </sec>
      <sec id="sec6dot2dot2-viruses-11-00059">
       <title>
        6.2.2. Camelidae
       </title>
       <p>
        As a reservoir of MERS-CoV, dromedary camels showed mild upper respiratory infections after the administration of MERS-CoV [
        <xref ref-type="bibr" rid="B198-viruses-11-00059">
         198
        </xref>
        ]. Oronasal infection of MERS-CoV in alpacas, a close relative within the Camelidae family, resulted in an asymptomatic infection with no signs of upper or lower respiratory tract disease [
        <xref ref-type="bibr" rid="B199-viruses-11-00059">
         199
        </xref>
        ,
        <xref ref-type="bibr" rid="B200-viruses-11-00059">
         200
        </xref>
        ]. Additionally, owing to their high cost and relatively large size, these animal models are not available for high-throughput studies of MERS.
       </p>
      </sec>
      <sec id="sec6dot2dot3-viruses-11-00059">
       <title>
        6.2.3. Non-Human Primates
       </title>
       <p>
        NHPs, such as the rhesus macaques [
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ] and common marmosets [
        <xref ref-type="bibr" rid="B202-viruses-11-00059">
         202
        </xref>
        ], are useful models for studying the pathogenesis of mild MERS-CoV infection and evaluating novel therapies for humans, although the degree of replication and disease severity vary [
        <xref ref-type="bibr" rid="B192-viruses-11-00059">
         192
        </xref>
        ,
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ,
        <xref ref-type="bibr" rid="B203-viruses-11-00059">
         203
        </xref>
        ,
        <xref ref-type="bibr" rid="B204-viruses-11-00059">
         204
        </xref>
        ]. MERS-CoV caused transient lower respiratory tract infection in rhesus macaques, with associated pneumonia. Clinical signs were observed by day 1 pi and resolved as early as day 4 pi [
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ]. Relatively mild clinical symptoms were observed early on in infection without fatalities, indicating that rhesus macaques do not recapitulate the severe infections observed in human cases; however, treatment of MERS-CoV-infected rhesus macaques with IFN-α and ribavirin decreased virus replication, alleviated the host response, and improved the clinical outcome [
        <xref ref-type="bibr" rid="B205-viruses-11-00059">
         205
        </xref>
        ]. Infection of MERS-CoV in common marmosets demonstrated various extents of damage depending on the study, but successfully reproduced several features of MERS-CoV infection in humans. Importantly, one study indicated that the infection became progressive severe pneumonia [
        <xref ref-type="bibr" rid="B203-viruses-11-00059">
         203
        </xref>
        ], while other groups found that MERS-CoV-infected common marmosets only developed mild to moderate nonlethal respiratory diseases by intratracheal administration [
        <xref ref-type="bibr" rid="B206-viruses-11-00059">
         206
        </xref>
        ].
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="sec7-viruses-11-00059">
     <title>
      7. Role of Host Receptors in Animal Models of SARS-CoV and MERS-CoV
     </title>
     <p>
      The reasons for host restriction, none or limited clinical symptoms observed in varies animal models are complexity. The interaction between the host receptor and functional proteins of SARS and MERS, respectively, plays an important and predominant role. In the context of animal models of SARS-CoV infection, researchers have compared the ACE2 amino acids that interact with the S protein RBD from several species. In agreement with the permissive nature of these species, the ACE2 residues of marmoset and hamster are similar to those of hACE2 [
      <xref ref-type="bibr" rid="B53-viruses-11-00059">
       53
      </xref>
      ]. By comparison, many residues of mouse ACE2 are different from those of hACE2, and this meets with decreased replication of SARS-CoV in mouse cells [
      <xref ref-type="bibr" rid="B207-viruses-11-00059">
       207
      </xref>
      ] and the lungs of young mice [
      <xref ref-type="bibr" rid="B149-viruses-11-00059">
       149
      </xref>
      ]. The changes at positions 353 (histidine) and 82 (asparagine) of rat ACE2 relative to hACE2 partially disrupt the S protein-DPP4 interaction and contribute to abrogation of binding. Interestingly, ferrets are permissive to SARS-CoV infection, but most of their ACE2 interaction residues are different from those of hACE2 [
      <xref ref-type="bibr" rid="B53-viruses-11-00059">
       53
      </xref>
      ], while many of the ACE2 residues between civet and ferret are the same, which may result in similar affinity [
      <xref ref-type="bibr" rid="B208-viruses-11-00059">
       208
      </xref>
      ]. For MERS-CoV, 14 residues of the S protein RBD have direct contact with 15 residues of hDPP4 [
      <xref ref-type="bibr" rid="B57-viruses-11-00059">
       57
      </xref>
      ]. Comparisons of human DPP4 binding affinity to that of other species indicated that human DPP4 had the highest affinity to the S protein of MERS-CoV, where the decreasing order of affinity is as follows: human &gt; horses &gt; camels &gt; goats &gt; bats [
      <xref ref-type="bibr" rid="B209-viruses-11-00059">
       209
      </xref>
      ]. Further evidence demonstrates that the host restriction of MERS-CoV remarkably depends on the sequence of DPP4, such as the characterization of amino acid residues at the connector of DPP4 with the RBD of S proteins in mice [
      <xref ref-type="bibr" rid="B187-viruses-11-00059">
       187
      </xref>
      ,
      <xref ref-type="bibr" rid="B210-viruses-11-00059">
       210
      </xref>
      ], hamsters, and cotton rats [
      <xref ref-type="bibr" rid="B210-viruses-11-00059">
       210
      </xref>
      ]. However, the multiplicity in severity of disease between rhesus macaques and common marmosets indicate that other host factors can perhaps affect the infection and replication of the virus, such as the presence of S-cleaving proteases [
      <xref ref-type="bibr" rid="B187-viruses-11-00059">
       187
      </xref>
      ]. In general, although the structural analysis of receptors-S protein interactions cannot fully explain all the observations for host restriction, they agree with the improved replication in several animal models and that it should be the premier and remarkable focus of small-animal model development. These special residues for host affinity are important to build up transgenic animal models enhancing the permissiveness and infection of SARS and MERS.
     </p>
    </sec>
    <sec id="sec8-viruses-11-00059">
     <title>
      8. Outlook and Summary
     </title>
     <p>
      Unlike SARS-CoV, which resolved without more reported cases, continued outbreaks of MERS-CoV present an ongoing threat to public health. It should be noted that no specific treatment is currently available for HCoVs, and further research into the pathogenesis of HCoV infection is therefore imperative to identify appropriate therapeutic targets. Accordingly, at present, the prevention of viral transmission is of utmost importance to limit the spread of MERS. The enormous ratio of nosocomial infections indicates that preventive measures in hospitals have not been sufficiently implemented. Additionally, as an emerging zoonotic virus, prevention of transmission from dromedary camels is another possibility to reduce the quantity of MERS cases. Regarding clinical therapies, a combination of treatment administered as early as possible and aimed at synchronously disrupting viral replication, inhibiting viral dissemination, and restraining the host response is likely to be most suitable, due to the acute clinical features of MERS with diffuse lung damage and the important role of immunopathology.
     </p>
     <p>
      Potential treatments must undergo in vitro and in vivo studies to select the most promising options. The development of stable and reproducible animal models of MERS, especially in NHPs, is therefore a decisive step forward. The next step in the development of standardized and controllable therapies against SARS and MERS will be clinical trials in humans, validating a standard protocol for dosage and timing, and accruing data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.
     </p>
     <p>
      The comprehensive lessons and experiences that have resulted from the outbreaks of SARS and MERS provide valuable insight and advancements in how to react to future emerging and re-emerging infectious agents. Rapid identification of the pathogen via effective diagnostic assays is the first step, followed by the implementation of preventive measures, including raising awareness of the new agent, reporting and recording (suspected) cases, and infection control management in medical facilities. Studies are currently needed that focus on the epidemiology of these organisms, especially in terms of pathogen transmission and potential reservoirs and/or intermediate hosts. Animal models and prophylactic and therapeutic approaches should be promoted, followed by fast-tracked clinical trials.
     </p>
     <p>
      Our increasing understanding of novel emerging coronaviruses will be accompanied by increasing opportunities for the reasonable design of therapeutics. Importantly, understanding this basic information will not only aid our public health preparedness against SARS-CoV and MERS-CoV, but also help prepare for novel coronaviruses that may emerge.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank Kate Fox, DPhil, from Liwen Bianji, Edanz Group China (
       <uri xlink:href="www.liwenbianji.cn/ac">
        www.liwenbianji.cn/ac
       </uri>
       ), for editing the English text of a draft of this manuscript.
      </p>
     </ack>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This research was funded by CAMS Innovation Fund for Medical Science (CIFMS), grant number 2016-12M-2-006.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-11-00059">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wunderink
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS, SARS and other coronaviruses as causes of pneumonia
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2018
        </year>
        <volume>
         23
        </volume>
        <fpage>
         130
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/resp.13196
        </pub-id>
        <pub-id pub-id-type="pmid">
         29052924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-11-00059">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030747
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-viruses-11-00059">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030781
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-11-00059">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         300
        </volume>
        <fpage>
         1394
        </fpage>
        <lpage>
         1399
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1085952
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-viruses-11-00059">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Z.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)14630-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-viruses-11-00059">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Joynt
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ahuja
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030685
        </pub-id>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-11-00059">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12711
        </pub-id>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-viruses-11-00059">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plante
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         1508
        </fpage>
        <lpage>
         1513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.3985
        </pub-id>
        <pub-id pub-id-type="pmid">
         26552008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-11-00059">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-viruses-11-00059">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: Recent insights into emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <fpage>
         523
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-viruses-11-00059">
       <label>
        11.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         WHO Guidelines for the Global Surveillance of Severe Acute Respiratory Syndrome (SARS)
        </article-title>
        <comment>
         Updated Recommendations
        </comment>
        <month>
         10
        </month>
        <year>
         2004
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/mers-cov/en/">
          http://www.who.int/mediacentre/factsheets/mers-cov/en/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2018-10-08">
         (accessed on 8 October 2018)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B12-viruses-11-00059">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1087139
        </pub-id>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-viruses-11-00059">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-viruses-11-00059">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and evolution of pathogenic coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2018
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41579-018-0118-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         30531947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-viruses-11-00059">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bokhari
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Samman
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Boudjelal
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e01985-18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.01985-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30377284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-viruses-11-00059">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabiah
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hajjar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Barrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Flemban
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Nassir
          </surname>
          <given-names>
           W.N.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70204-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-viruses-11-00059">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arifi
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Najm
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aldawood
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ghabashi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alothman
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Khaldi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         160
        </volume>
        <fpage>
         389
        </fpage>
        <lpage>
         397
        </lpage>
        <pub-id pub-id-type="doi">
         10.7326/M13-2486
        </pub-id>
        <pub-id pub-id-type="pmid">
         24474051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-11-00059">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rha
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tohme
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Jarour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         59
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu359
        </pub-id>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-11-00059">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           H.F.
          </given-names>
         </name>
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alami
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Khudhair
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           El
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1162
        </fpage>
        <lpage>
         1168
        </lpage>
        <pub-id pub-id-type="pmid">
         27314227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-11-00059">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alabdullatif
          </surname>
          <given-names>
           Z.N.
          </given-names>
         </name>
         <name>
          <surname>
           Assad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Almulhim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         369
        </volume>
        <fpage>
         407
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-viruses-11-00059">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           HajOmar
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         60
        </volume>
        <fpage>
         369
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu812
        </pub-id>
        <pub-id pub-id-type="pmid">
         25323704
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-11-00059">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         21169
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2015.20.25.21169
        </pub-id>
        <pub-id pub-id-type="pmid">
         26132766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-11-00059">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Babiuk
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS): A year in review
        </article-title>
        <source>
         Annu. Rev. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         56
        </volume>
        <fpage>
         357
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev.med.56.091103.134135
        </pub-id>
        <pub-id pub-id-type="pmid">
         15660517
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-11-00059">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: An overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         1282
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-viruses-11-00059">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models
        </article-title>
        <source>
         J. Thorac. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         10
        </volume>
        <fpage>
         S2260
        </fpage>
        <lpage>
         S2271
        </lpage>
        <pub-id pub-id-type="doi">
         10.21037/jtd.2018.03.80
        </pub-id>
        <pub-id pub-id-type="pmid">
         30116605
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-viruses-11-00059">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV spike protein: A key target for antivirals
        </article-title>
        <source>
         Expert Opin. Ther. Targets
        </source>
        <year>
         2017
        </year>
        <volume>
         21
        </volume>
        <fpage>
         131
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14728222.2017.1271415
        </pub-id>
        <pub-id pub-id-type="pmid">
         27936982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-viruses-11-00059">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV—A target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2090
        </pub-id>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-viruses-11-00059">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-11-00059">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeffers
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tusell
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hemmila
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Achenbach
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thackray
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Mason
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         15748
        </fpage>
        <lpage>
         15753
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0403812101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15496474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-11-00059">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         4025
        </fpage>
        <lpage>
         4030
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02292-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21289121
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-11-00059">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-viruses-11-00059">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qinfen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jinming
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xiaojun
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huanying
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jicheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Kunpeng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jingqiang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The life cycle of SARS coronavirus in Vero E6 cells
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         73
        </volume>
        <fpage>
         332
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20095
        </pub-id>
        <pub-id pub-id-type="pmid">
         15170625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-11-00059">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           McNutt
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenetic mechanisms of severe acute respiratory syndrome
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         133
        </volume>
        <fpage>
         4
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2007.01.022
        </pub-id>
        <pub-id pub-id-type="pmid">
         17825937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-11-00059">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology and pathogenesis of severe acute respiratory syndrome
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2007
        </year>
        <volume>
         170
        </volume>
        <fpage>
         1136
        </fpage>
        <lpage>
         1147
        </lpage>
        <pub-id pub-id-type="doi">
         10.2353/ajpath.2007.061088
        </pub-id>
        <pub-id pub-id-type="pmid">
         17392154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-11-00059">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         622
        </fpage>
        <lpage>
         630
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1560
        </pub-id>
        <pub-id pub-id-type="pmid">
         15141376
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-11-00059">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lambertz
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         78
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2015.09.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         26597880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-11-00059">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kolijn
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           van Leenders
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Segales
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baumgartner
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         4838
        </fpage>
        <lpage>
         4842
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02994-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26889022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-11-00059">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           I.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           K.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—A link to health care facilities
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-11-00059">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute renal impairment in coronavirus-associated severe acute respiratory syndrome
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2005
        </year>
        <volume>
         67
        </volume>
        <fpage>
         698
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1523-1755.2005.67130.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15673319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-11-00059">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Bahloul
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elzein
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Matin
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Selim
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           N.D.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: A single-center experience in Saudi Arabia
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2014.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         25303830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-11-00059">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sameroff
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e814
        </fpage>
        <lpage>
         e884
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00884-14
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-viruses-11-00059">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambeir
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Durinx
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Scharpe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           De Meester
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV
        </article-title>
        <source>
         Crit. Rev. Clin. Lab. Sci.
        </source>
        <year>
         2003
        </year>
        <volume>
         40
        </volume>
        <fpage>
         209
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/713609354
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-11-00059">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2014
        </year>
        <volume>
         454–455
        </volume>
        <fpage>
         197
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2014.02.018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-11-00059">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <fpage>
         1331
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit504
        </pub-id>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-11-00059">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         904
        </fpage>
        <lpage>
         914
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv380
        </pub-id>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-viruses-11-00059">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2
        </article-title>
        <source>
         Nat. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         1
        </volume>
        <fpage>
         16004
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.4
        </pub-id>
        <pub-id pub-id-type="pmid">
         27572168
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-viruses-11-00059">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective T Cell Res.ponses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2017
        </year>
        <volume>
         198
        </volume>
        <fpage>
         873
        </fpage>
        <lpage>
         882
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.1601542
        </pub-id>
        <pub-id pub-id-type="pmid">
         27903740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-11-00059">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuok
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         6604
        </fpage>
        <lpage>
         6614
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00009-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23552422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49-viruses-11-00059">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         2679
        </fpage>
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.055533-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50-viruses-11-00059">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Khattra
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The Genome sequence of the SARS-associated coronavirus
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         300
        </volume>
        <fpage>
         1399
        </fpage>
        <lpage>
         1404
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1085953
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51-viruses-11-00059">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.X.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           X.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         280
        </volume>
        <fpage>
         29588
        </fpage>
        <lpage>
         29595
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M500662200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15980414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52-viruses-11-00059">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           I.C.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2
        </article-title>
        <source>
         EMBO J.
        </source>
        <year>
         2005
        </year>
        <volume>
         24
        </volume>
        <fpage>
         1634
        </fpage>
        <lpage>
         1643
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.emboj.7600640
        </pub-id>
        <pub-id pub-id-type="pmid">
         15791205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53-viruses-11-00059">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        <volume>
         309
        </volume>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1116480
        </pub-id>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54-viruses-11-00059">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor recognition mechanisms of coronaviruses: A decade of structural studies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         1954
        </fpage>
        <lpage>
         1964
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02615-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25428871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55-viruses-11-00059">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         500
        </volume>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12328
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56-viruses-11-00059">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         13134
        </fpage>
        <lpage>
         13140
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02433-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57-viruses-11-00059">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58-viruses-11-00059">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current advancements and potential strategies in the development of MERS-CoV vaccines
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2014
        </year>
        <volume>
         13
        </volume>
        <fpage>
         761
        </fpage>
        <lpage>
         774
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14760584.2014.912134
        </pub-id>
        <pub-id pub-id-type="pmid">
         24766432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59-viruses-11-00059">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Debnath
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         9939
        </fpage>
        <lpage>
         9942
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01048-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23824801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60-viruses-11-00059">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61-viruses-11-00059">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62-viruses-11-00059">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         10777
        </fpage>
        <lpage>
         10783
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01756-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23903833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63-viruses-11-00059">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         3067
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms4067
        </pub-id>
        <pub-id pub-id-type="pmid">
         24473083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64-viruses-11-00059">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Core structure of S2 from the human coronavirus NL63 spike glycoprotein
        </article-title>
        <source>
         Biochemistry
        </source>
        <year>
         2006
        </year>
        <volume>
         45
        </volume>
        <fpage>
         15205
        </fpage>
        <lpage>
         15215
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/bi061686w
        </pub-id>
        <pub-id pub-id-type="pmid">
         17176042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65-viruses-11-00059">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         49414
        </fpage>
        <lpage>
         49419
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M408782200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15345712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66-viruses-11-00059">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         30514
        </fpage>
        <lpage>
         30522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M403760200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15123674
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67-viruses-11-00059">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hattermann
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuate
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Uberla
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         6134
        </fpage>
        <lpage>
         6142
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.12.6134-6142.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15163706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68-viruses-11-00059">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-associated coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1948
        </fpage>
        <lpage>
         1951
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMp030078
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69-viruses-11-00059">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Berardi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dormitzer
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         6794
        </fpage>
        <lpage>
         6800
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02744-05
        </pub-id>
        <pub-id pub-id-type="pmid">
         16809285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70-viruses-11-00059">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         3197
        </fpage>
        <lpage>
         3201
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.C300520200
        </pub-id>
        <pub-id pub-id-type="pmid">
         14670965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71-viruses-11-00059">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chakraborti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gramatikoff
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-CoV S glycoprotein: Expression and functional characterization
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2003
        </year>
        <volume>
         312
        </volume>
        <fpage>
         1159
        </fpage>
        <lpage>
         1164
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2003.11.054
        </pub-id>
        <pub-id pub-id-type="pmid">
         14651994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72-viruses-11-00059">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2
        </article-title>
        <source>
         Comput. Biol. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         29
        </volume>
        <fpage>
         254
        </fpage>
        <lpage>
         257
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.compbiolchem.2005.04.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         15979045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73-viruses-11-00059">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2006
        </year>
        <volume>
         344
        </volume>
        <fpage>
         106
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2006.03.139
        </pub-id>
        <pub-id pub-id-type="pmid">
         16615996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B74-viruses-11-00059">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sainz
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rausch
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gallaher
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           Garry
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wimley
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         7195
        </fpage>
        <lpage>
         7206
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.11.7195-7206.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15890958
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75-viruses-11-00059">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ganesh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nabel
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         5642
        </fpage>
        <lpage>
         5650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.11.5642-5650.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76-viruses-11-00059">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lohani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         12029
        </fpage>
        <lpage>
         12039
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00315-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17715238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B77-viruses-11-00059">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: Strategies for controlling emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro3143
        </pub-id>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B78-viruses-11-00059">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lip
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Loh
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         3289
        </fpage>
        <lpage>
         3296
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.6.3289-3296.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15731223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B79-viruses-11-00059">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bunzel
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         7217
        </fpage>
        <lpage>
         7226
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.13.7217-7226.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15194798
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B80-viruses-11-00059">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Elkins
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mucosal immunisation of African green monkeys (
         <italic>
          Cercopithecus aethiops
         </italic>
         ) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         2122
        </fpage>
        <lpage>
         2127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)16501-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         15220033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B81-viruses-11-00059">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nabel
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2004
        </year>
        <volume>
         428
        </volume>
        <fpage>
         561
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02463
        </pub-id>
        <pub-id pub-id-type="pmid">
         15024391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B82-viruses-11-00059">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kam
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kien
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2007
        </year>
        <volume>
         25
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         740
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2006.08.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         17049691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B83-viruses-11-00059">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2005
        </year>
        <volume>
         23
        </volume>
        <fpage>
         2273
        </fpage>
        <lpage>
         2279
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.01.033
        </pub-id>
        <pub-id pub-id-type="pmid">
         15755610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B84-viruses-11-00059">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Neufeld
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Marszal
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Proulx
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Deschambault
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         12672
        </fpage>
        <lpage>
         12676
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.22.12672-12676.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15507655
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B85-viruses-11-00059">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e01651-16
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01651-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27795425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B86-viruses-11-00059">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lees
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kanekiyo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         7712
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms8712
        </pub-id>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B87-viruses-11-00059">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Warimwe
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         4461
        </fpage>
        <lpage>
         4464
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2017.04.085
        </pub-id>
        <pub-id pub-id-type="pmid">
         28576573
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B88-viruses-11-00059">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Okada
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kenniston
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gambotto
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2014
        </year>
        <volume>
         32
        </volume>
        <fpage>
         5975
        </fpage>
        <lpage>
         5982
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2014.08.058
        </pub-id>
        <pub-id pub-id-type="pmid">
         25192975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B89-viruses-11-00059">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         2069
        </fpage>
        <lpage>
         2075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2017.02.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         28314561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B90-viruses-11-00059">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Amri
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Abbas
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiq
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sanki
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Muhanna
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Alhabbab
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         44875
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep44875
        </pub-id>
        <pub-id pub-id-type="pmid">
         28332568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B91-viruses-11-00059">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV vaccine candidates in development: The current landscape
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2016
        </year>
        <volume>
         34
        </volume>
        <fpage>
         2982
        </fpage>
        <lpage>
         2987
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.03.104
        </pub-id>
        <pub-id pub-id-type="pmid">
         27083424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B92-viruses-11-00059">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mangalam
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           David
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Airway Memory CD4
         <sup>
          +
         </sup>
         T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2016
        </year>
        <volume>
         44
        </volume>
        <fpage>
         1379
        </fpage>
        <lpage>
         1391
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2016.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27287409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B93-viruses-11-00059">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rehm
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS vaccines: Where are we?
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2009
        </year>
        <volume>
         8
        </volume>
        <fpage>
         887
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/erv.09.43
        </pub-id>
        <pub-id pub-id-type="pmid">
         19538115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94-viruses-11-00059">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2007
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1107
        </fpage>
        <lpage>
         1113
        </lpage>
        <pub-id pub-id-type="pmid">
         18018769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95-viruses-11-00059">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <year>
         2018
        </year>
        <volume>
         7
        </volume>
        <fpage>
         60
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41426-018-0056-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         29618723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96-viruses-11-00059">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zitzow
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Karunakaran
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hitt
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         641
        </fpage>
        <lpage>
         650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.81579-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         16476986
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B97-viruses-11-00059">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         133
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2007.01.021
        </pub-id>
        <pub-id pub-id-type="pmid">
         17416434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98-viruses-11-00059">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bolles
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Whitmore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ferris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Funkhouser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Totura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         12201
        </fpage>
        <lpage>
         12215
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06048-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         21937658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99-viruses-11-00059">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishioka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kita
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Obuchi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hoshino
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Noda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nishina
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kozawa
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549)
        </article-title>
        <source>
         Cell Biol. Int.
        </source>
        <year>
         2011
        </year>
        <volume>
         35
        </volume>
        <fpage>
         467
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/CBI20100255
        </pub-id>
        <pub-id pub-id-type="pmid">
         20977431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B100-viruses-11-00059">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         6551
        </fpage>
        <lpage>
         6559
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00087-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23576515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B101-viruses-11-00059">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Bolles
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         18
        </volume>
        <fpage>
         1820
        </fpage>
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.2972
        </pub-id>
        <pub-id pub-id-type="pmid">
         23142821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B102-viruses-11-00059">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Marquez-Jurado
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Andres
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e613
        </fpage>
        <lpage>
         e650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00650-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24023385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103-viruses-11-00059">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wendt
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Andino
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineering attenuated virus vaccines by controlling replication fidelity
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2008
        </year>
        <volume>
         14
        </volume>
        <fpage>
         154
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1726
        </pub-id>
        <pub-id pub-id-type="pmid">
         18246077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B104-viruses-11-00059">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         503
        </fpage>
        <lpage>
         511
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.1.503-511.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15596843
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105-viruses-11-00059">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Suthar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harkema
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Whitmore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pickles
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e525
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030525
        </pub-id>
        <pub-id pub-id-type="pmid">
         17194199
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B106-viruses-11-00059">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2678
        </fpage>
        <lpage>
         2688
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.5.2678-2688.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15708987
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B107-viruses-11-00059">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge
        </article-title>
        <source>
         EBioMedicine
        </source>
        <year>
         2015
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1438
        </fpage>
        <lpage>
         1446
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ebiom.2015.08.031
        </pub-id>
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B108-viruses-11-00059">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiaming
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yanfeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Yawei
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linlin
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Baoying
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jinghua
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chuan
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wenjie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         10
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.11.064
        </pub-id>
        <pub-id pub-id-type="pmid">
         27899228
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B109-viruses-11-00059">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         334
        </volume>
        <fpage>
         160
        </fpage>
        <lpage>
         165
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.01.042
        </pub-id>
        <pub-id pub-id-type="pmid">
         15780866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B110-viruses-11-00059">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2005
        </year>
        <volume>
         23
        </volume>
        <fpage>
         4959
        </fpage>
        <lpage>
         4968
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.05.023
        </pub-id>
        <pub-id pub-id-type="pmid">
         15993989
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B111-viruses-11-00059">
       <label>
        111.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization
        </article-title>
        <source>
         Mol. Immunol.
        </source>
        <year>
         2006
        </year>
        <volume>
         43
        </volume>
        <fpage>
         1791
        </fpage>
        <lpage>
         1798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.molimm.2005.11.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         16423399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B112-viruses-11-00059">
       <label>
        112.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Tabiin
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chandrasekaran
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Anwar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chikhlikar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Salmon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brusic
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Marques
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2006
        </year>
        <volume>
         347
        </volume>
        <fpage>
         127
        </fpage>
        <lpage>
         139
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.11.042
        </pub-id>
        <pub-id pub-id-type="pmid">
         16387339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B113-viruses-11-00059">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Saitoh
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         82
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2009.02.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         19428598
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B114-viruses-11-00059">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library
        </article-title>
        <source>
         J. Comb. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         7
        </volume>
        <fpage>
         648
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/cc0500607
        </pub-id>
        <pub-id pub-id-type="pmid">
         16153058
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B115-viruses-11-00059">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hez
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2005
        </year>
        <volume>
         10
        </volume>
        <fpage>
         393
        </fpage>
        <lpage>
         403
        </lpage>
        <pub-id pub-id-type="pmid">
         15918330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B116-viruses-11-00059">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Van Der Zee
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lepault
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Haijema
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Versluis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Heck
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           De Groot
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         8455
        </fpage>
        <lpage>
         8460
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0400576101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15150417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B117-viruses-11-00059">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qing
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2004
        </year>
        <volume>
         319
        </volume>
        <fpage>
         746
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.05.046
        </pub-id>
        <pub-id pub-id-type="pmid">
         15184046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B118-viruses-11-00059">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McRoy
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         1414
        </fpage>
        <lpage>
         1424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01674-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18032498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B119-viruses-11-00059">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Heck
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lustigman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         5757
        </fpage>
        <lpage>
         5767
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00083-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         16731915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B120-viruses-11-00059">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lustigman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2006
        </year>
        <volume>
         176
        </volume>
        <fpage>
         6085
        </fpage>
        <lpage>
         6092
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.176.10.6085
        </pub-id>
        <pub-id pub-id-type="pmid">
         16670317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B121-viruses-11-00059">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         334
        </volume>
        <fpage>
         74
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.01.034
        </pub-id>
        <pub-id pub-id-type="pmid">
         15749124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B122-viruses-11-00059">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jan
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <fpage>
         711
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s11373-005-9004-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         16132115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B123-viruses-11-00059">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lian
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         190
        </volume>
        <fpage>
         1119
        </fpage>
        <lpage>
         1126
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423286
        </pub-id>
        <pub-id pub-id-type="pmid">
         15319862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B124-viruses-11-00059">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Traggiai
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Uematsu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gismondo
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rappuoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         871
        </fpage>
        <lpage>
         875
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1080
        </pub-id>
        <pub-id pub-id-type="pmid">
         15247913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B125-viruses-11-00059">
       <label>
        125.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Stadler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         3220
        </fpage>
        <lpage>
         3235
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02377-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18199635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B126-viruses-11-00059">
       <label>
        126.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chakraborti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Prabakaran
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sidorov
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2007
        </year>
        <volume>
         104
        </volume>
        <fpage>
         12123
        </fpage>
        <lpage>
         12128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0701000104
        </pub-id>
        <pub-id pub-id-type="pmid">
         17620608
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B127-viruses-11-00059">
       <label>
        127.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coughlin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Masterman
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           O.A.
          </given-names>
         </name>
         <name>
          <surname>
           Moksa
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Babcook
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Prabhakar
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         361
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2006.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         17161858
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B128-viruses-11-00059">
       <label>
        128.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jongeneelen
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Thijsse
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Throsby
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marissen
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Rood
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Gelderblom
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         1635
        </fpage>
        <lpage>
         1644
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.3.1635-1644.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15650189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B129-viruses-11-00059">
       <label>
        129.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tallarico
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Olurinde
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         2536
        </fpage>
        <lpage>
         2541
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0307140101
        </pub-id>
        <pub-id pub-id-type="pmid">
         14983044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B130-viruses-11-00059">
       <label>
        130.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Escalante
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farmar
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Debnath
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         938
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)15788-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         15043961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B131-viruses-11-00059">
       <label>
        131.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pedotti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Simonelli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Rodriguez
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Foglierini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Agatic
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Vanzetta
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         10473
        </fpage>
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1510199112
        </pub-id>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B132-viruses-11-00059">
       <label>
        132.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1237
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2015.113
        </pub-id>
        <pub-id pub-id-type="pmid">
         26391698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B133-viruses-11-00059">
       <label>
        133.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7045
        </fpage>
        <lpage>
         7053
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00433-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24719424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B134-viruses-11-00059">
       <label>
        134.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wiersma
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ouwendijk
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Spronken
          </surname>
          <given-names>
           M.I.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02935-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B135-viruses-11-00059">
       <label>
        135.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2016
        </year>
        <volume>
         291
        </volume>
        <fpage>
         9218
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M116.716100
        </pub-id>
        <pub-id pub-id-type="pmid">
         26953343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B136-viruses-11-00059">
       <label>
        136.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaup
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kramer-Kuhl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welsch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         5502
        </fpage>
        <lpage>
         5511
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00128-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B137-viruses-11-00059">
       <label>
        137.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12552
        </fpage>
        <lpage>
         12561
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01890-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B138-viruses-11-00059">
       <label>
        138.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Vedantham
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agudelo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Carrion
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Nunneley
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McKerrow
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Renslo
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         116
        </volume>
        <fpage>
         76
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2015.01.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B139-viruses-11-00059">
       <label>
        139.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         17
        </volume>
        <fpage>
         e792
        </fpage>
        <lpage>
         e798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.07.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23993766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B140-viruses-11-00059">
       <label>
        140.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kindrachuk
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Olinger
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B141-viruses-11-00059">
       <label>
        141.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Marissen
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Bogaards
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Deventer
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e237
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030237
        </pub-id>
        <pub-id pub-id-type="pmid">
         16796401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B142-viruses-11-00059">
       <label>
        142.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ning
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A serological survey on neutralizing antibody titer of SARS convalescent sera
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         77
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20431
        </pub-id>
        <pub-id pub-id-type="pmid">
         16121363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B143-viruses-11-00059">
       <label>
        143.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miyoshi-Akiyama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuoka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ishihara
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tsukahara
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hatakeyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Itoh
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Morisawa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2011
        </year>
        <volume>
         203
        </volume>
        <fpage>
         1574
        </fpage>
        <lpage>
         1581
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jir084
        </pub-id>
        <pub-id pub-id-type="pmid">
         21592986
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B144-viruses-11-00059">
       <label>
        144.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuwahara
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
        </article-title>
        <source>
         ACS Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         2
        </volume>
        <fpage>
         361
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acsinfecdis.6b00006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27627203
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B145-viruses-11-00059">
       <label>
        145.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         215
        </volume>
        <fpage>
         1807
        </fpage>
        <lpage>
         1815
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jix209
        </pub-id>
        <pub-id pub-id-type="pmid">
         28472421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B146-viruses-11-00059">
       <label>
        146.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Systematic Review of Treatment Effects
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e343
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030343
        </pub-id>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B147-viruses-11-00059">
       <label>
        147.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Clinical presentation, transmission, pathogenesis and treatment options
        </article-title>
        <source>
         Clin. Sci.
        </source>
        <year>
         2006
        </year>
        <volume>
         110
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         204
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/CS20050188
        </pub-id>
        <pub-id pub-id-type="pmid">
         16411895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B148-viruses-11-00059">
       <label>
        148.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B149-viruses-11-00059">
       <label>
        149.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McAuliffe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fahle
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tatti
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Packard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         3572
        </fpage>
        <lpage>
         3577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.7.3572-3577.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15016880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B150-viruses-11-00059">
       <label>
        150.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wentworth
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Espina
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mice susceptible to SARS coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1293
        </fpage>
        <lpage>
         1296
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1007.031119
        </pub-id>
        <pub-id pub-id-type="pmid">
         15324552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B151-viruses-11-00059">
       <label>
        151.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glass
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2004
        </year>
        <volume>
         173
        </volume>
        <fpage>
         4030
        </fpage>
        <lpage>
         4039
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.173.6.4030
        </pub-id>
        <pub-id pub-id-type="pmid">
         15356152
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B152-viruses-11-00059">
       <label>
        152.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection
        </article-title>
        <source>
         Comp. Med.
        </source>
        <year>
         2007
        </year>
        <volume>
         57
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         17974127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B153-viruses-11-00059">
       <label>
        153.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         5833
        </fpage>
        <lpage>
         5838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.9.5833-5838.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15827197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B154-viruses-11-00059">
       <label>
        154.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Flieder
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Paragas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wivel
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Crystal
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Boyer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11416
        </fpage>
        <lpage>
         11421
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11416-11421.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B155-viruses-11-00059">
       <label>
        155.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Woodruff
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Scorpio
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         884
        </fpage>
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.05957-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22072787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B156-viruses-11-00059">
       <label>
        156.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Legge
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice
        </article-title>
        <source>
         J. Clin. Investig.
        </source>
        <year>
         2011
        </year>
        <volume>
         121
        </volume>
        <fpage>
         4921
        </fpage>
        <lpage>
         4930
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI59777
        </pub-id>
        <pub-id pub-id-type="pmid">
         22105170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B157-viruses-11-00059">
       <label>
        157.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2010
        </year>
        <volume>
         84
        </volume>
        <fpage>
         9318
        </fpage>
        <lpage>
         9325
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01049-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20610717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B158-viruses-11-00059">
       <label>
        158.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Rooijen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evasion by stealth: Inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2009
        </year>
        <volume>
         5
        </volume>
        <elocation-id>
         e1000636
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000636
        </pub-id>
        <pub-id pub-id-type="pmid">
         19851468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B159-viruses-11-00059">
       <label>
        159.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
         <name>
          <surname>
           Funkhouser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Uematsu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Akira
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2008
        </year>
        <volume>
         4
        </volume>
        <elocation-id>
         e1000240
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000240
        </pub-id>
        <pub-id pub-id-type="pmid">
         19079579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B160-viruses-11-00059">
       <label>
        160.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Temperton
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brenchley
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         T cell responses to whole SARS coronavirus in humans
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2008
        </year>
        <volume>
         181
        </volume>
        <fpage>
         5490
        </fpage>
        <lpage>
         5500
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.181.8.5490
        </pub-id>
        <pub-id pub-id-type="pmid">
         18832706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B161-viruses-11-00059">
       <label>
        161.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           You
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <year>
         2004
        </year>
        <volume>
         53
        </volume>
        <fpage>
         435
        </fpage>
        <lpage>
         438
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.45561-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         15096554
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B162-viruses-11-00059">
       <label>
        162.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spruth
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kistner
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Savidis-Dacho
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hitter
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Crowe
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gerencer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bruhl
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Grillberger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Reiter
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tauer
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2006
        </year>
        <volume>
         24
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.08.055
        </pub-id>
        <pub-id pub-id-type="pmid">
         16214268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B163-viruses-11-00059">
       <label>
        163.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hernandez
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Coccia
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graziano
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lowy
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Finberg
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         191
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/427242
        </pub-id>
        <pub-id pub-id-type="pmid">
         15655773
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B164-viruses-11-00059">
       <label>
        164.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapadia
          </surname>
          <given-names>
           S.U.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         340
        </volume>
        <fpage>
         174
        </fpage>
        <lpage>
         182
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.06.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         16043204
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B165-viruses-11-00059">
       <label>
        165.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stadler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rappuoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Abrignani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS vaccine protective in mice
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1312
        </fpage>
        <lpage>
         1314
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1108.041003
        </pub-id>
        <pub-id pub-id-type="pmid">
         16110580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B166-viruses-11-00059">
       <label>
        166.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         6641
        </fpage>
        <lpage>
         6646
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0401939101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15096611
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B167-viruses-11-00059">
       <label>
        167.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schaecher
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Stabenow
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Oberle
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schriewer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Buller
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sagartz
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Pekosz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An immunosuppressed Syrian golden hamster model for SARS-CoV infection
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2008
        </year>
        <volume>
         380
        </volume>
        <fpage>
         312
        </fpage>
        <lpage>
         321
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2008.07.026
        </pub-id>
        <pub-id pub-id-type="pmid">
         18760437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B168-viruses-11-00059">
       <label>
        168.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pacal
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab’)2
        </article-title>
        <source>
         Viral Immunol.
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <fpage>
         495
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/vim.2007.0038
        </pub-id>
        <pub-id pub-id-type="pmid">
         17931120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B169-viruses-11-00059">
       <label>
        169.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is there an ideal animal model for SARS?
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <year>
         2006
        </year>
        <volume>
         14
        </volume>
        <fpage>
         299
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2006.05.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         16759866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B170-viruses-11-00059">
       <label>
        170.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.D.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         193
        </volume>
        <fpage>
         685
        </fpage>
        <lpage>
         692
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/500143
        </pub-id>
        <pub-id pub-id-type="pmid">
         16453264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B171-viruses-11-00059">
       <label>
        171.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virology: SARS virus infection of cats and ferrets
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         425
        </volume>
        <fpage>
         915
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/425915a
        </pub-id>
        <pub-id pub-id-type="pmid">
         14586458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B172-viruses-11-00059">
       <label>
        172.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leijten
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of experimental SARS coronavirus infection in cats and ferrets
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <year>
         2008
        </year>
        <volume>
         45
        </volume>
        <fpage>
         551
        </fpage>
        <lpage>
         562
        </lpage>
        <pub-id pub-id-type="doi">
         10.1354/vp.45-4-551
        </pub-id>
        <pub-id pub-id-type="pmid">
         18587105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B173-viruses-11-00059">
       <label>
        173.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Darnell
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plant
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2007
        </year>
        <volume>
         196
        </volume>
        <fpage>
         1329
        </fpage>
        <lpage>
         1338
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/522431
        </pub-id>
        <pub-id pub-id-type="pmid">
         17922397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B174-viruses-11-00059">
       <label>
        174.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Weverling
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           de Kruif
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         2139
        </fpage>
        <lpage>
         2141
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)16506-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         15220038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B175-viruses-11-00059">
       <label>
        175.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zitzow
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Karunakaran
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gauldie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         89
        </volume>
        <fpage>
         2136
        </fpage>
        <lpage>
         2146
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.2008/001891-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         18753223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B176-viruses-11-00059">
       <label>
        176.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           She
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2005
        </year>
        <volume>
         206
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         259
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1769
        </pub-id>
        <pub-id pub-id-type="pmid">
         15892035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B177-viruses-11-00059">
       <label>
        177.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McAuliffe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fahle
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2004
        </year>
        <volume>
         330
        </volume>
        <fpage>
         8
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2004.09.030
        </pub-id>
        <pub-id pub-id-type="pmid">
         15527829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B178-viruses-11-00059">
       <label>
        178.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Crystal
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wivel
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Macaque model for severe acute respiratory syndrome
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11401
        </fpage>
        <lpage>
         11404
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11401-11404.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B179-viruses-11-00059">
       <label>
        179.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           F.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Woodle
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         944
        </fpage>
        <lpage>
         951
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1280
        </pub-id>
        <pub-id pub-id-type="pmid">
         16116432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B180-viruses-11-00059">
       <label>
        180.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Midkiff
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lackner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques
        </article-title>
        <source>
         Mucosal Immunol.
        </source>
        <year>
         2016
        </year>
        <volume>
         9
        </volume>
        <fpage>
         1089
        </fpage>
        <lpage>
         1101
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/mi.2015.127
        </pub-id>
        <pub-id pub-id-type="pmid">
         26647718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B181-viruses-11-00059">
       <label>
        181.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Hoogen
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aetiology: Koch’s postulates fulfilled for SARS virus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         423
        </volume>
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/423240a
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B182-viruses-11-00059">
       <label>
        182.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Laman
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Jong
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         263
        </fpage>
        <lpage>
         270
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13967-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B183-viruses-11-00059">
       <label>
        183.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Carville
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Coderre
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mansfield
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonitis and multi-organ system disease in common marmosets (
         <italic>
          Callithrix jacchus
         </italic>
         ) infected with the severe acute respiratory syndrome-associated coronavirus
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2005
        </year>
        <volume>
         167
        </volume>
        <fpage>
         455
        </fpage>
        <lpage>
         463
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0002-9440(10)62989-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         16049331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B184-viruses-11-00059">
       <label>
        184.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawler
          </surname>
          <given-names>
           J.V.
          </given-names>
         </name>
         <name>
          <surname>
           Endy
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Garrison
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fritz
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lesar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kulesh
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Norwood
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wasieloski
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cynomolgus macaque as an animal model for severe acute respiratory syndrome
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e149
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030149
        </pub-id>
        <pub-id pub-id-type="pmid">
         16605302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B185-viruses-11-00059">
       <label>
        185.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models for SARS
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <year>
         2006
        </year>
        <volume>
         581
        </volume>
        <fpage>
         463
        </fpage>
        <lpage>
         471
        </lpage>
        <pub-id pub-id-type="pmid">
         17037579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B186-viruses-11-00059">
       <label>
        186.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2008
        </year>
        <volume>
         381
        </volume>
        <fpage>
         89
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2008.08.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         18801550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B187-viruses-11-00059">
       <label>
        187.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Curnes
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         5195
        </fpage>
        <lpage>
         5199
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03764-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24574399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B188-viruses-11-00059">
       <label>
        188.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Goicochea
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         408
        </fpage>
        <lpage>
         412
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.060640-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24197535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B189-viruses-11-00059">
       <label>
        189.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Horne
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Saturday
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Domestic Pig Unlikely Reservoir for MERS-CoV
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         985
        </fpage>
        <lpage>
         988
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2306.170096
        </pub-id>
        <pub-id pub-id-type="pmid">
         28318484
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B190-viruses-11-00059">
       <label>
        190.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Swanstrom
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Burch
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e00534-17
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00534-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         28747502
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B191-viruses-11-00059">
       <label>
        191.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Stittelaar
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Getu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Waal
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Verjans
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         6131
        </fpage>
        <lpage>
         6135
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00661-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B192-viruses-11-00059">
       <label>
        192.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lackemeyer
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <elocation-id>
         e69127
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0069127
        </pub-id>
        <pub-id pub-id-type="pmid">
         23844250
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B193-viruses-11-00059">
       <label>
        193.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Earnest
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Bair
          </surname>
          <given-names>
           T.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Brogden
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Flaherty
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2017
        </year>
        <volume>
         114
        </volume>
        <fpage>
         E3119
        </fpage>
        <lpage>
         E3128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1619109114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28348219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B194-viruses-11-00059">
       <label>
        194.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e145561
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0145561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B195-viruses-11-00059">
       <label>
        195.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gale
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1323279111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B196-viruses-11-00059">
       <label>
        196.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Watts
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Packard
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1162
        </fpage>
        <lpage>
         1173
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01702-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17108019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B197-viruses-11-00059">
       <label>
        197.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
        </article-title>
        <source>
         Nat. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         2
        </volume>
        <fpage>
         16226
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.226
        </pub-id>
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B198-viruses-11-00059">
       <label>
        198.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlsein
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fux
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aad1283
        </pub-id>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B199-viruses-11-00059">
       <label>
        199.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1031
        </fpage>
        <lpage>
         1037
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160192
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B200-viruses-11-00059">
       <label>
        200.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Durr
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Foord
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Riddell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haining
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Barr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1071
        </fpage>
        <lpage>
         1074
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160007
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B201-viruses-11-00059">
       <label>
        201.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An Animal Model of MERS Produced by Infection of Rhesus Macaques with MERS Coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         209
        </volume>
        <fpage>
         236
        </fpage>
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit590
        </pub-id>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B202-viruses-11-00059">
       <label>
        202.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2017
        </year>
        <volume>
         12
        </volume>
        <elocation-id>
         e172093
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0172093
        </pub-id>
        <pub-id pub-id-type="pmid">
         28234937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B203-viruses-11-00059">
       <label>
        203.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e1004250
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1004250
        </pub-id>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B204-viruses-11-00059">
       <label>
        204.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia from human coronavirus in a macaque model
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         368
        </volume>
        <fpage>
         1560
        </fpage>
        <lpage>
         1562
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMc1215691
        </pub-id>
        <pub-id pub-id-type="pmid">
         23550601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B205-viruses-11-00059">
       <label>
        205.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Brining
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.3362
        </pub-id>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B206-viruses-11-00059">
       <label>
        206.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Via
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cornish
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yellayi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huzella
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Oberlander
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bartos
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ork
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2015
        </year>
        <volume>
         485
        </volume>
        <fpage>
         422
        </fpage>
        <lpage>
         430
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2015.07.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         26342468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B207-viruses-11-00059">
       <label>
        207.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11429
        </fpage>
        <lpage>
         11433
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11429-11433.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B208-viruses-11-00059">
       <label>
        208.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2620
        </fpage>
        <lpage>
         2625
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.4.2620-2625.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15681462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B209-viruses-11-00059">
       <label>
        209.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkar
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4953
        </fpage>
        <lpage>
         4961
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00161-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24554656
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B210-viruses-11-00059">
       <label>
        210.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kinne
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         9220
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00676-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-11-00059-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Schematic representation of the genome organization and functional domains of S protein for SARS-CoV and MERS-CoV. The single-stranded RNA genomes of SARS-CoV and MERS-CoV encode two large genes, the ORF1a and ORF1b genes, which encode 16 non-structural proteins (nsp1–nsp16) that are highly conserved throughout coronaviruses. The structural genes encode the structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are common features to all coronaviruses. The accessory genes (shades of green) are unique to different coronaviruses in terms of number, genomic organization, sequence, and function. The structure of each S protein is shown beneath the genome organization. The S protein mainly contains the S1 and S2 subunits. The residue numbers in each region represent their positions in the S protein of SARS and MERS, respectively. The S1/S2 cleavage sites are highlighted by dotted lines. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CP, cytoplasm domain; FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; TM, transmembrane domain.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00059-g001">
      </graphic>
     </fig>
     <fig id="viruses-11-00059-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        The life cycle of SARS-CoV and MERS-CoV in host cells. SARS-CoV and MERS-CoV enter target cells through an endosomal pathway. The S proteins of SARS and MERS bind to cellular receptor angiotensin-converting enzyme 2 (ACE2) and cellular receptor dipeptidyl peptidase 4 (DPP4), respectively. Following entry of the virus into the host cell, the viral RNA is unveiled in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which are cleaved by the proteases that are encoded by ORF1a to yield 16 non-structural proteins that form the RNA replicase–transcriptase complex. This complex drives the production of negative-sense RNAs [(−) RNA] through both replication and transcription. During replication, full-length (−) RNA copies of the genome are produced and used as templates for full-length (+) RNA genomes. During transcription, a subset of 7–9 sub-genomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. Although the different sub-genomic mRNAs may contain several open reading frames (ORFs), only the first ORF (that closest to the 5′ end) is translated. Viral nucleocapsids are assembled from genomic RNA and N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi intermediate compartment). Virions are then released from the infected cell through exocytosis. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; S, spike; E, envelope; M, membrane; N, nucleocapsid.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00059-g002">
      </graphic>
     </fig>
     <table-wrap id="viruses-11-00059-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Epidemiology and biological characteristics of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          MERS-CoV
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Genus
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beta-CoVs, lineage B
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beta-CoVs, lineage C
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Possible Natural Reservoir
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Bat
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Bat
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Possible Intermediary Host
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Palm civet
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Dromedary camel
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Origin
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Guangdong province, China
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Arabian Peninsula
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
          <bold>
           Clinical Epidemiology
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Total global number reported to WHO
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 8098 people
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2254 (from 2012 through 16 September 2018)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Affected countries
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          27
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Number of deaths
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          916
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          800
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Mortality
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 10%
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 35%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Transmission region
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Globally
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Regionally
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Transmission patterns
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          From animal to human;
          <break>
          </break>
          from human to human
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           The predominant receptor
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Human angiotensin-converting enzyme 2 (ACE2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Human dipeptidyl peptidase 4 (DPP4 or CD26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Receptor
          </bold>
          <break>
          </break>
          <bold>
           distribution
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Arterial and venous endothelium; arterial smooth muscle; small intestine; respiratory tract epithelium; alveolar monocytes and macrophages
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract epithelium; kidney; small intestine; liver and prostate; activated leukocytes
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Cell line susceptibility
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract;
          <break>
          </break>
          kidney; liver
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract;
          <break>
          </break>
          intestinal tract;
          <break>
          </break>
          genitourinary tract;
          <break>
          </break>
          liver, kidney,
          <break>
          </break>
          neurons;
          <break>
          </break>
          monocyte;
          <break>
          </break>
          Tlymphocyte; and
          <break>
          </break>
          histiocytic cell lines
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Viral replication efficiency
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          High
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Higher
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Ability to inhibit IFN production
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Delayed recognition and proinflammatory response
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Delayed recognition and proinflammatory response
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        The genomic characterization of SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          MERS-CoV
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Length of nucleotides
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29,727
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          30,119
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Open reading frames (ORFs)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Structural protein
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike protein (length of amino acids)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1255
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1353
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          S1 subunit
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Receptor-binding domain (RBD)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          318–510
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          367–588
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Receptor-binding motif (RBM)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          424–494
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          484–567
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          S2 subunit
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Heptad repeat 1 (HR1) domains
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          892–1013
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          984–1104
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Heptad repeat 2 (HR2) domains
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1145–1195
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1246–1295
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Non-structural proteins (NSPs)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          At least 5
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          16
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Accessory proteins
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          8
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A characteristic gene order
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5′-replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Vaccine strategies of SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Vaccine Strategy
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Process of Production
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          References
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Advantages
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Disadvantages
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Inactivated virus vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Virus particles are inactivated by heat, chemicals, or radiation
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Whole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [
          <xref ref-type="bibr" rid="B93-viruses-11-00059">
           93
          </xref>
          ,
          <xref ref-type="bibr" rid="B94-viruses-11-00059">
           94
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Whole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [
          <xref ref-type="bibr" rid="B91-viruses-11-00059">
           91
          </xref>
          ,
          <xref ref-type="bibr" rid="B95-viruses-11-00059">
           95
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Maintained virus particles structure; rapidly develop; easy to prepare; safety; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B93-viruses-11-00059">
           93
          </xref>
          ]; protection with adjuvant [
          <xref ref-type="bibr" rid="B96-viruses-11-00059">
           96
          </xref>
          ,
          <xref ref-type="bibr" rid="B97-viruses-11-00059">
           97
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Potential inappropriate for highly immunosuppressed individuals; possible T
          <sub>
           H
          </sub>
          2 cell-distortive immune response [
          <xref ref-type="bibr" rid="B98-viruses-11-00059">
           98
          </xref>
          ,
          <xref ref-type="bibr" rid="B99-viruses-11-00059">
           99
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Live-attenuated virus vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Attenuated the virulence, but still keeping it viable by mutagenesis or targeted deletions
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Envelope protein deletion [
          <xref ref-type="bibr" rid="B100-viruses-11-00059">
           100
          </xref>
          ]; non-structural protein 14 (nsp14) and exonuclease (ExoN) inactivation [
          <xref ref-type="bibr" rid="B101-viruses-11-00059">
           101
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Full-length infectious cDNA clone or mutant viruses [
          <xref ref-type="bibr" rid="B102-viruses-11-00059">
           102
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Inexpensive; quick immunity; less adverse effect; activates all phases of the immune system [
          <xref ref-type="bibr" rid="B103-viruses-11-00059">
           103
          </xref>
          ]; more durable immunity; more targeted [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Phenotypic or genotypic reversion possible; need sufficient viral replication [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Viral vector vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Genetically engineered unrelated viral genome with deficient packaging elements for encoding targeted gene
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B100-viruses-11-00059">
           100
          </xref>
          ,
          <xref ref-type="bibr" rid="B104-viruses-11-00059">
           104
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B87-viruses-11-00059">
           87
          </xref>
          ,
          <xref ref-type="bibr" rid="B88-viruses-11-00059">
           88
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Safety; stronger and specific cellular and humoral immune responses [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Varies inoculation routes may produce different immune responses [
          <xref ref-type="bibr" rid="B96-viruses-11-00059">
           96
          </xref>
          ]; possibly incomplete protection; may fail in aged vaccinees; possible T
          <sub>
           H
          </sub>
          2 cell-distortive immune response [
          <xref ref-type="bibr" rid="B105-viruses-11-00059">
           105
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Subunit vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Antigenic components inducing the immune system without introducing viral particles, whole or otherwise.
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B53-viruses-11-00059">
           53
          </xref>
          ,
          <xref ref-type="bibr" rid="B59-viruses-11-00059">
           59
          </xref>
          ,
          <xref ref-type="bibr" rid="B106-viruses-11-00059">
           106
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B85-viruses-11-00059">
           85
          </xref>
          ,
          <xref ref-type="bibr" rid="B86-viruses-11-00059">
           86
          </xref>
          ,
          <xref ref-type="bibr" rid="B107-viruses-11-00059">
           107
          </xref>
          ,
          <xref ref-type="bibr" rid="B108-viruses-11-00059">
           108
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B109-viruses-11-00059">
           109
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Uncertain cost-effectiveness; relatively lower immunogenicity; need appropriate adjuvants [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          DNA vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Genetically engineered DNA for directly producing an antigen
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B110-viruses-11-00059">
           110
          </xref>
          ,
          <xref ref-type="bibr" rid="B111-viruses-11-00059">
           111
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B89-viruses-11-00059">
           89
          </xref>
          ,
          <xref ref-type="bibr" rid="B90-viruses-11-00059">
           90
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Easier to design; high safety; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B110-viruses-11-00059">
           110
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lower immune responses; potential T
          <sub>
           H
          </sub>
          2 cell-distortive immune response results; potential ineffective; possibly delayed-type hypersensitivity [
          <xref ref-type="bibr" rid="B112-viruses-11-00059">
           112
          </xref>
          ].
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t004_Table 4
      </object-id>
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Potential therapeutics for severe acute respiratory syndrome (SARS) and MERS.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Treatment
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stage of Development
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS (Notes)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS (Notes)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Host protease inhibitors
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse models [
          <xref ref-type="bibr" rid="B138-viruses-11-00059">
           138
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B138-viruses-11-00059">
           138
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Viral protease inhibitors
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B139-viruses-11-00059">
           139
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B140-viruses-11-00059">
           140
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Monoclonal and polyclonal antibodies
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse, ferrets, golden Syrian hamster [
          <xref ref-type="bibr" rid="B124-viruses-11-00059">
           124
          </xref>
          ,
          <xref ref-type="bibr" rid="B141-viruses-11-00059">
           141
          </xref>
          ,
          <xref ref-type="bibr" rid="B142-viruses-11-00059">
           142
          </xref>
          ] and non-human primate models [
          <xref ref-type="bibr" rid="B143-viruses-11-00059">
           143
          </xref>
          ,
          <xref ref-type="bibr" rid="B144-viruses-11-00059">
           144
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse, rabbit, and non-human primate models [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ,
          <xref ref-type="bibr" rid="B145-viruses-11-00059">
           145
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Convalescent plasma
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a mouse model; clinical trial approved [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Interferons
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (often in combination with immunoglobulins or thymosins) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in non-human primate models; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Ribavirin
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (often in combination with corticosteroids) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a non-human primate model; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lopinavir and ritonavir
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (improved the outcome in combination with ribavirin) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a non-human primate model; off-label use in patients [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ,
          <xref ref-type="bibr" rid="B148-viruses-11-00059">
           148
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Common Feature
          </bold>
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          None of these therapeutic agents are approved for commercial use in humans
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Biol Chem
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Biol. Chem
      </journal-id>
      <journal-id journal-id-type="hwp">
       jbc
      </journal-id>
      <journal-id journal-id-type="pmc">
       jbc
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JBC
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of Biological Chemistry
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0021-9258
      </issn>
      <issn pub-type="epub">
       1083-351X
      </issn>
      <publisher>
       <publisher-name>
        American Society for Biochemistry and Molecular
Biology
       </publisher-name>
       <publisher-loc>
        11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110,
U.S.A.
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29887526
      </article-id>
      <article-id pub-id-type="pmc">
       6066311
      </article-id>
      <article-id pub-id-type="publisher-id">
       RA118.001897
      </article-id>
      <article-id pub-id-type="doi">
       10.1074/jbc.RA118.001897
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Microbiology
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East respiratory syndrome coronavirus and bat coronavirus HKU9
both can utilize GRP78 for attachment onto host cells
       </article-title>
       <alt-title alt-title-type="short">
        MERS-CoV and bCoV-HKU9 both utilize GRP78 for
attachment
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          Hin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Che-Man
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Xi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Yixin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          Shuofeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Jie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Au-Yeung
         </surname>
         <given-names>
          Rex Kwok-Him
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <italic>
          <sup>
           c
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sze
         </surname>
         <given-names>
          Kong-Hung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Dong
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shuai
         </surname>
         <given-names>
          Huiping
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hou
         </surname>
         <given-names>
          Yuxin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Cun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Xiaoyu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Poon
         </surname>
         <given-names>
          Vincent Kwok-Man
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Leung
         </surname>
         <given-names>
          Sze Pui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yeung
         </surname>
         <given-names>
          Man-Lung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff4">
         <italic>
          <sup>
           d
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff5">
         <italic>
          <sup>
           e
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          Jinghua
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff8">
         <italic>
          <sup>
           f
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Guangwen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff9">
         <italic>
          <sup>
           g
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jin
         </surname>
         <given-names>
          Dong-Yan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         <italic>
          <sup>
           h
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          George Fu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff8">
         <italic>
          <sup>
           f
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff10">
         <italic>
          <sup>
           i
          </sup>
         </italic>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper Fuk-Woo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff4">
         <italic>
          <sup>
           d
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff5">
         <italic>
          <sup>
           e
          </sup>
         </italic>
        </xref>
        <xref ref-type="author-notes" rid="FN2">
         <sup>
          2
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <italic>
          <sup>
           a
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <italic>
          <sup>
           b
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff4">
         <italic>
          <sup>
           d
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff5">
         <italic>
          <sup>
           e
          </sup>
         </italic>
        </xref>
        <xref ref-type="aff" rid="aff7">
         <italic>
          <sup>
           j
          </sup>
         </italic>
        </xref>
        <xref ref-type="author-notes" rid="FN2">
         <sup>
          2
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor2">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        From the
        <label>
         a
        </label>
        State Key Laboratory of Emerging Infectious
Diseases,
       </aff>
       <aff id="aff2">
        Departments of
        <label>
         b
        </label>
        Microbiology and
       </aff>
       <aff id="aff3">
        <label>
         c
        </label>
        Pathology,
       </aff>
       <aff id="aff4">
        <label>
         d
        </label>
        Research Centre of Infection and Immunology,
       </aff>
       <aff id="aff5">
        <label>
         e
        </label>
        Carol Yu Centre for Infection,
       </aff>
       <aff id="aff6">
        <label>
         h
        </label>
        School of Biomedical Sciences, and
       </aff>
       <aff id="aff7">
        <label>
         j
        </label>
        Collaborative Innovation Center for Diagnosis and
Treatment of Infectious Diseases, Li Ka Shing Faculty of Medicine, University of
Hong Kong, Pokfulam, Hong Kong Special Administrative Region,
       </aff>
       <aff id="aff8">
        the
        <label>
         f
        </label>
        CAS Key Laboratory of Pathogenic Microbiology and
Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing
100101,
       </aff>
       <aff id="aff9">
        the
        <label>
         g
        </label>
        West China Hospital Emergency Department, State
Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and
Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, and
       </aff>
       <aff id="aff10">
        the
        <label>
         i
        </label>
        National Institute for Viral Disease Control and
Prevention, Chinese Center for Disease Control and Prevention (China CDC),
Beijing 102206, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <label>
         3
        </label>
        To whom correspondence may be addressed:
        <addr-line>
         State Key Laboratory of Emerging Infectious Diseases, Carol Yu
Centre for Infection, Dept. of Microbiology, University of Hong Kong, Queen
Mary Hospital, 102 Pokfulam Rd., Pokfulam, Hong Kong Special Administrative
Region, China.
        </addr-line>
        Tel.:
        <phone>
         852-22554897
        </phone>
        ; Fax:
        <fax>
         852-28551241
        </fax>
        ; E-mail:
        <email>
         jfwchan@hku.hk
        </email>
        .
       </corresp>
       <corresp id="cor2">
        <label>
         4
        </label>
        To whom correspondence may be addressed:
        <addr-line>
         State Key Laboratory of Emerging Infectious Diseases, Carol Yu
Centre for Infection, Dept. of Microbiology, University of Hong Kong, Queen
Mary Hospital, 102 Pokfulam Rd., Pokfulam, Hong Kong Special Administrative
Region, China.
        </addr-line>
        Tel.:
        <phone>
         852-22554897
        </phone>
        ; Fax:
        <fax>
         852-28551241
        </fax>
        ; E-mail:
        <email>
         kyyuen@hku.hk
        </email>
        .
       </corresp>
       <fn fn-type="equal" id="FN1">
        <label>
         1
        </label>
        <p>
         These authors contributed equally to this work.
        </p>
       </fn>
       <fn fn-type="other" id="FN2">
        <label>
         2
        </label>
        <p>
         Co-senior authors.
        </p>
       </fn>
       <fn fn-type="edited-by">
        <p>
         Edited by Charles E. Samuel
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        27
       </day>
       <month>
        7
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        10
       </day>
       <month>
        6
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       293
      </volume>
      <issue>
       30
      </issue>
      <fpage>
       11709
      </fpage>
      <lpage>
       11726
      </lpage>
      <history>
       <date date-type="received">
        <day>
         22
        </day>
        <month>
         1
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         26
        </day>
        <month>
         5
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2018 Chu et al.
       </copyright-statement>
       <copyright-year>
        2018
       </copyright-year>
       <copyright-holder>
        Chu et al.
       </copyright-holder>
       <license>
        <license-p>
         Published under exclusive license by The American Society for
Biochemistry and Molecular Biology, Inc.
        </license-p>
        <license-p>
         This article is made available via the PMC Open Access Subset for
unrestricted re-use and analyses in any form or by any means with
acknowledgement of the original source. These permissions are granted for
the duration of the COVID-19 pandemic or until permissions are revoked in
writing. Upon expiration of these permissions, PMC is granted a perpetual
license to make this article available via PMC and Europe PMC, consistent
with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zbc03018011709.pdf">
      </self-uri>
      <abstract>
       <p>
        Coronavirus tropism is predominantly determined by the interaction between
coronavirus spikes and the host receptors. In this regard, coronaviruses have
evolved a complicated receptor-recognition system through their spike proteins.
Spikes from highly related coronaviruses can recognize distinct receptors,
whereas spikes of distant coronaviruses can employ the same cell-surface
molecule for entry. Moreover, coronavirus spikes can recognize a broad range of
cell-surface molecules in addition to the receptors and thereby can augment
coronavirus attachment or entry. The receptor of Middle East respiratory
syndrome coronavirus (MERS-CoV) is dipeptidyl peptidase 4 (DPP4). In this study,
we identified membrane-associated 78-kDa glucose-regulated protein (GRP78) as an
additional binding target of the MERS-CoV spike. Further analyses indicated that
GRP78 could not independently render nonpermissive cells susceptible to MERS-CoV
infection but could facilitate MERS-CoV entry into permissive cells by
augmenting virus attachment. More importantly, by exploring potential
interactions between GRP78 and spikes of other coronaviruses, we discovered that
the highly conserved human GRP78 could interact with the spike protein of bat
coronavirus HKU9 (bCoV-HKU9) and facilitate its attachment to the host cell
surface. Taken together, our study has identified GRP78 as a host factor that
can interact with the spike proteins of two
        <italic>
         Betacoronaviruses
        </italic>
        ,
the lineage C MERS-CoV and the lineage D bCoV-HKU9. The capacity of GRP78 to
facilitate surface attachment of both a human coronavirus and a phylogenetically
related bat coronavirus exemplifies the need for continuous surveillance of the
evolution of animal coronaviruses to monitor their potential for human
adaptations.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        virology
       </kwd>
       <kwd>
        virus
       </kwd>
       <kwd>
        infectious disease
       </kwd>
       <kwd>
        infection
       </kwd>
       <kwd>
        GRP78
       </kwd>
       <kwd>
        attachment factors
       </kwd>
       <kwd>
        bat CoV-HKU9
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        GRP78
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        viral infection
       </kwd>
       <kwd>
        coronavirus spike
       </kwd>
       <kwd>
        viral attachment
       </kwd>
       <kwd>
        viral evolution
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group id="award1">
        <funding-source>
         Hong Kong Health and Medical Research Fund
        </funding-source>
        <award-id>
         14131392
        </award-id>
        <award-id>
         15140762
        </award-id>
        <award-id>
         16150572
        </award-id>
       </award-group>
       <award-group id="award2">
        <funding-source>
         Providence Foundation Limited in memory of the late Dr. Lui Hac
minh
        </funding-source>
        <award-id>
         NA
        </award-id>
       </award-group>
       <award-group id="award3">
        <funding-source>
         NSFC/RGC Joint Research Scheme
        </funding-source>
        <award-id>
         N_HKU728/14
        </award-id>
        <award-id>
         81461168030
        </award-id>
       </award-group>
       <award-group id="award4">
        <funding-source>
         Theme-Based Research Scheme, RGC
        </funding-source>
        <award-id>
         T11/707/15
        </award-id>
       </award-group>
       <award-group id="award5">
        <funding-source>
         Ministry of Education of China for the Collaborative Innovation
Center for Diagnosis and Treatment of Infectious Diseases
        </funding-source>
        <award-id>
         NA
        </award-id>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
    <sec sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      Coronaviruses are known to infect a broad spectrum of species, ranging from birds to
mammals, including humans (
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      <xref ref-type="bibr" rid="B2">
       –
      </xref>
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ). They are enveloped RNA viruses with large genome sizes of
∼28–32 kb. Currently, coronaviruses are classified into four genera:
      <italic>
       Alphacoronavirus, Betacoronavirus, Gammacoronavirus,
      </italic>
      and
      <italic>
       Deltacoronavirus
      </italic>
      (
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ).
Among them, six coronaviruses from the
      <italic>
       Alphacoronavirus
      </italic>
      genera and
the
      <italic>
       Betacoronavirus
      </italic>
      genera are known to cause human infections with
diverse outcomes. On the one hand, human coronavirus 229E (HCoV-229E),
      <xref ref-type="fn" rid="FN3">
       <sup>
        5
       </sup>
      </xref>
      human coronavirus NL63 (HCoV-NL63),
human coronavirus OC43 (HCoV-OC43), and human coronavirus HKU1 (HCoV-HKU1)
predominantly cause mild and self-limiting upper respiratory tract infections (
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ). In
stark contrast, severe acute respiratory syndrome coronavirus (SARS-CoV) that caused
the severe acute respiratory syndrome epidemic between 2002 and 2003 was highly
pathogenic, which infected more than 8000 people with a fatality rate of ∼10%
(
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ). Ten years later, another highly pathogenic human coronavirus, Middle
East respiratory syndrome coronavirus (MERS-CoV), emerged in the Middle East in 2012
(
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      ). MERS-CoV caused severe lower
respiratory tract infections with an exceptionally high fatality rate of
∼35%. Most importantly, despite global efforts trying to control the virus'
dissemination, MERS-CoV still spread to over 27 countries and has been causing
continuous infections in the Middle East since 2012 (
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ).
     </p>
     <p>
      The interaction between the spike protein and its receptor is the main determinant of
host tropism for coronaviruses (
      <xref ref-type="bibr" rid="B11">
       11
      </xref>
      ). Among
the six human coronaviruses, the
      <italic>
       Alphacoronavirus
      </italic>
      HCoV-229E spike
binds aminopeptidase N (
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      ), whereas the
lineage C
      <italic>
       Betacoronavirus
      </italic>
      the MERS-CoV spike recognizes dipeptidyl
peptidase 4 (DPP4) (
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ). Intriguingly, the
      <italic>
       Alphacoronavirus
      </italic>
      HCoV-NL63 and the lineage B
      <italic>
       Betacoronavirus
      </italic>
      SARS-CoV both utilize angiotensin-converting
enzyme 2 (ACE2) for cell entry (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ). However, the protein receptors for the
lineage A
      <italic>
       Betacoronavirus
      </italic>
      HCoV-OC43 and HCoV-HKU1 are currently
unknown. In addition to their designated receptors, coronavirus spikes are known to
recognize a broad array of cell-surface molecules, which serve to facilitate the
attachment or entry of the viruses. For example, HCoV-NL63 and mouse hepatitis virus
both employ heparan sulfate proteoglycans to enhance attachment (
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17">
       17
      </xref>
      ).
Similarly, transmissible gastroenteritis coronavirus, bovine coronavirus, HCoV-OC43,
and HCoV-HKU1 bind to
      <italic>
       O
      </italic>
      -acetylated sialic acid as key attachment
molecules (
      <xref ref-type="bibr" rid="B18">
       18
      </xref>
      <xref ref-type="bibr" rid="B19">
       –
      </xref>
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      ).
Interestingly, in addition to utilizing
      <italic>
       O-
      </italic>
      acetylated sialic acid as
a critical binding determinant (
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      ),
HCoV-HKU1 spike also recognizes major histocompatibility complex class I C as
another attachment molecule (
      <xref ref-type="bibr" rid="B22">
       22
      </xref>
      ). In the case
of SARS-CoV, dendritic cell–specific intercellular adhesion
molecule-3–grabbing nonintegrin (DC-SIGN) and DC-SIGN–related both
augment virus entry (
      <xref ref-type="bibr" rid="B23">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      ). For MERS-CoV, we previously reported
carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) as an attachment
factor that could modulate MERS-CoV entry in permissive cells (
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ). More recently, tetraspanin CD9 was identified as a host
cell- -surface factor that facilitated MERS-CoV entry by scaffolding host cell
receptors and proteases (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ).
     </p>
     <p>
      Knowledge of the interaction between coronavirus spikes and cell-surface host factors
contributes to the understanding of coronavirus biology on many aspects, including
tropism, pathogenicity, as well as potential intervention strategies. To this end,
we aimed to investigate whether additional cell-surface molecules were involved in
the attachment or entry of MERS-CoV. In this study, we reported that the MERS-CoV
spike could recognize a 78-kDa glucose–regulated protein (GRP78). Although
traditionally regarded as an ER protein with chaperone activity, recent discoveries
suggest that GRP78 is also localized to the cell surface, where they carry out
physiological functions that regulate signaling and cellular homeostasis (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ). Subsequent experiments demonstrated that
GRP78 did not render nonpermissive cells susceptible to MERS-CoV infection but
played a positive role in augmenting MERS-CoV entry in permissive cells, suggesting
that GRP78 is an attachment factor of MERS-CoV that can modulate MERS-CoV entry in
the presence of the host cell receptor DPP4. Importantly, our data further indicated
that the spike protein of a lineage D
      <italic>
       Betacoronavirus
      </italic>
      , bat
coronavirus HKU9 (bCoV-HKU9), also recognized GRP78, which played a key role in the
attachment of HKU9–S-pseudovirus to the bat
      <italic>
       Rousettus
leschenaulti
      </italic>
      kidney (RLK) cells. Our findings highlight the importance
of the possible evolution of different animal and human coronaviruses to become
capable of using not just the same host receptors but also the same attachment
factors, which may facilitate animal coronaviruses to jump the interspecies barrier
into human.
     </p>
    </sec>
    <sec sec-type="results">
     <title>
      Results
     </title>
     <sec>
      <title>
       GRP78 interacts with MERS-CoV spike
      </title>
      <p>
       We previously identified human carcinoembryonic antigen-related cell adhesion
molecule 5 (CEACAM5) as an attachment factor for MERS-CoV (
       <xref ref-type="bibr" rid="B25">
        25
       </xref>
       ). In this study, we asked whether additional membrane
proteins could interact with the MERS-CoV spike and facilitate the entry or
attachment of MERS-CoV. To this end, we transfected human bronchus epithelial
cells, BEAS2B, with the MERS-CoV spike and evaluated the membrane proteins that
might bind the MERS-CoV spike in the transfected cells. In brief, membrane
proteins from pcDNA–MERS-CoV–S1–V5-transfected BEAS2B cells
were extracted and sedimented (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       ). To
evaluate the extraction efficiency, the cell extracts were probed for markers of
different cellular fractions, including that of the plasma membrane (epidermal
growth factor receptor (EGFR) and pan-cadherin), endoplasmic reticulum (ER)
(calreticulin), Golgi (giantin), and nucleus (lamin A). Western blotting
analyses revealed that our membrane extracts were enriched with the plasma
membrane markers, EGFR and pan-cadherin. In contrast, only a trace amount of the
ER marker was observed, whereas the signal for Golgi and nucleus was not
detected (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        D
       </italic>
       and
       <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
        Fig.
S1
       </ext-link>
       ).
      </p>
      <fig id="F1" orientation="portrait" position="float">
       <label>
        Figure 1.
       </label>
       <caption>
        <p>
         <bold>
          Identification of GRP78 as a target membrane protein of the
MERS-CoV spike.
         </bold>
         <italic>
          A,
         </italic>
         silver staining of membrane proteins of BEAS2B cells
transfected with pcDNA–MERS-CoV–S1–V5. Membrane
extracts were immunoprecipitated (
         <italic>
          IP
         </italic>
         ) with V5 antibody
and Sepharose A/G beads, followed by washing and eluting with glycine
(
         <italic>
          lane 1
         </italic>
         ). Sepharose beads were boiled in sample
buffer after glycine elution (
         <italic>
          lane 2
         </italic>
         ). Membrane
extracts were immunoprecipitated with mouse isotype control and
Sepharose A/G beads (
         <italic>
          lane 3
         </italic>
         ).
         <italic>
          B,
         </italic>
         expression of MERS-CoV–S1-V5 was detected by Western blotting
(
         <italic>
          WB
         </italic>
         ) with an anti-ERS-CoV spike antibody.
         <italic>
          C,
         </italic>
         silver staining of membrane proteins of BEAS2B
cells. The membrane extracts were immunoprecipitated with purified
recombinant MERS-CoV–S1–FLAG protein using anti-FLAG M2
antibody and Sepharose A/G beads, followed by washing and eluting with
3× FLAG peptides (
         <italic>
          lane 1
         </italic>
         ). Sepharose beads were
boiled in sample buffer after 3× FLAG peptide elution (
         <italic>
          lane
2
         </italic>
         ). Membrane extracts were immunoprecipitated with mouse
isotype control and Sepharose A/G beads (
         <italic>
          lane 3
         </italic>
         ).
         <italic>
          D,
         </italic>
         5 μg of sedimented membrane extracts were
run on SDS-PAGE and subjected to Western blots using antibodies against
the plasma membrane marker (EGFR and pan-cadherin), endoplasmic
reticulum marker (calreticulin), Golgi marker (giantin), and nucleus
marker (lamin A).
         <italic>
          E,
         </italic>
         gel fragment indicated by the
         <italic>
          red arrowhead
         </italic>
         in
         <italic>
          A
         </italic>
         and
         <italic>
          C
         </italic>
         was excised for LC-MS/MS analysis. MS/MS data
were searched against all mammalian protein databases in NCBI and
Swiss-Prot. The protein was identified as GRP78 with significant hits
over different domains of the sequence.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840001">
       </graphic>
      </fig>
      <p>
       To identify potential proteins that could interact with the MERS-CoV spike, the
membrane extracts were immunoprecipitated with a V5 mAb and protein
A/G-Sepharose. The precipitated beads were then washed, and protein complexes
were eluted with 0.1
       <sc>
        m
       </sc>
       glycine. Co-immunoprecipitated proteins were
revealed in SDS-PAGE after silver staining (
       <xref ref-type="fig" rid="F1">
        Fig.
1
       </xref>
       <italic>
        A
       </italic>
       ,
       <italic>
        lane 1
       </italic>
       ). The eluted beads were
resuspended in sample loading buffer, boiled, and assessed for elution
efficiency (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        A
       </italic>
       ,
       <italic>
        lane 2
       </italic>
       ). As a control, the same set of membrane extracts
was immunoprecipitated with isotype antibody and protein A/G-Sepharose (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        A
       </italic>
       ,
       <italic>
        lane
3
       </italic>
       ). In parallel, the expression of the MERS-CoV spike in the
immunoprecipitated complexes was validated with Western blotting using a mouse
immune serum against the MERS-CoV spike (
       <xref ref-type="fig" rid="F1">
        Fig.
1
       </xref>
       <italic>
        B
       </italic>
       ). Specific protein bands that were pulled down by
the V5 antibody but not the isotype control were excised and sent for MS
analysis. The MS/MS result revealed one of the dominant bands (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        A
       </italic>
       ,
       <italic>
        lane 1,
arrowhead
       </italic>
       ) to be 78-kDa glucose-regulated protein (GRP78), also
known as heat shock 70-kDa protein 5 (HSPA5) or binding immunoglobulin protein
(BiP) (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        E
       </italic>
       ).
      </p>
      <p>
       To further verify the interaction between the MERS-CoV spike and GRP78, we
attempted to immunoprecipitate GRP78 with purified the MERS-CoV spike proteins.
To this end, recombinant MERS-CoV–S1–FLAG proteins were expressed,
purified, and immunoprecipitated against the membrane protein extracts from
BEAS2B cells. Notably, silver staining of the SDS-PAGE and the subsequent MS
confirmed the presence of GRP78 in the precipitated
MERS-CoV–S1–FLAG complex (
       <xref ref-type="fig" rid="F1">
        Fig.
1
       </xref>
       <italic>
        C
       </italic>
       ,
       <italic>
        lane 1, arrowhead
       </italic>
       ) but not in
the control (
       <xref ref-type="fig" rid="F1">
        Fig. 1
       </xref>
       <italic>
        C
       </italic>
       ,
       <italic>
        lane 3
       </italic>
       ). Taken together, our membrane pulldown assay
identified GRP78 as a potential membrane protein specifically bound by the
MERS-CoV spike.
      </p>
     </sec>
     <sec>
      <title>
       GRP78 is a specific binding target of MERS-CoV spike
      </title>
      <p>
       Next, to examine the direct interaction between GRP78 and the MERS-CoV spike, we
performed a series of co-immunoprecipitation (co-IP) assays in both
overexpression and endogenous settings. First, BHK21 cells were transfected with
GRP78–V5 or the pcDNA–V5 control vector. The cell lysates of the
transfected cells were then immunoprecipitated with either
MERS-CoV–S1–FLAG or
       <italic>
        Escherichia coli
       </italic>
       bacterial
alkaline phosphatase–FLAG (BAP–FLAG) pre-adsorbed on anti-FLAG
M2-agarose beads. The precipitated protein complexes were then detected by
Western blotting with the anti-FLAG or the anti-V5 antibody. As illustrated in
       <xref ref-type="fig" rid="F2">
        Fig. 2
       </xref>
       <italic>
        A
       </italic>
       , GRP78
specifically immunoprecipitated with MERS-CoV–S1 (
       <italic>
        lower panel,
lane 1
       </italic>
       ) but not the control bait protein, BAP (
       <italic>
        lower panel,
lane 2
       </italic>
       ). Additionally, GRP78 was not precipitated in cells
transfected with the empty vector (
       <xref ref-type="fig" rid="F2">
        Fig.
2
       </xref>
       <italic>
        A
       </italic>
       ,
       <italic>
        lower panel, lane 3
       </italic>
       ). To
confirm the interaction between GRP78 and MERS-CoV–S1, we performed
reciprocal co-IP using GRP78 as the bait protein (
       <xref ref-type="fig" rid="F2">
        Fig. 2
       </xref>
       <italic>
        B
       </italic>
       ). In this setting, cell lysates of
GRP78–V5 or empty vector transfected BHK21 cells were immunoprecipitated
with anti-V5 pre-adsorbed protein A/G-Sepharose and incubated with purified
MERS-CoV–S1–FLAG or BAP–FLAG. Our result demonstrated that
MERS-CoV–S1–FLAG but not BAP–FLAG was efficiently
immunoprecipitated by GRP78–V5 (
       <xref ref-type="fig" rid="F2">
        Fig.
2
       </xref>
       <italic>
        B
       </italic>
       ,
       <italic>
        upper panel, lanes 1
       </italic>
       and
       <italic>
        2
       </italic>
       ). As a negative control, the expression of
pcDNA–V5 empty vector failed to immunoprecipitate with
MERS-CoV–S1–FLAG (
       <xref ref-type="fig" rid="F2">
        Fig.
2
       </xref>
       <italic>
        B
       </italic>
       ,
       <italic>
        upper panel, lane 3
       </italic>
       ). In
parallel, MERS-CoV–S1–FLAG did not co-IP with the abundantly
expressed cell-surface protein EGFR, suggesting the interaction between
MERS-CoV–S1–FLAG and GRP78 was specific (
       <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
        Fig. S2,
        <italic>
         A
        </italic>
        and
        <italic>
         B
        </italic>
       </ext-link>
       ). Next, we
evaluated whether the interaction between the MERS-CoV spike and GRP78 could
occur at the cell surface. To this end, we obtained the membrane fraction of
Huh7 cells that was predominantly enriched with the plasma membrane contents of
the cells. We then added MERS-CoV–S1–FLAG protein to the membrane
extracts and performed co-IP between the MERS-CoV spike and GRP78. Our data
showed that the MERS-CoV spike and the endogenous GRP78 in the membrane extract
could efficiently interact with each other (
       <xref ref-type="fig" rid="F2">
        Fig.
2
       </xref>
       ,
       <italic>
        C
       </italic>
       and
       <italic>
        D
       </italic>
       ).
      </p>
      <fig id="F2" orientation="portrait" position="float">
       <label>
        Figure 2.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 interacts with the MERS-CoV spike.
         </bold>
         <italic>
          A,
         </italic>
         BHK21 cells were transfected with
pcDNA–GRP78–V5 (
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          2
         </italic>
         ) or empty vector (
         <italic>
          lane 3
         </italic>
         ). The
cell lysate was immunoprecipitated (
         <italic>
          IP
         </italic>
         ) with either
purified recombinant MERS-CoV–S1–FLAG protein
(
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          3
         </italic>
         ) or
         <italic>
          E.
coli
         </italic>
         bacterial alkaline phosphatase
(
         <italic>
          BAP
         </italic>
         )-FLAG protein (
         <italic>
          lane 2
         </italic>
         )
pre-adsorbed onto anti-FLAG M2-agarose beads. The precipitated protein
complex was detected using the anti-FLAG antibody or the anti-V5
antibody.
         <italic>
          B,
         </italic>
         reciprocal co-IP was performed using GRP78
as the bait protein. Purified MERS-CoV–S1–FLAG
(
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          3
         </italic>
         ) or BAP–FLAG
proteins (
         <italic>
          lane 2
         </italic>
         ) were immunoprecipitated with
overexpressed GRP78–V5 or pcDNA–V5 proteins pre-adsorbed
on anti-V5 Sepharose beads. The precipitated protein complex was
detected using the anti-FLAG antibody or the anti-GRP78 antibody.
         <italic>
          C,
         </italic>
         membrane fraction of Huh7 cells was extracted
and immunoprecipitated with either
MERS-CoV–S1–FLAG(
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          3
         </italic>
         ) or BAP–FLAG (
         <italic>
          lane 2
         </italic>
         ).
         <italic>
          D,
         </italic>
         reciprocal co-IP was performed using GRP78 as
the bait. Mouse IgG was used in place of the membrane extract as a
negative control.
         <italic>
          E,
         </italic>
         endogenous co-IP was performed in
MERS-CoV- or mock-infected Huh7 and BEAS2B cells. Immunoprecipitation
was performed using the anti-GRP78 antibody, the anti-MERS-CoV spike
antibody, or the mouse isotype control. The precipitated protein
complexes were detected with the anti-MERS-CoV spike antibody or the
anti-GRP78 antibody.
         <italic>
          WB
         </italic>
         , Western blotting.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840002">
       </graphic>
      </fig>
      <p>
       To further verify the physical interaction between GRP78 and the MERS-CoV spike
in a physiological relevant scenario, we performed endogenous co-IP experiments
in MERS-CoV–infected Huh7 and BEAS2B cells (
       <xref ref-type="fig" rid="F2">
        Fig. 2
       </xref>
       <italic>
        E
       </italic>
       ). In line with our earlier findings, GRP78
efficiently immunoprecipitated the MERS-CoV spike from cell lysates of the
infected samples. In contrast, the MERS-CoV spike was not detected from the
mock-infected samples or from infected samples immunoprecipitated with a control
isotype antibody. The reciprocal co-IP performed using the MERS-CoV spike as the
bait similarly immunoprecipitated endogenous GRP78 from the infected samples but
not from mock-infected samples or from infected samples immunoprecipitated with
the control isotype antibody (
       <xref ref-type="fig" rid="F2">
        Fig.
2
       </xref>
       <italic>
        E
       </italic>
       ). Collectively, our co-IP data established GRP78
as a specific binding target of the MERS-CoV spike.
      </p>
     </sec>
     <sec>
      <title>
       GRP78 is abundantly expressed on the surface of human and animal
cells
      </title>
      <p>
       GRP78 is a highly conserved protein that is traditionally described as an
ER-residing chaperone and plays key roles in facilitating protein folding and
assembly as well as the regulation of ER stress (
       <xref ref-type="bibr" rid="B28">
        28
       </xref>
       ). In recent years, multiple functions of GRP78 on the cell
surface have been reported, including a critical role of cell-surface GRP78 on
virus entry (
       <xref ref-type="bibr" rid="B29">
        29
       </xref>
       <xref ref-type="bibr" rid="B30">
        –
       </xref>
       <xref ref-type="bibr" rid="B31">
        31
       </xref>
       ). Because
our earlier data suggested that the MERS-CoV spike could interact with plasma
membrane GRP78, we hypothesized that GRP78 might be involved in modulating
MERS-CoV entry or attachment. To this end, we first analyzed GRP78 expression on
the cell surface of human lung cell lines that are susceptible to MERS-CoV
infection (
       <xref ref-type="bibr" rid="B32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="B33">
        33
       </xref>
       ). As illustrated in
       <xref ref-type="fig" rid="F3">
        Fig.
3
       </xref>
       <italic>
        A
       </italic>
       , GRP78 was readily detected on the cell surface
of human lung cell lines, including A549, BEAS2B, and Calu3. In addition, GRP78
expression was also observed on the cell surface of a broad array of human cell
lines (AD293, Caco2, HeLa, and Huh7) and primary cells (monocyte-derived
macrophage (MDM), T cell) of extrapulmonary origin (
       <xref ref-type="fig" rid="F3">
        Fig. 3
       </xref>
       <italic>
        B
       </italic>
       ). Intriguingly, surface GRP78
expression was similarly detected in nonhuman cell lines, including BHK21, L929,
VeroE6, and RLK. Quantitative analysis of the expression rate (
       <xref ref-type="fig" rid="F3">
        Fig. 3
       </xref>
       <italic>
        D
       </italic>
       ) and mean
fluorescent intensity (MFI) (
       <xref ref-type="fig" rid="F3">
        Fig.
3
       </xref>
       <italic>
        E
       </italic>
       ) from the immunolabeled cells revealed that
surface DPP4 and GRP78 were expressed at comparative levels in most measured
cell lines with the exception of L929. The ubiquitous detection of GRP78 across
cell lines from different species by the human GRP78 antibody could be
attributed to the high degree of GRP78 sequence homology between mammalian
species, suggesting that the protein is well conserved in mammalian cells (
       <xref ref-type="fig" rid="F3">
        Fig. 3
       </xref>
       <italic>
        F
       </italic>
       ). Altogether, the
surface expression of GRP78 on MERS-CoV–susceptible cells supported the
notion that GRP78 might be involved in modulating MERS-CoV entry. However, the
ubiquitous expression of GRP78, particularly on cells that are not permissive to
MERS-CoV infection, including BHK21 and L929, suggested that GRP78 might play an
auxiliary rather than a determining role in MERS-CoV entry.
      </p>
      <fig id="F3" orientation="portrait" position="float">
       <label>
        Figure 3.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 is abundantly expressed on the cell surface of mammalian
cells.
         </bold>
         Surface GRP78 expression was detected on mammalian
cell lines with flow cytometry with no cell permeabilization. The
immunostaining was performed for human lung cell lines
(
         <italic>
          A
         </italic>
         ), human extrapulmonary cell lines, human primary
macrophages, and human primary T cells (
         <italic>
          B
         </italic>
         ), as well as
nonhuman cell lines (
         <italic>
          C
         </italic>
         ).
         <italic>
          D,
         </italic>
         percentage
of GRP78-positive cells quantified with DPP4 included for comparisons.
         <italic>
          E,
         </italic>
         MFI of GRP78 on the cell surface was quantified
with isotype and DPP4 staining included as controls.
         <italic>
          F,
         </italic>
         sequence homology between human GRP78 and GRP78 in other mammals. Gates
in
         <italic>
          A–C
         </italic>
         represented the percentage of
GRP78-positive cells. Data in
         <italic>
          D
         </italic>
         and
         <italic>
          E
         </italic>
         represented mean and standard deviation from three independent
experiments.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840003">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       GRP78 is co-expressed with DPP4 in human pulmonary and extrapulmonary
tissues
      </title>
      <p>
       In order for GRP78 to modulate virus entry, it must be expressed by the
susceptible cells at the site of infection. To explore the potential
physiological relevance of GRP78 during MERS-CoV entry, we examined the
distribution of GRP78 in human lung tissues with confocal microscopy. Our
immunostaining results demonstrated that GRP78 was expressed at multiple regions
of the human lung tissues. In particular, specific GRP78 expression was
abundantly detected on the epithelial cells of the bronchus (
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       <italic>
        A
       </italic>
       ), bronchiole (
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       <italic>
        B
       </italic>
       ), and alveolus
(
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       <italic>
        C
       </italic>
       ). Most
importantly, double immunostaining of DPP4 and GRP78 revealed extensive
co-localization of DPP4 and GRP78 among the epithelial cells lining the human
airways (
       <xref ref-type="fig" rid="F4">
        Fig. 4
       </xref>
       ,
       <italic>
        A–C
       </italic>
       ). The co-localization between DPP4 and GRP78 on
the apical side of the epithelial cells indicated the potential of GRP78 in
facilitating MERS-CoV entry or attachment (
       <xref ref-type="fig" rid="F4">
        Fig.
4
       </xref>
       <italic>
        D
       </italic>
       ,
       <italic>
        arrows
       </italic>
       ). Interestingly, the
co-expression of DPP4 and GRP78 could also be recognized in extrapulmonary
tissues, including the small intestine (
       <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
        Fig.
S3
        <italic>
         A
        </italic>
       </ext-link>
       ) and the kidney (
       <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
        Fig.
S3
        <italic>
         B
        </italic>
       </ext-link>
       ). Overall, our data demonstrated that
GRP78 was co-expressed with DPP4 on physiologically relevant cell types in the
human lung and could potentially be involved during MERS-CoV infection in the
lower respiratory tract.
      </p>
      <fig id="F4" orientation="portrait" position="float">
       <label>
        Figure 4.
       </label>
       <caption>
        <p>
         <bold>
          Co-expression of GRP78 and DPP4 in human tissues.
         </bold>
         Immunostaining of GRP78 and DPP4 was performed on paraffin slides of
normal human tissues. GRP78 was labeled with a polyclonal rabbit
anti-GRP78 antibody, and DPP4 was labeled with a polyclonal goat
anti-DPP4 antibody. Cell nuclei were labeled with DAPI. The
co-expression of GRP78 and DPP4 was detected in the bronchus
(
         <italic>
          A
         </italic>
         ), bronchiole (
         <italic>
          B
         </italic>
         ), and alveolus
(
         <italic>
          C
         </italic>
         ). The co-localization of GRP78 and DPP4 was
examined at a higher magnification in
         <italic>
          D
         </italic>
         . Images were
acquired with a Carl Zeiss LSM 710 system.
         <italic>
          Bars,
         </italic>
         50
μm for
         <italic>
          A–C. Bars,
         </italic>
         5 μm for
         <italic>
          D
         </italic>
         .
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840004">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Antibody blocking or siRNA knockdown of GRP78 limits MERS-CoV entry
      </title>
      <p>
       To investigate the functional role of cell-surface GRP78 during MERS-CoV
infection, we first evaluated the capacity of GRP78 antibody in blocking the
entry of MERS–S-pseudovirus. In this set of experiments, Huh7 and BEAS2B
cells were pre-incubated with a rabbit polyclonal antibody against GRP78 or a
nontargeting rabbit control IgG. After the pre-incubation,
MERS–S-pseudoviruses were added to the cells for 1 h in the presence of
the GRP78 antibody or the control IgG. At 72 h post-inoculation, the cells were
lysed and incubated with luciferase substrate for the quantification of
infectivity. Our results demonstrated that GRP78 antibody but not the control
IgG reduced MERS–S-pseudovirus entry in both Huh7 (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       <italic>
        A
       </italic>
       ) and BEAS2B cells (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       <italic>
        B
       </italic>
       ) in a dose-dependent
manner. In stark contrast, the entry of the control vesicular stomatitis virus
glycoprotein (VSV-G)-pseudovirus in both cell lines was not inhibited by GRP78
antibody (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       ,
       <italic>
        A
       </italic>
       and
       <italic>
        B
       </italic>
       ). Next, we proceeded to validate the antibody blocking
results using infectious MERS-CoV. To this end, Huh7 cells were pre-incubated
with antibodies and subsequently infected with MERS-CoV in the presence of
control IgG, GRP78 antibody, or DPP4 antibody. Our data showed that the
treatment of GRP78 antibody similarly inhibited MERS-CoV entry in a
dose-dependent manner (
       <xref ref-type="fig" rid="F5">
        Fig.
5
       </xref>
       <italic>
        C
       </italic>
       ). For further verification, we infected Huh7 and
BEAS2B cells with MERS-CoV after siRNA knockdown of GRP78 or DPP4. Western
blotting detection demonstrated that GRP78 knockdown did not affect DPP4 or
CEACAM5 expression (
       <xref ref-type="fig" rid="F5">
        Fig.
5
       </xref>
       <italic>
        D
       </italic>
       ). In line with the antibody blocking results,
depletion of GRP78 reduced MERS-CoV entry in both Huh7 and BEAS2B cells (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       <italic>
        E
       </italic>
       ). Because CEACAM5
was expressed in Huh7 but not BEAS2B cells, our data implied that the role of
GRP78 in modulating MERS-CoV entry was independent of CEACAM5 expression. To
further evaluate the role of GRP78 on MERS-CoV replication, we assessed virus
growth in MERS-CoV–infected BEAS2B cells after siRNA knockdown of GRP78
or DPP4. Our data demonstrated that GRP78 depletion decreased MERS-CoV
replication, although to a lesser extent compared with that of DPP4 knockdown
(
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       ,
       <italic>
        F
       </italic>
       and
       <italic>
        G
       </italic>
       ). Next, we asked whether GRP78 could play a role in
MERS-CoV entry in the physiologically relevant primary cells. To this end, we
performed siRNA knockdown of GRP78 (
       <xref ref-type="fig" rid="F5">
        Fig.
5
       </xref>
       <italic>
        H
       </italic>
       ) in primary human MDM and primary human embryonic
lung fibroblasts (HFL), which are both susceptible to MERS-CoV infection as
reported in our previous studies (
       <xref ref-type="bibr" rid="B32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="B34">
        34
       </xref>
       ). In agreement with our results
from Huh7 and BEAS2B cells, GRP78 knockdown significantly reduced virus entry
(
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       <italic>
        I
       </italic>
       ) and
replication (
       <xref ref-type="fig" rid="F5">
        Fig. 5
       </xref>
       ,
       <italic>
        J
       </italic>
       and
       <italic>
        K
       </italic>
       ) in MDM and HFL. Collectively, with antibody blocking and
siRNA knockdown, we demonstrated a significant role of GRP78 during MERS-CoV
entry.
      </p>
      <fig id="F5" orientation="portrait" position="float">
       <label>
        Figure 5.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 is involved in MERS-CoV entry.
         </bold>
         Pseudovirus antibody
blocking assays were performed in Huh7 (
         <italic>
          A
         </italic>
         ) and BEAS2B
(
         <italic>
          B
         </italic>
         ) cells. A titration of GRP78 or isotype control
antibodies from 0 to 2.5 μg/ml was added and pre-incubated with
Huh7 and BEAS2B cells for 1 h at 37 °C. MERS–S-pseudovirus
or VSV-G–pseudovirus was subsequently added at a ratio of 100 LP
per cell for 1 h. Luciferase activity was determined at 72 h
post-inoculation and was normalized to that of the mock-treated cells.
         <italic>
          C,
         </italic>
         antibody blocking assay was performed in Huh7
cells using infectious MERS-CoV. Huh7 cells were pre-incubated with
antibodies at the indicated concentration for 1 h at 37 °C. The
cells were then challenged with MERS-CoV at 1 m.o.i. for 1 h at 37
°C in the presence of the antibodies. After 1 h, the cells were
washed and harvested. MERS-CoV entry was assessed with qPCR, and the
result was normalized to that of the mock-treated cells.
         <italic>
          D,
         </italic>
         Huh7 or BEAS2B cells were treated with 75
n
         <sc>
          m
         </sc>
         GRP78, DPP4, or scrambled siRNA for 2 consecutive days.
The knockdown efficiency was evaluated with Western blottings.
         <italic>
          E,
         </italic>
         siRNA-treated Huh7 or BEAS2B cells were infected
with MERS-CoV at 1 m.o.i. for 1 h at 37 °C. After 1 h, the cells
were harvested, and virus entry was evaluated with qPCR analysis. The
result was normalized to that of the scrambled siRNA-treated cells.
siRNA-treated BEAS2B cells were infected with MERS-CoV at 0.1 m.o.i. for
1 h at 37 °C. The cell lysates (
         <italic>
          F
         </italic>
         ) and
supernatants (
         <italic>
          G
         </italic>
         ) were harvested at 24 and 48 h
post-infection. MERS-CoV replication was evaluated with qPCR analysis.
         <italic>
          H,
         </italic>
         siRNA-treated MDM or HFL was infected with
MERS-CoV at 1 m.o.i. for 2 h at 37 °C. After 2 h, the cells were
harvested, and virus entry was evaluated with qPCR analysis
(
         <italic>
          I
         </italic>
         ). The result was normalized to that of the
scrambled siRNA-treated cells. siRNA-treated MDM or HFL was infected
with MERS-CoV at 0.1 m.o.i. for 1 h at 37 °C. The cell lysates
(
         <italic>
          J
         </italic>
         ) and supernatants (
         <italic>
          K
         </italic>
         ) were
harvested at 24 h post-infection. MERS-CoV replication was evaluated
with qPCR analysis. In all panels, data represented mean and S.D. from
three independent experiments. Statistical analyses were carried out
using Student's
         <italic>
          t
         </italic>
         test. Statistical significance was
indicated by
         <italic>
          asterisks
         </italic>
         when
         <italic>
          p
         </italic>
         &lt;
0.05.
         <italic>
          ns
         </italic>
         means not significant.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840005">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       GRP78 is an attachment factor of MERS-CoV
      </title>
      <p>
       Our earlier data supported the notion that cell-surface GRP78 was involved in
MERS-CoV entry. To define the functional role of GRP78 during this process, we
challenged AD293 or BHK21 cells with MERS-CoV after GRP78 overexpression. First,
we sought to evaluate the capacity of GRP78 in facilitating MERS-CoV attachment.
To this end, GRP78-transfected AD293 or BHK21 cells were challenged with
MERS-CoV at 4 °C for 2 h. After the incubation, the cells were washed,
fixed, and immunolabeled for MERS-CoV N. As illustrated in
       <xref ref-type="fig" rid="F6">
        Fig. 6
       </xref>
       <italic>
        A
       </italic>
       , GRP78 overexpression significantly
increased virus attachment in both AD293 and BHK21 cells. Interestingly, GRP78
overexpression appeared to induce a more substantial increase in MERS-CoV
attachment in the MERS-CoV–nonsusceptible BHK21 cells than that in the
MERS-CoV–susceptible AD293 cells (
       <xref ref-type="fig" rid="F6">
        Fig.
6
       </xref>
       <italic>
        B
       </italic>
       ). Next, to address whether GRP78 could
independently facilitate MERS-CoV entry, we assessed the level of MERS-CoV entry
in AD293 and BHK21 cells upon GRP78 overexpression. To this end,
GRP78-transfected AD293 and BHK21 cells were challenged with MERS-CoV at 37
°C for 2 h. After infection, the cells were washed and incubated for
another 4 h before harvesting for flow cytometry. Importantly, our result
demonstrated that the nonpermissive BHK21 cells remained refractory to MERS-CoV
infection despite GRP78 overexpression. In contrast, GRP78 overexpression
further enhanced the entry of MERS-CoV to the permissive AD293 cells (
       <xref ref-type="fig" rid="F6">
        Fig. 6
       </xref>
       ,
       <italic>
        C
       </italic>
       and
       <italic>
        D
       </italic>
       ). The effect of GRP78 on MERS-CoV entry was not due to ER
stress (
       <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
        Fig.
S4
       </ext-link>
       ). Overall, our data indicated that GRP78 could not facilitate
MERS-CoV entry independently but could serve as an attachment factor and
modulate MERS-CoV entry in the presence of DPP4.
      </p>
      <fig id="F6" orientation="portrait" position="float">
       <label>
        Figure 6.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 is an attachment factor of MERS-CoV.
         </bold>
         <italic>
          A,
         </italic>
         to assess the role of GRP78 on MERS-CoV attachment,
GRP78-overexpressing AD293 and BHK21 cells were challenged with MERS-CoV
at 15 m.o.i. for 2 h at 4 °C. After 2 h, the cells were washed,
detached with 10 m
         <sc>
          m
         </sc>
         EDTA on ice, and fixed in 4%
paraformaldehyde before immunolabeling for flow cytometry.
         <italic>
          B,
         </italic>
         percentage of MERS-CoV N–positive AD293
and BHK21 cells was quantified for MERS-CoV attachment.
         <italic>
          C,
         </italic>
         to assess the role of GRP78 on MERS-CoV entry,
GRP78-overexpressing AD293 and BHK21 cells were challenged with MERS-CoV
at 5 m.o.i. for 2 h at 37 °C. After 2 h, the inoculum was replaced
with culture media, and the cells were incubated for another 4 h before
harvesting for flow cytometry.
         <italic>
          D,
         </italic>
         percentage of
MERS-CoV N–positive AD293 and BHK21 cells was quantified for
MERS-CoV entry.
         <italic>
          B
         </italic>
         and
         <italic>
          D
         </italic>
         , percentage of
MERS-CoV N–positive cells among GRP78-transfected
(GRP78
         <sup>
          +
         </sup>
         ) cells was calculated as
(%GRP78
         <sup>
          +
         </sup>
         N
         <sup>
          +
         </sup>
         cells/(%GRP78
         <sup>
          +
         </sup>
         N
         <sup>
          +
         </sup>
         cells +
%GRP78
         <sup>
          +
         </sup>
         N
         <sup>
          −
         </sup>
         cells)) × 100%. The
percentage of MERS-CoV N–positive cells among
GRP78-nontransfected (GRP78
         <sup>
          −
         </sup>
         ) cells was calculated as
(%GRP78
         <sup>
          −
         </sup>
         N
         <sup>
          +
         </sup>
         cells/(%GRP78
         <sup>
          −
         </sup>
         N
         <sup>
          +
         </sup>
         cells +
%GRP78
         <sup>
          −
         </sup>
         N
         <sup>
          −
         </sup>
         cells)) × 100%.
Data represented mean and S.D. derived from three independent
experiments. Statistical analyses were carried out using Student's
         <italic>
          t
         </italic>
         test. Statistical significance was indicated by
         <italic>
          asterisks
         </italic>
         when
         <italic>
          p
         </italic>
         &lt; 0.05.
         <italic>
          ns
         </italic>
         means not significant.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840006">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       GRP78 is up-regulated on the surface of MERS-CoV–infected
cells
      </title>
      <p>
       Because infections by certain coronaviruses, including infectious bronchitis
virus and SARS-CoV, are known to induce ER stress (
       <xref ref-type="bibr" rid="B35">
        35
       </xref>
       <xref ref-type="bibr" rid="B36">
        –
       </xref>
       <xref ref-type="bibr" rid="B39">
        39
       </xref>
       ), which can
promote GRP78 expression on the cell surface (
       <xref ref-type="bibr" rid="B40">
        40
       </xref>
       <xref ref-type="bibr" rid="B41">
        –
       </xref>
       <xref ref-type="bibr" rid="B43">
        43
       </xref>
       ), we asked whether MERS-CoV infection
could up-regulate GRP78 expression on the cell surface. To address this
question, we infected Huh7 cells with MERS-CoV (
       <xref ref-type="fig" rid="F7">
        Fig. 7
       </xref>
       ,
       <italic>
        A
       </italic>
       and
       <italic>
        B
       </italic>
       ) and harvested
samples for flow cytometry at 24 h post-infection. Our result demonstrated that
although the percentage of surface DPP4-positive cells modestly decreased after
MERS-CoV infection, the percentage of surface GRP78-positive cells significantly
increased from ∼50 to ∼80% after MERS-CoV infection (
       <xref ref-type="fig" rid="F7">
        Fig. 7
       </xref>
       ,
       <italic>
        C
       </italic>
       and
       <italic>
        D
       </italic>
       ). In this regard, our results highlighted the potential
relevance of GRP78 on MERS-CoV attachment onto the infected cells.
      </p>
      <fig id="F7" orientation="portrait" position="float">
       <label>
        Figure 7.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 is up-regulated on the surface of MERS-CoV–infected
cells.
         </bold>
         <italic>
          A,
         </italic>
         Huh7 cells were infected with MERS-CoV at 0.01 and
0.1 m.o.i. and were harvested for flow cytometry analysis at 24 h
post-infection.
         <italic>
          B,
         </italic>
         percentage of MERS-CoV
N–positive cells was quantified.
         <italic>
          C,
         </italic>
         in parallel,
cell surface and total DPP4 and GRP78 among mock- or
MERS-CoV–infected samples were analyzed by flow cytometry.
         <italic>
          D,
         </italic>
         percentage of DPP4-positive cells and
GRP78-positive cells in mock- or MERS-CoV–infected samples were
quantified. Total DPP4 and GRP78 staining was performed by first
permeabilizing the cells with 0.1% Triton X-100, whereas the surface
DPP4 and GRP78 staining was performed in the absence of cell
permeabilization. The gate in
         <italic>
          A
         </italic>
         represented the
percentage of MERS-CoV N–positive cells. The gates in
         <italic>
          C
         </italic>
         represented the percentage of DPP4-
(
         <italic>
          upper panels
         </italic>
         ) and GRP78 (
         <italic>
          lower
panels
         </italic>
         )-positive cells. Data represented mean and S.D.
derived from three independent experiments. Statistical analyses were
carried out using Student's
         <italic>
          t
         </italic>
         test. Statistical
significance was indicated by
         <italic>
          asterisks
         </italic>
         when
         <italic>
          p
         </italic>
         &lt; 0.05.
         <italic>
          ns
         </italic>
         means not
significant.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840007">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       GRP78 facilitates the cell-surface attachment of bCoV-HKU9
      </title>
      <p>
       Coronaviruses have evolved a complicated receptor recognition system through
their spike proteins. Peculiarly, the spike proteins from highly-related
coronaviruses can recognize different cell-surface molecules, whereas the spike
proteins of phylogenetically distant coronaviruses can bind the same
cell-surface molecule for attachment or entry (
       <xref ref-type="bibr" rid="B11">
        11
       </xref>
       ). By exploring the potential interaction between GRP78 and the
spike proteins of other coronaviruses, we unexpectedly discovered that GRP78
could interact with the spike protein of bat coronavirus HKU9 (bCoV-HKU9) (
       <xref ref-type="fig" rid="F8">
        Fig. 8
       </xref>
       <italic>
        A
       </italic>
       ). Interestingly,
despite the capacity of binding the spike proteins of lineage C (MERS-CoV) and
lineage D (bCoV-HKU9)
       <italic>
        Betacoronavirus
       </italic>
       , GRP78 did not interact
with the spike protein of SARS-CoV, which is a lineage B
       <italic>
        Betacoronavirus
       </italic>
       (
       <xref ref-type="fig" rid="F8">
        Fig.
8
       </xref>
       <italic>
        B
       </italic>
       ). In 2007, we reported the first discovery and
genome characterization of bCoV-HKU9, which was identified from Leschenault's
rousette bats (
       <italic>
        R. leschenaulti
       </italic>
       ) (
       <xref ref-type="bibr" rid="B44">
        44
       </xref>
       ). Recently, with structural analysis and surface plasmon
resonance assay, it appeared that the receptor-binding domain of bCoV-HKU9 spike
was incapable of reacting with either human DPP4 or ACE2 (
       <xref ref-type="bibr" rid="B45">
        45
       </xref>
       ). In this regard, it would be important to explore the
potential physiological relevance of the interaction between GRP78 and bCoV-HKU9
spike. We first evaluated the cell tropism of HKU9–S-pseudovirus with
MERS–S-pseudovirus included as a control. Remarkably, our data suggested
that among the 10 evaluated mammalian cell lines, HKU9–S-pseudovirus
entry was most pronounced in
       <italic>
        R. leschenaulti
       </italic>
       kidney (RLK) cells
(
       <xref ref-type="fig" rid="F8">
        Fig. 8
       </xref>
       <italic>
        C
       </italic>
       ). Notably,
although MERS–S-pseudovirus entry was evident in RLK cells, culture for
bCoV-HKU9 in RLK or other cell lines has not been successful (
       <xref ref-type="bibr" rid="B44">
        44
       </xref>
       ). In line with the pseudovirus entry
result, the surface-binding efficiency of HKU9–S-pseudovirus on RLK cells
was ∼3-fold that on Caco2 cells (
       <xref ref-type="fig" rid="F8">
        Fig.
8
       </xref>
       <italic>
        D
       </italic>
       ), which is a human colon cell line known to be
permissive for both MERS-CoV and SARS-CoV infection. Notably, overexpression of
human GRP78 in the apparently nonpermissive L929 and BHK21 cells did not render
the cells permissive to HKU9–S-pseudovirus entry, indicating that GRP78
could not function as an independent receptor for bCoV-HKU9 (
       <xref ref-type="fig" rid="F8">
        Fig. 8
       </xref>
       <italic>
        E
       </italic>
       ). In contrast, with
a flow cytometry-based surface-binding assay, we demonstrated that the GRP78
antibody (
       <xref ref-type="fig" rid="F8">
        Fig. 8
       </xref>
       <italic>
        G
       </italic>
       ) but not
the control IgG (
       <xref ref-type="fig" rid="F8">
        Fig. 8
       </xref>
       <italic>
        F
       </italic>
       )
reduced the binding of HKU9–S-pseudovirus to the cell surface of RLK
cells in a dose-dependent manner, which was evidenced by the drop in the
percentage of HKU9–S-positive cells (
       <xref ref-type="fig" rid="F8">
        Fig.
8
       </xref>
       <italic>
        H
       </italic>
       ) as well as the decrease in the
HKU9–S-mean fluorescent intensity (
       <xref ref-type="fig" rid="F8">
        Fig.
8
       </xref>
       <italic>
        I
       </italic>
       ). Taken together, our data identified GRP78 as an
important cell surface–binding protein for both MERS-CoV and bCoV-HKU9 by
serving as an attachment factor.
      </p>
      <fig id="F8" orientation="portrait" position="float">
       <label>
        Figure 8.
       </label>
       <caption>
        <p>
         <bold>
          GRP78 interacts with the bCoV-HKU9 spike and serves as an
attachment factor for bCoV-HKU9.
         </bold>
         <italic>
          A,
         </italic>
         BHK21 cells were transfected with
pcDNA–GRP78–V5 (
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          2
         </italic>
         ) or empty vector (
         <italic>
          lane 3
         </italic>
         ). Co-IP
between GRP78 and bCoV-HKU9 spike was performed using GRP78 as the bait
protein. Purified bCoV–HKU9–S1–FLAG (
         <italic>
          lanes
1
         </italic>
         and
         <italic>
          3
         </italic>
         ) or BAP–FLAG proteins
(
         <italic>
          lane 2
         </italic>
         ) were immunoprecipitated
(
         <italic>
          IP
         </italic>
         ) with overexpressed GRP78–V5 or
pcDNA–V5 proteins pre-adsorbed on anti-V5–Sepharose beads.
The precipitated protein complex was detected using the anti-V5 antibody
or the anti-FLAG antibody.
         <italic>
          B,
         </italic>
         co-IP between GRP78 and
SARS-CoV spike was performed using GRP78 as the bait protein. Purified
SARS-CoV–S1–FLAG (
         <italic>
          lanes 1
         </italic>
         and
         <italic>
          3
         </italic>
         ) or BAP–FLAG proteins (
         <italic>
          lane
2
         </italic>
         ) were immunoprecipitated with overexpressed
GRP78–V5 or pcDNA–V5 proteins pre-adsorbed on
anti-V5–Sepharose beads. The precipitated protein complex was
detected using the anti-V5 antibody or the anti-FLAG antibody.
         <italic>
          C,
         </italic>
         HKU9–S-pseudovirus entry assays were
performed in a number of mammalian cell lines. Mock-inoculated and
MERS–S-pseudovirus–inoculated cells were included as
negative and positive controls, respectively. HKU9–S-pseudovirus
and MERS–S-pseudovirus were added at a ratio of 100 LP per cell
for 1 h. Luciferase activity was determined at 72 h post-inoculation.
         <italic>
          D,
         </italic>
         HKU9–S-pseudovirus attachment efficiency
was evaluated in Caco2 and RLK cells. HKU9–S-pseudovirus was
inoculated on Caco2 and RLK cells at 100 LP per cell for 2 h at 4
°C. After 2 h, the cells were washed, fixed, and immunolabeled for
flow cytometry. HKU9–S-pseudovirus binding was identified with an
in-house mouse bCoV-HKU9 spike immune serum.
         <italic>
          E,
         </italic>
         HKU9–S-pseudovirus entry in L929 and BHK21 cells was assessed
with or without GRP78 overexpression. HKU9–S-pseudovirus was
inoculated at 100 LP per cell for 1 h at 37 °C. Luciferase activity
was determined at 72 h post-inoculation.
         <italic>
          F
         </italic>
         and
         <italic>
          G,
         </italic>
         antibody-blocking assay for
HKU9–S-pseudovirus binding was performed in RLK cells. RLK cells
were pre-incubated with the rabbit anti-GRP78 antibody and the rabbit
control IgG from 0 to 5 μg/ml. After the pre-incubation,
HKU9–S-pseudovirus was inoculated to the cells at 100 LP per cell
for 2 h at 4 °C. The cells were then washed, fixed, and
immunolabeled for flow cytometry. HKU9–S-pseudovirus binding was
identified with an in-house mouse bCoV-HKU9 spike immune serum. The
percentage of bCoV-HKU9 spike-positive cells was quantified in
         <italic>
          H,
         </italic>
         and the MFI of the bCoV-HKU9 spike on the cell
surface was quantified in
         <italic>
          I
         </italic>
         . Gates in
         <italic>
          D,
F,
         </italic>
         and
         <italic>
          G
         </italic>
         represented the percentage of
HKU9 spike-positive cells. Data represented mean and S.D. derived from
three independent experiments. Statistical analyses were carried out
using Student's
         <italic>
          t
         </italic>
         test. Statistical significance was
indicated by
         <italic>
          asterisks
         </italic>
         when
         <italic>
          p
         </italic>
         &lt;
0.05.
         <italic>
          WB,
         </italic>
         Western blot.
         <italic>
          ns
         </italic>
         means not
significant.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840008">
       </graphic>
      </fig>
     </sec>
     <sec>
      <title>
       Sialic acids and GRP78 act independently to facilitate the surface attachment
of MERS-CoV
      </title>
      <p>
       Sialic acids were recently identified as an attachment determinant of MERS-CoV
(
       <xref ref-type="bibr" rid="B46">
        46
       </xref>
       ). To investigate whether GRP78
and sialic acids could act in conjunction with each other in facilitating the
attachment of MERS-CoV, we assessed MERS–S-pseudovirus entry in the
presence of a combination of neuraminidase treatment and GRP78 antibody
blocking. Our results demonstrated that although neuraminidase treatment
decreased MERS–S-pseudovirus entry in a dose-dependent manner, the
addition of GRP78 antibody further enhanced the inhibitory effect (
       <xref ref-type="fig" rid="F9">
        Fig. 9
       </xref>
       <italic>
        A
       </italic>
       ). However, the entry
of HKU9–S-pseudovirus was inhibited by GRP78 antibody but not
neuraminidase treatment (
       <xref ref-type="fig" rid="F9">
        Fig.
9
       </xref>
       <italic>
        B
       </italic>
       ). Overall, the additive effect of neuraminidase
treatment and GRP78 antibody on limiting MERS–S-pseudovirus entry
suggested that sialic acids and GRP78 both independently facilitated the
attachment of MERS-CoV onto the cell surface, whereas GRP78 but not sialic acids
played an important role for virus attachment of bCoV-HKU9.
      </p>
      <fig id="F9" orientation="portrait" position="float">
       <label>
        Figure 9.
       </label>
       <caption>
        <p>
         <bold>
          Sialic acids and GRP78 act independently to facilitate the surface
attachment of MERS-CoV.
         </bold>
         <italic>
          A,
         </italic>
         Huh7 cells were treated with neuraminidase from
         <italic>
          C. perfringens
         </italic>
         , with or without pre-incubation with
the GRP78 polyclonal antibody. The cells were subsequently challenged
with MERS–S-pseudovirus and assessed at 72 h post-infection for
pseudovirus entry.
         <italic>
          B,
         </italic>
         RLK cells were treated with
neuraminidase from
         <italic>
          Clostridium perfringens
         </italic>
         , with or
without pre-incubation with the GRP78 polyclonal antibody. The cells
were subsequently challenged with HKU9–S-pseudovirus and assessed
at 72 h post infection for pseudovirus entry. Pseudovirus entry was
quantified using a microplate reader as relative light units
(
         <italic>
          RLU
         </italic>
         ). Data represented mean and standard deviation
derived from three independent experiments. Statistical analyses were
carried out using Student's
         <italic>
          t
         </italic>
         test. Statistical
significance was indicated by
         <italic>
          asterisk
         </italic>
         marks when
         <italic>
          p
         </italic>
         &lt; 0.05.
        </p>
       </caption>
       <graphic xlink:href="zbc0311890840009">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      Host tropism is predominantly determined by the interaction between coronavirus
spikes and their corresponding host receptors. In addition, the spike proteins of
coronaviruses can recognize a broad range of cell-surface molecules, which serve to
augment coronavirus attachment or entry. In this study, we identified host GRP78 as
a novel interacting target of the MERS-CoV spike (
      <xref ref-type="fig" rid="F1">
       Figs. 1
      </xref>
      and
      <xref ref-type="fig" rid="F2">
       2
      </xref>
      ). GRP78 was expressed
on the surface of MERS-CoV–susceptible cell lines of pulmonary and
extrapulmonary origin (
      <xref ref-type="fig" rid="F3">
       Fig. 3
      </xref>
      ). At the same
time, immunostaining of human lung tissues identified abundant co-expression of DPP4
and GRP78 in the epithelial cells along the human airways (
      <xref ref-type="fig" rid="F4">
       Fig. 4
      </xref>
      ). Next, with antibody blocking and siRNA knockdown
experiments, our data indicated the involvement of GRP78 in MERS-CoV entry (
      <xref ref-type="fig" rid="F5">
       Fig. 5
      </xref>
      ). Overexpression assays of GRP78 in
MERS-CoV–permissive and MERS-CoV–nonpermissive cells unambiguously
demonstrated that GRP78 did not independently render nonpermissive cells susceptible
to MERS-CoV infection but could facilitate MERS-CoV entry in conjunction with DPP4
by serving as an attachment factor (
      <xref ref-type="fig" rid="F6">
       Fig. 6
      </xref>
      ).
Intriguingly, GRP78 was up-regulated upon MERS-CoV infection, which might further
facilitate virus attachment among the infected cells (
      <xref ref-type="fig" rid="F7">
       Fig. 7
      </xref>
      ). Most importantly, GRP78 was also recognized by the spike
protein of a bat
      <italic>
       Betacoronavirus
      </italic>
      , bCoV-HKU9. Our result further
indicated that GRP78 was not the functional receptor of bCoV-HKU9 but could modulate
HKU9–S-pseudovirus attachment to RLK cells (
      <xref ref-type="fig" rid="F8">
       Fig. 8
      </xref>
      ). Simultaneous treatments of neuraminidase and GRP78 antibody
blocking revealed that sialic acids and GRP78 both independently facilitated the
attachment of MERS-CoV onto the cell surface, whereas virus attachment of bCoV-HKU9
was mediated by GRP78 but not sialic acids (
      <xref ref-type="fig" rid="F9">
       Fig.
9
      </xref>
      ). Overall, our study identified GRP78 as an attachment factor that
might modulate virus entry for two phylogenetically related
      <italic>
       Betacoronaviruses
      </italic>
      of different lineages, MERS-CoV and
bCoV-HKU9.
     </p>
     <p>
      GRP78, also referred to as BiP or HSPA5, is traditionally recognized as an ER
chaperone (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ). It is involved in a wide
range of physiological processes, including protein folding and assembly,
translocation of newly synthesized polypeptides, degradation of misfolded proteins,
as well as maintaining the ER homeostasis (
      <xref ref-type="bibr" rid="B27">
       27
      </xref>
      ). In addition, GRP78 is an essential regulator of ER stress due to its
critical role in the unfolded protein response pathway. Despite its participation in
ER-related functions, GRP78 is also detected in other cellular fractions, including
mitochondria, nucleus, cytosol, and plasma membrane (
      <xref ref-type="bibr" rid="B43">
       43
      </xref>
      ). In recent years, an increasing number of studies have described the
physiological role of cell-surface GRP78 during virus entry. For instance, GRP78 was
identified as a co-receptor for coxsackievirus A9 (CVA9) (
      <xref ref-type="bibr" rid="B30">
       30
      </xref>
      ) and dengue virus (
      <xref ref-type="bibr" rid="B47">
       47
      </xref>
      ). In addition, cell-surface GRP78 also facilitates the entry of Japanese
encephalitis virus (
      <xref ref-type="bibr" rid="B29">
       29
      </xref>
      ). Here, we reported
GRP78 as a host factor that could serve as an attachment protein for two
      <italic>
       Betacoronaviruses
      </italic>
      , MERS-CoV and bCoV-HKU9. In its capacity as
an attachment factor, GRP78 may serve to concentrate virus particles on the cell
surface, which may then increase the possibility of receptor-mediated virus entry
for MERS-CoV and bCoV-HKU9. Importantly, MERS-CoV infection resulted in an
up-regulation of GRP78 on the cell surface, which may in turn increase the
attachment of MERS-CoV and further enhance the possibility of virus entry in the
infected cells.
     </p>
     <p>
      Coronaviruses can recognize a wide range of cell-surface molecules, including cell
membrane proteins and sugars in addition to their cellular receptors. As an example,
HCoV-NL63 employs ACE2 for host cell entry (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ) but can bind to cell-surface heparan sulfate proteoglycans to
enhance attachment and infection of target cells (
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      ). We have previously reported the identification of CEACAM5 as an
attachment factor of MERS-CoV, which could facilitate MERS-CoV entry in the presence
of DPP4 (
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ). Recently, CD9 was reported as a
host factor that could augment MERS-CoV entry by bringing the cellular receptor and
proteases into close proximity, thus increasing the infection efficiency (
      <xref ref-type="bibr" rid="B26">
       26
      </xref>
      ). In this study, the identification of GRP78
as an attachment factor of MERS-CoV further indicated that the spike protein of
MERS-CoV is highly efficient in engaging multiple cell surface factors to facilitate
virus entry. In contrast to CEACAM5, which is expressed on limited cell types (
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ), surface GRP78 expression appeared to be
relatively abundant across various cell types of different tissue origin (
      <xref ref-type="fig" rid="F3">
       Fig. 3
      </xref>
      ). In addition, a remarkable level of GRP78
was specifically detected on the epithelial cells along the human airways, where it
was found to colocalize with DPP4 (
      <xref ref-type="fig" rid="F4">
       Fig. 4
      </xref>
      ). In
this regard, it is tempting to speculate that the capacity of the MERS-CoV spike to
utilize multiple host surface proteins, including CEACAM5, CD9, and GRP78, may give
MERS-CoV a physiological advantage in establishing efficient infections, which may
contribute to the high pathogenicity of the virus.
     </p>
     <p>
      Bat coronavirus HKU9 (bCoV-HKU9) is a representative lineage D
      <italic>
       Betacoronavirus
      </italic>
      . The virus was first identified in 2007 in a
territory-wide molecular surveillance study on bat samples from the Guangdong
province of Southern China (
      <xref ref-type="bibr" rid="B44">
       44
      </xref>
      ). Subsequent
studies suggested that the virus was widely distributed and was circulating in
different bat species (
      <xref ref-type="bibr" rid="B48">
       48
      </xref>
      <xref ref-type="bibr" rid="B49">
       –
      </xref>
      <xref ref-type="bibr" rid="B51">
       51
      </xref>
      ). Structural and functional features of the receptor-binding domain
(RBD) of bCoV-HKU9 demonstrated that the spike protein of the virus was incapable of
interacting with either DPP4 or ACE2 (
      <xref ref-type="bibr" rid="B45">
       45
      </xref>
      ).
However, the RBD of bCoV-HKU9 contained a conserved core structure that was shared
across other
      <italic>
       Betacoronaviruses
      </italic>
      , including MERS-CoV, SARS-CoV, and
bat coronavirus HKU4 (bCoV-HKU4) (
      <xref ref-type="bibr" rid="B45">
       45
      </xref>
      ).
Notably, recent reports demonstrated that bCoV-HKU4 could recognize human DPP4 as a
functional receptor, indicating the potential of bat coronaviruses in human
adaptations. In this regard, the identification of GRP78 as a shared attachment
factor for MERS-CoV and bCoV-HKU9 is interesting but alarming, which highlighted the
importance of continuous surveillance on the other members of the
      <italic>
       Betacoronavirus
      </italic>
      genus for their capacity of interspecies
transmission.
     </p>
     <p>
      In summary, almost all presently circulating human coronaviruses have a
phylogenetically-related virus partner found in animals. The human
      <italic>
       Alphacoronavirus
      </italic>
      HCoV-NL63 may be a recombinant between
NL63-like viruses in
      <italic>
       Triaenops
      </italic>
      bats and 229E-like viruses
circulating in
      <italic>
       Hipposideros
      </italic>
      bats (
      <xref ref-type="bibr" rid="B52">
       52
      </xref>
      ). Another human
      <italic>
       Alphacoronavirus
      </italic>
      HCoV-229E has
closely-related 229E-like coronaviruses recently isolated from dromedary camels
(
      <xref ref-type="bibr" rid="B53">
       53
      </xref>
      ). Similarly, the lineage A
      <italic>
       Betacoronavirus
      </italic>
      HCoV-OC43 was postulated to originate from a
bovine coronavirus and jumped into human in the 1890s (
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B54">
       54
      </xref>
      ). The lineage B
      <italic>
       Betacoronavirus
      </italic>
      , SARS-CoV, originated from either civets or
bats, which jumped into human in 2003 (
      <xref ref-type="bibr" rid="B55">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="B56">
       56
      </xref>
      ), whereas the lineage C
      <italic>
       Betacoronavirus
      </italic>
      , MERS-CoV, is likely to have jumped from camels
into human in 2012 (
      <xref ref-type="bibr" rid="B57">
       57
      </xref>
      ,
      <xref ref-type="bibr" rid="B58">
       58
      </xref>
      ). Because three (lineages A, B, and C) out of four lineages
of animal
      <italic>
       Betacoronaviruses
      </italic>
      have independently jumped from animal
into human in the recent past, there is enough reason to suspect that a lineage D
      <italic>
       Betacoronavirus
      </italic>
      may also jump into human one day. Our finding
of the lineage C MERS-CoV and lineage D bCoV-HKU9 sharing the same host attachment
factor GRP78 highlights the importance of monitoring the evolution of bCoV-HKU9,
which may jump the interspecies barrier into human leading to another major epidemic
in the future.
     </p>
    </sec>
    <sec sec-type="methods">
     <title>
      Experimental procedures
     </title>
     <sec>
      <title>
       Cells
      </title>
      <p>
       A549, AD293 (a derivative of the commonly used HEK293 cell line, with improved
cell adherence), HeLa, Huh7, Caco2, and VeroE6 cells were maintained in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml
streptomycin. BEAS2B (transformed epithelial cells isolated from normal human
bronchial epithelium) and Calu3 cells were maintained in supplemented DMEM/F-12.
BHK21, L929, RLK, and HFL were maintained in supplemented minimum essential
medium. Human primary monocytes were obtained from human peripheral blood
mononuclear cells (PBMCs) as described previously (
       <xref ref-type="bibr" rid="B59">
        59
       </xref>
       ). Primary human monocyte-derived macrophages (MDMs) were
differentiated from monocytes in Roswell Park Memorial Institute (RPMI)-1640
media supplemented with 10% FBS, 100 μg/ml streptomycin, 100 units/ml
penicillin, 2 m
       <sc>
        m
       </sc>
       glutamine, 1% sodium pyruvate, 1% nonessential amino
acids, and 10 ng/ml recombinant human granulocyte macrophage colony-stimulating
factor (GM-CSF) (R&amp;D Systems) (
       <xref ref-type="bibr" rid="B60">
        60
       </xref>
       ).
Human primary T cells were isolated from PBMCs with negative selection using the
Dynabeads Untouched Human T cells kit (Invitrogen) as we described previously
(
       <xref ref-type="bibr" rid="B61">
        61
       </xref>
       ). Isolated T cells were
maintained in RPMI 1640 medium supplemented with 10% FBS, 100 μg/ml
streptomycin, 100 units/ml penicillin, 1% sodium pyruvate, and 1% nonessential
amino acids.
      </p>
     </sec>
     <sec>
      <title>
       Virus
      </title>
      <p>
       MERS-CoV was a gift from Dr. Ron Fouchier (Erasmus Medical Center, Rotterdam, the
Netherlands) and cultured in VeroE6 cells in serum-free DMEM. Virus titers were
quantified with plaque assays as described previously (
       <xref ref-type="bibr" rid="B25">
        25
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Antibodies
      </title>
      <p>
       MERS-CoV nucleocapsid protein (N) was detected with the in-house guinea pig
anti-MERS–CoV N serum as we described previously (
       <xref ref-type="bibr" rid="B32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="B62">
        62
       </xref>
       ). The
MERS-CoV spike was detected with either the in-house mouse anti-MERS-CoV spike
immune serum or a rabbit anti-MERS-CoV spike antibody from Sino Biological
(40069-RP02). An in-house mouse anti-bCoV-HKU9-spike immune serum was used to
detect bCoV-HKU9 spike. Primary antibodies, including rabbit anti-DPP4
(ab28340), rabbit anti-GRP78 (ab21685), rabbit anti-pan-cadherin (ab16505),
rabbit anti-calreticulin (ab2907), rabbit anti-GM130 (ab52649), rabbit anti-EGFR
(ab52894), and rabbit anti-CEACAM5 (ab131070), were from Abcam. Rabbit
anti-lamin A was from Sigma (SAB4501764). Rabbit control IgG was from
ThermoFisher Scientific (31235). Mouse anti-GRP78 antibody for Western blotting
was from R&amp;D Systems (MAB4846). Rabbit anti-GRP78 from Novus Biologicals
(NBP1-54318) and goat anti-CD26 from R&amp;D Systems (AF1180) were used for
antibody-blocking experiments. Rabbit anti-giantin was from Biolegend
(A488-114L). The mouse anti-β-actin was from Sigma (A5441). The
recombinant FLAG-conjugated proteins were detected with an anti-FLAG M2 antibody
from Sigma (F1804). The V5-tagged proteins were detected with mouse anti-V5
antibodies from Immnoway (YM3005) or ThermoFisher Scientific (R96025). The
eGFP-tagged proteins were detected with a rabbit anti-eGFP from Abcam (ab290).
Secondary antibodies, including Alexa Fluor 488/647 goat anti-guinea pig
(A11073/A21450) and Alexa Fluor 488/647 goat anti-rabbit (A11008/A21245) from
ThermoFisher Scientific, were used for flow cytometry. The goat anti-mouse HRP
(626520) and goat anti-rabbit HRP (656120) antibodies from ThermoFisher
Scientific were used for Western blottings.
      </p>
     </sec>
     <sec>
      <title>
       Plasmid construction
      </title>
      <p>
       The construction of pcDNA–MERS–CoV–S was previously
described (
       <xref ref-type="bibr" rid="B25">
        25
       </xref>
       ). Codon-optimized
bCoV-HKU9-spike DNA was synthesized at GeneArt (ThermoFisher Scientific) based
on amino acid sequence of the bCoV-HKU9 (
       <xref ref-type="bibr" rid="B44">
        44
       </xref>
       ) and cloned into the pcDNA3.1(+) vector. In parallel,
bCoV-HKU9–S1 was subcloned into the pSFV1 vector with a FLAG sequence
in-frame in the 3′-end for protein expression. The expression construct
for codon-optimized SARS-CoV spike, pcDNA-Sopt9, was a gift from Dr. Chen Zhiwei
and was previously described (
       <xref ref-type="bibr" rid="B63">
        63
       </xref>
       ). The
construction of pSFV–MERS-CoV–S1–FLAG was previously
described (
       <xref ref-type="bibr" rid="B25">
        25
       </xref>
       ). The same ORF was
PCR-amplified and subcloned into pcDNA3.1(+) vector in-frame with a V5 epitope,
which resulted in pcDNA–MERS-CoV–S1–V5. The GRP78-coding
region, including the N-terminal signal peptide, was obtained with RT-PCR from
BEAS2B cells and cloned into pcDNA3.1(+) vector fused with V5, which resulted in
pcDNA–GRP78–V5.
      </p>
     </sec>
     <sec>
      <title>
       Immunoaffinity purification of MERS-CoV–S1–FLAG protein
      </title>
      <p>
       Expression of FLAG-tagged recombinant proteins was previously described (
       <xref ref-type="bibr" rid="B64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="B65">
        65
       </xref>
       ). In brief, linearized pSFV–FLAG plasmids were transcribed
       <italic>
        in vitro,
       </italic>
       and the derived capped RNAs were electroporated
into BHK21 cells. At 15 h post-transfection, the cells were lysed, and the
expressed recombinant proteins were immunopurified using anti-FLAG
M2–coated beads (Sigma) according to the manufacturer's instructions. The
purified S protein was assessed by SDS-PAGE and Western blotting. Protein
concentration was quantified with the Pierce BCA assay (ThermoFisher
Scientific).
      </p>
     </sec>
     <sec>
      <title>
       Membrane extraction
      </title>
      <p>
       pcDNA–MERS-CoV–S1–V5–transfected BEAS2B cells
cultured in 10-cm dishes were harvested by scraping cells into HEPES solution
(10 m
       <sc>
        m
       </sc>
       HEPES, pH 7.5, 1.5 m
       <sc>
        m
       </sc>
       MgCl
       <sub>
        2
       </sub>
       , 1 m
       <sc>
        m
       </sc>
       KCl) and centrifuging briefly at 500 ×
       <italic>
        g
       </italic>
       for 3 min. Cell
pellets were then homogenized in membrane lysis buffer (20 m
       <sc>
        m
       </sc>
       Tris-HCl,
pH 7.5, 150 m
       <sc>
        m
       </sc>
       NaCl, 1% Nonidet P-40 (Calbiochem), 1%
       <italic>
        n
       </italic>
       -dodecyl β-maltoside (ThermoFisher Scientific), 5%
glycerol, pH 7.5, with protease inhibitor mixture (Roche Applied Science)) and
incubated on ice for 30 min. Residual cellular debris and nuclei in the
resulting extracts were sedimented by centrifugation at 4 °C for 5 min at
6000 ×
       <italic>
        g
       </italic>
       . The solubilized membrane proteins in the
supernatant were transferred and subjected to an additional spin at 16,000
×
       <italic>
        g
       </italic>
       for 30 min at 4 °C, and the membrane extracts
were then resuspended in lysis buffer. All extracts were quantitated using the
Pierce BCA assay kit (ThermoFisher Scientific) and stored in aliquots at
−80 °C until used.
      </p>
     </sec>
     <sec>
      <title>
       Identification of GRP78 by immunoprecipitation and MS
      </title>
      <p>
       Membrane proteins from
pcDNA–MERS-CoV–S1–V5–transfected BEAS2B cells were
immunoprecipitated with mAb against V5 (ThermoFisher Scientific, R96025) and
Sepharose A/G beads (ThermoFisher Scientific). In parallel, the membrane
proteins from the BEAS2B cells were immunoprecipitated with purified
MERS-CoV–S1–FLAG protein, anti-FLAG M2 antibody (Sigma, F1804),
and Sepharose A/G beads (ThermoFisher Scientific). Pulled down proteins reactive
to anti-V5 beads were washed and incubated with 0.1
       <sc>
        m
       </sc>
       glycine, pH 3.5,
and those reactive to anti-FLAG M2 beads were eluted in 3× FLAG peptide
solution (Sigma, 150 ng/μl final concentration). Eluted samples were
spin-dialyzed in Amicon spin column with 10-kDa cutoff (Millipore) and separated
by SDS-PAGE, stained with SilverQuest kit (ThermoFisher Scientific). The gel
fragment was excised for LC-MS/MS analysis carried out in the Center for Genomic
Sciences, University of Hong Kong. MS/MS data were searched against all
mammalian protein databases in NCBI and Swiss-Prot. The protein was identified
as GRP78 with significant hits over different domains of the sequence.
      </p>
     </sec>
     <sec>
      <title>
       Production of pseudotyped viruses
      </title>
      <p>
       Lentivirus-based coronavirus spike pseudoviruses were generated by
co-transfection of 293FT cells with the pcDNA full-length spike plasmids in
combination with the HIV-1 backbone plasmid-bearing luciferase reporter gene,
pNL4–3-ΔE-Luc (obtained from the AIDS Research and Reference
Reagent Program) using Lipofectamine 2000 (ThermoFisher Scientific). Cells
transfected overnight were replenished with fresh medium supplemented with 1
m
       <sc>
        m
       </sc>
       sodium pyruvate (ThermoFisher Scientific). Supernatants were
harvested 48 h post-transfection, filtered through a 0.45-μm syringe
filter, and concentrated by ultracentrifugation in 30% sucrose solution in a
Beckman rotor SW32Ti at 32,000 rpm for 1 h at 4 °C. The virus pellets were
resuspended in PBS, aliquoted, and stored at −80 °C. The p24
concentrations were quantified using a p24 enzyme-linked immunoassay kit (Cell
BioLabs). Pseudovirus titer was quantified in units of lentiviral particle (LP)
per ml according to the manufacturer's instruction.
      </p>
     </sec>
     <sec>
      <title>
       Luciferase activity assay for pseudovirus entry
      </title>
      <p>
       Coronavirus spike pseudoviruses were used to infect 5 × 10
       <sup>
        3
       </sup>
       target cells in white 96-well plates (Corning-Costar). After incubating the
cultures for 72 h at 37 °C, the cells were first washed with PBS
(ThermoFisher Scientific). The cells were then lysed with the lysis buffer
(Promega) on ice, and luciferase substrate (Promega) was then added immediately.
The infectivity was measured using a microplate reader (Beckman DTX880) as
relative light units (RLU). Uninfected cells were included as mock controls for
all experiments. All experiments were performed in triplicate and repeated at
least two times.
      </p>
     </sec>
     <sec>
      <title>
       Quantitative RT-PCR
      </title>
      <p>
       Cells were lysed in RLT buffer with 40 m
       <sc>
        m
       </sc>
       DTT and extracted with the
RNeasy mini kit (Qiagen). Viral RNA in the supernatant was extracted with the
PureLink Viral RNA/DNA mini kit (Life Technologies, Inc.). Reverse transcription
(RT) and quantitative PCR (qPCR) were performed with the Transcriptor First
Strand cDNA synthesis kit and LightCycler 480 master mix from Roche Applied
Science as we previously described (
       <xref ref-type="bibr" rid="B34">
        34
       </xref>
       ).
In the RT reactions, reverse primers against the N gene of MERS-CoV were used to
detect cDNA complementary to the positive strand of viral genomes. The following
sets of primers were used to detect N in qPCR: forward,
5′-CAAAACCTTCCCTAAGAAGGAAAAG-3′, reverse,
5′-GCTCCTTTGGAGGTTCAGACAT-3′, and probe (6-carboxyfluorescein),
5′-ACAAAAGGCACCAAAAGAAGAATCAACAGACC-3′ BHQ1.
      </p>
     </sec>
     <sec>
      <title>
       Antibody-blocking assay for HKU9–S-pseudovirus binding
      </title>
      <p>
       RLK cells were pre-incubated with the rabbit anti-GRP78 antibody (Novus
Biologicals, NBP1-54318) or the rabbit control IgG (ThermoFisher Scientific,
31235) for 1 h at 37 °C. After the pre-incubation,
HKU9–S-pseudoviruses were inoculated to the cells for attachment at 100
LP per cell at 4 °C for 2 h. After 2 h of incubation, the cells were washed
twice with chilled PBS and fixed in 4% paraformaldehyde for 15 min. The fixed
cells were immunolabeled for the bCoV-HKU9 spike with the in-house mouse
bCoV-HKU9 spike immune serum and the mouse Alexa Fluor 488 goat anti-mouse
secondary antibody (ThermoFisher Scientific). The binding of the
HKU9–S-pseudoviruses was assessed with flow cytometry.
      </p>
     </sec>
     <sec>
      <title>
       Antibody-blocking assay for MERS-CoV entry
      </title>
      <p>
       Huh7 cells were pre-incubated with rabbit polyclonal anti-GRP78 (Novus
Biologicals, NBP1-54318) at different concentrations ranging from 0 to 5
μg/ml. Goat polyclonal anti-DPP4 at 5 μg/ml (R&amp;D, AF1180) and
rabbit IgG at 5 μg/ml (ThermoFisher Scientific, 31235) were included as
controls. After pre-incubating with the antibodies for 1 h at 37 °C, the
cells were challenged with MERS-CoV at 1 m.o.i. for 1 h at 37 °C in the
presence of antibodies. The cells were subsequently washed with PBS and lysed
with RLT (Qiagen) with 40 m
       <sc>
        m
       </sc>
       dithiothreitol (DTT). The virus copy
number was quantified with qPCR as described previously (
       <xref ref-type="bibr" rid="B25">
        25
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       siRNA knockdown and virus entry assessment
      </title>
      <p>
       ON-TARGETplus human GRP78 siRNA (L-008198-00-0005) and ON-TARGETplus nontargeting
siRNA (L-001810-10-0020) were obtained from Dharmacon. Transfection of siRNA on
BEAS2B, Huh7, MDM, or HFL cells was performed using Lipofectamine RNAiMAX
(ThermoFisher Scientific) following the manufacturer's manual. In brief, the
cells were transfected with 75 n
       <sc>
        m
       </sc>
       siRNA for 2 consecutive days. At 24 h
after the second siRNA transfection, the cells were counted and harvested in
RIPA for Western blottings. In parallel, siRNA-transfected cells were challenged
with MERS-CoV at 1 m.o.i. for 1 h at 37 °C. Following the incubation, the
cells were washed with PBS and lysed in RLT buffer (Qiagen) with 40 m
       <sc>
        m
       </sc>
       DTT. The virus copy number was determined with qPCR.
      </p>
     </sec>
     <sec>
      <title>
       Neuraminidase treatment and GRP78 antibody blocking for pseudovirus
entry
      </title>
      <p>
       Huh7 and RLK cells grown in 96-well plates were washed twice with PBS
(ThermoFisher Scientific) and incubated with neuraminidase from
       <italic>
        Clostridium perfringens
       </italic>
       (Sigma) diluted in FBS-free growth
medium at 37 °C for 3 h. After the incubation, the cells were washed three
times and challenged with MERS–S- or HKU9–S-pseudoviruses, with or
without pre-incubation with the GRP78 polyclonal antibody (Abcam) for 1 h at 37
°C. Fresh complete medium with 10% FBS was replaced at 18 h post-infection.
Pseudovirus entry was quantified using a microplate reader (Beckman DTX880) as
RLU at 72 h post-infection.
      </p>
     </sec>
     <sec>
      <title>
       Flow cytometry
      </title>
      <p>
       Immunostaining for flow cytometry was performed following standard procedures as
we previously described (
       <xref ref-type="bibr" rid="B61">
        61
       </xref>
       ). To
determine the surface-expression level of GRP78 and DPP4, the cells were
detached with 10 m
       <sc>
        m
       </sc>
       EDTA in PBS, fixed in 4% paraformaldehyde, followed
by immunolabeling with antibodies against GRP78 (Abcam, 21685) or DPP4 (Abcam,
28340) without cell permeabilization. For experiments with intracellular
stainings, cells were detached with 10 m
       <sc>
        m
       </sc>
       EDTA in PBS, fixed in 4%
paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS. The flow
cytometry was performed using a FACSCanto II flow cytometer (BD Biosciences),
and data were analyzed using FlowJo version X (Tree Star).
      </p>
     </sec>
     <sec>
      <title>
       Flow cytometry of BHK21 and AD293 cells with GRP78 overexpression
      </title>
      <p>
       AD293 and BHK21 cells were transfected with pcDNA–GRP78–V5 with
Lipofectamine 3000 (ThermoFisher Scientific). The transfected cells were
inoculated with MERS-CoV at 48 h post- transfection. To determine virus entry,
the cells were inoculated with MERS-CoV at 5 m.o.i. at 37 °C for 2 h. After
2 h, the cells were washed with PBS and incubated for another 4 h. At 6 h
post-infection, the cells were washed extensively with PBS, fixed in 4%
paraformaldehyde, and immunolabeled for flow cytometry. To determine virus
attachment, the cells were inoculated with MERS-CoV at 15 m.o.i. at 4 °C
for 2 h. After 2 h, the cells were washed with PBS, fixed in 4%
paraformaldehyde, and immunolabeled for flow cytometry.
      </p>
     </sec>
     <sec>
      <title>
       Confocal microscopy of human tissues
      </title>
      <p>
       This study was approved by the Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster. Normal human lung sections
were deparaffinized and rehydrated following standard procedures. Antigen
unmasking was performed by boiling tissue sections with the antigen unmasking
solution from Vector Laboratories. Goat anti-DPP4 was obtained from R&amp;D
Systems (AF1180) and rabbit anti-GRP78 was obtained from Abcam (ab21685). Cell
nuclei were labeled with the DAPI nucleic acid stain from ThermoFisher
Scientific (D21490). Alexa Fluor secondary antibodies were obtained from
ThermoFisher Scientific. Mounting was performed with the Vectashield mounting
medium (Vector Laboratories). Images were acquired with a Carl Zeiss LSM 710
system.
      </p>
     </sec>
     <sec>
      <title>
       Statistical analysis
      </title>
      <p>
       Data on figures represent the means and standard deviations. Statistical
comparison between different groups was performed by Student's
       <italic>
        t
       </italic>
       test using GraphPad Prism 6. Differences were considered
statistically significant when
       <italic>
        p
       </italic>
       &lt; 0.05.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Author contributions
     </title>
     <p>
      H. C., C.-M. C., J. F.-W. C., and K.-Y. Y. conceptualization; H. C., C.-M. C., X.
Zhang, Y. W., S. Y., K.-H. S., D. Y., H. S., Y. H., C. L., X. Zhao, V. K.-M. P.,
S.-P. L., and K.-Y. Y. data curation; H. C., C.-M. C., X. Zhang, Y. W., S. Y., J.
Z., R. K.-H. A.-Y., K.-H. S., D. Y., H. S., Y. H., C. L., X. Zhao, V. K.-M. P., and
K.-Y. Y. formal analysis; H. C. and K.-Y. Y. supervision; H. C. and C.-M. C.
validation; H. C. and C.-M. C. investigation; H. C. visualization; H. C., C.-M. C.,
X. Zhang, Y. W., S. Y., J. Z., R. K.-H. A.-Y., K.-H. S., D. Y., H. S., Y. H., C. L.,
X. Zhao, V. K.-M. P., S.-P. L., and K.-Y. Y. methodology; H. C., J. F.-W. C., and
K.-Y. Y. writing-original draft; H. C., G. F. G., J. F.-W. C., and K.-Y. Y. project
administration; H. C., X. Zhang, J. Z., M.-L. Y., J. Y., G. L., D.-Y. J., G. F. G.,
J. F.-W. C., and K.-Y. Y. writing-review and editing; R. K.-H. A.-Y., K.-H. S.,
M.-L. Y., J. Y., G. L., D.-Y. J., G. F. G., J. F.-W. C., and K.-Y. Y. resources;
K.-H. S. software; G. F. G., J. F.-W. C., and K.-Y. Y. funding acquisition.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="supported-by">
       <p>
        This work was supported in part by the donations of Michael Seak-Kan Tong, Hui
Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan Yin Chuen Memorial
Charitable Foundation, and the Providence Foundation Limited in memory of the
late Dr. Lui Hac Minh; Hong Kong Health and Medical Research Fund Grants
14131392, 15140762, and 16150572; National Natural Science Foundation of
China/Research Grants Council (NSFC/RGC) Joint Research Scheme Grants
N_HKU728/14 and 81461168030; Theme-Based Research Scheme Grant T11/707/15 of the
Research Grants Council, Hong Kong Special Administrative Region, and by funding
from the Ministry of Education of China for the Collaborative Innovation Center
for Diagnosis and Treatment of Infectious Diseases.
        <named-content content-type="COI-statement">
         The authors declare that they have no conflicts
of interest with the contents of this article
        </named-content>
        .
       </p>
      </fn>
      <fn fn-type="supplementary-material">
       <p>
        This article contains
        <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.001897/DC1">
         Figs.
S1–S4
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
     <fn-group content-type="abbreviations">
      <fn id="FN3">
       <label>
        5
       </label>
       <p>
        The abbreviations used are:
        <def-list>
         <def-item>
          <term id="G1">
           HCoV
          </term>
          <def>
           <p>
            human coronavirus
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G2">
           MERS-CoV
          </term>
          <def>
           <p>
            Middle East respiratory syndrome coronavirus
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G3">
           SARS-CoV
          </term>
          <def>
           <p>
            severe acute respiratory syndrome coronavirus
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G4">
           DC-SIGN
          </term>
          <def>
           <p>
            dendritic cell-specific intercellular adhesion
molecule-3-grabbing nonintegrin
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G5">
           RBD
          </term>
          <def>
           <p>
            receptor-binding domain
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G6">
           qPCR
          </term>
          <def>
           <p>
            quantitative PCR
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G7">
           MDM
          </term>
          <def>
           <p>
            monocyte-derived macrophage
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G8">
           MFI
          </term>
          <def>
           <p>
            mean fluorescent intensity
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G9">
           HFL
          </term>
          <def>
           <p>
            human embryonic lung fibroblast
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G10">
           ER
          </term>
          <def>
           <p>
            endoplasmic reticulum
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G11">
           DMEM
          </term>
          <def>
           <p>
            in Dulbecco's modified Eagle's medium
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G12">
           FBS
          </term>
          <def>
           <p>
            fetal bovine serum
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G13">
           PBMC
          </term>
          <def>
           <p>
            peripheral blood mononuclear cell
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G14">
           LP
          </term>
          <def>
           <p>
            lentiviral particle
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G15">
           m.o.i.
          </term>
          <def>
           <p>
            multiplicity of infection
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G16">
           RLU
          </term>
          <def>
           <p>
            relative light unit
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G17">
           BAP
          </term>
          <def>
           <p>
            bacterial alkaline phosphatase
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G18">
           EGFR
          </term>
          <def>
           <p>
            epidermal growth factor receptor
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G19">
           co-IP
          </term>
          <def>
           <p>
            co-immunoprecipitation
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G20">
           DAPI
          </term>
          <def>
           <p>
            4,6-diamidino-2-phenylindole
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G21">
           VSV-G
          </term>
          <def>
           <p>
            vesicular stomatitis virus glycoprotein
           </p>
          </def>
         </def-item>
         <def-item>
          <term id="G22">
           eGFP
          </term>
          <def>
           <p>
            enhanced GFP.
           </p>
          </def>
         </def-item>
        </def-list>
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgment
      </title>
      <p>
       We thank the staff at the Core Facility, Li Ka Shing Faculty of Medicine, University
of Hong Kong, for facilitation of the study.
      </p>
     </ack>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Peck
          </surname>
          <given-names>
           K.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Burch
          </surname>
          <given-names>
           C. L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heise
          </surname>
          <given-names>
           M.
T.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           R.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Coronavirus host range expansion and Middle East respiratory
syndrome coronavirus emergence: biochemical mechanisms and evolutionary
perspectives
        </article-title>
        .
        <source>
         Annu. Rev. Virol
        </source>
        .
        <volume>
         2
        </volume>
        ,
        <fpage>
         95
        </fpage>
        –
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev-virology-100114-055029
        </pub-id>
        <pub-id pub-id-type="pmid">
         26958908
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jin
          </surname>
          <given-names>
           D.
Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Interspecies transmission and emergence of novel viruses:
lessons from bats and birds
        </article-title>
        .
        <source>
         Trends
Microbiol
        </source>
        .
        <volume>
         21
        </volume>
        ,
        <fpage>
         544
        </fpage>
        –
        <lpage>
         555
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2013.05.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23770275
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Cross-species transmission and emergence of novel viruses
from birds
        </article-title>
        .
        <source>
         Curr. Opin. Virol
        </source>
        .
        <volume>
         10
        </volume>
        ,
        <fpage>
         63
        </fpage>
        –
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2015.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         25644327
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V. C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P.
C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Middle East respiratory syndrome coronavirus: another
zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        .
        <source>
         Clin. Microbiol. Rev
        </source>
        .
        <volume>
         28
        </volume>
        ,
        <fpage>
         465
        </fpage>
        –
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           J.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           T. T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zaraket
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.
I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drews
          </surname>
          <given-names>
           S.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hatchette
          </surname>
          <given-names>
           T.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Heraud
          </surname>
          <given-names>
           J.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.
P.
          </given-names>
         </name>
        </person-group>
        , and
        <collab>
         INSPIRE
investigators
        </collab>
        . (
        <year>
         2017
        </year>
        )
        <article-title>
         Global
epidemiology of non-influenza RNA respiratory viruses: data gaps and a
growing need for surveillance
        </article-title>
        .
        <source>
         Lancet Infect.
Dis
        </source>
        .
        <volume>
         17
        </volume>
        ,
        <fpage>
         e320
        </fpage>
        –
        <lpage>
         e326
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(17)30238-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         28457597
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V. C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Is the discovery of the novel human betacoronavirus 2c
EMC/2012 (HCoV-EMC) the beginning of another SARS-like
pandemic?
        </article-title>
        <source>
         J. Infect
        </source>
        .
        <volume>
         65
        </volume>
        ,
        <fpage>
         477
        </fpage>
        –
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2012.10.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23072791
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Peiris
          </surname>
          <given-names>
           J.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           S. T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           L.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yam
          </surname>
          <given-names>
           L.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yee
          </surname>
          <given-names>
           W.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yan
          </surname>
          <given-names>
           W. W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheung
          </surname>
          <given-names>
           M.
T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsang
          </surname>
          <given-names>
           D. N.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yung
          </surname>
          <given-names>
           R.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ng
          </surname>
          <given-names>
           T. K.
          </given-names>
         </name>
         ,
         <etal>
          et
al
         </etal>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Coronavirus as
a possible cause of severe acute respiratory syndrome
        </article-title>
        .
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        ,
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13077-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P.
C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Severe acute respiratory syndrome coronavirus as an agent of
emerging and reemerging infection
        </article-title>
        .
        <source>
         Clin. Microbiol.
Rev
        </source>
        .
        <volume>
         20
        </volume>
        ,
        <fpage>
         660
        </fpage>
        –
        <lpage>
         694
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00023-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17934078
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van
Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
D.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in
Saudi Arabia
        </article-title>
        .
        <source>
         N. Engl. J. Med
        </source>
        .
        <volume>
         367
        </volume>
        ,
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hui
          </surname>
          <given-names>
           D.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Azhar
          </surname>
          <given-names>
           E. I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Oh
          </surname>
          <given-names>
           M. D.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2018
        </year>
        )
        <article-title>
         Middle East respiratory syndrome
coronavirus: risk factors and determinants of primary, household, and
nosocomial transmission
        </article-title>
        .
        <source>
         Lancet Infect.
Dis
        </source>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(18)30127-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         29680581
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Receptor recognition mechanisms of
coronaviruses: a decade of structural studies
        </article-title>
        .
        <source>
         J.
Virol
        </source>
        .
        <volume>
         89
        </volume>
        ,
        <fpage>
         1954
        </fpage>
        –
        <lpage>
         1964
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02615-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25428871
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yeager
          </surname>
          <given-names>
           C.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ashmun
          </surname>
          <given-names>
           R. A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Williams
          </surname>
          <given-names>
           R.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cardellichio
          </surname>
          <given-names>
           C.
B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shapiro
          </surname>
          <given-names>
           L.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Look
          </surname>
          <given-names>
           A.
T.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Holmes
          </surname>
          <given-names>
           K.
V.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Human aminopeptidase N is a receptor for human coronavirus
229E
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         357
        </volume>
        ,
        <fpage>
         420
        </fpage>
        –
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/357420a0
        </pub-id>
        <pub-id pub-id-type="pmid">
         1350662
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           V.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           S.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Demmers
          </surname>
          <given-names>
           J.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Thiel
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rottier
          </surname>
          <given-names>
           P.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bosch
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.
L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the
emerging human coronavirus-EMC
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        ,
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van
der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Human coronavirus NL63 employs the severe
acute respiratory syndrome coronavirus receptor for cellular
entry
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci. U.S.A
        </source>
        .
        <volume>
         102
        </volume>
        ,
        <fpage>
         7988
        </fpage>
        –
        <lpage>
         7993
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0409465102
        </pub-id>
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Moore
          </surname>
          <given-names>
           M.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           S.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Berne
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Greenough
          </surname>
          <given-names>
           T.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Angiotensin-converting enzyme 2 is a
functional receptor for the SARS coronavirus
        </article-title>
        .
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        ,
        <fpage>
         450
        </fpage>
        –
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Milewska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zarebski
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nowak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stozek
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Potempa
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Human coronavirus NL63 utilizes heparan
sulfate proteoglycans for attachment to target cells
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         88
        </volume>
        ,
        <fpage>
         13221
        </fpage>
        –
        <lpage>
         13230
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02078-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25187545
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Watanabe
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sawicki
          </surname>
          <given-names>
           S.
G.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Taguchi
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Heparan sulfate is a binding molecule but
not a receptor for CEACAM1-independent infection of murine
coronavirus
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         366
        </volume>
        ,
        <fpage>
         16
        </fpage>
        –
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.06.034
        </pub-id>
        <pub-id pub-id-type="pmid">
         17692355
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schultze
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Krempl
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ballesteros
          </surname>
          <given-names>
           M.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shaw
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schauer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Transmissible gastroenteritis
coronavirus, but not the related porcine respiratory coronavirus, has a
sialic acid (
         <italic>
          N
         </italic>
         -glycolylneuraminic acid) binding
activity
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         70
        </volume>
        ,
        <fpage>
         5634
        </fpage>
        –
        <lpage>
         5637
        </lpage>
        <pub-id pub-id-type="pmid">
         8764078
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Schultze
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gross
          </surname>
          <given-names>
           H.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Brossmer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         The S protein of bovine coronavirus is a
hemagglutinin recognizing 9-
         <italic>
          O
         </italic>
         -acetylated sialic acid as a
receptor determinant
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         65
        </volume>
        ,
        <fpage>
         6232
        </fpage>
        –
        <lpage>
         6237
        </lpage>
        <pub-id pub-id-type="pmid">
         1920630
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Krempl
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Schultze
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         1995
        </year>
        )
        <article-title>
         Analysis of cellular receptors for human
coronavirus OC43
        </article-title>
        .
        <source>
         Adv. Exp. Med. Biol
        </source>
        .
        <volume>
         380
        </volume>
        ,
        <fpage>
         371
        </fpage>
        –
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/978-1-4615-1899-0_60
        </pub-id>
        <pub-id pub-id-type="pmid">
         8830510
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Milewska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Golda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Marasco
          </surname>
          <given-names>
           W.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           R.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sims
          </surname>
          <given-names>
           A.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Human coronavirus HKU1 spike protein uses
         <italic>
          O-
         </italic>
         acetylated sialic acid as an attachment receptor
determinant and employs hemagglutinin-esterase protein as a
receptor-destroying enzyme
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         89
        </volume>
        ,
        <fpage>
         7202
        </fpage>
        –
        <lpage>
         7213
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00854-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           C.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           J.
D.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Identification of major histocompatibility complex class I C
molecule as an attachment factor that facilitates coronavirus HKU1
spike-mediated infection
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         83
        </volume>
        ,
        <fpage>
         1026
        </fpage>
        –
        <lpage>
         1035
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01387-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18987136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jeffers
          </surname>
          <given-names>
           S.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tusell
          </surname>
          <given-names>
           S. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hemmila
          </surname>
          <given-names>
           E.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Achenbach
          </surname>
          <given-names>
           J.
E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Babcock
          </surname>
          <given-names>
           G.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Thomas
          </surname>
          <given-names>
           W.
D.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         ,
         <name name-style="western">
          <surname>
           Thackray
          </surname>
          <given-names>
           L.
B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Young
          </surname>
          <given-names>
           M.
D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mason
          </surname>
          <given-names>
           R.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ambrosino
          </surname>
          <given-names>
           D.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wentworth
          </surname>
          <given-names>
           D.
E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Demartini
          </surname>
          <given-names>
           J.
C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Holmes
          </surname>
          <given-names>
           K.
V.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         CD209L (L-SIGN) is a receptor for severe acute respiratory
syndrome coronavirus
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci.
U.S.A
        </source>
        .
        <volume>
         101
        </volume>
        ,
        <fpage>
         15748
        </fpage>
        –
        <lpage>
         15753
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0403812101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15496474
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Möller
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rennekamp
          </surname>
          <given-names>
           A.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Eisemann
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Turza
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Saunier
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Steinkasserer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bates
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         DC-SIGN and DC-SIGNR interact with the
glycoprotein of Marburg virus and the S protein of severe acute respiratory
syndrome coronavirus
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         78
        </volume>
        ,
        <fpage>
         12090
        </fpage>
        –
        <lpage>
         12095
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.21.12090-12095.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15479853
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           C.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leung
          </surname>
          <given-names>
           S.
P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeung
          </surname>
          <given-names>
           M. L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           G.
F.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Carcinoembryonic antigen-related cell adhesion molecule 5 is
an important surface attachment factor that facilitates entry of Middle East
respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         90
        </volume>
        ,
        <fpage>
         9114
        </fpage>
        –
        <lpage>
         9127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01133-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27489282
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Earnest
          </surname>
          <given-names>
           J.
T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hantak
          </surname>
          <given-names>
           M. P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McCray
          </surname>
          <given-names>
           P.
B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         The tetraspanin CD9 facilitates
MERS-coronavirus entry by scaffolding host cell receptors and
proteases
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <volume>
         13
        </volume>
        ,
        <fpage>
         e1006546
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006546
        </pub-id>
        <pub-id pub-id-type="pmid">
         28759649
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           A.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Glucose-regulated proteins in cancer: molecular mechanisms
and therapeutic potential
        </article-title>
        .
        <source>
         Nat. Rev. Cancer
        </source>
        <volume>
         14
        </volume>
        ,
        <fpage>
         263
        </fpage>
        –
        <lpage>
         276
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrc3701
        </pub-id>
        <pub-id pub-id-type="pmid">
         24658275
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ni
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           A.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Beyond the endoplasmic reticulum: atypical GRP78 in cell
viability, signalling and therapeutic targeting
        </article-title>
        .
        <source>
         Biochem. J
        </source>
        .
        <volume>
         434
        </volume>
        ,
        <fpage>
         181
        </fpage>
        –
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/BJ20101569
        </pub-id>
        <pub-id pub-id-type="pmid">
         21309747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nain
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mukherjee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Karmakar
          </surname>
          <given-names>
           S.
P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paton
          </surname>
          <given-names>
           A.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paton
          </surname>
          <given-names>
           J.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Abdin
          </surname>
          <given-names>
           M.
Z.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Basu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kalia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Vrati
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         GRP78 is an important host factor for
Japanese encephalitis virus entry and replication in mammalian
cells
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         91
        </volume>
        ,
        <fpage>
         e02274
        </fpage>
        <pub-id pub-id-type="pmid">
         28053106
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Triantafilou
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fradelizi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wilson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Triantafilou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2002
        </year>
        )
        <article-title>
         GRP78, a coreceptor for coxsackievirus
A9, interacts with major histocompatibility complex class I molecules which
mediate virus internalization
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         76
        </volume>
        ,
        <fpage>
         633
        </fpage>
        –
        <lpage>
         643
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.76.2.633-643.2002
        </pub-id>
        <pub-id pub-id-type="pmid">
         11752154
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Honda
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Horie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Daito
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ikuta
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Tomonaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Molecular chaperone BiP interacts with
Borna disease virus glycoprotein at the cell surface
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         83
        </volume>
        ,
        <fpage>
         12622
        </fpage>
        –
        <lpage>
         12625
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01201-09
        </pub-id>
        <pub-id pub-id-type="pmid">
         19776128
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Choi
          </surname>
          <given-names>
           G.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cai
          </surname>
          <given-names>
           J.
P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           V.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Che
          </surname>
          <given-names>
           X.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P.
C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Differential cell line susceptibility to the emerging novel
human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and
clinical manifestation
        </article-title>
        .
        <source>
         J. Infect. Dis
        </source>
        .
        <volume>
         207
        </volume>
        ,
        <fpage>
         1743
        </fpage>
        –
        <lpage>
         1752
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit123
        </pub-id>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           C. C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           C. P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jin
          </surname>
          <given-names>
           D.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Delayed induction of proinflammatory cytokines and
suppression of innate antiviral response by the novel Middle East
respiratory syndrome coronavirus: implications for pathogenesis and
treatment
        </article-title>
        .
        <source>
         J. Gen. Virol
        </source>
        .
        <volume>
         94
        </volume>
        ,
        <fpage>
         2679
        </fpage>
        –
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.055533-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           V.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           C.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           K.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J. Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Active replication of Middle East respiratory syndrome
coronavirus and aberrant induction of inflammatory cytokines and chemokines
in human macrophages: implications for pathogenesis
        </article-title>
        .
        <source>
         J. Infect. Dis
        </source>
        .
        <volume>
         209
        </volume>
        ,
        <fpage>
         1331
        </fpage>
        –
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit504
        </pub-id>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           C.
P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Siu
          </surname>
          <given-names>
           K. L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chin
          </surname>
          <given-names>
           K.
T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Jin
          </surname>
          <given-names>
           D.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Modulation of the unfolded protein response by the severe
acute respiratory syndrome coronavirus spike protein
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         80
        </volume>
        ,
        <fpage>
         9279
        </fpage>
        –
        <lpage>
         9287
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00659-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         16940539
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Versteeg
          </surname>
          <given-names>
           G.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van de
Nes
          </surname>
          <given-names>
           P. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           P.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Spaan
          </surname>
          <given-names>
           W.
J.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         The coronavirus spike protein induces endoplasmic reticulum
stress and upregulation of intracellular chemokine mRNA
concentrations
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         81
        </volume>
        ,
        <fpage>
         10981
        </fpage>
        –
        <lpage>
         10990
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01033-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17670839
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jiménez-Guardeno
          </surname>
          <given-names>
           J. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Oliveros
          </surname>
          <given-names>
           J.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Severe acute respiratory syndrome
coronavirus envelope protein regulates cell stress response and
apoptosis
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        .
        <volume>
         7
        </volume>
        ,
        <fpage>
         e1002315
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1002315
        </pub-id>
        <pub-id pub-id-type="pmid">
         22028656
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Liao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fung
          </surname>
          <given-names>
           T.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fang
          </surname>
          <given-names>
           S.
G.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           D.
X.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Upregulation of CHOP/GADD153 during coronavirus infectious
bronchitis virus infection modulates apoptosis by restricting activation of
the extracellular signal-regulated kinase pathway
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         87
        </volume>
        ,
        <fpage>
         8124
        </fpage>
        –
        <lpage>
         8134
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00626-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23678184
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Fung
          </surname>
          <given-names>
           T.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           D.
X.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         The endoplasmic reticulum stress sensor IRE1α protects
cells from apoptosis induced by the coronavirus infectious bronchitis
virus
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         88
        </volume>
        ,
        <fpage>
         12752
        </fpage>
        –
        <lpage>
         12764
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02138-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25142592
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ni
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gill
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           A.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Cell surface relocalization of the endoplasmic reticulum
chaperone and unfolded protein response regulator GRP78/BiP
        </article-title>
        .
        <source>
         J. Biol. Chem
        </source>
        .
        <volume>
         285
        </volume>
        ,
        <fpage>
         15065
        </fpage>
        –
        <lpage>
         15075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M109.087445
        </pub-id>
        <pub-id pub-id-type="pmid">
         20208072
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tsai
          </surname>
          <given-names>
           Y.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tseng
          </surname>
          <given-names>
           C.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Stanciauskas
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pinaud
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           A.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Characterization and mechanism of stress-induced
translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell
surface
        </article-title>
        .
        <source>
         J. Biol. Chem
        </source>
        .
        <volume>
         290
        </volume>
        ,
        <fpage>
         8049
        </fpage>
        –
        <lpage>
         8064
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M114.618736
        </pub-id>
        <pub-id pub-id-type="pmid">
         25673690
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Arap
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lahdenranta
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mintz
          </surname>
          <given-names>
           P.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hajitou
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sarkis
          </surname>
          <given-names>
           A.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Arap
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pasqualini
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Cell surface expression of the stress
response chaperone GRP78 enables tumor targeting by circulating
ligands
        </article-title>
        .
        <source>
         Cancer Cell
        </source>
        <volume>
         6
        </volume>
        ,
        <fpage>
         275
        </fpage>
        –
        <lpage>
         284
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ccr.2004.08.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         15380518
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Gonzalez-Gronow
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Selim
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Papalas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Pizzo
          </surname>
          <given-names>
           S.
V.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         GRP78: a multifunctional receptor on the cell
surface
        </article-title>
        .
        <source>
         Antioxid. Redox Signal
        </source>
        .
        <volume>
         11
        </volume>
        ,
        <fpage>
         2299
        </fpage>
        –
        <lpage>
         2306
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/ars.2009.2568
        </pub-id>
        <pub-id pub-id-type="pmid">
         19331544
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           R.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guo
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Comparative analysis of twelve genomes of three novel group
2c and group 2d coronaviruses reveals unique group and subgroup
features
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         81
        </volume>
        ,
        <fpage>
         1574
        </fpage>
        –
        <lpage>
         1585
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02182-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17121802
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           G.
F.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Putative receptor binding domain of bat-derived coronavirus
HKU9 spike protein: evolution of betacoronavirus receptor binding
Motifs
        </article-title>
        .
        <source>
         Biochemistry
        </source>
        <volume>
         55
        </volume>
        ,
        <fpage>
         5977
        </fpage>
        –
        <lpage>
         5988
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acs.biochem.6b00790
        </pub-id>
        <pub-id pub-id-type="pmid">
         27696819
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hulswit
          </surname>
          <given-names>
           R. J.
G.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Widjaja
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           V.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           McBride
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Peng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van
Dieren
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van
Lent
          </surname>
          <given-names>
           J. W. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Paulson
          </surname>
          <given-names>
           J.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de
Haan
          </surname>
          <given-names>
           C. A. M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Groot
          </surname>
          <given-names>
           R.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van
Kuppeveld
          </surname>
          <given-names>
           F. J.
M.
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        .
(
        <year>
         2017
        </year>
        )
        <article-title>
         Identification of sialic acid-binding
function for the Middle East respiratory syndrome coronavirus spike
glycoprotein
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci. U.S.A
        </source>
        .
        <volume>
         114
        </volume>
        ,
        <fpage>
         E8508
        </fpage>
        –
        <lpage>
         E8517
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1712592114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28923942
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Jindadamrongwech
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Thepparit
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Smith
          </surname>
          <given-names>
           D.
R.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Identification of GRP 78 (BiP) as a liver cell expressed
receptor element for dengue virus serotype 2
        </article-title>
        .
        <source>
         Arch.
Virol
        </source>
        .
        <volume>
         149
        </volume>
        ,
        <fpage>
         915
        </fpage>
        –
        <lpage>
         927
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-003-0263-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15098107
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Conrardy
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Anderson
          </surname>
          <given-names>
           L.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Genomic characterization of seven
distinct bat coronaviruses in Kenya
        </article-title>
        .
        <source>
         Virus
Res
        </source>
        .
        <volume>
         167
        </volume>
        ,
        <fpage>
         67
        </fpage>
        –
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.04.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         22561208
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           R. W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guo
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Coexistence of different genotypes in the same bat and
serological characterization of Rousettus bat coronavirus HKU9 belonging to
a novel betacoronavirus subgroup
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         84
        </volume>
        ,
        <fpage>
         11385
        </fpage>
        –
        <lpage>
         11394
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01121-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20702646
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Ge
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Metagenomic analysis of viruses from bat
fecal samples reveals many novel viruses in insectivorous bats in
China
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         86
        </volume>
        ,
        <fpage>
         4620
        </fpage>
        –
        <lpage>
         4630
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06671-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22345464
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Conrardy
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ruone
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kuzmin
          </surname>
          <given-names>
           I.
V.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guo
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Niezgoda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haynes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Agwanda
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Breiman
          </surname>
          <given-names>
           R.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Anderson
          </surname>
          <given-names>
           L.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Rupprecht
          </surname>
          <given-names>
           C.
E.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Detection of novel SARS-like and other coronaviruses in bats
from Kenya
        </article-title>
        .
        <source>
         Emerg. Infect. Dis
        </source>
        .
        <volume>
         15
        </volume>
        ,
        <fpage>
         482
        </fpage>
        –
        <lpage>
         485
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1503.081013
        </pub-id>
        <pub-id pub-id-type="pmid">
         19239771
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chommanard
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Queen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Markotter
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kuzmin
          </surname>
          <given-names>
           I.
V.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Holmes
          </surname>
          <given-names>
           E.
C.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2017
        </year>
        )
        <article-title>
         Surveillance of bat coronaviruses in
Kenya identifies relatives of human coronaviruses NL63 and 229E and their
recombination history
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         91
        </volume>
       </mixed-citation>
      </ref>
      <ref id="B53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           V.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liljander
          </surname>
          <given-names>
           A.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jonsdottir
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Juma Ngeiywa
          </surname>
          <given-names>
           K.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kamau
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Younan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gluecks
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Musa
          </surname>
          <given-names>
           B.
E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        .
(
        <year>
         2016
        </year>
        )
        <article-title>
         Link of a ubiquitous human coronavirus to
dromedary camels
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci.
U.S.A
        </source>
        .
        <volume>
         113
        </volume>
        ,
        <fpage>
         9864
        </fpage>
        –
        <lpage>
         9869
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1604472113
        </pub-id>
        <pub-id pub-id-type="pmid">
         27528677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B54">
       <label>
        54.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Graham
          </surname>
          <given-names>
           R.
L.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           R.
S.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Recombination, reservoirs, and the modular spike: mechanisms
of coronavirus cross-species transmission
        </article-title>
        .
        <source>
         J.
Virol
        </source>
        .
        <volume>
         84
        </volume>
        ,
        <fpage>
         3134
        </fpage>
        –
        <lpage>
         3146
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01394-09
        </pub-id>
        <pub-id pub-id-type="pmid">
         19906932
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           He
          </surname>
          <given-names>
           Y. Q.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           X.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.
X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheung
          </surname>
          <given-names>
           C.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Luo
          </surname>
          <given-names>
           S. W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           P.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           L. J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Butt
          </surname>
          <given-names>
           K.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           K. L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shortridge
          </surname>
          <given-names>
           K.
F.
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        .
(
        <year>
         2003
        </year>
        )
        <article-title>
         Isolation and characterization of viruses
related to the SARS coronavirus from animals in southern
China
        </article-title>
        .
        <source>
         Science
        </source>
        <volume>
         302
        </volume>
        ,
        <fpage>
         276
        </fpage>
        –
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1087139
        </pub-id>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           S.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           P. C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           K.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.
W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           S. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leung
          </surname>
          <given-names>
           S.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in
Chinese horseshoe bats
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci.
U.S.A
        </source>
        .
        <volume>
         102
        </volume>
        ,
        <fpage>
         14040
        </fpage>
        –
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0506735102
        </pub-id>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           M.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Godeke
          </surname>
          <given-names>
           G.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           V.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits-De
Vries
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           V.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Drexler
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           S.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           El
Tahir
          </surname>
          <given-names>
           Y. E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           De Sousa
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Beek
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <etal>
          et
al
         </etal>
        </person-group>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Middle East
respiratory syndrome coronavirus neutralising serum antibodies in dromedary
camels: a comparative serological study
        </article-title>
        .
        <source>
         Lancet
Infect. Dis
        </source>
        .
        <volume>
         13
        </volume>
        ,
        <fpage>
         859
        </fpage>
        –
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B58">
       <label>
        58.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al
Dhahiry
          </surname>
          <given-names>
           S. H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           V. S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Godeke
          </surname>
          <given-names>
           G.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ghobashy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Alhajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Thani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al-Marri
          </surname>
          <given-names>
           S.
A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al
Romaihi
          </surname>
          <given-names>
           H. E.
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary
camels: an outbreak investigation
        </article-title>
        .
        <source>
         Lancet Infect.
Dis
        </source>
        .
        <volume>
         14
        </volume>
        ,
        <fpage>
         140
        </fpage>
        –
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B59">
       <label>
        59.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           J.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yoon
          </surname>
          <given-names>
           J.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ding
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Spearman
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         The intracellular virus-containing
compartments in primary human macrophages are largely inaccessible to
antibodies and small molecules
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <volume>
         7
        </volume>
        ,
        <fpage>
         e35297
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0035297
        </pub-id>
        <pub-id pub-id-type="pmid">
         22567100
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B60">
       <label>
        60.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           J.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yoon
          </surname>
          <given-names>
           J.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hammonds
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ding
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Spearman
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Tetherin/BST-2 is essential for the
formation of the intracellular virus-containing compartment in HIV-infected
macrophages
        </article-title>
        .
        <source>
         Cell Host Microbe
        </source>
        <volume>
         12
        </volume>
        ,
        <fpage>
         360
        </fpage>
        –
        <lpage>
         372
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.chom.2012.07.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         22980332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B61">
       <label>
        61.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lee
          </surname>
          <given-names>
           A.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cai
          </surname>
          <given-names>
           J. P.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           I.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ho
          </surname>
          <given-names>
           W. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K.
K.
          </given-names>
         </name>
         ,
         <etal>
          et al
         </etal>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Middle East respiratory syndrome
coronavirus efficiently infects human primary T lymphocytes and activates
the extrinsic and intrinsic apoptosis pathways
        </article-title>
        .
        <source>
         J.
Infect. Dis
        </source>
        .
        <volume>
         213
        </volume>
        ,
        <fpage>
         904
        </fpage>
        –
        <lpage>
         914
        </lpage>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B62">
       <label>
        62.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           B.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.
S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           V.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           C.
C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           K.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
J.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Productive replication of Middle East respiratory syndrome
coronavirus in monocyte-derived dendritic cells modulates innate immune
response
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         454–455
        </volume>
        ,
        <fpage>
         197
        </fpage>
        –
        <lpage>
         205
        </lpage>
       </mixed-citation>
      </ref>
      <ref id="B63">
       <label>
        63.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yi
          </surname>
          <given-names>
           C.
E.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           He
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gettie
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Ho
          </surname>
          <given-names>
           D.
D.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Recombinant modified vaccinia virus Ankara expressing the
spike glycoprotein of severe acute respiratory syndrome coronavirus induces
protective neutralizing antibodies primarily targeting the receptor binding
region
        </article-title>
        .
        <source>
         J. Virol
        </source>
        .
        <volume>
         79
        </volume>
        ,
        <fpage>
         2678
        </fpage>
        –
        <lpage>
         2688
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.5.2678-2688.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15708987
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B64">
       <label>
        64.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           C.
M.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           A.
J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Leung
          </surname>
          <given-names>
           L.
H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Sze
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kao
          </surname>
          <given-names>
           R.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chik
          </surname>
          <given-names>
           K.
K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           K. K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           J.
F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jin
          </surname>
          <given-names>
           D.
Y.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2016
        </year>
        )
        <article-title>
         Hemagglutinin of influenza A virus binds specifically to cell
surface nucleolin and plays a role in virus internalization
        </article-title>
        .
        <source>
         Virology
        </source>
        <volume>
         494
        </volume>
        ,
        <fpage>
         78
        </fpage>
        –
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2016.04.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         27085069
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="B65">
       <label>
        65.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Nal
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kien
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Siu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tse
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Kam
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Staropoli
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Crescenzo-Chaigne
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           K.
Y.
          </given-names>
         </name>
         , and
         <name name-style="western">
          <surname>
           Altmeyer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Differential maturation and subcellular
localization of severe acute respiratory syndrome coronavirus surface
proteins S, M, and E
        </article-title>
        .
        <source>
         J. Gen. Virol
        </source>
        .
        <volume>
         86
        </volume>
        ,
        <fpage>
         1423
        </fpage>
        –
        <lpage>
         1434
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.80671-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         15831954
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jvi
      </journal-id>
      <journal-id journal-id-type="pmc">
       jvi
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVI
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-538X
      </issn>
      <issn pub-type="epub">
       1098-5514
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23903833
      </article-id>
      <article-id pub-id-type="pmc">
       3807420
      </article-id>
      <article-id pub-id-type="publisher-id">
       01756-13
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/JVI.01756-13
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Structure and Assembly
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Yaoqing
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rajashankar
         </surname>
         <given-names>
          Kanagalaghatta R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Yang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Agnihothram
         </surname>
         <given-names>
          Sudhakar S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          c
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Chang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Yi-Lun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baric
         </surname>
         <given-names>
          Ralph S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          c
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Fang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, USA
        <label>
         a
        </label>
       </aff>
       <aff id="aff2">
        Department of Chemistry and Chemical Biology, Cornell University, NE-CAT, Advanced Photon Source, Argonne, Illinois, USA
        <label>
         b
        </label>
       </aff>
       <aff id="aff3">
        Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
        <label>
         c
        </label>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Fang Li,
        <email>
         lifang@umn.edu
        </email>
        .
       </corresp>
       <fn fn-type="equal">
        <p>
         Y.C., K.R.R., and Y.Y. contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        10
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       87
      </volume>
      <issue>
       19
      </issue>
      <fpage>
       10777
      </fpage>
      <lpage>
       10783
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         6
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         7
        </month>
        <year>
         2013
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2013, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2013
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri xlink:href="zjv01913010777.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 77 people, with a fatality rate of more than 50%. Alarmingly, the virus demonstrates the capability of human-to-human transmission, raising the possibility of global spread and endangering world health and economy. Here we have identified the receptor-binding domain (RBD) from the MERS-CoV spike protein and determined its crystal structure. This study also presents a structural comparison of MERS-CoV RBD with other coronavirus RBDs, successfully positioning MERS-CoV on the landscape of coronavirus evolution and providing insights into receptor binding by MERS-CoV. Furthermore, we found that MERS-CoV RBD functions as an effective entry inhibitor of MERS-CoV. The identified MERS-CoV RBD may also serve as a potential candidate for MERS-CoV subunit vaccines. Overall, this study enhances our understanding of the evolution of coronavirus RBDs, provides insights into receptor recognition by MERS-CoV, and may help control the transmission of MERS-CoV in humans.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Nat Rev Microbiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Nat. Rev. Microbiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Nature Reviews. Microbiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1740-1526
      </issn>
      <issn pub-type="epub">
       1740-1534
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27344959
      </article-id>
      <article-id pub-id-type="pmc">
       7097822
      </article-id>
      <article-id pub-id-type="publisher-id">
       BFnrmicro201681
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/nrmicro.2016.81
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        SARS and MERS: recent insights into emerging coronaviruses
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          de Wit
         </surname>
         <given-names>
          Emmie
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par1">
          Emmie de Wit is a staff scientist in the Disease Modelling and Transmission Section of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. She received her Ph.D. in virology from Erasmus University Rotterdam, The Netherlands, where she studied the molecular determinants of influenza A virus replication and pathogenesis. Her current research focuses on the pathogenesis and transmission of Ebola virus, Nipah virus and Middle East respiratory syndrome coronavirus (MERS-CoV), and the development of countermeasures against these viruses.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          Neeltje
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par2">
          Neeltje van Doremalen is a visiting postdoctoral fellow in the Virus Ecology Unit of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. She received her B.Sc. in biochemistry from the Hogeschool of Arnhem and Nijmegen, Nijmegen, The Netherlands; her M.Sc. in biomedical science from Radboud University, Nijmegen; and her Ph.D. from Imperial College, London, UK, for her studies of the receptor-binding and transmission of influenza viruses. She currently studies the species tropism and transmission of Middle East respiratory syndrome coronavirus (MERS-CoV).
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Falzarano
         </surname>
         <given-names>
          Darryl
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
        <bio>
         <p id="Par3">
          Darryl Falzarano is a research scientist at the Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO–InterVac) and an adjunct professor in the Department of Veterinary Microbiology, both at the University of Saskatchewan, Saskatoon, Canada. He received his Ph.D. in medical microbiology from the University of Manitoba, Winnipeg, Canada, where he studied the relationship between protein structure and function of Ebola virus glycoproteins. As a visiting fellow at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA, he developed antiviral therapeutic strategies and animal models for MERS-CoV. His laboratory is currently focused on the development of vaccine strategies and large-animal models for Middle East respiratory syndrome coronavirus (MERS-CoV).
          <ext-link ext-link-type="uri" xlink:href="http://vido.org/team/project-leaders/darryl-falzarano">
           Darryl Falzarano's homepage
          </ext-link>
          .
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Munster
         </surname>
         <given-names>
          Vincent J.
         </given-names>
        </name>
        <address>
         <email>
          vincent.munster@nih.gov
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par4">
          Vincent J. Munster is the chief of the Virus Ecology Unit of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. He received his Ph.D. in virology from Erasmus University Rotterdam, The Netherlands, where he studied the ecology, evolution and pathogenesis of avian influenza viruses. His laboratory focuses on the ecology of emerging viruses and drivers of zoonotic and cross-species transmission.
          <ext-link ext-link-type="uri" xlink:href="http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/lv/virusecology/Pages/default.aspx">
           Vincent J. Munster's homepage
          </ext-link>
          .
         </p>
        </bio>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.419681.3
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2164 9667
         </institution-id>
         <institution>
          Division of Intramural Research,
         </institution>
         <institution>
          Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories,
         </institution>
        </institution-wrap>
        Hamilton, 59840 Montana USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.25152.31
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2154 235X
         </institution-id>
         <institution>
          Vaccine and Infectious Disease Organization – International Vaccine Centre and Department of Veterinary Microbiology,
         </institution>
         <institution>
          University of Saskatchewan,
         </institution>
        </institution-wrap>
        120 Veterinary Road, Saskatoon, S7N 5E3 Saskatchewan Canada
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        6
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       523
      </fpage>
      <lpage>
       534
      </lpage>
      <permissions>
       <copyright-statement>
        © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2016
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="KeyPoints" id="Abs1">
       <title>
        Key Points
       </title>
       <p id="Par5">
        <list list-type="bullet">
         <list-item>
          <p id="Par6">
           Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are zoonotic pathogens that can cause severe respiratory disease in humans. Although disease progression is fairly similar for SARS and MERS, the case fatality rate of MERS is much higher than that of SARS.
          </p>
         </list-item>
         <list-item>
          <p id="Par7">
           Comorbidities have an important role in SARS and MERS. Several risk factors are associated with progression to acute respiratory distress syndrome (ARDS) in SARS and MERS cases, especially advanced age and male sex. For MERS, additional risk factors that are associated with severe disease include chronic conditions such as diabetes mellitus, hypertension, cancer, renal and lung disease, and co-infections.
          </p>
         </list-item>
         <list-item>
          <p id="Par8">
           Although the ancestors of SARS-CoV and MERS-CoV probably circulate in bats, zoonotic transmission of SARS-CoV required an incidental amplifying host. Dromedary camels are the MERS-CoV reservoir from which zoonotic transmission occurs; serological evidence indicates that MERS-CoV-like viruses have been circulating in dromedary camels for at least three decades.
          </p>
         </list-item>
         <list-item>
          <p id="Par9">
           Human-to-human transmission of SARS-CoV and MERS-CoV occurs mainly in health care settings. Patients do not shed large amounts of virus until well after the onset of symptoms, when patients are most probably already seeking medical care. Analysis of hospital surfaces after the treatment of patients with MERS showed the ubiquitous presence of infectious virus.
          </p>
         </list-item>
         <list-item>
          <p id="Par10">
           Our understanding of the pathogenesis of SARS-CoV and MERS-CoV is still incomplete, but the combination of viral replication in the lower respiratory tract and an aberrant immune response is thought to have a crucial role in the severity of both syndromes.
          </p>
         </list-item>
         <list-item>
          <p id="Par11">
           The severity of the diseases that are caused by emerging coronaviruses highlights the need to develop effective therapeutic measures against these viruses. Although several treatments for SARS and MERS (based on inhibition of viral replication with drugs or neutralizing antibodies, or on dampening the host response) have been identified in animal models and
           <italic>
            in vitro
           </italic>
           studies, efficacy data from human clinical trials are urgently required.
          </p>
         </list-item>
        </list>
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="web-summary" id="Abs2">
       <p id="Par12">
        Insights into coronavirus emergence, replication and pathogenesis gained from the SARS and MERS outbreaks have guided the development of preventive and therapeutic measures. In this Review, Munster and colleagues highlight recent achievements and areas that need to be addressed to combat novel coronaviruses.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract id="Abs3">
       <p id="Par13">
        The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 marked the second introduction of a highly pathogenic coronavirus into the human population in the twenty-first century. The continuing introductions of MERS-CoV from dromedary camels, the subsequent travel-related viral spread, the unprecedented nosocomial outbreaks and the high case-fatality rates highlight the need for prophylactic and therapeutic measures. Scientific advancements since the 2002–2003 severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic allowed for rapid progress in our understanding of the epidemiology and pathogenesis of MERS-CoV and the development of therapeutics. In this Review, we detail our present understanding of the transmission and pathogenesis of SARS-CoV and MERS-CoV, and discuss the current state of development of measures to combat emerging coronaviruses.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        SARS virus
       </kwd>
       <kwd>
        Viral pathogenesis
       </kwd>
       <kwd>
        Antivirals
       </kwd>
       <kwd>
        Viral transmission
       </kwd>
       <kwd>
        Viral reservoirs
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Nature Limited 2016
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Main
     </title>
     <p id="Par14">
      This century has seen the global spread of two previously unknown coronaviruses. In November 2002, the first known case of severe acute respiratory syndrome (SARS) occurred in Foshan, China
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . New cases emerged in mainland China, and by February 2003, more than 300 cases had been reported, around one-third of which were in health care workers
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . Individuals who were infected and subsequently travelled spread the outbreak to Hong Kong
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
      </sup>
      and from there to Vietnam, Canada and several other countries
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      . In March 2003, the WHO established a network of laboratories to determine the causative agent of SARS. A remarkable global effort led to the identification of SARS coronavirus (SARS-CoV) in early April of that year
      <sup>
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      . By July 2003 and after a total of 8,096 reported cases, including 774 deaths in 27 countries
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      , no more infections were detected, and the SARS pandemic was declared to be over. Five additional SARS cases, resulting from zoonotic transmission, occurred in December 2003–January 2004 (Ref.
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ), but no human SARS cases have been detected since. Measures of infection control, rather than medical interventions, ended the SARS pandemic. However, certain SARS-CoV-like viruses found in bats have recently been shown to be able to infect human cells without prior adaptation
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      , which indicates that SARS could re-emerge.
     </p>
     <p id="Par15">
      In June 2012, 10 years after the first emergence of SARS-CoV, a man in Saudi Arabia died of acute pneumonia and renal failure. A novel coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), was isolated from his sputum
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      . A cluster of cases of severe respiratory disease had occurred in April 2012 in a hospital in Jordan and was retrospectively diagnosed as MERS
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      , and a cluster of three cases of MERS in the UK was identified in September 2012 (Ref.
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ). MERS-CoV continued to emerge and spread to countries outside of the Arabian Peninsula as a result of travel of infected persons; often, these imported MERS cases resulted in
      <xref ref-type="list" rid="Glos1">
       nosocomial transmission
      </xref>
      . In May 2015, a single person returning from the Middle East started a nosocomial outbreak of MERS in South Korea that involved 16 hospitals and 186 patients
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      . As of 26 April 2016, there have been 1,728 confirmed cases of MERS, including 624 deaths in 27 countries
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
      .
     </p>
     <p id="Par16">
      This Review highlights the pandemic and epidemic potential of emerging coronaviruses and discusses our current knowledge of the biology of SARS-CoV and MERS-CoV, including their transmission, their pathogenesis and the development of medical countermeasures. Key features of these viruses are the dominance of nosocomial transmission, and pathogenesis that is driven by a combination of viral replication in the lower respiratory tract and an aberrant host immune response. Several potential treatments for SARS and MERS have been identified in animal and
      <italic>
       in vitro
      </italic>
      models, including small-molecule protease inhibitors, neutralizing antibodies and inhibitors of the host immune response. However, efficacy data from human clinical trials are lacking but are needed to move these potential countermeasures forward.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Replication of SARS-CoV and MERS-CoV
     </title>
     <p id="Par17">
      SARS-CoV and MERS-CoV belong to the Coronavirus genus in the
      <italic>
       Coronaviridae
      </italic>
      family and have large, positive-sense RNA genomes of 27.9 kb and 30.1 kb, respectively (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1a
      </xref>
      ). Similarly to all viruses in the order
      <italic>
       Nidovirales
      </italic>
      , SARS-CoV and MERS-CoV have a unique coding strategy: two-thirds of the viral RNA is translated into two large polyproteins, and the remainder of the viral genome is transcribed into a nested set of subgenomic mRNAs
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
      </sup>
      (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1b
      </xref>
      ). The two polyproteins, pp1a and pp1ab, encode 16 non-structural proteins (nsp1–nsp16)
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      that make up the viral replicase–transcriptase complex. The polyproteins are cleaved by two proteases, papain-like protease (PLpro; corresponding to nsp3) and a main protease, 3C-like protease (3CLpro; corresponding to nsp5). The nsps rearrange membranes that are derived from the rough endoplasmic reticulum (RER) into double-membrane vesicles, in which viral replication and transcription occur
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      . One unique feature of coronaviruses is the exoribonuclease (ExoN) function of nsp14 (Ref.
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ), which provides the
      <xref ref-type="list" rid="Glos2">
       proofreading
      </xref>
      capability required to maintain a large RNA genome without the accumulation of detrimental mutations
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
      </sup>
      . SARS-CoV and MERS-CoV transcribe 12 and 9 subgenomic RNAs, respectively, and these encode the four structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N), as well as several accessory proteins that are not involved in viral replication but interfere with the host innate immune response or are of unknown or poorly understood function.
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <title>
         SARS-CoV and MERS-CoV structure and replication.
        </title>
        <p>
         <bold>
          a
         </bold>
         | The single-stranded RNA (ssRNA) genomes of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) encode two large polyproteins, pp1a and pp1ab, which are proteolytically cleaved into 16 non-structural proteins (nsps), including papain-like protease (PLpro), 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), helicase (Hel) and exonuclease (ExoN). An additional 9–12 ORFs are encoded through the transcription of a nested set of subgenomic RNAs. SARS-CoV and MERS-CoV form spherical particles that consist of four structural proteins. The envelope glycoprotein spike (S) forms a layer of glycoproteins that protrude from the envelope. Two additional transmembrane glycoproteins are incorporated in the virion: envelope (E) and membrane (M). Inside the viral envelope resides the helical nucleocapsid, which consists of the viral positive-sense RNA ((+)RNA) genome encapsidated by protein nucleocapsid (N).
         <bold>
          b
         </bold>
         | Following entry of the virus into the host cell, the viral RNA is uncoated in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab, which are cleaved by the proteases that are encoded by ORF1a to yield 16 nsps that form the RNA replicase–transcriptase complex. This complex localizes to modified intracellular membranes that are derived from the rough endoplasmic reticulum (ER) in the perinuclear region, and it drives the production of negative-sense RNAs ((−)RNAs) through both replication and transcription. During replication, full-length (−)RNA copies of the genome are produced and used as templates for full-length (+)RNA genomes. During transcription, a subset of 7–9 subgenomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. In this process, subgenomic (−)RNAs are synthesized by combining varying lengths of the 3′ end of the genome with the 5′ leader sequence necessary for translation. These subgenomic (−)RNAs are then transcribed into subgenomic (+)mRNAs. Although the different subgenomic mRNAs may contain several ORFs, only the first ORF (that closest to the 5′ end) is translated. The resulting structural proteins are assembled into the nucleocapsid and viral envelope at the ER–Golgi intermediate compartment (ERGIC), followed by release of the nascent virion from the infected cell.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM6">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e432" xlink:href="41579_2016_Article_BFnrmicro201681_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par18">
      The envelope spike glycoprotein binds to its cellular receptor, angiotensin-converting enzyme 2 (ACE2) for SARS-CoV and dipeptidyl peptidase 4 (DPP4) for MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      . After membrane fusion, either directly with the host cell membrane or with the endosome membrane, the viral RNA genome is released into the cytoplasm, and the RNA is uncoated to allow translation of the two polyproteins, transcription of the subgenomic RNAs and replication of the viral genome (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1b
      </xref>
      ). Newly formed envelope glycoproteins are inserted in the RER or Golgi membranes; genomic RNA and nucleocapsid proteins combine to form nucleocapsids, and the viral particles bud into the
      <xref ref-type="list" rid="Glos3">
       ER–Golgi intermediate compartment
      </xref>
      (ERGIC). Virion-containing vesicles subsequently fuse with the plasma membrane to release the virus
      <sup>
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Reservoirs and transmission
     </title>
     <p id="Par19">
      The first indication of the source of SARS-CoV was the detection of the virus in masked palm civets and a raccoon dog and the detection of antibodies against the virus in Chinese ferret badgers in a live-animal market in Shenzhen, China
      <sup>
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
      </sup>
      . However, these animals were only incidental hosts, as there was no evidence for the circulation of SARS-CoV-like viruses in palm civets in the wild or in breeding facilities
      <sup>
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
      </sup>
      . Rather, bats are the reservoir of a wide variety of coronaviruses, including SARS-CoV-like and MERS-CoV-like viruses
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      (
      <xref ref-type="fig" rid="Fig2">
       Fig. 2
      </xref>
      ).
      <fig id="Fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <title>
         The emergence of SARS-CoV and MERS-CoV.
        </title>
        <p>
         Bats harbour a wide range of coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV)-like and Middle East respiratory syndrome coronavirus (MERS-CoV)-like viruses. SARS-CoV crossed the species barrier into masked palm civets and other animals in live-animal markets in China; genetic analysis suggests that this occurred in late 2002. Several people in close proximity to palm civets became infected with SARS-CoV. A MERS-CoV ancestral virus crossed the species barrier into dromedary camels; serological evidence suggests that this happened more than 30 years ago. Abundant circulation of MERS-CoV in dromedary camels results in frequent zoonotic transmission of this virus. SARS-CoV and MERS-CoV spread between humans mainly through nosocomial transmission, which results in the infection of health care workers and patients at a higher frequency than infection of their relatives.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM7">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e484" xlink:href="41579_2016_Article_BFnrmicro201681_Fig2_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par20">
      Thus, the search for the reservoir of MERS-CoV initially focused on bats, but a serological survey in dromedary camels from Oman and the Canary Islands showed a high prevalence of MERS-CoV-neutralizing antibodies in these animals
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
      </sup>
      . In addition, MERS-CoV RNA was detected in swabs that were collected from dromedary camels at a farm in Qatar that was linked to two human cases of MERS, and infectious virus was isolated from dromedary camels in Saudi Arabia and Qatar
      <sup>
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . Serological evidence for the circulation of a MERS-CoV-like virus in dromedary camels has been obtained in the Middle East, Eastern Africa and Northern Africa, dating back as far as 1983 (Ref.
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ). Dromedary camels in Saudi Arabia harbour several viral genetic lineages
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
      , including those that have caused human outbreaks. Taken together, these data strongly point to the role of dromedary camels as a reservoir for MERS-CoV. The ubiquity of infected dromedary camels close to humans and the resulting continuing zoonotic transmission may explain why MERS-CoV continues to cause infections in humans, whereas SARS-CoV, without the continuing presence of an infected intermediate host and with relatively infrequent human–bat interactions, has caused no more infections in humans.
     </p>
     <p id="Par21">
      Human-to-human transmission of SARS-CoV and MERS-CoV occurs mainly through nosocomial transmission; 43.5–100% of MERS cases in individual outbreaks were linked to hospitals, and very similar observations were made for some of the SARS clusters
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
      </sup>
      . Transmission between family members occurred in only 13–21% of MERS cases and 22–39% of SARS cases. Transmission of MERS-CoV between patients was the most common route of infection (62–79% of cases), whereas for SARS-CoV, infection of health care workers by infected patients was very frequent (33–42%)
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      . The predominance of nosocomial transmission is probably due to the fact that substantial virus shedding occurs only after the onset of symptoms
      <sup>
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
      </sup>
      , when most patients are already seeking medical care
      <sup>
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
      </sup>
      . An analysis of hospital surfaces after the treatment of patients with MERS showed the ubiquitous presence of viral RNA in the environment for several days after patients no longer tested positive
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
      </sup>
      . Moreover, many patients with SARS or MERS were infected through
      <xref ref-type="list" rid="Glos4">
       super spreaders
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      The pathogenesis of SARS-CoV and MERS-CoV
     </title>
     <p id="Par22">
      The clinical courses of SARS and MERS are remarkably similar, although there are subtle differences (
      <xref ref-type="sec" rid="Sec5">
       Box 1
      </xref>
      ). Owing to the current sparsity of data on human MERS-CoV infections
      <sup>
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
      </sup>
      , the pathogenesis of this virus is poorly understood; however, similar mechanisms may underlie the pathogenesis of both MERS and SARS.
     </p>
     <p id="Par23">
      The binding of spike protein to ACE2 and the subsequent downregulation of this receptor contribute to lung injury during SARS
      <sup>
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
      </sup>
      . Although it seems counterintuitive that receptor downregulation would increase pathology, it has been shown that ACE2 can protect against acute lung injury. The downregulation of ACE2 results in the excessive production of angiotensin II by the related enzyme ACE, and it has been suggested that the stimulation of type 1a angiotensin II receptor (AGTR1A) increases pulmonary vascular permeability, thus potentially explaining the increased lung pathology when the expression of ACE2 is decreased
      <sup>
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
      </sup>
      .
     </p>
     <p id="Par24">
      <bold>
       <italic>
        Immunopathology.
       </italic>
      </bold>
      The immune response is essential for the resolution of an infection, but it can also result in immunopathogenesis. One indication that immunopathogenesis may contribute to SARS was the observation that viral loads were found to be decreasing while disease severity increased
      <sup>
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
      </sup>
      . It is unclear whether a similar trend applies to MERS
      <sup>
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ,
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
      </sup>
      . Moreover, progression to
      <xref ref-type="list" rid="Glos5">
       acute respiratory distress syndrome
      </xref>
      (ARDS) is associated with the upregulation of pro-inflammatory cytokines and chemokines, particularly interleukin-1β (IL-1β), IL-8, IL-6, CXC-chemokine ligand 10 (CXCL10) and CC-chemokine ligand 2 (CCL2)
      <sup>
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
      </sup>
      ; increased plasma levels of these molecules have been detected in patients with SARS
      <sup>
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ,
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
      </sup>
      . Retrospective longitudinal studies in patients who recovered from SARS versus those who succumbed to the disease have shown an early expression of interferon-α (IFNα), IFNγ, CXCL10, CCL2 and proteins that are encoded by IFN-stimulated genes (ISGs) in all patients, but only patients who survived then had gene expression profiles that are indicative of the development of an adaptive immune response. By contrast, patients who succumbed maintained high levels of CXCL10, CCL2 and ISG-encoded proteins, whereas spike-specific antibodies were present at low levels or were absent
      <sup>
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
      </sup>
      , which suggests that severe disease is related to the lack of a switch from an innate immune response to an adaptive immune response.
     </p>
     <p id="Par25">
      Experiments using
      <xref ref-type="list" rid="Glos6">
       Collaborative Cross mouse
      </xref>
      lines and mouse-adapted SARS-CoV identified one host gene,
      <italic>
       Trim55
      </italic>
      , as important for SARS pathogenesis. Although there was no difference in clinical signs or viral replication in
      <italic>
       Trim55
      </italic>
      <sup>
       −/−
      </sup>
      mice compared with wild-type mice,
      <xref ref-type="list" rid="Glos7">
       perivascular cuffing
      </xref>
      and the number of inflammatory cells in the lungs were reduced in the
      <italic>
       Trim55
      </italic>
      <sup>
       −/−
      </sup>
      mice
      <sup>
       <xref ref-type="bibr" rid="CR57">
        57
       </xref>
      </sup>
      .
     </p>
     <p id="Par26">
      The involvement of the host immune response in the pathogenesis of SARS, and most likely also that of MERS, suggests that drugs which inhibit viral replication will need to be combined with treatments that control detrimental immune responses.
     </p>
     <p id="Par27">
      <bold>
       <italic>
        Immune evasion.
       </italic>
      </bold>
      SARS-CoV and MERS-CoV use several strategies to avoid the innate immune response. Viral pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA) or uncapped mRNA, are detected by pattern recognition receptors (PRRs), such as retinoic acid-inducible gene I protein (RIG-I; also known as DDX58) or melanoma differentiation-associated protein 5 (MDA5; also known as IFIH1)
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
      </sup>
      . This triggers complex signalling cascades involving MYD88 that lead to the production of
      <xref ref-type="list" rid="Glos8">
       type I IFNs
      </xref>
      and the activation of the transcription factor nuclear factor-κB (NF-κB). In turn, active NF-κB induces the transcription of pro-inflammatory cytokines (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3a
      </xref>
      ). Type I IFNs signal through IFNα/β receptor (IFNAR) and downstream molecules such as signal transducer and activator of transcription (STAT) proteins to stimulate the production of antiviral proteins that are encoded by ISGs, such as IFN-induced protein with tetratricopeptide repeats 1 (IFIT1;
      <xref ref-type="fig" rid="Fig3">
       Fig. 3b
      </xref>
      ). Collectively, this establishes an antiviral immune response that limits viral replication in infected and in neighbouring cells (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3
      </xref>
      ).
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <title>
         Evasion of the innate immune response by SARS-CoV and MERS-CoV.
        </title>
        <p>
         <bold>
          a
         </bold>
         | The innate immune response is activated by the detection of viral pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA) or uncapped mRNA. This occurs via host pattern recognition receptors (PRRs), such as retinoic acid-inducible gene I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), potentially via dsRNA-binding partners such as IFN-inducible dsRNA-dependent protein kinase activator A (PRKRA). Following PRR-mediated detection of a PAMP, the resulting interaction of PRRs with mitochondrial antiviral-signalling protein (MAVS) activates nuclear factor-κB (NF-κB) through a signalling cascade involving several kinases. Activated NF-κB translocates to the nucleus, where it induces the transcription of pro-inflammatory cytokines. The kinases also phosphorylate (P) IFN-regulatory factor 3 (IRF3) and IRF7, which form homodimers and heterodimers and enter the nucleus to initiate the transcription of type I interferons (type I IFNs). Both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have developed mechanisms to interfere with these signalling pathways, as shown; these subversion strategies involve both structural proteins (membrane (M) and nucleocapsid (N)) and non-structural proteins (nsp1, nsp3b, nsp4a, nsp4b, nsp5, nsp6 and papain-like protease (PLpro); indicated in the figure by just their nsp numbers and letters).
         <bold>
          b
         </bold>
         | Binding of type I IFNs to their dimeric receptor, IFNα/β receptor (IFNAR), activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway, in which JAK1 and TYK2 kinases phosphorylate STAT1 and STAT2, which form complexes with IRF9. These complexes move into the nucleus to initiate the transcription of IFN-stimulated genes (ISGs) under the control of promoters that contain an IFN-stimulated response element (ISRE). Collectively, the expression of cytokines, IFNs and ISGs establishes an antiviral innate immune response that limits viral replication in infected and in neighbouring cells. Again, viral proteins have been shown to inhibit these host signalling pathways to evade this immune response. IκBα, NF-κB inhibitor-α.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM8">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e698" xlink:href="41579_2016_Article_BFnrmicro201681_Fig3_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par28">
      Infection of knockout mice revealed the importance of innate immunity. Infection of
      <italic>
       Myd88
      </italic>
      <sup>
       −/−
      </sup>
      and
      <italic>
       Stat1
      </italic>
      <sup>
       −/−
      </sup>
      mice, but not mice that were deficient in IFN receptors, with a mouse-adapted strain of SARS-CoV resulted in more severe disease than infection with a non-adapted SARS-CoV strain
      <sup>
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
      </sup>
      . Moreover, MERS-CoV infection of wild-type mice that were transduced with human DPP4 caused mild disease, but symptoms were more severe in
      <italic>
       Myd88
      </italic>
      <sup>
       −/−
      </sup>
      mice and
      <italic>
       Ifnar1
      </italic>
      <sup>
       −/−
      </sup>
      mice
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
      </sup>
      .
     </p>
     <p id="Par29">
      SARS-CoV and MERS-CoV avoid host detection of their dsRNA by replicating in virus-induced double-membrane vesicles that lack PRRs
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      . Moreover, the recognition of SARS-CoV mRNAs, for example, by MDA5 and IFIT1 is prevented by capping of the viral mRNAs by nsp14 and the nsp10–nsp16 complex
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Recombinant SARS-CoV that lacks the methylation activity of nsp16 is attenuated and exhibits increased sensitivity to type I IFNs. This effect is dependent on IFIT1 or MDA5, as the same virus is not attenuated in mice that are deficient in either molecule
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Although mRNA capping has not yet been shown for MERS-CoV, structural similarity between the MERS-CoV nsp10–nsp16 complex and the SARS-CoV nsp10–nsp16 complex suggests that a similar mechanism exists to avoid host recognition of MERS-CoV mRNAs by cytosolic PRRs
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
      </sup>
      .
     </p>
     <p id="Par30">
      SARS-CoV encodes at least eight proteins that interact with the signalling cascades downstream of PRRs; in MERS-CoV, several proteins have been identified with similar functions (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3
      </xref>
      ). The nucleocapsid protein of SARS-CoV has been associated with the suppression of
      <xref ref-type="list" rid="Glos9">
       RNAi
      </xref>
      in mammalian cells
      <sup>
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      . Furthermore, this protein antagonizes IFN induction, probably early in the signalling cascade, as downstream signalling molecules relieve the inhibition
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      . MERS-CoV ORF4a has a similar IFN-antagonistic function, involving the binding of dsRNA and subsequent inhibition of MDA5 activation
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
      </sup>
      , potentially through interaction with IFN-inducible dsRNA-dependent protein kinase activator A (PRKRA; also known as PACT), which interacts with MDA5 and RIG-I
      <sup>
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
      </sup>
      . Moreover, MERS-CoV ORF4a, ORF4b, ORF5 and membrane protein inhibit the nuclear trafficking of IFN-regulatory factor 3 (IRF3) and activation of the
      <italic>
       IFNB
      </italic>
      promoter
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      . These viral proteins, except for ORF5, also inhibit the expression of genes that are under the control of an IFN-stimulated response element (ISRE), and ORF4a reduces the expression of genes that are stimulated by NF-κB
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      . Finally, MERS-CoV ORF4b interacts with TBK1 and inhibitor of NF-κB kinase-ɛ (IKKɛ), thereby suppressing the interaction between IKKɛ and mitochondrial antiviral-signalling protein (MAVS) and inhibiting the phosphorylation of IRF3 (Ref.
      <xref ref-type="bibr" rid="CR72">
       72
      </xref>
      ).
     </p>
     <p id="Par31">
      The membrane protein of SARS-CoV inhibits the formation of a signalling complex that contains IKKɛ, thus repressing the activation of IRF3 and IRF7 and their induction of type I IFN expression. The membrane protein of MERS-CoV inhibits IRF3 function and the expression of genes that are regulated by an ISRE, including IFNβ
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      , but whether this occurs through a mechanism similar to that of SARS-CoV is unclear.
     </p>
     <p id="Par32">
      SARS-CoV PLpro disrupts NF-κB signalling
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      and blocks the phosphorylation of IRF3 indirectly
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
      </sup>
      . Furthermore, SARS-CoV PLpro inhibits the induction of type I IFNs, potentially through the deubiquitylation of phosphorylated IRF3 (Refs
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
      ,
      <xref ref-type="bibr" rid="CR75">
       75
      </xref>
      ). Similar functions have been described for MERS-CoV PLpro
      <sup>
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
      </sup>
      .
     </p>
     <p id="Par33">
      Experiments involving recombinantly expressed proteins,
      <italic>
       in vitro
      </italic>
      translation, protein overexpression and
      <xref ref-type="list" rid="Glos10">
       minireplicon systems
      </xref>
      have shown that nsp1 of SARS-CoV blocks the IFN response through the inhibition of STAT1, degradation of host mRNAs and inactivation of the host translational machinery through a tight association with the 40S ribosomal subunit
      <sup>
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="CR79">
        79
       </xref>
       ,
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
      </sup>
      . Nsp1 of MERS-CoV also inhibits the translation of mRNAs and induces mRNA degradation, although the translational inhibition is achieved through a different mechanism than ribosome binding, which selectively targets the translation of nuclear mRNAs and thereby spares cytoplasmic viral mRNAs
      <sup>
       <xref ref-type="bibr" rid="CR81">
        81
       </xref>
      </sup>
      .
     </p>
     <p id="Par34">
      SARS-CoV ORF3b inhibits the production of type I IFN, the phosphorylation of IRF3 and gene expression from an ISRE promoter
      <sup>
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ,
       <xref ref-type="bibr" rid="CR83">
        83
       </xref>
      </sup>
      . SARS-CoV ORF6 also blocks the nuclear translocation of STAT1 (Ref.
      <xref ref-type="bibr" rid="CR83">
       83
      </xref>
      ).
     </p>
     <p id="Par35">
      Both nsp7 and nsp15 from SARS-CoV were also suggested to be IFN antagonists, but the underlying mechanism is unknown
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      . nsp15 is an inhibitor of MAVS-induced apoptosis; however, this occurs through an IFN-independent mechanism
      <sup>
       <xref ref-type="bibr" rid="CR84">
        84
       </xref>
      </sup>
      . Finally, transcriptomic and proteomic analysis of human airway cell cultures showed that MERS-CoV but not SARS-CoV induces repressive histone modifications that downregulate the expression of certain ISGs
      <sup>
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
      </sup>
      .
     </p>
     <p id="Par36">
      It should be noted that most of the interactions of SARS-CoV and MERS-CoV proteins with innate immune pathways were established in
      <italic>
       in vitro
      </italic>
      systems, which rely on the overexpression of viral and, sometimes, cellular proteins, and these interactions have rarely been confirmed in the context of viral replication
      <italic>
       in vitro
      </italic>
      or
      <italic>
       in vivo
      </italic>
      .
     </p>
     <sec id="Sec5">
      <boxed-text>
       <label>
        Box 1: Clinical features of SARS and MERS
       </label>
       <p id="Par37">
        Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have an incubation period of ∼5 days, and 95% of patients develop disease within 13 days of exposure
        <sup>
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR145">
          145
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
        </sup>
        . Common early symptoms are fever, chills, coughing, malaise, myalgia and headache, and less common symptoms include diarrhoea, vomiting and nausea
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
         ,
         <xref ref-type="bibr" rid="CR90">
          90
         </xref>
         ,
         <xref ref-type="bibr" rid="CR92">
          92
         </xref>
         ,
         <xref ref-type="bibr" rid="CR95">
          95
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR147">
          147
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        . Upper respiratory tract symptoms and viral shedding are rare, which explains difficulties in obtaining a laboratory diagnosis from nasal or nasopharyngeal swabs
        <sup>
         <xref ref-type="bibr" rid="CR149">
          149
         </xref>
        </sup>
        . Abnormal chest X-rays are more common in patients with MERS (90–100%)
        <sup>
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        than in those with SARS (60–100%)
        <sup>
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
        </sup>
        . Accordingly, only 20–30% of patients with SARS require intensive care and subsequent mechanical ventilation, whereas 50–89% of patients with MERS require intensive care
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
         ,
         <xref ref-type="bibr" rid="CR90">
          90
         </xref>
         ,
         <xref ref-type="bibr" rid="CR95">
          95
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR147">
          147
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        . The higher incidence of acute respiratory distress syndrome (ARDS) in individuals with MERS is reflected in the case fatality rate: this is ∼36% for MERS compared with ∼10% for SARS
        <sup>
         <xref ref-type="bibr" rid="CR15">
          15
         </xref>
         ,
         <xref ref-type="bibr" rid="CR145">
          145
         </xref>
        </sup>
        .
       </p>
       <p id="Par38">
        Comorbidities have an important role in both SARS and MERS. Several risk factors are associated with poor disease outcome, especially advanced age and male sex
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
         ,
         <xref ref-type="bibr" rid="CR150">
          150
         </xref>
         ,
         <xref ref-type="bibr" rid="CR151">
          151
         </xref>
        </sup>
        . For MERS, additional risk factors for a poor outcome include diabetes mellitus, hypertension, cancer, renal and lung disease, and co-infections
        <sup>
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
         ,
         <xref ref-type="bibr" rid="CR150">
          150
         </xref>
         ,
         <xref ref-type="bibr" rid="CR151">
          151
         </xref>
        </sup>
        .
       </p>
       <p id="Par39">
        Health care settings seem to increase the risk of viral transmission owing to aerosol-generating procedures such as intubation and bronchoscopy. Appropriate hospital hygiene practices and awareness are crucial to limit future nosocomial outbreaks.
       </p>
      </boxed-text>
     </sec>
    </sec>
    <sec id="Sec6">
     <title>
      Treatment of severe coronavirus infections
     </title>
     <p id="Par40">
      Several strategies are being considered to treat infections with MERS-CoV (
      <xref ref-type="table" rid="Tab1">
       Table 1
      </xref>
      ) and SARS-CoV, including the use of antibodies, IFNs, inhibitors of viral and host proteases, and host-directed therapies.
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Potential therapeutics for MERS
        </title>
        <p>
         <xref ref-type="media" rid="MOESM9">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Treatment
          </th>
          <th>
           Stage of development
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Host protease inhibitors
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR132">
            132
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Viral protease inhibitors
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR112">
            112
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
           ,
           <xref ref-type="bibr" rid="CR114">
            114
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Repurposed FDA-approved drugs
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR62">
            62
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
           ,
           <xref ref-type="bibr" rid="CR115">
            115
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Monoclonal and polyclonal antibodies
          </td>
          <td>
           Effective in mouse, rabbit and non-human primate models
          </td>
          <td>
           <xref ref-type="bibr" rid="CR118">
            118
           </xref>
           ,
           <xref ref-type="bibr" rid="CR119">
            119
           </xref>
           ,
           <xref ref-type="bibr" rid="CR120">
            120
           </xref>
           ,
           <xref ref-type="bibr" rid="CR121">
            121
           </xref>
           ,
           <xref ref-type="bibr" rid="CR123">
            123
           </xref>
           ,
           <xref ref-type="bibr" rid="CR124">
            124
           </xref>
           ,
           <xref ref-type="bibr" rid="CR125">
            125
           </xref>
           ,
           <xref ref-type="bibr" rid="CR126">
            126
           </xref>
           ,
           <xref ref-type="bibr" rid="CR127">
            127
           </xref>
           ,
           <xref ref-type="bibr" rid="CR128">
            128
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Convalescent plasma
          </td>
          <td>
           Effective in a mouse model; clinical trial approved
          </td>
          <td>
           <xref ref-type="bibr" rid="CR122">
            122
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Interferons
          </td>
          <td>
           Effective in non-human primate models; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR87">
            87
           </xref>
           ,
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR98">
            98
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR101">
            101
           </xref>
           ,
           <xref ref-type="bibr" rid="CR102">
            102
           </xref>
           ,
           <xref ref-type="bibr" rid="CR103">
            103
           </xref>
           ,
           <xref ref-type="bibr" rid="CR104">
            104
           </xref>
           ,
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR108">
            108
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Ribavirin
          </td>
          <td>
           Effective in a non-human primate model; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR87">
            87
           </xref>
           ,
           <xref ref-type="bibr" rid="CR88">
            88
           </xref>
           ,
           <xref ref-type="bibr" rid="CR101">
            101
           </xref>
           ,
           <xref ref-type="bibr" rid="CR102">
            102
           </xref>
           ,
           <xref ref-type="bibr" rid="CR108">
            108
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Mycophenolic acid
          </td>
          <td>
           Failed to protect in a non-human primate model
          </td>
          <td>
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Lopinavir and ritonavir
          </td>
          <td>
           Effective in a non-human primate model; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         MERS, Middle East respiratory syndrome.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="Par41">
      <bold>
       <italic>
        Current therapies.
       </italic>
      </bold>
      In the absence of a clinically proven effective antiviral therapy against SARS-CoV and MERS-CoV, patients mainly receive supportive care, which is often supplemented by different combinations of drugs.
      <xref ref-type="list" rid="Glos11">
       Ribavirin
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR86">
        86
       </xref>
      </sup>
      and various types of IFN have been given to patients with MERS in Saudi Arabia
      <sup>
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
      </sup>
      and China
      <sup>
       <xref ref-type="bibr" rid="CR88">
        88
       </xref>
      </sup>
      , typically in combination with a broad-spectrum antibiotic and oxygen. The efficacy of treatments for SARS-CoV and MERS-CoV infection currently remains unclear. In addition, treatment for MERS is typically started only in a late disease stage, when immunopathology predominates and antiviral drugs are likely to provide little benefit.
     </p>
     <p id="Par42">
      Ribavirin was used most frequently during the SARS outbreak, often in combination with corticosteroids, which have an anti-inflammatory effect
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ,
       <xref ref-type="bibr" rid="CR91">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
      </sup>
      . IFNα was also given, usually in combination with immunoglobulins or thymosins, which stimulate the development of T cells, and in a small number of cases in combination with ribavirin
      <sup>
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ,
       <xref ref-type="bibr" rid="CR94">
        94
       </xref>
      </sup>
      . None of these treatments was tested in a clinical trial, which makes it difficult to assess their efficacy. In fact, retrospective analysis did not yield a treatment combination that was clearly effective. Moreover, the data from patients are contradictory about whether ribavirin, when used alone, provided a benefit or was possibly even detrimental
      <sup>
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ,
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
       ,
       <xref ref-type="bibr" rid="CR95">
        95
       </xref>
      </sup>
      .
      <italic>
       In vitro
      </italic>
      coronaviruses have a lower sensitivity to ribavirin than other viruses. Deletion of the nsp14-encoding sequence increases the sensitivity of coronaviruses to ribavirin; however, the underlying mechanism is unclear and is not related to the proofreading function of nsp14 (Ref.
      <xref ref-type="bibr" rid="CR96">
       96
      </xref>
      ). Therefore, ribavirin should be considered only in combination with other antiviral treatments.
     </p>
     <p id="Par43">
      Although IFNs are effective against MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      , their effect in humans has yet to be proved. The effectiveness of IFN is increased
      <italic>
       in vitro
      </italic>
      if ribavirin is added
      <sup>
       <xref ref-type="bibr" rid="CR98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="CR100">
        100
       </xref>
      </sup>
      , and a combined use of the two drugs reduces disease severity in a rhesus macaque model of MERS
      <sup>
       <xref ref-type="bibr" rid="CR101">
        101
       </xref>
      </sup>
      . The potential side effects of these treatments, such as fatigue, depression and anaemia, have inhibited their use as a first-line treatment for MERS, and they are generally administered only after a patient's condition starts to deteriorate. For example, one study of five patients who were infected with MERS-CoV indicated no survival following ribavirin and IFNα2b therapy; however, therapy was not started until 10 days after admission
      <sup>
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
      </sup>
      . A separate study found an improvement in survival 14 days after MERS diagnosis and the start of treatment, but not 28 days after
      <sup>
       <xref ref-type="bibr" rid="CR102">
        102
       </xref>
      </sup>
      . In a third study, a combination of IFNα2a and ribavirin or IFNβ1a and ribavirin did not improve survival; however, some of the patients were more than 50 years old and had pre-existing renal failure
      <sup>
       <xref ref-type="bibr" rid="CR103">
        103
       </xref>
      </sup>
      . In a single case in which ribavirin and IFNα2b were started shortly after admission to hospital, the patient started to improve on day 6 after admission and made a complete recovery
      <sup>
       <xref ref-type="bibr" rid="CR104">
        104
       </xref>
      </sup>
      .
     </p>
     <p id="Par44">
      IFNβ1b is a more potent inhibitor of MERS-CoV replication
      <italic>
       in vitro
      </italic>
      than other types of IFN
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      , and an improved outcome of disease was observed in common marmosets after challenge with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      . Thus, the type of IFN that is used for treatment in humans should be reconsidered (usually, IFNα is used). Furthermore, ribavirin and/or IFNs should be tested in clinical trials to determine their efficacy in MERS treatment and to establish treatment protocols.
     </p>
     <p id="Par45">
      <bold>
       <italic>
        Additional antiviral treatments.
       </italic>
      </bold>
      The protease inhibitors lopinavir and ritonavir, which are used in combination to treat infection with HIV, improved the outcome of patients with SARS when combined with ribavirin, compared with patients who were treated with ribavirin alone
      <sup>
       <xref ref-type="bibr" rid="CR106">
        106
       </xref>
       ,
       <xref ref-type="bibr" rid="CR107">
        107
       </xref>
      </sup>
      . Lopinavir showed no clear antiviral activity against MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
      </sup>
      , and it is thus rarely used in patients with MERS. However, lopinavir and ritonavir improve the outcome in common marmosets when treatment is initiated 6 hours after infection with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      . Thus, the testing of lopinavir and ritonavir in clinical trials in patients with MERS should be reconsidered. One patient who received
      <xref ref-type="list" rid="Glos12">
       pegylated
      </xref>
      IFNα, ribavirin, lopinavir and ritonavir in combination had undetectable levels of MERS-CoV in the blood 2 days after the initiation of therapy; however, this patient did not survive
      <sup>
       <xref ref-type="bibr" rid="CR108">
        108
       </xref>
      </sup>
      . The combination of IFNα, ribavirin, lopinavir and ritonavir was also used for MERS treatment in South Korea, but efficacy data are not yet available. However, three case reports indicate recovery in five out of seven patients who were treated with this combination
      <sup>
       <xref ref-type="bibr" rid="CR109">
        109
       </xref>
       ,
       <xref ref-type="bibr" rid="CR110">
        110
       </xref>
       ,
       <xref ref-type="bibr" rid="CR111">
        111
       </xref>
      </sup>
      .
     </p>
     <p id="Par46">
      As 3CLpro and PLpro are essential for cleavage of the viral polyproteins and are distinct from cellular proteases, they are ideal drug targets, in particular PLpro, which is involved in both viral replication and IFN antagonism. Indeed, most antiviral drug-like molecules have been developed against 3CLpro and PLpro, which was aided by the rapid report of crystal structures of these proteases
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
      </sup>
      .
     </p>
     <p id="Par47">
      PLpro was initially identified as a drugable target for SARS-CoV; recently, it has been noted that some of the compounds that target PLpro from SARS-CoV are also active against PLpro from MERS-CoV. For example, both 6-mercaptopurine and 6-thioguanine inhibit MERS-CoV and SARS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
      </sup>
      ; however, the efficacy of these molecules has not yet been tested
      <italic>
       in vivo
      </italic>
      . Mycophenolic acid also inhibits the replication of MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      through the inhibition of PLpro
      <sup>
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
      </sup>
      , but it had no effect in marmosets
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      .
     </p>
     <p id="Par48">
      As new coronaviruses are likely to emerge from bats, protease inhibitors were designed against bat coronaviruses with the goal of developing a universal antiviral compound against emerging zoonotic coronaviruses. This approach yielded an inhibitor of Tylonycteris bat coronavirus HKU4 (HKU4-CoV), which is closely related to MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      . This inhibitor, named SG85, indeed inhibits MERS-CoV replication
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
      </sup>
      . Similarly,
      <xref ref-type="list" rid="Glos13">
       peptidomimetics
      </xref>
      that target and inhibit 3CLpro of MERS-CoV, HKU4-CoV and Pipistrellus bat coronavirus HKU5 (HKU5-CoV) have also been identified, but have not yet progressed beyond the
      <italic>
       in vitro
      </italic>
      stage
      <sup>
       <xref ref-type="bibr" rid="CR114">
        114
       </xref>
      </sup>
      .
     </p>
     <p id="Par49">
      Several other drugs that were approved for use in humans were shown to inhibit the replication of MERS-CoV
      <italic>
       in vitro
      </italic>
      , notably chloroquine, chlorpromazine, loperamide and cyclosporine A
      <sup>
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
       ,
       <xref ref-type="bibr" rid="CR115">
        115
       </xref>
      </sup>
      , although their mechanisms of action are unknown, and the benefit of cyclosporine A in patients is debatable owing to the immunosuppressive effect of the drug. Although cyclophilin inhibitors that do not result in immunosuppression are available, their activity against MERS-CoV has not yet been tested.
     </p>
     <p id="Par50">
      <bold>
       <italic>
        Antibody and plasma therapy.
       </italic>
      </bold>
      Plasma from convalescent patients and/or antibody therapies have been the leading proposed treatment for MERS so far
      <sup>
       <xref ref-type="bibr" rid="CR116">
        116
       </xref>
      </sup>
      . There are several potential advantages to this approach. For example, as case numbers increase, the pool of survivors becomes larger; provided these individuals have sufficiently high antibody titres and are willing and able to donate plasma, this is a low-tech, reasonably safe treatment option. Furthermore, generation of monoclonal antibodies for use in humans is well established, with a fairly straightforward path to safety and efficacy testing. However, to date, there are very few reports on the use of convalescent plasma and none on the use of monoclonal antibodies as treatments for acute, severe respiratory disease in humans. A post hoc meta-analysis of 32 studies of either SARS or severe influenza found a significant reduction in the pooled odds of mortality when convalescent plasma was used
      <sup>
       <xref ref-type="bibr" rid="CR117">
        117
       </xref>
      </sup>
      . However, study design was rated as low or very low quality, as there were generally a lack of control groups and a moderate-to-high risk of bias, which suggests that a properly designed clinical trial of convalescent plasma use in severe respiratory infections is needed
      <sup>
       <xref ref-type="bibr" rid="CR117">
        117
       </xref>
      </sup>
      . Potent monoclonal antibodies that neutralize the MERS-COV spike protein
      <italic>
       in vitro
      </italic>
      have been developed
      <sup>
       <xref ref-type="bibr" rid="CR118">
        118
       </xref>
       ,
       <xref ref-type="bibr" rid="CR119">
        119
       </xref>
       ,
       <xref ref-type="bibr" rid="CR120">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="CR121">
        121
       </xref>
      </sup>
      . However, with a few exceptions,
      <italic>
       in vivo
      </italic>
      data relating to the use of convalescent plasma or monoclonal antibodies in the treatment of MERS are currently lacking. Serum from high-titre dromedary camels decreased MERS-CoV loads in the lungs of mice that had been transduced with human DPP4 (Ref.
      <xref ref-type="bibr" rid="CR122">
       122
      </xref>
      ). Human polyclonal antibodies against the spike protein were generated by vaccinating transchromosomic bovines, and treatment with these antibodies reduced viral titres in the lungs of DPP4-transduced mice when treatment was administered 24 or 48 hours after challenge with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR123">
        123
       </xref>
      </sup>
      . DPP4-transduced mice were also treated with humanized neutralizing monoclonal antibody 4C2h, which is directed against the receptor-binding domain of the MERS-CoV spike protein, 1 day after MERS-CoV challenge, and this treatment also decreased viral titres in the lungs
      <sup>
       <xref ref-type="bibr" rid="CR124">
        124
       </xref>
      </sup>
      , as did the neutralizing antibody LCA60, which was obtained from a convalescent patient and produced recombinantly
      <sup>
       <xref ref-type="bibr" rid="CR125">
        125
       </xref>
      </sup>
      . Human neutralizing monoclonal antibodies REGN3048 and REGN3051 also provided a benefit in mice that expressed human DPP4 and were challenged with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR126">
        126
       </xref>
      </sup>
      . The human neutralizing monoclonal antibody m332 reduced MERS-CoV replication in the lungs of rabbits following prophylactic, but not therapeutic, treatment
      <sup>
       <xref ref-type="bibr" rid="CR127">
        127
       </xref>
      </sup>
      . Treatment of rhesus macaques with the human monoclonal antibody 311B-N1 day after challenge resulted in reduced lung pathology
      <sup>
       <xref ref-type="bibr" rid="CR128">
        128
       </xref>
      </sup>
      . In all of these studies, viral replication was not completely inhibited, and there were some pathological alterations to the lungs, despite the therapy. Furthermore, none of the studies addressed the potential emergence of escape mutants
      <italic>
       in vivo
      </italic>
      .
     </p>
     <p id="Par51">
      Alternatively, antibodies that target the region of DPP4 that binds to the spike protein could be used to prevent entry of MERS-CoV; this approach was successful
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR129">
        129
       </xref>
      </sup>
      . However, whether such a treatment would be feasible and would not have substantial adverse effects in humans remains to be determined.
     </p>
     <p id="Par52">
      <bold>
       <italic>
        Host-directed therapies.
       </italic>
      </bold>
      Host-directed strategies can also limit viral replication. For example, the spike protein of SARS-CoV is cleaved by cathepsin B and cathepsin L, transmembrane protease serine 2 (TMPRSS2) and possibly other host proteases
      <sup>
       <xref ref-type="bibr" rid="CR130">
        130
       </xref>
       ,
       <xref ref-type="bibr" rid="CR131">
        131
       </xref>
      </sup>
      . Inhibition of host serine proteases by camostat reduced the entry of SARS-CoV and increased survival in a mouse model
      <sup>
       <xref ref-type="bibr" rid="CR132">
        132
       </xref>
      </sup>
      . However, the targeting of host proteases is more likely to result in undesirable side effects than the targeting of viral proteases.
     </p>
     <p id="Par53">
      Another underappreciated strategy is attenuation of detrimental host responses. The development of such treatments would require a thorough understanding of the host responses that are involved in acute lung injury and ARDS, processes that are unfortunately poorly understood at the moment. Nonetheless,
      <italic>
       in vitro
      </italic>
      studies and limited studies in animal models with other respiratory viruses have shown that
      <xref ref-type="list" rid="Glos14">
       anaphylatoxin C5a
      </xref>
      is important for the development of acute lung injury, and blocking anaphylatoxin C5a can reduce lung pathology
      <sup>
       <xref ref-type="bibr" rid="CR133">
        133
       </xref>
      </sup>
      .
     </p>
     <p id="Par54">
      Changes in gene expression during
      <italic>
       in vitro
      </italic>
      MERS-CoV infection were used to predict potential effective drugs. One of the drugs with predicted efficacy, the kinase inhibitor SB203580, modestly inhibited SARS-CoV and MERS-CoV replication following the treatment of cells prior to infection, but treatment after infection inhibited replication of only SARS-CoV and not MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR134">
        134
       </xref>
      </sup>
      .
     </p>
     <p id="Par55">
      <bold>
       <italic>
        Vaccines.
       </italic>
      </bold>
      Vaccination could be used to prevent infection or to reduce disease severity, viral shedding and thereby transmission, thus helping to control MERS outbreaks. Several vaccination strategies were developed against SARS-CoV and tested in animals, such as an inactivated virus, a live-attenuated virus, viral vectors,
      <xref ref-type="list" rid="Glos15">
       subunit vaccines
      </xref>
      , recombinant proteins and
      <xref ref-type="list" rid="Glos16">
       DNA vaccines
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR135">
        135
       </xref>
       ,
       <xref ref-type="bibr" rid="CR136">
        136
       </xref>
      </sup>
      . Similar approaches have been used for the development of experimental MERS-CoV vaccines
      <sup>
       <xref ref-type="bibr" rid="CR137">
        137
       </xref>
      </sup>
      . To date, three MERS-CoV vaccines have been evaluated in non-human primates. In one study, rhesus macaques were primed with DNA encoding the spike protein, followed by boosts with spike DNA and with recombinant protein consisting of the spike subunit containing the receptor-binding domain, or primed and boosted once with the subunit protein. Both approaches reduced pathological changes in lung function in animals that were infected with MERS-CoV 19 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR138">
        138
       </xref>
      </sup>
      . Moreover, three vaccinations with a recombinantly expressed protein that contains the receptor-binding domain of the spike protein reduced viral loads and lung pathology in rhesus macaques that were infected 2 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR139">
        139
       </xref>
      </sup>
      . Three DNA vaccinations with a construct encoding the full-length spike sequence reduced viral loads and pathology in the lungs after challenge with MERS-CoV 5 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR140">
        140
       </xref>
      </sup>
      .
     </p>
     <p id="Par56">
      One concern of vaccination in humans is vaccine-mediated enhancement of disease, a process in which the disease following infection is more severe in vaccinated individuals than in unvaccinated individuals. Although this was observed in only a small subset of vaccine studies that were carried out for SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR136">
        136
       </xref>
      </sup>
      and has not yet been observed in any of the published MERS-CoV vaccine studies, it is an important concern. Moreover, it is unclear who to vaccinate against MERS-CoV, as healthy individuals seem to be at little risk of severe disease. Older patients or patients with underlying disease, who have the highest risk of severe MERS, would be important target populations. However, vaccination in such patients can be problematic owing to their poor immune responses, as has been established for influenza virus
      <sup>
       <xref ref-type="bibr" rid="CR141">
        141
       </xref>
      </sup>
      . In addition, vaccination of people with a high risk of exposure to MERS-CoV, such as health care workers, slaughterhouse workers and camel herders, is advisable
      <sup>
       <xref ref-type="bibr" rid="CR142">
        142
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec7">
     <title>
      Outlook
     </title>
     <p id="Par57">
      As our understanding of the pathogenesis of emerging coronaviruses increases, so will the opportunities for the rational design of therapeutics that target viral replication or immunopathology. The rational design of new drugs and the repurposing of existing compounds have already resulted in the development of PLpro inhibitors and the identification of kinase inhibitors that inhibit the replication of SARS-CoV and MERS-CoV
      <italic>
       in vitro
      </italic>
      . However, only a few potential treatments have progressed past the identification of an effect
      <italic>
       in vitro
      </italic>
      , and
      <italic>
       in vivo
      </italic>
      studies to select the most promising treatment options are required. The development of several mouse models of MERS is thus an important step forward (
      <xref ref-type="sec" rid="Sec8">
       Box 2
      </xref>
      ). Owing to the acute nature of MERS and the important role of immunopathology, combination therapies aimed at simultaneously inhibiting viral replication, limiting viral dissemination and dampening the host response are likely to yield the best results. Furthermore, treatment should be started as early as possible, rather than waiting until the patient has already developed extensive lung damage.
     </p>
     <p id="Par58">
      The development of therapies against SARS and MERS needs to focus on testing in humans, in properly controlled clinical trials. The current non-standardized, uncontrolled approach to treatment is not informative and may not be beneficial to the patient. The recent Ebola outbreak has demonstrated that rapid clinical trial design and approval are possible and that exceptional situations call for deviations from normal procedures (
      <xref ref-type="sec" rid="Sec9">
       Box 3
      </xref>
      ).
     </p>
     <p id="Par59">
      While treatments are being developed and evaluated, the prevention of viral transmission is key to reducing the burden of MERS. The large proportion of nosocomial MERS-CoV infections indicates that preventive measures in hospitals are currently either not fully implemented or insufficient. Prevention of zoonotic transmission from dromedary camels is another possibility to decrease the number of MERS cases. The first vaccines against MERS-CoV have been tested in dromedary camels
      <sup>
       <xref ref-type="bibr" rid="CR140">
        140
       </xref>
       ,
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
      </sup>
      ; indeed, when camels were vaccinated with a modified vaccinia virus that expresses the MERS-CoV spike protein, subsequent challenge of these animals with MERS-CoV resulted in less viral shedding than in unvaccinated animals
      <sup>
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
      </sup>
      , thereby potentially limiting the transmission to naive animals or to humans. Certainly, there has been progress in the development of vaccines and therapies against emerging coronaviruses, but more research and rigorous testing is required if we are to successfully combat these novel pathogens.
     </p>
     <sec id="Sec8">
      <boxed-text>
       <label>
        Box 2: Animal models
       </label>
       <p id="Par60">
        Most of our understanding of the pathogenesis of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) comes from animal studies. Ideally, these models recapitulate all or specific aspects of human disease. Several mouse models have been established, for example by using mouse-adapted SARS coronavirus (SARS-CoV) or expressing human receptors in mice
        <sup>
         <xref ref-type="bibr" rid="CR152">
          152
         </xref>
        </sup>
        . Although it has been recognized that mice might poorly mimic specific human responses to infection, the availability of knockout and transgenic mice enables the targeted study of virus–host interactions. Several non-human primate models have been developed for SARS-CoV and MERS coronavirus (MERS-CoV)
        <sup>
         <xref ref-type="bibr" rid="CR152">
          152
         </xref>
        </sup>
        . The close relationship of non-human primates to humans often allows faithful recapitulation of a disease and the host response. However, these benefits are countered by the need for specialized husbandry, the sometimes limited availability of the animals and reagents, and high costs.
       </p>
       <p id="Par61">
        The pathogenesis of SARS-CoV and MERS-CoV in their respective reservoir hosts is not nearly as well studied as that in humans. Currently, only one experimental-infection study has been carried out in bats with MERS-CoV
        <sup>
         <xref ref-type="bibr" rid="CR153">
          153
         </xref>
        </sup>
        , and none has been carried out for other coronaviruses. Thus, data are mostly limited to the detection of coronaviruses in naturally infected bats. The detection of coronaviruses mainly in faecal samples from bats and not in oral swabs suggests that replication in bats occurs predominantly in the gastrointestinal tract
        <sup>
         <xref ref-type="bibr" rid="CR9">
          9
         </xref>
         ,
         <xref ref-type="bibr" rid="CR154">
          154
         </xref>
         ,
         <xref ref-type="bibr" rid="CR155">
          155
         </xref>
        </sup>
        . By contrast, a combination of intratracheal and intranasal inoculation of masked palm civets with SARS-CoV resulted in interstitial pneumonia, with oral and rectal viral shedding
        <sup>
         <xref ref-type="bibr" rid="CR156">
          156
         </xref>
        </sup>
        .
       </p>
       <p id="Par62">
        The pathogenesis of MERS-CoV in dromedary camels has been studied experimentally in a limited number of animals. These animals developed transient mild disease; however, large quantities of MERS-CoV were shed from the upper respiratory tract, in line with the predominant replication of MERS-CoV in the nasal turbinates and larynx in these animals, which explains the frequent zoonotic transmission
        <sup>
         <xref ref-type="bibr" rid="CR157">
          157
         </xref>
        </sup>
        .
       </p>
      </boxed-text>
     </sec>
     <sec id="Sec9">
      <boxed-text>
       <label>
        Box 3: Preparing for emerging viruses: lessons from SARS-CoV, MERS-CoV and Ebola virus
       </label>
       <p id="Par63">
        When the severe acute respiratory syndrome (SARS) outbreak developed into the first pandemic of the twenty-first century, it became clear that the medical and scientific communities were not adequately prepared for the emergence of highly pathogenic viruses. Whereas several months elapsed and several thousand cases of SARS were observed before the causative agent was identified as SARS coronavirus (SARS-CoV)
        <sup>
         <xref ref-type="bibr" rid="CR4">
          4
         </xref>
         ,
         <xref ref-type="bibr" rid="CR5">
          5
         </xref>
         ,
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
        </sup>
        , subsequent advances in molecular diagnostic tools, such as next generation sequencing, meant that Middle East respiratory syndrome coronavirus (MERS-CoV) was identified before it caused a large outbreak of MERS
        <sup>
         <xref ref-type="bibr" rid="CR11">
          11
         </xref>
        </sup>
        . The availability of the full-length genome of MERS-CoV enabled the rapid development and distribution of diagnostic assays. The first animal models of disease, several treatment efficacy studies and the identification of the reservoir followed soon after. Unfortunately, the SARS pandemic did not yield solid clinical data on the efficacy of treatment regimens. These data are urgently needed for the treatment of MERS, as well as to prepare for novel coronaviruses that may emerge. Several studies have used synthetic biology to study the zoonotic transmission potential of SARS-CoV-like viruses from bats
        <sup>
         <xref ref-type="bibr" rid="CR9">
          9
         </xref>
         ,
         <xref ref-type="bibr" rid="CR10">
          10
         </xref>
         ,
         <xref ref-type="bibr" rid="CR158">
          158
         </xref>
         ,
         <xref ref-type="bibr" rid="CR159">
          159
         </xref>
        </sup>
        .
       </p>
       <p id="Par64">
        The Ebola virus outbreak in West Africa has highlighted the need for fast-tracking of potential treatments, as several clinical trials were started only towards the end of the outbreak. The combined experiences of the outbreaks of SARS, MERS and Ebola provide a blueprint for the response to emerging pathogens: after the identification of the causative agent, diagnostic assays need to be developed and distributed rapidly, and simultaneously, awareness of the new syndrome and reporting of (suspected) cases must be increased. In addition, infection control measures in health care facilities are essential. Research needs to focus on understanding the epidemiology, including pathogen transmission and identification of the reservoir and/or intermediate hosts. Animal models need to be developed, as well as therapeutic and prophylactic measures. Finally, promising treatments need to be fast-tracked into clinical trials.
       </p>
      </boxed-text>
     </sec>
    </sec>
    <back>
     <app-group>
      <app id="App1">
       <sec id="Sec10">
        <title>
         PowerPoint slides
        </title>
        <p id="Par66">
         <media id="MOESM6" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM6_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 1
           </p>
          </caption>
         </media>
         <media id="MOESM7" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM7_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 2
           </p>
          </caption>
         </media>
         <media id="MOESM8" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM8_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 3
           </p>
          </caption>
         </media>
        </p>
        <p id="Par67">
         <media id="MOESM9" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM9_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Table 1
           </p>
          </caption>
         </media>
        </p>
       </sec>
      </app>
     </app-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health.
      </p>
     </ack>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par65">
       The authors declare no competing financial interests.
      </p>
     </notes>
     <glossary>
      <title>
       Glossary
      </title>
      <def-list>
       <def-item id="Glos1">
        <term>
         Nosocomial transmission
        </term>
        <def>
         <p>
          Transmission of an infectious agent by staff, equipment or the environment in a health care setting.
         </p>
        </def>
       </def-item>
       <def-item id="Glos2">
        <term>
         Proofreading
        </term>
        <def>
         <p>
          The correction of errors that are acquired during the replication of DNA or RNA.
         </p>
        </def>
       </def-item>
       <def-item id="Glos3">
        <term>
         ER–Golgi intermediate compartment
        </term>
        <def>
         <p>
          (ERGIC). A cellular compartment that facilitates transport between the endoplasmic reticulum (ER) and the Golgi complex.
         </p>
        </def>
       </def-item>
       <def-item id="Glos4">
        <term>
         Super spreaders
        </term>
        <def>
         <p>
          Infected individuals who each infect a disproportionately large number of secondary cases.
         </p>
        </def>
       </def-item>
       <def-item id="Glos5">
        <term>
         Acute respiratory distress syndrome
        </term>
        <def>
         <p>
          (ARDS). A life-threatening condition in which the accumulation of fluid and inflammatory cells in the lungs decreases the exchange of oxygen and carbon dioxide to dangerously low levels.
         </p>
        </def>
       </def-item>
       <def-item id="Glos6">
        <term>
         Collaborative Cross mouse
        </term>
        <def>
         <p>
          One of a panel of recombinant inbred mouse strains derived from a genetically diverse set of founder strains and designed for the analysis of complex traits.
         </p>
        </def>
       </def-item>
       <def-item id="Glos7">
        <term>
         Perivascular cuffing
        </term>
        <def>
         <p>
          The aggregation of leukocytes around blood vessels.
         </p>
        </def>
       </def-item>
       <def-item id="Glos8">
        <term>
         Type I IFNs
        </term>
        <def>
         <p>
          (Type I interferons). A group of IFNs, including IFNα and IFNβ, with immune-modulating and antiviral functions.
         </p>
        </def>
       </def-item>
       <def-item id="Glos9">
        <term>
         RNAi
        </term>
        <def>
         <p>
          A biological process in which small RNA molecules induce the degradation of specific mRNA molecules, thereby inhibiting gene expression.
         </p>
        </def>
       </def-item>
       <def-item id="Glos10">
        <term>
         Minireplicon systems
        </term>
        <def>
         <p>
          Systems in which a DNA molecule is produced that contains the viral leader and trailer sequences, with an assayable reporter replacing the viral ORFs. When combined with the expression of viral proteins in
          <italic>
           trans
          </italic>
          , this system can be used to model the viral life cycle without the necessity of using infectious virus.
         </p>
        </def>
       </def-item>
       <def-item id="Glos11">
        <term>
         Ribavirin
        </term>
        <def>
         <p>
          A broadly active antiviral nucleoside analogue with several direct and indirect mechanisms of action; mainly used for the treatment of hepatitis C, in combination with interferon.
         </p>
        </def>
       </def-item>
       <def-item id="Glos12">
        <term>
         Pegylated
        </term>
        <def>
         <p>
          Having polyethylene glycol (PEG) attached, to a drug for example; this moiety improves the solubility, decreases the immunogenicity and increases the stability, of the drug of interest, thereby allowing a reduced dosing frequency to be used.
         </p>
        </def>
       </def-item>
       <def-item id="Glos13">
        <term>
         Peptidomimetics
        </term>
        <def>
         <p>
          Compounds that mimic biologically active peptides or proteins.
         </p>
        </def>
       </def-item>
       <def-item id="Glos14">
        <term>
         Anaphylatoxin C5a
        </term>
        <def>
         <p>
          A complement-activated molecule that is important for the recruitment to and activation of inflammatory cells in the lungs.
         </p>
        </def>
       </def-item>
       <def-item id="Glos15">
        <term>
         Subunit vaccines
        </term>
        <def>
         <p>
          Vaccines that contain immunogenic parts of a pathogen rather than the entire pathogen.
         </p>
        </def>
       </def-item>
       <def-item id="Glos16">
        <term>
         DNA vaccines
        </term>
        <def>
         <p>
          Vaccines based on the direct introduction of a plasmid encoding an antigen; following
          <italic>
           in situ
          </italic>
          production of this antigen, an immune response is mounted against it.
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         99
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         14726162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7
       </label>
       <mixed-citation publication-type="other">
        WHO. Summary of probably SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
        <italic>
         WHO
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2004_04_21/en/">
         http://www.who.int/csr/sars/country/table2004_04_21/en/
        </ext-link>
        (2004).
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1860
        </fpage>
        <lpage>
         1865
        </lpage>
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         1508
        </fpage>
        <lpage>
         1513
        </lpage>
        <pub-id pub-id-type="pmid">
         26552008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation
        </article-title>
        <source>
         East. Mediterr. Health J.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <fpage>
         S12
        </fpage>
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wise
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patient with new strain of coronavirus is treated in intensive care at London hospital
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2012
        </year>
        <volume>
         345
        </volume>
        <fpage>
         e6455
        </fpage>
        <pub-id pub-id-type="pmid">
         23008211
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14
       </label>
       <mixed-citation publication-type="other">
        Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015.
        <italic>
         Osong Public Health Res. Perspect.
        </italic>
        <bold>
         6
        </bold>
        , 269–278 (2015).
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15
       </label>
       <mixed-citation publication-type="other">
        WHO. Coronavirus infections: disease outbreak news.
        <italic>
         WHO
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/26-april-2016-mers-saudi-arabia/en/">
         http://www.who.int/csr/don/26-april-2016-mers-saudi-arabia/en/
        </ext-link>
        (2016).
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pasternak
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nidovirus transcription: how to make sense...?
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         1403
        </fpage>
        <lpage>
         1421
        </lpage>
        <pub-id pub-id-type="pmid">
         16690906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         1282
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knoops
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
        </article-title>
        <source>
         PLoS Biol.
        </source>
        <year>
         2008
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e226
        </fpage>
        <pub-id pub-id-type="pmid">
         18798692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <year>
         2003
        </year>
        <volume>
         331
        </volume>
        <fpage>
         991
        </fpage>
        <lpage>
         1004
        </lpage>
        <pub-id pub-id-type="pmid">
         12927536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infidelity of SARS-CoV nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000896
        </fpage>
        <pub-id pub-id-type="pmid">
         20463816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sevajol
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Subissi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Decroly
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Canard
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Imbert
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         90
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         25451065
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <year>
         2013
        </year>
        <fpage>
         825
        </fpage>
        <lpage>
         858
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Review of bats and SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1840
        </lpage>
        <pub-id pub-id-type="pmid">
         17326933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         101
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         24184128
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralizing serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus in dromedary camel herd, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1231
        </fpage>
        <lpage>
         1234
        </lpage>
        <pub-id pub-id-type="pmid">
         24964193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         2093
        </fpage>
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study
        </article-title>
        <source>
         BMC Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         13
        </volume>
        <fpage>
         210
        </fpage>
        <pub-id pub-id-type="pmid">
         26336062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         647
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic
        </article-title>
        <source>
         Philos. Trans. R. Soc. Lond. B. Biol. Sci.
        </source>
        <year>
         2004
        </year>
        <volume>
         359
        </volume>
        <fpage>
         1091
        </fpage>
        <lpage>
         1105
        </lpage>
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         7
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         62
        </volume>
        <fpage>
         755
        </fpage>
        <lpage>
         760
        </lpage>
        <pub-id pub-id-type="pmid">
         26679623
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         14
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015
        </article-title>
        <source>
         J. Korean Med. Sci.
        </source>
        <year>
         2015
        </year>
        <volume>
         30
        </volume>
        <fpage>
         1701
        </fpage>
        <lpage>
         1705
        </lpage>
        <pub-id pub-id-type="pmid">
         26539018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS, SARS, and Ebola: the role of super-spreaders in infectious disease
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2015
        </year>
        <volume>
         18
        </volume>
        <fpage>
         398
        </fpage>
        <lpage>
         401
        </lpage>
        <pub-id pub-id-type="pmid">
         26468744
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        <volume>
         436
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         61
        </volume>
        <fpage>
         275
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         25073585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Binnie
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           dos Santos
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biomarkers in acute respiratory distress syndrome
        </article-title>
        <source>
         Curr. Opin. Crit. Care
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         24296379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Chambers
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The mercurial nature of neutrophils: still an enigma in ARDS?
        </article-title>
        <source>
         Am. J. Physiol. Lung Cell. Mol. Physiol.
        </source>
        <year>
         2014
        </year>
        <volume>
         306
        </volume>
        <fpage>
         L217
        </fpage>
        <lpage>
         L230
        </lpage>
        <pub-id pub-id-type="pmid">
         24318116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baas
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Taubenberger
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Katze
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV virus–host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues
        </article-title>
        <source>
         J. Interferon Cytokine Res.
        </source>
        <year>
         2006
        </year>
        <volume>
         26
        </volume>
        <fpage>
         309
        </fpage>
        <lpage>
         317
        </lpage>
        <pub-id pub-id-type="pmid">
         16689659
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faure
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e88716
        </fpage>
        <pub-id pub-id-type="pmid">
         24551142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Salto-Tellez
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         145
        </volume>
        <fpage>
         260
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         19635508
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         51
        </volume>
        <fpage>
         2333
        </fpage>
        <lpage>
         2340
        </lpage>
        <pub-id pub-id-type="pmid">
         16195357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         8692
        </fpage>
        <lpage>
         8706
        </lpage>
        <pub-id pub-id-type="pmid">
         17537853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genome wide identification of SARS-CoV susceptibility loci using the Collaborative Cross
        </article-title>
        <source>
         PLoS Genet.
        </source>
        <year>
         2015
        </year>
        <volume>
         11
        </volume>
        <fpage>
         e1005504
        </fpage>
        <pub-id pub-id-type="pmid">
         26452100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Thomsen
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         2900
        </fpage>
        <lpage>
         2910
        </lpage>
        <pub-id pub-id-type="pmid">
         22258243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000849
        </fpage>
        <pub-id pub-id-type="pmid">
         20386712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2008
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e1000240
        </fpage>
        <pub-id pub-id-type="pmid">
         19079579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-coronavirus replication induces severe
         <italic>
          in vitro
         </italic>
         cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1749
        </fpage>
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="pmid">
         23620378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         5927
        </fpage>
        <lpage>
         5940
        </lpage>
        <pub-id pub-id-type="pmid">
         16731931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bouvet
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         <italic>
          In vitro
         </italic>
         reconstitution of SARS-coronavirus mRNA cap methylation
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000863
        </fpage>
        <pub-id pub-id-type="pmid">
         20421945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-O-methyltransferase activity
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4251
        </fpage>
        <lpage>
         4264
        </lpage>
        <pub-id pub-id-type="pmid">
         24478444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         191
        </fpage>
        <lpage>
         199
        </lpage>
        <pub-id pub-id-type="pmid">
         25278144
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         9029
        </fpage>
        <lpage>
         9043
        </lpage>
        <pub-id pub-id-type="pmid">
         26085159
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism
        </article-title>
        <source>
         Virus Genes
        </source>
        <year>
         2011
        </year>
        <volume>
         42
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="pmid">
         20976535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12489
        </fpage>
        <lpage>
         12495
        </lpage>
        <pub-id pub-id-type="pmid">
         24027320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4866
        </fpage>
        <lpage>
         4876
        </lpage>
        <pub-id pub-id-type="pmid">
         24522921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists
        </article-title>
        <source>
         Protein Cell
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         951
        </fpage>
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2015
        </year>
        <volume>
         5
        </volume>
        <fpage>
         17554
        </fpage>
        <pub-id pub-id-type="pmid">
         26631542
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         6689
        </fpage>
        <lpage>
         6705
        </lpage>
        <pub-id pub-id-type="pmid">
         19369340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Devaraj
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2007
        </year>
        <volume>
         282
        </volume>
        <fpage>
         32208
        </fpage>
        <lpage>
         32221
        </lpage>
        <pub-id pub-id-type="pmid">
         17761676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity
        </article-title>
        <source>
         Virol. J.
        </source>
        <year>
         2014
        </year>
        <volume>
         11
        </volume>
        <fpage>
         209
        </fpage>
        <pub-id pub-id-type="pmid">
         25481026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bailey-Elkin
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2014
        </year>
        <volume>
         289
        </volume>
        <fpage>
         34667
        </fpage>
        <lpage>
         34682
        </lpage>
        <pub-id pub-id-type="pmid">
         25320088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2011
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e1002433
        </fpage>
        <pub-id pub-id-type="pmid">
         22174690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lokugamage
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         A two-pronged strategy to suppress host protein synthesis by SARS coronavirus nsp1 protein
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <year>
         2009
        </year>
        <volume>
         16
        </volume>
        <fpage>
         1134
        </fpage>
        <lpage>
         1140
        </lpage>
        <pub-id pub-id-type="pmid">
         19838190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Matsuura
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         11128
        </fpage>
        <lpage>
         11137
        </lpage>
        <pub-id pub-id-type="pmid">
         22855488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wathelet
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Orr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         11620
        </fpage>
        <lpage>
         11633
        </lpage>
        <pub-id pub-id-type="pmid">
         17715225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lokugamage
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         10970
        </fpage>
        <lpage>
         10981
        </lpage>
        <pub-id pub-id-type="pmid">
         26311885
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freundt
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lenardo
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           XN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         6631
        </fpage>
        <lpage>
         6640
        </lpage>
        <pub-id pub-id-type="pmid">
         19403678
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kopecky-Bromberg
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Sobrido
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Palese
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         548
        </fpage>
        <lpage>
         557
        </lpage>
        <pub-id pub-id-type="pmid">
         17108024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MAVS-mediated apoptosis and its inhibition by viral proteins
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2009
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e5466
        </fpage>
        <pub-id pub-id-type="pmid">
         19404494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e01174-14
        </fpage>
        <pub-id pub-id-type="pmid">
         24846384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graci
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of ribavirin against distinct viruses
        </article-title>
        <source>
         Rev. Med. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         16
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         16287208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         42
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical analysis of the first patient with imported Middle East respiratory syndrome in China
        </article-title>
        <source>
         Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
        </source>
        <year>
         2015
        </year>
        <volume>
         27
        </volume>
        <fpage>
         630
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         26255008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        <volume>
         289
        </volume>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
        <pub-id pub-id-type="pmid">
         12734147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1995
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           So
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of a standard treatment protocol for severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1615
        </fpage>
        <lpage>
         1617
        </lpage>
        <pub-id pub-id-type="pmid">
         12747883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        <volume>
         290
        </volume>
        <fpage>
         3222
        </fpage>
        <lpage>
         3228
        </lpage>
        <pub-id pub-id-type="pmid">
         14693875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         713
        </fpage>
        <lpage>
         717
        </lpage>
        <pub-id pub-id-type="pmid">
         12781012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Surdel
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2013
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e1003565
        </fpage>
        <pub-id pub-id-type="pmid">
         23966862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2013
        </year>
        <volume>
         3
        </volume>
        <fpage>
         1686
        </fpage>
        <pub-id pub-id-type="pmid">
         23594967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Baer
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2005
        </year>
        <volume>
         326
        </volume>
        <fpage>
         905
        </fpage>
        <lpage>
         908
        </lpage>
        <pub-id pub-id-type="pmid">
         15607755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         1090
        </fpage>
        <lpage>
         1095
        </lpage>
        <pub-id pub-id-type="pmid">
         25278221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
        </article-title>
        <source>
         J. Antimicrob. Chemother.
        </source>
        <year>
         2015
        </year>
        <volume>
         70
        </volume>
        <fpage>
         2129
        </fpage>
        <lpage>
         2132
        </lpage>
        <pub-id pub-id-type="pmid">
         25900158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         87
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         24831606
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        <source>
         Hong Kong Med. J.
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2004
        </year>
        <volume>
         59
        </volume>
        <fpage>
         252
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spanakis
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
        </article-title>
        <source>
         Int. J. Antimicrob. Agents
        </source>
        <year>
         2014
        </year>
        <volume>
         44
        </volume>
        <fpage>
         528
        </fpage>
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         25288266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome-coronavirus infection: a case report of serial computed tomographic findings in a young male patient
        </article-title>
        <source>
         Korean J. Radiol
        </source>
        <year>
         2016
        </year>
        <volume>
         17
        </volume>
        <fpage>
         166
        </fpage>
        <lpage>
         170
        </lpage>
        <pub-id pub-id-type="pmid">
         26798230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        110
       </label>
       <mixed-citation publication-type="other">
        Kim, U. J., Won, E. J., Kee, S. J., Jung, S. I. &amp; Jang, H. C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome: a case report.
        <italic>
         Antivir. Ther.
        </italic>
        10.3851/IMP3002 (2015).
       </mixed-citation>
      </ref>
      <ref id="CR111">
       <label>
        111
       </label>
       <mixed-citation publication-type="other">
        Rhee, J. Y., Hong, G. &amp; Ryu, K. M. Clinical implications of five cases of Middle East respiratory syndrome coronavirus infection in South Korea Outbreak.
        <italic>
         Jpn J. Infect. Dis.
        </italic>
        10.7883/yoken.JJID.2015.445 (2016).
       </mixed-citation>
      </ref>
      <ref id="CR112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilgenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
        </article-title>
        <source>
         FEBS J.
        </source>
        <year>
         2014
        </year>
        <volume>
         281
        </volume>
        <fpage>
         4085
        </fpage>
        <lpage>
         4096
        </lpage>
        <pub-id pub-id-type="pmid">
         25039866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR114">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tomar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CL
         <sup>
          pro
         </sup>
         ): implications for nsp5 regulation and the development of antivirals
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2015
        </year>
        <volume>
         290
        </volume>
        <fpage>
         19403
        </fpage>
        <lpage>
         19422
        </lpage>
        <pub-id pub-id-type="pmid">
         26055715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR115">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        <source>
         Antimicrob. Agents Chemother.
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <fpage>
         4875
        </fpage>
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR116">
       <label>
        116
       </label>
       <mixed-citation publication-type="other">
        International Severe Acute Respiratory &amp; Emerging Infection Consortium. Treatment of MERS-CoV: decision support tool.
        <italic>
         International Severe Acute Respiratory &amp; Emerging Infection Consortium
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="https://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf">
         https://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf
        </ext-link>
        (updated 29 July 2013).
       </mixed-citation>
      </ref>
      <ref id="CR117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         211
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7045
        </fpage>
        <lpage>
         7053
        </lpage>
        <pub-id pub-id-type="pmid">
         24719424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR119">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <fpage>
         234ra59
        </fpage>
        <pub-id pub-id-type="pmid">
         24778414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR120">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           XC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         E2018
        </fpage>
        <lpage>
         E2026
        </lpage>
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7796
        </fpage>
        <lpage>
         7805
        </lpage>
        <pub-id pub-id-type="pmid">
         24789777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR122">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         6117
        </fpage>
        <lpage>
         6120
        </lpage>
        <pub-id pub-id-type="pmid">
         25787284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR123">
       <label>
        123
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luke
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2016
        </year>
        <volume>
         8
        </volume>
        <fpage>
         326ra21
        </fpage>
        <pub-id pub-id-type="pmid">
         26888429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR124">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1237
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="pmid">
         26391698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR125">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         10473
        </fpage>
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR126">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascal
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         8738
        </fpage>
        <lpage>
         8743
        </lpage>
        <pub-id pub-id-type="pmid">
         26124093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR127">
       <label>
        127
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houser
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylaxis with a MERS-CoV-specific human monoclonal antibody protects rabbits from MERS-CoV infection
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         1557
        </fpage>
        <lpage>
         1561
        </lpage>
        <pub-id pub-id-type="pmid">
         26941283
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR128">
       <label>
        128
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2016
        </year>
        <volume>
         490
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         58
        </lpage>
        <pub-id pub-id-type="pmid">
         26828465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR129">
       <label>
        129
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohnuma
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         13892
        </fpage>
        <lpage>
         13899
        </lpage>
        <pub-id pub-id-type="pmid">
         24067970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR130">
       <label>
        130
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elshabrawy
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4353
        </fpage>
        <lpage>
         4365
        </lpage>
        <pub-id pub-id-type="pmid">
         24501399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR131">
       <label>
        131
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR132">
       <label>
        132
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         116
        </volume>
        <fpage>
         76
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR133">
       <label>
        133
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of C5a in acute lung injury induced by highly pathogenic viral infections
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <year>
         2015
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e28
        </fpage>
        <pub-id pub-id-type="pmid">
         26060601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR134">
       <label>
        134
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Josset
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e00165
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         23631916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR135">
       <label>
        135
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: strategies for controlling emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR136">
       <label>
        136
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Rehm
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS vaccines: where are we?
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2009
        </year>
        <volume>
         8
        </volume>
        <fpage>
         887
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="pmid">
         19538115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR137">
       <label>
        137
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: current status and future prospects for vaccine development
        </article-title>
        <source>
         Expert Opin. Biol. Ther.
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         1647
        </fpage>
        <lpage>
         1651
        </lpage>
        <pub-id pub-id-type="pmid">
         26414077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR138">
       <label>
        138
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         7712
        </fpage>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR139">
       <label>
        139
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge
        </article-title>
        <source>
         EBioMedicine
        </source>
        <year>
         2015
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1438
        </fpage>
        <lpage>
         1446
        </lpage>
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR140">
       <label>
        140
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         7
        </volume>
        <fpage>
         301ra132
        </fpage>
        <pub-id pub-id-type="pmid">
         26290414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR141">
       <label>
        141
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mastalerz-Migas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bujnowska-Fedak
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brydak
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune efficacy of first and repeat trivalent influenza vaccine in healthy subjects and hemodialysis patients
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         836
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         25248348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR142">
       <label>
        142
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         629
        </fpage>
        <pub-id pub-id-type="pmid">
         26008827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR143">
       <label>
        143
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR144">
       <label>
        144
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR145">
       <label>
        145
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         141
        </volume>
        <fpage>
         662
        </fpage>
        <lpage>
         673
        </lpage>
        <pub-id pub-id-type="pmid">
         15520422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR146">
       <label>
        146
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR147">
       <label>
        147
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         59
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR148">
       <label>
        148
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         25303830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR149">
       <label>
        149
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         210
        </volume>
        <fpage>
         1590
        </fpage>
        <lpage>
         1594
        </lpage>
        <pub-id pub-id-type="pmid">
         24837403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR150">
       <label>
        150
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feikin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         2029
        </fpage>
        <lpage>
         2035
        </lpage>
        <pub-id pub-id-type="pmid">
         26488195
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR151">
       <label>
        151
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Kluberg
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Mekaru
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Brownstein
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mortality risk factors for Middle East respiratory syndrome outbreak, South Korea, 2015
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         2088
        </fpage>
        <lpage>
         2090
        </lpage>
        <pub-id pub-id-type="pmid">
         26488869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR152">
       <label>
        152
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gretebeck
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models for SARS and MERS coronaviruses
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         13
        </volume>
        <fpage>
         123
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         26184451
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR153">
       <label>
        153
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in Jamaican fruit bats (
         <italic>
          Artibeus jamaicensis
         </italic>
         )
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2016
        </year>
        <volume>
         6
        </volume>
        <fpage>
         21878
        </fpage>
        <pub-id pub-id-type="pmid">
         26899616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR154">
       <label>
        154
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR155">
       <label>
        155
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        <volume>
         310
        </volume>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR156">
       <label>
        156
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2620
        </fpage>
        <lpage>
         2625
        </lpage>
        <pub-id pub-id-type="pmid">
         15681462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR157">
       <label>
        157
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1999
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR158">
       <label>
        158
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2008
        </year>
        <volume>
         105
        </volume>
        <fpage>
         19944
        </fpage>
        <lpage>
         19949
        </lpage>
        <pub-id pub-id-type="pmid">
         19036930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR159">
       <label>
        159
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-like WIV1-CoV poised for human emergence
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2016
        </year>
        <volume>
         113
        </volume>
        <fpage>
         3048
        </fpage>
        <lpage>
         3053
        </lpage>
        <pub-id pub-id-type="pmid">
         26976607
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Biomed Res Int
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Biomed Res Int
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       BMRI
      </journal-id>
      <journal-title-group>
       <journal-title>
        BioMed Research International
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2314-6133
      </issn>
      <issn pub-type="epub">
       2314-6141
      </issn>
      <publisher>
       <publisher-name>
        Hindawi Publishing Corporation
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27243037
      </article-id>
      <article-id pub-id-type="pmc">
       4868892
      </article-id>
      <article-id pub-id-type="doi">
       10.1155/2016/8560691
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Feline Coronavirus 3c Protein: A Candidate for a Virulence Marker?
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hora
         </surname>
         <given-names>
          A. S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          *
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tonietti
         </surname>
         <given-names>
          P. O.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Taniwaki
         </surname>
         <given-names>
          S. A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Asano
         </surname>
         <given-names>
          K. M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Maiorka
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Richtzenhain
         </surname>
         <given-names>
          L. J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Brandão
         </surname>
         <given-names>
          P. E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="I1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="I2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="I1">
       <sup>
        1
       </sup>
       Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of São Paulo, Avenida Professor Dr. Orlando Marques de Paiva 87, Cidade Universitária, 05508-270 São Paulo, SP, Brazil
      </aff>
      <aff id="I2">
       <sup>
        2
       </sup>
       Coronavirus Research Group, School of Veterinary Medicine, University of São Paulo, Avenida Professor Dr. Orlando Marques de Paiva 87, Cidade Universitária, 05508-270 São Paulo, SP, Brazil
      </aff>
      <aff id="I3">
       <sup>
        3
       </sup>
       Department of Pathology, School of Veterinary Medicine, University of São Paulo, Avenida Professor Dr. Orlando Marques de Paiva 87, Cidade Universitária, 05508-270 São Paulo, SP, Brazil
      </aff>
      <author-notes>
       <corresp id="cor1">
        *A. S. Hora:
        <email>
         alineshora@gmail.com
        </email>
       </corresp>
       <fn fn-type="other">
        <p>
         Academic Editor: Nikolai V. Ravin
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        5
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       2016
      </volume>
      <elocation-id>
       8560691
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         2
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         1
        </day>
        <month>
         4
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         4
        </month>
        <year>
         2016
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2016 A. S. Hora et al.
       </copyright-statement>
       <copyright-year>
        2016
       </copyright-year>
       <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Feline infectious peritonitis virus (FIPV) is highly virulent and responsible for the highly fatal disease feline infectious peritonitis (FIP), whereas feline enteric coronavirus (FECV) is widespread among the feline population and typically causes asymptomatic infections. Some candidates for genetic markers capable of differentiating these two pathotypes of a unique virus (feline coronavirus) have been proposed by several studies. In the present survey, in order to search for markers that can differentiate FECV and FIPV, several clones of the 3a–c, E, and M genes were sequenced from samples obtained from cats with or without FIP. All genes showed genetic diversity and suggested the presence of FCoV mutant spectrum capable of producing a virulent pathotype in an individual-specific way. In addition, all the feline coronavirus FIPV strains demonstrated a truncated 3c protein, and the 3c gene was the only observed pathotypic marker for FCoVs, showing that 3c gene is a candidate marker for the distinction between the two pathotypes when the mutant spectrum is taken into account.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec id="sec1">
     <title>
      1. Introduction
     </title>
     <p>
      Feline coronavirus (FCoV) (
      <italic>
       Nidovirales; Coronaviridae; Coronavirinae; Alphacoronavirus 1
      </italic>
      ) is a widespread pathogen among the domestic cat population. FCoV occurs as two pathotypes, feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV), both of which with strains of serotypes I and II [
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ].
     </p>
     <p>
      Phenotypically, the main difference between the pathotypes is that FIPV is able to infect monocytes and macrophages, causing systemic infection and fatal disease, while FECV is limited to replication in the mature intestinal epithelium, which mainly results in asymptomatic infection. However, FECV may undergo a short systemic viremia phase that also involves monocytes [
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      ].
     </p>
     <p>
      The FCoV genome (single-stranded positive-sense linear RNA, 29 kb) encodes proteins directly involved in viral replication (ORF1), the structural spike protein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein (N), as well as the accessory proteins 3a–c and 7a-b [
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ].
     </p>
     <p>
      There is a major controversy regarding the existence of genetic markers to differentiate between FECV and FIPV pathotypes [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ]. Numerous markers that correlate with the manifestation of FIP have been proposed for S [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      –
      <xref ref-type="bibr" rid="B12">
       12
      </xref>
      ], 3a–c [
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      –
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      ], 7a-b [
      <xref ref-type="bibr" rid="B16">
       16
      </xref>
      –
      <xref ref-type="bibr" rid="B18">
       18
      </xref>
      ], and M [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ] genes.
     </p>
     <p>
      The most studied gene is 3c [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      –
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ], which is present in the truncated form in the majority of all strains obtained from animals with FIP. However, previous studies on 3c genes focused only on the dominant sequence and not on the mutant spectrum or the clonal diversity and the information obtained from a dominant sequence may not be suitable to detect mutations [
      <xref ref-type="bibr" rid="B10">
       10
      </xref>
      ], with the exception of a study [
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ] in which clones were used to assess the presence of alterations in the gene 3c in ascites and/or faeces from FIP and healthy cats, and again 3c truncated protein was not observed in 100% of FIPV samples.
     </p>
     <p>
      Considering (i) the current discussion on molecular markers capable of distinguishing the pathotypes of FCoV and (ii) the lack of knowledge of the diversity of such markers in the mutant spectrum of RNA, the present study was designed to investigate the clonal diversity of the 3a–c, E, and M genes in FCoV strains present in tissue and/or faecal samples from cats with and without FIP.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      2. Materials and Methods
     </title>
     <sec id="sec2.1">
      <title>
       2.1. Animals and Samples
      </title>
      <p>
       From 2010 to 2013, tissue (eye, cerebrum, cerebellum, lung, heart muscle, thoracic lymph node, thymus, liver, spleen, stomach, mesenteric lymph node, peripancreatic lymph node, kidneys, large and small intestines, and urinary bladder), abdominal, thoracic, and pericardial effusions, aqueous humor, and faecal samples were collected during the necropsies of 6 cats with clinical manifestations and histopathological changes consistent with FIP, such as localized inflammation with macrophages, neutrophils, lymphocytes, and plasma cells. Vascular lesions were found surrounded by a proliferation of inflammatory cells in heart, lung, omentum, kidneys, cerebrum, and cerebellum. Focal accumulations of inflammatory cells and necrotic-proliferative lesions were observed in granulomatous lesions. Intestinal samples were collected including mucosa, submucosa, muscular layer, and serosa. Only 2 animals (USP6, and USP7) showed signs of dry-form FIP (neurological changes), while the remaining 4 (USP8, USP16, USP17, and USP18) showed an accumulation of effusion in body cavities (effusive FIP).
      </p>
      <p>
       All FIP-positive cats were sampled from different geographic locations, with the exception of 2 cats (USP17 and USP18) that lived in the same house. USP17 was euthanized 1 month prior to USP18 due to FIP related reasons.
      </p>
      <p>
       In parallel, faecal samples were also obtained from 2 cats (USP2, and USP14) without clinical signs of FIP and from two different locations not related to the locations from the FIP+ cats.
      </p>
      <p>
       This study has been approved by Commission on Ethics on Animal Use from School of Veterinary Medicine, University of São Paulo (CEUA N. 2055211113).
      </p>
     </sec>
     <sec id="sec2.2">
      <title>
       2.2. Messenger RNA Detection for the M Gene of FCoVs
      </title>
      <p>
       All tissues were complete homogenized after tissue maceration and before RNA extraction. Total RNA extraction and RT-PCR to detect mRNA of the M gene of FCoVs were performed in all samples as previously described [
       <xref ref-type="bibr" rid="B21">
        21
       </xref>
       ] as a screening test for FCoV replication.
      </p>
     </sec>
     <sec id="sec2.3">
      <title>
       2.3. Amplification of the 3a–c, E, and M Genes of FCoVs
      </title>
      <p>
       All samples from 6FIP+ and 2FIP− cats were submitted to amplification of the 3a–c, E, and M genes of FCoVs, even if the mRNA detection was negative. To amplify all these five genes of FCoVs in only one amplicon, a single pair of previously described primers [
       <xref ref-type="bibr" rid="B14">
        14
       </xref>
       ] was used (nucleotides 24,380 to 26,996 corresponding to the FCoV-WSU 79-1146; genome GenBank DQ010921).
      </p>
      <p>
       cDNA synthesis was performed with 6
       <italic>
        μ
       </italic>
       L total RNA extracted with TRIzol
       <italic>
        ™
       </italic>
       Reagent (Life Technologies Corporation, Carlsbad, CA, USA) and ThermoScript
       <italic>
        ™
       </italic>
       (Life Technologies Corporation, Carlsbad, CA, USA) using Random Primers
       <italic>
        ™
       </italic>
       (Life Technologies Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions.
      </p>
      <p>
       For PCR, 5
       <italic>
        μ
       </italic>
       L of cDNA was added to 1x PCR buffer (Life Technologies Corporation, Carlsbad, CA, USA), 2 mM MgSO
       <sub>
        4
       </sub>
       , 0.2 mM of each dNTP, 0.25
       <italic>
        μ
       </italic>
       M of each primer, 1.5 U Platinum
       <italic>
        ™
       </italic>
       Taq DNA Polymerase High Fidelity (Life Technologies Corporation, Carlsbad, CA, USA), and DEPC water for a final reaction volume of 50
       <italic>
        μ
       </italic>
       L. The cycling conditions were as follows: 94°C/2 min; 10 cycles of 94°C/15 s, 50°C/15 s with an increase of 0.5°C per cycle, and 68°C/4 min; 10 cycles of 94°C/15 s, 55°C/15 s, and 68°C/4 min; 25 additional cycles of 94°C/15 s, 55°C/15 s, and 68°C/4 min with an increase of 10 s per cycle; and a final extension of 72°C/10 min.
      </p>
      <p>
       Specific bands were excised from the gels and purified using the Gene Jet
       <italic>
        ™
       </italic>
       Gel Extraction kit (Thermo Fisher Scientific Inc., Vilnius, Lithuania) according to the manufacturer's instructions.
      </p>
     </sec>
     <sec id="sec2.4">
      <title>
       2.4. Molecular Cloning
      </title>
      <p>
       The purified amplicons (2,617 bp containing 3abc-E-M) were cloned using pGEM
       <italic>
        ™
       </italic>
       -T Easy Vector Systems (Promega Madison, WI, USA) and
       <italic>
        E. coli
       </italic>
       JM109 competent cells according to the manufacturer's recommendations. After the transformation protocol, transformation culture was plated onto duplicate LB/ampicillin/IPTG/X-Gal plates and the plates were incubated overnight (16 hours) at 37°C. Then, the transformed colonies were transferred to LB liquid medium and were incubated overnight (16 hours) at 37°C and 180 rpm. Recombinant plasmid extraction was performed with the Illustra
       <italic>
        ™
       </italic>
       plasmidPrep Mini Spin Kit (GE Healthcare, Buckinghamshire, UK) as per manufacturer's recommendations.
      </p>
      <p>
       For an easier identification of the clones, the following nomenclature was used: cat identification/sample source/presence (+) or absence (−) of FIP/cat origin/clone number.
      </p>
     </sec>
     <sec id="sec2.5">
      <title>
       2.5. DNA Sequencing
      </title>
      <p>
       Sense primers were designed at approximately every 500 nucleotides to obtain full coverage of genes 3a–c, E, and M (
       <xref ref-type="table" rid="tab1">
        Table 1
       </xref>
       ). Primers for the plasmid (pUC/M13F and R) were also used to reach the full length of the amplicon sequence.
      </p>
      <p>
       DNA sequencing with each primer in duplicate was performed using the BigDye
       <italic>
        ™
       </italic>
       Terminator v3.1 Cycle Sequencing Kit (Life Technologies Corporation, Carlsbad, CA, USA) with a Genetic Analyzer 3500
       <italic>
        ™
       </italic>
       capillary sequencer (Applied Biosystems Foster City, CA, USA), according to the manufacturers' instructions.
      </p>
     </sec>
     <sec id="sec2.6">
      <title>
       2.6. Sequence Editing
      </title>
      <p>
       Chromatograms were generated in duplicate for each segment and evaluated for their base quality using the online application Phred (
       <ext-link ext-link-type="uri" xlink:href="http://asparagin.cenargen.embrapa.br/phph/">
        http://asparagin.cenargen.embrapa.br/phph/
       </ext-link>
       ). Only those chromatograms with scores greater than 20 (probability lower than 1 error per 100 nucleotides) were used. The chromatograms were analyzed and manually edited with the software FinchTV version 1.4 (
       <ext-link ext-link-type="uri" xlink:href="http://www.geospiza.com/Products/finchtv.shtml">
        http://www.geospiza.com/Products/finchtv.shtml
       </ext-link>
       ). The final sequences of each sample were obtained using the CAP contig application with the software BioEdit version 7.0.9.0 [
       <xref ref-type="bibr" rid="B22">
        22
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.7">
      <title>
       2.7. Phylogenetic Analyses
      </title>
      <p>
       The nucleotides and amino acids corresponding to the 3a–c, E, and M genes were aligned using the application Clustal/W in BioEdit 7.0.9.0 [
       <xref ref-type="bibr" rid="B22">
        22
       </xref>
       ]. Clones were classified in serotypes based on comparative analysis of the amino acid sequences encoded by the 3a gene with the sequences available in GenBank (serotype I: DQ160294 and DQ848678 and serotype II: DQ010921). Nucleotide phylogenetic trees (neighbor-joining, MCL model, 1,000 bootstrap replicates) were constructed using the computer software Mega version 5.05 [
       <xref ref-type="bibr" rid="B23">
        23
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      3. Results
     </title>
     <sec id="sec3.1">
      <title>
       3.1. Messenger RNA Detection for the M Gene and Amplification, Sequencing, and Cloning of the 3a–c, E, and M Genes of FCoVs
      </title>
      <p>
       mRNA was not obtained from all samples; nevertheless sequences for the 3a–c, E, and M amplicons were obtained from a total of 292 clones originating from 8 animals [6FIP+ (USP6, USP7, USP8, USP17, USP16, and USP18) and 2FIP− (USP2 and USP14)]. Sequences from extraintestinal tissue samples and faecal/intestines samples were obtained simultaneously for 3 animals (USP6, USP7, and USP17) with FIP (
       <xref ref-type="table" rid="tab2">
        Table 2
       </xref>
       ). Due to poor sequence quality for some clones and/or regions in a clone, not all full length amplicons could be sequenced or used in the analyses. The sequences obtained in the present study were deposited in GenBank under access numbers KJ879334 to KJ879438.
      </p>
     </sec>
     <sec id="sec3.2">
      <title>
       3.2. Phylogenetic Analysis of the 3a–c, E, and M Genes of FCoVs
      </title>
      <p>
       All sequences of the 3a genes obtained from a total of 79 clones belong to serotype I. Phylogenetic trees generated for the 3a, 3c, E, and M genes showed similar topologies and thus only the 3c and 3b trees are shown (Figures
       <xref ref-type="fig" rid="fig1">
        1
       </xref>
       and
       <xref ref-type="fig" rid="fig2">
        2
       </xref>
       , resp.). Sample from cat USP14 (non-FIP) showed a remarkable clonal diversity as their clones are present in five different clusters of the 3b tree. High clonal diversity was observed in samples from FIP+ (USP8, USP16, USP17, and USP18) and FIP− cat (USP14); however FIP+ cats USP6 and USP7 and USP2 FIP− cat showed a lower clonal diversity. In the 3c gene tree, for cats USP6 and USP7, differences can be noticed between the FCoV strains obtained from tissue and faecal clones; that is, for each animal, there was a distinction between systemic (FIPV) and enteric (FECV) strains. However, no generic grouping per pathotype (FECV or FIPV) was observed for all samples and trees generated from this study.
      </p>
      <p>
       Conversely, in the 3b gene tree samples obtained from cat USP7 (FIP+) could not be separated into systemic (cerebrum) and enteric (faeces) strains.
      </p>
      <p>
       The overall nucleotide identity of all clones (FIP+ and FIP−) obtained from the 5 genes was ≥92.09% for faecal samples and ≥90.09% for tissue samples (
       <xref ref-type="table" rid="tab3">
        Table 3
       </xref>
       ). The greatest nucleotide diversity when all available sequences for each gene were compared together was observed for the 3b gene, for which a 90.09% identity was found, with the exception of comparisons between cats living in the same house, for which the identity between the 3b gene sequences was 97.09%.
      </p>
      <p>
       For tissue and faecal samples, 3a was the most conserved gene (nucleotide identities of 99.38% and 97.70%, resp.) considering each individual cat. The mean identity between clones from the two cohabitating FIP+ cats (USP17 and USP18) ranged from 96.17% (3c gene) to 99.83% (E gene).
      </p>
      <p>
       Premature stop codons were observed in the 3a (USP18, 3/3 cerebrum clones), 3b (USP17, 1/8 cerebrum; USP7, 1/10 faeces), 3c (USP17, 8/8 cerebrum and 2/2 large intestine; USP18, 2/2 cerebrum; USP7, 2/2 cerebrum; USP16, 1/9 cerebrum; USP8, 1/1 stomach; USP6, 6/6 stomach), and M (USP7, 1/5 cerebrum) genes from FIP+ cats. No premature stop codon in the 3a–c or E genes was observed in faecal samples from cats without FIP, with exception of M gene (USP2, 1/6 faeces).
      </p>
      <p>
       Stop codons in 3c were evident in at least one of the clones from tissue samples from cats with FIP. The faecal samples from cats with or without FIP did not demonstrate this truncated gene in any of the clones, and no other molecular marker capable of differentiating the biotypes (FECV and FIPV) was observed in the sequenced genes.
      </p>
     </sec>
    </sec>
    <sec id="sec4">
     <title>
      4. Discussion and Conclusions
     </title>
     <p>
      The existence of genetic markers to differentiate these two biotypes is currently a topic of the highest interest on the FIP field not only from the clinical and epidemiological points of view but also as a basis for an in-deep comprehension of the pathogenesis of this highly complex disease. Considering that, in the present study, clones of structural (E and M) and accessory (3a–c) genes were obtained from cats with and without FIP, and the results demonstrate a highly likely candidate FCoV pathotypic marker in the 3c gene.
     </p>
     <p>
      Amplicons obtained from the cerebrum and large intestine of the cat USP17 (FIP+) were also cloned and sequenced. When assessing the 46 clones (32 clones from cerebrum and 14 from large intestine) obtained from this cat, the nucleotide identity among the five genes was greater than 99%, and according to the phylogenetic trees generated, clones from this cat resulted in a single cluster. In the 3c gene, a single nucleotide transversion (G → T) was observed at position 10 in all clones from samples from this cat, resulting in premature stop codons and truncated proteins. The observation of truncated proteins in large intestine observed herein is in contrast to what has been observed for FECV in other studies [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ].
     </p>
     <p>
      Possibly because it serves as a preferential organ for viral replication and therefore for pathological changes in FIP cases, the intestine of the cat USP17 (FIP+) was also affected by the systemic strain. Chang et al. [
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ] suggested that viruses with an inactivated 3c gene rarely replicate in the intestine, which helps to explain the rare incidence of FIP outbreaks due to a less frequent faecal-oral transmission. A premature stop codon in the 3c gene was previously reported in a strain of FCoV from the jejunum of a cat with FIP, and the same intestinal strain showed 100% identity with a strain obtained from a liver sample of the same cat [
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ].
     </p>
     <p>
      In recent studies [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ], 3c genes with premature termination were detected in faecal and extraintestinal samples from cats with FIP, although it was not determined whether the viruses were replicating. Also, after an experimental inoculation of cats with truncated and complete 3abc, the role of the truncation in this region on FIP pathogenesis could not be clearly determined, despite it led to lower viral replication in the gut [
      <xref ref-type="bibr" rid="B24">
       24
      </xref>
      ]. However, in the present study, the sample from the large intestine of the cat USP17 (FIP+), from which the studied clones originated and which demonstrated a truncated 3c gene, was positive for FCoV mRNA. This result indicated the presence of viral replication in that sample.
     </p>
     <p>
      When comparing the sequences obtained from the extraintestinal organs and faeces of the FIP+ cats USP7 and USP6, the presence of a premature stop codon in the 3c gene was not observed in faecal clones from both cats, in contrast to what was observed for tissue clones. Moreover, the nucleotide identity of the 3c gene for tissue and faecal samples was 99.09% and 95.58% for the cats USP7 and USP6, respectively. In a study comparing FCoV from extraintestinal FIP lesions and the faeces of the same cat, the identity between the sequences of the structural and accessory genes evaluated (S, M, N, E, 3a–c and 7a-b) was always higher than 99%, corroborating the hypothesis of
      <italic>
       in vivo
      </italic>
      mutation [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ].
     </p>
     <p>
      As FIPV lineages may be derived from FECV mutations, it was expected that nucleotide diversity between faecal and tissue samples from the cat USP6 (FIP+) would be lower. However, the difference was 8.84% for the 3b genes, consisting exclusively in point mutations, indicating that this cat could be coinfected with an FCoV strain that is distinct from the systemic strain. Furthermore, the high nucleotide identity between samples from the cerebrum and faeces of the cat USP7 (FIP+), along with the topology of the generated trees, showed that the intestinal viral replication of the enteric pathotype may be maintained even during FIP in some cases, as demonstrated by the presence of mRNA.
     </p>
     <p>
      As previously described and according with results from the present study, FIPV can both emerge endogenously and be transmitted to different cats as a “ready” virulent pathotype, which has major implications for the understanding of the dynamics of viral transmission [
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B21">
       21
      </xref>
      ].
     </p>
     <p>
      Among the structural proteins genes (E and M) studied herein, premature stop codons were detected only in the M gene. The M protein of FCoVs is the most abundant structural protein [
      <xref ref-type="bibr" rid="B25">
       25
      </xref>
      ]. The presence of a premature stop codon in a constitutive gene such as the M gene is incompatible with the functionality of the virion. However, this defective virus is no less important than the others, as it provides genetic background for recombination with other FCoVs, resulting in greater genetic diversity and possibly increased virulence of some viral quasispecies. Recent studies suggest that the 3c gene, which encodes a small protein (238aa) of unknown function, is associated with most FIPV isolates when present in truncated form, although not all FCoV strains in FIP+ samples present this 3c form [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ]. In the present study, the 3c truncated protein was observed in all clones obtained from tissue samples from FIP+ cats, with the exception of those obtained from the cat USP16, where only 11% (1/9) of the clones demonstrated the truncated protein.
     </p>
     <p>
      It is essential to note that if the predominant viral population in the present study had been assessed by direct amplicon sequencing only, as in studies conducted by other authors [
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      –
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20">
       20
      </xref>
      ], without using the previous cloning step, the truncated 3c gene could have been undetected as it was only present in a minority of the sequences observed in the cerebrum of the cat USP16 (FIP+).
     </p>
     <p>
      The transversions observed at position 10 of the 3c gene, which resulted in premature stop codons, were the same as those observed in the clone sequences obtained from the cerebrum and stomach of the FIP+ cats USP17 and USP6, respectively. With the exception of this finding and in agreement with the results of Pedersen et al. [
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15">
       15
      </xref>
      ], the 3c gene mutations were unique to each cat, including the sequences obtained from the cohabitating FIP+ cats (USP17 and USP18).
     </p>
     <p>
      It can be concluded that the presence of a truncated 3c protein is a suggestive factor for differentiation between the FECV and FIPV pathotypes and therefore serves as a genetic marker of virulence. It still remains to be answered whether 3c is expendable for FCoV replication in phagocytic cells and a nontruncated 3c is thus selected-against during the FECV/FIPV transition. Moreover, the 3a–c, E, and M genes showed a level of genetic diversity indicative of the constitution of FCoV quasispecies or mutant spectrum and the likelihood of emergence of a highly virulent, individual-specific biotype.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       Funding for this study was provided by Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (Grants nos. 09/17535-9 and 10/07492-8), Conselho Nacional de Desenvolvimento Científico e Tecnológico (Grant no. 300513/2010-0), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES/PROEX 2327/2015). The authors are also grateful to the veterinarians and cat owners who provided FIP cases and cat faecal samples for this study.
      </p>
     </ack>
     <sec>
      <title>
       Competing Interests
      </title>
      <p>
       None of the authors has any financial or personal relationships that could inappropriately influence or bias the content of the paper.
      </p>
     </sec>
     <ref-list>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N. C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of feline infectious peritonitis virus infection: 1963–2008
        </article-title>
        <source>
         <italic>
          Journal of Feline Medicine and Surgery
         </italic>
        </source>
        <year>
         2009
        </year>
        <volume>
         11
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         225
        </fpage>
        <lpage>
         258
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jfms.2008.09.008
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-61749103803
        </pub-id>
        <pub-id pub-id-type="pmid">
         19254859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kipar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Meli
          </surname>
          <given-names>
           M. L.
          </given-names>
         </name>
         <name>
          <surname>
           Baptiste
          </surname>
          <given-names>
           K. E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowker
          </surname>
          <given-names>
           L. J.
          </given-names>
         </name>
         <name>
          <surname>
           Lutz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sites of feline coronavirus persistence in healthy cats
        </article-title>
        <source>
         <italic>
          Journal of General Virology
         </italic>
        </source>
        <year>
         2010
        </year>
        <volume>
         91
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1698
        </fpage>
        <lpage>
         1707
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.020214-0
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-77954153941
        </pub-id>
        <pub-id pub-id-type="pmid">
         20237226
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           van der Lubben
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           te Lintelo
          </surname>
          <given-names>
           E. G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenic characteristics of persistent feline enteric coronavirus infection in cats
        </article-title>
        <source>
         <italic>
          Veterinary Research
         </italic>
        </source>
        <year>
         2010
        </year>
        <volume>
         41
        </volume>
        <issue>
         5, article 71
        </issue>
        <pub-id pub-id-type="doi">
         10.1051/vetres/2010043
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-77957834658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P. S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        <source>
         <italic>
          Advances in Virus Research
         </italic>
        </source>
        <year>
         2006
        </year>
        <volume>
         65
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         292
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/s0065-3527(06)66005-3
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-33746317830
        </pub-id>
        <pub-id pub-id-type="pmid">
         16877062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         <name>
          <surname>
           Troyer
          </surname>
          <given-names>
           J. L.
          </given-names>
         </name>
         <name>
          <surname>
           Pecon-Slattery
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Roelke
          </surname>
          <given-names>
           M. E.
          </given-names>
         </name>
         <name>
          <surname>
           O'Brien
          </surname>
          <given-names>
           S. J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetics and pathogenesis of feline infectious peritonitis virus
        </article-title>
        <source>
         <italic>
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         1445
        </fpage>
        <lpage>
         1452
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1509.081573
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-70249097413
        </pub-id>
        <pub-id pub-id-type="pmid">
         19788813
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dye
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S. G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic RNA sequence of feline coronavirus strain FCoV C1Je
        </article-title>
        <source>
         <italic>
          Journal of Feline Medicine and Surgery
         </italic>
        </source>
        <year>
         2007
        </year>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         202
        </fpage>
        <lpage>
         213
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jfms.2006.12.002
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-34248550456
        </pub-id>
        <pub-id pub-id-type="pmid">
         17363313
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bank-Wolf
          </surname>
          <given-names>
           B. R.
          </given-names>
         </name>
         <name>
          <surname>
           Stallkamp
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Wiese
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Moritz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tekes
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           H.-J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mutations of 3c and spike protein genes correlate with the occurrence of feline infectious peritonitis
        </article-title>
        <source>
         <italic>
          Veterinary Microbiology
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         173
        </volume>
        <issue>
         3-4
        </issue>
        <fpage>
         177
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2014.07.020
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84908226321
        </pub-id>
        <pub-id pub-id-type="pmid">
         25150756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           H.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Egberink
          </surname>
          <given-names>
           H. F.
          </given-names>
         </name>
         <name>
          <surname>
           Halpin
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Spiro
          </surname>
          <given-names>
           D. J.
          </given-names>
         </name>
         <name>
          <surname>
           Rottie
          </surname>
          <given-names>
           P. J. M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spike protein fusion peptide and feline coronavirus virulence
        </article-title>
        <source>
         <italic>
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2012
        </year>
        <volume>
         18
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1089
        </fpage>
        <lpage>
         1095
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1807.120143
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84862509132
        </pub-id>
        <pub-id pub-id-type="pmid">
         22709821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genotyping coronaviruses associated with feline infectious peritonitis
        </article-title>
        <source>
         <italic>
          Journal of General Virology
         </italic>
        </source>
        <year>
         2015
        </year>
        <volume>
         96
        </volume>
        <fpage>
         1358
        </fpage>
        <lpage>
         1368
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.000084
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84937611387
        </pub-id>
        <pub-id pub-id-type="pmid">
         25667330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Licitra
          </surname>
          <given-names>
           B. N.
          </given-names>
         </name>
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J. K.
          </given-names>
         </name>
         <name>
          <surname>
           Regan
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mutation in spike protein cleavage site and pathogenesis of feline coronavirus
        </article-title>
        <source>
         <italic>
          Emerging Infectious Diseases
         </italic>
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1066
        </fpage>
        <lpage>
         1073
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1907.121094
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84879160321
        </pub-id>
        <pub-id pub-id-type="pmid">
         23763835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Regan
          </surname>
          <given-names>
           A. D.
          </given-names>
         </name>
         <name>
          <surname>
           Shraybman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           R. D.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G. R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses
        </article-title>
        <source>
         <italic>
          Veterinary Microbiology
         </italic>
        </source>
        <year>
         2008
        </year>
        <volume>
         132
        </volume>
        <issue>
         3-4
        </issue>
        <fpage>
         235
        </fpage>
        <lpage>
         248
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2008.05.019
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-53549129721
        </pub-id>
        <pub-id pub-id-type="pmid">
         18606506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P. J. M.
          </given-names>
         </name>
         <name>
          <surname>
           Nakamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Schellen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Volders
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Haijema
          </surname>
          <given-names>
           B. J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein
        </article-title>
        <source>
         <italic>
          Journal of Virology
         </italic>
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <issue>
         22
        </issue>
        <fpage>
         14122
        </fpage>
        <lpage>
         14130
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.22.14122-14130.2005
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-27644491880
        </pub-id>
        <pub-id pub-id-type="pmid">
         16254347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           L.-E.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           W.-P.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           D.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Chueh
          </surname>
          <given-names>
           L.-L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         3C protein of feline coronavirus inhibits viral replication independently of the autophagy pathway
        </article-title>
        <source>
         <italic>
          Research in Veterinary Science
         </italic>
        </source>
        <year>
         2013
        </year>
        <volume>
         95
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         1241
        </fpage>
        <lpage>
         1247
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.rvsc.2013.08.011
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84888015689
        </pub-id>
        <pub-id pub-id-type="pmid">
         24050534
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N. C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           K. A.
          </given-names>
         </name>
         <name>
          <surname>
           Pesavento
          </surname>
          <given-names>
           P. A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Significance of coronavirus mutants in feces and diseased tissues of cats suffering from feline infectious peritonitis
        </article-title>
        <source>
         <italic>
          Viruses
         </italic>
        </source>
        <year>
         2009
        </year>
        <volume>
         1
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         166
        </fpage>
        <lpage>
         184
        </lpage>
        <pub-id pub-id-type="doi">
         10.3390/v1020166
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-76449100762
        </pub-id>
        <pub-id pub-id-type="pmid">
         21994544
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N. C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Scarlett
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Feline infectious peritonitis: role of the feline coronavirus 3c gene in intestinal tropism and pathogenicity based upon isolates from resident and adopted shelter cats
        </article-title>
        <source>
         <italic>
          Virus Research
         </italic>
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         17
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2011.12.020
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84862776927
        </pub-id>
        <pub-id pub-id-type="pmid">
         22280883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vennema
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Poland
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Foley
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N. C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses
        </article-title>
        <source>
         <italic>
          Virology
         </italic>
        </source>
        <year>
         1998
        </year>
        <volume>
         243
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         150
        </fpage>
        <lpage>
         157
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/viro.1998.9045
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-0032579804
        </pub-id>
        <pub-id pub-id-type="pmid">
         9527924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dedeurwaerder
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Olyslaegers
          </surname>
          <given-names>
           D. A. J.
          </given-names>
         </name>
         <name>
          <surname>
           Desmarets
          </surname>
          <given-names>
           L. M. B.
          </given-names>
         </name>
         <name>
          <surname>
           Roukaerts
          </surname>
          <given-names>
           I. D. M.
          </given-names>
         </name>
         <name>
          <surname>
           Theuns
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nauwynck
          </surname>
          <given-names>
           H. J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ORF7-encoded accessory protein 7a of feline infectious peritonitis virus as a counteragent against IFN-
         <italic>
          α
         </italic>
         -induced antiviral response
        </article-title>
        <source>
         <italic>
          Journal of General Virology
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         393
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.058743-0
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84892582752
        </pub-id>
        <pub-id pub-id-type="pmid">
         24189622
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kennedy
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Boedeker
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gibbs
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kania
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Deletions in the 7a ORF of feline coronavirus associated with an epidemic of feline infectious peritonitis
        </article-title>
        <source>
         <italic>
          Veterinary Microbiology
         </italic>
        </source>
        <year>
         2001
        </year>
        <volume>
         81
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         227
        </fpage>
        <lpage>
         234
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0378-1135(01)00354-6
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-0035828241
        </pub-id>
        <pub-id pub-id-type="pmid">
         11390106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Borschensky
          </surname>
          <given-names>
           C. M.
          </given-names>
         </name>
         <name>
          <surname>
           Reinacher
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mutations in the 3c and 7b genes of feline coronavirus in spontaneously affected FIP cats
        </article-title>
        <source>
         <italic>
          Research in Veterinary Science
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         97
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         333
        </fpage>
        <lpage>
         340
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.rvsc.2014.07.016
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84925182505
        </pub-id>
        <pub-id pub-id-type="pmid">
         25128417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           H.-W.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R. J.
          </given-names>
         </name>
         <name>
          <surname>
           Egberink
          </surname>
          <given-names>
           H. F.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P. J. M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feline infectious peritonitis: Insights into feline coronavirus pathobiogenesis and epidemiology based on genetic analysis of the viral 3c gene
        </article-title>
        <source>
         <italic>
          Journal of General Virology
         </italic>
        </source>
        <year>
         2010
        </year>
        <volume>
         91
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         415
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.016485-0
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-76249091386
        </pub-id>
        <pub-id pub-id-type="pmid">
         19889934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hora
          </surname>
          <given-names>
           A. S.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           K. M.
          </given-names>
         </name>
         <name>
          <surname>
           Guerra
          </surname>
          <given-names>
           J. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intrahost diversity of feline coronavirus: a consensus between the circulating virulent/avirulent strains and the internal mutation hypotheses?
        </article-title>
        <source>
         <italic>
          The Scientific World Journal
         </italic>
        </source>
        <year>
         2013
        </year>
        <volume>
         2013
        </volume>
        <fpage>
         8
        </fpage>
        <pub-id pub-id-type="publisher-id">
         572325
        </pub-id>
        <pub-id pub-id-type="doi">
         10.1155/2013/572325
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84876570390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           T. A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
        </article-title>
        <source>
         <italic>
          Nucleic Acids Symposium Series
         </italic>
        </source>
        <year>
         1999
        </year>
        <volume>
         41
        </volume>
        <fpage>
         95
        </fpage>
        <lpage>
         98
        </lpage>
       </element-citation>
      </ref>
      <ref id="B23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Nei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods
        </article-title>
        <source>
         <italic>
          Molecular Biology and Evolution
         </italic>
        </source>
        <year>
         2011
        </year>
        <volume>
         28
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         2731
        </fpage>
        <lpage>
         2739
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/molbev/msr121
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-79957613599
        </pub-id>
        <pub-id pub-id-type="pmid">
         21546353
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bálint
          </surname>
          <given-names>
           Á.
          </given-names>
         </name>
         <name>
          <surname>
           Farsang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zádori
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Belák
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative
         <italic>
          in vivo
         </italic>
         analysis of recombinant type II feline coronaviruses with truncated and completed ORF3 region
        </article-title>
        <source>
         <italic>
          PLoS ONE
         </italic>
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <pub-id pub-id-type="publisher-id">
         e88758
        </pub-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0088758
        </pub-id>
        <pub-id pub-id-type="other">
         2-s2.0-84896756703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25">
       <label>
        25
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P. J. M.
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S. G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus membrane glycoprotein
        </article-title>
        <source>
         <italic>
          The Coronaviridae
         </italic>
        </source>
        <year>
         1995
        </year>
        <publisher-loc>
         New York, NY, USA
        </publisher-loc>
        <publisher-name>
         Plenum Press
        </publisher-name>
        <fpage>
         115
        </fpage>
        <lpage>
         140
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="fig1" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Phylogenetic tree constructed using the neighbor-joining method and the maximum composite likelihood substitution model for the FCoV 3c gene. The numbers next to each node represent the values of 1,000 bootstrap repetitions, and only those above 50% are shown. The scale represents the number of substitutions per site. For easy identification of the samples, the following nomenclature was used: cat identification/sample source/presence (+) or absence (−) of FIP/cat origin/clone number.
       </p>
      </caption>
      <graphic xlink:href="BMRI2016-8560691.001">
      </graphic>
     </fig>
     <fig id="fig2" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Phylogenetic tree constructed using the neighbor-joining method and the maximum composite likelihood substitution model for the FCoV 3b gene. The numbers next to each node represent the values of 1,000 bootstrap repetitions, and only those above 50% are shown. The scale represents the number of substitutions per site. For easy identification of the samples, the following nomenclature was used: cat identification/sample source/presence (+) or absence (−) of FIP/cat origin/clone number.
       </p>
      </caption>
      <graphic xlink:href="BMRI2016-8560691.002">
      </graphic>
     </fig>
     <table-wrap id="tab1" orientation="portrait" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Primers used to obtain full coverage of genes 3a–c, E, and M.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Primers
         </th>
         <th align="center" colspan="1" rowspan="1">
          Sequence (5′-3′)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Position
          <sup>
           a
          </sup>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          2B
         </td>
         <td align="center" colspan="1" rowspan="1">
          YATYACWGTKTAYRABTT
         </td>
         <td align="center" colspan="1" rowspan="1">
          487–505
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          3B
         </td>
         <td align="center" colspan="1" rowspan="1">
          ACRACWYTNAKKTTTGTA
         </td>
         <td align="center" colspan="1" rowspan="1">
          1058–1075
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          4B
         </td>
         <td align="center" colspan="1" rowspan="1">
          AATAGCATTGCTAAATRT
         </td>
         <td align="center" colspan="1" rowspan="1">
          1479–1496
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          5B
         </td>
         <td align="center" colspan="1" rowspan="1">
          CGGCTTTAGTRTYGCAGG
         </td>
         <td align="center" colspan="1" rowspan="1">
          1999–2008
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          a
         </sup>
         Position defined according to genome FCoV-WSU 79-1146 (DQ010921).
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="tab2" orientation="portrait" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Identification, sorting according to the presence of FIP detection of mRNA FCoVs, and the number of clones obtained from cats.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="3">
          ID
         </th>
         <th align="center" colspan="1" rowspan="3">
          Location
         </th>
         <th align="center" colspan="1" rowspan="3">
          FIP
         </th>
         <th align="center" colspan="1" rowspan="3">
          Sample
         </th>
         <th align="center" colspan="1" rowspan="3">
          mRNA
         </th>
         <th align="center" colspan="5" rowspan="1">
          Number of clones obtained from each gene
         </th>
         <th align="center" colspan="1" rowspan="3">
          Total
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1">
          E
         </th>
         <th align="center" colspan="1" rowspan="1">
          M
         </th>
         <th align="center" colspan="1" rowspan="1">
          3a
         </th>
         <th align="center" colspan="1" rowspan="1">
          3b
         </th>
         <th align="center" colspan="1" rowspan="1">
          3c
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1">
          249nt
         </th>
         <th align="center" colspan="1" rowspan="1">
          792nt
         </th>
         <th align="center" colspan="1" rowspan="1">
          213nt
         </th>
         <th align="center" colspan="1" rowspan="1">
          222nt
         </th>
         <th align="center" colspan="1" rowspan="1">
          714nt
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP2
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          Absent
         </td>
         <td align="center" colspan="1" rowspan="1">
          Faeces
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          6
         </td>
         <td align="center" colspan="1" rowspan="1">
          6
         </td>
         <td align="center" colspan="1" rowspan="1">
          6
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          26
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2">
          USP6
         </td>
         <td align="center" colspan="1" rowspan="2">
          7
         </td>
         <td align="center" colspan="1" rowspan="2">
          Noneffusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Stomach
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          10
         </td>
         <td align="center" colspan="1" rowspan="1">
          11
         </td>
         <td align="center" colspan="1" rowspan="1">
          10
         </td>
         <td align="center" colspan="1" rowspan="1">
          9
         </td>
         <td align="center" colspan="1" rowspan="1">
          6
         </td>
         <td align="center" colspan="1" rowspan="1">
          46
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Faeces
         </td>
         <td align="center" colspan="1" rowspan="1">
          Neg
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          8
         </td>
         <td align="center" colspan="1" rowspan="1">
          7
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          23
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2">
          USP7
         </td>
         <td align="center" colspan="1" rowspan="2">
          3
         </td>
         <td align="center" colspan="1" rowspan="2">
          Noneffusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Cerebrum
         </td>
         <td align="center" colspan="1" rowspan="1">
          Neg
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          22
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Faeces
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          7
         </td>
         <td align="center" colspan="1" rowspan="1">
          10
         </td>
         <td align="center" colspan="1" rowspan="1">
          10
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          35
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2">
          USP8
         </td>
         <td align="center" colspan="1" rowspan="2">
          6
         </td>
         <td align="center" colspan="1" rowspan="2">
          Effusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Stomach
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Urinary bladder
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          8
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2">
          USP17
         </td>
         <td align="center" colspan="1" rowspan="2">
          2
         </td>
         <td align="center" colspan="1" rowspan="2">
          Effusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Cerebrum
         </td>
         <td align="center" colspan="1" rowspan="1">
          Neg
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          8
         </td>
         <td align="center" colspan="1" rowspan="1">
          8
         </td>
         <td align="center" colspan="1" rowspan="1">
          8
         </td>
         <td align="center" colspan="1" rowspan="1">
          32
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1">
          Large intestine
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          14
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP14
         </td>
         <td align="center" colspan="1" rowspan="1">
          4
         </td>
         <td align="center" colspan="1" rowspan="1">
          Absent
         </td>
         <td align="center" colspan="1" rowspan="1">
          Faeces
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          1
         </td>
         <td align="center" colspan="1" rowspan="1">
          12
         </td>
         <td align="center" colspan="1" rowspan="1">
          12
         </td>
         <td align="center" colspan="1" rowspan="1">
          9
         </td>
         <td align="center" colspan="1" rowspan="1">
          35
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP16
         </td>
         <td align="center" colspan="1" rowspan="1">
          5
         </td>
         <td align="center" colspan="1" rowspan="1">
          Effusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Cerebrum
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          6
         </td>
         <td align="center" colspan="1" rowspan="1">
          0
         </td>
         <td align="center" colspan="1" rowspan="1">
          9
         </td>
         <td align="center" colspan="1" rowspan="1">
          9
         </td>
         <td align="center" colspan="1" rowspan="1">
          9
         </td>
         <td align="center" colspan="1" rowspan="1">
          33
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP18
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          Effusive
         </td>
         <td align="center" colspan="1" rowspan="1">
          Cerebrum
         </td>
         <td align="center" colspan="1" rowspan="1">
          Pos
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          3
         </td>
         <td align="center" colspan="1" rowspan="1">
          2
         </td>
         <td align="center" colspan="1" rowspan="1">
          13
         </td>
        </tr>
        <tr>
         <td align="center" colspan="11" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="5" rowspan="1">
          Total of clones (
          <italic>
           n
          </italic>
          = 292)
         </td>
         <td align="center" colspan="1" rowspan="1">
          38
         </td>
         <td align="center" colspan="1" rowspan="1">
          43
         </td>
         <td align="center" colspan="1" rowspan="1">
          79
         </td>
         <td align="center" colspan="1" rowspan="1">
          77
         </td>
         <td align="center" colspan="1" rowspan="1">
          55
         </td>
         <td align="center" colspan="1" rowspan="1">
          292
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         ID: identification; Pos: positive; Neg: negative.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="tab3" orientation="portrait" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Mean, maximum, and minimum nucleotide identities of 3a–c, E, and M FCoV genes from different clones.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="2">
          Identification
         </th>
         <th align="center" colspan="3" rowspan="1">
          3a gene
         </th>
         <th align="center" colspan="3" rowspan="1">
          3b gene
         </th>
         <th align="center" colspan="3" rowspan="1">
          3c gene
         </th>
         <th align="center" colspan="3" rowspan="1">
          E gene
         </th>
         <th align="center" colspan="3" rowspan="1">
          M gene
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1">
          Mean (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Max (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Min (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Mean (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Max (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Min (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Mean (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Max (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Min (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Mean (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Max (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Min (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Mean (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Max (%)
         </th>
         <th align="center" colspan="1" rowspan="1">
          Min (%)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP2/Faeces/PIF−/local1
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.83
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.45
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.40
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.75
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.52
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.30
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP6/Stomach/PIF+/local7
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.67
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.92
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.90
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.77
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.70
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP6/Faeces/PIF+/local7
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.03
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.60
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.20
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.20
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.20
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.77
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.70
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP7/Cerebrum/PIF+/local3
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.02
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          96.39
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          88.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.79
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.53
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.48
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.40
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP7/Faeces/PIF+/local3
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.42
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          97.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          92.16
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          83.30
         </td>
         <td align="center" colspan="1" rowspan="1">
          97.29
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          95.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.54
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.10
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP8/UB/PIF+/local6
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.89
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.73
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.20
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP14/Faeces/PIF−/local4
         </td>
         <td align="center" colspan="1" rowspan="1">
          95.86
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          91.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.96
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          97.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.48
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP16/Cerebrum/PIF+/local5
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.42
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.33
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.83
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.40
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP17/Cerebrum/PIF+/local2
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.25
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          97.92
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          94.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.33
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.67
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.18
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.60
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.70
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP17/LI/PIF+/local2
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.03
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.60
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.67
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1">
          <italic>
           ∗
          </italic>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          USP18/Cerebrum/PIF+/local2
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.68
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.80
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.53
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.60
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.40
         </td>
        </tr>
        <tr>
         <td align="center" colspan="16" rowspan="1">
          <hr/>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Intestinal samples
         </td>
         <td align="center" colspan="1" rowspan="1">
          97.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          91.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          92.09
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          81.50
         </td>
         <td align="center" colspan="1" rowspan="1">
          95.64
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          93.20
         </td>
         <td align="center" colspan="1" rowspan="1">
          93.87
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          91.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.59
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.10
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1">
          Extraintestinal samples
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.38
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.10
         </td>
         <td align="center" colspan="1" rowspan="1">
          90.09
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          75.60
         </td>
         <td align="center" colspan="1" rowspan="1">
          95.37
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          92.70
         </td>
         <td align="center" colspan="1" rowspan="1">
          95.19
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          89.90
         </td>
         <td align="center" colspan="1" rowspan="1">
          99.53
         </td>
         <td align="center" colspan="1" rowspan="1">
          100.00
         </td>
         <td align="center" colspan="1" rowspan="1">
          98.70
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         Max: maximum; Min: minimum; LI: large intestine; UB: urinary bladder.
        </p>
       </fn>
       <fn>
        <p>
         <sup>
          <italic>
           ∗
          </italic>
         </sup>
         Samples that only one clone was obtained or no clone was obtained at all.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Proc Natl Acad Sci U S A
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Proc. Natl. Acad. Sci. U.S.A
      </journal-id>
      <journal-id journal-id-type="hwp">
       pnas
      </journal-id>
      <journal-id journal-id-type="pmc">
       pnas
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       PNAS
      </journal-id>
      <journal-title-group>
       <journal-title>
        Proceedings of the National Academy of Sciences of the United States of America
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0027-8424
      </issn>
      <issn pub-type="epub">
       1091-6490
      </issn>
      <publisher>
       <publisher-name>
        National Academy of Sciences
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25114257
      </article-id>
      <article-id pub-id-type="pmc">
       4151778
      </article-id>
      <article-id pub-id-type="publisher-id">
       201405889
      </article-id>
      <article-id pub-id-type="doi">
       10.1073/pnas.1405889111
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Biological Sciences
        </subject>
        <subj-group>
         <subject>
          Microbiology
         </subject>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
       </article-title>
       <alt-title alt-title-type="short">
        MERS and related coronaviruses
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Yang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          Lanying
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Chang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Lili
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          Cuiqing
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          Jian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baric
         </surname>
         <given-names>
          Ralph S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          c
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Shibo
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff4">
         <sup>
          d
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Fang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <sup>
         a
        </sup>
        Department of Pharmacology,
        <institution>
         University of Minnesota Medical School
        </institution>
        , Minneapolis,
        <addr-line>
         MN
        </addr-line>
        55455;
       </aff>
       <aff id="aff2">
        <sup>
         b
        </sup>
        Lindsley F. Kimball Research Institute,
        <institution>
         New York Blood Center
        </institution>
        , New York,
        <addr-line>
         NY
        </addr-line>
        10065;
       </aff>
       <aff id="aff3">
        <sup>
         c
        </sup>
        Department of Epidemiology,
        <institution>
         University of North Carolina
        </institution>
        , Chapel Hill,
        <addr-line>
         NC
        </addr-line>
        27559; and
       </aff>
       <aff id="aff4">
        <sup>
         d
        </sup>
        Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology,
        <institution>
         Fudan University
        </institution>
        , Shanghai 200032,
        <country>
         China
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <sup>
         2
        </sup>
        To whom correspondence may be addressed. E-mail:
        <email>
         lifang@umn.edu
        </email>
        or
        <email>
         sjiang@nybloodcenter.org
        </email>
        .
       </corresp>
       <fn fn-type="edited-by">
        <p>
         Edited by Michael Farzan, The Scripps Research Institute, Jupiter, Florida, and accepted by the Editorial Board July 10, 2014 (received for review March 29, 2014)
        </p>
       </fn>
       <fn fn-type="con">
        <p>
         Author contributions: Y.Y., L.D., C.L., S.J., and F.L. designed research; Y.Y., L.D., C.L., L.W., C.M., and J.T. performed research; R.S.B. contributed new reagents/analytic tools; Y.Y., L.D., C.L., L.W., C.M., J.T., S.J., and F.L. analyzed data; and F.L. wrote the paper.
        </p>
       </fn>
       <fn fn-type="equal" id="fn1">
        <p>
         <sup>
          1
         </sup>
         Y.Y., L.D., and C.L. contributed equally to this work.
        </p>
       </fn>
       <fn fn-type="conflict">
        <p>
         The authors declare no conflict of interest.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        26
       </day>
       <month>
        8
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        8
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       111
      </volume>
      <issue>
       34
      </issue>
      <fpage>
       12516
      </fpage>
      <lpage>
       12521
      </lpage>
      <self-uri xlink:href="pnas.201405889.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract abstract-type="executive-summary">
       <title>
        Significance
       </title>
       <p>
        A constant and long-term threat to human health is cross-species transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) from bats to humans. However, this process is poorly understood. Examining the cross-species transmissibility of bat coronavirus HKU4, which is genetically related to MERS-CoV, can provide critical information about the likely causes of MERS-CoV infections in humans. Here we investigate the receptor usage and cell entry mechanism of HKU4 compared with MERS-CoV. Our results reveal that MERS-CoV has adapted to use human receptor and cellular proteases for efficient human cell entry, whereas HKU4 can potentially follow-up and also infect human cells. These findings are critical for evaluating emerging disease potentials of bat coronaviruses and for preventing and controlling their spread in humans.
       </p>
      </abstract>
      <abstract>
       <p>
        Middle East respiratory syndrome coronavirus (MERS-CoV) currently spreads in humans and causes ∼36% fatality in infected patients. Believed to have originated from bats, MERS-CoV is genetically related to bat coronaviruses HKU4 and HKU5. To understand how bat coronaviruses transmit to humans, we investigated the receptor usage and cell entry activity of the virus-surface spike proteins of HKU4 and HKU5. We found that dipeptidyl peptidase 4 (DPP4), the receptor for MERS-CoV, is also the receptor for HKU4, but not HKU5. Despite sharing a common receptor, MERS-CoV and HKU4 spikes demonstrated functional differences. First, whereas MERS-CoV prefers human DPP4 over bat DPP4 as its receptor, HKU4 shows the opposite trend. Second, in the absence of exogenous proteases, both MERS-CoV and HKU4 spikes mediate pseudovirus entry into bat cells, whereas only MERS-CoV spike, but not HKU4 spike, mediates pseudovirus entry into human cells. Thus, MERS-CoV, but not HKU4, has adapted to use human DPP4 and human cellular proteases for efficient human cell entry, contributing to the enhanced pathogenesis of MERS-CoV in humans. These results establish DPP4 as a functional receptor for HKU4 and host cellular proteases as a host range determinant for HKU4. They also suggest that DPP4-recognizing bat coronaviruses threaten human health because of their spikes’ capability to adapt to human cells for cross-species transmissions.
       </p>
      </abstract>
      <counts>
       <page-count count="6">
       </page-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jid
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-1899
      </issn>
      <issn pub-type="epub">
       1537-6613
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
       <publisher-loc>
        US
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29346682
      </article-id>
      <article-id pub-id-type="pmc">
       7107427
      </article-id>
      <article-id pub-id-type="doi">
       10.1093/infdis/jiy018
      </article-id>
      <article-id pub-id-type="publisher-id">
       jiy018
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Major Articles and Brief Reports
        </subject>
        <subj-group subj-group-type="category-toc-heading">
         <subject>
          Viruses
         </subject>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna K P
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Libiao
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0005">
         5
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Luk
         </surname>
         <given-names>
          Hayes K H
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xiong
         </surname>
         <given-names>
          Lifeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn-0001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Peng
         </surname>
         <given-names>
          Xingwen
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0005">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Kenneth S M
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          He
         </surname>
         <given-names>
          Xiangyang
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0005">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Pyrear Su-Hui
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Fan
         </surname>
         <given-names>
          Rachel Y Y
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Antonio C P
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ahmed
         </surname>
         <given-names>
          Syed Shakeel
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cai
         </surname>
         <given-names>
          Jian-Piao
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F W
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Yinyan
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0006">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Jin
         </surname>
         <given-names>
          Dongyan
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0007">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Honglin
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Terrence C K
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0008">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kok
         </surname>
         <given-names>
          Raven K H
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Wenhui
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0006">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C Y
         </given-names>
        </name>
        <xref ref-type="aff" rid="AF0001">
         1
        </xref>
        <xref ref-type="aff" rid="AF0002">
         2
        </xref>
        <xref ref-type="aff" rid="AF0003">
         3
        </xref>
        <xref ref-type="aff" rid="AF0004">
         4
        </xref>
        <xref ref-type="corresp" rid="c1">
        </xref>
        <!--<email>pcywoo@hku.hk</email>-->
       </contrib>
      </contrib-group>
      <aff id="AF0001">
       <label>
        1
       </label>
       State Key Laboratory of Emerging Infectious Diseases The University of Hong Kong, China
      </aff>
      <aff id="AF0002">
       <label>
        2
       </label>
       Department of Microbiology The University of Hong Kong, China
      </aff>
      <aff id="AF0003">
       <label>
        3
       </label>
       Carol Yu Centre for Infection The University of Hong Kong, China
      </aff>
      <aff id="AF0004">
       <label>
        4
       </label>
       Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China
      </aff>
      <aff id="AF0005">
       <label>
        5
       </label>
       Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, and Guangdong Institute of Applied Biological Resources, Guangzhou, Guangdong Province, China
      </aff>
      <aff id="AF0006">
       <label>
        6
       </label>
       National Institute of Biological Sciences, Zhongguancun Life Science Park, Changping, Beijing, China
      </aff>
      <aff id="AF0007">
       <label>
        7
       </label>
       School of Biomedical Sciences, The University of Hong Kong, China
      </aff>
      <aff id="AF0008">
       <label>
        8
       </label>
       Department of Biomedical Sciences, City University of Hong Kong, China
      </aff>
      <author-notes>
       <fn id="fn-0001">
        <p>
         S. K. P. L., L.. Z., H. K. H. L., and L. X. contributed equally to the manuscript.
        </p>
       </fn>
       <corresp id="c1">
        Correspondence: P. C. Y. Woo, MD, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong, China (
        <email>
         pcywoo@hku.hk
        </email>
        ).
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        15
       </day>
       <month>
        7
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date iso-8601-date="2018-01-16" pub-type="epub">
       <day>
        16
       </day>
       <month>
        1
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        20
       </day>
       <month>
        6
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
      <volume>
       218
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       197
      </fpage>
      <lpage>
       207
      </lpage>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         11
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         15
        </day>
        <month>
         1
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
       </copyright-statement>
       <copyright-year>
        2018
       </copyright-year>
       <license license-type="oup-standard" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">
        <license-p>
         This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
         <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/about_us/legal/notices">
          https://academic.oup.com/journals/pages/about_us/legal/notices
         </ext-link>
         )
        </license-p>
       </license>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="jiy018.pdf">
      </self-uri>
      <abstract abstract-type="teaser">
       <p>
        The discovery of Hp-BatCoV HKU25 bridges the evolutionary gap between MERS-CoV and existing bat viruses, and suggests that bat viruses may have evolved to generate MERS-CoV through modulation of the spike protein for binding to hDPP4.
       </p>
      </abstract>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        Although bats are known to harbor Middle East Respiratory Syndrome coronavirus (MERS-CoV)-related viruses, the role of bats in the evolutionary origin and pathway remains obscure. We identified a novel MERS-CoV-related betacoronavirus, Hp-BatCoV HKU25, from Chinese pipistrelle bats. Although it is closely related to MERS-CoV in most genome regions, its spike protein occupies a phylogenetic position between that of Ty-BatCoV HKU4 and Pi-BatCoV HKU5. Because Ty-BatCoV HKU4 but not Pi-BatCoV HKU5 can use the MERS-CoV receptor human dipeptidyl peptidase 4 (hDPP4) for cell entry, we tested the ability of Hp-BatCoV HKU25 to bind and use hDPP4. The HKU25-receptor binding domain (RBD) can bind to hDPP4 protein and hDPP4-expressing cells, but it does so with lower efficiency than that of MERS-RBD. Pseudovirus assays showed that HKU25-spike can use hDPP4 for entry to hDPP4-expressing cells, although with lower efficiency than that of MERS-spike and HKU4-spike. Our findings support a bat origin of MERS-CoV and suggest that bat CoV spike proteins may have evolved in a stepwise manner for binding to hDPP4.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        dipeptidyl peptidase 4
       </kwd>
       <kwd>
        <italic>
         Hypsugo
        </italic>
        bat
       </kwd>
       <kwd>
        Middle East Respiratory Syndrome coronavirus
       </kwd>
       <kwd>
        spike glycoprotein
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Theme-Based Research Scheme
         </named-content>
        </funding-source>
        <award-id>
         T11-707/15-R
        </award-id>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Research Grant Council Grant, University Grant Council
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Health and Medical Research Fund
         </named-content>
         <named-content content-type="funder-identifier">
          10.13039/501100005847
         </named-content>
        </funding-source>
        <award-id>
         13121102
        </award-id>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Food and Health Bureau of Hong Kong Special Administrative Region
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Croucher Senior Medical Research Fellowships
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Committee for Research and Conference Grant
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Strategic Research Theme Fund
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          The University of Hong Kong
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Disease for the HKSAR Department of Health
         </named-content>
        </funding-source>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          National Science and Technology Major Project of China
         </named-content>
        </funding-source>
        <award-id>
         2012ZX10004213
        </award-id>
       </award-group>
       <award-group award-type="grant">
        <funding-source>
         <named-content content-type="funder-name">
          GDAS Special Project of Science and Technology Development
         </named-content>
        </funding-source>
        <award-id>
         2017GDASCX-0107
        </award-id>
       </award-group>
      </funding-group>
      <counts>
       <page-count count="11">
       </page-count>
      </counts>
     </article-meta>
    </front>
    <p>
     The Middle East Respiratory Syndrome (MERS) has affected 27 countries in 4 continents with 2090 cases and a fatality rate of 34.9% since its emergence in 2012. The etiological agent, MERS coronavirus (MERS-CoV), belongs to
     <italic>
      Betacoronavirus
     </italic>
     lineage C [
     <xref ref-type="bibr" rid="CIT0001">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0002">
      2
     </xref>
     ] and uses human dipeptidyl peptidase 4 (hDPP4) as receptor for cell entry [
     <xref ref-type="bibr" rid="CIT0003">
      3
     </xref>
     ]. Although dromedaries are likely the immediate animal source of the epidemic [
     <xref ref-type="bibr" rid="CIT0004">
      4–6
     </xref>
     ], bats also harbor MERS-CoV-related viruses, which suggests a possible bat origin [
     <xref ref-type="bibr" rid="CIT0007">
      7–13
     </xref>
     ]. However, the evolutionary pathway and direct ancestor of MERS-CoV remains obscure. In particular, there is an evolutionary gap between MERS-CoV and related bat viruses.
    </p>
    <p>
     Since the severe acute respiratory syndrome (SARS) epidemic, numerous novel CoVs have been discovered [
     <xref ref-type="bibr" rid="CIT0014">
      14–16
     </xref>
     ], with bats uncovered as an important reservoir for alphacoronaviruses and betacoronaviruses [
     <xref ref-type="bibr" rid="CIT0017">
      17–21
     </xref>
     ]. When MERS-CoV was first discovered, it was most closely related to
     <italic>
      Tylonycteris
     </italic>
     bat CoV HKU4 (Ty-BatCoV HKU4) and
     <italic>
      Pipistrellus
     </italic>
     bat CoV HKU5 (Pi-BatCoV HKU5) previously discovered in the Lesser bamboo bat (
     <italic>
      Tylonycteris pachypus
     </italic>
     ) and Japanese pipistrelle (
     <italic>
      Pipistrellus abramus
     </italic>
     ), respectively, in Hong Kong [
     <xref ref-type="bibr" rid="CIT0001">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0007">
      7–10
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0022">
      22
     </xref>
     ]. The spike of Ty-BatCoV HKU4, but not that of Pi-BatCoV HKU5, was able to use the MERS-CoV receptor, hDPP4 or CD26, for cell entry [
     <xref ref-type="bibr" rid="CIT0003">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0023">
      23
     </xref>
     ]. Subsequently, 3 other lineage C betacoronaviruses (Coronavirus Neoromicia/PML-PHE1/RSA/2011 [NeoCoV], BtVs-BetaCoV/SC2013, and BatCoV PREDICT/PDF-2180) were also detected in vesper bats from China or Africa [
     <xref ref-type="bibr" rid="CIT0011">
      11–13
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0024">
      24
     </xref>
     ]. A lineage C betacoronavirus, Erinaceus CoV VMC/DEU, has also been found in European hedgehogs [
     <xref ref-type="bibr" rid="CIT0025">
      25
     </xref>
     ]. This is interesting because hedgehogs are phylogenetically closely related to bats. The MERS-CoV can infect bat cell lines and Jamaican fruit bats [
     <xref ref-type="bibr" rid="CIT0025">
      25
     </xref>
     ,
     <xref ref-type="bibr" rid="CIT0026">
      26
     </xref>
     ], further suggesting that bats may be the primary host of MERS-CoV ancestors.
    </p>
    <p>
     Although NeoCoV represents the closest bat counterpart of MERS-CoV in most genome regions, its spike (S) protein is genetically divergent from that of MERS-CoV [
     <xref ref-type="bibr" rid="CIT0011">
      11
     </xref>
     ], suggesting an evolutionary gap between existing MERS-CoV and bat viruses and an immediate ancestor of MERS-CoV yet to be discovered. To identify the potential bat origin and understand the evolutionary path of MERS-CoV, we collected bat samples from various regions in China. Diverse CoVs were detected, including a novel lineage C betacoronavirus from Chinese pipistrelle (
     <italic>
      Hypsugo pulveratus
     </italic>
     ), which can use hDPP4 for cell entry. The results support a bat origin of MERS-CoV and suggested stepwise evolution of spike protein in hDPP4 binding.
    </p>
    <sec id="s1" sec-type="materials|methods">
     <title>
      MATERIALS AND METHODS
     </title>
     <sec id="s2">
      <title>
       Ethics Statement
      </title>
      <p>
       Bat samples were collected by the Guangdong Institute of Applied Biological Resources (Guangzhou, China) in accordance with guidelines of Regulations for Administration of Laboratory Animals under a license from Guangdong Entomological Institute Administrative Panel on Laboratory Animal Care.
      </p>
     </sec>
     <sec id="s3">
      <title>
       Detection of Coronavirus From Bats
      </title>
      <p>
       Samples were collected from bats captured from various locations in 7 provinces of China (
       <xref ref-type="fig" rid="F1">
        Figure 1
       </xref>
       ) during 2013−2015 using procedures described previously [
       <xref ref-type="bibr" rid="CIT0027">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0028">
        28
       </xref>
       ]. Viral ribonucleic acid (RNA) extraction was performed using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany). Coronavirus detection was performed by reverse-transcription polymerase chain reaction (RT-PCR) targeting a 440-base pair (bp) fragment of RNA-dependent RNA polymerase (RdRp) gene using conserved primers (5’-GGTTGGGACTATCCTAAGTGTGA-3’ and 5’-ACCATCATCNGANARDATCATNA-3’) as described previously [
       <xref ref-type="bibr" rid="CIT0016">
        16
       </xref>
       ]. A phylogenetic tree was constructed with maximum likelihood method using GTR+G+I substitution model by MEGA 6.0.
      </p>
      <fig fig-type="figure" id="F1" orientation="portrait" position="float">
       <label>
        Figure 1.
       </label>
       <caption>
        <p>
         Map showing various sampling locations in seven provinces of China (Guangxi, Guangdong, Shanxi, Zhejiang, Yunnan, Hainan and Guizhou). Sampling locations with Hp-BatCoV HKU25 and other CoVs detected are indicated with triangle and diamond respectively.
        </p>
       </caption>
       <graphic xlink:href="jiy01801">
       </graphic>
      </fig>
     </sec>
     <sec id="s4">
      <title>
       Viral Culture
      </title>
      <p>
       The 2 Hp-BatCoV HKU25 samples were subject to virus isolation in Vero E6 (ATCC CRL-1586), Huh-7 (JCRB0403), PK15 (ATCC CCL-33), and
       <italic>
        Rousettus lechenaultii
       </italic>
       primary kidney cells (in-house) as described previously [
       <xref ref-type="bibr" rid="CIT0029">
        29
       </xref>
       ].
      </p>
     </sec>
     <sec id="s5">
      <title>
       Complete Genome Sequencing and Analysis of
       <italic>
        Hypsugo pulveratus
       </italic>
       Bat Coronavirus HKU25
      </title>
      <p>
       Two Hp-BatCoV HKU25 complete genomes were sequenced according to our published strategy [
       <xref ref-type="bibr" rid="CIT0027">
        27
       </xref>
       ]. A total of 75 sets of primers, available on request, were used for PCR. The assembled genome sequences were compared with those of other CoVs using the comprehensive CoV database CoVDB (
       <ext-link ext-link-type="uri" xlink:href="http://covdb.microbiology.hku.hk">
        http://covdb.microbiology.hku.hk
       </ext-link>
       ) [
       <xref ref-type="bibr" rid="CIT0030">
        30
       </xref>
       ]. The time of the most recent common ancestor (tMRCA) was estimated based on ORF1ab sequences, using uncorrelated exponential distributed relaxed clock model in BEAST version 1.8 (
       <ext-link ext-link-type="uri" xlink:href="http://evolve.zoo.ox.ac.uk/beast/">
        http://evolve.zoo.ox.ac.uk/beast/
       </ext-link>
       ) [
       <xref ref-type="bibr" rid="CIT0031">
        31
       </xref>
       ].
      </p>
     </sec>
     <sec id="s6">
      <title>
       Cloning of Recombinant S1 Receptor-Binding Domain Proteins
      </title>
      <p>
       The S1-RBD sequences of of Hp-BatCoV HKU25 (residues 374–604) and MERS-CoV (residues 367–606) were cloned into mammalian expression vector pCAGGS containing signal peptide (CD5) and C-terminal Fc tag from mouse IgG2a (mFc) [
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0033">
        33
       </xref>
       ]. The expression plasmids were transiently transfected into human embryonic kidney HEK293T cells (American Type Culture Collection CRL-3216). The recombinant HKU25-RBD-mFc and MERS-RBD-mFc proteins were purified by protein A-based affinity chromatography.
      </p>
     </sec>
     <sec id="s7">
      <title>
       Protein Binding with Flow Cytometry and Fluorescence-Activated Cell Sorter Analysis
      </title>
      <p>
       Huh7 (normal or DPP4 knockdown using small interfering RNA [siRNA]) or 293T (normal or transfected with DPP4-expressing plasmid) cells were incubated with 10 μg/mL MERS-RBD-mFc or 40 µg/mL HKU25-RBD-mFc at 4°C for 1 hour. Cells were then stained with Alexa Fluor 488-conjugated goat antimouse IgG on ice for 30 minutes. Protein-to-cell binding was analyzed using BD fluorescence-activated cell sorter (FACS) LSRII instrument (BD Bioscience, East Rutherford, NJ).
      </p>
     </sec>
     <sec id="s8">
      <title>
       Immunostaining and Confocal Microscopy
      </title>
      <p>
       Huh7 cells were fixed on glass coverslips and incubated with 50 μg/mL HKU25-RBD-mFc or 20 µg/mL MERS-RBD-mFc in phosphate-buffered saline at 4°C for 1 hour, followed by staining with Alexa Fluor 488-conjugated goat antimouse or anti-rabbit IgG. Cell nuclei were stained using 4’,6-diamidino-2-phenylindole in mounting medium. Images were acquired with 63× oil objectives using a Zeiss LSM510 Meta laser scanning confocal microscope.
      </p>
     </sec>
     <sec id="s9">
      <title>
       Knockdown of Human Dipeptidyl Peptidase 4 Expression Using Small Interfering Ribonucleic Acids
      </title>
      <p>
       The siRNA duplexes against hDPP4 (5′-UGACAUGCCUC AGUUGUAUU-3′) were synthesized by Nucleic Acids Center at National Institute of Biological Sciences (Beijing, China), with nontargeting siRNA as negative control (Ctrl-si). Ten picomoles of siRNA were transfected into Huh7 cells with Lipofectamine RNAiMax (Invitrogen). Knockdown efficiency was determined by quantitative RT-PCR analysis using primers specific for hDPP4 (5′-CCTGCTTCTATGTTGATA-3′; 5′-CGAATAGTTCTGAATCCT-3′) and Western blot analysis using anti-hDPP4 antibody (Abcam, Cambridge, United Kingdom). The messenger RNA (mRNA) levels of target genes were normalized to that of the glyceraldehyde 3-phosphate dehydrogenase (
       <italic>
        gapdh
       </italic>
       ) gene [
       <xref ref-type="bibr" rid="CIT0034">
        34
       </xref>
       ].
      </p>
     </sec>
     <sec id="s10">
      <title>
       Immunoprecipitation
      </title>
      <p>
       To identify the direct interaction between MERS-RBD-mFc or HKU25-RBD-mFc and hDPP4, HEK293T cells were transfected with hDPP4-expressing plasmids and lysed with radioimmunoprecipitation assay buffer containing 1× protease inhibitor cocktail (Roche) 48 hours after transfection. Cell lysates were incubated with purified MERS-RBD-mFc or HKU25-RBD-mFc and Dynal protein A Sepharose beads at 4°C overnight. The bound fractions of immunoprecipitates and total cell lysate (as input) were analyzed by Western blot with anti-mFc, anti-hDPP4, or anti-GAPDH antibodies.
      </p>
     </sec>
     <sec id="s11">
      <title>
       Pseudovirus Production
      </title>
      <p>
       Retroviruses pseudotyped with MERS-CoV, Ty-BatCoV HKU4, Pi-BatCoV HKU5, and Hy-BatCoV HKU25 S proteins were packaged by HEK293FT cells (R70007; Invitrogen). Briefly, plasmid containing the respective CoV S gene was cotransfected with a plasmid containing luciferase gene but env-defective human immunodeficiency virus-1 (pNL 4-3.Luc.RE) into 293FT cells using Lipofectamine 2000 (Invitrogen). Culture supernatant was concentrated with 5× PEG-it virus precipitation solution (SBI). For mock pseudoviruses (∆env) bearing no S protein, empty plasmid was cotransfected with pNL 4-3.Luc.RE.
      </p>
     </sec>
     <sec id="s12">
      <title>
       Pseudovirus Cell Entry Assay
      </title>
      <p>
       HEK293T cells were transfected with plasmid containing hDPP4 gene and empty plasmid (as mock-transfected control) by Lipofectamine 2000. Pseudoviruses bearing CoV S proteins were treated by 100 µg/mL Tosyl phenylalanyl chloromethyl ketone-treated trypsin at 37°C for 30 minutes before infection. After trypsin inactivation, pseudovirus infections were performed by spinning at 1200 ×
       <italic>
        g
       </italic>
       at 4°C for 2 hours and incubation at 37°C for 5 hours. Cells were then incubated for 72 hours and lysed for luciferase activity determination using Luciferase Assay System (Promega, Fitchburg, WI). To test for inhibition of pseudovirus-mediated cell entry by anti-hDPP4 antibodies, HEK293T cells transfected with hDPP4 were preincubated with 10 µg/mL anti-hDPP4 polyclonal antibodies (R&amp;D Systems) at 37°C for 1 hour before pseudovirus infection.
      </p>
     </sec>
     <sec id="s13">
      <title>
       Structural Modeling of
       <italic>
        Hypsugo pulveratus
       </italic>
       Bat Coronavirus HKU25 Receptor-Binding Domain
      </title>
      <p>
       The model of HKU25-RBD and HKU5-RBD was built with the crystal structure of MERS-RBD/hDPP4 using SWISS-MODEL with default parameters and analyzed using Discovery Studio visualizer (Accelrys, San Diego, CA), and the Ramachandran plots were examined to ensure that the structure of the models were not in any unfavorable region. The models of HKU4-RBD and HKU5-RBD were also built as positive and negative controls, respectively, with the same parameters, and were superimposed for comparison.
      </p>
     </sec>
     <sec id="s14">
      <title>
       Nucleotide Sequence Accession Numbers
      </title>
      <p>
       The nucleotide (nt) and genome sequences of CoVs detected in this study have been lodged within GenBank under accession numbers KX442564, KX442565, and KX447541 to KX447565.
      </p>
     </sec>
    </sec>
    <sec id="s15">
     <title>
      RESULTS
     </title>
     <sec id="s16">
      <title>
       Detection of Coronavirus in Bats and Discovery of a Novel Lineage C Betacoronavirus From Chinese Pipistrelle
      </title>
      <p>
       A total of 1964 alimentary samples from bats belonging to 19 different genera and 44 species were obtained from 7 provinces of China. The RT-PCR for a 440-bp fragment of RdRp gene of CoVs was positive in samples from 29 bats of 5 species belonging to 4 genera (
       <xref ref-type="fig" rid="F1">
        Figure 1
       </xref>
       and
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Table 1
       </xref>
       ). Sequence analysis showed that 4 samples contained alphacoronaviruses, 5 contained lineage B betacoronaviruses, and 20 contained lineage C betacoronaviruses (
       <xref ref-type="supplementary-material" rid="sup6">
        Supplementary Figure 1
       </xref>
       ).
      </p>
      <p>
       Of the 20 lineage C betacoronavirus sequences, 18 sequences from
       <italic>
        Tylonycteris pachypus
       </italic>
       possessed 96% nt identities to Ty-BatCoV HKU4. The other 2 lineage C betacoronavirus sequences (YD131305 and NL140462) showed ≤86% nt identities to MERS-CoV or other lineage C betacoronaviruses, suggesting a potentially novel lineage C betacoronavirus closely related to MERS-CoV (
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Table 1
       </xref>
       and
       <xref ref-type="supplementary-material" rid="sup6">
        Supplementary Figure 1
       </xref>
       ). Both samples were collected from Chinese pipistrelle (
       <italic>
        Hypsugo pulveratus
       </italic>
       ) bats, which belong to the family Vespertilionidae, captured in Guangdong Province (
       <xref ref-type="fig" rid="F1">
        Figure 1
       </xref>
       ). We proposed this novel CoV to be named
       <italic>
        Hypsugo pulveratus
       </italic>
       bat CoV HKU25 (Hp-BatCoV HKU25). Attempts to passage Hp-BatCoV HKU25 YD131305 and NL140462 in cell cultures were not successful.
      </p>
     </sec>
     <sec id="s17">
      <title>
       Genome Features of
       <italic>
        Hypsugo pulveratus
       </italic>
       Bat Coronavirus HKU25
      </title>
      <p>
       The complete genome sequences of the 2 Hp-BatCoV HKU25 strains, YD131305 and NL140462, were determined, with genome features similar to MERS-CoV including conserved ORF4a and ORF4b (
       <xref ref-type="supplementary-material" rid="sup2">
        Supplementary Table 2
       </xref>
       ,
       <xref ref-type="supplementary-material" rid="sup4">
        Supplementary Table 4
       </xref>
       ,
       <xref ref-type="supplementary-material" rid="sup7">
        Supplementary Figure 2
       </xref>
       , and
       <xref ref-type="supplementary-material" rid="sup8">
        Supplementary Figure 3
       </xref>
       ). They shared 95.9% overall nt identities, while possessing 82.0%, 73.2%–73.9%, 73.5%, and 69.3% nt identities to the genomes of BtVs-BetaCoV/SC2013, human/camel MERS-CoVs, NeoCoV, and Ty-BatCoV HKU4, respectively. Comparison of the 7 conserved replicase domains for CoV species demarcation showed that Hp-BatCoV HKU25 represents a novel species under
       <italic>
        Betacoronavirus
       </italic>
       lineage C (
       <xref ref-type="supplementary-material" rid="sup5">
        Supplementary Table 5
       </xref>
       ), with the concatenated sequence being most closely related to that of BtVs-BetaCoV/SC2013 with 88.5% amino acid (aa) identities.
      </p>
     </sec>
     <sec id="s18">
      <title>
       Phylogenetic and Molecular Clock Analysis
      </title>
      <p>
       Phylogenetic trees constructed using RdRp, ORF1, S1, and N sequences of Hp-BatCoV HKU25 are shown in
       <xref ref-type="fig" rid="F2">
        Figure 2
       </xref>
       . Hp-BatCoV HKU25 was most closely related to BtVs-BetaCoV/SC2013, forming a distinct branch among lineage C betacoronaviruses. In RdRp, ORF1, and N genes, MERS-CoVs were most closely related to NeoCoV followed by the branch formed by Hp-BatCoV HKU25 and BtVs-BetaCoV/SC2013. In contrast, in S1 region, MERS-CoVs were most closely related to Ty-BatCoV HKU4, followed by the branch formed by Hp-BatCoV HKU25 and BtVs-BetaCoV/SC2013, but was only distantly related to NeoCoV. Thus, Hp-BatCoV HKU25 and BtVs-BetaCoV/SC2013 represent close relatives of MERS-CoV, while they occupied a position in between Ty-BatCoV HKU4 and Pi-BatCoV HKU5 in relation to MERS-CoV in S1 region.
      </p>
      <fig fig-type="figure" id="F2" orientation="portrait" position="float">
       <label>
        Figure 2.
       </label>
       <caption>
        <p>
         Phylogenetic analyses of RdRp, ORF1, S1 and N nucleotide sequences of Hp-BatCoV HKU25 and other lineage C betacoronaviruses (B). The trees were constructed by maximum likelihood method using GTR+G substitution models respectively and bootstrap values calculated from 1000 trees. Trees were rooted using corresponding sequences of HCoV HKU1 (GenBank accession number NC_006577). Only bootstrap values &gt;70% are shown. (A) 2775 nt (B) 20694 nt (C) 3740 nt (D) 1167 nt positions respectively were included in the analyses. The scale bars represent (A) 20 (B) 20 (C) 10 (D) 10 substitutions per site respectively. The two Hp-BatCoV HKU25 strains, YD131305 and NL140462, detected in this study are bolded and underlined.
        </p>
       </caption>
       <graphic xlink:href="jiy01802">
       </graphic>
      </fig>
      <p>
       Using the uncorrelated relaxed clock model on ORF1ab, tMRCA of human and camel MERS-CoVs was dated to 2009.56 (highest posterior density [HPD], 2006.8−2011.3), whereas that of MERS-CoV, NeoCoV, Hp-BatCoV HKU25, and BtVs-BetaCoV/SC2013 was dated to 1939.32 (HPDs, 1899.5−1969.0) (
       <xref ref-type="supplementary-material" rid="sup9">
        Supplementary Figure 4
       </xref>
       ).
      </p>
     </sec>
     <sec id="s19">
      <title>
       Sequence Analysis of
       <italic>
        Hypsugo pulveratus
       </italic>
       Bat Coronavirus Spike Protein
      </title>
      <p>
       The MERS-CoV uses hDPP4, a type II transmembrane protein, as receptor for initiation of infection [
       <xref ref-type="bibr" rid="CIT0003">
        3
       </xref>
       ]. The S1 domain responsible for hDPP4 receptor binding is located in a C-terminal 240-residue RBD that contains the receptor-binding motif, which engages the receptor [
       <xref ref-type="bibr" rid="CIT0035">
        35
       </xref>
       ]. Using binding and pseudovirus assays, it was shown that Ty-BatCoV HKU4 S, but not Pi-BatCoV HKU5 S, can bind to and use hDPP4 for cell entry [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ]. Because phylogenetic analysis placed Hp-BatCoV HKU25-S1 at a position between Ty-BatCoV HKU4 and Pi-BatCoV HKU5 in relation to MERS-CoV, it would be interesting to know whether Hp-BatCoV HKU25 may bind to and use hDPP4 for cell entry. As in other CoVs, Hp-BatCoV HKU25-S is predicted to be a type I membrane glycoprotein with 2 heptad repeats. The predicted Hp-BatCoV HKU25-S1-RBD shared 53.5% aa identities to that of MERS-CoV, with 2 short deletions compared with MERS-CoV and Ty-BatCoV HKU4 (
       <xref ref-type="fig" rid="F3">
        Figure 3
       </xref>
       ).
      </p>
      <fig fig-type="figure" id="F3" orientation="portrait" position="float">
       <label>
        Figure 3.
       </label>
       <caption>
        <p>
         Multiple alignment of the amino acid sequences of the receptor-binding domain (RBD) of the spike protein of MERS-CoV and corresponding sequences in Hp-BatCoV HKU25 and other lineage C betacoronaviruses. Asterisks indicate positions with fully conserved residues. The two amino acid deletions in Hp-BatCoV HKU25 compared to MERS-CoV and Ty-BatCoV HKU4 are indicated with boxes. The 12 critical residues for receptor binding in MERS-CoV are highlighted. The 10 residues marked below the alignment are based on (Wang, 2013) [
         <xref ref-type="bibr" rid="CIT0037">
          37
         </xref>
         ] and the other two residues marked above the alignment are based on (Wang, 2014) [
         <xref ref-type="bibr" rid="CIT0023">
          23
         </xref>
         ]. Y499 formed hydrogen bond with DPP4 residue. L506, W553 and V555 formed a hydrophobic core surrounded by hydrophilic residues D510, E513 and Y540. D510 and E513 also contributed to salt bridge interaction and hydrogen bonding with DPP4 residues. E536, D537 and D539 formed negative-charged surface. W535 and R542 are residues that have strong polar contact with DPP4 residues.
        </p>
       </caption>
       <graphic xlink:href="jiy01803">
       </graphic>
      </fig>
      <p>
       Previous structural studies have identified 12 critical residues (Y499, L506, D510, E513, W535, E536, D537, D539, Y540, R542, W553, and V555) for hDPP4 binding in MERS-CoV [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0037">
        37
       </xref>
       ]. In Ty-BatCoV HKU4, 5 (Y503, L510, E518, E541, and D542 corresponding to Y499, L506, E513, E536, and D537 in MERS-RBD) residues were conserved, which may allow binding to hDPP4. In Pi-BatCoV HKU5, 1 of the 12 conserved residues (D543 corresponding to D537 in MERS-RBD) was found. In Hp-BatCoV HKU25, 1 residue (R546 in strain YD131305/R547 in strain NL140462 corresponding to R542 in MERS-RBD) was conserved in both strains, and an additional residue (V554 corresponding to V555 in MERS-RBD) was conserved in strain NL140462 (
       <xref ref-type="fig" rid="F3">
        Figure 3
       </xref>
       ).
      </p>
     </sec>
     <sec id="s20">
      <title>
       <italic>
        Hypsugo pulveratus
       </italic>
       Bat Coronavirus (CoV) HKU25-S1-Receptor-Binding Domain (S1-RBD) Binds Human Dipeptidyl Peptidase 4 but With Lower Efficiency Than Middle East Respiratory Syndrome CoV S1-RBD
      </title>
      <p>
       To examine the ability of Hp-BatCoV HKU25-S to bind hDPP4, we expressed and purified hDPP4 and the S1-RBD domains of Hp-BatCoV HKU25 (residues 374−604) and MERS-CoV (residues 367−606) using procedures described previously [
       <xref ref-type="bibr" rid="CIT0032">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CIT0033">
        33
       </xref>
       ]. We first tested the binding efficiency of the S1-RBD domains to Huh7 cells (human hepatocellular carcinoma cells with endogenous hDPP4 expression) using flow cytometry. The HKU25-RBD can bind to Huh7 cells, although the observed fluorescence shift was smaller than MERS-RBD (
       <xref ref-type="fig" rid="F4">
        Figure 4A
       </xref>
       ). This indicates that HKU25-RBD can bind to hDPP4-expressing Huh7 cells with lower binding efficiency than that of MERS-RBD. To confirm that the binding is mediated by hDPP4, we obtained Huh7 cells with siRNA knockdown of hDPP4 (confirmed by mRNA expression and Western blot) (
       <xref ref-type="fig" rid="F4">
        Figure 4C
       </xref>
       ). A significant reduction of fluorescence shift was observed in both HKU25-RBD- and MERS-RBD-mediated binding to hDPP4-knockdown Huh7 cells compared with hDPP4-expressing Huh7 cells (
       <xref ref-type="fig" rid="F4">
        Figure 4A
       </xref>
       ). Moreover, HKU25-RBD and MERS-RBD could only bind to HEK293T cells (lacking endogenous hDPP4 expression) after transfection with hDPP4-expressing plasmid, although the binding efficiency to hDPP4-expressing HEK293T cells was lower for HKU25-RBD than MERS-RBD (
       <xref ref-type="fig" rid="F4">
        Figure 4B
       </xref>
       ). Second, we also confirmed the binding of HKU25-RBD to Huh7 cell surface by confocal microscopy (
       <xref ref-type="fig" rid="F4">
        Figure 4D
       </xref>
       ). Third, immunoprecipitation assays showed that hDPP4 protein can be specifically pulled down by both MERS-RBD and HKU25-RBD (
       <xref ref-type="fig" rid="F5">
        Figure 5
       </xref>
       ). These results indicated that HKU25-RBD can bind to hDPP4 on cell surface but with lower efficiency than MERS-CoV-RBD.
      </p>
      <fig fig-type="figure" id="F4" orientation="portrait" position="float">
       <label>
        Figure 4.
       </label>
       <caption>
        <p>
         Binding of HKU25-RBD with human cells was mediated by interacting with human dipeptidyl peptidase 4 (hDPP4) receptor. (A) Fluorescence-activated cell sorter (FACS) analysis of Middle East Respiratory Syndrome receptor-binding domain (MERS-RBD)-mFc (10 µg/mL) and HKU25-RBD-mFc (40 µg/mL) binding to Huh7 cells and hDPP4-knockdown Huh7 cells. (B) FACS analysis of MERS-RBD-mFc and HKU25-RBD-mFc binding to 293T cells and 293T cells transfected with hDPP4-expressing plasmid. The shaded area represents the secondary antibody control. (C) Determination of small interfering ribonucleic acid (siRNA) efficiency by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot analysis using primers and antibody specific for hDPP4. (D) MERS-RBD-mFc and HKU25-RBD-mFc binding to a molecule(s) located on the Huh7 cell surface. MERS-RBD-mFc and HKU25-RBD-mFc were detected by an Alexa Fluor 488-conjugated goat anti-mFc antibody. Empty expressing plasmid was used as a negative control.
        </p>
       </caption>
       <graphic xlink:href="jiy01804">
       </graphic>
      </fig>
      <fig fig-type="figure" id="F5" orientation="portrait" position="float">
       <label>
        Figure 5.
       </label>
       <caption>
        <p>
         Middle East Respiratory Syndrome receptor-binding domain (MERS-RBD)-mFc (A) and HKU25-RBD-mFc (B) proteins directly bind with human dipeptidyl peptidase 4 (hDPP4). HEK293 T cells were transfected with hDPP4-expressing plasmids, and MERS-RBD-mFc (A) and HKU25-RBD-mFc (B) proteins were used for immunoprecipitation of lysates of HEK293 T cells transfected with hDPP4-expressing or empty plasmids. Empty plasmid was mock-transfected as negative control. The hDPP4 was coprecipitated from the lysates, as detected by antibody specific for hDPP4. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control.
        </p>
       </caption>
       <graphic xlink:href="jiy01805">
       </graphic>
      </fig>
     </sec>
     <sec id="s21">
      <title>
       HKU25 Pseudovirus Can Use Human Dipeptidyl Peptidase 4 for Cell Entry but With Lower Infection Efficiency Than Middle East Respiratory Syndrome and HKU4 Pseudoviruses
      </title>
      <p>
       To determine whether Hp-BatCoV HKU25-S can mediate viral entry into hDPP4-expressing human cells, we performed HKU25-S-mediated pseudovirus entry assay. Because the S protein of Ty-BatCoV HKU4 but not that of Pi-BatCoV HKU5 can use hDPP4 for cell entry [
       <xref ref-type="bibr" rid="CIT0036">
        36
       </xref>
       ], we included HKU4-S-, HKU5-S-, and MERS-S-mediated pseudovirus entry assays for comparison. Pseudovirus assays were used because isolation of live Hp-BatCoV HKU25 was not successful, as with most bat CoVs that are often difficult to culture. Retroviruses pseudotyped with luciferase and the respective S proteins were tested for entry to HEK293T cells with or without hDPP4 expression. The MERS-S most robustly mediated pseudovirus entry into hDDP4-expressing HEK293T cells, followed by HKU4-S and HKU25-S, as shown by luciferase activities measured. All 3 pseudoviruses showed a marked increase in luciferase activities in hDDP4-expressing HEK293T cells compared with cells without hDPP4 expression (
       <xref ref-type="fig" rid="F6">
        Figure 6
       </xref>
       ). Moreover, anti-hDPP4 polyclonal antibodies could competitively block HKU25-S, HKU4-S, and MERS-S pseudovirus entry to hDPP4-expresssing HEK293T cells, further confirming the binding specificity. In contrast, HKU5-S and control retroviruses not pseudotyped with S did not mediate pseudovirus entry into hDPP4-expressing HEK293T cells (
       <xref ref-type="fig" rid="F6">
        Figure 6
       </xref>
       ). These results showed that hDPP4 is a possible functional receptor for Hp-BatCoV HKU25, although cell entry may be less efficient than Ty-BatCoV HKU4 and MERS-CoV.
      </p>
      <fig fig-type="figure" id="F6" orientation="portrait" position="float">
       <label>
        Figure 6.
       </label>
       <caption>
        <p>
         HEK293 T cells transfected with empty plasmid or human dipeptidyl peptidase 4 (hDPP4) were infected by retroviruses pseudotyped with Middle East Respiratory Syndrome coronavirus (MERS-CoV), Ty-BatCoV HKU4, Pi-BatCoV HKU5, and Hp-BatCoV HKU25 S proteins with mock pseudovirus (∆env) as control. The cells were also preincubated with anti-hDPP4 antibodies (Ab) to test for cell entry inhibition. Cell entry efficiencies were assayed by luciferase activity measurement after 72 hours.
        </p>
       </caption>
       <graphic xlink:href="jiy01806">
       </graphic>
      </fig>
     </sec>
     <sec id="s22">
      <title>
       Structural Modeling of Receptor Binding Domain Human Dipeptidyl Peptidase 4 Binding Interphase
      </title>
      <p>
       To predict the RBD-hDPP4 binding interface, the structures of HKU25-, MERS-, HKU4-, and HKU5-RBDs were modeled with that of hDPP4 using homology modeling. The sequence identity between HKU25-RBD and MERS-RBD (template) was &gt;50%, and the RBD-hDPP4 interface for all RBDs was similar (
       <xref ref-type="supplementary-material" rid="sup10">
        Supplementary Figure 5
       </xref>
       ), except that only MERS-RBD and HKU4-RBD possess the extended loop between β6 and β7 involved in interaction with hDPP4 [
       <xref ref-type="bibr" rid="CIT0023">
        23
       </xref>
       ]. A negative-charge residue, E536, located in MERS-RBD, corresponding to E541 in HKU4-RBD, can interact with the carbohydrate moiety of hDPP4, whereas HKU5-RBD contains a positive-charge residue, R542, and HKU25-RBD contains an uncharged residue, T540/A541, at the corresponding position. These findings supported that the binding of HKU25-RBD to hDPP4 may be weaker than that of MERS-RBD and HKU4-RBD but stronger than that of HKU5-RBD.
      </p>
     </sec>
    </sec>
    <sec id="s23">
     <title>
      DISCUSSION
     </title>
     <p>
      The novel lineage C betacoronavirus, Hp-BatCoV HKU25, helps to fill the evolutionary gap between existing bat viruses and MERS-CoV, and it offers new insights into the evolutionary origin of MERS-CoV. Hp-BatCoV HKU25 shared similar genome features with MERS-CoV, including the conserved ORF4a and ORF4b with predicted domains for double-stranded RNA binding and antagonizing interferon signals, respectively [
      <xref ref-type="bibr" rid="CIT0038">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="CIT0039">
       39
      </xref>
      ]. Phylogenetically, Hp-BatCoV HKU25, together with BtVs-BetaCoV/SC2013, was closely related to MERS-CoV and NeoCoV in most genome regions, suggesting that these viruses share a common ancestral origin. Although the S1 of NeoCoV is only distantly related to MERS-CoV, the S1 of Hp-BatCoV HKU25 was at a phylogenetic position closely related to MERS-CoV, only second to Ty-BatCoV HKU4. On the other hand, the S1 of NeoCoV is most closely related to
      <italic>
       Erinaceus
      </italic>
      CoV from European hedgehogs. Because NeoCoV was detected in an African bat, it is more likely a recombinant virus between bat and hedgehog CoVs in Africa. Moreover, it was shown that the S of BatCoV PREDICT/PDF-2180, which is closely related to NeoCoV in all genome regions, cannot mediate entry to hDPP4-expressing cells [
      <xref ref-type="bibr" rid="CIT0013">
       13
      </xref>
      ]. This further supported that NeoCoV and PREDICT/PDF-2180 are unlikely the immediate ancestors of MERS-CoV. On the other hand, Hp-BatCoV HKU25 and related viruses may represent close relatives to the immediate ancestor of MERS-CoV, based on its phylogenetic position in all genome regions including S protein.
     </p>
     <p>
      The ability of Hp-BatCoV HKU25 to use hDPP4 for cell entry suggests that the S protein of related bat viruses may have evolved to cross the species barrier during the emergence of MERS-CoV. Using binding and pseudovirus assays, we demonstrated the ability of HKU25-S to bind to and use hDPP4 for cell entry,although with infection efficiency lower than that of MERS-S and HKU4-S. This is not only in line with the phylogenetic position of HKU25-S1 between HKU4-S1 (which can bind to hDPP4) and HKU5-S1 (which cannot), but it is also consistent with findings from structural modeling. Our results suggested that MERS-CoV may have originated from bat viruses having acquired a stepwise increasing ability to bind hDPP4 as they evolved. Previous molecular dating studies estimated that the time of divergence of MERS-CoVs was approximately 2010/2011 [
      <xref ref-type="bibr" rid="CIT0040">
       40–43
      </xref>
      ]. The present dating results are in line with such estimation, with the tMRCA of MERS-CoVs dated to approximately 2009, and that of MERS-CoV, NeoCoV, Hp-BatCoV HKU25, and BtVs-BetaCoV/SC2013 dated to approximately 1939. Therefore, the immediate ancestor of MERS-CoV could well have emerged from bats in the last century through evolution in its S protein before jumping to camels and humans.
     </p>
     <p>
      The evolutionary path of MERS-CoV may be different from that of SARS-CoV. For SARS-CoV, the overlapping habitat and geographical distribution of different horseshoe bats in China is believed to have fostered viral recombination leading to the epidemic. The SARS-CoV is most likely a recombinant virus arising from ancestral viruses in horseshoe bats before it jumped to civet and then humans [
      <xref ref-type="bibr" rid="CIT0044">
       44–47
      </xref>
      ]. In contrast, there is currently no evidence to suggest that MERS-CoV is a recombinant virus. A previous study suggested that the genetically divergent S1 in NeoCoV may indicate intraspike recombination events involved in the emergence of MERS-CoV [
      <xref ref-type="bibr" rid="CIT0011">
       11
      </xref>
      ]. As explained above, NeoCoV, rather than MERS-CoV, is more likely a recombinant virus. On the other hand, a stepwise evolution of the S protein in gaining the ability to use camel and human DPP4 may be an important mechanism for interspecies transmission during the emergence of MERS-CoV.
     </p>
    </sec>
    <sec id="s24">
     <title>
      CONCLUSIONS
     </title>
     <p>
      Our results further support a possible bat origin of MERS-CoV and suggest that continuous surveillance of bats in the Middle East, Africa, and other regions may reveal the immediate animal origin of MERS-CoV. The application of similar state-of-the-art molecular studies on naturally evolving ancestral and intermediate viruses along the evolutionary path may provide further clues in understanding the mechanism of interspecies transmission of emerging viruses, while obviating the risks of generating dangerous mutants using the controversial, gain-of-function studies.
     </p>
    </sec>
    <sec id="s25" sec-type="supplementary-material">
     <title>
      Supplementary Data
     </title>
     <p>
      Supplementary materials are available at
      <italic>
       The Journal of Infectious Diseases
      </italic>
      online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
     </p>
     <supplementary-material content-type="local-data" id="sup1">
      <label>
       Supplementary Table 1
      </label>
      <media xlink:href="jiy018_suppl_supplementary_table_1.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup2">
      <label>
       Supplementary Table 2
      </label>
      <media xlink:href="jiy018_suppl_supplementary_table_2.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup3">
      <label>
       Supplementary Table 3
      </label>
      <media xlink:href="jiy018_suppl_supplementary_table_3.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup4">
      <label>
       Supplementary Table 4
      </label>
      <media xlink:href="jiy018_suppl_supplementary_table_4.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup5">
      <label>
       Supplementary Table 5
      </label>
      <media xlink:href="jiy018_suppl_supplementary_table_5.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup6">
      <label>
       Supplementary Figure 1
      </label>
      <media xlink:href="jiy018_suppl_supplementary_figure_1.png">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup7">
      <label>
       Supplementary Figure 2
      </label>
      <media xlink:href="jiy018_suppl_supplementary_figure_2.png">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup8">
      <label>
       Supplementary Figure 3
      </label>
      <media xlink:href="jiy018_suppl_supplementary_figure_3.png">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup9">
      <label>
       Supplementary Figure 4
      </label>
      <media xlink:href="jiy018_suppl_supplementary_figure_4.png">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup10">
      <label>
       Supplementary Figure 5
      </label>
      <media xlink:href="jiy018_suppl_supplementary_figure_5.jpeg">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
     <supplementary-material content-type="local-data" id="sup11">
      <label>
       Legends to Supporting Information
      </label>
      <media xlink:href="jiy018_suppl_legends_to_supporting_information.docx">
       <caption>
        <p>
         Click here for additional data file.
        </p>
       </caption>
      </media>
     </supplementary-material>
    </sec>
    <back>
     <notes id="n1">
      <title>
       Notes
      </title>
      <p>
       <bold>
        <italic>
         Financial support.
        </italic>
       </bold>
       This work is partly funded by Theme-Based Research Scheme (T11-707/15-R) and Research Grant Council Grant, University Grant Council; Health and Medical Research Fund (13121102) of the Food and Health Bureau of Hong Kong Special Administrative Region (HKSAR); Croucher Senior Medical Research Fellowships, Committee for Research and Conference Grant, Strategic Research Theme Fund, University Development Fund and Special Research Achievement Award, The University of Hong Kong; Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Disease for the HKSAR Department of Health; National Science and Technology Major Project of China (grant number 2012ZX10004213); and GDAS Special Project of Science and Technology Development (2017GDASCX-0107).
      </p>
      <p>
       <bold>
        <italic>
         Potential conflicts of interest.
        </italic>
       </bold>
       All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="CIT0001">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0002">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         7790
        </fpage>
        –
        <lpage>
         2
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0003">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0004">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         859
        </fpage>
        –
        <lpage>
         66
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0005">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         140
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0006">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        .
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         28
        </volume>
        :
        <fpage>
         465
        </fpage>
        –
        <lpage>
         522
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0007">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        :
        <fpage>
         1574
        </fpage>
        –
        <lpage>
         85
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17121802
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0008">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Molecular diversity of coronaviruses in bats
        </article-title>
        .
        <source>
         Virology
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         180
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0009">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsang
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         8638
        </fpage>
        –
        <lpage>
         50
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23720729
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0010">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tsang
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic relatedness of the novel human group C betacoronavirus to
         <italic>
          Tylonycteris
         </italic>
         bat coronavirus HKU4 and
         <italic>
          Pipistrellus
         </italic>
         bat coronavirus HKU5
        </article-title>
        .
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         1
        </volume>
        :
        <fpage>
         e35
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26038405
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0011">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ithete
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Richards
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         11297
        </fpage>
        –
        <lpage>
         303
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25031349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0012">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ren
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         MERS-related betacoronavirus in
         <italic>
          Vespertilio superans
         </italic>
         bats, China
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1260
        </fpage>
        –
        <lpage>
         2
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24960574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0013">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Anthony
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Gilardi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         pii
        </fpage>
        :
        <fpage>
         e00373
        </fpage>
        –
        <lpage>
         17
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0014">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Identification of a new human coronavirus
        </article-title>
        .
        <source>
         Nat Med
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         368
        </fpage>
        –
        <lpage>
         73
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0015">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         25
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0016">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         884
        </fpage>
        –
        <lpage>
         95
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0017">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –
        <lpage>
         4008
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0018">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel coronavirus, China
         <italic>
          Rattus
         </italic>
         coronavirus HKU24, from Norway rats supports the murine origin of
         <italic>
          Betacoronavirus
         </italic>
         1 and has implications for the ancestor of
         <italic>
          Betacoronavirus
         </italic>
         lineage A
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3076
        </fpage>
        –
        <lpage>
         92
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25552712
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0019">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lai
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        .
        <source>
         Adv Virus Res
        </source>
        <year>
         1997
        </year>
        ;
        <volume>
         48
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         100
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9233431
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0020">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Brian
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus genome structure and replication
        </article-title>
        .
        <source>
         Curr Top Microbiol Immunol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         287
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15609507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0021">
       <label>
        21.
       </label>
       <mixed-citation publication-type="confproc">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Baric
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Coronaviridae
        </article-title>
        . In:
        <source>
         Virus Taxonomy, Classification and Nomenclature of Viruses
        </source>
        .
        <conf-name>
         Ninth Report of the International Committee on Taxonomy of Viruses
        </conf-name>
        ,
        <publisher-name>
         International Union of Microbiological Societies, Virology Division
        </publisher-name>
        ;
        <year>
         2011
        </year>
        : pp
        <fpage>
         806
        </fpage>
        –
        <lpage>
         28
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0022">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           de Graaf
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lauber
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         pii
        </fpage>
        :
        <fpage>
         e00473
        </fpage>
        –
        <lpage>
         12
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0023">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        .
        <source>
         Cell Host Microbe
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         328
        </fpage>
        –
        <lpage>
         37
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0024">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Agnarsson
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zambrana-Torrelio
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Flores-Saldana
          </surname>
          <given-names>
           NP
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           May-Collado
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A time-calibrated species-level phylogeny of bats (Chiroptera, Mammalia)
        </article-title>
        .
        <source>
         PLoS Curr
        </source>
        <year>
         2011
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         RRN1212
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21327164
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0025">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Caì
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yú
          </surname>
          <given-names>
           SQ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Postnikova
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         CD26/DPP4 cell-surface expression in bat cells correlates with bat cell susceptibility to Middle East respiratory syndrome coronavirus (MERS-CoV) infection and evolution of persistent infection
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e112060
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         25409519
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0026">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in Jamaican fruit bats (
         <italic>
          Artibeus jamaicensis
         </italic>
         )
        </article-title>
        .
        <source>
         Sci Rep
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         21878
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26899616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0027">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        :
        <fpage>
         14040
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0028">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yob
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Field
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Rashdi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2001
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         439
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11384522
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0029">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a novel betacoronavirus subgroup A coronavirus, rabbit coronavirus HKU14, from domestic rabbits
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         5481
        </fpage>
        –
        <lpage>
         96
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22398294
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0030">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         CoVDB: a comprehensive database for comparative analysis of coronavirus genes and genomes
        </article-title>
        .
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         D504
        </fpage>
        –
        <lpage>
         11
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17913743
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0031">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wernery
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wong
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Polyphyletic origin of MERS coronaviruses and isolation of a novel clade A strain from dromedary camels in the United Arab Emirates
        </article-title>
        .
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e128
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27999424
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0032">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Dong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Milewska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         7202
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0033">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sun
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Qi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         237
        </fpage>
        –
        <lpage>
         48
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24155382
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0034">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Xiong
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ye
          </surname>
          <given-names>
           YN
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         <italic>
          Laribacter hongkongensis
         </italic>
         anaerobic adaptation mediated by arginine metabolism is controlled by the cooperation of FNR and ArgR
        </article-title>
        .
        <source>
         Environ Microbiol
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         1266
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28028888
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0035">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         500
        </volume>
        :
        <fpage>
         227
        </fpage>
        –
        <lpage>
         31
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0036">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Liu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         12516
        </fpage>
        –
        <lpage>
         21
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25114257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0037">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        .
        <source>
         Cell Res
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         986
        </fpage>
        –
        <lpage>
         93
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0038">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zillinger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         12489
        </fpage>
        –
        <lpage>
         95
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24027320
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0039">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Thornbrough
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Jha
          </surname>
          <given-names>
           BK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         e00258
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27025250
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0040">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Watson
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zumla
          </surname>
          <given-names>
           AI
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Spread, circulation, and evolution of the middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         pii
        </fpage>
        :
        <fpage>
         e01062
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="CIT0041">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Sabir
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           TT
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Ahmed
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         81
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0042">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         50
        </fpage>
        –
        <lpage>
         6
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24239323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0043">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        .
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         745
        </fpage>
        –
        <lpage>
         51
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0044">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Huang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related rhinolophus bat coronavirus in china reveal bats as a reservoir for acute, self-limiting infection that allows recombination events
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        ;
        <volume>
         84
        </volume>
        :
        <fpage>
         2808
        </fpage>
        –
        <lpage>
         19
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20071579
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0045">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Hon
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Lam
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Shi
          </surname>
          <given-names>
           ZL
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        ;
        <volume>
         82
        </volume>
        :
        <fpage>
         1819
        </fpage>
        –
        <lpage>
         26
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18057240
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0046">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus ORF8 protein is acquired from SARS-related coronavirus from greater horseshoe bats through recombination
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         10532
        </fpage>
        –
        <lpage>
         47
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26269185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="CIT0047">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name name-style="western">
          <surname>
           Song
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Tu
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         ,
         <name name-style="western">
          <surname>
           Zhang
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <etal>
          et al
         </etal>
        </person-group>
        <article-title>
         Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         102
        </volume>
        :
        <fpage>
         2430
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15695582
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       BMC Vet Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       BMC Vet. Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        BMC Veterinary Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1746-6148
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30971240
      </article-id>
      <article-id pub-id-type="pmc">
       6458635
      </article-id>
      <article-id pub-id-type="publisher-id">
       1862
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s12917-019-1862-4
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Analysis of long non-coding RNAs in neonatal piglets at different stages of porcine deltacoronavirus infection
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          Xiaoyu
         </given-names>
        </name>
        <address>
         <email>
          929697010@qq.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lan
         </surname>
         <given-names>
          Tian
         </given-names>
        </name>
        <address>
         <email>
          lantian2016@scau.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Ruiting
         </given-names>
        </name>
        <address>
         <email>
          ruiting.wu@foxmail.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Zhihai
         </given-names>
        </name>
        <address>
         <email>
          595422648@qq.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Yuqi
         </given-names>
        </name>
        <address>
         <email>
          452911063@qq.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Yuan
         </given-names>
        </name>
        <address>
         <email>
          sunyuan@scau.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zheng
         </surname>
         <given-names>
          Yaoyao
         </given-names>
        </name>
        <address>
         <email>
          564197902@qq.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0002-5229-8799
        </contrib-id>
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          Jingyun
         </given-names>
        </name>
        <address>
         <email>
          majy2400@scau.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0000 9546 5767
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.20561.30
         </institution-id>
         <institution>
          College of Animal Science, South China Agricultural University,
         </institution>
        </institution-wrap>
        Tianhe District, Wushan Road 483, Guangzhou, 510642 China
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        Key Laboratory of Animal Health Aquaculture and Environmental Control, Guangzhou, Guangdong China
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       15
      </volume>
      <elocation-id>
       111
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         1
        </day>
        <month>
         11
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         3
        </day>
        <month>
         4
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s). 2019
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p id="Par1">
         PDCoV (Porcine Deltacoronavirus) is a novel porcine coronavirus that causes intestinal necrosis of piglets, thinning of the intestinal wall and severe villus atrophy in the small intestine. PDCoV is a highly contagious infectious disease characterized by diarrhea, dehydration and vomiting. It has been reported that lncRNA has a significant effect on viral replication and increased or decreased virulence. At present, there is almost no research on lncRNA related to PDCoV infection. With the development of the research, a large number of lncRNAs related to PDCoV infection have been discovered. Identifying the role of these lncRNAs in the infection process facilitates the screening of diagnostically significant biomarkers.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p id="Par2">
         Using high throughput sequencing to screen differentially expressed long non-coding RNA (lncRNA) during PDCoV infection, we identified 99, 41 and 33 differentially expressed lncRNAs in the early, middle and late stages of infection, respectively. These lncRNAs were involved in glycolysis / gluconeogenesis, histidine metabolism and pentose and Chloroalkane and chloroalkene degradation pathway. We obtained expression data of miRNAs, lncRNAs and mRNAs during PDCoV infection and constructed and investigated an interaction network. The qRT-PCR validation results of 6 differentially expressed lncRNAs were consistent with RNA-Seq results.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p id="Par3">
         This study is the first to examine differentially expressed lncRNAs after PDCoV infection of piglets. These results can provide new insights into PDCoV infection and antiviral strategies.
        </p>
       </sec>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (10.1186/s12917-019-1862-4) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Long non-coding RNA (lncRNA)
       </kwd>
       <kwd>
        Porcine deltacoronavirus infection
       </kwd>
       <kwd>
        Functional enrichment
       </kwd>
       <kwd>
        High throughput sequencing
       </kwd>
       <kwd>
        Interaction network
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          the National Key Research and Development Program of China
         </institution>
        </funding-source>
        <award-id>
         No. 2016YFD0501304
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Jingyun
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2019
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p id="Par33">
      Porcine deltacoronavirus (PDCoV) belongs to the newly identified deltacoronavirus genus in the Coronaviridae family. This family possesses single-stranded positive-strand RNA genomes contained in an nucleocapside, so PDCoV is an enveloped virus. Intestinal infections in pigs result in diarrhea, vomiting and dehydration and are highly lethal. In 2009, 17 cases of swine diarrhea were positive for PDCoV and were linked to the deltacoronavirus [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. The virus appeared again in 2014 causing large-scale outbreaks of pig diarrhea in the United States [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. A retrospective study in 2015 identified PDCoV from samples collected from four Chinese provinces between 2004 and 2014 indicated an infection rate of 6.5% [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. Subsequently, Thailand, Laos, Vietnam and the Philippines successively reported the existence of PDCoV [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ].
     </p>
     <p id="Par34">
      PDCoV has a broad host range and interacts with the catalytic domain of receptor aminopeptidase N (APN) in cat, chicken and human cells through the S1 domain B of the S protein, even though PDCoV infections in animals other than pigs have not been reported [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Ectopic expression of porcine aminopeptidase N (pAPN) in non-susceptible cells converted them to PDCoV-susceptible although pAPN is not a critical receptor but is an important accessory factor for infection [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. PDCoV infection also affects the host’s innate immunity. PDCoV infection inhibited Interferon-beta (IFN-β) production by inhibiting nuclear factor-κB (NF-κB) and interferon regulation factor 3(IFN3) activation and inhibiting IFN-β promoter activation in the RIG-I pathway by suppressing IFN3 [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ].
     </p>
     <p id="Par35">
      Long non-coding RNAs (lncRNA) are RNAs &gt; 200 nucleotides in length with no protein encoding function. These RNAs play key roles in numerous biological functions as well as human disease. LncRNAs are involved as regulatory factors and are involved in epigenetic and transcriptional and post-transcriptional regulation. The functions of mammalian lncRNAs have been linked to metabolism, apoptosis and cell proliferation as well as immune responses including regulation of pattern recognition receptors and inflammation [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      –
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ].
     </p>
     <p id="Par36">
      LncRNAs play crucial roles in host-virus interactions that include immune responsiveness and viral infections can induce their expression. For example, the differential expression of &gt; 4800 lncRNAs were found in rhabdomyosarcoma cells after Enterovirus 71 infection [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ]. In addition, &gt; 3000 differentially expressed genes (DEG) were associated with lncRNAs during infectious salmon anaemia (ISA) virus infection and most were regulated in response to infection [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ]. A total of 1236 lncRNA transcripts were differentially regulated at different stages of bovine viral diarrhea virus infected Madin Darby bovine kidney (MDBK) cells [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ].
     </p>
     <p id="Par37">
      In the current study, we analyzed lncRNAs that were differentially expressed after PDCoV infection of piglets to examine whether lncRNAs are involved in PDCoV infection.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Results
     </title>
     <sec id="Sec3">
      <title>
       Determination of tissue viral loads
      </title>
      <p id="Par38">
       We plaque-purified the virus that we used for swine testicular cells (ST) cell infections and the virus with titer 1.0 × 10
       <sup>
        8.6
       </sup>
       TCID50/ml was used for experimental infection of piglets. We found distinct differences in intestinal pathology between the experimental and the control groups at 2, 4 and 11 day post-infection (dpi) (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ). Piglet tissue samples taken at 2, 4 and 11 dpi were aseptically collected and the PDCoV RNA viral loads in each organ were determined by qPCR. The virus was found primarily in the small intestine. At mid-infection, viral loads in all organs except the kidney reached a maximum for all three periods. The heart, spleen, kidney, duodenum, jejunum, ileum, mesenteric lymph nodes and tonsils were all positive for PDCoV. At the late stage of infection, all organs except the ileum were PDCoV-negative (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       ). The ileum was the most serious site of infection, so we used these samples for high throughput sequencing.
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Abdominal anatomy of pigs at different infection stages of PDCoV infection.
          <bold>
           a
          </bold>
          , Experimental group at 2dpi;
          <bold>
           b
          </bold>
          , Control group at 2dpi;
          <bold>
           c
          </bold>
          , Experimental group at 4dpi;
          <bold>
           d
          </bold>
          , Control group at 4dpi;
          <bold>
           e
          </bold>
          , Experimental group at 11dpi;
          <bold>
           f
          </bold>
          , Control group at 11dpi
         </p>
        </caption>
        <graphic id="MO1" xlink:href="12917_2019_1862_Fig1_HTML">
        </graphic>
       </fig>
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          qRT-PCR results of tissue viral load after PDCoV infection in piglets
         </p>
        </caption>
        <graphic id="MO2" xlink:href="12917_2019_1862_Fig2_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Identification of lncRNAs in PDCoV -infected piglets by RNA-Seq
      </title>
      <p id="Par39">
       The samples we used for RNA-Seq were taken in the pre-onset (2 dpi), mid-onset (4 dpi) and late-onset (11 dpi). During the experiment, we chose three piglets from eighteen experimental piglets during the corresponding infection period for dissection, and the control group also dissected three piglets. The samples we used for RNA-seq were obtained from six piglets dissected at each stage. We analyzed the RNA-Seq data for 18 samples and each contained between 53,173,880 and 94,027,536 raw data points. After filtering, 52,830,072 to 93,138,526 clean data points were obtained for each sample and after assembly resulted in 2130 novel lncRNAs. In this group there were 173 differentially expressed lncRNAs identified in the three infection phases at a fold change &gt; 2 and
       <italic>
        P
       </italic>
       &lt; 0.05. The early, middle and late periods included 99 (21 up, 78 down), 41 (9 up, 32 down) and 33 (10 up, 23 down) lncRNAs, respectively (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ).
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Quantitative analysis of differential expression of lncRNA between experimental group and control group in different periods
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Infection stage
           </th>
           <th>
            Experimental group
           </th>
           <th>
            Control group
           </th>
           <th>
            Up-regulated lncRNAs
           </th>
           <th>
            Down-regulated lncRNAs
           </th>
           <th>
            Total differentially expressed lncRNA
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Early
           </td>
           <td>
            B1
           </td>
           <td>
            A1
           </td>
           <td>
            21
           </td>
           <td>
            78
           </td>
           <td>
            99
           </td>
          </tr>
          <tr>
           <td>
            Middle
           </td>
           <td>
            B2
           </td>
           <td>
            A2
           </td>
           <td>
            9
           </td>
           <td>
            32
           </td>
           <td>
            41
           </td>
          </tr>
          <tr>
           <td>
            Late
           </td>
           <td>
            B3
           </td>
           <td>
            A3
           </td>
           <td>
            10
           </td>
           <td>
            23
           </td>
           <td>
            33
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Target gene prediction and lncRNA analysis
      </title>
      <p id="Par40">
       LncRNAs are regulators of protein coding genes that lie near their genomic locations. We analyzed these RNAs for all protein coding genes within 100 kb of the lncRNA as potential cis-regulatory targets (Additional file
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ).
      </p>
      <p id="Par41">
       Gene ontology (GO) analysis of DEGs indicated that 7, 7 and 9 terms were significantly enriched (
       <italic>
        P
       </italic>
       &lt; 0.05) during early, middle and late infection periods, respectively. Molecular functions in the early period involved ferric-chelate reductase and oxidoreductase activity and metal ion oxidization. The middle period had terms related to oxidoreductase and prenyltransferase activity as well as positive regulation of activated T cell proliferation and catalytic activity. The late period terms were related to oxidoreductase activity, chromosome organization involved in the meiotic cell cycle and small molecule binding. Target genes related to oxidoreductase activity were found in all three periods (Additional file
       <xref ref-type="media" rid="MOESM2">
        2
       </xref>
       ).
      </p>
      <p id="Par42">
       To elucidate the role of lncRNAs in the virus-host relationship, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of lncRNA target genes during each challenge period. We found that 6 pathways in the early period, 11 pathways in the middle and 14 pathways in the late period that were significantly enriched (
       <italic>
        P
       </italic>
       &lt; 0.05). The temporal expression pattern of these pathways was related to both anabolic and catabolic functions. Anabolic functions included ascorbate and aldarate metabolism, histidine, β-alanine, glyoxylate and dicarboxylate metabolism. Catabolic pathways involved metabolism of limonene, pinene, chloroalkane and chloroalkene (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       a, b and c).
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          KEGG pathway enrichment analysis of target genes.
          <bold>
           a
          </bold>
          , The enrichment pathway of genes in the early infection stage;
          <bold>
           b
          </bold>
          , The enrichment pathway of genes in the middle infection stage;
          <bold>
           c
          </bold>
          , The enrichment pathway of genes in the late infection stage. Dot diameter is proportional to the number of differential genes and color depth is proportional to significance. Abscissa, enrichment ratio; ordinate, the different pathways. (The signal pathway shown in the figure that represents in the top 20
          <italic>
           p
          </italic>
          -value ranking)
         </p>
        </caption>
        <graphic id="MO3" xlink:href="12917_2019_1862_Fig3_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       lncRNA-miRNA-mRNA interaction network analysis
      </title>
      <p id="Par43">
       CeRNAs (competitive endogenous RNA) are a class of functionally defined RNAs possessing miRNA binding sites that can compete with miRNA and inhibit their regulation of target genes [
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ]. Some lncRNAs in the network we constructed function as ceRNAs and we were able to construct a network based on these RNAs. The network was composed of 11 lncRNA nodes, 33 mRNA nodes and 10 miRNA nodes. The expression level of lncRNA is significantly up-regulated or down-regulated, and its target miRNA is down-regulated or up-regulated. The target gene expression level of miRNA is consistent with lncRNA. This suggests that there may be significant competitive RNA during infection. During the early infection stage, a total of 3 differentially expressed miRNAs were targeted by 4 lncRNAs and 9 mRNAs in the network. MSTRG.20658.3 and MSTRG.24537.4 can competitively bind to ssc-miR-194b-3p with mRNA. MSTRG.16902.19 and MSTRG.43450.4 can competitively bind to ssc-miR-885-5p and MSTRG.16902.19 can also competitively bind to ssc-miR-7857-3p (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       a). In the middle period, a total of 6 differentially expressed miRNAs were targeted by 5 lncRNAs and 18 mRNAs in the network. We found that MSTRG.45362.10 was capable of competitive binding to both ssc-miR-490-5p and ssc-miR-216, and MSTRG.31817.2 was capable of competitive binding to ssc-miR-215, ssc-miR-874 and ssc-miR-184. MSTRG.35510.2, MSTRG.22938.2 and MSTRG.53204.2 can competitively bind to ssc-miR-133b, ssc-miR-184, ssc-miR-874, respectively (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       b). In the late stage, a total of 2 differentially expressed miRNAs were targeted by 2 lncRNAs and 6 mRNAs in the network. MSTRG.31541.4 was capable of competitive binding to ssc-miR-196b-5p, and MSTRG.41555.2 can competitively bind to ssc-miR-9785-5p (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       c). The biological significance of ceRNA network in PDCoV infection was also reflected by topological structures including hubs and nodes as well as direct connections.
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          The lncRNA-miRNA-mRNA interaction network.
          <bold>
           a
          </bold>
          , pre-infection;
          <bold>
           b
          </bold>
          , middle stage and
          <bold>
           c
          </bold>
          , late stage of infection. Triangle, lncRNA; rectangle, miRNA; circle, mRNA. Red, up-regulation; green, down-regulation
         </p>
        </caption>
        <graphic id="MO4" xlink:href="12917_2019_1862_Fig4_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Validation of differentially expressed lncRNAs
      </title>
      <p id="Par44">
       The RNA-Seq analysis indicated that the expression level of many lncRNAs were significantly changed in the experimental group compared with the control group. In the mid-infection period, we randomly selected 6 lncRNAs (MSTRG.35510.2, MSTRG.4915.1, MSTRG.16902.37, MSTRG.45362.10, MSTRG.16541.3, MSTRG.45362.9) for expression level verification. Our validation results were consistent with the RNA-Seq results, so the results of RNA-Seq were credible. (Fig.
       <xref ref-type="fig" rid="Fig5">
        5
       </xref>
       ).
       <fig id="Fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Verification of RNA-Seq results. Six differentially expressed lncRNAs in the middle stages of infection were randomly selected for real-time qRT-PCR experiments to verify whether their expression levels were consistent with the RNA-Seq results.
          <bold>
           a
          </bold>
          , the expression verification result of six lncRNAs (MSTRG.35510.2, MSTRG.4915.1, MSTRG.16902.37, MSTRG.45362.10, MSTRG.16541.3, MSTRG.45362.9);
          <bold>
           b
          </bold>
          , the RNA-Seq results of lncRNAs (MSTRG.35510.2, MSTRG.4915.1, MSTRG.16902.37, MSTRG.45362.10, MSTRG.16541.3, MSTRG.45362.9). (
          <italic>
           n
          </italic>
          = 3;
          <sup>
           *
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.05,
          <sup>
           **
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.01,
          <sup>
           ***
          </sup>
          <italic>
           p
          </italic>
          &lt; 0.001)
         </p>
        </caption>
        <graphic id="MO5" xlink:href="12917_2019_1862_Fig5_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec8">
     <title>
      Discussion
     </title>
     <p id="Par45">
      PDCoV infects pigs of all ages, but primarily causes diarrhea in newborn pigs. Clinically, PDCoV infection is similar to porcine intestinal coronavirus, but PDCoV infection has a wider tissue tropism and can be detected in organs other than the digestive tract. This suggests a complex pathogenic mechanism for this virus and an in-depth understanding of its pathogenic and immune mechanisms is necessary for infection control.
     </p>
     <p id="Par46">
      Current lncRNA research has focused on human medicine including cardiovascular disease and cancer [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      –
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ]. In livestock and poultry, examination of lncRNAs is in its infancy and existing research has focused on muscle, bone and embryonic development as well as fat metabolism [
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      –
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ]. Additionally, these studies have focused on lncRNA regulation of protein-coding genes.
     </p>
     <p id="Par47">
      Recent studies have shown that viral infections can induce lncRNAs to promote or inhibit viral responses. The lncRNA NEAT1 can up-regulate anti-HIV factors during infection and promote human immunodeficiency virus 1(HIV-1) replication [
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ]. The lncRNA ACOD1 enhances the replication of multiple viruses in both mouse and human cells [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. However, an examination of lncRNA expression during PDCoV infections was lacking. The current study is the first to use comprehensive deep-sequencing technology that implicates lncRNAs in the response to PDCoV infection in pigs.
     </p>
     <p id="Par48">
      Our RNA-Seq data can assist in understanding the mechanism of action of differentially expressed lncRNAs at different stages of PDCoV infection. We established a lncRNA gene library that was generated during the early, middle and late stages of PDCoV infection. We identified 173 differentially expressed lncRNAs and 2130 novel lncRNAs. The greatest number of differentially expressed lncRNAs were found during the early stage of infection (2 dpi). The number of down regulated was &gt;up-regulated lncRNAs. In addition, we found lncRNA MSTRG.18455 was significantly down regulated (− 7-fold) and its target gene IGF1 was significantly enriched. The insulin-like growth factor 1 (IGF1) is a member of the growth and development promoting signaling system and the main determinant of animal growth [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ].
     </p>
     <p id="Par49">
      Porcine enteroviruses can enter the digestive system through the mouth and subsequently attach to the intestinal villi. This causes villus atrophy resulting in diarrhea, dehydration, vomiting and weight loss. Our results from target mRNA pathway analysis revealed that pre-challenge target mRNAs of lncRNA were enriched for the signaling pathway of glyoxylate and dicarboxylate metabolism, limonene and pinene degradation, chloroalkane and chloroalkene degradation as well as glycolysis / gluconeogenesis. During the middle stages of infection, limonene and pinene degradation, glycolysis / gluconeogenesis, ascorbate and aldarate metabolism, histidine metabolism signaling pathway were prominent and late-stage target mRNAs were primarily concentrated on histidine metabolism, glyoxylate and dicarboxylate metabolism, beta-Alanine metabolism. It can be seen that some differentially expressed lncRNAs are related to the metabolism of organisms. The GO analysis indicated that at the middle stage of infection, these target genes were significantly enriched in the biological process category including regulation of activated T cell proliferation. Our future work will include determining lncRNA mechanisms of T cell activation and proliferation. This will assist in determining how the immune system is compromised by PDCoV infection in pigs.
     </p>
     <p id="Par50">
      In this study, we constructed a lncRNA-miRNA-mRNA interaction network containing a ceRNA network. Interestingly, both lncRNA and mRNA in the ceRNA network were negatively correlated with miRNA. Previous studies have confirmed that ceRNAs can act as miRNA ‘sponges’ and this is especially important for cancer and tumor diseases [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. By analyzing the miRNAs in the ceRNA network we found that the target miRNAs ssc-miR-885-5p, ssc-miR-490-5p, ssc-miR-196b-5p and ssc-miR-133b of lncRNAs were all up regulated. MiR-885-5p is a direct regulator of the IGF1 receptor that in combination with p73 regulate emergence of aggressive cancer stem-like features [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. Decreased expression of miR-133b is associated with poor survival and increased metastasis in colorectal cancer [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. miR-490-5p inhibits cell proliferation, migration and invasion but miR-490-5p can promote apoptosis of Human hepatoma (Hep3B) cells by inhibiting Roundabout Guidance Receptor 1 (ROBO1) [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ]. MiR-196b-5p overexpression may also be associated with a risk of conversion of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML) [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ]. The target miRNAs ssc-miR-194b-3p, ssc-miR-184, ssc-miR-215, ssc-miR-874 were all down regulated. miR-874 and miR-215 can act as a tumor suppressor [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. Therefore, this network plays a role in the expression of immune-related genes and the stimulation of host immune responses.
     </p>
     <p id="Par51">
      Our research provides a scientific reference for the lncRNAs that regulate PDCoV replication that can assist studies of ceRNA and PDCoV infection. This work can also aid the development of effective drugs and genetic engineering of pigs with PDCoV resistance.
     </p>
    </sec>
    <sec id="Sec9">
     <title>
      Conclusions
     </title>
     <p id="Par52">
      In this study, we provide the first analysis of differentially expressed lncRNAs after PDCoV infection in piglets. we constructed a lncRNA-miRNA-mRNA interaction network. This study provides insights into the relationships between lncRNAs and PDCoV immune modulation. Future studies will address lncRNA functions in immune escape used by PDCoV.
     </p>
    </sec>
    <sec id="Sec10">
     <title>
      Methods
     </title>
     <sec id="Sec11">
      <title>
       Cell culture and virus
      </title>
      <p id="Par53">
       ST cells used for experimental PDCoV infections in the study were kept in the Poultry Laboratory of the College of Animal Science, South China Agricultural University and cultured at 37 °C in a humidified 5% CO
       <sub>
        2
       </sub>
       atmosphere in Dulbecco’s modified Eagle’s medium (DMEM, HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone) [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ]. ST cells and culture media were checked to ensure the absence of PDCoV, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV) by gel electrophoresis of RT-PCR products. The virus strain PDCoV-CHN-GD16–05 (GenBank 74 accession no.KY363868.1) [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ] was isolated and preserved by our laboratory from the watery diarrhea feces of nursing piglets in Guangdong Province, China. ST monolayers at 80% confluency were infected at a multiplicity of infection (MOI) of 1.5. The cells were cultured in serum-free medium at 37 °C for 1 h and the medium was replaced with fresh culture medium containing 2% FBS. Infected cells were collected 36 h post-infection (hpi).
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Determination of viral growth in tissues
      </title>
      <p id="Par54">
       The tissues we have taken include heart, liver, spleen, lung, kidney, duodenum, jejunum, ileum, mesenteric lymph nodes (MLN), inguinal lymph nodes and tonsils. Absolute quantification of viral RNA is done by real-time qRT-PCR. using the PCR primer pair 5′-TGGCTGATCCTCGCATCATGG-3’and 5′-GAGCGCATCCTTAAGTCT CTC-3′. One-step RT-PCR reactions were performed using an ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA) instrument according to the TAKARA company ‘PrimeScript™ RT reagent Kit with gDNA Eraser’ operating instructions. We used SYBR Green qPCR Super Mix (Invitrogen) for real-time qRT-PCR experiments based on amplification conditions. The following steps were used: denaturation at 95 °C for 10 mins and 40 cycles at 95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s and finally a melting curve.
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Piglet challenge experiments
      </title>
      <p id="Par55">
       The piglets were purchased from a farm in Huanong Wen’s Co., Ltd. Thirty 5-day-old piglets lacking any overt signs of infection were selected after observation for 24 h to ensure they were not exposed to stress before infection. The animals were infected with 5 mL of a virus solution containing 1.0 × 10
       <sup>
        8.6
       </sup>
       TCID50/mL administered orally (18 piglets), and 12 control piglets were administered the same volume of DMEM. At the end of the experiment, the experimental animals showed weight loss, loss of appetite, and diarrhea, so they were euthanized. Experimental animal euthanasia method is based on the experimental animal management and practical technical manual. Intravenous injection of sodium pentobarbital at a dose of 90–100 mg/kg. Corpses were put into the septic tank, and they were fermented and used for fertilizer.
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       RNA-Seq analysis
      </title>
      <p id="Par56">
       Three piglets were euthanized and dissected at the early (2 dpi), middle stage (4 dpi) and the late stages of infection period (11 dpi). Intestinal tissues with the most obvious lesions at each stage were collected in triplicate, frozen in liquid nitrogen and stored at − 80 °C. For controls, intestinal tissue was taken from control animals at similar time points.
      </p>
      <p id="Par57">
       Total RNA was extracted using Trizol reagent (Invitrogen) and purified using the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA concentration and integrity were measured using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). We prepared RNA sequencing libraries from small intestine samples and performed 150-bp paired-end sequencing using the Illumina HiSeq platform. RNA sequencing libraries were prepared from 2 μg of total RNA using the TruSeq Kit (Illumina, San Diego, CA, USA) with the following modification. Instead of purifying poly-A RNA using poly-dT primer beads, we removed ribosomal RNA using the Ribo-Zero rRNA Removal Kit (Illumina). All other steps were performed according to the manufacturer’s protocol.
      </p>
      <p id="Par58">
       RNA-Seq libraries were quality control analyzed and the average insert size was 200 to 300 bp. The library was sequenced using a Hiseq platform (Illumina) at Shanghai Personal Biotechnology (Shanghai, China). Raw data was filtered and high-quality data was obtained. At the same time, the quality of the clean data was checked using the Q20, Q30 and GC content.
      </p>
      <p id="Par59">
       The Stringtie algorithm (
       <ext-link ext-link-type="uri" xlink:href="https://ccb.jhu.edu/software/stringtie/">
        https://ccb.jhu.edu/software/stringtie/
       </ext-link>
       ) was used to analyze expression levels of lncRNA transcripts. The coding potential of candidate lncRNAs was analyzed to obtain high-confidence lncRNA using the Coding Potential Calculator (
       <ext-link ext-link-type="uri" xlink:href="http://cpc.cbi.pku.edu.cn/">
        http://cpc.cbi.pku.edu.cn/
       </ext-link>
       ), Coding-noncoding Index and Pfamscan (
       <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/pfa/pfamscan">
        http://www.ebi.ac.uk/Tools/pfa/pfamscan
       </ext-link>
       ).
      </p>
      <p id="Par60">
       LncRNAs are primarily located near genes with coding functions and the function of the associated lncRNA can be approximated by determining target gene function within 100 kb. GO (
       <ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org/">
        http://www.geneontology.org/
       </ext-link>
       ) and KEGG (
       <ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg">
        https://www.genome.jp/kegg
       </ext-link>
       ) databases were used to determine functions and metabolic pathways of DEGs. GO terms and KEGG pathways with Q-values ≤0.05 were considered significantly enriched.
      </p>
     </sec>
     <sec id="Sec15">
      <title>
       Construction of lncRNA-miRNA-mRNA interaction network
      </title>
      <p id="Par61">
       LncRNAs, miRNAs and mRNAs that were differentially expressed between the experimental and control group tissues were chosen for analysis. The differential expression of miRNAs and lncRNAs was identified using standard selection criteria at
       <italic>
        P
       </italic>
       &lt; 0.05 and fold change &gt; 2. We used miRanda and psRobot software to predict target miRNA for lncRNA and target mRNA for miRNA (
       <ext-link ext-link-type="uri" xlink:href="http://regrna2.mbc.nctu.edu.tw">
        http://regrna2.mbc.nctu.edu.tw
       </ext-link>
       and
       <ext-link ext-link-type="uri" xlink:href="http://miranda.org.uk">
        http://miranda.org.uk
       </ext-link>
       ) Target mRNAs were separately analyzed. The ceRNA network was generated from the interaction network and used Pearson correlation coefficient (PCC) to calculate the correlation between mRNA and lncRNA and chose pairs with positive correlations (PCC &gt; 0.99 and P &lt; 0.05). Visualization of the lncRNA-miRNA-mRNA interaction network was constructed using Cytoscape software (version 3.0;
       <ext-link ext-link-type="uri" xlink:href="http://www.cytoscape.org/download.php">
        http://www.cytoscape.org/download.php
       </ext-link>
       ).
      </p>
     </sec>
     <sec id="Sec16">
      <title>
       Screening and qRT-PCR validation of differentially expressed lncRNAs
      </title>
      <p id="Par62">
       Six lncRNAs (MSTRG.35510.2, MSTRG.4915.1, MSTRG.16902.37, MSTRG.45362.10, MSTRG.16541.3, MSTRG.45362.9) were randomly selected from the middle of the infection for real-time qRT-PCR validation, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as an endogenous control. Total RNA was extracted from uninfected and infected cells using a total RNA extraction kit (Tiangen Biotech, Beijing, China). cDNA was synthesized using a reverse transcription kit (Fisher Scientific, Pittsburg, PA, USA) with 2 μg of total RNA according to the manufacturer’s instructions. The primers were designed using Primer 5.0 software
       <ext-link ext-link-type="uri" xlink:href="http://www.premierbiosoft.com">
        www.premierbiosoft.com
       </ext-link>
       (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ). One-step real-time RT-PCR reactions were performed using a One Step PrimeScript RT-PCR kit (Takara) on an ABI PRISM 7500 instrument. The following steps were used: reverse transcription at 42 °C for 10 min, denaturation at 95 °C for 10 s and 40 cycles at 95 °C for 5 s, 55 °C for 20 s, 72 °C for 10 s and finally a melting curve. Each reaction was performed in triplicate. LncRNA expression levels were calculated based on the 2 -ΔΔCT method [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. Expression levels were normalized to those of GAPDH.
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          DNA primers used for qRT-PCR
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            primers
           </th>
           <th>
            Sequence (5′-3′)
           </th>
           <th>
            amplicon
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            qPDCoV-F
           </td>
           <td>
            TGGCTGATCCTCGCATCATGG
           </td>
           <td>
            155 bp
           </td>
          </tr>
          <tr>
           <td>
            qPDCoV-R
           </td>
           <td>
            GAGCGCATCCTTAAGTCTCTC
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            GADPH-F
           </td>
           <td>
            ACATGGCCTCCAAGGAGTAAGA
           </td>
           <td>
            150 bp
           </td>
          </tr>
          <tr>
           <td>
            GADPH-R
           </td>
           <td>
            GATCGAGTTGGGGCTGTGACT
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.35510.2-F
           </td>
           <td>
            CCACCAGCAACCAGGAACAGC
           </td>
           <td>
            177 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.35510.2-R
           </td>
           <td>
            GCTCACAGCAACGCCAGATCC
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.45362.9-F
           </td>
           <td>
            TGCCGATTCCATTGTGCCATGAC
           </td>
           <td>
            169 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.45362.9-R
           </td>
           <td>
            GTTGCTGTGGCTGTGGCTGTAG
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.4915.1-F
           </td>
           <td>
            ACTGTTGAAGCATGGCACAGA
           </td>
           <td>
            90 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.4915.1-R
           </td>
           <td>
            TGTGGATGAAGGAACAGCAGG
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.16902.37-F
           </td>
           <td>
            AAGGAAGGTAACCGCAGGAGGAAG
           </td>
           <td>
            107 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.16902.37-R
           </td>
           <td>
            GCTGCTGAGCTGAATTGCTAGGC
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.45362.10-F
           </td>
           <td>
            ATAGGAACCAGCAGGCGAGGAG
           </td>
           <td>
            108 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.45362.10-R
           </td>
           <td>
            GGAGAGTGAGGAGGAAGGCAGTC
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.16541.3-F
           </td>
           <td>
            AGCAGTCAGAACCACCTGGAGAG
           </td>
           <td>
            188 bp
           </td>
          </tr>
          <tr>
           <td>
            MSTRG.16541.3-R
           </td>
           <td>
            CACCACAGCTCACGGCAAGG
           </td>
           <td>
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec17">
      <title>
       Statistical analysis
      </title>
      <p id="Par63">
       RNA-Seq data was analyzed using statistical R and expression levels of lncRNAs were compared using the paired sample t-test. Data were expressed as the mean ± standard deviation from at least three independent experiments. SPSS 17.0 software package (SPSS, Chicago, IL, USA) was used to analyze the qRT-PCR data. P &lt; 0.05 was considered statistically significant. Statistical differences between the control and PDCoV infected cells were analyzed using the Student’s t-test.
      </p>
     </sec>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Additional files
     </title>
     <sec id="Sec18">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="12917_2019_1862_MOESM1_ESM.xlsx">
         <label>
          Additional file 1:
         </label>
         <caption>
          <p>
           The target gene of lncRNAs. (XLSX 238 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM2">
        <media xlink:href="12917_2019_1862_MOESM2_ESM.xlsx">
         <label>
          Additional file 2:
         </label>
         <caption>
          <p>
           Gene ontology (GO) analysis of target genes. (XLSX 10 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         AML
        </term>
        <def>
         <p id="Par4">
          Acute myeloid leukemia
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         APN
        </term>
        <def>
         <p id="Par5">
          Aminopeptidase N
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CeRNA
        </term>
        <def>
         <p id="Par6">
          Competitive endogenous RNA
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         DEG
        </term>
        <def>
         <p id="Par7">
          Differentially expressed genes
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         DMEM
        </term>
        <def>
         <p id="Par8">
          Dulbecco’s modified Eagle’s medium
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         dpi
        </term>
        <def>
         <p id="Par9">
          days post-infection
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         FBS
        </term>
        <def>
         <p id="Par10">
          Fetal bovine serum
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         GADPH
        </term>
        <def>
         <p id="Par11">
          Glyceraldehyde-3-phosphate dehydrogenase
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         GO
        </term>
        <def>
         <p id="Par12">
          Gene ontology
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         Hep3B
        </term>
        <def>
         <p id="Par13">
          Human hepatoma
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         HIV
        </term>
        <def>
         <p id="Par14">
          Human immunodeficiency virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         hpi
        </term>
        <def>
         <p id="Par15">
          hours post-infection
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IFN3
        </term>
        <def>
         <p id="Par16">
          Interferon regulation factor 3
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IFN-β
        </term>
        <def>
         <p id="Par17">
          Interferon-beta
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IGF1
        </term>
        <def>
         <p id="Par18">
          Insulin-like growth factor 1
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ISA
        </term>
        <def>
         <p id="Par19">
          Infectious salmon anaemia
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         KEGG
        </term>
        <def>
         <p id="Par20">
          Kyoto Encyclopedia of Genes and Genomes
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         lncRNA
        </term>
        <def>
         <p id="Par21">
          Long non-coding RNA
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MDBK
        </term>
        <def>
         <p id="Par22">
          Madin Darby bovine kidney
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MDS
        </term>
        <def>
         <p id="Par23">
          Myelodysplastic syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MOI
        </term>
        <def>
         <p id="Par24">
          A multiplicity of infection
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         NF-κB
        </term>
        <def>
         <p id="Par25">
          Nuclear factor-κB
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         pAPN
        </term>
        <def>
         <p id="Par26">
          Porcine aminopeptidase N
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PCC
        </term>
        <def>
         <p id="Par27">
          Pearson correlation coefficient
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PDCoV
        </term>
        <def>
         <p id="Par28">
          Porcine deltacoronavirus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PEDV
        </term>
        <def>
         <p id="Par29">
          Porcine epidemic diarrhea virus
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ROBO1
        </term>
        <def>
         <p id="Par30">
          Roundabout Guidance Receptor 1
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         ST
        </term>
        <def>
         <p id="Par31">
          Swine testicular cells
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         TGEV
        </term>
        <def>
         <p id="Par32">
          Transmissible gastroenteritis virus
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <ack>
      <p>
       we would like to acknowledge Guangdong Wen’s Foodstuffs Group Co., Ltd. China, for providing us with piglets’ tissue samples.
      </p>
      <sec id="FPar1">
       <title>
        Funding
       </title>
       <p id="Par64">
        This work was supported by the National Key Research and Development Program of China (No. 2016YFD0501304). The funders did not play any role in the design, conclusions or interpretation of the study.
       </p>
      </sec>
      <sec id="FPar2" sec-type="data-availability">
       <title>
        Availability of data and materials
       </title>
       <p id="Par65">
        The data and material used and analyzed during the current study are available from the corresponding author on reasonable request. The cells used in the study were kept in the Poultry Laboratory of the College of Animal Science, South China Agricultural University and the Piglets purchased from a farm in Huanong Wen’s Co., Ltd. Do not require any administrative or ethical approval to use them.
       </p>
      </sec>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Authors’ contributions
      </title>
      <p>
       Conceptualization, JYM; Data curation, ZHZ; Formal analysis, RTW; Funding acquisition, JYM; Investigation, XYT and YYZ; Project administration, TL and YS; Resources, JYM; Supervision, TL; Validation, YQC and XYT; Visualization, XYT; Writing – original draft, XYT. All authors read and approved the final manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Ethics approval
      </title>
      <p id="Par66">
       This study was carried out in accordance with the recommendations of National Standards for Laboratory Animals of the People’s Republic of China (GB149258–2010). The protocol was approved by Animal Research Committees of South China Agricultural University. Pigs used for the study were handled in accordance with good animal practices required by the Animal Ethics Procedures and Guidelines of the People’s Republic of China.
      </p>
     </notes>
     <notes>
      <title>
       Consent for publication
      </title>
      <p id="Par67">
       “Not applicable”.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par68">
       The authors report no conflicts of interest. The authors themselves are responsible for the content and writing of the paper.
      </p>
     </notes>
     <notes>
      <title>
       Publisher’s Note
      </title>
      <p id="Par69">
       Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SKP
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CSF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus Deltacoronavirus supports bat coronaviruses as the gene source of Alphacoronavirus and Betacoronavirus and avian coronaviruses as the gene source of Gammacoronavirus and Deltacoronavir
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06540-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection and genetic characterization of deltacoronavirus in pigs, Ohio, USA, 2014
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1227
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2007.140296
        </pub-id>
        <pub-id pub-id-type="pmid">
         24964136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine Deltacoronavirus in mainland China
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         2254
        </fpage>
        <lpage>
         2255
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2112.150283
        </pub-id>
        <pub-id pub-id-type="pmid">
         26584185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lorsirigool
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Saeng-Chuto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Temeeyasen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Madapong
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tripipat
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wegner
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The first detection and full-length genome sequence of porcine deltacoronavirus isolated in Lao PDR
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         2016
        </year>
        <volume>
         161
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         2909
        </fpage>
        <lpage>
         2911
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-016-2983-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         27424024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madapong
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Saeng-Chuto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lorsirigool
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Temeeyasen
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Srijangwad
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tripipat
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Complete genome sequence of porcine Deltacoronavirus isolated in Thailand in 2015
        </article-title>
        <source>
         Genome Announc
        </source>
        <year>
         2016
        </year>
        <volume>
         4
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         e408
        </fpage>
        <lpage>
         e416
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/genomeA.00408-16
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Hulswit
          </surname>
          <given-names>
           RJG
          </given-names>
         </name>
         <name>
          <surname>
           Kenney
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Alhamo
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility
        </article-title>
        <source>
         Pnas.
        </source>
        <year>
         2018
        </year>
        <volume>
         115
        </volume>
        <issue>
         22
        </issue>
        <fpage>
         E5135
        </fpage>
        <lpage>
         E5143
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1802879115
        </pub-id>
        <pub-id pub-id-type="pmid">
         29760102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Contribution of porcine aminopeptidase N to porcine deltacoronavirus infection
        </article-title>
        <source>
         Emerging Microbes &amp; Infections
        </source>
        <year>
         2018
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         65
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41426-018-0068-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         29636467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Porcine deltacoronavirus (PDCoV) infection suppresses RIG-I mediated interferon-β production
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2016
        </year>
        <volume>
         495
        </volume>
        <fpage>
         10
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2016.04.025
        </pub-id>
        <pub-id pub-id-type="pmid">
         27152478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Lnc-mg is a long non-coding RNA that promotes myogenesis
        </article-title>
        <source>
         Nat Commun
        </source>
        <year>
         2017
        </year>
        <volume>
         8
        </volume>
        <fpage>
         14718
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms14718
        </pub-id>
        <pub-id pub-id-type="pmid">
         28281528
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rapicavoli
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Mikhail
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Laberge
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics
        </article-title>
        <source>
         Elife.
        </source>
        <year>
         2013
        </year>
        <volume>
         2
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         e00762
        </fpage>
        <pub-id pub-id-type="doi">
         10.7554/eLife.00762
        </pub-id>
        <pub-id pub-id-type="pmid">
         23898399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Kuang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The STAT3-regulated long non-coding RNA Lethe promote the HCV replication
        </article-title>
        <source>
         Biomed Pharmacother
        </source>
        <year>
         2015
        </year>
        <volume>
         72
        </volume>
        <fpage>
         165
        </fpage>
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.biopha.2015.04.019
        </pub-id>
        <pub-id pub-id-type="pmid">
         26054691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Landeras-Bueno
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ortín
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Regulation of influenza virus infection by long noncoding RNAs
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2016
        </year>
        <volume>
         212
        </volume>
        <fpage>
         78
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2015.08.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         26321158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         lncRNA expression signatures in response to enterovirus 71 infection
        </article-title>
        <source>
         Biochemical &amp; Biophysical Research Communications
        </source>
        <year>
         2013
        </year>
        <volume>
         430
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         629299 633
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2012.11.101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boltaña
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Valenzuela-Miranda
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Aguilar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gallardo-Escárate
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long noncoding RNAs (lncRNAs) dynamics evidence immunomodulation during ISAV-infected Atlantic salmon (Salmo salar)
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2016
        </year>
        <volume>
         6
        </volume>
        <fpage>
         22698
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep22698
        </pub-id>
        <pub-id pub-id-type="pmid">
         26939752
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analyses of long non-coding RNAs and mRNA profiling through RNA sequencing of MDBK cells at different stages of bovine viral diarrhea virus infection
        </article-title>
        <source>
         Res Vet Sci
        </source>
        <year>
         2017
        </year>
        <volume>
         115
        </volume>
        <fpage>
         508
        </fpage>
        <lpage>
         516
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.rvsc.2017.09.020
        </pub-id>
        <pub-id pub-id-type="pmid">
         28968572
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ghanekar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Versican 3′-untranslated region (3′-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity
        </article-title>
        <source>
         FASEB J
        </source>
        <year>
         2013
        </year>
        <volume>
         27
        </volume>
        <fpage>
         907
        </fpage>
        <lpage>
         919
        </lpage>
        <pub-id pub-id-type="doi">
         10.1096/fj.12-220905
        </pub-id>
        <pub-id pub-id-type="pmid">
         23180826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           MZ
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Weng
          </surname>
          <given-names>
           MZ
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           YY
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p
        </article-title>
        <source>
         Cell Death Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         e1583
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/cddis.2014.541
        </pub-id>
        <pub-id pub-id-type="pmid">
         25569100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Shao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Xi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Long noncoding RNA associated-competing endogenous RNAs in gastric cancer
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2014
        </year>
        <volume>
         4
        </volume>
        <fpage>
         6088
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep06088
        </pub-id>
        <pub-id pub-id-type="pmid">
         25124853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Pu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Long noncoding RNA NKILA enhances the anti-cancer effects of baicalein in hepatocellular carcinoma via the regulation of NF-κB signaling
        </article-title>
        <source>
         Chem Biol Interact
        </source>
        <year>
         2018
        </year>
        <volume>
         285
        </volume>
        <fpage>
         48
        </fpage>
        <lpage>
         58
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cbi.2018.02.027
        </pub-id>
        <pub-id pub-id-type="pmid">
         29481769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of long non-protein coding RNAs in chicken skeletal muscle using next generation sequencing
        </article-title>
        <source>
         Genomics.
        </source>
        <year>
         2012
        </year>
        <volume>
         99
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         292
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ygeno.2012.02.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         22374175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roeszler
          </surname>
          <given-names>
           Kelly N.
          </given-names>
         </name>
         <name>
          <surname>
           Itman
          </surname>
          <given-names>
           Catherine
          </given-names>
         </name>
         <name>
          <surname>
           Sinclair
          </surname>
          <given-names>
           Andrew H.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           Craig A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The long non-coding RNA, MHM, plays a role in chicken embryonic development, including gonadogenesis
        </article-title>
        <source>
         Developmental Biology
        </source>
        <year>
         2012
        </year>
        <volume>
         366
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         317
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ydbio.2012.03.025
        </pub-id>
        <pub-id pub-id-type="pmid">
         22546690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Divoux
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Karastergiou
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Fried
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel lncRNA in gluteal adipose tissue and evidence for its positive effect on preadipocyte differentiation
        </article-title>
        <source>
         Obesity.
        </source>
        <year>
         2014
        </year>
        <volume>
         22
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1781
        </fpage>
        <lpage>
         1785
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/oby.20793
        </pub-id>
        <pub-id pub-id-type="pmid">
         24862299
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Yedavalli
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Jeang
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
        </person-group>
        <article-title>
         NEAT1 long noncoding RNA and Paraspeckle bodies modulate HIV-1 posttranscriptional expression
        </article-title>
        <source>
         Mbio.
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         00596
        </fpage>
        <lpage>
         00512
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00596-12
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism
        </article-title>
        <source>
         Science.
        </source>
        <year>
         2017
        </year>
        <volume>
         358
        </volume>
        <issue>
         6366
        </issue>
        <fpage>
         1051
        </fpage>
        <lpage>
         1055
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aao0409
        </pub-id>
        <pub-id pub-id-type="pmid">
         29074580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           LeRoith
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology
        </article-title>
        <source>
         Endocrinology.
        </source>
        <year>
         2001
        </year>
        <volume>
         142
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         1685
        </fpage>
        <lpage>
         1688
        </lpage>
        <pub-id pub-id-type="doi">
         10.1210/endo.142.5.8148
        </pub-id>
        <pub-id pub-id-type="pmid">
         11316729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stratikopoulos
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Szabolcs
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dragatsis
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Klinakis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Efstratiadis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hormonal action of IGF1 in postnatal mouse growth
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2008
        </year>
        <volume>
         105
        </volume>
        <issue>
         49
        </issue>
        <fpage>
         19378
        </fpage>
        <lpage>
         19383
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0809223105
        </pub-id>
        <pub-id pub-id-type="pmid">
         19033454
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of an lncRNA-miRNA-mRNA interaction mechanism in breast cancer based on bioinformatic analysis
        </article-title>
        <source>
         Mol Med Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         16
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         5113
        </fpage>
        <lpage>
         5120
        </lpage>
        <pub-id pub-id-type="doi">
         10.3892/mmr.2017.7304
        </pub-id>
        <pub-id pub-id-type="pmid">
         28849135
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion by acting as a ceRNA of miR-101-3p in colorectal cancer cells
        </article-title>
        <source>
         Tumour Biol
        </source>
        <year>
         2017
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1010428317716250
        </fpage>
        <pub-id pub-id-type="doi">
         10.1177/1010428317716250
        </pub-id>
        <pub-id pub-id-type="pmid">
         28720069
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meier
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Hardtstock
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Joost
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Alla
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Pützer
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
        </person-group>
        <article-title>
         p73 and IGF1R regulate emergence of aggressive Cancer stem-like features via miR-885-5p control
        </article-title>
        <source>
         Cancer Res
        </source>
        <year>
         2016
        </year>
        <volume>
         76
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         197
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="doi">
         10.1158/0008-5472
        </pub-id>
        <pub-id pub-id-type="pmid">
         26554827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo
        </article-title>
        <source>
         Cancer Biol Ther
        </source>
        <year>
         2010
        </year>
        <volume>
         10
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         190
        </fpage>
        <lpage>
         197
        </lpage>
        <pub-id pub-id-type="doi">
         10.4161/cbt.10.2.12186
        </pub-id>
        <pub-id pub-id-type="pmid">
         20505319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Weiqing
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Lijun
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           Dengcheng
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Feihua
          </given-names>
         </name>
        </person-group>
        <article-title>
         MiR-490-5p Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Directly Regulating ROBO1
        </article-title>
        <source>
         Pathology &amp; Oncology Research
        </source>
        <year>
         2017
        </year>
        <volume>
         25
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12253-017-0305-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         28924964
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome
        </article-title>
        <source>
         Int J Hematol
        </source>
        <year>
         2017
        </year>
        <volume>
         105
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         777
        </fpage>
        <lpage>
         783
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12185-017-2201-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         28224273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer
        </article-title>
        <source>
         Oncotarget.
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         1605
        </fpage>
        <lpage>
         1617
        </lpage>
        <pub-id pub-id-type="doi">
         10.18632/oncotarget.2748
        </pub-id>
        <pub-id pub-id-type="pmid">
         25596740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           White
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Khella
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Grigull
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Adzovic
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Youssef
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Honey
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MiRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215
        </article-title>
        <source>
         Br J Cancer
        </source>
        <year>
         2011
        </year>
        <volume>
         105
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1741
        </fpage>
        <lpage>
         1749
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/bjc.2011.401
        </pub-id>
        <pub-id pub-id-type="pmid">
         22033272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine deltacoronavirus infection: etiology, cell culture for virus isolation and propagation, molecular epidemiology and pathogenesis
        </article-title>
        <source>
         Virus Research Volume
        </source>
        <year>
         2016
        </year>
        <volume>
         226
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         50
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2016.04.009
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="other">
        Mai K, Li D, Wu J, Wu Z, Cheng J, He L, et al. Complete genome sequences of two porcine Deltacoronavirus strains, CHN-GD16-03 and CHN-GD16-05, isolated in southern China, 2016. Genome Announc. 2018;6(4). Pii: e01545-17). 10.1128/genomeA.01545-17.
       </mixed-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schmittgen
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Livak
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analyzing real-time PCR data by the comparative C(T) method
        </article-title>
        <source>
         Nat Protoc
        </source>
        <year>
         2008
        </year>
        <volume>
         3
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1108
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nprot.2008.73
        </pub-id>
        <pub-id pub-id-type="pmid">
         18546601
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30654597
      </article-id>
      <article-id pub-id-type="pmc">
       6357182
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v11010073
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-11-00073
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          Bingpeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-11-00073">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0003-2855-9837
        </contrib-id>
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          Hin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-11-00073">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Dong
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-11-00073">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sze
         </surname>
         <given-names>
          Kong-Hung
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-11-00073">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-7967-8126
        </contrib-id>
        <name>
         <surname>
          Lai
         </surname>
         <given-names>
          Pok-Man
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          Shuofeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shuai
         </surname>
         <given-names>
          Huiping
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Yixin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kao
         </surname>
         <given-names>
          Richard Yi-Tsun
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper Fuk-Woo
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00073">
         3
        </xref>
        <xref ref-type="aff" rid="af4-viruses-11-00073">
         4
        </xref>
        <xref ref-type="aff" rid="af5-viruses-11-00073">
         5
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-11-00073">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00073">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00073">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00073">
         3
        </xref>
        <xref ref-type="aff" rid="af4-viruses-11-00073">
         4
        </xref>
        <xref ref-type="aff" rid="af5-viruses-11-00073">
         5
        </xref>
        <xref ref-type="aff" rid="af6-viruses-11-00073">
         6
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-11-00073">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-11-00073">
       <label>
        1
       </label>
       State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China;
       <email>
        ybp1205@hku.hk
       </email>
       (B.Y.);
       <email>
        hinchu@hku.hk
       </email>
       (H.C.);
       <email>
        khsze@hku.hk
       </email>
       (K.-H.S.);
       <email>
        yuansf@hku.hk
       </email>
       (S.Y.);
       <email>
        rytkao@hku.hk
       </email>
       (R.Y.-T.K.)
      </aff>
      <aff id="af2-viruses-11-00073">
       <label>
        2
       </label>
       Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China;
       <email>
        u3005140@connect.hku.hk
       </email>
       (D.Y.);
       <email>
        vangor@hku.hk
       </email>
       (P.-M.L.);
       <email>
        shuaihp@connect.hku.hk
       </email>
       (H.S.);
       <email>
        jasyx@connect.hku.hk
       </email>
       (Y.W.)
      </aff>
      <aff id="af3-viruses-11-00073">
       <label>
        3
       </label>
       Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
      </aff>
      <aff id="af4-viruses-11-00073">
       <label>
        4
       </label>
       Hainan-Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Hainan Medical University, Haikou 96708, China
      </aff>
      <aff id="af5-viruses-11-00073">
       <label>
        5
       </label>
       Hainan-Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
      </aff>
      <aff id="af6-viruses-11-00073">
       <label>
        6
       </label>
       The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
      </aff>
      <author-notes>
       <corresp id="c1-viruses-11-00073">
        <label>
         *
        </label>
        Correspondence:
        <email>
         jfwchan@hku.hk
        </email>
        (J.F.-W.C.);
        <email>
         kyyuen@hku.hk
        </email>
        (K.-Y.Y.); Tel.: +852-2255-2413 (J.F.-W.C. &amp; K.-Y.Y.); Fax: +852-2855-1241 (J.F.-W.C. &amp; K.-Y.Y.)
       </corresp>
       <fn id="fn1-viruses-11-00073">
        <label>
         †
        </label>
        <p>
         These authors contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        16
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       1
      </issue>
      <elocation-id>
       73
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         14
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         15
        </day>
        <month>
         1
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 by the authors.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Lipids play numerous indispensable cellular functions and are involved in multiple steps in the replication cycle of viruses. Infections by human-pathogenic coronaviruses result in diverse clinical outcomes, ranging from self-limiting flu-like symptoms to severe pneumonia with extrapulmonary manifestations. Understanding how cellular lipids may modulate the pathogenicity of human-pathogenic coronaviruses remains poor. To this end, we utilized the human coronavirus 229E (HCoV-229E) as a model coronavirus to comprehensively characterize the host cell lipid response upon coronavirus infection with an ultra-high performance liquid chromatography-mass spectrometry (UPLC–MS)-based lipidomics approach. Our results revealed that glycerophospholipids and fatty acids (FAs) were significantly elevated in the HCoV-229E-infected cells and the linoleic acid (LA) to arachidonic acid (AA) metabolism axis was markedly perturbed upon HCoV-229E infection. Interestingly, exogenous supplement of LA or AA in HCoV-229E-infected cells significantly suppressed HCoV-229E virus replication. Importantly, the inhibitory effect of LA and AA on virus replication was also conserved for the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV). Taken together, our study demonstrated that host lipid metabolic remodeling was significantly associated with human-pathogenic coronavirus propagation. Our data further suggested that lipid metabolism regulation would be a common and druggable target for coronavirus infections.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        lipidomics
       </kwd>
       <kwd>
        UHPLC–MS
       </kwd>
       <kwd>
        HCoV-229E
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-11-00073">
     <title>
      1. Introduction
     </title>
     <p>
      Coronaviruses are enveloped viruses with a large single-strand, positive-sense RNA genome [
      <xref ref-type="bibr" rid="B1-viruses-11-00073">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-viruses-11-00073">
       2
      </xref>
      ]. As of today, there are a total of six coronaviruses that are known to infect humans, including human coronavirus OC43 (HCoV-OC43), human coronavirus 229E (HCoV-229E), severe acute respiratory syndrome coronavirus (SARS-CoV), human coronavirus HKU1 (HCoV-HKU1), human coronavirus NL63 (HCoV-NL63), and the Middle East respiratory syndrome coronavirus (MERS-CoV) [
      <xref ref-type="bibr" rid="B3-viruses-11-00073">
       3
      </xref>
      ]. These human-pathogenic coronaviruses cause a broad range of clinical manifestations. HCoV-OC43, HCoV-229E, HCoV-HKU1, and HCoV-NL63 cause mild, self-limiting upper respiratory tract infections. In contrast, SARS-CoV and the recently emerged MERS-CoV may cause severe pneumonia with acute respiratory distress syndrome, multi-organ failure, and death in both immunocompetent and immunocompromised hosts [
      <xref ref-type="bibr" rid="B4-viruses-11-00073">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B5-viruses-11-00073">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-viruses-11-00073">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B7-viruses-11-00073">
       7
      </xref>
      ].
     </p>
     <p>
      Lipids play crucial roles at various stages in the virus life cycle. First, lipids can serve as the direct receptors or entry co-factors for enveloped and non-enveloped viruses at the cell surface or the endosomes [
      <xref ref-type="bibr" rid="B8-viruses-11-00073">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-viruses-11-00073">
       9
      </xref>
      ]. Second, lipids and lipid synthesis play important roles in the formation and function of the viral replication complex [
      <xref ref-type="bibr" rid="B10-viruses-11-00073">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-viruses-11-00073">
       11
      </xref>
      ]. Third, lipid metabolism can generate the required energy for efficient viral replication [
      <xref ref-type="bibr" rid="B12-viruses-11-00073">
       12
      </xref>
      ]. Moreover, lipids can dictate the proper cellular distribution of viral proteins, as well as the trafficking, assembly, and release of virus particles [
      <xref ref-type="bibr" rid="B13-viruses-11-00073">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14-viruses-11-00073">
       14
      </xref>
      ]. In this regard, the host lipid biogenesis pathways play indispensable roles in modulating virus propagation.
     </p>
     <p>
      As in other viruses, lipids play key roles in the life cycle of coronaviruses. Coronaviruses confiscate intracellular membranes of the host cells to generate new compartments known as double membrane vesicles (DMVs) for the amplification of the viral genome. DMVs are membranous structures that not only harbor viral proteins but also contain a specific array of hijacked host factors, which collectively orchestrate a unique lipid micro-environment optimal for coronavirus replication [
      <xref ref-type="bibr" rid="B15-viruses-11-00073">
       15
      </xref>
      ]. A recent study indicated that a key lipid processing enzyme, cytosolic phospholipase A2α enzyme (cPLA2α) that belongs to the phospholipase A2 (PLA2) superfamily, was closely associated with DMVs’ formation and coronaviruses’ replication [
      <xref ref-type="bibr" rid="B16-viruses-11-00073">
       16
      </xref>
      ]. The viral protein and RNA accumulation, as well as the production of infectious virus progeny, were significantly diminished in the presence of cPLA2α inhibitor [
      <xref ref-type="bibr" rid="B16-viruses-11-00073">
       16
      </xref>
      ]. At the same time, phospholipase A2 group IID (PLA2G2D), an enzyme that predominantly contributes to anti-inflammatory/pro-resolving lipid mediator expression, contributed to worsened outcomes in mice infected with SARS-CoV by modulating the immune response [
      <xref ref-type="bibr" rid="B17-viruses-11-00073">
       17
      </xref>
      ]. However, to date, the change and modulating effects of the specific lipids involved in lipid rearrangement upon coronavirus infection remains largely unexplored.
     </p>
     <p>
      To obtain a comprehensive and unbiased profile of perturbed lipids upon coronavirus infection, we performed mass spectrometry (MS)-based lipidomics profiling on coronavirus-infected cells using HCoV-229E as a model virus. Specific lipids including glycerophospholipids and fatty acids (FAs) upon virus infection were identified, which represented the lipid species that were rearranged by HCoV-229E infection. Further pathway analysis revealed that the linoleic acid (LA) and arachidonic acid (AA) metabolism axis was the most perturbed pathway upon HCoV-229E infection. Importantly, supplement of additional LA and AA to coronavirus-infected cells significantly inhibited virus replication of both HCoV-229E and the highly virulent MERS-CoV, suggesting that the LA–AA metabolism axis is a common and essential pathway that could modulate coronavirus replication. In this regard, temporal modulation of the host lipid profile is a potential novel strategy to combat emerging human coronaviruses.
     </p>
    </sec>
    <sec id="sec2-viruses-11-00073">
     <title>
      2. Materials and Methods
     </title>
     <sec id="sec2dot1-viruses-11-00073">
      <title>
       2.1. Materials
      </title>
      <p>
       High performance liquid chromatography (HPLC)-grade methanol, acetonitrile, chloroform and 2-propanol were purchased from Merck (Darmstadt, Germany). HPLC-grade water was prepared using a Milli-Q water purification system (Millipore, Burlington, MA, USA). Analytical grade acetic acid and commercial standards used for biomarker identification were purchased from Sigma-Aldrich (St. Louis, MO, USA). Internal standards (IS) including Arachidonic acid-d8, 15(S)-HETE-d8, Leukotriene-B4-d4 and Platelet-activating factor C-16-d4 (PAF C-16-d4) were purchased from Cayman Chemical (Ann Arbor, MI, USA) [
       <xref ref-type="bibr" rid="B18-viruses-11-00073">
        18
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2dot2-viruses-11-00073">
      <title>
       2.2. Viruses and Cells
      </title>
      <p>
       Huh-7 and VeroE6 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL streptomycin (5% CO
       <sub>
        2
       </sub>
       at 37 °C). MERS-CoV (EMC/2012 strain) was kindly provided by Professor Ron Fouchier (Erasmus Medical Center, Rotterdam, The Netherlands). MERS-CoV and HCoV-229E were cultured in VeroE6 cells in serum-free DMEM supplemented with 100 U/mL penicillin and 100 g/mL streptomycin as we described previously [
       <xref ref-type="bibr" rid="B19-viruses-11-00073">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="B20-viruses-11-00073">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="B21-viruses-11-00073">
        21
       </xref>
       ]. The supernatants were harvested when cytopathic effects (CPE) were observed and centrifuged to generate the viral stocks. The viral stocks were titrated by plaque assay on VeroE6 cells and stored at −80 °C as previously described [
       <xref ref-type="bibr" rid="B22-viruses-11-00073">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="B23-viruses-11-00073">
        23
       </xref>
       ]. Briefly, confluent VeroE6 cells were infected with 10-fold serial viral dilutions. The cells were incubated with diluted viruses at 37 °C for 1 h and subsequently overlaid with 1% low-melting-point agarose (Promega, Madison, WI, USA). The cells were fixed with 4% formaldehyde as the plaques were observed and then stained with 0.2% crystal violet. All experiments involving live MERS-CoV followed the approved standard operating procedures of the biosafety level 3 facility as previously described [
       <xref ref-type="bibr" rid="B24-viruses-11-00073">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="B25-viruses-11-00073">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="B26-viruses-11-00073">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="B27-viruses-11-00073">
        27
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2dot3-viruses-11-00073">
      <title>
       2.3. Lipid Treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Infected and Human Coronavirus (HCoV-229E)-Infected Huh-7 Cells
      </title>
      <p>
       Huh-7 cells were seeded into 24-well plate to reach 90% confluency and infected with MERS-CoV or HCoV-229E at multiplicity of infection (MOI) of 0.005 or 1, respectively. After 1 h of inoculation, the cells were washed with phosphate-buffered saline (PBS) and maintained in lipids-supplemented medium at the indicated concentrations for 24 h. AA, LA, oleic acid (OA), and palmitic acid (PA) were dissolved in ethanol and ethanol was used as a negative control. The lipids were purchased from Cayman Chemical (Ann Arbor, MI, USA). The supernatants and cell lysates were collected at 24 h post-infection. The viral genome copy numbers were determined by reverse-transcription quantitative polymerase chain reaction (RT-qPCR) as previously described [
       <xref ref-type="bibr" rid="B28-viruses-11-00073">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="B29-viruses-11-00073">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="B30-viruses-11-00073">
        30
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2dot4-viruses-11-00073">
      <title>
       2.4. Lipid Extraction for Lipidomics Profiling
      </title>
      <p>
       Confluent Huh-7 cells were mock infected or infected with HCoV-229E at MOI of 1 and incubated in DMEM medium. At 24 hpi, cells were collected for cellular lipid extraction. The lipid extraction was performed for liquid chromatography-mass spectrometry (LC-MS) analysis according to a previously described protocol with slight modifications [
       <xref ref-type="bibr" rid="B31-viruses-11-00073">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="B32-viruses-11-00073">
        32
       </xref>
       ]. Inactivation of virus infectivity was confirmed before further processing as we previously described with some modifications [
       <xref ref-type="bibr" rid="B33-viruses-11-00073">
        33
       </xref>
       ]. Briefly, 500 µL of ice-cold 150 mM ammonium bicarbonate solution was added to dissociate cells. Two millilitres of chloroform/methanol (
       <italic>
        v
       </italic>
       /
       <italic>
        v
       </italic>
       2:1) containing IS were added, followed by vortexing and centrifugation at 4500 rpm for 10 min at 4 °C. The bottom phase was transferred to glass vials and dried using a vacuum concentrator for storage at −80 °C. The dried samples were reconstituted in 250 µL solvent mixture containing methanol/2-propanol/water (
       <italic>
        v
       </italic>
       /
       <italic>
        v
       </italic>
       /
       <italic>
        v
       </italic>
       5:4:1) for LC-MS analysis. After centrifugation at 14,000 rpm for 10 min at 4 °C, supernatants were transferred to LC vials for LC-MS analysis.
      </p>
     </sec>
     <sec id="sec2dot5-viruses-11-00073">
      <title>
       2.5. Ultra-High Performance Liquid Chromatography-Electrospray Ionization-Quadrupole-Time of Flight-Mass Spectrometry (UPLC-ESI-Q-TOF-MS) Analysis
      </title>
      <p>
       The lipid extract was analyzed using an Acquity UPLC system coupled to a Synapt G2-Si High Definition Mass Spectrometry (HDMS) system (Waters Corp., Milford, MA, USA). The chromatography was performed on a Waters ACQUITY BEH C18 column (1.7 μm, 2.1 × 100 mm, I.D., 1.7 mm, Waters Corp., Milford, MA, USA). The mobile phase consisted of (A) 0.1% acetic acid in water and (B) acetonitrile. Gradient elution applied for ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) analysis was described in
       <xref ref-type="app" rid="app1-viruses-11-00073">
        Table S1
       </xref>
       . The column and autosampler temperature were maintained at 45 °C and 4 °C, respectively. The injection volume was 5 µL [
       <xref ref-type="bibr" rid="B34-viruses-11-00073">
        34
       </xref>
       ].
      </p>
      <p>
       The mass spectral data were acquired in both positive and negative modes. The capillary voltage, sampling cone voltage and source offset were maintained at 2.5 kV, 60 V, and 60 V, respectively. Nitrogen was used as desolvation gas at a flow rate of 800 L/h. The source and desolvation temperatures were maintained at 120 °C and 400 °C, respectively. Mass spectra were acquired over the
       <italic>
        m
       </italic>
       /
       <italic>
        z
       </italic>
       range of 50 to 1200. The SYNAPT G2-Si HDMS system was calibrated using sodium formate clusters and operated in sensitivity mode. Leucine enkephalin was used as a lock mass for all experiments. MS/MS acquisition was operated in the same parameters as MS acquisition. Collision energy was applied at the range from 20 to 40 eV for fragmentation to allow putative identification and structural elucidation of the significant lipids.
      </p>
     </sec>
     <sec id="sec2dot6-viruses-11-00073">
      <title>
       2.6. Data Processing and Statistical Data Analysis
      </title>
      <p>
       Acquisition of the raw data was performed using MassLynx software version 4.1 (Waters Corp., Milford, MA, USA) and raw data were converted to the common data format (NetCDF) files using conversion software Databridge (Waters Corp., Milford, MA, USA). The NetCDF data were subsequently deconvolved into a usable data matrix using the XCMS software (
       <uri xlink:href="http://metlin.scripps.edu/download/">
        http://metlin.scripps.edu/download/
       </uri>
       ) [
       <xref ref-type="bibr" rid="B35-viruses-11-00073">
        35
       </xref>
       ] and the grouping of features was performed using the CAMERA R package [
       <xref ref-type="bibr" rid="B36-viruses-11-00073">
        36
       </xref>
       ]. Preprocessed data were then exported as a .csv file for further data statistical analysis. MetaboAnalyst 3.0 (
       <uri xlink:href="http://www.metaboanalyst.ca">
        http://www.metaboanalyst.ca
       </uri>
       ) and SIMCA-P V12.0 (Umetrics, Umeå, Sweden) were used for univariate and multivariate statistical analysis, respectively [
       <xref ref-type="bibr" rid="B37-viruses-11-00073">
        37
       </xref>
       ]. For univariate analysis, statistical significance of features was determined between the mock and HCoV-229E infected group using the Student’s
       <italic>
        t
       </italic>
       -test and fold change. The
       <italic>
        p
       </italic>
       -value &lt; 0.05 and fold change &gt; 2 were used as criteria for significant features selection. For multivariate analysis, the features were subjected to Pareto scaling firstly then orthogonal partial least squares discriminant analysis (OPLS-DA) was performed as a supervised method to find important variables with discriminative power. The OPLS-DA model was evaluated with the relevant R2 and Q2. The variable importance in projection (VIP), which reflects both the loading weights for each component and the variability of the response explained by this component, was used for feature selection [
       <xref ref-type="bibr" rid="B38-viruses-11-00073">
        38
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2dot7-viruses-11-00073">
      <title>
       2.7. Lipids Identification
      </title>
      <p>
       MS/MS fragmentation was performed on the significant features with high abundances. The significant features identification were carried out by searching accurate MS and MS/MS fragmentation pattern data in the METLIN database (Metabolomics Database,
       <uri xlink:href="http://metlin.scripps.edu/">
        http://metlin.scripps.edu/
       </uri>
       ), Human Metabolome Database (
       <uri xlink:href="http://www.hmdb.ca/">
        http://www.hmdb.ca/
       </uri>
       ), and LIPD MAPS (Lipidomics Gateway,
       <uri xlink:href="http://www.lipidmaps.org/">
        http://www.lipidmaps.org/
       </uri>
       ). For confirmation of lipid identity using authentic chemical standard, MS/MS fragmentation pattern of the chemical standard was compared with that of candidate lipid under the same LC-MS condition to reveal any matching [
       <xref ref-type="bibr" rid="B18-viruses-11-00073">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="B39-viruses-11-00073">
        39
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec3-viruses-11-00073">
     <title>
      3. Results
     </title>
     <sec id="sec3dot1-viruses-11-00073">
      <title>
       3.1. Omics-Based Statistical Analysis for Significant Features
      </title>
      <p>
       To investigate how coronavirus perturbs host lipid metabolism, we performed lipidomics analysis on HCoV-229E-infected Huh7 cells and compared the results with those of the mock-infected cells. The preliminary features list included precursor ions, adducts and isotope ions, which were imported into the MetaboAnalyst and SIMCA-P software for further analysis. The R2X/ R2Y, represented the X/Y variables explanation rate of the OPLS-DA model, were 83.0% and 98.8%, respectively. The predicted component, as estimated by cross-validation, was 0.97 (Q2). These cross-validated parameters were satisfactory for OPLS-DA mode (
       <xref ref-type="app" rid="app1-viruses-11-00073">
        Supplementary Figure S1a
       </xref>
       ). At the same time, the permutation test (100 times) also indicated that the validated model was satisfied (
       <xref ref-type="app" rid="app1-viruses-11-00073">
        Supplementary Figure S1b
       </xref>
       ). Overall, our results demonstrated that these significant lipid features could be selected by the validated statistical model for subsequent identification.
      </p>
     </sec>
     <sec id="sec3dot2-viruses-11-00073">
      <title>
       3.2. Identification of Lipids Specific to HCoV-229E
      </title>
      <p>
       A total of 206 (positive mode) and 100 (negative mode) ion features were selected according to the omics-based statistical analysis method. These ion features were significantly discriminative between HCoV-229E-infected and mock-infected cells. To observe the discrimination trend in more detail, a hierarchical clustering analysis was performed based on the degree of similarity of lipid abundance profiles to show the overview trend of all significant ion features. As indicated in
       <xref ref-type="fig" rid="viruses-11-00073-f001">
        Figure 1
       </xref>
       , most of the significant features from both negative mode (
       <xref ref-type="fig" rid="viruses-11-00073-f001">
        Figure 1
       </xref>
       A) and positive mode (
       <xref ref-type="fig" rid="viruses-11-00073-f001">
        Figure 1
       </xref>
       B) expressed an up-regulation trend after HCoV-229E infection compared with the mock infection controls. Furthermore, to identify lipids specific to HCoV-229E infection, these significant features were grouped and annotated using the CAMERA software, and the potential precursor ions were used to perform further MS/MS experiments for obtaining their fragmentation patterns. Finally, a total of 24 lipids were identified, which could be classified into three lipid classes, including lysophosphatidylcholine (lysoPC), lysophosphatidylethanolamine (lysoPE) and fatty acid (FA). The chromatogram peak heights of these identified lipids were generated by LC-MS raw data and the ratio between infected and mock-infected cells was determined. As demonstrated in
       <xref ref-type="fig" rid="viruses-11-00073-f002">
        Figure 2
       </xref>
       , we found a consistent up-regulation trend of the identified lipids in HCoV-229E-infected cells. In particular, lysoPC was the predominant lipid class of all identified, accounting for approximately 60% of all identified lipids with significant elevation (
       <xref ref-type="fig" rid="viruses-11-00073-f002">
        Figure 2
       </xref>
       A). At the same time, arachidonic acid (AA), which belongs to the FA class, showed the highest increase in fold-change among all identified lipids with a maximum of 7.1-fold increase (
       <xref ref-type="fig" rid="viruses-11-00073-f002">
        Figure 2
       </xref>
       B). In addition, the level of lysoPEs (
       <xref ref-type="fig" rid="viruses-11-00073-f002">
        Figure 2
       </xref>
       C) was also up-regulated with a maximum fold change of 2.93, which was comparatively less than that of the lysoPCs and FAs. The identities of lysoPC (16:0/0:0), platelet-activating factor C-16 (PAF C-16), lysoPE (16:0/0:0), AA, LA, PA and OA were confirmed by matching the retention time (RT) and MS/MS fragmentation patterns of the authentic chemical standards that distinguish between HCoV-229E-infected cases and non-infected controls (
       <xref ref-type="fig" rid="viruses-11-00073-f003">
        Figure 3
       </xref>
       ). The detailed information of the 24 identified lipids was listed in
       <xref ref-type="table" rid="viruses-11-00073-t001">
        Table 1
       </xref>
       . MS/MS fragmentation patterns of five representative lipids and corresponding standards are also demonstrated in
       <xref ref-type="app" rid="app1-viruses-11-00073">
        Supplementary Figure S2
       </xref>
       .
      </p>
     </sec>
     <sec id="sec3dot3-viruses-11-00073">
      <title>
       3.3. Pathway Analysis of HCoV-229E-Infected Huh7 Cells
      </title>
      <p>
       Based on the list of significantly up-regulated lipids after HCoV-229E-infection, MetaboAnalyst (
       <uri xlink:href="http://www.metaboanalyst.ca">
        http://www.metaboanalyst.ca
       </uri>
       ) was applied to investigate which pathway might be markedly perturbed. The result of the pathway analysis was graphically presented in
       <xref ref-type="fig" rid="viruses-11-00073-f004">
        Figure 4
       </xref>
       . From the enrichment analysis results, the LA metabolism pathway and FA biosynthesis pathway had a statistically significant raw
       <italic>
        p
       </italic>
       -value (raw
       <italic>
        p
       </italic>
       &lt; 0.05, as shown in the
       <italic>
        Y
       </italic>
       -axis). Pathway impact results indicated that the LA metabolism and AA metabolism pathways presented higher impact than the other pathways, as indicated in the
       <italic>
        X
       </italic>
       -axis value. Combining the above two analysis results, we postulated that the LA metabolism pathway to be a markedly perturbed pathway that correlated with the lipid rearrangement process induced by HCoV-229E infection.
      </p>
      <p>
       To better understand the current pathway analysis results and the cellular lipid signaling response upon HCoV-229E infection, we constructed a global LA pathway map based on the pathway information in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (
       <uri xlink:href="https://www.genome.jp/kegg/">
        https://www.genome.jp/kegg/
       </uri>
       ) and literature mining (
       <xref ref-type="fig" rid="viruses-11-00073-f005">
        Figure 5
       </xref>
       ). Upon HCoV-229E infection, the glycerophospholipids, as main components of the cell membrane, were metabolized to lysophospholipids and FAs after cPLA2 enzyme activation. Lysophospholipids such as lysoPCs and lysoPEs were correspondingly increased after HCoV-229E infection. Moreover, lysoPCs could be further metabolized to platelet-activating factor. FAs were also released from glycerophospholipids but only LA and AA could initiate downstream pathways to generate corresponding metabolites. The up-regulation of both lysophospholipids and FAs were partially confirmed by authentic standards. Furthermore, to investigate the downstream pathways trend of FAs, the authentic standards were also applied in LC-MS method to confirm whether these downstream lipids were changed correspondingly. As illustrated in
       <xref ref-type="fig" rid="viruses-11-00073-f005">
        Figure 5
       </xref>
       , AA is a downstream lipid of LA and the origin lipid of AA metabolism pathway. The identity of AA was confirmed by authentic standard (
       <xref ref-type="app" rid="app1-viruses-11-00073">
        Supplementary Figure S2D
       </xref>
       ), which was found to be significantly up-regulated. Therefore, combining pathway analysis and the authentic standards verification results, our data suggested that the LA–AA metabolism axis was the most significantly perturbed pathway and might be associated with lipids rearrangement or other processes in HCoV-229E infection.
      </p>
     </sec>
     <sec id="sec3dot4-viruses-11-00073">
      <title>
       3.4. Lipids Treatment of Virus-Infected Cells
      </title>
      <p>
       To investigate the potential implication of the perturbed LA-AA metabolism axis in HCoV-229E infection, we treated HCoV-229E-infected Huh7 cells with LA and AA and included PA and OA for comparison. The LA and AA were mapped and played a vital role in the perturbed LA-AA metabolism axis (
       <xref ref-type="fig" rid="viruses-11-00073-f005">
        Figure 5
       </xref>
       ). In contrast, PA and OA were not mapped in the perturbed pathway and may only be produced from glycerophospholipids due to cPLA2 enzyme activation. Huh-7 cells were infected with HCoV-229E and treated with AA, LA, PA, or OA. The cell lysates and culture supernatants were harvested at 24 h post-infection to determine the viral genome copy number by RT-qPCR. As shown in
       <xref ref-type="fig" rid="viruses-11-00073-f006">
        Figure 6
       </xref>
       , LA and AA consistently inhibited the replication of HCoV-229E as evidenced by the decrease in virus genome copies in both cell lysate (
       <xref ref-type="fig" rid="viruses-11-00073-f006">
        Figure 6
       </xref>
       A,C) and supernatant samples (
       <xref ref-type="fig" rid="viruses-11-00073-f006">
        Figure 6
       </xref>
       B–D). In contrast, PA inhibited HCoV-229E replication only when supplied at high concentration while HCoV-229E replication was largely independent of OA (
       <xref ref-type="fig" rid="viruses-11-00073-f006">
        Figure 6
       </xref>
       A–D).
      </p>
      <p>
       To further investigate if the modulatory effects of LA and AA were conserved among other human-pathogenic coronaviruses, we evaluated the effects of these lipids on the replication of the recently emerged and highly virulent MERS-CoV. Our data demonstrated that LA and AA potently suppressed MERS-CoV replication in a similar manner as HCoV-229E (
       <xref ref-type="fig" rid="viruses-11-00073-f006">
        Figure 6
       </xref>
       E,F). Overall, our results demonstrated that exogenously supplied LA and AA could interfere with the optimal replication of human-pathogenic coronaviruses, which suggested that the LA–AA metabolism axis was significantly involved in the propagation of these viruses.
      </p>
     </sec>
    </sec>
    <sec id="sec4-viruses-11-00073">
     <title>
      4. Discussion
     </title>
     <p>
      In this study, a MS-based lipidomics approach was established to characterize the host cell lipid changes upon coronavirus infection. Univariate and multivariate statistical analyses were applied in data processing for the selection of significant lipid features. A total of 24 lipids including lysophospholipids and FAs were identified and were consistently up-regulated in HCoV-229E-infected cells. Seven representative lipids were confirmed by authentic standards, including lysoPC (16:0/0:0), PAF C-16, lysoPE (16:0/0:0), AA, LA, PA and OA. Subsequent pathway analysis indicated that the LA–AA metabolism axis, consisting of LA and AA as important precursor lipids, was substantially perturbed after HCoV-229E infection. Moreover, we demonstrated that exogenously supplied LA and AA were capable of inhibiting the replication of HCoV-229E and the highly pathogenic MERS-CoV, which suggested the LA–AA metabolism axis to be a conserved and essential pathway in the propagation of human coronaviruses.
     </p>
     <p>
      A total of 24 lipids including lysoPCs, lysoPEs and unsaturated/saturated FAs were identified to be significantly upregulated after HCoV-229E infection. Twenty of these 24 (83.3%) lipids were lysoPC and lysoPE. LysoPC is the most abundant lysophospholipid in humans, with a high plasma concentration of several hundred micromoles. In addition, lysoPC was a potent inhibitor and could reversely arrest pore expansion during syncytium formation mediated by diverse viral fusogens [
      <xref ref-type="bibr" rid="B40-viruses-11-00073">
       40
      </xref>
      ]. Another lysophospholipid, lysoPE, is present at low concentrations in vivo but they induce various cellular responses such as activation of mitogen-activated protein kinase (MAPK) and neuronal differentiation when applied to cells in vitro [
      <xref ref-type="bibr" rid="B41-viruses-11-00073">
       41
      </xref>
      ]. Among the identified FAs, the LA and AA both belong to polyunsaturated omega-6 fatty acid and are essential fatty acids. In addition, LA is the metabolic precursor of AA, both of which are key components of the cell membrane. LA and AA also play fundamental roles in the biological function of many tissues by modulating enzymes, ion channels, receptors, as well as inflammation [
      <xref ref-type="bibr" rid="B42-viruses-11-00073">
       42
      </xref>
      ].
     </p>
     <p>
      Coronavirus replication is associated with intracellular membrane rearrangement and depends on the formation of double membrane vesicles (DMVs) and other membranous structures as replicative organelles [
      <xref ref-type="bibr" rid="B16-viruses-11-00073">
       16
      </xref>
      ]. The cell membrane components consist mainly of glycerophospholipid components such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), lysophosphatidylcholine (lysoPC), and lysophosphatidylethanolamine (lysoPE). A specific phospholipids composition is required by different viruses to form the optimal replicative organelles best suited for their replication [
      <xref ref-type="bibr" rid="B43-viruses-11-00073">
       43
      </xref>
      ]. Moreover, the lysoPC/PE was produced from PC/PE by cPLA2 activation, which simultaneously generated corresponding fatty acid moiety. In this regard, cPLA2 activation is commonly believed to be beneficial for virus replication [
      <xref ref-type="bibr" rid="B16-viruses-11-00073">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17-viruses-11-00073">
       17
      </xref>
      ].
     </p>
     <p>
      In our study, we found that a number of lysophospholipids and FAs downstream of cPLA2 activation, were upregulated upon HCoV-229E infection. The upregulation of these lipid species including LA and AA were believed to promote efficient coronavirus replication. However, when we evaluate this hypothesis by exogenously supplementing additional LA and AA to HCoV-229E- or MERS-CoV-infected cells, we noticed a significant reduction in virus replication. Taken together, our data suggested that coronavirus infection did not randomly perturb the cellular lipid compositions. Instead, we speculate that coronaviruses precisely modulate and rearrange the host lipid profile to reach an intricate homeostasis optimized for its replication. Any exogenous manipulation that disrupts the equilibrium may interfere with the optimal replication of the viruses. Alternatively, supplementing LA and AA might disturb the LA–AA metabolism axis and result in feedback reversion of lysophospholipids into phospholipids through Land’s cycle [
      <xref ref-type="bibr" rid="B44-viruses-11-00073">
       44
      </xref>
      ], thus limiting virus replication.
     </p>
     <p>
      In addition, LA and AA are polyunsaturated fatty acids that are biological signaling precursors. They can be metabolized to important eicosanoids and metabolites, which play multiple roles in the host immune response and the pathogenesis of viral infections [
      <xref ref-type="bibr" rid="B45-viruses-11-00073">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="B46-viruses-11-00073">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="B47-viruses-11-00073">
       47
      </xref>
      ]. However, previous study had suggested that arachidonic acid (AA) downstream metabolites show no evidence of anti-coronaviral activity as observed through special inhibitors of cyclooxygenases (COX) 1/2 and 5-lipoxygenase (LOX), which are two key enzymes requiring AA as a precursor. The results indicated AA downstream products may not have a significant effect on coronaviruses replication, at least in vitro [
      <xref ref-type="bibr" rid="B16-viruses-11-00073">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B48-viruses-11-00073">
       48
      </xref>
      ]. In this regard, the function of the downstream metabolites of LA and AA may play key roles in the pathogenesis of coronaviruses in vivo.
     </p>
    </sec>
    <sec id="sec5-viruses-11-00073">
     <title>
      5. Conclusions
     </title>
     <p>
      In the present study, we revealed that the cellular lipid profile was rearranged upon HCoV-229E infection. A total of 24 lipids including lysoPCs, lysoPEs and FAs were upregulated. Among them, LA and AA, which were mapped into the LA-AA metabolism axis, demonstrated strong modulatory effects on the replication of HCoV-229E and the highly pathogenic MERS-CoV. In this regard, our data suggested that optimal coronavirus replication required a specific composition of cellular lipids and any disruption could decrease the efficiency of coronavirus replication. Thus, the MS-based lipidomics strategy could be used to monitor virus-specific lipid requirement, to discover the perturbed pathways and identify novel lipids to interfere with virus replication. In further studies, combining lipidomics data with biological and immunological data may help to elucidate specific pathogenic mechanisms and identify novel treatment strategies for virus infections.
     </p>
    </sec>
    <back>
     <app-group>
      <app id="app1-viruses-11-00073">
       <title>
        Supplementary Materials
       </title>
       <p>
        The following are available online at
        <uri xlink:href="http://www.mdpi.com/1999-4915/11/1/73/s1">
         http://www.mdpi.com/1999-4915/11/1/73/s1
        </uri>
        , Table S1: Gradient elution program applied for UPLC-MS analysis, Figure S1: OPLS-DA model validation and permutation test. (a) The cross-validated parameters (R2X = 0.83, R2Y = 0.98, Q2 = 0.97) are satisfactory for the OPLS-DA model; (b) The permutation test (100 times) indicates that the validated model is acceptable, Figure S2: The MS/MS mass spectra and predicted structures with expected fragmentation profiles of the 5 lipids in cell lysate: (A) Linoleic acid; (B) LysoPC(16:0/0:0); (C) LysoPE(16:0/0:0); (D) Arachidonic acid; and (E) PAF C-16.
       </p>
       <supplementary-material content-type="local-data" id="viruses-11-00073-s001">
        <media xlink:href="viruses-11-00073-s001.pdf">
         <caption>
          <p>
           Click here for additional data file.
          </p>
         </caption>
        </media>
       </supplementary-material>
      </app>
     </app-group>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       B.Y., H.C., and K.-Y.Y. conceived and designed research. B.Y., D.Y., P.-M.L., H.S., Y.W., S.Y., and K.-H.S. conducted experiments. B.Y., H.C. and D.Y. analyzed data. B.Y., H.C., D.Y., J.F.-W.C., and K.-Y.Y. wrote the manuscript. R.Y.-T.K. and J.F.-W.C. interpreted the results and gave advice. K.-H.S. and K.-Y.Y. supervised the study. All authors read and approved the manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This work was partly supported by the donations of Michael Seak-Kan Tong, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Chan Yin Chuen Memorial Charitable Foundation, and Respiratory Viral Research Foundation Limited; and funding from the Health and Medical Research Fund (HKM-15-M05) of the Food and Health Bureau, Hong Kong Special Administrative Region Government; the Theme-based Research Scheme (T11-707/15-R) of the Research Grants Council, Hong Kong Special Administrative Region; the High Level Hospital-Summit Program in Guangdong, The University of Hong Kong-Shenzhen Hospital; and the Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the Ministry of Education of China. The sponsors had no role in the design and conduct of the study, in the collection, analysis and interpretation of data, or in the preparation, review or approval of the manuscript.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declared no conflict of interest. The funding sources had no role in study design, data collection, analysis or interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-11-00073">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2012
        </year>
        <volume>
         65
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         489
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2012.10.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23072791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-11-00073">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interspecies transmission and emergence of novel viruses: lessons from bats and birds
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         21
        </volume>
        <fpage>
         544
        </fpage>
        <lpage>
         555
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2013.05.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23770275
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-viruses-11-00073">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”
        </article-title>
        <source>
         J. Formos Med. Assoc.
        </source>
        <year>
         2013
        </year>
        <volume>
         112
        </volume>
        <fpage>
         372
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jfma.2013.05.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         23883791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-11-00073">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <year>
         2015
        </year>
        <volume>
         28
        </volume>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-viruses-11-00073">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <fpage>
         660
        </fpage>
        <lpage>
         694
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00023-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17934078
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-viruses-11-00073">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13077-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-11-00073">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses—Drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <year>
         2016
        </year>
        <volume>
         15
        </volume>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrd.2015.37
        </pub-id>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-viruses-11-00073">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taube
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wobus
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycosphingolipids as receptors for non-enveloped viruses
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2010
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1011
        </fpage>
        <lpage>
         1049
        </lpage>
        <pub-id pub-id-type="doi">
         10.3390/v2041011
        </pub-id>
        <pub-id pub-id-type="pmid">
         21994669
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-11-00073">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chazal
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Gerlier
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus entry, assembly, budding, and membrane rafts
        </article-title>
        <source>
         Microbiol. Mol. Biol. Rev.
        </source>
        <year>
         2003
        </year>
        <volume>
         67
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         237
        </lpage>
        <comment>
         table of contents
        </comment>
        <pub-id pub-id-type="doi">
         10.1128/MMBR.67.2.226-237.2003
        </pub-id>
        <pub-id pub-id-type="pmid">
         12794191
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-viruses-11-00073">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Strating
          </surname>
          <given-names>
           J.R.P.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Kuppeveld
          </surname>
          <given-names>
           F.J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Building Viral Replication Organelles: Close Encounters of the Membrane Types
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2016
        </year>
        <volume>
         12
        </volume>
        <elocation-id>
         e1005912
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1005912
        </pub-id>
        <pub-id pub-id-type="pmid">
         27788266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-viruses-11-00073">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           N.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ilnytska
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Belov
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Santiana
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Takvorian
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pau
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           van der Schaar
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik-Basu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Balla
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral reorganization of the secretory pathway generates distinct organelles for RNA replication
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2010
        </year>
        <volume>
         141
        </volume>
        <fpage>
         799
        </fpage>
        <lpage>
         811
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cell.2010.03.050
        </pub-id>
        <pub-id pub-id-type="pmid">
         20510927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-viruses-11-00073">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Diamond
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Syder
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jacobs
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sorensen
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Walters
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Proll
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           McDermott
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Gritsenko
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <elocation-id>
         e1000719
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000719
        </pub-id>
        <pub-id pub-id-type="pmid">
         20062526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-viruses-11-00073">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ono
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ablan
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Lockett
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Nagashima
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Freed
          </surname>
          <given-names>
           E.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         14889
        </fpage>
        <lpage>
         14894
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0405596101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15465916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-viruses-11-00073">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pekosz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lamb
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza virus assembly and lipid raft microdomains: A role for the cytoplasmic tails of the spike glycoproteins
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2000
        </year>
        <volume>
         74
        </volume>
        <fpage>
         4634
        </fpage>
        <lpage>
         4644
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.74.10.4634-4644.2000
        </pub-id>
        <pub-id pub-id-type="pmid">
         10775599
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-viruses-11-00073">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knoops
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Worm
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Koster
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mommaas
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
        </article-title>
        <source>
         PLoS Biol.
        </source>
        <year>
         2008
        </year>
        <volume>
         6
        </volume>
        <elocation-id>
         e226
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pbio.0060226
        </pub-id>
        <pub-id pub-id-type="pmid">
         18798692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-viruses-11-00073">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hardt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schwudke
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pleschka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of Cytosolic Phospholipase A2alpha Impairs an Early Step of Coronavirus Replication in Cell Culture
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01463-17
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-viruses-11-00073">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijay
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hua
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Miki
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gelb
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection
        </article-title>
        <source>
         J. Exp. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1851
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="doi">
         10.1084/jem.20150632
        </pub-id>
        <pub-id pub-id-type="pmid">
         26392224
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-11-00073">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         UHPLC-LTQ-Orbitrap MS combined with spike-in method for plasma metabonomics analysis of acute myocardial ischemia rats and pretreatment effect of Danqi Tongmai tablet
        </article-title>
        <source>
         Mol. Biosyst.
        </source>
        <year>
         2015
        </year>
        <volume>
         11
        </volume>
        <fpage>
         486
        </fpage>
        <lpage>
         496
        </lpage>
        <pub-id pub-id-type="doi">
         10.1039/C4MB00529E
        </pub-id>
        <pub-id pub-id-type="pmid">
         25418780
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-11-00073">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: Implications for disease pathogenesis and clinical manifestation
        </article-title>
        <source>
         J. Infect. Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         207
        </volume>
        <fpage>
         1743
        </fpage>
        <lpage>
         1752
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit123
        </pub-id>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-11-00073">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-viruses-11-00073">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         2679
        </fpage>
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.055533-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-11-00073">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Au-Yeung
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sze
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shuai
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2018
        </year>
        <volume>
         293
        </volume>
        <fpage>
         11709
        </fpage>
        <lpage>
         11726
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.RA118.001897
        </pub-id>
        <pub-id pub-id-type="pmid">
         29887526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-11-00073">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         9114
        </fpage>
        <lpage>
         9127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01133-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27489282
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-11-00073">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tee
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2015
        </year>
        <volume>
         53
        </volume>
        <fpage>
         2722
        </fpage>
        <lpage>
         2726
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.01224-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26019210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-viruses-11-00073">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <fpage>
         130
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.03.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         23583636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-viruses-11-00073">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         904
        </fpage>
        <lpage>
         914
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv380
        </pub-id>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-viruses-11-00073">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <fpage>
         1331
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit504
        </pub-id>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-viruses-11-00073">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2014
        </year>
        <volume>
         454–455
        </volume>
        <fpage>
         197
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2014.02.018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-11-00073">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.T.
          </given-names>
         </name>
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           F.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-11-00073">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by severe acute respiratory syndrome coronavirus and human coronavirus 229E
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         6180
        </fpage>
        <lpage>
         6193
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.10.6180-6193.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15858003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-11-00073">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burnum-Johnson
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kyle
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Eisfeld
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Casey
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gonzalez
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Habyarimana
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Negretti
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chauhan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MPLEx: A method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling
        </article-title>
        <source>
         Analyst
        </source>
        <year>
         2017
        </year>
        <volume>
         142
        </volume>
        <fpage>
         442
        </fpage>
        <lpage>
         448
        </lpage>
        <pub-id pub-id-type="doi">
         10.1039/C6AN02486F
        </pub-id>
        <pub-id pub-id-type="pmid">
         28091625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-viruses-11-00073">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakayasu
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nicora
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burnum-Johnson
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kyle
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Matzke
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shukla
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Schepmoes
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MPLEx: A Robust and Universal Protocol for Single-Sample Integrative Proteomic, Metabolomic, and Lipidomic Analyses
        </article-title>
        <source>
         mSystems
        </source>
        <year>
         2016
        </year>
        <volume>
         1
        </volume>
        <pub-id pub-id-type="doi">
         10.1128/mSystems.00043-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27822525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-11-00073">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sze
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ke
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tung
          </surname>
          <given-names>
           E.T.K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Talaromyces marneffei Mp1p Is a Virulence Factor that Binds and Sequesters a Key Proinflammatory Lipid to Dampen Host Innate Immune Response
        </article-title>
        <source>
         Cell Chem. Biol.
        </source>
        <year>
         2017
        </year>
        <volume>
         24
        </volume>
        <fpage>
         182
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.chembiol.2016.12.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         28111099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-11-00073">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Z.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tee
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         120
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41467-018-08015-x
        </pub-id>
        <pub-id pub-id-type="pmid">
         30631056
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-11-00073">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Want
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           O’Maille
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Abagyan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Siuzdak
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification
        </article-title>
        <source>
         Anal. Chem.
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <fpage>
         779
        </fpage>
        <lpage>
         787
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/ac051437y
        </pub-id>
        <pub-id pub-id-type="pmid">
         16448051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-11-00073">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuhl
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tautenhahn
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bottcher
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Neumann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CAMERA: An integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets
        </article-title>
        <source>
         Anal. Chem.
        </source>
        <year>
         2012
        </year>
        <volume>
         84
        </volume>
        <fpage>
         283
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/ac202450g
        </pub-id>
        <pub-id pub-id-type="pmid">
         22111785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-11-00073">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sinelnikov
          </surname>
          <given-names>
           I.V.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wishart
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MetaboAnalyst 3.0—Making metabolomics more meaningful
        </article-title>
        <source>
         Nucleic Acids Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         43
        </volume>
        <fpage>
         W251
        </fpage>
        <lpage>
         W257
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/nar/gkv380
        </pub-id>
        <pub-id pub-id-type="pmid">
         25897128
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-11-00073">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galindo-Prieto
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Eriksson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Trygg
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS)
        </article-title>
        <source>
         J. Chemom.
        </source>
        <year>
         2014
        </year>
        <volume>
         28
        </volume>
        <fpage>
         623
        </fpage>
        <lpage>
         632
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/cem.2627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-11-00073">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.P.
          </given-names>
         </name>
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Q.R.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           W.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Colon-derived uremic biomarkers induced by the acute toxicity of Kansui radix: A metabolomics study of rat plasma and intestinal contents by UPLC-QTOF-MS(E)
        </article-title>
        <source>
         J. Chromatogr. B Anal. Technol. Biomed. Life Sci.
        </source>
        <year>
         2016
        </year>
        <volume>
         1026
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         203
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jchromb.2015.09.022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-11-00073">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ciechonska
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Duncan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysophosphatidylcholine reversibly arrests pore expansion during syncytium formation mediated by diverse viral fusogens
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         6528
        </fpage>
        <lpage>
         6531
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00314-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24672027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-11-00073">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Makide
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Uwamizu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shinjo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ishiguro
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Okutani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Inoue
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Aoki
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel lysophosphoplipid receptors: Their structure and function
        </article-title>
        <source>
         J. Lipid Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         55
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1995
        </lpage>
        <pub-id pub-id-type="doi">
         10.1194/jlr.R046920
        </pub-id>
        <pub-id pub-id-type="pmid">
         24891334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-viruses-11-00073">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tallima
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           El Ridi
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Arachidonic acid: Physiological roles and potential health benefits—A review
        </article-title>
        <source>
         J. Adv. Res.
        </source>
        <year>
         2018
        </year>
        <volume>
         11
        </volume>
        <fpage>
         33
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jare.2017.11.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         30034874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-11-00073">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         RNA virus replication depends on enrichment of phosphatidylethanolamine at replication sites in subcellular membranes
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         E1782
        </fpage>
        <lpage>
         E1791
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1418971112
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-11-00073">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kazachkov
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Carlsson
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Stymne
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Weselake
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Metabolic interactions between the Lands cycle and the Kennedy pathway of glycerolipid synthesis in Arabidopsis developing seeds
        </article-title>
        <source>
         Plant. Cell
        </source>
        <year>
         2012
        </year>
        <volume>
         24
        </volume>
        <fpage>
         4652
        </fpage>
        <lpage>
         4669
        </lpage>
        <pub-id pub-id-type="doi">
         10.1105/tpc.112.104604
        </pub-id>
        <pub-id pub-id-type="pmid">
         23150634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-11-00073">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Demetz
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Schroll
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Auer
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Heim
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Patsch
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Eller
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Theurl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Theurl
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Theurl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Seifert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism
        </article-title>
        <source>
         Cell Metab.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         787
        </fpage>
        <lpage>
         798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cmet.2014.09.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         25444678
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-viruses-11-00073">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Persichini
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mastrantonio
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Del Matto
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Palomba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cantoni
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Colasanti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of arachidonic acid in the regulation of nitric oxide synthase isoforms by HIV gp120 protein in astroglial cells
        </article-title>
        <source>
         Free Radic. Biol. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         74
        </volume>
        <fpage>
         14
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.freeradbiomed.2014.06.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         24953535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-viruses-11-00073">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chandrasekharan
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marginean
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sharma-Walia
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An insight into the role of arachidonic acid derived lipid mediators in virus associated pathogenesis and malignancies
        </article-title>
        <source>
         Prostaglandins Other Lipid Mediat.
        </source>
        <year>
         2016
        </year>
        <volume>
         126
        </volume>
        <fpage>
         46
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.prostaglandins.2016.07.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         27450483
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-11-00073">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Karl
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pleschka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         D, L-lysine acetylsalicylate + glycine Impairs Coronavirus Replication
        </article-title>
        <source>
         J. Antivir. Antiretrovir.
        </source>
        <year>
         2016
        </year>
        <volume>
         8
        </volume>
        <fpage>
         4
        </fpage>
        <pub-id pub-id-type="doi">
         10.4172/jaa.1000151
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-11-00073-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Heatmap showing the lipidomic analysis of human coronavirus 229E (HCoV-229E)-infected versus non-infected Huh-7 cells. Each rectangle represents an ion feature colored by its normalized intensity scale from blue (decreased level) to red (increased level). The dendrogram on the top was constructed based on the lipid intensity (similarity measure using Euclidean, and the Ward clustering algorithm). HCoV-229E, HCoV-229E-infected cells; Mock, non-infected cells. (
        <bold>
         A
        </bold>
        ) Significant ion features in negative detection mode; (
        <bold>
         B
        </bold>
        ) significant ion features in positive detection mode.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g001">
      </graphic>
     </fig>
     <fig id="viruses-11-00073-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Liquid chromatography-mass spectrometry (LC/MS) analysis of HCoV-229E-infected cells revealed a homeostatic change in lipid levels. Huh-7 cells were mock- or HCoV-229E-infected and harvested at 24 hpi. The peak heights of these lipids were calculated and the fold change plotted with GraphPad Prism 5. (
        <bold>
         A
        </bold>
        ) Lysophosphatidylcholine (LysoPC), (
        <bold>
         B
        </bold>
        ) fatty acid (FA), (
        <bold>
         C
        </bold>
        ) lysophosphatidylethanolamine (LysoPE). AA, arachidonic acid; LA, linoleic acid; PA, palmitic acid; OA, oleic acid.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g002">
      </graphic>
     </fig>
     <fig id="viruses-11-00073-f003" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Box-whisker plots of the 7 standard confirmed lipids that were distinguished between the HCoV-229E-infected samples and the non-infected controls. The peak height was generated by LC-MS raw data. Control, non-infected cells; 229E, HCoV-229E-infected cells.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g003">
      </graphic>
     </fig>
     <fig id="viruses-11-00073-f004" orientation="portrait" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        Pathway analysis associate with HCoV-229E infection was carried out by MetaboAnalyst. The
        <italic>
         Y
        </italic>
        -axis, “log(p)”, represented the transformation of the original
        <italic>
         p
        </italic>
        -value calculated from the enrichment analysis. The
        <italic>
         X
        </italic>
        -axis, “Pathway Impact”, represented the value calculated from the pathway topology analysis.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g004">
      </graphic>
     </fig>
     <fig id="viruses-11-00073-f005" orientation="portrait" position="float">
      <label>
       Figure 5
      </label>
      <caption>
       <p>
        The pathway map based on identified lipids and linoleic acid metabolism recorded in the Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY Database. The star mark “
        <bold>
         <styled-content style="color:red">
          *
         </styled-content>
        </bold>
        ” indicates the lipids could be matched with commercial standards and have an up-regulation trend. The red arrow represents the up-regulation trend. The blue dashed rectangle and green solid rectangles represent lipids and corresponding enzyme in this pathway, respectively. The orange dashed line represents the LA–AA metabolism axis.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g005">
      </graphic>
     </fig>
     <fig id="viruses-11-00073-f006" orientation="portrait" position="float">
      <label>
       Figure 6
      </label>
      <caption>
       <p>
        Modulatory effect of lipids on HCoV-229E and Middle East respiratory syndrome coronavirus (MERS-CoV). Huh-7 cells were infected with HCoV-229E. After 1 h of inoculation, the virus inoculum was replaced with medium containing 50 µM (
        <bold>
         A
        </bold>
        ,
        <bold>
         B
        </bold>
        ) or 100 μM (
        <bold>
         C
        </bold>
        ,
        <bold>
         D
        </bold>
        ) of lipids and incubated for 24 h. The supernatants and cell lysates were collected for reverse-transcription quantitative polymerase chain reaction (RT-qPCR) analysis. In parallel, Huh-7 cells were infected with MERS-CoV. After 1 h of inoculation, the virus inoculum was replaced with medium containing 100 μM (
        <bold>
         E
        </bold>
        ,
        <bold>
         F
        </bold>
        ) of lipids and incubated for 24 h. The supernatants and cell lysates were collected for RT-qPCR analysis. Statistical significance was determined by Student’s t-test by comparing the individual lipid-treated group with the mock-treated group (
        <italic>
         n
        </italic>
        = 4). The difference was considered significant when
        <italic>
         p
        </italic>
        &lt; 0.05.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00073-g006">
      </graphic>
     </fig>
     <table-wrap id="viruses-11-00073-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00073-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        The 24 lipids that were significantly different between HCoV-229E-infected and mock-infected samples.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Significant Lipids
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Trend in HCoV-229E vs. Control
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Molecular Formula
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Detection Mode
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Retention Time
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Accurate Mass in Detection Mode
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Fold Change
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          <italic>
           p
          </italic>
          -Value
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          VIP
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          lysoPC(16:0/0:0)
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C24H50NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12.75
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          496.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.14
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0027
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.40
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          PAF C-16
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H54NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.38
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          524.37
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.49
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0214
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.60
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(18:1/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H52NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg/pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.22
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          580.3611/522.3582
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.23
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0049
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.71
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(18:0/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H54NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg/pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.77
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          582.4761/524.3715
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.29
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0051
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8.61
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(16:1(9Z))
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C24H48NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.48
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          494.32
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0086
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.12
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(18:2/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H50NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.98
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          520.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.81
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0158
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.33
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(18:3/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H48NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12.74
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          518.32
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.73
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0046
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.68
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(14:0/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C22H46NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10.73
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          468.31
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6.36
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0081
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.35
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(20:2/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C28H54NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.74
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          548.37
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.24
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0124
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.52
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(20:3/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C28H52NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.14
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          546.35
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.23
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0146
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.26
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(20:4/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C26H52NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.93
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          544.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.27
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0073
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.89
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(22:6/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C30H50NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.86
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          568.34
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.78
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0079
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.97
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(15:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C23H48NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.72
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          482.32
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.68
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0083
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.88
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPC(17:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C25H52NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.36
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          510.36
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.01
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0101
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.02
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(16:0/0:0)
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C21H44NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12.65
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          454.29
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.44
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0047
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.90
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(20:4/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C25H44NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.87
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          502.29
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.18
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0147
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.98
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(22:6/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C27H44NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.80
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          526.29
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.52
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0223
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.02
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(16:1/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C21H42NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11.20
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          452.28
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.43
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0165
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.75
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(18:1/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C23H46NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13.07
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          478.48
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.04
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0000
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.67
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LysoPE(22:1/0:0)
          <sup>
           p
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C27H54NO7P
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          pos
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14.11
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          536.37
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.93
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0142
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.34
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Arachidonic acid
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C20H32O2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          17.15
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          303.20
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7.16
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0200
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.05
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Linoleic acid
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C18H32O2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          16.55
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          279.23
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.03
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0085
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6.57
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Palmitic acid
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          C16H32O2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          neg
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          18.02
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          281.18
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.61
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0.0028
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.20
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Oleic acid
          <sup>
           S
          </sup>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          up-regulation
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          C18H34O2
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          neg
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          17.72
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          255.45
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4.21
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          0.0009
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3.28
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         pos and neg represented positive mode and negative mode respectively; s Lipids that were confirmed with authentic standards; p Lipids that putatively annotated and matched the fragmentation pattern with the database.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30893947
      </article-id>
      <article-id pub-id-type="pmc">
       6466079
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v11030280
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-11-00280
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Host Determinants of MERS-CoV Transmission and Pathogenesis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Widagdo
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sooksawasdi Na Ayudhya
         </surname>
         <given-names>
          Syriam
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hundie
         </surname>
         <given-names>
          Gadissa B.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-6221-2015
        </contrib-id>
        <name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          Bart L.
         </given-names>
        </name>
        <xref ref-type="corresp" rid="c1-viruses-11-00280">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-11-00280">
       Department of Viroscience, Erasmus Medical Center, 3025 Rotterdam, The Netherlands;
       <email>
        w.widagdo@erasmusmc.nl
       </email>
       (W.W.);
       <email>
        s.sooksawasdi@erasmusmc.nl
       </email>
       (S.S.N.A.);
       <email>
        g.hundie@erasmusmc.nl
       </email>
       (G.B.H.)
      </aff>
      <author-notes>
       <corresp id="c1-viruses-11-00280">
        <label>
         *
        </label>
        Correspondence:
        <email>
         b.haagmans@erasmusmc.nl
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        3
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        3
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       3
      </issue>
      <elocation-id>
       280
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         01
        </day>
        <month>
         3
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         13
        </day>
        <month>
         3
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 by the authors.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that causes respiratory infection in humans, ranging from asymptomatic to severe pneumonia. In dromedary camels, the virus only causes a mild infection but it spreads efficiently between animals. Differences in the behavior of the virus observed between individuals, as well as between humans and dromedary camels, highlight the role of host factors in MERS-CoV pathogenesis and transmission. One of these host factors, the MERS-CoV receptor dipeptidyl peptidase-4 (DPP4), may be a critical determinant because it is variably expressed in MERS-CoV-susceptible species as well as in humans. This could partially explain inter- and intraspecies differences in the tropism, pathogenesis, and transmissibility of MERS-CoV. In this review, we explore the role of DPP4 and other host factors in MERS-CoV transmission and pathogenesis—such as sialic acids, host proteases, and interferons. Further characterization of these host determinants may potentially offer novel insights to develop intervention strategies to tackle ongoing outbreaks.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        transmission
       </kwd>
       <kwd>
        pathogenesis
       </kwd>
       <kwd>
        host factors
       </kwd>
       <kwd>
        DPP4
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-11-00280" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen that was isolated in late 2012 [
      <xref ref-type="bibr" rid="B1-viruses-11-00280">
       1
      </xref>
      ]. Since then, the virus has caused multiple outbreaks and infected more than 2000 individuals, [
      <xref ref-type="bibr" rid="B2-viruses-11-00280">
       2
      </xref>
      ] who then develop a respiratory infection ranging in severity from asymptomatic to fatal [
      <xref ref-type="bibr" rid="B3-viruses-11-00280">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="B4-viruses-11-00280">
       4
      </xref>
      ]. Severe-to-fatal MERS-CoV patients have a higher chance of transmitting this virus since they shed a higher amount of virus progeny in comparison to the asymptomatic-to-mild ones [
      <xref ref-type="bibr" rid="B5-viruses-11-00280">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-viruses-11-00280">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="B7-viruses-11-00280">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-viruses-11-00280">
       8
      </xref>
      ]. Identifying and quarantining these patients in healthcare facilities where outbreaks have occurred, together with implementing proper infection control, has been effective in reducing transmission and containing these outbreaks [
      <xref ref-type="bibr" rid="B9-viruses-11-00280">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B10-viruses-11-00280">
       10
      </xref>
      ]. However, new MERS-CoV cases are still being reported, especially in the Arabian Peninsula [
      <xref ref-type="bibr" rid="B2-viruses-11-00280">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-viruses-11-00280">
       11
      </xref>
      ]. This is partly due to the continuous zoonotic introduction of this virus to the human population in this region by dromedaries [
      <xref ref-type="bibr" rid="B12-viruses-11-00280">
       12
      </xref>
      ]. The dromedary camel is the only animal species that has been reported to transmit this virus to humans [
      <xref ref-type="bibr" rid="B13-viruses-11-00280">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14-viruses-11-00280">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15-viruses-11-00280">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B16-viruses-11-00280">
       16
      </xref>
      ]. MERS-CoV infection in these animals merely causes mild upper respiratory tract infection [
      <xref ref-type="bibr" rid="B17-viruses-11-00280">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B18-viruses-11-00280">
       18
      </xref>
      ], but seroepidemiological studies showed that this virus has been circulating in dromedary camels for decades, suggesting the efficient transmission of MERS-CoV in this species [
      <xref ref-type="bibr" rid="B19-viruses-11-00280">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-viruses-11-00280">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-11-00280">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-11-00280">
       22
      </xref>
      ].
     </p>
     <p>
      Although the clinical manifestations, as well as transmission, are remarkably different in MERS-CoV-infected humans and dromedary camels, the viruses isolated from these two species are highly similar, if not indistinguishable [
      <xref ref-type="bibr" rid="B12-viruses-11-00280">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="B16-viruses-11-00280">
       16
      </xref>
      ]. This indicates that host factors play a significant role in MERS-CoV pathogenesis and transmission. However, the identity of these host factors and how they affect the pathogenesis and transmission of MERS-CoV are generally not well understood. Dipeptidyl peptidase-4 (DPP4)—the MERS-CoV receptor, sialic acids, proteases, and interferons are all examples of potentially critical host factors that have been shown to affect MERS-CoV infection in vitro [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B24-viruses-11-00280">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="B25-viruses-11-00280">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B26-viruses-11-00280">
       26
      </xref>
      ]. This review highlights the role of some MERS-CoV-interacting host factors—especially DPP4—in MERS-CoV pathogenesis and transmission.
     </p>
    </sec>
    <sec id="sec2-viruses-11-00280">
     <title>
      2. MERS-CoV-Interacting Host Factors
     </title>
     <p>
      MERS-CoV infection of a target cell is initiated by the virus attachment to the cell surface [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B27-viruses-11-00280">
       27
      </xref>
      ]. MERS-CoV uses the N-terminal part of its spike (S)—the so called S1 protein (
      <xref ref-type="fig" rid="viruses-11-00280-f001">
       Figure 1
      </xref>
      A)—to bind to two host cell surface molecules, dipeptidyl peptidase-4 (DPP4) and α2,3-sialic acids [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B24-viruses-11-00280">
       24
      </xref>
      ]. DPP4 is the functional receptor of MERS-CoV; its absence renders cells resistant to this virus, while its transient expression in non-susceptible cells permits viral replication [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ]. DPP4 is a serine exopeptidase, which is either expressed at the cell surface or shed in a soluble form. It has the capacity to cleave-off dipeptides from polypeptides with either
      <sc>
       l
      </sc>
      -proline or
      <sc>
       l
      </sc>
      -alanine at the penultimate position. Accordingly, DPP4 is capable of cutting various substrates, such as hormones, cytokines, chemokines, and neuropeptides, allowing it to be involved in multiple physiological functions as well as pathophysiological conditions [
      <xref ref-type="bibr" rid="B28-viruses-11-00280">
       28
      </xref>
      ]. This enzymatic activity is mediated by the α/β hydrolase domain of DPP4, while MERS-CoV infection is mediated by the binding of S1 protein to the β-propeller domain of this exopeptidase (
      <xref ref-type="fig" rid="viruses-11-00280-f001">
       Figure 1
      </xref>
      B) [
      <xref ref-type="bibr" rid="B28-viruses-11-00280">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="B29-viruses-11-00280">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-viruses-11-00280">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="B31-viruses-11-00280">
       31
      </xref>
      ]. There are 11 critical residues within the β-propeller domain that directly interact with the S1 protein [
      <xref ref-type="bibr" rid="B29-viruses-11-00280">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-viruses-11-00280">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="B31-viruses-11-00280">
       31
      </xref>
      ]. These residues are quite conserved in camelids, primates, and rabbits—species shown to be susceptible to MERS-CoV [
      <xref ref-type="bibr" rid="B17-viruses-11-00280">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B31-viruses-11-00280">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="B32-viruses-11-00280">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="B33-viruses-11-00280">
       33
      </xref>
      ]. In contrast, ferrets, rats, and mice resist MERS-CoV infection due to differences in some critical DPP4 residues [
      <xref ref-type="bibr" rid="B31-viruses-11-00280">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="B34-viruses-11-00280">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="B35-viruses-11-00280">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="B36-viruses-11-00280">
       36
      </xref>
      ]. These data illustrate that DPP4 has the capacity to determine the host range of MERS-CoV.
     </p>
     <p>
      Other MERS-CoV-interacting host factors besides DPP4 are less extensively studied and have mostly been investigated in vitro. Glycotopes of α2,3-sialic acids coupled with 5-N-acetylated neuraminic acid are recognized by the S1 protein of MERS-CoV during attachment [
      <xref ref-type="bibr" rid="B24-viruses-11-00280">
       24
      </xref>
      ]. In the absence of these glycotopes, MERS-CoV entry is reduced but not abolished, indicating their function as an attachment factor rather than a receptor [
      <xref ref-type="bibr" rid="B24-viruses-11-00280">
       24
      </xref>
      ]. Besides α2,3-sialic acids, CEACAM5 and GRP78 have also been suggested to be attachment factors for MERS-CoV, but their roles in vivo during MERS-CoV infection are not clear at this moment [
      <xref ref-type="bibr" rid="B37-viruses-11-00280">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="B38-viruses-11-00280">
       38
      </xref>
      ]. Post attachment, MERS-CoV uses the C-terminal part of its S protein—known as S2 (
      <xref ref-type="fig" rid="viruses-11-00280-f001">
       Figure 1
      </xref>
      A)—to interact with host proteases, such as furin, TMPRSS2, and cathepsins [
      <xref ref-type="bibr" rid="B39-viruses-11-00280">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-viruses-11-00280">
       40
      </xref>
      ,
      <xref ref-type="bibr" rid="B41-viruses-11-00280">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="B42-viruses-11-00280">
       42
      </xref>
      ]. These proteases cleave the S protein and induce conformational changes, allowing fusion between viral and host cellular membranes, resulting in the release of viral RNA into the cell cytoplasm [
      <xref ref-type="bibr" rid="B27-viruses-11-00280">
       27
      </xref>
      ]. TMPRSS2 and DPP4 are held in one complex at the cell surface by a scaffolding protein, the tetraspanin CD9, leading to a rapid and efficient entry of MERS-CoV into the susceptible cells [
      <xref ref-type="bibr" rid="B43-viruses-11-00280">
       43
      </xref>
      ]. Once fusion with host cell membranes has occurred, MERS-CoV subsequently replicates its genetic material and produces viral proteins in the cell cytoplasm to generate new virus progeny. During this stage, MERS-CoV uses its nsp3–4 polyproteins to build its replication organelles as well as its accessory proteins such as the 4a and 4b proteins to inhibit host anti-viral defense mechanisms [
      <xref ref-type="bibr" rid="B44-viruses-11-00280">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="B45-viruses-11-00280">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="B46-viruses-11-00280">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="B47-viruses-11-00280">
       47
      </xref>
      ,
      <xref ref-type="bibr" rid="B48-viruses-11-00280">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="B49-viruses-11-00280">
       49
      </xref>
      ,
      <xref ref-type="bibr" rid="B50-viruses-11-00280">
       50
      </xref>
      ,
      <xref ref-type="bibr" rid="B51-viruses-11-00280">
       51
      </xref>
      ,
      <xref ref-type="bibr" rid="B52-viruses-11-00280">
       52
      </xref>
      ,
      <xref ref-type="bibr" rid="B53-viruses-11-00280">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="B54-viruses-11-00280">
       54
      </xref>
      ]. However, the capacity of MERS-CoV accessory proteins to impede several pathways of host immune response in the lungs may be limited. MERS-CoV inoculation of macaques and genetically modified mice generally results in limited clinical manifestations; thus, adapting this virus through serial passaging or defecting the type I interferon pathway may be needed to enhance viral replication and pathogenesis in these animals [
      <xref ref-type="bibr" rid="B32-viruses-11-00280">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="B55-viruses-11-00280">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="B56-viruses-11-00280">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="B57-viruses-11-00280">
       57
      </xref>
      ,
      <xref ref-type="bibr" rid="B58-viruses-11-00280">
       58
      </xref>
      ]. These observations, together with studies showing type I interferon capacity to inhibit MERS-CoV infection in vitro [
      <xref ref-type="bibr" rid="B25-viruses-11-00280">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B59-viruses-11-00280">
       59
      </xref>
      ], highlight the importance of the innate immune response, especially type I interferon, as an inhibiting factor for MERS-CoV.
     </p>
    </sec>
    <sec id="sec3-viruses-11-00280">
     <title>
      3. Host Factors in MERS-CoV Transmission
     </title>
     <p>
      So far MERS-CoV has been isolated from dromedary camels and humans [
      <xref ref-type="bibr" rid="B1-viruses-11-00280">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B60-viruses-11-00280">
       60
      </xref>
      ]. Both species are not only susceptible to MERS-CoV infection, but also capable of transmitting this virus [
      <xref ref-type="bibr" rid="B7-viruses-11-00280">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B12-viruses-11-00280">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="B13-viruses-11-00280">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="B14-viruses-11-00280">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15-viruses-11-00280">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B16-viruses-11-00280">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17-viruses-11-00280">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B18-viruses-11-00280">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-11-00280">
       22
      </xref>
      ]. However, current data indicate that virus spread is more efficient in dromedary camels than in humans [
      <xref ref-type="bibr" rid="B5-viruses-11-00280">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B7-viruses-11-00280">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B19-viruses-11-00280">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-viruses-11-00280">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-11-00280">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B61-viruses-11-00280">
       61
      </xref>
      ]. This difference in transmissibility could be partially due to the different tropism of MERS-CoV in these two species. In dromedaries, MERS-CoV has been shown to replicate in the nasal epithelium upon experimental in vivo infection [
      <xref ref-type="bibr" rid="B17-viruses-11-00280">
       17
      </xref>
      ], while in humans, MERS-CoV mainly replicates in the lower respiratory tract, particularly in the bronchiolar and alveolar epithelia [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B62-viruses-11-00280">
       62
      </xref>
      ,
      <xref ref-type="bibr" rid="B63-viruses-11-00280">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="B64-viruses-11-00280">
       64
      </xref>
      ,
      <xref ref-type="bibr" rid="B65-viruses-11-00280">
       65
      </xref>
      ]. Higher viral RNA levels in the sputum and lavage samples of MERS-CoV patients compared to nasal and throat swabs are consistent with the tropism of MERS-CoV in humans [
      <xref ref-type="bibr" rid="B66-viruses-11-00280">
       66
      </xref>
      ,
      <xref ref-type="bibr" rid="B67-viruses-11-00280">
       67
      </xref>
      ,
      <xref ref-type="bibr" rid="B68-viruses-11-00280">
       68
      </xref>
      ]. This different MERS-CoV tropism in dromedary camels and humans is in line with the localization of DPP4 in the respiratory tract tissues of these two species. In humans, DPP4 is absent in the nasal epithelium but present in the lower respiratory tract epithelium, mainly in type II pneumocytes [
      <xref ref-type="bibr" rid="B69-viruses-11-00280">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="B70-viruses-11-00280">
       70
      </xref>
      ]. In contrast, DPP4 is expressed in the nasal epithelium of dromedary camels [
      <xref ref-type="bibr" rid="B69-viruses-11-00280">
       69
      </xref>
      ]. This difference in DPP4 localization between humans and dromedary camels therefore explains MERS-CoV tropism in these two species and highlights DPP4 as an essential determinant of MERS-CoV tropism.
     </p>
     <p>
      DPP4 localization has also been investigated in many other MERS-CoV-susceptible species. In Gambian and Egyptian fruit bats, DPP4 is expressed in the respiratory tract and intestinal epithelium, suggesting that MERS-CoV can target both tissues [
      <xref ref-type="bibr" rid="B71-viruses-11-00280">
       71
      </xref>
      ]. In line with this finding, MERS-CoV inoculation via intranasal and intraperitoneal routes in the Jamaican fruit bat led to viral RNA shedding both in the respiratory tract and the intestinal tract [
      <xref ref-type="bibr" rid="B72-viruses-11-00280">
       72
      </xref>
      ]. In contrast to frugivorous bats, DPP4 is limitedly expressed in the respiratory tract epithelium of two insectivorous bats, i.e., common pipistrelle and common serotine bats, but abundant in their intestinal epithelium [
      <xref ref-type="bibr" rid="B71-viruses-11-00280">
       71
      </xref>
      ]. Accordingly, sequences of MERS-like-CoVs were mainly obtained from rectal swabs and fecal samples of insectivorous bats [
      <xref ref-type="bibr" rid="B73-viruses-11-00280">
       73
      </xref>
      ,
      <xref ref-type="bibr" rid="B74-viruses-11-00280">
       74
      </xref>
      ,
      <xref ref-type="bibr" rid="B75-viruses-11-00280">
       75
      </xref>
      ,
      <xref ref-type="bibr" rid="B76-viruses-11-00280">
       76
      </xref>
      ,
      <xref ref-type="bibr" rid="B77-viruses-11-00280">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="B78-viruses-11-00280">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="B79-viruses-11-00280">
       79
      </xref>
      ,
      <xref ref-type="bibr" rid="B80-viruses-11-00280">
       80
      </xref>
      ]. These findings not only support insectivorous bats as the origin host of MERS-CoV [
      <xref ref-type="bibr" rid="B73-viruses-11-00280">
       73
      </xref>
      ,
      <xref ref-type="bibr" rid="B74-viruses-11-00280">
       74
      </xref>
      ,
      <xref ref-type="bibr" rid="B75-viruses-11-00280">
       75
      </xref>
      ,
      <xref ref-type="bibr" rid="B76-viruses-11-00280">
       76
      </xref>
      ,
      <xref ref-type="bibr" rid="B77-viruses-11-00280">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="B78-viruses-11-00280">
       78
      </xref>
      ,
      <xref ref-type="bibr" rid="B79-viruses-11-00280">
       79
      </xref>
      ,
      <xref ref-type="bibr" rid="B80-viruses-11-00280">
       80
      </xref>
      ], but also indicate the importance of intestinal tropism and fecal–oral transmission of MERS-like-CoV in these insectivorous bats.
     </p>
     <p>
      Besides bats, humans, and dromedary camels, other animal species have also been proposed as potential hosts of MERS-CoV. Remarkably, DPP4 of horses, llamas, alpacas, pigs, bovines, goats, sheep, and rabbits has been demonstrated to recognize the S protein of MERS-CoV [
      <xref ref-type="bibr" rid="B81-viruses-11-00280">
       81
      </xref>
      ,
      <xref ref-type="bibr" rid="B82-viruses-11-00280">
       82
      </xref>
      ]. In most of these species, there is a preferential upper respiratory tract expression of DPP4 observed. Rabbits express DPP4 in the upper and lower respiratory tract epithelium, and thus may allow MERS-CoV to replicate in both compartments [
      <xref ref-type="bibr" rid="B33-viruses-11-00280">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="B83-viruses-11-00280">
       83
      </xref>
      ]. Horses, llamas, and pigs mainly express DPP4 in the upper respiratory tract—particularly the nasal epithelium [
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ]. Upon intranasal MERS-CoV inoculation, llamas, alpacas, and pigs developed upper respiratory tract infection, while horses did not seroconvert and only shed infectious virus in a limited amount [
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ,
      <xref ref-type="bibr" rid="B85-viruses-11-00280">
       85
      </xref>
      ,
      <xref ref-type="bibr" rid="B86-viruses-11-00280">
       86
      </xref>
      ,
      <xref ref-type="bibr" rid="B87-viruses-11-00280">
       87
      </xref>
      ,
      <xref ref-type="bibr" rid="B88-viruses-11-00280">
       88
      </xref>
      ]. The reason why horses seem to be less permissive to MERS-CoV remains to be investigated, but a chronic co-infection in the guttural pouch, a common disease among horses, might be one of the explanations. This guttural pouch infection results in excessive mucus production that might hinder MERS-CoV from attaching and entering the nasal epithelium [
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ,
      <xref ref-type="bibr" rid="B89-viruses-11-00280">
       89
      </xref>
      ,
      <xref ref-type="bibr" rid="B90-viruses-11-00280">
       90
      </xref>
      ]. Sheep, on the other hand, did not seem to express significant levels of DPP4 in their respiratory tract, and thus did not seroconvert nor shed infectious virus upon experimental MERS-CoV inoculation [
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ,
      <xref ref-type="bibr" rid="B88-viruses-11-00280">
       88
      </xref>
      ]. Comparable to sheep, goats limitedly shed infectious virus upon experimental infection and did not transmit this virus to other naïve goats upon direct contact [
      <xref ref-type="bibr" rid="B88-viruses-11-00280">
       88
      </xref>
      ]. The results of experimental MERS-CoV infection in livestock animals are in line with data from epidemiological studies. MERS-CoV seropositive llamas and alpacas are present in the field, while horses, goats, and sheep are generally found to be seronegative [
      <xref ref-type="bibr" rid="B22-viruses-11-00280">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="B86-viruses-11-00280">
       86
      </xref>
      ,
      <xref ref-type="bibr" rid="B87-viruses-11-00280">
       87
      </xref>
      ,
      <xref ref-type="bibr" rid="B91-viruses-11-00280">
       91
      </xref>
      ,
      <xref ref-type="bibr" rid="B92-viruses-11-00280">
       92
      </xref>
      ,
      <xref ref-type="bibr" rid="B93-viruses-11-00280">
       93
      </xref>
      ,
      <xref ref-type="bibr" rid="B94-viruses-11-00280">
       94
      </xref>
      ,
      <xref ref-type="bibr" rid="B95-viruses-11-00280">
       95
      </xref>
      ,
      <xref ref-type="bibr" rid="B96-viruses-11-00280">
       96
      </xref>
      ,
      <xref ref-type="bibr" rid="B97-viruses-11-00280">
       97
      </xref>
      ,
      <xref ref-type="bibr" rid="B98-viruses-11-00280">
       98
      </xref>
      ].
     </p>
     <p>
      Given the fact that experimental in vivo infection studies and DPP4 expression analysis in different animal species revealed that dromedary camels are not the only animals in which MERS-CoV has an upper respiratory tract tropism [
      <xref ref-type="bibr" rid="B17-viruses-11-00280">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="B18-viruses-11-00280">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B83-viruses-11-00280">
       83
      </xref>
      ,
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ], it is then relevant to question whether other animals can potentially spread MERS-CoV as well. New World camelids, i.e., alpacas and llamas, are able to transmit the virus to respective naïve animals upon contact [
      <xref ref-type="bibr" rid="B86-viruses-11-00280">
       86
      </xref>
      ]. Pigs and rabbits, on the other hand, hardly transmit the virus—neither by contact nor airborne routes [
      <xref ref-type="bibr" rid="B83-viruses-11-00280">
       83
      </xref>
      ,
      <xref ref-type="bibr" rid="B99-viruses-11-00280">
       99
      </xref>
      ]. Most likely, this is caused by the fact that pigs and rabbits, unlike dromedary camels, shed low levels of infectious virus upon MERS-CoV inoculation (
      <xref ref-type="fig" rid="viruses-11-00280-f002">
       Figure 2
      </xref>
      ). This difference indicates that other host factors besides DPP4 could cause interspecies variation in MERS-CoV infection. Indeed, several glycotopes of α2,3-sialic acids that function as attachment factors of MERS-CoV are present in the nasal epithelium of dromedary camels but absent in that of rabbits and pigs (
      <xref ref-type="fig" rid="viruses-11-00280-f003">
       Figure 3
      </xref>
      ) [
      <xref ref-type="bibr" rid="B24-viruses-11-00280">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="B100-viruses-11-00280">
       100
      </xref>
      ]. The lack of these glycotopes in pigs and rabbits might limit the susceptibility and transmission of MERS-CoV in these animals. Although the role of these glycotopes in MERS-CoV transmission still requires further investigation, it remains plausible that an efficient transmission of this virus might require the presence of both DPP4 and MERS-CoV-recognized glycotopes of α2,3-sialic acids (
      <xref ref-type="fig" rid="viruses-11-00280-f003">
       Figure 3
      </xref>
      ).
     </p>
     <p>
      Besides entry and attachment receptors, MERS-CoV has been demonstrated to use both cell surface and lysosomal proteases to enter its target cells [
      <xref ref-type="bibr" rid="B39-viruses-11-00280">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-viruses-11-00280">
       40
      </xref>
      ,
      <xref ref-type="bibr" rid="B43-viruses-11-00280">
       43
      </xref>
      ,
      <xref ref-type="bibr" rid="B101-viruses-11-00280">
       101
      </xref>
      ]. The preference of MERS-CoV to use certain host proteases is influenced by the type of target cell and the cleavage stage of their S protein prior to infection [
      <xref ref-type="bibr" rid="B40-viruses-11-00280">
       40
      </xref>
      ]. It has also been reported that the lysosomal proteases from bat cells support coronavirus spike-mediated virus entry more efficiently than their counterparts from human cells [
      <xref ref-type="bibr" rid="B39-viruses-11-00280">
       39
      </xref>
      ]. These observations suggest that host proteases from different host species may determine the species and tissue tropism of MERS-CoV.
     </p>
     <p>
      Because MERS-CoV has been circulating in dromedary camels for decades before emerging in the human population [
      <xref ref-type="bibr" rid="B19-viruses-11-00280">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-viruses-11-00280">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-11-00280">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-11-00280">
       22
      </xref>
      ], it is plausible that this virus inhibits the immune response of dromedary camels more efficiently than that of other species, including pigs and rabbits. The difference in immune response among MERS-CoV-susceptible species is therefore another factor that might yield interspecies variation in permissiveness to MERS-CoV. Characterizing the difference in host proteases and immune responses among MERS-CoV-susceptible species, as performed for DPP4 and MERS-CoV-recognized α2,3-sialic acid glycotopes (
      <xref ref-type="fig" rid="viruses-11-00280-f003">
       Figure 3
      </xref>
      ), has not yet been investigated. These data, however, may further explain interspecies variation in MERS-CoV infection and transmission.
     </p>
    </sec>
    <sec id="sec4-viruses-11-00280">
     <title>
      4. Host Factors in MERS-CoV Pathogenesis
     </title>
     <p>
      MERS-CoV causes respiratory infection in humans ranging from asymptomatic to severe pneumonia [
      <xref ref-type="bibr" rid="B3-viruses-11-00280">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="B4-viruses-11-00280">
       4
      </xref>
      ]. However, it is currently unclear what causes this intraspecies variation. Epidemiology data indicate that individuals with certain risk factors are at higher risk of developing severe MERS-CoV infection [
      <xref ref-type="bibr" rid="B4-viruses-11-00280">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B102-viruses-11-00280">
       102
      </xref>
      ]. This implies that some host factors may dictate the outcome of MERS-CoV infection, thus rendering intraspecies variation. Two of the risk factors, i.e., smoking and chronic obstructive pulmonary disease (COPD), have been shown to upregulate DPP4 expression in the lungs [
      <xref ref-type="bibr" rid="B70-viruses-11-00280">
       70
      </xref>
      ,
      <xref ref-type="bibr" rid="B102-viruses-11-00280">
       102
      </xref>
      ,
      <xref ref-type="bibr" rid="B103-viruses-11-00280">
       103
      </xref>
      ,
      <xref ref-type="bibr" rid="B104-viruses-11-00280">
       104
      </xref>
      ], suggesting DPP4 as a possible reason for intraspecies variation observed among MERS-CoV patients. In healthy human lungs, DPP4 is almost exclusively expressed in type II pneumocytes [
      <xref ref-type="bibr" rid="B69-viruses-11-00280">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="B70-viruses-11-00280">
       70
      </xref>
      ]. Type II pneumocytes are small cuboidal cells that can regenerate alveolar epithelium upon injury, and roughly cover 2% of the alveolar surface area. Meanwhile, around 95% of the surface area of the alveolus is occupied by type I pneumocytes that are morphologically flat and responsible for gas exchange [
      <xref ref-type="bibr" rid="B105-viruses-11-00280">
       105
      </xref>
      ,
      <xref ref-type="bibr" rid="B106-viruses-11-00280">
       106
      </xref>
      ]. In the lungs of smokers and COPD patients, unlike in healthy human lungs, DPP4 is prominently expressed in both type I and II pneumocytes, indicating upregulated expression on type I pneumocytes [
      <xref ref-type="bibr" rid="B104-viruses-11-00280">
       104
      </xref>
      ]. Autopsy reports from fatal MERS-CoV patients showed that both type I and II pneumocytes expressed DPP4 and became infected by MERS-CoV, proposing a role of DPP4-expressing type I pneumocytes in MERS-CoV pathogenesis [
      <xref ref-type="bibr" rid="B64-viruses-11-00280">
       64
      </xref>
      ,
      <xref ref-type="bibr" rid="B107-viruses-11-00280">
       107
      </xref>
      ]. Damage to type I cells in the lung alveoli during viral infection may lead to diffuse alveolar damage [
      <xref ref-type="bibr" rid="B108-viruses-11-00280">
       108
      </xref>
      ]. In line with observations made in human MERS cases, common marmosets that express DPP4 in both type I and II pneumocytes have been reported to produce more infectious virus upon experimental MERS-CoV infection, compared to rhesus and cynomolgus macaques that merely expressed DPP4 in type II pneumocytes [
      <xref ref-type="bibr" rid="B58-viruses-11-00280">
       58
      </xref>
      ,
      <xref ref-type="bibr" rid="B109-viruses-11-00280">
       109
      </xref>
      ,
      <xref ref-type="bibr" rid="B110-viruses-11-00280">
       110
      </xref>
      ,
      <xref ref-type="bibr" rid="B111-viruses-11-00280">
       111
      </xref>
      ,
      <xref ref-type="bibr" rid="B112-viruses-11-00280">
       112
      </xref>
      ]. Accordingly, these common marmosets developed moderate-to-severe infection, while macaques generally developed mild transient pneumonia [
      <xref ref-type="bibr" rid="B32-viruses-11-00280">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="B58-viruses-11-00280">
       58
      </xref>
      ,
      <xref ref-type="bibr" rid="B109-viruses-11-00280">
       109
      </xref>
      ,
      <xref ref-type="bibr" rid="B110-viruses-11-00280">
       110
      </xref>
      ,
      <xref ref-type="bibr" rid="B111-viruses-11-00280">
       111
      </xref>
      ,
      <xref ref-type="bibr" rid="B112-viruses-11-00280">
       112
      </xref>
      ]. Similarly, in genetically modified mice that displayed MERS-CoV tropism for type II pneumocytes, only mild clinical manifestations were observed upon MERS-CoV infection [
      <xref ref-type="bibr" rid="B56-viruses-11-00280">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="B113-viruses-11-00280">
       113
      </xref>
      ]. Adapting MERS-CoV through serial passaging or upregulating DPP4 expression throughout the airway epithelium in mice, however, will induce severe clinical disease [
      <xref ref-type="bibr" rid="B55-viruses-11-00280">
       55
      </xref>
      ,
      <xref ref-type="bibr" rid="B56-viruses-11-00280">
       56
      </xref>
      ]. These data altogether support the role of DPP4-expressing type I pneumocytes in the pathogenesis of severe MERS-CoV infection.
     </p>
     <p>
      The differential expression of host factors that limits the infection should also be taken into account. DPP4 in soluble form has been demonstrated to protect against MERS-CoV infection in vitro and in a mouse model [
      <xref ref-type="bibr" rid="B23-viruses-11-00280">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="B114-viruses-11-00280">
       114
      </xref>
      ]; however, its presence in the lungs and role in MERS-CoV pathogenesis remain to be investigated. The host immune response also has the capacity to inhibit MERS-CoV infection. MERS-CoV has been shown to replicate to higher levels in immunocompromised rhesus macaques [
      <xref ref-type="bibr" rid="B115-viruses-11-00280">
       115
      </xref>
      ], consistent with the observation that immunocompromised individuals have difficulties clearing MERS-CoV upon infection [
      <xref ref-type="bibr" rid="B68-viruses-11-00280">
       68
      </xref>
      ,
      <xref ref-type="bibr" rid="B107-viruses-11-00280">
       107
      </xref>
      ,
      <xref ref-type="bibr" rid="B116-viruses-11-00280">
       116
      </xref>
      ]. The survivors of MERS-CoV infection have been shown to develop virus-specific CD4+ and CD8+ T cell responses, implying the role of T cells in virus clearance [
      <xref ref-type="bibr" rid="B117-viruses-11-00280">
       117
      </xref>
      ]. However, the depletion of T cells in mice can either lead to failure in MERS-CoV clearance or improvement in clinical outcome, depending on the type of mouse model used [
      <xref ref-type="bibr" rid="B57-viruses-11-00280">
       57
      </xref>
      ,
      <xref ref-type="bibr" rid="B118-viruses-11-00280">
       118
      </xref>
      ]. Therefore, the role of adaptive immune response in MERS-CoV pathogenesis is currently unclear. On the other hand, one of the main components of the host innate immune response, type I interferon, inhibits MERS-CoV replication in susceptible cells, partly by inhibiting double membrane vesicles (DMV) formation [
      <xref ref-type="bibr" rid="B25-viruses-11-00280">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B57-viruses-11-00280">
       57
      </xref>
      ,
      <xref ref-type="bibr" rid="B59-viruses-11-00280">
       59
      </xref>
      ,
      <xref ref-type="bibr" rid="B119-viruses-11-00280">
       119
      </xref>
      ,
      <xref ref-type="bibr" rid="B120-viruses-11-00280">
       120
      </xref>
      ]. The absence of type I interferon signaling in mice also resulted in more severe clinical manifestations and histopathological lesions upon MERS-CoV infection [
      <xref ref-type="bibr" rid="B57-viruses-11-00280">
       57
      </xref>
      ]. Advance age, which can cause delayed type I interferon response upon viral infection, is a well-known risk factor for fatal MERS-CoV infection [
      <xref ref-type="bibr" rid="B4-viruses-11-00280">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B102-viruses-11-00280">
       102
      </xref>
      ,
      <xref ref-type="bibr" rid="B121-viruses-11-00280">
       121
      </xref>
      ,
      <xref ref-type="bibr" rid="B122-viruses-11-00280">
       122
      </xref>
      ,
      <xref ref-type="bibr" rid="B123-viruses-11-00280">
       123
      </xref>
      ]. Collectively, these data highlight the role of host innate immune response as a potent inhibitor for MERS-CoV infection.
     </p>
     <p>
      It is indubitable that severe MERS-CoV infection is not solely driven by the pathogen. Additional underlying conditions increase MERS-CoV replication and induce severe-to-fatal clinical manifestations [
      <xref ref-type="bibr" rid="B4-viruses-11-00280">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B11-viruses-11-00280">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="B103-viruses-11-00280">
       103
      </xref>
      ,
      <xref ref-type="bibr" rid="B124-viruses-11-00280">
       124
      </xref>
      ,
      <xref ref-type="bibr" rid="B125-viruses-11-00280">
       125
      </xref>
      ]. It is plausible that more than one underlying condition is needed to yield a fatal outcome. DPP4 upregulation in type I pneumocytes and insufficient type I interferon response might be crucial determinants for severe MERS-CoV infection (
      <xref ref-type="fig" rid="viruses-11-00280-f004">
       Figure 4
      </xref>
      ). Further investigation of the host determinants of MERS-CoV pathogenesis may offer insights for developing novel therapeutic measures.
     </p>
    </sec>
    <sec id="sec5-viruses-11-00280">
     <title>
      5. Concluding Remarks and Future Perspectives
     </title>
     <p>
      Although MERS-CoV has been reported to undergo some genotypic changes since it emerged in the human population [
      <xref ref-type="bibr" rid="B12-viruses-11-00280">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="B126-viruses-11-00280">
       126
      </xref>
      ,
      <xref ref-type="bibr" rid="B127-viruses-11-00280">
       127
      </xref>
      ,
      <xref ref-type="bibr" rid="B128-viruses-11-00280">
       128
      </xref>
      ,
      <xref ref-type="bibr" rid="B129-viruses-11-00280">
       129
      </xref>
      ], this has not resulted in distinct phenotypic changes so far [
      <xref ref-type="bibr" rid="B63-viruses-11-00280">
       63
      </xref>
      ,
      <xref ref-type="bibr" rid="B126-viruses-11-00280">
       126
      </xref>
      ]. Therefore, host factors remain the most significant determinant in explaining inter- and intraspecies variations observed in MERS-CoV pathogenesis and transmission. DPP4 and MERS-CoV-recognized α2,3-sialic acids might partially explain these variations, since their localization has been demonstrated to be variable between MERS-CoV-susceptible species [
      <xref ref-type="bibr" rid="B69-viruses-11-00280">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="B71-viruses-11-00280">
       71
      </xref>
      ,
      <xref ref-type="bibr" rid="B84-viruses-11-00280">
       84
      </xref>
      ,
      <xref ref-type="bibr" rid="B100-viruses-11-00280">
       100
      </xref>
      ]. DPP4 expression in human lungs has also been shown to vary due to certain comorbidities [
      <xref ref-type="bibr" rid="B70-viruses-11-00280">
       70
      </xref>
      ,
      <xref ref-type="bibr" rid="B96-viruses-11-00280">
       96
      </xref>
      ,
      <xref ref-type="bibr" rid="B104-viruses-11-00280">
       104
      </xref>
      ]. Nevertheless, it is undoubtable that the inter- and intraspecies variation in MERS-CoV pathogenesis and transmission is a complex phenomenon influenced by more than one host factor. Current data suggest proteases and interferons as other critical host factors, but how they instigate inter- and intraspecies variations, as well as their role in MERS-CoV pathogenesis and transmission, still remain to be further elucidated. Characterization of the host determinants of MERS-CoV pathogenesis and transmission could potentially offer insight into this virus epidemiology and guide novel therapeutic development. It may also help to identify the most vulnerable individuals to protect against MERS-CoV infection—for example, by using vaccination.
     </p>
    </sec>
    <back>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       All authors contributed to the writing of the manuscript and carefully evaluated the manuscript before submission.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       Our work is supported by Zoonotic Anticipation and Preparedness Initiative (Innovative Medicines Initiative grant 115760), with assistance and financial support from Innovative Medicines Initiative and the European Commission, and contributions from European Federation of Pharmaceutical Industries and Associations partners. Syriam Sooksawasdi Na Ayudhya received the Royal Thai Government Scholarship supported by the Ministry of Science and Technology of Thailand to perform her doctoral study.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-11-00280">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-11-00280">
       <label>
        2.
       </label>
       <element-citation publication-type="web">
        <article-title>
         World Health Organization MERS Situation Update, March 2018
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-march-2018.html">
          http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-march-2018.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2019-03-01">
         (accessed on 1 March 2019)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B3-viruses-11-00280">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Stalin Raj
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-coronavirus: From discovery to intervention
        </article-title>
        <source>
         One Health
        </source>
        <year>
         2017
        </year>
        <volume>
         3
        </volume>
        <fpage>
         11
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.onehlt.2016.12.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         28616497
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-11-00280">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          The WHO Mers-CoV Research Group
         </collab>
        </person-group>
        <article-title>
         State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
        </article-title>
        <source>
         PLoS Curr.
        </source>
        <year>
         2013
        </year>
        <volume>
         5
        </volume>
        <pub-id pub-id-type="doi">
         10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-viruses-11-00280">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Son
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectivity of an Asymptomatic Patient With Middle East Respiratory Syndrome Coronavirus Infection
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <fpage>
         1457
        </fpage>
        <lpage>
         1458
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/cix170
        </pub-id>
        <pub-id pub-id-type="pmid">
         28444154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-viruses-11-00280">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           AlRabiah
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hajjar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Flemban
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: A prospective descriptive study
        </article-title>
        <source>
         Clin. Microbiol. Infect.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         469
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/1469-0691.12562
        </pub-id>
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-11-00280">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hossain
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of MERS-coronavirus in household contacts
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         371
        </volume>
        <fpage>
         828
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-viruses-11-00280">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kwon
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hur
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk factors for transmission of Middle East respiratory syndrome coronavirus infection during the 2015 outbreak in South Korea
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <fpage>
         551
        </fpage>
        <lpage>
         557
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciw768
        </pub-id>
        <pub-id pub-id-type="pmid">
         27940937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-11-00280">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Normile
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         South Korea finally MERS-free
        </article-title>
        <source>
         Science
        </source>
        <year>
         2015
        </year>
        <pub-id pub-id-type="doi">
         10.1126/science.aae0157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-viruses-11-00280">
       <label>
        10.
       </label>
       <element-citation publication-type="web">
        <article-title>
         World Health Organization Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Republic of Korea—Disease Outbreak News 25 October 2015
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/25-october-2015-mers-korea/en/">
          http://www.who.int/csr/don/25-october-2015-mers-korea/en/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2019-03-01">
         (accessed on 1 March 2019)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B11-viruses-11-00280">
       <label>
        11.
       </label>
       <element-citation publication-type="web">
        <article-title>
         World Health Organization MERS-CoV Global Summary and Assessment of Risk
        </article-title>
        <month>
         7
        </month>
        <year>
         2017
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1">
          http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2019-03-01">
         (accessed on 1 March 2019)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B12-viruses-11-00280">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dudas
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Carvalho
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bedford
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV spillover at the camel-human interface
        </article-title>
        <source>
         Elife
        </source>
        <year>
         2018
        </year>
        <volume>
         7
        </volume>
        <fpage>
         eLife.31257
        </fpage>
       </element-citation>
      </ref>
      <ref id="B13-viruses-11-00280">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-viruses-11-00280">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Alsahafi
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1012
        </fpage>
        <lpage>
         1015
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2006.140402
        </pub-id>
        <pub-id pub-id-type="pmid">
         24857749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-viruses-11-00280">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paden
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yusof
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hammadi
          </surname>
          <given-names>
           Z.M.
          </given-names>
         </name>
         <name>
          <surname>
           Queen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Eltahir
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Elsayed
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Marzoug
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bensalah
          </surname>
          <given-names>
           O.K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Khalafalla
          </surname>
          <given-names>
           A.I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE
        </article-title>
        <source>
         Zoonoses. Public Health
        </source>
        <year>
         2018
        </year>
        <volume>
         65
        </volume>
        <fpage>
         322
        </fpage>
        <lpage>
         333
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/zph.12435
        </pub-id>
        <pub-id pub-id-type="pmid">
         29239118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-viruses-11-00280">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jabado
          </surname>
          <given-names>
           O.J.
          </given-names>
         </name>
         <name>
          <surname>
           Karesh
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           O.B.
          </given-names>
         </name>
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e01146-14
        </fpage>
        <pub-id pub-id-type="pmid">
         24781747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-viruses-11-00280">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlsein
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fux
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aad1283
        </pub-id>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-11-00280">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           V.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1999
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-11-00280">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Siemens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           van Beek
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         552
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2004.131746
        </pub-id>
        <pub-id pub-id-type="pmid">
         24655412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-11-00280">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Younan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liljander
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lattwein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hilali
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Musa
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         2093
        </fpage>
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-viruses-11-00280">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Messadi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Feyisa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ularamu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Danmarwa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dawo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jemli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Melaku
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shamaki
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Geographic distribution of MERS coronavirus among dromedary camels, Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1370
        </fpage>
        <lpage>
         1374
        </lpage>
        <pub-id pub-id-type="pmid">
         25062254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-11-00280">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sameroff
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e00884-14
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.01002-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-11-00280">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-11-00280">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Hulswit
          </surname>
          <given-names>
           R.J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Widjaja
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           McBride
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Dieren
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2017
        </year>
        <volume>
         114
        </volume>
        <fpage>
         E8508
        </fpage>
        <lpage>
         E8517
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1712592114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28923942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-viruses-11-00280">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Wilde
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oudshoorn
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Nieuwkoop
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Limpens
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Posthuma
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Barcena
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <issue-part>
         Pt 8
        </issue-part>
        <fpage>
         1749
        </fpage>
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.052910-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         23620378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-viruses-11-00280">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwata-Yoshikawa
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Okamura
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Shimizu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2019
        </year>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01815-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-viruses-11-00280">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: An overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods. Mol. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         1282
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-viruses-11-00280">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boonacker
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Van Noorden
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The multifunctional or moonlighting protein CD26/DPPIV
        </article-title>
        <source>
         Eur. J. Cell. Biol.
        </source>
        <year>
         2003
        </year>
        <volume>
         82
        </volume>
        <fpage>
         53
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="doi">
         10.1078/0171-9335-00302
        </pub-id>
        <pub-id pub-id-type="pmid">
         12647932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-11-00280">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-11-00280">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         500
        </volume>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12328
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-11-00280">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spiking the MERS-coronavirus receptor
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         1069
        </fpage>
        <lpage>
         1070
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.108
        </pub-id>
        <pub-id pub-id-type="pmid">
         23938293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-viruses-11-00280">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brining
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2013
        </year>
        <volume>
         110
        </volume>
        <fpage>
         16598
        </fpage>
        <lpage>
         16603
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1310744110
        </pub-id>
        <pub-id pub-id-type="pmid">
         24062443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-11-00280">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Stittelaar
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Getu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Waal
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Verjans
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         6131
        </fpage>
        <lpage>
         6135
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00661-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-11-00280">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wiersma
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ouwendijk
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Spronken
          </surname>
          <given-names>
           M.I.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02935-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-11-00280">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Goicochea
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue-part>
         Pt 2
        </issue-part>
        <fpage>
         408
        </fpage>
        <lpage>
         412
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.060640-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24197535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-11-00280">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iwata-Yoshikawa
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fukuma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tashiro
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Non Susceptibility of Neonatal and Adult Rats against the Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         Jpn. J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         69
        </volume>
        <fpage>
         510
        </fpage>
        <lpage>
         516
        </lpage>
        <pub-id pub-id-type="doi">
         10.7883/yoken.JJID.2015.589
        </pub-id>
        <pub-id pub-id-type="pmid">
         27000459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-11-00280">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Au-Yeung
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sze
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shuai
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2018
        </year>
        <volume>
         293
        </volume>
        <fpage>
         11709
        </fpage>
        <lpage>
         11726
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.RA118.001897
        </pub-id>
        <pub-id pub-id-type="pmid">
         29887526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-11-00280">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         9114
        </fpage>
        <lpage>
         9127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01133-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27489282
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-11-00280">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lysosomal proteases are a determinant of coronavirus tropism
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <fpage>
         e01504
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01504-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30258004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-11-00280">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2016
        </year>
        <volume>
         113
        </volume>
        <fpage>
         12262
        </fpage>
        <lpage>
         12267
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1608147113
        </pub-id>
        <pub-id pub-id-type="pmid">
         27791014
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-11-00280">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12552
        </fpage>
        <lpage>
         12561
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01890-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-viruses-11-00280">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         15214
        </fpage>
        <lpage>
         15219
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1407087111
        </pub-id>
        <pub-id pub-id-type="pmid">
         25288733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-11-00280">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Earnest
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Hantak
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2017
        </year>
        <volume>
         13
        </volume>
        <elocation-id>
         e1006546
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006546
        </pub-id>
        <pub-id pub-id-type="pmid">
         28759649
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-11-00280">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hardt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schwudke
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Pleschka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of Cytosolic Phospholipase A2alpha Impairs an Early Step of Coronavirus Replication in Cell Culture
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <fpage>
         e01463-17
        </fpage>
        <pub-id pub-id-type="pmid">
         29167338
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-11-00280">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belov
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Kuppeveld
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         (+)RNA viruses rewire cellular pathways to build replication organelles
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         2
        </volume>
        <fpage>
         740
        </fpage>
        <lpage>
         747
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2012.09.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         23036609
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-viruses-11-00280">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belov
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nair
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Hansen
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Hoyt
          </surname>
          <given-names>
           F.H.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ehrenfeld
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complex dynamic development of poliovirus membranous replication complexes
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         302
        </fpage>
        <lpage>
         312
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.05937-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22072780
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-viruses-11-00280">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabouw
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Langereis
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Knaap
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Dalebout
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Canton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2016
        </year>
        <volume>
         12
        </volume>
        <elocation-id>
         e1005982
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1005982
        </pub-id>
        <pub-id pub-id-type="pmid">
         27783669
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-11-00280">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Canton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez-Alvarez
          </surname>
          <given-names>
           F.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez-Aparicio
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Sastre
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2018
        </year>
        <volume>
         14
        </volume>
        <elocation-id>
         e1006838
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1006838
        </pub-id>
        <pub-id pub-id-type="pmid">
         29370303
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49-viruses-11-00280">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kew
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lui
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4866
        </fpage>
        <lpage>
         4876
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03649-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24522921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50-viruses-11-00280">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakagawa
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Popov
          </surname>
          <given-names>
           V.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cajimat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The endonucleolytic RNA cleavage function of nsp1 of Middle East respiratory syndrome coronavirus promotes the production of infectious virus particles in specific human cell lines
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <fpage>
         e01157-18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01157-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30111568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51-viruses-11-00280">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knoops
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Worm
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Koster
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mommaas
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
        </article-title>
        <source>
         PLoS Biol.
        </source>
        <year>
         2008
        </year>
        <volume>
         6
        </volume>
        <elocation-id>
         e226
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pbio.0060226
        </pub-id>
        <pub-id pub-id-type="pmid">
         18798692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52-viruses-11-00280">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thornbrough
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jha
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Silverman
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2016
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e00258-16
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00258-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27025250
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53-viruses-11-00280">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           McAnarney
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2017
        </year>
        <volume>
         8
        </volume>
        <fpage>
         e00665-17
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00665-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         28830941
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54-viruses-11-00280">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudshoorn
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rijs
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Limpens
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Groen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Koster
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Barcena
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2017
        </year>
        <volume>
         8
        </volume>
        <fpage>
         e01658-17
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.01658-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         29162711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55-viruses-11-00280">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Earnest
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Bair
          </surname>
          <given-names>
           T.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Brogden
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Flaherty
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2017
        </year>
        <volume>
         114
        </volume>
        <fpage>
         E3119
        </fpage>
        <lpage>
         E3128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1619109114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28348219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56-viruses-11-00280">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
        </article-title>
        <source>
         Nat. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         2
        </volume>
        <fpage>
         16226
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.226
        </pub-id>
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57-viruses-11-00280">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gale
          </surname>
          <given-names>
           M.J.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1323279111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58-viruses-11-00280">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <fpage>
         236
        </fpage>
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit590
        </pub-id>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59-viruses-11-00280">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Callison
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2013
        </year>
        <volume>
         3
        </volume>
        <fpage>
         1686
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep01686
        </pub-id>
        <pub-id pub-id-type="pmid">
         23594967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60-viruses-11-00280">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lamers
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pas
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Voermans
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mawlawi
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Romaihi
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140663
        </pub-id>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61-viruses-11-00280">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           I.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: An epidemiological outbreak study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2016
        </year>
        <volume>
         388
        </volume>
        <fpage>
         994
        </fpage>
        <lpage>
         1001
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(16)30623-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         27402381
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62-viruses-11-00280">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuok
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         6604
        </fpage>
        <lpage>
         6614
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00009-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23552422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63-viruses-11-00280">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: An in-vitro and ex-vivo study
        </article-title>
        <source>
         Lancet Respir. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         2
        </volume>
        <fpage>
         813
        </fpage>
        <lpage>
         822
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(14)70158-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         25174549
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64-viruses-11-00280">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Hosani
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Keating
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Metcalfe
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Alami
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in United Arab Emirates, April 2014
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2015.10.024
        </pub-id>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65-viruses-11-00280">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hocke
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Becher
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Knepper
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Peter
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Holland
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Tonnies
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Neudecker
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs
        </article-title>
        <source>
         Am. J. Respir. Crit. Care Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         188
        </volume>
        <fpage>
         882
        </fpage>
        <lpage>
         886
        </lpage>
        <pub-id pub-id-type="doi">
         10.1164/rccm.201305-0954LE
        </pub-id>
        <pub-id pub-id-type="pmid">
         24083868
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66-viruses-11-00280">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Aarons
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Langrish
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hoschler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2012
        </year>
        <volume>
         17
        </volume>
        <fpage>
         20290
        </fpage>
        <pub-id pub-id-type="pmid">
         23078800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67-viruses-11-00280">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Albarrak
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Farah
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Almasri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         62
        </volume>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/civ951
        </pub-id>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68-viruses-11-00280">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seilmaier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hartmann
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Scheible
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sack
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Guggemos
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Junglen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70154-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69-viruses-11-00280">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kolijn
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           van Leenders
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Segales
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baumgartner
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         4838
        </fpage>
        <lpage>
         4842
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02994-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26889022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70-viruses-11-00280">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lambertz
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         78
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2015.09.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         26597880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71-viruses-11-00280">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Begeman
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Run
          </surname>
          <given-names>
           P.R.V.
          </given-names>
         </name>
         <name>
          <surname>
           Cunningham
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kley
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue Distribution of the MERS-Coronavirus Receptor in Bats
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         1193
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-01290-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         28446791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72-viruses-11-00280">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           V.R.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hawkinson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in Jamaican fruit bats (
         <italic>
          Artibeus jamaicensis
         </italic>
         )
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2016
        </year>
        <volume>
         6
        </volume>
        <fpage>
         21878
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep21878
        </pub-id>
        <pub-id pub-id-type="pmid">
         26899616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73-viruses-11-00280">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baldwin
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Klose
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nkrumah
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Badu
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Anti
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         456
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1903.121503
        </pub-id>
        <pub-id pub-id-type="pmid">
         23622767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B74-viruses-11-00280">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-related betacoronavirus in Vespertilio superans bats, China
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1260
        </fpage>
        <lpage>
         1262
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2007.140318
        </pub-id>
        <pub-id pub-id-type="pmid">
         24960574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75-viruses-11-00280">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wacharapluesadee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sintunawa
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kaewpom
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Khongnomnan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Rodpan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sangsri
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Intarut
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Chindamporn
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Group C betacoronavirus in bat guano fertilizer, Thailand
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1349
        </fpage>
        <lpage>
         1351
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1908.130119
        </pub-id>
        <pub-id pub-id-type="pmid">
         23880503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76-viruses-11-00280">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Koo
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Noh
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           Y.G.
          </given-names>
         </name>
         <name>
          <surname>
           Na
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of Severe Acute Respiratory Syndrome-Like, Middle East Respiratory Syndrome-Like Bat Coronaviruses and Group H Rotavirus in Faeces of Korean Bats
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         63
        </volume>
        <fpage>
         365
        </fpage>
        <lpage>
         372
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/tbed.12515
        </pub-id>
        <pub-id pub-id-type="pmid">
         27213718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B77-viruses-11-00280">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         11297
        </fpage>
        <lpage>
         11303
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01498-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25031349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B78-viruses-11-00280">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Stoffberg
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1697
        </fpage>
        <lpage>
         1699
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1910.130946
        </pub-id>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B79-viruses-11-00280">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gilardi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ssebide
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Mbabazi
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Navarrete-Macias
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hicks
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2017
        </year>
        <volume>
         8
        </volume>
        <fpage>
         e00373-17
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00373-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         28377531
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B80-viruses-11-00280">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Q.B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of Novel Bat Coronaviruses in South China That Use the Same Receptor as Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <fpage>
         e00116-18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00116-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         29669833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B81-viruses-11-00280">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkar
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4953
        </fpage>
        <lpage>
         4961
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00161-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24554656
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B82-viruses-11-00280">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kinne
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         9220
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00676-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B83-viruses-11-00280">
       <label>
        83.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Richard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           de Muelder
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lexmond
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           J.M.A. v. d.
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Herfst
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus transmission in rabbits
        </article-title>
        <comment>
         Unpublished work
        </comment>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="B84-viruses-11-00280">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vergara-Alert
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Munoz
          </surname>
          <given-names>
           M.t.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Solanes
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cordon
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         232
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2302.161239
        </pub-id>
        <pub-id pub-id-type="pmid">
         27901465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B85-viruses-11-00280">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Horne
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Saturday
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Domestic Pig Unlikely Reservoir for MERS-CoV
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         985
        </fpage>
        <lpage>
         988
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2306.170096
        </pub-id>
        <pub-id pub-id-type="pmid">
         28318484
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B86-viruses-11-00280">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1031
        </fpage>
        <lpage>
         1037
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160192
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B87-viruses-11-00280">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Durr
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Foord
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Riddell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haining
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Barr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1071
        </fpage>
        <lpage>
         1074
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160007
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B88-viruses-11-00280">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           V.R.
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inoculation of Goats, Sheep, and Horses with MERS-CoV Does Not Result in Productive Viral Shedding
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2016
        </year>
        <volume>
         8
        </volume>
        <elocation-id>
         230
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/v8080230
        </pub-id>
        <pub-id pub-id-type="pmid">
         27548203
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B89-viruses-11-00280">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Steward
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Webb
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Paillot
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Parkhill
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Waller
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genome specialization and decay of the strangles pathogen, Streptococcus equi, is driven by persistent infection
        </article-title>
        <source>
         Genome Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1360
        </fpage>
        <lpage>
         1371
        </lpage>
        <pub-id pub-id-type="doi">
         10.1101/gr.189803.115
        </pub-id>
        <pub-id pub-id-type="pmid">
         26160165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B90-viruses-11-00280">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Waller
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Strangles: A pathogenic legacy of the war horse
        </article-title>
        <source>
         Vet. Rec.
        </source>
        <year>
         2016
        </year>
        <volume>
         178
        </volume>
        <fpage>
         91
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/vr.i123
        </pub-id>
        <pub-id pub-id-type="pmid">
         26795860
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B91-viruses-11-00280">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits-De Vries
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70164-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B92-viruses-11-00280">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Alhammadi
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2013
        </year>
        <volume>
         18
        </volume>
        <fpage>
         20659
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2013.18.50.20659
        </pub-id>
        <pub-id pub-id-type="pmid">
         24342517
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B93-viruses-11-00280">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hijazeen
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Holloway
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Al Omari
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           McDowell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Talafha
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Guitian
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Steel
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Amarin
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High Prevalence of Middle East Respiratory Coronavirus in Young Dromedary Camels in Jordan
        </article-title>
        <source>
         Vector Borne Zoonotic Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         17
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/vbz.2016.2062
        </pub-id>
        <pub-id pub-id-type="pmid">
         28009529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94-viruses-11-00280">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Bocanegra
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Wernery
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sieberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Serologic assessment of possibility for MERS-CoV infection in equids
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         182
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2101.141342
        </pub-id>
        <pub-id pub-id-type="pmid">
         25531820
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95-viruses-11-00280">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           R.L.W.
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           R.T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           B.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alhammadi
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus infections in horses in Saudi Arabia and Oman
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <fpage>
         2093
        </fpage>
        <lpage>
         2103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/tbed.12630
        </pub-id>
        <pub-id pub-id-type="pmid">
         28296228
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96-viruses-11-00280">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           El-Shesheny
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kandeil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Elsokary
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           El Sayed
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           El-Taweel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sobhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2017
        </year>
        <volume>
         22
        </volume>
        <fpage>
         30487
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES.2017.22.11.30487
        </pub-id>
        <pub-id pub-id-type="pmid">
         28333616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B97-viruses-11-00280">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           David
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rotenberg
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Khinich
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Erster
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Bardenstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           van Straten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Miculitzki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
        </article-title>
        <source>
         One Health
        </source>
        <year>
         2018
        </year>
        <volume>
         5
        </volume>
        <fpage>
         65
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.onehlt.2018.05.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         29911167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98-viruses-11-00280">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Schilp
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           De Bruin
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Kohl
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Romaihi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Le Grange
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1129
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.152113
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99-viruses-11-00280">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vergara-Alert
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Munoz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Abad
          </surname>
          <given-names>
           F.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cordon
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Segales
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus experimental transmission using a pig model
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <fpage>
         1342
        </fpage>
        <lpage>
         1345
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/tbed.12668
        </pub-id>
        <pub-id pub-id-type="pmid">
         28653496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B100-viruses-11-00280">
       <label>
        100.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           de Jong
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           de Swart
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Begeman
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cunningham
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Segales
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Species specific binding of the MERS-coronavirus S1
         <sup>
          A
         </sup>
         protein
        </article-title>
        <comment>
         Unpublished work
        </comment>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="B101-viruses-11-00280">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         12516
        </fpage>
        <lpage>
         12521
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1405889111
        </pub-id>
        <pub-id pub-id-type="pmid">
         25114257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B102-viruses-11-00280">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nam
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yeon
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         58
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2017.02.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         28223175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103-viruses-11-00280">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Almarashi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Turkistani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sadran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Housa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Almazroa
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alraihan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2201.151340
        </pub-id>
        <pub-id pub-id-type="pmid">
         26692185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B104-viruses-11-00280">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seys
          </surname>
          <given-names>
           L.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Verhamme
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleinjan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Janssens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Joos
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Bracke
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Brusselle
          </surname>
          <given-names>
           G.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         66
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/cix741
        </pub-id>
        <pub-id pub-id-type="pmid">
         29020176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105-viruses-11-00280">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dahlin
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mager
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tigue
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Goodglick
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wadehra
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dobbs
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of genes differentially expressed in rat alveolar type I cells
        </article-title>
        <source>
         Am. J. Respir. Cell. Mol. Biol.
        </source>
        <year>
         2004
        </year>
        <volume>
         31
        </volume>
        <fpage>
         309
        </fpage>
        <lpage>
         316
        </lpage>
        <pub-id pub-id-type="doi">
         10.1165/rcmb.2003-0423OC
        </pub-id>
        <pub-id pub-id-type="pmid">
         15205179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B106-viruses-11-00280">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cabral
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Renewal of alveolar epithelium in the rat following exposure to NO
         <sub>
          2
         </sub>
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         1973
        </year>
        <volume>
         70
        </volume>
        <fpage>
         175
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         4566990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B107-viruses-11-00280">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alsaad
          </surname>
          <given-names>
           K.O.
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al Balwi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Moaiqel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Oudah
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Al Ajlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           AlJohani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alsolamy
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gmati
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study
        </article-title>
        <source>
         Histopathology
        </source>
        <year>
         2018
        </year>
        <volume>
         72
        </volume>
        <fpage>
         516
        </fpage>
        <lpage>
         524
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/his.13379
        </pub-id>
        <pub-id pub-id-type="pmid">
         28858401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B108-viruses-11-00280">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Jong
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Itamura
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         290
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1001
        </pub-id>
        <pub-id pub-id-type="pmid">
         14981511
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B109-viruses-11-00280">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         215
        </volume>
        <fpage>
         1807
        </fpage>
        <lpage>
         1815
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jix209
        </pub-id>
        <pub-id pub-id-type="pmid">
         28472421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B110-viruses-11-00280">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B111-viruses-11-00280">
       <label>
        111.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        <source>
         PLoS. Pathog.
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e1004250
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1004250
        </pub-id>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B112-viruses-11-00280">
       <label>
        112.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wiersma
          </surname>
          <given-names>
           L.C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           de Vries
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           van den Ham
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kondova
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         DPP4-expressing type I pneumocytes in a fatal human MERS-coronavirus case
        </article-title>
        <comment>
         Unpublished work
        </comment>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="B113-viruses-11-00280">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jewell
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Reznikov
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Gibson-Corley
          </surname>
          <given-names>
           K.N.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         712
        </fpage>
        <lpage>
         722
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv499
        </pub-id>
        <pub-id pub-id-type="pmid">
         26486634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B114-viruses-11-00280">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Couch
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         219
        </volume>
        <fpage>
         829
        </fpage>
        <lpage>
         835
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiy574
        </pub-id>
        <pub-id pub-id-type="pmid">
         30256968
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B115-viruses-11-00280">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hardcastle
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques
        </article-title>
        <source>
         Front. Immunol.
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         205
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fimmu.2018.00205
        </pub-id>
        <pub-id pub-id-type="pmid">
         29483914
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B116-viruses-11-00280">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Huh
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Atypical presentations of MERS-CoV infection in immunocompromised hosts
        </article-title>
        <source>
         J. Infect. Chemother.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         769
        </fpage>
        <lpage>
         773
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jiac.2017.04.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         28545936
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B117-viruses-11-00280">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bokhari
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Al Gethamy
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Dada
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses
        </article-title>
        <source>
         Sci. Immunol.
        </source>
        <year>
         2017
        </year>
        <volume>
         2
        </volume>
        <fpage>
         eaan5393
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/sciimmunol.aan5393
        </pub-id>
        <pub-id pub-id-type="pmid">
         28778905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B118-viruses-11-00280">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sisk
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Halasz
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Beck
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Venkataraman
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rajagopalan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kyratsous
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e01825-16
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01825-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27795435
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B119-viruses-11-00280">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kindrachuk
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Olinger
          </surname>
          <given-names>
           G.G.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue-part>
         Pt 3
        </issue-part>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B120-viruses-11-00280">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudshoorn
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoeven
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Limpens
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Beugeling
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Barcena
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kikkert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral Innate Immune Response Interferes with the Formation of Replication-Associated Membrane Structures Induced by a Positive-Strand RNA Virus
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2016
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e01991-16
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.01991-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27923923
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B121-viruses-11-00280">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uno
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yagi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshimori
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tanigawa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         IFN production ability and healthy ageing: Mixed model analysis of a 24 year longitudinal study in Japan
        </article-title>
        <source>
         BMJ Open
        </source>
        <year>
         2013
        </year>
        <volume>
         3
        </volume>
        <fpage>
         e002113
        </fpage>
        <pub-id pub-id-type="doi">
         10.1136/bmjopen-2012-002113
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B122-viruses-11-00280">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ju
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Weyand
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Goronzy
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age-Associated Failure To Adjust Type I IFN Receptor Signaling Thresholds after T Cell Activation
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2015
        </year>
        <volume>
         195
        </volume>
        <fpage>
         865
        </fpage>
        <lpage>
         874
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.1402389
        </pub-id>
        <pub-id pub-id-type="pmid">
         26091718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B123-viruses-11-00280">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Vijay
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mack
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2016
        </year>
        <volume>
         19
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.chom.2016.01.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         26867177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B124-viruses-11-00280">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B125-viruses-11-00280">
       <label>
        125.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alzahrani
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Altwaijri
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of co-infection of influenza A virus on the severity of Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2017
        </year>
        <volume>
         74
        </volume>
        <fpage>
         521
        </fpage>
        <lpage>
         523
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2017.02.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         28189714
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B126-viruses-11-00280">
       <label>
        126.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Miguel
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Dudas
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Oladipo
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
         <name>
          <surname>
           Traore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2018
        </year>
        <volume>
         115
        </volume>
        <fpage>
         3144
        </fpage>
        <lpage>
         3149
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1718769115
        </pub-id>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B127-viruses-11-00280">
       <label>
        127.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bin Saeed
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abdalla
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Abdely
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Algarni
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Increase in Middle East Respiratory Syndrome-Coronavirus Cases in Saudi Arabia Linked to Hospital Outbreak With Continued Circulation of Recombinant Virus, July 1-August 31, 2015
        </article-title>
        <source>
         Open Forum Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         3
        </volume>
        <fpage>
         ofw165
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/ofid/ofw165
        </pub-id>
        <pub-id pub-id-type="pmid">
         27704019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B128-viruses-11-00280">
       <label>
        128.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Alsanouri
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Al Nsour
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Multihospital Outbreak of a Middle East Respiratory Syndrome Coronavirus Deletion Variant, Jordan: A Molecular, Serologic, and Epidemiologic Investigation
        </article-title>
        <source>
         Open Forum Infect. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         5
        </volume>
        <fpage>
         ofy095
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/ofid/ofy095
        </pub-id>
        <pub-id pub-id-type="pmid">
         30294616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B129-viruses-11-00280">
       <label>
        129.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamers
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Shafei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Abdallh
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gazo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nofal
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         716
        </fpage>
        <lpage>
         719
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2204.152065
        </pub-id>
        <pub-id pub-id-type="pmid">
         26981770
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-11-00280-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Schematic figure depicting four structural proteins of Middle East respiratory syndrome coronavirus (MERS-CoV), i.e., S, E, M, and N proteins (
        <bold>
         A
        </bold>
        ); a cartoon representation of MERS-CoV S1 protein binding to DPP4 (PDB code 4L72) (
        <bold>
         B
        </bold>
        ). The S protein consists of the S1 and S2 subunits. The α/β hydrolase domain of DPP4 is indicated in red, β-propeller domain in green, while part of the MERS-CoV S1 protein is shown in blue.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00280-g001">
      </graphic>
     </fig>
     <fig id="viruses-11-00280-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Schematic overview of viral RNA and infectious virus shedding of MERS-CoV-inoculated dromedary camels, pigs, and rabbits. Each data point represents the average data from previous experiments [
        <xref ref-type="bibr" rid="B17-viruses-11-00280">
         17
        </xref>
        ,
        <xref ref-type="bibr" rid="B33-viruses-11-00280">
         33
        </xref>
        ,
        <xref ref-type="bibr" rid="B84-viruses-11-00280">
         84
        </xref>
        ]. Viral RNA is measured in TCID
        <sub>
         50
        </sub>
        /mL genome equivalents, while infectious virus is expressed in TCID
        <sub>
         50
        </sub>
        /mL.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00280-g002">
      </graphic>
     </fig>
     <fig id="viruses-11-00280-f003" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Schematic representation of DPP4 expression and MERS-CoV-recognized α2,3-sialic acid glycotopes in the respiratory tract of dromedary camel, pig, rabbit, human, and sheep.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00280-g003">
      </graphic>
     </fig>
     <fig id="viruses-11-00280-f004" orientation="portrait" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        MERS-CoV infection in the lungs of asymptomatic-to-mild (left panel) and severe-to-fatal cases (right panel). Shown is a hypothetical model with two critical host determinants, DPP4 and interferon, differentially expressed in asymptomatic-to-mild and severe-to-fatal MERS-CoV infection.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00280-g004">
      </graphic>
     </fig>
    </floats-group>
   </article>
   <article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="publisher-id">
       978-1-59745-304-2
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1007/978-1-59745-304-2
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Microarrays
      </journal-id>
      <journal-title-group>
       <journal-title>
        Microarrays
       </journal-title>
       <journal-subtitle>
        Volume 2: Applications and Data Analysis
       </journal-subtitle>
      </journal-title-group>
      <isbn publication-format="print">
       978-1-58829-944-4
      </isbn>
      <isbn publication-format="electronic">
       978-1-59745-304-2
      </isbn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       18220240
      </article-id>
      <article-id pub-id-type="pmc">
       7120874
      </article-id>
      <article-id pub-id-type="publisher-id">
       20
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/978-1-59745-304-2_20
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Application of ProteinChip Array Profiling in Serum Biomarker Discovery for Patients Suffering From Severe Acute Respiratory Syndrome
       </article-title>
      </title-group>
      <contrib-group content-type="book editors">
       <contrib contrib-type="editor">
        <name>
         <surname>
          Rampal
         </surname>
         <given-names>
          Jang B.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.418254.e
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2155 2777
         </institution-id>
         <institution>
          Beckman Coulter, Inc.,
         </institution>
        </institution-wrap>
        Brea, CA
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yip
         </surname>
         <given-names>
          Timothy T. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cho
         </surname>
         <given-names>
          William C. S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Wai Wai
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Johnny W. M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          Victor W. S.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yip
         </surname>
         <given-names>
          Tai-Tung
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau Yip
         </surname>
         <given-names>
          Christine N. B.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ngan
         </surname>
         <given-names>
          Roger K. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Law
         </surname>
         <given-names>
          Stephen C. K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.415499.4
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000041771451X
         </institution-id>
         <institution>
          Department of Clinical Oncology,
         </institution>
         <institution>
          Queen Elizabeth Hospital,
         </institution>
        </institution-wrap>
        Kowloon, Hong Kong
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.415499.4
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000041771451X
         </institution-id>
         <institution>
          Department of Medicine,
         </institution>
         <institution>
          Queen Elizabeth Hospital,
         </institution>
        </institution-wrap>
        Kowloon, Hong Kong,
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        Ciphergen Biosystems Incorporation, Fremont, CA
       </aff>
      </contrib-group>
      <pub-date pub-type="ppub">
       <year>
        2007
       </year>
      </pub-date>
      <volume>
       382
      </volume>
      <fpage>
       313
      </fpage>
      <lpage>
       331
      </lpage>
      <permissions>
       <copyright-statement>
        © Humana Press Inc., Totowa, NJ 2007
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        A new strain of coronavirus has caused an outbreak of severe acute respiratory syndrome (SARS) from 2002 to 2003 resulting in 774 deaths worldwide. By protein chip array profiling technology, a number of serum biomarkers that might be useful in monitoring the clinical course of SARS patients were identified. This book chapter describes how the protein chip array profiling was carried out for this study. Briefly, SARS patients’ serum samples were first fractionated in Q Ceramic HyperD ion exchange sorbent beads by buffers at different pH. Serum protein fractions thus obtained were then bound onto a copper (II) immobilized metal affinity capture (IMAC30 Cu [II]) ProteinChip® Array or a weak cation-exchange (CM10) ProteinChip Array. After washing and addition of sinapinic acid, the chips were read in a Protein Biological System (PBS) IIc mass spectrometer. Ions were generated by laser shots and flied in a time of flight mode to the ion detector according to their mass over charge (m/z) ratio. The serum profiling spectra in SARS patients were acquired, baseline subtracted and analyzed in parallel with those from the control subjects by Ciphergen ProteinChip Software 3.0.2 with their peak intensities compared by a nonparametric two sample Mann-Whitney-
        <italic>
         U
        </italic>
        test. More than twelve peaks were differentially expressed in SARS patients with one at m/z of 11,695 (later identified to be serum amyloid A protein), which had increase in peak intensity correlating with the extent of SARS-coronavirus induced pneumonia as defined by a serial chest X-ray opacity score. The remaining biomarkers could also be useful in the study of other clinical parameters in SARS patients.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Key Words
       </title>
       <kwd>
        Pneumonia
       </kwd>
       <kwd>
        ProteinChip array profiling
       </kwd>
       <kwd>
        SARS-Coronavirus (CoV)
       </kwd>
       <kwd>
        serum amyloid A protein (SAA)
       </kwd>
       <kwd>
        severe acute respiratory syndrome (SARS)
       </kwd>
       <kwd>
        surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS)
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Humana Press 2007
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p>
      A new strain of coronavirus (CoV) caused a pandemic outbreak of severe acute respiratory syndrome (SARS) in China, Hong Kong, Singapore, Toronto, and Taiwan from 2002 to 2003, resulting in 8098 individuals being infected and 774 deaths (
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ). As compared to other upper viral respiratory infections (
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ), SARS-CoV can rapidly induce pneumonia. The accompanying adult respiratory distress syndrome can quickly progress resulting in rapid death of the patients (
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ). The most commonly used laboratory diagnostic tests for SARS-CoV-infection are reverse transcription (RT)-PCR and anti-SARS-CoV antibody serological tests (
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      –
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ), but their roles in monitoring the extent of pneumonia are rather limited. Although, serial chest radiography is helpful for monitoring the progress of disease (
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ), it is also limited by its subjectivity and variability in the interpretation of the imaging results and occasionally suboptimal quality of portable films taken in isolation ward to avoid the spread of the disease. In a recent article, the discovery of 12 up-or downregulated serum biomarkers were reported in SARS patients by a novel protein chip array profiling approach (
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      –
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ) with one biomarker appears to be useful in monitoring the extent of pneumonia (
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ). In this chapter, how this protein chip array profiling technique is carried out is described. The technique involves four steps with the first step being serum fractionation in ceramic ion exchange sorbent beads. This step separates serum proteins into several fractions aiming at reducing their complexity before protein chip profiling is performed. The second step involves the binding of serum protein biomarkers onto protein chip array surfaces. The third step is desorption of bound serum biomarkers by laser shots in the mass spectrometer generating a time of flight spectrum for each sample. The fourth step concerns with data acquisition, data processing and statistical analyses of the spectra in SARS patients in comparison with the control groups. These procedures will be described in full details in the following chapter and summarized in the flow chart diagram as in
      <xref ref-type="fig" rid="Fig1">
       <bold>
        Fig. 1
       </bold>
      </xref>
      .
      <fig id="Fig1">
       <label>
        Fig. 1.
       </label>
       <caption>
        <p>
         Sample fractionation, chip binding, and reading in protein chip array profiling technique. Serum samples from SARS patients and various control groups were fractionated in Q Ceramic Hyper D F anion exchange sorbent beads. The eluted fractions were in turn spotted onto two types of protein chips, namely, copper IMAC30 Cu(II) ProteinChip array and weak cation-exchange (CM10) ProteinChip array. Each sample bound protein chip was in turn inserted into a Protein Biology System II SELDI-TOF-mass spectrometer and the protein biomarkers were ionized and desorbed by laser beam. The ions flied to the ion detector generating a biomarker peak intensity spectrum according to their mass over charge values (m/z).
        </p>
       </caption>
       <graphic id="d29e329" xlink:href="978-1-59745-304-2_20_Fig1_HTML">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Materials
     </title>
     <sec id="Sec3">
      <title>
       SARS Patients
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          28 Patients with confirmed SARS-CoV infection managed in the Department of Medicine, Queen Elizabeth Hospital, Hong Kong.
         </p>
        </list-item>
        <list-item>
         <p>
          87% of the patients have abnormal chest radiographs on admission.
         </p>
        </list-item>
        <list-item>
         <p>
          13% of the patients present early thus requiring high-resolution thoracic computer tomography scanning to confirm the presence of pulmonary involvement.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Serum Samples
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          44 Serum samples from 24 SARS patients for differential mapping of SARS associated biomarkers.
         </p>
        </list-item>
        <list-item>
         <p>
          45 Serial serum samples from four additional SARS patients with comprehensive clinical follow-up for longitudinal correlation with clinical manifestation.
         </p>
        </list-item>
        <list-item>
         <p>
          10 Sera from 10 apparently healthy individuals (from a familial cancer screening clinic) as normal controls.
         </p>
        </list-item>
        <list-item>
         <p>
          72 Sera from 51 patients suffering from other viral or bacterial infections (influenza A virus [
          <italic>
           n
          </italic>
          = 12], influenza B virus [
          <italic>
           n
          </italic>
          = 8], respiratory adenovirus [
          <italic>
           n
          </italic>
          = 12], respiratory syncytial virus [
          <italic>
           n
          </italic>
          = 10], hepatitis B virus [
          <italic>
           n
          </italic>
          = 10],
          <italic>
           Mycobacterium tuberculosis
          </italic>
          [
          <italic>
           n
          </italic>
          = 10], other bacteria [
          <italic>
           n
          </italic>
          = 10]) as control patients for comparison with SARS patients.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Ion Exchange Fractionation of Serum
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          BioSepra Q Ceramic Hyper D F ion exchange sorbent beads (Ciphergen Biosystems Incorporation, Fremont, CA).
         </p>
        </list-item>
        <list-item>
         <p>
          96-Well sample plates (Nalge Nunc International, Rochester, NY).
         </p>
        </list-item>
        <list-item>
         <p>
          96-Well Silent Screen filter plates with Loprodyne membrane filter (0.45 µm pore size; Nalge Nunc International).
         </p>
        </list-item>
        <list-item>
         <p>
          96-Well collection plates (Nalge Nunc International).
         </p>
        </list-item>
        <list-item>
         <p>
          50 m
          <italic>
           M
          </italic>
          Tris-HCl buffer at pH 9.0 (W1 ion exchange bead washing buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          50 m
          <italic>
           M
          </italic>
          Tris-HCl buffer containing 9 mol/L urea and 20 g/L CHAPS (3,3-cholmido-propyl-dimethylammonio-1-propanesulfonate) (D1 sample denaturing buffer) at pH 9.0.
         </p>
        </list-item>
        <list-item>
         <p>
          50 m
          <italic>
           M
          </italic>
          Tris-HCl buffer containing 1 mol/L urea and 2.2 g/L CHAPS at pH 9.0 (Q1 bead equilibration buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          50 m
          <italic>
           M
          </italic>
          Tris-HCl buffer containing 1 g/L
          <italic>
           N
          </italic>
          -octyl-β-D-glucopyranoside (OGP) at pH 9.0 (E1 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Sodium phosphate containing 1 g/L OGP at pH 7.0 (E2 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Sodium acetate containing 1 g/L OGP at pH 5.0 (E3 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Sodium acetate containing 1 g/L OGP at pH 4.0 (E4 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          50 m
          <italic>
           M
          </italic>
          Sodium citrate containing 1 g/L OGP at pH 3.0 (E5 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          33.3% Isopropanol, 16.7% acetonitrile, and 0.1% trifluoroacetic acid (E6 elution buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          Micromix 5-01 shaker (Euro/DPC Ltd., Gwynedd, UK).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Chip Pretreatment, Sample Binding, and Analysis
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          Copper (II) immobilized metal affinity capture [IMAC30 Cu(II)] ProteinChip® Array (Ciphergen Biosystems Inc., Fremont, CA).
         </p>
        </list-item>
        <list-item>
         <p>
          Weak cation-exchange (CM10) ProteinChip Array (Ciphergen Biosystems, Inc.).
         </p>
        </list-item>
        <list-item>
         <p>
          96-Well ProteinChip bioprocessor (Ciphergen Biosystems, Inc.).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Copper sulfate (CuSO4; Sigma-Adrich, St. Louis, MO).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Sodium phosphate containing 0.5 mol/L NaCl (IMAC30 chip binding buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          100 m
          <italic>
           M
          </italic>
          Sodium acetate buffer pH 4.0 (serves as both IMAC30 chip neutralizing buffer and CM10 chip binding buffer).
         </p>
        </list-item>
        <list-item>
         <p>
          50% Sinapinic acid (Ciphergen Biosystems Inc.) in 500 mL/L acetonitrile and 5 mL/L trifluoroacetic acid (Sigma-Adrich).
         </p>
        </list-item>
        <list-item>
         <p>
          Protein Biological System (PBS) IIc mass spectrometer reader (Ciphergen Biosystems).
         </p>
        </list-item>
        <list-item>
         <p>
          All-in-1 peptide molecular mass standard (Ciphergen Biosystems Inc.).
         </p>
        </list-item>
        <list-item>
         <p>
          Ciphergen ProteinChip Software 3.0.2 (Ciphergen Biosystems Inc.).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
    </sec>
    <sec id="Sec7">
     <title>
      Methods
     </title>
     <sec id="Sec8">
      <title>
       Treatment of SARS Patients
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          Patients with fever and other symptoms of respiratory infection are initially managed with broad-spectrum antibiotics and supportive therapy.
         </p>
        </list-item>
        <list-item>
         <p>
          After the diagnosis of clinical SARS is made and if there is no response to antibiotic therapy, combination therapy with ribavirin and systemic steroids is initiated.
         </p>
        </list-item>
        <list-item>
         <p>
          Intravenous pulse methylprednisolone is initiated when the clinical condition, radiological presentation, or oxygen saturation status of the SARS patients further deteriorates.
         </p>
        </list-item>
        <list-item>
         <p>
          The clinical characteristics, detailed management plan, and treatment regimen of this cohort of patients can be referred to a previous publication from our hospital (
          <xref ref-type="bibr" rid="CR3">
           3
          </xref>
          ).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec9">
      <title>
       Serial Chest Radiographic Score
      </title>
      <p>
       The extent of pneumonia in the SARS patients with longitudinal follow-up is assessed by a radiologist according to a serial chest radiographic score, modified from a score system initially proposed to assess computer tomography of the chest (
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ) and summarized as in
       <xref ref-type="fig" rid="Fig2">
        <bold>
         Fig. 2
        </bold>
       </xref>
       .
       <fig id="Fig2">
        <label>
         Fig. 2.
        </label>
        <caption>
         <p>
          Assessing the extent of pneumonia by chest X-ray opacity score. The opacity in each zone (apex+upper, middle, and lower zones) from the left and right regions of the lung was scored by a “coarse semiquantitative method” with a 5 points’ scale of grades 0–4 representing involved areas of 0, 5–24, 25–49, 50–74, and 75–100%, respectively. A total score was then calculated by adding up all the grades in the six zones (Apex and upper zones were considered as one zone) to provide a 0–24 points’ scale with the higher number representing more severe pneumonic disease.
         </p>
        </caption>
        <graphic id="d29e667" xlink:href="978-1-59745-304-2_20_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          After X-ray chest radiography is taken, divide the frontal chest X-ray radiograph into six lung zones, namely, left upper zone, left middle zone, left lower zone, right upper zone, right middle zone, and right lower zone.
         </p>
        </list-item>
        <list-item>
         <p>
          The upper zone (left or right) represents area above carina (including the apex).
         </p>
        </list-item>
        <list-item>
         <p>
          The middle zone (left or right) represents area from carina to the level of inferior pulmonary veins.
         </p>
        </list-item>
        <list-item>
         <p>
          The lower zone (left or right) represents area from the lower margin of middle zone to the lung base.
         </p>
        </list-item>
        <list-item>
         <p>
          Score the opacity in each lung zone by a “coarse semiquantitative method” with a five points’ scale of grades 0–4.
         </p>
        </list-item>
        <list-item>
         <p>
          Grade 0 represents no opacity involved area.
         </p>
        </list-item>
        <list-item>
         <p>
          Grade 1 represents 5–24% opacity involved areas.
         </p>
        </list-item>
        <list-item>
         <p>
          Grade 2 represents 25–49% opacity involved areas.
         </p>
        </list-item>
        <list-item>
         <p>
          Grade 3 represents 50–74% opacity involved areas.
         </p>
        </list-item>
        <list-item>
         <p>
          Grade 4 represents 75–100% opacity involved areas.
         </p>
        </list-item>
        <list-item>
         <p>
          Add the grading from each of the six lung zones to provide a 0–24 point summation scale for assessing the extent of pneumonia.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Serum Preparation
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          8 mL Blood is collected from each patient or control subject.
         </p>
        </list-item>
        <list-item>
         <p>
          Incubate the blood for approx 2 h at 4°C to clot the blood cells.
         </p>
        </list-item>
        <list-item>
         <p>
          Separate the serum portion from the clotted cells by centrifugation at 230
          <italic>
           g
          </italic>
          for 15 min.
         </p>
        </list-item>
        <list-item>
         <p>
          Aliquot the sera for various routine laboratory diagnostic tests.
         </p>
        </list-item>
        <list-item>
         <p>
          Freeze the remaining sera at −70°C for protein chip array profiling analysis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       Ion Exchange Fractionation of Serum Proteins
      </title>
      <p>
       Owing to the protein complexity in the serum sample, an initial fractionation in Q Ceramic Hyper D F ion exchange sorbent beads is performed to generate serum fractions for chip binding experiments (
       <xref ref-type="fig" rid="Fig1">
        <bold>
         Fig. 1
        </bold>
       </xref>
       ) (
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ).
      </p>
      <sec id="Sec12">
       <title>
        Washing of Ion Exchange Beads
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Wash Q Ceramic Hyper D Fanion exchange sorbent beads three times each with five bed volumes of W1 bead washing buffer.
          </p>
         </list-item>
         <list-item>
          <p>
           Drain the washing buffer each time in vacuum after washing.
          </p>
         </list-item>
         <list-item>
          <p>
           Keep beads in 50% suspension in W1 buffer at RT.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="Sec13">
       <title>
        Denaturation of Serum Proteins
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Thaw serum from −70°C freezer immediately before serum fractionation.
          </p>
         </list-item>
         <list-item>
          <p>
           Aliquot 20 µL of serum to each well in a 96-well sample plate.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 30 µL of D1 denaturing buffer to the well containing the serum to denature the serum proteins.
          </p>
         </list-item>
         <list-item>
          <p>
           Shake the sample plate on a Micromix 5-01 shaker vigorously (in an amplitude of 7 and form of 20 Hg) for 20 min at 4°C to mix the serum with the D1 buffer well.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="Sec14">
       <title>
        Equalibration of Ion Exchange Beads and Binding of Serum Samples
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Add 180 µL of 50% suspension of ion exchange beads to each well of a 96-well Silent Screen filter plate and drain off the W1 bead-washing buffer by vacuum.
          </p>
         </list-item>
         <list-item>
          <p>
           Wash the ion exchange beads in each well three more times by adding 200 µL of Q1 bead equilibration buffer to the beads and draining off the buffer by vacuum.
          </p>
         </list-item>
         <list-item>
          <p>
           After the last vacuum drain, transfer 50 µL of the denatured serum sample from the well in the sample plate to the corresponding well in the filter plate containing the equilibrated ion exchange beads.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 50 µL of Q1 buffer to the well in the sample plate where serum was originally placed and rinse the residual serum by pipetting up and down five times.
          </p>
         </list-item>
         <list-item>
          <p>
           Transfer the 50 µL of the serum rinse to the well in the filter plate containing the mixture of denatured serum sample and ion exchange beads.
          </p>
         </list-item>
         <list-item>
          <p>
           Shake the filter plate vigorously on the Micromix shaker (in an amplitude of 7 and form of 20 Hg) for 30 min at 4°C to mix the serum and beads well.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="Sec15">
       <title>
        Elution of Serum Fractions
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           After shaking, place a 96-well F1 collection plate under the filter plate and centrifuge at 1600
           <italic>
            g
           </italic>
           for 1 min to collect the flow-through fraction in the wells of the F1 collection plate.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 100 µL of E1 elution buffer (at pH 9.0) to each well in the filter plate containing the serum bound beads and shake vigorously again on orbital shaker (speed and time as before) for 10 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Collect the eluate in the same collection plate F1 by centrifugation at 1600
           <italic>
            g
           </italic>
           for 1 min again.
          </p>
         </list-item>
         <list-item>
          <p>
           This represents fraction 1, which contains both the flow-through fraction at pH 9.0 and the pH 9.0 eluate.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 100 µL of E2 elution buffer (at pH 7.0) to each well in the filter plate and again shake at the same speed and time.
          </p>
         </list-item>
         <list-item>
          <p>
           Collect the eluate in another new F2 collection plate by centrifugation as before.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 100 µL of E2 elution buffer again to each filter well and elute a second time by shaking and centrifugation as before onto F2 collection plate again.
          </p>
         </list-item>
         <list-item>
          <p>
           This represents fraction 2, which contains the pH 7.0 eluate.
          </p>
         </list-item>
         <list-item>
          <p>
           Elute the serum protein bound beads similarly in turn with E3, E4, and E5 elution buffers as above resulting in fractions 3, 4, and 5 containing pH 5.0, pH 4.0, and pH 3.0 eluates, respectively, in three new F3, F4, and F5 collection plates.
          </p>
         </list-item>
         <list-item>
          <p>
           Final elution is achieved by adding E6 organic solvent elution buffer and centrifugation at 2000
           <italic>
            g
           </italic>
           for 5 min giving rise to fraction 6 containing the organic solvent eluate in collection plate F6.
          </p>
         </list-item>
         <list-item>
          <p>
           Freeze fractions 1–6 in collection plates E1–6 at −70°C until the chip binding protocol proceeds.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="Sec16">
      <title>
       Chip Pretreatment
      </title>
      <p>
       The ProteinChip Array Profiling technique is also called surface enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOFMS, Ciphergen Biosystems Inc., Fremont, CA). The chip array used is a 10 mm wide × 80 mm long metal chip having eight 2-mm spots with a specific chromatographic surface for binding of biomarkers of interest (
       <italic>
        see
       </italic>
       <xref ref-type="fig" rid="Fig1">
        <bold>
         Fig. 1
        </bold>
       </xref>
       ). For IMAC30 Cu(II) ProteinChip Array, a pretreatment procedure is required for loading copper ions onto the chip for binding protein biomarkers with affinity to copper ions. This metal loading step is, however, not required for CM10 ProteinChip Array, which is impregnated with carboxylate ions as weak cation exchanger for biomarker binding. CM10 chips only requires buffer washing instead. Both types of chips are tested to be ideal for binding serum proteins/peptides for the study.
      </p>
      <sec id="Sec17">
       <title>
        IMAC30 Chip Pretreatment
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Assemble the 96-well bioprocessor for chip pretreatment by placing 12 strips of protein chips in the base clamp assembly and then putting a 96-hole rubber gasket sheet and a 96-well bioprocessor reservoir on top of the chips.
          </p>
         </list-item>
         <list-item>
          <p>
           Clamp this sandwich tight with the 96 incubation wells in the reservoir placed directly on top of the 96 chip spots.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 50 µL of 100 m
           <italic>
            M
           </italic>
           CuSO4 solution into each well in the reservoir making direct contact with each IMAC30 chip spot.
          </p>
         </list-item>
         <list-item>
          <p>
           Get rid of air bubbles if present.
          </p>
         </list-item>
         <list-item>
          <p>
           Shake the chips in the bioprocessor for 5 min at the same speed and time as before in the orbital shaker at RT to allow copper ions from CuSO4 solution to bind to the chip surface.
          </p>
         </list-item>
         <list-item>
          <p>
           Pipet away the CuSO4 solution.
          </p>
         </list-item>
         <list-item>
          <p>
           Rinse the chip spot in each well with 100 µL of Milli-Q grade of water and shake again under the same condition for 1 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Rinse each well with 100 µL of sodium acetate buffer at pH 4.0 (IMAC30 chip neutralizing buffer) for 5 min with shaking at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the neutralizing buffer after shaking.
          </p>
         </list-item>
         <list-item>
          <p>
           Rinse the well again with 100 µL of Milli-Q water by shaking for 1 min at room temperature.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 150 µL of 100 m
           <italic>
            M
           </italic>
           sodium phosphate buffer containing 0.5 mol/L NaCl (IMAC30 chip binding buffer) onto each well and shake for 5 min at RT to wash the chip spot.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the buffer after shaking.
          </p>
         </list-item>
         <list-item>
          <p>
           Wash with the same IMAC30 chip-binding buffer one more time.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the buffer after washing.
          </p>
         </list-item>
         <list-item>
          <p>
           Proceed immediately to
           <xref ref-type="sec" rid="Sec20">
            <bold>
             Subheading 3.6.1.
            </bold>
           </xref>
           for sample binding without letting the chip surface to dry.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="Sec18">
       <title>
        CM10 Chip Pretreatment
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           After assembling the CM10 chips onto the 96-well bioprocessor (
           <italic>
            see
           </italic>
           <bold>
            steps 1–2
           </bold>
           in
           <xref ref-type="sec" rid="Sec17">
            <bold>
             Subheading 3.5.1.
            </bold>
           </xref>
           ), add 150 µL of 100 m
           <italic>
            M
           </italic>
           sodium acetate buffer at pH 4. (CM10 chip binding buffer) onto each reservoir well and shake vigorously on micromix shaker again as before for 5 min at RT to wash the chip spot.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the buffer from the well.
          </p>
         </list-item>
         <list-item>
          <p>
           Wash with the same chip-binding buffer one more time.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the buffer.
          </p>
         </list-item>
         <list-item>
          <p>
           Proceed immediately to
           <xref ref-type="sec" rid="Sec21">
            <bold>
             Subheading 3.6.2.
            </bold>
           </xref>
           for sample binding without letting the chip surface to dry.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="Sec19">
      <title>
       Serum Fraction Binding on Chips
      </title>
      <sec id="Sec20">
       <title>
        IMAC30 Chips
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Add 80 µL of the IMAC30 chip-binding buffer into each well in the bioprocessor set up containing the IMAC30 chips.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 20 µL of each ion exchange bead eluate (serum fractions 1–6) to the well for sample binding.
          </p>
         </list-item>
         <list-item>
          <p>
           Mix well by shaking for 30 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the serum fractions.
          </p>
         </list-item>
         <list-item>
          <p>
           Wash the chip spot in the well by adding 150 µL of IMAC30 chip-binding buffer onto each well and shake for 5 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove buffer.
          </p>
         </list-item>
         <list-item>
          <p>
           Repeat washing (
           <bold>
            steps 5
           </bold>
           and
           <bold>
            6
           </bold>
           ) once more.
          </p>
         </list-item>
         <list-item>
          <p>
           Rinse with water two times by adding 200 µL of Milli-Q water to each well and discard immediately.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the chips from bioprocessor and air-dry the chips for 5 min.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 1 µL of 50% sinapinic acid (which is an energy absorbing molecule solution) to each chip spot.
          </p>
         </list-item>
         <list-item>
          <p>
           Air-dry the chips for about 10 min.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 1 µL of 50% sinapinic acid and air-dry again.
          </p>
         </list-item>
         <list-item>
          <p>
           The chip is ready to be read in the PBS IIc mass spectrometer reader.
          </p>
         </list-item>
         <list-item>
          <p>
           Remember to process at least one reference control serum concurrently with the patients’ samples on each chip for quality control of chip-to-chip variability.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="Sec21">
       <title>
        CM10 Chips
       </title>
       <p>
        <list list-type="order">
         <list-item>
          <p>
           Add 90 µL of 100 m
           <italic>
            M
           </italic>
           sodium acetate buffer at pH 4.0 (CM10 chip binding buffer) into each well in the bioprocessor set up containing the CM10 chips.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 10 µL of each ion exchange bead eluate (sample fractions 1–6) to the well for sample binding.
          </p>
         </list-item>
         <list-item>
          <p>
           Mix well by shaking for 30 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the sample fractions.
          </p>
         </list-item>
         <list-item>
          <p>
           Wash the chip spot in the well by adding 150 µL of CM10 chip binding buffer again into each well and shake for 5 min at RT.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove buffer.
          </p>
         </list-item>
         <list-item>
          <p>
           Repeat washing (
           <bold>
            steps 5
           </bold>
           and
           <bold>
            6
           </bold>
           ) once more.
          </p>
         </list-item>
         <list-item>
          <p>
           Rinse with water two times by adding 200 µL of Milli-Q water to each well and discard immediately.
          </p>
         </list-item>
         <list-item>
          <p>
           Remove the chips from bioprocessor and air-dry the chips for 5 min.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 1 µL of 50% sinapinic acid to each chip spot.
          </p>
         </list-item>
         <list-item>
          <p>
           Air-dry the chip for around 10 min.
          </p>
         </list-item>
         <list-item>
          <p>
           Add 1 µL of 50% sinapinic acid and air-dry again.
          </p>
         </list-item>
         <list-item>
          <p>
           The chip is ready to be read in the PBS IIc mass spectrometer reader.
          </p>
         </list-item>
         <list-item>
          <p>
           Process at least one reference control serum concurrently with the patients’ samples on each chip for quality control of chip-to-chip variability as before.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="Sec22">
      <title>
       Chip Reading and Data Acquisition
      </title>
      <p>
       The PBS IIc SELDI-TOF mass spectrometer reader is a laser desorption ionization time of flight mass spectrometer equipped with a pulsed ultraviolet nitrogen laser source. When the laser activates the bound serum biomarkers on the chip surface, the biomarkers become desorbed and ionized. Ionized molecules fly along the mass spectrometer to the ion detector in a time of flight manner according to their mass over charge ratio (m/z). When the ion signal is detected in the ion detector, signal processing is accomplished by high-speed analog-to-digital converter linking to a computer. Detected protein biomarkers are displayed in spectral, map or gel view formats by the Ciphergen ProteinChip software 3.0.2. The following steps show how the chips are read in the mass spectrometer.
      </p>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          Click the “Sample Exchange Dialog” button from the manu bar of the Ciphergen ProteinChip software 3.0.2 in the PBS IIc SELDI-TOF mass spectrometer reader.
         </p>
        </list-item>
        <list-item>
         <p>
          Click “Open Lid” button in the “Sample Exchange Dialog” box to open the lid of the chip chamber.
         </p>
        </list-item>
        <list-item>
         <p>
          Place the sample treated chips into the slot of the chip chamber.
         </p>
        </list-item>
        <list-item>
         <p>
          Click “Close Lid” button.
         </p>
        </list-item>
        <list-item>
         <p>
          The chip is automatically inserted into the chip chamber.
         </p>
        </list-item>
        <list-item>
         <p>
          In the “Sample Exchange Dialog” box, input the serial number, chip type, and chip format.
         </p>
        </list-item>
        <list-item>
         <p>
          Click “Chip” button from the “Sample Exchange Dialog” box.
         </p>
        </list-item>
        <list-item>
         <p>
          Input sample name and sample group.
         </p>
        </list-item>
        <list-item>
         <p>
          Click “OK” button.
         </p>
        </list-item>
        <list-item>
         <p>
          Click “Chip Protocol” button from the menu bar.
         </p>
        </list-item>
        <list-item>
         <p>
          Input spectrum tag (which is the sample name) and the following spot protocols:
          <list list-type="alpha-lower">
           <list-item>
            <p>
             Starting laser intensity to 165.
            </p>
           </list-item>
           <list-item>
            <p>
             Starting detector sensitivity to 9.
            </p>
           </list-item>
           <list-item>
            <p>
             Highest mass of detection to 200,000 Da.
            </p>
           </list-item>
           <list-item>
            <p>
             Optimal mass range of detection from m/z of 2000 to 20,000 (signals from m/z of 0–2000 are not analyzed as artifacts can be produced by energy-absorbing molecules or other chemical contaminants at this mass range).
            </p>
           </list-item>
           <list-item>
            <p>
             Focus lag time at 800 ns.
            </p>
           </list-item>
           <list-item>
            <p>
             Mass deflector to Auto.
            </p>
           </list-item>
           <list-item>
            <p>
             Data acquisition method to SELDI quantitation.
            </p>
           </list-item>
           <list-item>
            <p>
             338 laser shots per sample.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item>
         <p>
          Click “Start Running” button from the menu bar.
         </p>
        </list-item>
        <list-item>
         <p>
          By the time 338 laser shots are fired, the collected data is automatically saved.
         </p>
        </list-item>
        <list-item>
         <p>
          It is important to first carry out external calibration of the equipment using the All-In-1 Peptide molecular mass standard (according to the instruction sheet from the manufacturer) to ensure mass accuracy of the spectra before running the samples.
         </p>
        </list-item>
        <list-item>
         <p>
          Carry out baseline subtraction and calibration for the spectra.
         </p>
        </list-item>
        <list-item>
         <p>
          Generate labeled peak groups (clusters) across multiple spectra by the Biomarker Wizard mode.
         </p>
        </list-item>
        <list-item>
         <p>
          Compare peak groups detected in the SARS patients with those of the controls by nonparametric two sample Mann-Whitney
          <italic>
           U
          </italic>
          -test in the Biomarker Wizard mode.
         </p>
        </list-item>
        <list-item>
         <p>
          Biomarker Wizard operates in two passes, with the first pass uses low sensitivity settings to detect obvious and well-defined peaks and the second pass uses higher sensitivity settings to search for smaller peaks.
         </p>
        </list-item>
        <list-item>
         <p>
          This will identify both strong and weak peaks that are significantly increased or decreased in the patients vs the controls.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="Sec23">
      <title>
       Data Analyses
      </title>
      <p>
       <list list-type="order">
        <list-item>
         <p>
          As an example,
          <xref ref-type="fig" rid="Fig3">
           <bold>
            Fig. 3
           </bold>
          </xref>
          illustrates a comparison of multiple biomarkers in serum fraction 1 (pH 9.0 eluate) of SARS patients vs all the other controls in a gel view format in the m/z range of 2000–15,000.
         </p>
        </list-item>
        <list-item>
         <p>
          Highlighted in three boxes (A, B, and C) with arrows are biomarkers at m/z of 11,695, 9159, and 7784, respectively with biomarker at 11,695 being significantly increased in the SARS patients vs the controls and biomarkers 9159 and 7784 being significantly decreased.
         </p>
        </list-item>
        <list-item>
         <p>
          Nine biomarker were found within m/z range of 4900–15,000 with highly significant increase in their normalized peak intensities in the SARS patients vs those of the controls and three biomarkers with highly significant decrease (
          <xref ref-type="table" rid="Tab1">
           <bold>
            Table 1
           </bold>
          </xref>
          ).
         </p>
        </list-item>
        <list-item>
         <p>
          Separating the controls into individual groups, a highly significant increase of biomarker at 11,695 is also observed in SARS patients vs each control group (
          <xref ref-type="fig" rid="Fig4">
           <bold>
            Fig. 4
           </bold>
          </xref>
          ).
         </p>
        </list-item>
        <list-item>
         <p>
          As pneumonia is a frequent life threatening clinical manifestation in the SARS patients, we further monitor the biomarker—11,695 level in a SARS patient longitudinally (
          <xref ref-type="fig" rid="Fig5">
           <bold>
            Fig. 5
           </bold>
          </xref>
          ) and correlate the biomarker level with the extent of pneumonia by chest X-ray opacity score (
          <xref ref-type="fig" rid="Fig2">
           <bold>
            Fig. 2
           </bold>
          </xref>
          ).
         </p>
        </list-item>
        <list-item>
         <p>
          <xref ref-type="fig" rid="Fig5">
           <bold>
            Figure 5
           </bold>
          </xref>
          illustrates, in this patient, an elevation of the biomarker—11,695 level preceding the development of pneumonia at the onset of disease (as indicated by an increasing opacity score) followed by a rapid drop of the biomarker level down to the background on recovery from the illness after stringent antiviral and steroid treatments (
          <italic>
           see
          </italic>
          <xref ref-type="sec" rid="Sec24">
           <bold>
            Note 1
           </bold>
          </xref>
          for details of clinical presentation of the patients).
         </p>
        </list-item>
        <list-item>
         <p>
          On the other hand,
          <xref ref-type="fig" rid="Fig6">
           <bold>
            Fig. 6
           </bold>
          </xref>
          shows low biomarker—11,695 level during the whole monitoring period in another SARS patient who has low X-ray scores and whose clinical course is relatively mild (
          <italic>
           see
          </italic>
          <xref ref-type="sec" rid="Sec24">
           <bold>
            Note 2
           </bold>
          </xref>
          ).
         </p>
        </list-item>
        <list-item>
         <p>
          By means of peptide mapping and tandem MS/MS mass spectrometry, this biomarker is identified to be Serum Amyloid A protein (SAA), which is an acute phase reactant frequently and rapidly induced in abundance at pneumonia (
          <italic>
           see
          </italic>
          <bold>
           ref.
          </bold>
          <xref ref-type="bibr" rid="CR15">
           15
          </xref>
          for the protein ID results and
          <bold>
           ref.
          </bold>
          <xref ref-type="bibr" rid="CR17">
           17
          </xref>
          –
          <xref ref-type="bibr" rid="CR20">
           20
          </xref>
          for the techniques adopted).
         </p>
        </list-item>
        <list-item>
         <p>
          This serial study demonstrates the potential of the biomarkers discovered by protein chip array profiling in monitoring the disease manifestation in SARS patients.
         </p>
        </list-item>
       </list>
       <fig id="Fig3">
        <label>
         Fig. 3.
        </label>
        <caption>
         <p>
          Gel view of partial protein chip array profiling results in SARS patients’ sera vs control infection groups’ sera. Part of the profiling results of fraction 1 from the ion exchange serum eluate in SARS patients vs the control patients in m/z range from 2000 to 15,000 was illustrated. HBV, hepatitis B virus; TB,
          <italic>
           M. tuberculosis
          </italic>
          ; RSV, respiratory syncytial virus. The three arrows showed three clusters of biomarkers,
          <bold>
           A–C
          </bold>
          at m/z of 11695, 9159, and 7784, respectively, with cluster
          <bold>
           A
          </bold>
          being significantly increased in SARS patients and the last two clusters (
          <bold>
           B
          </bold>
          and
          <bold>
           C
          </bold>
          ) significantly decreased.
         </p>
        </caption>
        <graphic id="d29e1671" xlink:href="978-1-59745-304-2_20_Fig3_HTML">
        </graphic>
       </fig>
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          <bold>
           Serum Biomarkers Significantly Increased or Decreased in SARS Patients vs Seven Control Groups of Patients With Other Infections and Healthy Individuals
          </bold>
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Biomarker number
           </th>
           <th>
            Mass over charge (
            <italic>
             m/z
            </italic>
            )
           </th>
           <th>
            Differential expression
           </th>
           <th>
            <italic>
             p
            </italic>
            -value
            <sup>
             <italic>
              a
             </italic>
            </sup>
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            1
           </td>
           <td>
            4922
           </td>
           <td>
            Increased
           </td>
           <td>
            1.1 × 10
            <sup>
             −4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            2
           </td>
           <td>
            5104
           </td>
           <td>
            Increased
           </td>
           <td>
            7.1 × 10
            <sup>
             −8
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            3
           </td>
           <td>
            5215
           </td>
           <td>
            Increased
           </td>
           <td>
            6.4 × 10
            <sup>
             −4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            4
           </td>
           <td>
            5833
           </td>
           <td>
            Increased
           </td>
           <td>
            3.1 × 10
            <sup>
             −9
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            5
           </td>
           <td>
            7784
           </td>
           <td>
            Decreased
           </td>
           <td>
            4.9 × 10
            <sup>
             −8
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            6
           </td>
           <td>
            8416
           </td>
           <td>
            Decreased
           </td>
           <td>
            1.6 × 10
            <sup>
             −7
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            7
           </td>
           <td>
            9159
           </td>
           <td>
            Decreased
           </td>
           <td>
            1 × 10
            <sup>
             −10
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            8
           </td>
           <td>
            10,867
           </td>
           <td>
            Increased
           </td>
           <td>
            3.6 × 10
            <sup>
             −7
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            9
           </td>
           <td>
            11,508
           </td>
           <td>
            Increased
           </td>
           <td>
            1.3 × 10
            <sup>
             −5
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            10
           </td>
           <td>
            11,695
           </td>
           <td>
            Increased
           </td>
           <td>
            5.4 × 10
            <sup>
             −6
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            11
           </td>
           <td>
            11,871
           </td>
           <td>
            Increased
           </td>
           <td>
            8.4 × 10
            <sup>
             −4
            </sup>
           </td>
          </tr>
          <tr>
           <td>
            12
           </td>
           <td>
            14,715
           </td>
           <td>
            Increased
           </td>
           <td>
            3.9 × 10
            <sup>
             −9
            </sup>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <sup>
           <italic>
            a
           </italic>
          </sup>
          <italic>
           p
          </italic>
          -values were obtained in Mann-Whitney U-test by comparing the normalized peaki intensities of the biomarkers in 44 sera from 24 SARS patients vs those in 72 sera from 51 control patients with various viral or bacterial infections (see Materials for individual control group) plus 10 sera from 10 apparently healthy individuals.
         </p>
        </table-wrap-foot>
       </table-wrap>
       <fig id="Fig4">
        <label>
         Fig. 4.
        </label>
        <caption>
         <p>
          Comparison of normalized peak intensities of the biomarker at m/z of 11,695 in sera from SARS patients and control groups. The normalized peak intensities of this marker in SARS patients’ sera were compared with those of the other seven control infection groups and the normal individuals by Mann-Whitney
          <italic>
           U
          </italic>
          -test. A
          <italic>
           p
          </italic>
          -value of 0.05 or less demonstrated a statistically significant difference between the two groups. Adeno, adenovirus; Bact, bacterial culture positive; HBV, hepatitis B virus; Influ A, influenza A virus; Influ B, influenza B virus; Normal, apparently normal subjects; RSV, respiratory syncytial virus; TB,
          <italic>
           M. tuberculosis
          </italic>
          .
         </p>
        </caption>
        <graphic id="d29e1930" xlink:href="978-1-59745-304-2_20_Fig4_HTML">
        </graphic>
       </fig>
       <fig id="Fig5">
        <label>
         Fig. 5.
        </label>
        <caption>
         <p>
          Correlation of the level of serum biomarker—11,695 with the extent of pneumonia in a SARS patient under clinical follow-up. Longitudinal follow- up of the clinical profile of this patient was illustrated in the top panel. Monitoring of the biomarker—11,695 level and chest X-ray opacity score (an indicator of the extent o pneumonia) was shown in the lower left panel. The lower right panel illustrates the biomarker—11,695 in a gel view measured at different time points. CoV IgG &lt;25 and 100, Serum SARS-Coronavirus IgG antibody titers of &lt;1/25 and 1/100; CXR, Lung consolidation as shown by chest X-ray imaging; FU outpatient, During follow-up as outpatient; ICU, Admitted to Intensive care unit; i.v. Ig, Intravenous injection of immune globulin; MP, Daily treatment by 500 mg × 2 of methylprednisolone; NP Swab CoV −ve, RT-PCR negative for SARS Coronavirus in nasopharyngeal swab; Rectal Swab CoV +ve, RT-PCR positive for SARS Coronavirus in rectal swab; Ribavirin, Daily treatment by 400 mg Ribavirin; Stool CoV +ve, RT-PCR positive for SARS Coronavirus in the stool; Throat Swab CoV +ve, RT PCR positive for SARS Coronavirus in throat swab.
         </p>
        </caption>
        <graphic id="d29e1940" xlink:href="978-1-59745-304-2_20_Fig5_HTML">
        </graphic>
       </fig>
       <fig id="Fig6">
        <label>
         Fig. 6.
        </label>
        <caption>
         <p>
          Correlation of the level of serum biomarker—11,695 with the extent of pneumonia in the second SARS patient under clinical follow-up. Longitudinal follow-up of the clinical profile of this patient was illustrated in the top panel. Monitoring of the biomarker—11,695 level and chest X-ray opacity score was shown in the lower panel. Annotations were similar to those as tabulated in
          <xref ref-type="fig" rid="Fig5">
           <bold>
            Fig. 5
           </bold>
          </xref>
          . Antibiotic, Treatment with conventional antibiotics; CoV IgG &lt;10 and 160, Serum SARS-Coronavirus IgG antibody titers of &lt;1/10 and 1/160; NP Swab CoV −ve, RT-PCR negative for SARS Coronavirus in nasopharyngeal swab; Rectal Swab CoV −ve, RT-PCR negative for SARS Coronavirus in rectal swab; Throat Swab CoV −ve, RT PCR negative for SARS Coronavirus in throat swab.
         </p>
        </caption>
        <graphic id="d29e1955" xlink:href="978-1-59745-304-2_20_Fig6_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec24">
     <title>
      Notes
     </title>
     <p>
      <list list-type="order">
       <list-item>
        <p>
         Clinical and protein chip monitoring of the first SARS patient (
         <italic>
          see
         </italic>
         <xref ref-type="fig" rid="Fig5">
          <bold>
           Fig. 5
          </bold>
         </xref>
         ): one day after SARS-CoV infection was diagnosed, the radiographic score of this patient was increased from 6 to a peak value of &gt;16 and then dropped to 12, 9, and finally to 4 demonstrating a progressive recovery. The biomarker—11,695 level by protein chip array profiling study showed an elevation that peaked earlier than the radiographic score but it then gradually subsided along with the score to a nadir when the patient was discharged.
        </p>
       </list-item>
       <list-item>
        <p>
         Clinical and protein chip monitoring of the second SARS patient (
         <italic>
          see
         </italic>
         <xref ref-type="fig" rid="Fig6">
          <bold>
           Fig. 6
          </bold>
          )
         </xref>
         : the second patient had all the typical clinical symptoms of SARS-CoV infection with left upper lobe consolidation in chest radiographs. Despite negative SARS-CoV RT-PCR, titer elevation in paired anti-SARS CoV serum antibody tests performed in two laboratories confirmed the viral infection. He was managed as SARS on the next day. The clinical course was uneventful and uncomplicated. His pneumonia had never been extensive and hence his radiographic score showed just a low level of lung involvement from May 8th to 15th and then totally subsided from May 16th onwards. Biomarker—11,695 level was essentially low throughout the monitoring period.
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         WHO issued consensus document on the epidemiology of SARS
        </article-title>
        <source>
         WHO Wkly Epidemiol. Rec.
        </source>
        <year>
         2003
        </year>
        <volume>
         78
        </volume>
        <fpage>
         373
        </fpage>
        <lpage>
         375
        </lpage>
        <pub-id pub-id-type="pmid">
         14601330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Engel
          </surname>
          <given-names>
           J. P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral upper respiratory infections
        </article-title>
        <source>
         Semin. Respir. Infect.
        </source>
        <year>
         1995
        </year>
        <volume>
         10
        </volume>
        <fpage>
         3
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         7761711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. W. M.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           C. K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           Y. H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2003
        </year>
        <volume>
         58
        </volume>
        <fpage>
         686
        </fpage>
        <lpage>
         689
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/thorax.58.8.686
        </pub-id>
        <pub-id pub-id-type="pmid">
         12885985
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C. A.
          </given-names>
         </name>
         <name>
          <surname>
           Ghani
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G. M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological determinants of spread of casual agent of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1761
        </fpage>
        <lpage>
         1766
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13410-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781533
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           W. C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K. H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of reverse transcriptase-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         41
        </volume>
        <fpage>
         4521
        </fpage>
        <lpage>
         4524
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.41.10.4521-4524.2003
        </pub-id>
        <pub-id pub-id-type="pmid">
         14532176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Primary investigation on the changing mode of plasma specific IgG antibody in SARS patients and their physicians and nurses
        </article-title>
        <source>
         Beijing Da Xue Xue Bao
        </source>
        <year>
         2003
        </year>
        <volume>
         35
        </volume>
        <fpage>
         23
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L. L. M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           O. K.
          </given-names>
         </name>
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K. Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J. S. M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <year>
         2003
        </year>
        <volume>
         49
        </volume>
        <fpage>
         953
        </fpage>
        <lpage>
         955
        </lpage>
        <pub-id pub-id-type="doi">
         10.1373/49.6.953
        </pub-id>
        <pub-id pub-id-type="pmid">
         12765993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grinblat
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shulman
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Glickman
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matukas
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Paul
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: radiographic review of 40 probable cases in Toronto, Canada
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2003
        </year>
        <volume>
         228
        </volume>
        <fpage>
         802
        </fpage>
        <lpage>
         809
        </lpage>
        <pub-id pub-id-type="doi">
         10.1148/radiol.2283030671
        </pub-id>
        <pub-id pub-id-type="pmid">
         12853655
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           N. L.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           G. C.
          </given-names>
         </name>
         <name>
          <surname>
           Khong
          </surname>
          <given-names>
           P. L.
          </given-names>
         </name>
         <name>
          <surname>
           Nicolaou
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: radiographic and CT findings
        </article-title>
        <source>
         AJR Am. J. Roentgenol.
        </source>
        <year>
         2003
        </year>
        <volume>
         181
        </volume>
        <fpage>
         3
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         12818821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           E. T.
          </given-names>
         </name>
         <name>
          <surname>
           Thulasiraman
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Dalmasso
          </surname>
          <given-names>
           E. A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein biochips for differential profiling
        </article-title>
        <source>
         Curr. Opin. Biotechnol.
        </source>
        <year>
         2001
        </year>
        <volume>
         12
        </volume>
        <fpage>
         65
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0958-1669(00)00167-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         11167075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wright
          </surname>
          <given-names>
           G. L. Jr.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis
        </article-title>
        <source>
         Expert Rev. Mol. Diagn.
        </source>
        <year>
         2002
        </year>
        <volume>
         2
        </volume>
        <fpage>
         549
        </fpage>
        <lpage>
         563
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14737159.2.6.549
        </pub-id>
        <pub-id pub-id-type="pmid">
         12465452
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Dalmasso
          </surname>
          <given-names>
           E. A.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           E. T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current achievements using ProteinChip Array technology
        </article-title>
        <source>
         Curr. Opin. Chem. Biol.
        </source>
        <year>
         2002
        </year>
        <volume>
         6
        </volume>
        <fpage>
         86
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1367-5931(01)00282-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         11827829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Issaq
          </surname>
          <given-names>
           H. J.
          </given-names>
         </name>
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           T. D.
          </given-names>
         </name>
         <name>
          <surname>
           Conrads
          </surname>
          <given-names>
           T. P.
          </given-names>
         </name>
         <name>
          <surname>
           Felschow
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SELDITOF MS approach to proteomics: protein profiling and biomarker identification
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2002
        </year>
        <volume>
         292
        </volume>
        <fpage>
         587
        </fpage>
        <lpage>
         592
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/bbrc.2002.6678
        </pub-id>
        <pub-id pub-id-type="pmid">
         11922607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vorderwulbecke
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cleverley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein quantification by the SELDI-TOF-MS-based ProteinChip® system
        </article-title>
        <source>
         Nat. Method
        </source>
        <year>
         2005
        </year>
        <volume>
         2
        </volume>
        <fpage>
         393
        </fpage>
        <lpage>
         395
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nmeth0505-393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           T. T. C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J. W. M.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           W. C. S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         51
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="doi">
         10.1373/clinchem.2004.031229
        </pub-id>
        <pub-id pub-id-type="pmid">
         15364884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           C. S.
          </given-names>
         </name>
         <name>
          <surname>
           Desai
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         <name>
          <surname>
           Rubens
          </surname>
          <given-names>
           M. B.
          </given-names>
         </name>
         <name>
          <surname>
           Padley
          </surname>
          <given-names>
           S. P. G.
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           A. U.
          </given-names>
         </name>
         <name>
          <surname>
           Hansell
          </surname>
          <given-names>
           D. M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Visual quantitation and observer variation of signs of small airways disease at inspiratory and expiratory CT
        </article-title>
        <source>
         J. Thorac. Imag.
        </source>
        <year>
         1999
        </year>
        <volume>
         14
        </volume>
        <fpage>
         279
        </fpage>
        <lpage>
         285
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00005382-199910000-00008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cleveland
          </surname>
          <given-names>
           D. W.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           S. G.
          </given-names>
         </name>
         <name>
          <surname>
           Kirschner
          </surname>
          <given-names>
           M. W.
          </given-names>
         </name>
         <name>
          <surname>
           Laemmli
          </surname>
          <given-names>
           U. K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         1977
        </year>
        <volume>
         252
        </volume>
        <fpage>
         1102
        </fpage>
        <lpage>
         1106
        </lpage>
        <pub-id pub-id-type="pmid">
         320200
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baudys
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Foundling
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pavlik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Blundell
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kostka
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protein chemical characterization of Mucor pusillus aspartic proteinase amino acid sequence homology with the other aspartic proteinases disulfide bond arrangement and site of carbohydrate attachment
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         1988
        </year>
        <volume>
         235
        </volume>
        <fpage>
         271
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0014-5793(88)81277-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         3042459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fournier
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Chaurand
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bolbach
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lutzenkirchen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Spengler
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tabet
          </surname>
          <given-names>
           J. C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sequencing of a branched peptide using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
        </article-title>
        <source>
         J. Mass Spectrom.
        </source>
        <year>
         2000
        </year>
        <volume>
         35
        </volume>
        <fpage>
         1425
        </fpage>
        <lpage>
         1433
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/1096-9888(200012)35:12&lt;1425::AID-JMS77&gt;3.0.CO;2-C
        </pub-id>
        <pub-id pub-id-type="pmid">
         11180633
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perkins
          </surname>
          <given-names>
           D. N.
          </given-names>
         </name>
         <name>
          <surname>
           Pappin
          </surname>
          <given-names>
           D. J.
          </given-names>
         </name>
         <name>
          <surname>
           Creasy
          </surname>
          <given-names>
           D. M.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           J. S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Probabilitybased protein identification by searching sequence databases using mass spectrometry data
        </article-title>
        <source>
         Electrophoresis
        </source>
        <year>
         1999
        </year>
        <volume>
         20
        </volume>
        <fpage>
         3551
        </fpage>
        <lpage>
         3567
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/(SICI)1522-2683(19991201)20:18&lt;3551::AID-ELPS3551&gt;3.0.CO;2-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         10612281
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Exp Mol Med
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Exp. Mol. Med
      </journal-id>
      <journal-title-group>
       <journal-title>
        Experimental &amp; Molecular Medicine
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1226-3613
      </issn>
      <issn pub-type="epub">
       2092-6413
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26315600
      </article-id>
      <article-id pub-id-type="pmc">
       4558490
      </article-id>
      <article-id pub-id-type="publisher-id">
       BFemm201576
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/emm.2015.76
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Durai
         </surname>
         <given-names>
          Prasannavenkatesh
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Batool
         </surname>
         <given-names>
          Maria
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shah
         </surname>
         <given-names>
          Masaud
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Choi
         </surname>
         <given-names>
          Sangdun
         </given-names>
        </name>
        <address>
         <email>
          sangdunchoi@ajou.ac.kr
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.251916.8
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0004 0532 3933
         </institution-id>
         <institution>
          Department of Molecular Science and Technology,
         </institution>
         <institution>
          Ajou University,
         </institution>
        </institution-wrap>
        Suwon, Korea
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        28
       </day>
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        28
       </day>
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        8
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       47
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       e181
      </fpage>
      <lpage>
       e181
      </lpage>
      <history>
       <date date-type="received">
        <day>
         12
        </day>
        <month>
         7
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         5
        </day>
        <month>
         8
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2015
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~487 deaths, have been reported worldwide. Notably, the recent human-to-human ‘superspreading’ of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.
       </p>
      </abstract>
      <abstract abstract-type="ResearchSummary" id="Abs2">
       <title>
        Middle East respiratory syndrome: Potential therapeutic targets
       </title>
       <p id="Par2">
        Urgent research into anti-viral drugs to tackle Middle East respiratory syndrome coronavirus (MERS-CoV) is vital to avoid a future pandemic. MERS-CoV has a fatality rate four times that of similar acute respiratory infections, yet no clinically approved drugs are available. Scientists believe MERS-CoV originates from dromedary camels, though there may be unidentified intermediate hosts. Concerned by the recent human-to-human spread of MERS-CoV in South Korean hospitals, Sangdun Choi and co-workers at Ajou University in Suwon, South Korea, reviewed current understanding of MERS-CoV, the proteins involved in viral entry and replication, and potential therapeutic targets. Three such vital targets are spike protein and proteases, PLpro and 3CLpro, involved in viral entry or replication, respectively. Host receptor DPP4 and viral accessory protein 4a could be other promising targets. Multiple compounds against viral proteases and two antibodies directed against the viral protein to prevent binding showed promise, but further research is needed.
       </p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Viral infection
       </kwd>
       <kwd>
        Viral infection
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par3">
      In 2012, a new human disease called Middle East respiratory syndrome (MERS), having a high mortality rate, emerged in the Middle East. It was caused by a virus that was originally called human coronavirus-Erasmus Medical Center/2012 (HCoV-EMC/2012), but was later renamed as Middle East respiratory syndrome coronavirus (MERS-CoV).
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      MERS-CoV is comparable to severe acute respiratory syndrome coronavirus (SARS-CoV), which killed almost 10% of the affected individuals in China between 2002 and 2003.
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
      </sup>
      The first MERS patient reported in Saudi Arabia in June 2012 was possibly infected by direct or indirect transmission of the virus from dromedary camels.
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
      </sup>
      Moreover, MERS-CoV similar to the isolates from dromedary camels and humans was found in bats.
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      Evidence suggests that MERS-CoV can be transmitted to humans via both animals and humans.
      <sup>
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      However, the successive epidemics of MERS indicate that the pathogen has spread to various parts of the world predominantly via interhuman transmission (
      <xref ref-type="fig" rid="Fig1">
       Figure 1
      </xref>
      ). Human-to-human transmission is confirmed by the fact that secondarily infected individuals had come in close contact with a primarily infected individual; these secondarily infected individuals included family members, health-care workers and people who shared the hospital room or visited the patients.
      <sup>
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      For instance, the first Korean patient affected by MERS-CoV was diagnosed on 20 May 2015 after he returned from Qatar. Owing to the secondary mode of transmission, 186 of Korean citizens have been infected with MERS-CoV in a short span of time. Phylogenetic analysis also suggests that the MERS-CoV isolate found in the Korean patient is closely related to the Qatar strain (
      <xref ref-type="fig" rid="Fig2">
       Figure 2
      </xref>
      ).
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Global distribution map of Middle East respiratory syndrome coronavirus (MERS-CoV). Individuals in 26 countries have been infected by MERS-CoV. The infographic was generated based on MERS-CoV updates released on 7 July 2015 by World Health Organization. (WHO;
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-7july2015/en/">
          http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-7july2015/en/
         </ext-link>
         ).
        </p>
       </caption>
       <graphic id="d29e267" xlink:href="12276_2015_Article_BFemm201576_Fig1_HTML">
       </graphic>
      </fig>
      <fig id="Fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Phylogenetic analysis of the complete Middle East respiratory syndrome coronavirus (MERS-CoV) genomes using the maximum-likelihood method based on Tamura-Nei model implemented in MEGA5. The analysis involved 14 (human and camel) complete MERS-CoV genomes selected from different countries and their accession numbers are given at the end of each branch. The tree was rooted using the Egyptian camel sequence as the most divergent. CH, China, EG, Egypt; FR, France; KR, Republic of Korea; OM, Oman; QT, Qatar; SA, Saudi Arabia, UAE, United Arab Emirates; UK, United Kingdom; US: United States.
        </p>
       </caption>
       <graphic id="d29e276" xlink:href="12276_2015_Article_BFemm201576_Fig2_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par4">
      Coronaviruses, members of the
      <italic>
       Coronaviridae
      </italic>
      family and the
      <italic>
       Coronavirinae
      </italic>
      subfamily, are found in mammals and birds.
      <sup>
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      Coronaviruses are divided into four genera: α, β, γ and δ. The human coronaviruses HKU1 (strain named after discovery in the Hong Kong University),
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      OC43 (labeled with OC because these viruses are grown in ‘Organ Culture’),
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
      </sup>
      SARS-CoV and MERS-CoV belong to the genus β.
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      SARS-CoV and MERS-CoV are genetically subgrouped into lineages B and C, respectively.
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      MERS-CoV mainly causes respiratory diseases and systemic disorders.
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      Gastrointestinal symptoms, including diarrhea and queasiness, are also occasionally observed.
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      Most MERS-CoV-infected individuals develop chronic comorbidities such as renal failure, diabetes and cardiac disease, resulting in high fatality rates in patients with a history of diabetes and renal failure.
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      The median age of patients in reported cases is 49 years, and the incubation period ranges between 2 and 13 days, with a median of 5 days.
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
     </p>
     <p id="Par5">
      The physicochemical features of MERS-CoV are listed in
      <xref ref-type="table" rid="Tab1">
       Table 1
      </xref>
      . The MERS-CoV genome is 30 119 nucleotides long and contains 11 open reading frames (ORFs).
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      The single positive-stranded RNA genome has 5'- and 3'-untranslated regions that are 278 and 300 nucleotides in length, respectively. The 5' end comprises two overlapping ORFs, ORF1a and ORF1b, which are translated to yield two large polyproteins, polyprotein 1a (pp1a) and polyprotein 1ab (pp1ab). These polyproteins are cleaved into 16 functional nonstructural proteins (nsps) by the proteolytic activity of two viral proteases called papain-like protease (PLpro) and 3C-like protease (3CLpro) after their self-cleavage from pp1ab.
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      Proteolytic processing of MERS-CoV polyproteins is required for the activation of viral replication.
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      In addition to these two proteases, the two ORFs encode other nsps that are responsible for viral RNA-dependent RNA polymerase activity (nsp12), RNA helicase activity (nsp13), exoribonuclease activity (nsp14), endoribonuclease activity (nsp15) and methyltransferase activity (nsp16).
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      The role of nsp14 is essential, as it is involved in proofreading by monitoring the mutation rate, a unique feature for an RNA virus.
      <sup>
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
      </sup>
      More genes downstream of ORF1ab encode structural and accessory proteins. Spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins are all structural proteins, whereas the accessory proteins, unique to this lineage of viruses, are encoded by ORF3, ORF4a, ORF4b, ORF5 and ORF8b.
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      Although the exact function of these accessory proteins is still unknown, some recent studies have shown that they may have an important role in evading the host immune response.
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Physicochemical features of MERS-CoV proteins
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           <italic>
            Protein
           </italic>
          </th>
          <th align="left">
           <italic>
            GenBank ID (protein)
           </italic>
          </th>
          <th align="center">
           <italic>
            Start position (nt)
           </italic>
          </th>
          <th align="center">
           <italic>
            End position (nt)
           </italic>
          </th>
          <th align="center">
           <italic>
            Length (aa)
           </italic>
          </th>
          <th align="center">
           <italic>
            MW
           </italic>
           <sup>
            a
           </sup>
          </th>
          <th align="left">
           <italic>
            Stability
           </italic>
           <sup>
            a
           </sup>
          </th>
          <th align="left">
           <italic>
            SP
           </italic>
           <sup>
            b
           </sup>
          </th>
          <th align="left">
           <italic>
            Crystal structure
           </italic>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           PL protease
          </td>
          <td>
           AGV08556
          </td>
          <td>
           4728
          </td>
          <td>
           5678
          </td>
          <td>
           317
          </td>
          <td>
           35.9
          </td>
          <td>
           Stable
          </td>
          <td>
           No
          </td>
          <td>
           Yes
          </td>
         </tr>
         <tr>
          <td>
           3CL protease
          </td>
          <td>
           YP_009047217
          </td>
          <td>
           10 020
          </td>
          <td>
           10 937
          </td>
          <td>
           306
          </td>
          <td>
           33.3
          </td>
          <td>
           Stable
          </td>
          <td>
           No
          </td>
          <td>
           Yes
          </td>
         </tr>
         <tr>
          <td>
           RdRp
          </td>
          <td>
           YP_009047223
          </td>
          <td>
           13 410
          </td>
          <td>
           16 202
          </td>
          <td>
           933
          </td>
          <td>
           106.9
          </td>
          <td>
           Stable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           Helicase
          </td>
          <td>
           YP_009047224
          </td>
          <td>
           20 606
          </td>
          <td>
           21 493
          </td>
          <td>
           598
          </td>
          <td>
           66.1
          </td>
          <td>
           Stable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           Spike
          </td>
          <td>
           AKL59401
          </td>
          <td>
           21 456
          </td>
          <td>
           25 517
          </td>
          <td>
           1353
          </td>
          <td>
           149.4
          </td>
          <td>
           Stable
          </td>
          <td>
           Yes
          </td>
          <td>
           Yes
          </td>
         </tr>
         <tr>
          <td>
           ORF3
          </td>
          <td>
           AKL59402
          </td>
          <td>
           25 532
          </td>
          <td>
           25 843
          </td>
          <td>
           103
          </td>
          <td>
           11.2
          </td>
          <td>
           Stable
          </td>
          <td>
           Yes
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           ORF4a
          </td>
          <td>
           AKL59403
          </td>
          <td>
           25 851
          </td>
          <td>
           26 180
          </td>
          <td>
           109
          </td>
          <td>
           12.2
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           ORF4b
          </td>
          <td>
           AKL59404
          </td>
          <td>
           26 092
          </td>
          <td>
           26 832
          </td>
          <td>
           246
          </td>
          <td>
           28.5
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           ORF5
          </td>
          <td>
           AKL59405
          </td>
          <td>
           26 839
          </td>
          <td>
           27 513
          </td>
          <td>
           224
          </td>
          <td>
           25.2
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           Envelope
          </td>
          <td>
           AKL59406
          </td>
          <td>
           27 590
          </td>
          <td>
           27 838
          </td>
          <td>
           82
          </td>
          <td>
           9.3
          </td>
          <td>
           Stable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           Membrane
          </td>
          <td>
           AKL59407
          </td>
          <td>
           27 853
          </td>
          <td>
           28 512
          </td>
          <td>
           219
          </td>
          <td>
           24.5
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           Nucleoprotein
          </td>
          <td>
           AKL59408
          </td>
          <td>
           28 566
          </td>
          <td>
           29 807
          </td>
          <td>
           413
          </td>
          <td>
           45.0
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
         <tr>
          <td>
           ORF8b
          </td>
          <td>
           AJD81448
          </td>
          <td>
           28 718
          </td>
          <td>
           29 056
          </td>
          <td>
           112
          </td>
          <td>
           12.2
          </td>
          <td>
           Unstable
          </td>
          <td>
           No
          </td>
          <td>
           No
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         Abbreviations: aa, amino acid; MW, molecular weight; nt, nucleotide; ORF, open reading frame; PL, papain like; RdRp, RNA-dependent RNA polymerase; SP, signal peptides.
        </p>
        <p>
         <sup>
          a
         </sup>
         The online tool Protparam is used for the prediction of the MW and stability of proteins.
        </p>
        <p>
         <sup>
          b
         </sup>
         The online tool SignalP is used to predict the presence of SPs in the proteins.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="Par6">
      MERS-CoV enters the host through its S protein, a type I transmembrane glycoprotein with 1353 amino acids (aa) that exists on the virion surface as a trimer.
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      Subsequently, it is recognized by cluster of differentiation 26 (CD26) (also known as dipeptidyl peptidase 4 (DPP4)), which facilitates the infection of the host cells.
      <sup>
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
      </sup>
      SARS-CoV uses angiotensin-converting enzyme 2 as a functional receptor.
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      MERS-CoV and SARS-CoV differ in their cellular selection for infection, possibly owing to their selective binding with different receptors.
      <sup>
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Transmission and pathogenesis of MERS-CoV
     </title>
     <p id="Par7">
      MERS-CoV infection was initially thought to spread by zoonotic events via bats as phylogenetic studies revealed that it is genetically connected to
      <italic>
       Tylonycteris
      </italic>
      bat coronavirus HKU4 (BatCoV-HKU4) and
      <italic>
       Pipistrellus
      </italic>
      bat coronavirus HKU5 (BatCoV-HKU5).
      <sup>
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
      </sup>
      However, evidence indicates that MERS-CoV originated from dromedary camels. A serological study suggests that almost 90% of all camels in Africa and the Middle East were seropositive for MERS-CoV, whereas other animals such as sheep, goats and cows were found to be negative.
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      A population-based seroepidemiologic study suggests that the seroprevalence of the virus was several folds higher in people who were exposed to camels compared with that in the general population.
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      Moreover, antibodies against MERS-CoV were found in samples obtained from camels in Saudi Arabia in 1993, which reinforces the hypothesis that dromedary camels are most likely the main reservoirs of MERS-CoV.
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      In contrast, no seroreactivities were reported in the blood samples obtained from blood donors and abattoir workers in Saudi Arabia during 2012.
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      MERS-CoV was detected in camels in Egypt that were locally raised or imported from countries where no MERS cases were reported.
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      The mode of transmission is still unknown but is suspected to be through saliva during direct contact with infected camels or through consumption of milk or uncooked meat. However, we cannot rule out the existence of another intermediate host for MERS-CoV transmission to humans.
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      Secondary infection may occur through droplets or contact, and the virus could spread either via air or fomites.
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      A few recent studies on infected patients showed that the most common MERS-CoV infection causes acute pneumonia and renal failure and that almost every patient developed respiratory problems.
      <sup>
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      In addition, at least one-third of the studied patients were also reported to have abdominal disorders.
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      Other effects include inflammation of the pericardium, consumptive coagulopathy, increase in leukocytes and neutrophils, and low levels of lymphocytes, platelets and red blood cells.
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      Moreover, hyponatremia and low blood levels of albumin were detected during the case study.
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Entry and replication of MERS-CoV in the host cell
     </title>
     <p id="Par8">
      An overview of the entry and replication process of MERS-CoV in the infected host cell is shown in
      <xref ref-type="fig" rid="Fig3">
       Figure 3
      </xref>
      and is discussed below. The S glycoprotein located on the surface of the MERS-CoV virion interacts with functional receptor DPP4 to facilitate viral entry into the host.
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
      </sup>
      The S protein consists of a globular S1 domain at the N-terminal region; an S2 domain with two heptad repeats (HR), HR1 and HR2; and a transmembrane domain.
      <sup>
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
      </sup>
      The S1 domain determines cell tropism and receptor interaction, whereas membrane-fusing mediators have been identified within the S2 domain.
      <sup>
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
      </sup>
      MERS-CoV binds to DPP4 through a receptor-binding domain (RBD) located in the S1 subunit. Subsequently, protease cleavage of the S protein leads to virus–cell fusion and the release of viral genomic RNA into the host cytoplasm.
      <sup>
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
      </sup>
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Schematic of the replication cycle of Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV binds to dipeptidyl peptidase 4 (DPP4) on the host cell through its receptor-binding domain (RBD) in the S1 subunit of the spike (S) glycoprotein, which leads to virus–cell fusion and the release of genomic RNA into the cytoplasm. Initially open reading frame 1a (ORF1a) and ORF1b are translated into polyproteins, polyprotein 1a (pp1a) and pp1ab, respectively, which are cleaved by the virus-encoded proteases papain-like protease (PLpro) and 3C-like protease (3CLpro) into 16 mature nonstructural proteins (nsps). The proteins involved in replication and transcription are gathered into replication-transcription complexes (RTCs) that associate with double-membrane vesicles (DMVs) derived from the endoplasmic reticulum (ER). The genomic RNA contains adenylate uridylate (AU)-rich sequences called transcription regulation sequences (TRSs). If the TRSs are recognized by RTCs, then RNA of subgenomic length for transcription will be generated, otherwise a full-length template RNA of genomic length for replication will be synthesized. The newly produced genomic RNAs are encapsidated in the nucleocapsid (N) proteins in the cytoplasm and then transported to the ER–Golgi intermediate compartment (ERGIC) for further assembly. The S, membrane (M) and envelope (E) proteins are inserted into the membrane of the rough ER (RER), from where they are transported to the ERGIC to interact with the RNA-encapsidated N proteins and assemble into viral particles. The budded vesicles containing mature viral particles are then transported to the cell surface for release after maturation in the Golgi bodies. Double-stranded RNAs (dsRNAs) are partially generated during viral replication. The 4a competes with Toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I product (RIG-I)-like helicases (RIG-I and melanoma differentiation-associated protein 5 (MDA5)) to bind to dsRNAs and evades the host immune response.
        </p>
       </caption>
       <graphic id="d29e945" xlink:href="12276_2015_Article_BFemm201576_Fig3_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par9">
      The initial translation begins in ORF1a and continues in ORF1b after a frameshift, thereby producing the polyproteins pp1a and pp1ab, respectively.
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
      ORF1ab, which comprises two-thirds of the genome, is responsible for encoding nsps, whereas the remaining one-third of the genome encodes structural proteins (E, N, S and M) and five accessory proteins.
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      The virus-encoded proteases PLpro and 3CLpro cleave the pp1a and pp1ab proteins at 3 and 11 different sites, respectively, resulting in 16 mature nsps.
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      The proteins involved in replication and transcription (RNA-dependent RNA polymerase and helicase encoded by ORF1ab) form replication-transcription complexes.
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
      These complexes assemble at the perinuclear regions and associate with double-membrane vesicles derived from the endoplasmic reticulum (ER).
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      It has been confirmed through electron tomography and three-dimensional reconstruction imaging of the SARS-CoV-infected Vero E6 cells that double-membrane vesicles are not separate vesicles but are instead part of a reticulovesicular system of altered ER membranes.
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      The genomic RNA contains adenylate uridylate-rich sequences called transcription regulation sequences that are about 10 nucleotides long; these sequences divide the genomic RNA into different body elements of various lengths.
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
      These transcription regulation sequences are either recognized by the replication-transcription complexes to generate discontinued short negative-strand RNA of subgenomic length for the transcription of accessory and structural proteins or continuous full-length minus-strand template RNA of genomic length for replication.
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
     </p>
     <p id="Par10">
      The newly synthesized genomic RNAs are encapsidated in the N proteins in the cytoplasm and then transported to the ER–Golgi intermediate compartment for further assembly.
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      The proteins S, M and E are inserted into the membrane of the rough ER and are subsequently transported to the ER–Golgi intermediate compartment where they interact with the N proteins and assemble into particles.
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      The budded vesicles are then transported to the cell surface for release after maturation in Golgi bodies.
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
     </p>
     <p id="Par11">
      In the life cycle of RNA viruses, interferons (IFNs) have a crucial role in the anti-viral defense and are activated by the double-stranded RNAs (dsRNAs) generated during viral replication.
      <sup>
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
      </sup>
      Pattern recognition receptors including Toll-like receptors (TLRs) and retinoic acid inducible gene-I (RIG-I)-like receptors (RIG-I and melanoma differentiation-associated protein 5 (MDA5)) have an essential role in innate immunity.
      <sup>
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
      </sup>
      Among TLRs, TLR3 specifically recognizes dsRNAs through its ecto domain,
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
      </sup>
      whereas RIG-I and MDA5 also recognize dsRNAs through their helicase domain.
      <sup>
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
      </sup>
      After sensing dsRNAs, the activated immune response induces IFNs and cytokines to block viral replication. To evade this cellular immune response, MERS-CoV 4a protein binds to dsRNAs and blocks the induction of type 1 IFN.
      <sup>
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      Therapeutic targets
     </title>
     <sec id="Sec5">
      <title>
       Spike protein
      </title>
      <p id="Par12">
       As we mentioned earlier, the RBD located in S1 subunit binds to DPP4 to initiate infection, and the HR1 and HR2 motifs in S2 subunit facilitate membrane fusion, resulting in the release of the viral genetic material into the host cell cytoplasm.
       <sup>
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       Based on the crystallographic study, the RBD of the MERS-CoV S1 subunit ranges from residues 367 to 606 and can be divided into a core and an external subdomain.
       <sup>
        <xref ref-type="bibr" rid="CR22">
         22
        </xref>
       </sup>
       The receptor-binding motif (V484 to L567) of RBD is located in the external subdomain.
       <sup>
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
       </sup>
       The core subdomain contains a five-stranded antiparallel β-sheet in the center. The six connecting helices and two small β-strands collectively make a globular fold. Three disulfide bonds balance the core domain structure from the internal region. The RBD ends are located close to one another. The external subdomain of MERS-CoV RBD comprises a β-sheet with one small and three large strands organized in an antiparallel manner. It is attached to the RBD core through intervening loops and it attaches to the core subdomain like a clamp at the upper and lower positions. Two small 3
       <sub>
        10
       </sub>
       helices and most of the joining loops are present on the inner side of the sheet. The fourth disulfide bond is formed between the C503 and C526 residues, connecting the η3-helix with the β6-strand. Mutational studies have confirmed that residues Y499, L506, W513 and E553 in RBD are required for receptor binding and thus for viral entry.
       <sup>
        <xref ref-type="bibr" rid="CR22">
         22
        </xref>
        ,
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
       </sup>
       Mutation of these residues significantly inhibits the interaction of RBD with DPP4. Three HR1 helices at the center and three HR2 chains adjacent to the core in the HR1 side grooves facilitate the release of the viral particles into the cytoplasm.
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       HR2P (HR2 peptide) that binds to the HR1 domain to block MERS-CoV S protein-induced membrane fusion has been reported.
       <sup>
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       Moreover, other effective inhibitors that target RBD and could be used to control MERS-CoV infection have recently been reviewed by Xia
       <italic>
        et al.
       </italic>
       <sup>
        <xref ref-type="bibr" rid="CR21">
         21
        </xref>
       </sup>
      </p>
      <p id="Par13">
       Two antibodies (REGN3051 and REGN3048) targeting RBD of S protein to prevent its binding to DPP4 were developed and found to be the potential inhibitors of MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="CR44">
         44
        </xref>
       </sup>
       These two antibodies were tested on a mouse model that was developed by substituting mouse DPP4 ORF with human DPP4 (hDPP4) ORF, assuring normal physiological expression of hDPP4. A previously developed animal model was effective but expressed hDPP4 in all types of cells, resulting in non-physiological expression.
       <sup>
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
       </sup>
       In a recent
       <italic>
        in vivo
       </italic>
       study, modified vaccinia virus Ankara, which stably expresses the MERS-CoV S protein, exhibited less or no MERS-CoV replication.
       <sup>
        <xref ref-type="bibr" rid="CR46">
         46
        </xref>
       </sup>
       Moreover, the vaccinated mouse was further infected with MERS-CoV and transduced with hDPP4 to prove its efficacy.
       <sup>
        <xref ref-type="bibr" rid="CR46">
         46
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       DPP4/CD26 host receptor
      </title>
      <p id="Par14">
       DPP4 is mainly expressed on epithelial cells and controls the activity of hormones and chemokines.
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="CR47">
         47
        </xref>
       </sup>
       DPP4, a 766-aa-long type-II transmembrane glycoprotein, acts as a unique receptor for MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="CR26">
         26
        </xref>
       </sup>
       Crystallographic study reveals that the DPP4 receptor has an α/β-hydrolase domain and a β-propeller domain with eight blades, where MERS-CoV RBD binds. Small molecules or peptides that prevent the binding of DPP4 and RBD are potential MERS-CoV entry inhibitors and a few have been identified. Adenosine deaminase, a DPP4 binding protein, acts as a competitive inhibitor for MERS-CoV S protein.
       <sup>
        <xref ref-type="bibr" rid="CR48">
         48
        </xref>
       </sup>
       An anti-CD26 polyclonal antibody has also shown inhibitory effects on MERS-CoV infection
       <italic>
        in vitro
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="CR49">
         49
        </xref>
       </sup>
       A humanized monoclonal antibody against DPP4, mAb YS110, has also been reported to inhibit MERS-CoV infection.
       <sup>
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
       </sup>
       In a recent study, a murine model was developed by transducing a mouse with non-replicating adenovirus that expresses hDPP4.
       <sup>
        <xref ref-type="bibr" rid="CR51">
         51
        </xref>
       </sup>
       The transduced mouse developed pneumonia when infected with MERS-CoV. A subunit vaccine (Venezuelan equine encephalitis replicon particles that express MERS-CoV S protein) and an anti-viral drug (poly-I:C) were evaluated by infecting the mouse with MERS-CoV, and the subunit vaccine was found to be effective against the virus. This mouse model can be developed in a period of 2–3 weeks. However, this transduction system regulates hDPP4 expression to a low level and limits the expression to the lungs.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       PLpro and 3CLpro
      </title>
      <p id="Par15">
       Processing of the viral polyproteins is necessary for the discharge of mature proteins as they guide the replication and transcription of the MERS-CoV genome.
       <sup>
        <xref ref-type="bibr" rid="CR10">
         10
        </xref>
       </sup>
       This is achieved by the two viral proteases PLpro and 3CLpro, located in nsp3 and nsp5, respectively.
       <sup>
        <xref ref-type="bibr" rid="CR10">
         10
        </xref>
       </sup>
       These proteases cleave pp1a and pp1ab at several locations.
       <sup>
        <xref ref-type="bibr" rid="CR10">
         10
        </xref>
       </sup>
       Initially, both proteases are released in the immature form by the autoproteolytic process. In addition to the role mentioned above, MERS-CoV PLpro also affects ubiquitination and IFN-stimulated gene 15-linked ISGylation, probably to block host anti-viral responses.
       <sup>
        <xref ref-type="bibr" rid="CR52">
         52
        </xref>
       </sup>
       MERS-CoV PLpro is able to deubiquitinate IRF3, thereby inhibiting the synthesis of IFNβ.
       <sup>
        <xref ref-type="bibr" rid="CR19">
         19
        </xref>
       </sup>
       The MERS-CoV PLpro domain spans residues 1484–1800 in the pp1a protein.
       <sup>
        <xref ref-type="bibr" rid="CR53">
         53
        </xref>
       </sup>
       Similar to the PLpro of other coronaviruses, the Cys1592, His1759 and Asp1774 residues of MERS-CoV PLpro coordinate catalysis.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       The crystal structure of the MERS-CoV PLpro bound to ubiquitin revealed the interacting amino acids in the active site of PLpro.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       In addition, eight different PLpro residues (Arg1649, Thr1653, Ala1656, Asn1673, Val1674, Val1691, Val1706 and Gln1708) were mutated, either individually or in combination, to verify which of them are required for the binding of ubiquitin to MERS-CoV PLpro.
       <sup>
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
       </sup>
       In particular, mutation of Val1691 with Arg had a major effect on deubiquitination. As processing of the polyprotein is essential for viral maturation, MERS-CoV PLpro is considered a promising anti-viral target. In a recent study, a dual non-covalent inhibitor for MERS-CoV PLpro and SARS-CoV PLpro was identified in a high-throughput screening of 25 000 compounds.
       <sup>
        <xref ref-type="bibr" rid="CR9">
         9
        </xref>
       </sup>
       The currently available crystal structures and the results of mutational studies on MERS-CoV PLpro will aid in developing new inhibitors.
      </p>
      <p id="Par16">
       3CLpro is an essential part of the polyprotein and is usually present as a monomer.
       <sup>
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
       </sup>
       However, upon substrate binding, dimer formation has been observed.
       <sup>
        <xref ref-type="bibr" rid="CR54">
         54
        </xref>
       </sup>
       Each monomer has two domains (I and II) along with a C-terminal domain.
       <sup>
        <xref ref-type="bibr" rid="CR54">
         54
        </xref>
       </sup>
       3CLpro is an important drug target, as its protease activity is crucial for viral survival and replication. In a recent study, 11 inhibitors of 3CLpro were identified, two of which were cocrystallized with 3CLpro enzyme.
       <sup>
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
       </sup>
       One of those two peptidomimetic compounds contains a Michael acceptor group and the other has non-covalent properties. The irreversible compounds with a Michael acceptor group prevent the dimerization of 3CLpro in a time-dependent manner. Similarly, non-covalent peptidomimetic compounds inhibit the activity of 3CLpro, but only at high concentrations. Although a limited number of 3CLpro inhibitors are available, the current knowledge of key conserved and non-conserved residues is valuable. The knowledge of interacting residues from the cocrystallized compounds will enable the development of 3CLpro inhibitors that are relatively more effective. A recent study has found that the chloropyridine ester CE-5 inhibitor of SARS-CoV also inhibited the activity of MERS-CoV 3CLpro, reducing it to 30%. This was achieved by transfection of HEK293T cells with 3CLpro-expressing plasmid and evaluation of the protease activity by a luciferase-based biosensor assay.
       <sup>
        <xref ref-type="bibr" rid="CR55">
         55
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Accessory proteins
      </title>
      <p id="Par17">
       Each coronavirus has a specific group of genes, which is responsible for encoding accessory proteins.
       <sup>
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
       </sup>
       These accessory proteins do not participate in the structure of MERS-CoV particles but have an essential role in viral replication and evasion of the host immune response.
       <sup>
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="CR58">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="CR59">
         59
        </xref>
        ,
        <xref ref-type="bibr" rid="CR60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="CR61">
         61
        </xref>
       </sup>
       They are difficult to study because of their low expression level as well as their low molecular weight. In addition, they are not conserved in the coronavirus subfamilies. Although the accessory proteins can be targeted by anti-viral therapeutics, the biological function of these proteins is still not well understood. MERS-CoV has five accessory proteins: 3, 4a, 4b, 5 and 8b, encoded by various ORFs.
       <sup>
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
       </sup>
       The first four accessory proteins are located between the structural proteins S and E, whereas 8b resides downstream of the N protein.
       <sup>
        <xref ref-type="bibr" rid="CR59">
         59
        </xref>
       </sup>
       Proteins 3, 4a, 4b, 5 and 8b contain 103, 109, 246, 224 and 112 aa, respectively.
      </p>
      <p id="Par18">
       IFNs are secreted by the virus-infected host cells and provide a protective shield to the other exposed cells.
       <sup>
        <xref ref-type="bibr" rid="CR62">
         62
        </xref>
       </sup>
       Type 1 IFNs and inflammatory cytokines are produced as a result of the recognition of pathogen-associated molecular patterns by TLRs or RIG-I-like helicases.
       <sup>
        <xref ref-type="bibr" rid="CR63">
         63
        </xref>
       </sup>
       The proteins M, 4a, 4b and 5 have been demonstrated to be involved in the inhibition of IFN production and 4a, in particular, strongly affects viral pathogenesis.
       <sup>
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
       </sup>
      </p>
      <p id="Par19">
       Protein 4a, one of the accessory proteins, blocks IFN induction and works as a strong inhibitor of type 1 IFN by inhibiting dsRNA recognition by cellular RIG-I and MDA5.
       <sup>
        <xref ref-type="bibr" rid="CR41">
         41
        </xref>
        ,
        <xref ref-type="bibr" rid="CR42">
         42
        </xref>
       </sup>
       RIG-I-like helicases (RIG-I and MDA5) recognize dsRNA in the cytoplasm at the time of viral replication and initiate IFN induction through IRF3. RIG-I-like helicases comprise two domains: an RNA-binding domain and a caspase activation and recruitment domain. The dsRNA binds to the RNA-binding domain and induces a conformational change in RIG-I, thereby exposing the caspase activation and recruitment domain. The caspase activation and recruitment domain initiates the downstream signaling, which is detected by the mitochondrial anti-viral signaling adaptor protein, present on the mitochondrial surface. Downstream signaling involves the activation of IRF3, which is phosphorylated and forms a homodimer. The dimer enters the nucleus and initiates the transcription of IFNα and β.
       <sup>
        <xref ref-type="bibr" rid="CR64">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="CR65">
         65
        </xref>
       </sup>
       In case of infection with MERS-CoV, infected cells are not able to produce IFN because of the interference of the 4a protein that hinders the binding of dsRNA to RIG-I-like helicases.
      </p>
      <p id="Par20">
       Protein 4a is 109 aa long and contains an RNA-binding domain comprising 72 aa. The RNA-binding domain of 4a binds dsRNA and does not allow it to bind to the RNA-binding domain of RIG-I, thereby inhibiting the anti-viral signaling pathway. Thus, the virus blocks the innate immune response and continues infecting cells. The two key residues involved in the binding of RNA to the RNA-binding domain in 4a are K63 and K67.
       <sup>
        <xref ref-type="bibr" rid="CR42">
         42
        </xref>
       </sup>
       Inhibition of the 4a protein can allow the host cell to initiate an immune response against the virus.
      </p>
     </sec>
    </sec>
    <sec id="Sec9">
     <title>
      Other therapeutics
     </title>
     <p id="Par21">
      With reference to other therapeutic findings for SARS-CoV, the possibilities and findings on MERS-CoV subunit vaccines have been reviewed by Zhang
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      Mycophenolic acid, cyclosporin A, IFNα and IFNβ effectively inhibit MERS-CoV replication.
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      Ribavirin has previously been used against SARS-CoV but has also been found to control MERS-CoV.
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
      </sup>
      Moreover, the efficiency of ribavirin against MERS-CoV was increased when cotreated with IFNα2b.
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
      </sup>
      A collection of 27 dual inhibitors for MERS-CoV and SARS-CoV were selected from a list of 290 compounds through an
      <italic>
       in vitro
      </italic>
      study using the MERS-CoV Jordan strain.
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
      </sup>
      Additionally, SSYA10-001 was found to inhibit MERS-CoV replication when tested using the same strain.
      <sup>
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
      </sup>
      In a similar study, four Food and Drug Administration-approved drugs, loperamide, chlorpromazine, lopinavir and chloroquine, were identified to inhibit MERS-CoV replication at micromolar concentrations.
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      In addition, K22, a small molecule that inhibits membrane-bound MERS-CoV replication, was identified by screening 16 671 compounds.
      <sup>
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      The MERS-CoV E protein, which is involved in viral assembly, budding and intracellular trafficking, can be targeted for anti-viral activity.
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      The
      <italic>
       in vitro
      </italic>
      studies have a major role to confirm the initial anti-viral findings and thus several cell lines and their suitability for MERS-CoV transfection were reported; this information is summarized in
      <xref ref-type="table" rid="Tab2">
       Table 2
      </xref>
      .
      <sup>
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       ,
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
       ,
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
      </sup>
      <table-wrap id="Tab2">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Cell lines and their suitability for MERS-CoV transfection
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           <italic>
            No.
           </italic>
          </th>
          <th align="left">
           <italic>
            Cell line
           </italic>
          </th>
          <th align="left">
           <italic>
            MERS-CoV transfection
           </italic>
          </th>
          <th align="left">
           <italic>
            References
           </italic>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           1
          </td>
          <td>
           Human primary bronchial epithelial cells
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR75">
             75
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           2
          </td>
          <td>
           Mouse embryonic fibroblasts (NIH-3T3)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           3
          </td>
          <td>
           Human primary kidney epithelial cells
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR75">
             75
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           4
          </td>
          <td>
           Porcine kidney epithelial cells (PK-15)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           5
          </td>
          <td>
           Rat kidney mesangium cells (RMC)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           6
          </td>
          <td>
           Chicken fibroblasts (DF-1)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           7
          </td>
          <td>
           Human kidney cancer cells (769-P)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           8
          </td>
          <td>
           Human alveolar adenocarcinoma epithelial cells (A549)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           9
          </td>
          <td>
           Bat kidney cells (
           <italic>
            Rousettus aegyptiacus
           </italic>
           , RoNi/7;
           <italic>
            Pipistrellus pipistrellus
           </italic>
           , PipNi/1 and PipNi/3;
           <italic>
            Carollia perspicillata
           </italic>
           , CarNi/1)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
            ,
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           10
          </td>
          <td>
           Insect
           <italic>
            Aedes albopictus
           </italic>
           cells (C6-36)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           11
          </td>
          <td>
           Bat lung epithelial cells (
           <italic>
            Rhinolophus landeri
           </italic>
           , RhiLu;
           <italic>
            Myotis daubentonii
           </italic>
           , MyDauNi/2)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
            ,
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           12
          </td>
          <td>
           Goat lung primary epithelial cells (ZLu-R)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           13
          </td>
          <td>
           Alpaca kidney epithelial cells (LGK-1-R)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR78">
             78
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           14
          </td>
          <td>
           Dromedary umbilical cord cells (TT-R.B)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           15
          </td>
          <td>
           Baby hamster kidney epithelial cells (BHK)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           16
          </td>
          <td>
           African green monkey kidney epithelial cells (MA104)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR76">
             76
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           17
          </td>
          <td>
           Madin-Darby canine kidney epithelial cells (MDCK)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           18
          </td>
          <td>
           Feline kidney epithelial cells (CRFK)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           19
          </td>
          <td>
           Rabbit kidney epithelial cells (RK-13)
          </td>
          <td>
           No
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           20
          </td>
          <td>
           Human colorectal adenocarcinoma cell line (Caco-2)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td>
           21
          </td>
          <td>
           Human hepatocellular carcinoma cell line (Huh-7)
          </td>
          <td>
           Yes
          </td>
          <td>
           <sup>
            <xref ref-type="bibr" rid="CR74">
             74
            </xref>
            ,
            <xref ref-type="bibr" rid="CR77">
             77
            </xref>
           </sup>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         Abbreviation: MERS-CoV, Middle East respiratory syndrome coronavirus.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec id="Sec10">
     <title>
      Concluding remarks
     </title>
     <p id="Par22">
      MERS-CoV persists as a life-threatening disease. This coronavirus has rapidly evolved and MERS has emerged as a global pandemic. Despite the research efforts undertaken so far, the exact intermediate host for MERS-CoV and spatial distribution are still not well known. In addition, data on the origin and evolution of MERS-CoV are lacking. Global health concerns about this virus are increasing, and effective anti-MERS-CoV drugs and vaccines have yet to be developed and approved. The proteins involved in MERS-CoV entry and replication are attractive targets for the development of anti-viral therapeutics. The available crystal structures of the viral structural, nonstructural and accessory proteins and understanding the binding mechanism of their reported inhibitors may help to develop effective anti-MERS-CoV drugs. Development of suitable murine models and availability of drug-testing techniques have sped up the identification of new drugs and the confirmation of their anti-viral efficacy. Companies are not eager to develop effective vaccines or drugs considering the lack of commercial benefits from their sales. However, to avoid another unexpected global pandemic in the future, it is necessary to develop effective therapies. If this initiative cannot be taken by profit-pursuing companies, it must be carried forward by the governments of developed countries or by philanthropic scientists.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by the Mid-Career Researcher Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology (NRF-2015R1A2A2A09001059) and by a grant of the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (HI14C1992). This work was also partially supported by a grant from the Priority Research Centers Program (NRF 2012-0006687).
      </p>
     </ack>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par23">
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baez-Santos
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         12511
        </fpage>
        <lpage>
         12527
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01294-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25142582
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Banik
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Khandaker
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Rashid
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus ‘MERS-CoV’: current knowledge gaps
        </article-title>
        <source>
         Paediatr Respir Rev
        </source>
        <year>
         2015
        </year>
        <volume>
         16
        </volume>
        <fpage>
         197
        </fpage>
        <lpage>
         202
        </lpage>
        <pub-id pub-id-type="pmid">
         26002405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kayali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A more detailed picture of the epidemiology of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         495
        </fpage>
        <lpage>
         497
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70128-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863563
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The emergence of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Pathog Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         71
        </volume>
        <fpage>
         121
        </fpage>
        <lpage>
         136
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/2049-632X.12166
        </pub-id>
        <pub-id pub-id-type="pmid">
         24585737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution
        </article-title>
        <source>
         Trends Microbiol
        </source>
        <year>
         2014
        </year>
        <volume>
         22
        </volume>
        <fpage>
         573
        </fpage>
        <lpage>
         579
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2014.08.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         25178651
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         884
        </fpage>
        <lpage>
         895
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.2.884-895.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kahn
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         History and recent advances in coronavirus discovery
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <year>
         2005
        </year>
        <volume>
         24
        </volume>
        <fpage>
         S223
        </fpage>
        <lpage>
         S227
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/01.inf.0000188166.17324.60
        </pub-id>
        <pub-id pub-id-type="pmid">
         16378050
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Santarsiero
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Gatuz
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rice
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV
        </article-title>
        <source>
         ACS Chem Biol
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1456
        </fpage>
        <lpage>
         1465
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/cb500917m
        </pub-id>
        <pub-id pub-id-type="pmid">
         25746232
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2147
        </pub-id>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS: emergence of a novel human coronavirus
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         58
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2014.01.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         24584035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hocke
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Becher
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Knepper
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Peter
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Holland
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Tonnies
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging human middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2013
        </year>
        <volume>
         188
        </volume>
        <fpage>
         882
        </fpage>
        <lpage>
         886
        </lpage>
        <pub-id pub-id-type="doi">
         10.1164/rccm.201305-0954LE
        </pub-id>
        <pub-id pub-id-type="pmid">
         24083868
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13
       </label>
       <mixed-citation publication-type="other">
        Zumla A, Hui DS, Perlman S . Middle East respiratory syndrome.
        <italic>
         Lancet
        </italic>
        2015; doi:10.1016/S0140-6736(15)60454-8 (in press).
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unraveling the mysteries of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1054
        </fpage>
        <lpage>
         1056
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2006.140322
        </pub-id>
        <pub-id pub-id-type="pmid">
         24983095
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <name>
          <surname>
           Swerdlow
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: update for clinicians
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         60
        </volume>
        <fpage>
         1686
        </fpage>
        <lpage>
         1689
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/civ118
        </pub-id>
        <pub-id pub-id-type="pmid">
         25701855
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current advancements and potential strategies in the development of MERS-CoV vaccines
        </article-title>
        <source>
         Expert Rev Vaccines
        </source>
        <year>
         2014
        </year>
        <volume>
         13
        </volume>
        <fpage>
         761
        </fpage>
        <lpage>
         774
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14760584.2014.912134
        </pub-id>
        <pub-id pub-id-type="pmid">
         24766432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tomar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           ML
          </given-names>
          <suffix>
           St
          </suffix>
         </name>
         <name>
          <surname>
           John
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Osswald
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Nyalapatla
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Paul
          </surname>
          <given-names>
           LN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ligand-induced dimerization of MERS coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2015
        </year>
        <volume>
         290
        </volume>
        <fpage>
         19403
        </fpage>
        <lpage>
         19422
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M115.651463
        </pub-id>
        <pub-id pub-id-type="pmid">
         26055715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bailey-Elkin
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Knaap
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
         <name>
          <surname>
           Dalebout
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Ninaber
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           van Kasteren
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2014
        </year>
        <volume>
         289
        </volume>
        <fpage>
         34667
        </fpage>
        <lpage>
         34682
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M114.609644
        </pub-id>
        <pub-id pub-id-type="pmid">
         25320088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Bian
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         614
        </fpage>
        <lpage>
         626
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.059014-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24362959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Surdel
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2013
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e1003565
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1003565
        </pub-id>
        <pub-id pub-id-type="pmid">
         23966862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         200
        </fpage>
        <lpage>
         210
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.10.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         25451066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         500
        </volume>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12328
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: strategies for controlling emerging coronaviruses
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro3143
        </pub-id>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        <year>
         2012
        </year>
        <volume>
         1
        </volume>
        <fpage>
         e35
        </fpage>
        <pub-id pub-id-type="pmid">
         26038405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The emerging novel Middle East respiratory syndrome coronavirus: the ‘knowns’ and ‘unknowns’
        </article-title>
        <source>
         J Formos Med Assoc
        </source>
        <year>
         2013
        </year>
        <volume>
         112
        </volume>
        <fpage>
         372
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jfma.2013.05.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         23883791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27
       </label>
       <mixed-citation publication-type="other">
        Who Mers-Cov Research G. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans.
        <italic>
         PLoS Curr
        </italic>
        2013;
        <bold>
         5
        </bold>
        : doi:10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Debnath
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
        </person-group>
        <article-title>
         A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         66
        </volume>
        <fpage>
         464
        </fpage>
        <lpage>
         466
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2012.12.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         23266463
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol Mol Biol Rev
        </source>
        <year>
         2005
        </year>
        <volume>
         69
        </volume>
        <fpage>
         635
        </fpage>
        <lpage>
         664
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/MMBR.69.4.635-664.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV—a target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2090
        </pub-id>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ujike
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Morikawa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tashiro
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Taguchi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         12543
        </fpage>
        <lpage>
         12547
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0503203102
        </pub-id>
        <pub-id pub-id-type="pmid">
         16116101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sawicki
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Sawicki
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
        </person-group>
        <article-title>
         A contemporary view of coronavirus transcription
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         20
        </fpage>
        <lpage>
         29
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01358-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         16928755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular interactions in the assembly of coronaviruses
        </article-title>
        <source>
         Adv Virus Res
        </source>
        <year>
         2005
        </year>
        <volume>
         64
        </volume>
        <fpage>
         165
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0065-3527(05)64006-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         16139595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balachandran
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Truong
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pattnaik
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Archer
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2000
        </year>
        <volume>
         13
        </volume>
        <fpage>
         129
        </fpage>
        <lpage>
         141
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1074-7613(00)00014-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         10933401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Takahasi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         RIG-I-like receptors: cytoplasmic sensors for non-self RNA
        </article-title>
        <source>
         Immunol Rev
        </source>
        <year>
         2011
        </year>
        <volume>
         243
        </volume>
        <fpage>
         91
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1600-065X.2011.01052.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         21884169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anwar
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Basith
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Negative regulatory approaches to the attenuation of Toll-like receptor signaling
        </article-title>
        <source>
         Exp Mol Med
        </source>
        <year>
         2013
        </year>
        <volume>
         45
        </volume>
        <fpage>
         e11
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/emm.2013.28
        </pub-id>
        <pub-id pub-id-type="pmid">
         23429360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krishnan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Selvarajoo
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tsuchiya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toll-like receptor signal transduction
        </article-title>
        <source>
         Exp Mol Med
        </source>
        <year>
         2007
        </year>
        <volume>
         39
        </volume>
        <fpage>
         421
        </fpage>
        <lpage>
         438
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/emm.2007.47
        </pub-id>
        <pub-id pub-id-type="pmid">
         17934330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alexopoulou
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Medzhitov
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Flavell
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2001
        </year>
        <volume>
         413
        </volume>
        <fpage>
         732
        </fpage>
        <lpage>
         738
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/35099560
        </pub-id>
        <pub-id pub-id-type="pmid">
         11607032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zillinger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Zielecki
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Horvath
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Suliman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12489
        </fpage>
        <lpage>
         12495
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01845-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Kew
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lui
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4866
        </fpage>
        <lpage>
         4876
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03649-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24522921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
        </article-title>
        <source>
         Nat Commun
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         3067
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms4067
        </pub-id>
        <pub-id pub-id-type="pmid">
         24473083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascal
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Mujica
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Kamat
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Badithe
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fairhurst
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         8738
        </fpage>
        <lpage>
         8743
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1510830112
        </pub-id>
        <pub-id pub-id-type="pmid">
         26124093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           BH
          </given-names>
         </name>
         <name>
          <surname>
           Wakamiya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         3659
        </fpage>
        <lpage>
         3670
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03427-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25589660
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kupke
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Jany
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fux
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Shams-Eldin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East respiratory syndrome coronavirus spike glycoprotein
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         8651
        </fpage>
        <lpage>
         8656
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00614-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26018172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spiking the MERS-coronavirus receptor
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         1069
        </fpage>
        <lpage>
         1070
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.108
        </pub-id>
        <pub-id pub-id-type="pmid">
         23938293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Wiersma
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ouwendijk
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02935-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohnuma
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Hatano
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Iwata
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         13892
        </fpage>
        <lpage>
         13899
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02448-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24067970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         What are our pharmacotherapeutic options for MERS-CoV?
        </article-title>
        <source>
         Expert Rev Clin Pharmacol
        </source>
        <year>
         2014
        </year>
        <volume>
         7
        </volume>
        <fpage>
         235
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/17512433.2014.890515
        </pub-id>
        <pub-id pub-id-type="pmid">
         24580083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1323279111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Kilianski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Baez-Santos
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV papain-like protease has deISGylating and deubiquitinating activities
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2014
        </year>
        <volume>
         450-451
        </volume>
        <fpage>
         64
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2013.11.040
        </pub-id>
        <pub-id pub-id-type="pmid">
         24503068
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Chuang
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural and functional characterization of MERS coronavirus papain-like protease
        </article-title>
        <source>
         J Biomed Sci
        </source>
        <year>
         2014
        </year>
        <volume>
         21
        </volume>
        <fpage>
         54
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1423-0127-21-54
        </pub-id>
        <pub-id pub-id-type="pmid">
         24898546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Needle
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lountos
          </surname>
          <given-names>
           GT
          </given-names>
         </name>
         <name>
          <surname>
           Waugh
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity
        </article-title>
        <source>
         Acta Crystallogr D
        </source>
        <year>
         2015
        </year>
        <volume>
         71
        </volume>
        <fpage>
         1102
        </fpage>
        <lpage>
         1111
        </lpage>
        <pub-id pub-id-type="doi">
         10.1107/S1399004715003521
        </pub-id>
        <pub-id pub-id-type="pmid">
         25945576
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kilianski
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         11955
        </fpage>
        <lpage>
         11962
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02105-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23986593
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists
        </article-title>
        <source>
         Protein Cell
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         951
        </fpage>
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s13238-013-3096-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2002
        </year>
        <volume>
         296
        </volume>
        <fpage>
         177
        </fpage>
        <lpage>
         189
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/viro.2002.1412
        </pub-id>
        <pub-id pub-id-type="pmid">
         12036329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haijema
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Volders
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         3863
        </fpage>
        <lpage>
         3871
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.8.3863-3871.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15047802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           DX
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Shukla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hilgenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Accessory proteins of SARS-CoV and other coronaviruses
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2014
        </year>
        <volume>
         109
        </volume>
        <fpage>
         97
        </fpage>
        <lpage>
         109
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.06.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         24995382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Sastre
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion
        </article-title>
        <source>
         Cytokine Growth Factor Rev
        </source>
        <year>
         2001
        </year>
        <volume>
         12
        </volume>
        <fpage>
         143
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1359-6101(00)00027-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         11325598
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         874
        </fpage>
        <lpage>
         882
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.062059-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24443473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Billiau
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon: the pathways of discovery I. Molecular and cellular aspects
        </article-title>
        <source>
         Cytokine Growth Factor Rev
        </source>
        <year>
         2006
        </year>
        <volume>
         17
        </volume>
        <fpage>
         381
        </fpage>
        <lpage>
         409
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cytogfr.2006.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16931108
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Locarnini
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response
        </article-title>
        <source>
         Immunol Cell Biol
        </source>
        <year>
         2007
        </year>
        <volume>
         85
        </volume>
        <fpage>
         435
        </fpage>
        <lpage>
         445
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.icb.7100100
        </pub-id>
        <pub-id pub-id-type="pmid">
         17667934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fujita
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Onoguchi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Onomoto
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hirai
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yoneyama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Triggering antiviral response by RIG-I-related RNA helicases
        </article-title>
        <source>
         Biochimie
        </source>
        <year>
         2007
        </year>
        <volume>
         89
        </volume>
        <fpage>
         754
        </fpage>
        <lpage>
         760
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.biochi.2007.01.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         17379377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kowalinski
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lunardi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           McCarthy
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Louber
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Brunel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Grigorov
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2011
        </year>
        <volume>
         147
        </volume>
        <fpage>
         423
        </fpage>
        <lpage>
         435
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cell.2011.09.039
        </pub-id>
        <pub-id pub-id-type="pmid">
         22000019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Oudshoorn
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           van Nieuwkoop
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Limpens
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-coronavirus replication induces severe
         <italic>
          in vitro
         </italic>
         cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1749
        </fpage>
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.052910-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         23620378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Kindrachuk
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Venkataraman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Kindrachuk
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <fpage>
         4885
        </fpage>
        <lpage>
         4893
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03036-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24841273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adedeji
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kassim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <fpage>
         4894
        </fpage>
        <lpage>
         4898
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.02994-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24841268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Jochmans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Posthuma
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Zevenhoven-Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           van Nieuwkoop
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <fpage>
         4875
        </fpage>
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03011-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lundin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bergstrom
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kann
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Adamiak
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hannoun
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e1004166
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1004166
        </pub-id>
        <pub-id pub-id-type="pmid">
         24874215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Surya
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Verdia-Baguena
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2015
        </year>
        <volume>
         201
        </volume>
        <fpage>
         61
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2015.02.023
        </pub-id>
        <pub-id pub-id-type="pmid">
         25733052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name>
          <surname>
           Arden
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: an emerging coronavirus infection tracked by the crowd
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2015
        </year>
        <volume>
         202
        </volume>
        <fpage>
         60
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2015.01.021
        </pub-id>
        <pub-id pub-id-type="pmid">
         25656066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gotthardt
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          In-vitro
         </italic>
         renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) Coronavirus infection
        </article-title>
        <source>
         Virol J
        </source>
        <year>
         2013
        </year>
        <volume>
         10
        </volume>
        <fpage>
         359
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1743-422X-10-359
        </pub-id>
        <pub-id pub-id-type="pmid">
         24364985
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2012
        </year>
        <volume>
         3
        </volume>
        <fpage>
         e00515
        </fpage>
        <lpage>
         00512
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00515-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23232719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         207
        </volume>
        <fpage>
         1743
        </fpage>
        <lpage>
         1752
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit123
        </pub-id>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Lenk
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ulrich
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replicative capacity of MERS coronavirus in livestock cell lines
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         279
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2002.131182
        </pub-id>
        <pub-id pub-id-type="pmid">
         24457147
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cell Host Microbe
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cell Host Microbe
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cell Host &amp; Microbe
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1931-3128
      </issn>
      <issn pub-type="epub">
       1934-6069
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25211075
      </article-id>
      <article-id pub-id-type="pmc">
       7104937
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1931-3128(14)00301-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.chom.2014.08.009
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human Receptor CD26
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Qihui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Qi
         </surname>
         <given-names>
          Jianxun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          Yuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Xuan
         </surname>
         <given-names>
          Yifang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Pengcheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Wan
         </surname>
         <given-names>
          Yuhua
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Ji
         </surname>
         <given-names>
          Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Yan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au9">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Ying
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Jianwei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff7">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au11">
        <name>
         <surname>
          Iwamoto
         </surname>
         <given-names>
          Aikichi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff8">
         8
        </xref>
        <xref ref-type="aff" rid="aff9">
         9
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au12">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C.Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff10">
         10
        </xref>
        <xref ref-type="aff" rid="aff11">
         11
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au13">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff10">
         10
        </xref>
        <xref ref-type="aff" rid="aff11">
         11
        </xref>
        <xref ref-type="aff" rid="aff12">
         12
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au14">
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          Jinghua
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au15">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Guangwen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au16">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          George F.
         </given-names>
        </name>
        <email>
         gaof@im.ac.cn
        </email>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
        <xref ref-type="aff" rid="aff6">
         6
        </xref>
        <xref ref-type="aff" rid="aff12">
         12
        </xref>
        <xref ref-type="aff" rid="aff13">
         13
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       School of Life Sciences, University of Science and Technology of China, Hefei 230027, Anhui Province, China
      </aff>
      <aff id="aff3">
       <label>
        3
       </label>
       Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff4">
       <label>
        4
       </label>
       State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff5">
       <label>
        5
       </label>
       School of Life Sciences, Anhui University, Hefei 230039, China
      </aff>
      <aff id="aff6">
       <label>
        6
       </label>
       National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
      </aff>
      <aff id="aff7">
       <label>
        7
       </label>
       MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China
      </aff>
      <aff id="aff8">
       <label>
        8
       </label>
       China-Japan Joint Laboratory of Molecular Microbiology and Molecular Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff9">
       <label>
        9
       </label>
       Division of Infectious Diseases, Advanced Clinical Research Center, Department of Infectious Diseases and Applied Immunology, Research Hospital, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
      </aff>
      <aff id="aff10">
       <label>
        10
       </label>
       State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region 999077, China
      </aff>
      <aff id="aff11">
       <label>
        11
       </label>
       Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region 999077, China
      </aff>
      <aff id="aff12">
       <label>
        12
       </label>
       Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310003, China
      </aff>
      <aff id="aff13">
       <label>
        13
       </label>
       Office of Director-General, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding author
        <email>
         gaof@im.ac.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        9
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        10
       </day>
       <month>
        9
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        9
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       16
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       328
      </fpage>
      <lpage>
       337
      </lpage>
      <history>
       <date date-type="received">
        <day>
         14
        </day>
        <month>
         5
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         30
        </day>
        <month>
         7
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         8
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2014 Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <title>
        Summary
       </title>
       <p>
        The recently reported Middle East respiratory syndrome coronavirus (MERS-CoV) is phylogenetically closely related to the bat coronaviruses (BatCoVs) HKU4 and HKU5. However, the evolutionary pathway of MERS-CoV is still unclear. A receptor binding domain (RBD) in the MERS-CoV envelope-embedded spike protein specifically engages human CD26 (hCD26) to initiate viral entry. The high sequence identity in the viral spike protein prompted us to investigate if HKU4 and HKU5 can recognize hCD26 for cell entry. We found that HKU4-RBD, but not HKU5-RBD, binds to hCD26, and pseudotyped viruses embedding HKU4 spike can infect cells via hCD26 recognition. The structure of the HKU4-RBD/hCD26 complex revealed a hCD26-binding mode similar overall to that observed for MERS-RBD. HKU4-RBD, however, is less adapted to hCD26 than MERS-RBD, explaining its lower affinity for receptor binding. Our findings support a bat origin for MERS-CoV and indicate the need for surveillance of HKU4-related viruses in bats.
       </p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0015">
       <title>
        Graphical Abstract
       </title>
       <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1_lrg">
        </graphic>
       </fig>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0020">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           The bat coronavirus HKU4 is phylogenetically closely related to MERS-CoV
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           The BatCoV HKU4, but not HUK5, spike protein binds to the MERS-CoV human receptor hCD26
          </p>
         </list-item>
         <list-item id="u0020">
          <label>
           •
          </label>
          <p id="p0020">
           Virus particles pseudotyped with BatCoV HKU4 spike infect cells by engaging hCD26
          </p>
         </list-item>
         <list-item id="u0025">
          <label>
           •
          </label>
          <p id="p0025">
           HKU4-RBD/hCD26 structure delineates the recognition basis and interaction details
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract abstract-type="teaser" id="abs0025">
       <p>
        Bat origin has been suggested for the recently identified MERS coronavirus (CoV). Wang et al. provide structural and functional evidence that bat coronavirus HKU4 can utilize the MERS-CoV human receptor CD26 for cell entry. These studies support the possible adaptation of HKU4 coronavirus to infect humans and the need for continued surveillance.
       </p>
      </abstract>
     </article-meta>
     <notes>
      <p id="misc0010">
       Published: September 10, 2014
      </p>
     </notes>
    </front>
    <sec id="sec1">
     <title>
      Introduction
     </title>
     <p id="p0030">
      Coronaviruses (CoVs) are a group of enveloped, single-stranded RNA viruses taxonomically affiliated with the
      <italic>
       Coronaviridae
      </italic>
      family (
      <xref ref-type="bibr" rid="bib22">
       Lai et al., 2007
      </xref>
      ). Based on genotypic and serological characteristics, coronaviruses are further classified into four species:
      <italic>
       Alpha
      </italic>
      ,
      <italic>
       Beta
      </italic>
      ,
      <italic>
       Gamma
      </italic>
      (
      <xref ref-type="bibr" rid="bib20">
       King et al., 2012
      </xref>
      ), and
      <italic>
       Deltacoronavirus
      </italic>
      (
      <xref ref-type="bibr" rid="bib47">
       Woo et al., 2009
      </xref>
      ). Both alpha (alphaCoVs) and betacoronaviruses (betaCoVs) can cause human diseases (
      <xref ref-type="bibr" rid="bib22">
       Lai et al., 2007
      </xref>
      ). Most human infections related to alpha and betaCoVs, such as coronaviruses NL63, 229E, OC43, and HKU1 (reviewed in
      <xref ref-type="bibr" rid="bib42">
       Wevers and van der Hoek, 2009
      </xref>
      ), which commonly manifest as self-limiting common cold-like illnesses, though more severe diseases can develop in children, the elderly, and immunocompromised patients (
      <xref ref-type="bibr" rid="bib2">
       Chiu et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib11">
       Gorse et al., 2009
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       Jean et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       Jevšnik et al., 2012
      </xref>
      ). BetaCoVs, however, can also be life threatening and have pandemic potential (
      <xref ref-type="bibr" rid="bib21">
       Ksiazek et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       Zaki et al., 2012
      </xref>
      ). In 2003, the severe acute respiratory syndrome coronavirus (SARS-CoV), a lineage B betaCoV (
      <xref ref-type="bibr" rid="bib27">
       Lu and Liu, 2012
      </xref>
      ), caused &gt;8,000 infections and &gt;800 deaths worldwide (
      <xref ref-type="bibr" rid="bib43">
       WHO, 2004
      </xref>
      ). In 2012, another lineage C betaCoV named the Middle East respiratory syndrome coronavirus (MERS-CoV) (
      <xref ref-type="bibr" rid="bib20">
       King et al., 2012
      </xref>
      ) initially emerged in Saudi Arabia (
      <xref ref-type="bibr" rid="bib1">
       Bermingham et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       Zaki et al., 2012
      </xref>
      ) and then spread to other countries in the Middle East, Europe, Asia, and the US, leading to 701 confirmed cases as of June 16
      <sup>
       th
      </sup>
      , 2014 (
      <xref ref-type="bibr" rid="bib44">
       WHO, 2014
      </xref>
      ) with a fatality rate of approximately 35%. These unexpected outbreaks highlight the public health significance of betaCoVs, especially those in lineages B and C.
     </p>
     <p id="p0035">
      In addition to MERS-CoV, lineage C betaCoVs include two other important members: the bat coronaviruses (BatCoVs) HKU4 and HKU5 (
      <xref ref-type="bibr" rid="bib27">
       Lu and Liu, 2012
      </xref>
      ). These viruses were first identified as genomes in 2006 in lesser bamboo bats (
      <italic>
       Tylonycteris pachypus
      </italic>
      ) and Japanese pipistrelles (
      <italic>
       Pipistrellus abramus
      </italic>
      ), respectively (
      <xref ref-type="bibr" rid="bib45">
       Woo et al., 2006
      </xref>
      ), and remain circulating in bats (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ). Bats have been implicated as the largest reservoir of alpha and betaCoVs (
      <xref ref-type="bibr" rid="bib26">
       Li et al., 2005b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib48">
       Woo et al., 2012
      </xref>
      ) and play pivotal roles in interspecies transmission of coronaviruses. This is best exemplified by SARS-CoV, which was recently shown to originate from Chinese horseshoe bats (
      <xref ref-type="bibr" rid="bib8">
       Ge et al., 2013
      </xref>
      ) and likely transmitted directly to humans (
      <xref ref-type="bibr" rid="bib8">
       Ge et al., 2013
      </xref>
      ) or through an intermediate host such as the palm civet (
      <xref ref-type="bibr" rid="bib13">
       Guan et al., 2003
      </xref>
      ). The emergent MERS-CoV might also be of bat origin, with gene fragments being identified in bats from both Saudi Arabia (
      <xref ref-type="bibr" rid="bib29">
       Memish et al., 2013
      </xref>
      ) and Africa (
      <xref ref-type="bibr" rid="bib17">
       Ithete et al., 2013
      </xref>
      ) that are nearly identical to those of MERS-CoV in sequence. Despite the fact that the BatCoVs HKU4 and HKU5 are bat derived, the potential of both viruses evolving for human adaptation cannot be excluded because of their close phylogenetic relationship with MERS-CoV (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       Lu and Liu, 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       van Boheemen et al., 2012
      </xref>
      ). Nevertheless, such presumptions are largely based on their genomic features and phylogenetic status (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib45">
       Woo et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Woo et al., 2007
      </xref>
      ).
     </p>
     <p id="p0040">
      Virus infections initiate with the binding of viral particles to host surface cellular receptors. Identification of the functional receptors represents a central issue in studying viral pathogenesis. Several host peptidases, including aminopeptidase N (
      <xref ref-type="bibr" rid="bib3">
       Delmas et al., 1992
      </xref>
      ,
      <xref ref-type="bibr" rid="bib53">
       Yeager et al., 1992
      </xref>
      ) and angiotensin converting enzyme 2 (hACE2) (
      <xref ref-type="bibr" rid="bib16">
       Hofmann et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       Li et al., 2003
      </xref>
      ), are utilized by coronaviruses for cell entry. A timely study on MERS-CoV identified a third peptidase recognized by coronaviruses: dipeptidyl peptidase 4 (DPP4 or CD26) (
      <xref ref-type="bibr" rid="bib32">
       Raj et al., 2013
      </xref>
      ). This enzyme is a type II transmembrane protein contributing to the regulation of various physiological processes (
      <xref ref-type="bibr" rid="bib10">
       Gorrell et al., 2001
      </xref>
      ) and is “hijacked” by MERS-CoV to infect humans. This work pioneered the study on lineage C betaCoVs for potential cellular receptors. However, it remains unknown which molecules can be recognized by BatCoVs HKU4 and HKU5.
     </p>
     <p id="p0045">
      The receptor binding of coronaviruses is mediated by the spike (S) protein embedded in the viral envelope (
      <xref ref-type="bibr" rid="bib22">
       Lai et al., 2007
      </xref>
      ). In most cases, S is further cleaved by host proteases into S1 and S2 subunits that function to engage receptors and mediate membrane fusion, respectively (
      <xref ref-type="bibr" rid="bib22">
       Lai et al., 2007
      </xref>
      ). High sequence identities (&gt;50%) in S have been observed between BatCoV HKU4/HKU5 and MERS-CoV (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ), raising the possibility that these two viruses may use human CD26 (hCD26) as a receptor.
     </p>
     <p id="p0050">
      We previously delineated the molecular basis of MERS-CoV binding to hCD26. The S1 domain responsible for hCD26 recognition is located in a C-terminal 240-residue receptor binding domain (RBD) that is composed of a core and an external subdomain (
      <xref ref-type="bibr" rid="bib28">
       Lu et al., 2013
      </xref>
      ). The latter engages the receptor and is therefore also designated as the receptor binding motif (RBM) (
      <xref ref-type="bibr" rid="bib28">
       Lu et al., 2013
      </xref>
      ). Despite the overall high sequence identities in S, amino acid variance in the RBD region, especially in the RBM region, is still obvious among BatCoV HKU4, HKU5, and MERS-CoV. Investigation of the hCD26-binding potential of BatCoVs HKU4 and HKU5 is therefore a key to understanding the biology of these bat-derived viruses, their potential threat to human health, and the evolutionary pathway of MERS-CoV.
     </p>
     <p id="p0055">
      In this study, we demonstrated that the RBD domain of BatCoV HKU4 (HKU4-RBD), but not the equivalent domain of BatCoV HKU5 (HKU5-RBD), can bind to hCD26. The binding affinity between HKU4-RBD and hCD26 was determined by surface plasmon resonance (SPR) to be within the micromolar range. Despite the observed lower affinity compared to that between the MERS-CoV RBD (MERS-RBD) and hCD26, we found that pseudoviruses containing BatCoV HKU4 S can infect human Huh7 cells via hCD26. The findings provided solid evidence that BatCoV HKU4 recognizes hCD26 as a cellular receptor, indicating its potential for adaptation to infect humans. We further solved the complex structure of HKU4-RBD bound to hCD26 to delineate the basis of receptor recognition. Our structural analysis and mutagenesis also demonstrated a similar hCD26-binding mode between BatCoV HKU4 and MERS-CoV, but the details of variant amino acid interactions responsible for the differences in binding affinity are distinct. Our work also supports the notion that MERS-CoV most likely originated from bats.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Results
     </title>
     <sec id="sec2.1">
      <title>
       HKU4-RBD, but Not HKU5-RBD, Binds to hCD26
      </title>
      <p id="p0060">
       Our previous study determined the hCD26-interacting region as an RBD spanning amino acids 367–606 of the MERS-CoV S (
       <xref ref-type="bibr" rid="bib28">
        Lu et al., 2013
       </xref>
       ). The phylogenetic relatedness between BatCoV HKU4/HKU5 and MERS-CoV (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       A) prompted us to further investigate the equivalent RBD regions (S amino acids 372–611 for BatCoV HKU4, HKU4-RBD; and 375–604 for BatCoV HKU5, HKU5-RBD) in these bat-derived viruses for their potential to bind hCD26. A recent phylogenetic analysis of 13 BatCoV HKU4 and 15 BatCoV HKU5 strains revealed that the S gene of MERS-CoV is more closely related to BatCoV HKU4 than to BatCoV HKU5 (
       <xref ref-type="bibr" rid="bib23">
        Lau et al., 2013
       </xref>
       ). Using only the RBD amino acids, a concise phylogenetic tree was constructed, and a sequence alignment comparison was performed among BatCoV HKU4, HKU5, MERS-CoV, and SARS-CoV. Consistently, BatCoV HKU4 clustered with MERS-CoV with high bootstrap support, together joining BatCoV HKU5 to form an evolutionary branch distant from SARS-CoV (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       A). At the sequence level, MERS-RBD exhibits identity to HKU4-RBD slightly higher than HKU5-RBD does (54.4% versus 52.9%). Nevertheless, the pairwise alignment clearly showed two marked deletions located in a region corresponding to the external subdomain of MERS-RBD in HKU5-RBD, but not in HKU4-RBD (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       B). According to our previous study (
       <xref ref-type="bibr" rid="bib28">
        Lu et al., 2013
       </xref>
       ), this subdomain is responsible for receptor recognition. Therefore, we hypothesized that BatCoV HKU4 stands a better chance than BatCoV HKU5 of engaging hCD26.
       <fig id="fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Comparison of the HKU4-RBD, HKU5-RBD, MERS-RBD, and SARS-RBD Sequences
         </p>
         <p>
          (A) Phylogenetic tree generated using MEGA (
          <xref ref-type="bibr" rid="bib38">
           Tamura et al., 2013
          </xref>
          ) with the indicated RBD sequences.
         </p>
         <p>
          (B) Structure-based sequence alignment. The secondary structure elements are defined based on an ESPript (
          <xref ref-type="bibr" rid="bib12">
           Gouet et al., 1999
          </xref>
          ) algorithm and are labeled as in a previous report on the MERS-RBD structure (
          <xref ref-type="bibr" rid="bib28">
           Lu et al., 2013
          </xref>
          ). Spiral lines indicate α or 3
          <sub>
           10
          </sub>
          helices, while arrows represent β strands. Helices α1 and η4 and strands β2 and β11 are not preserved in the HKU4-RBD structure and are marked in red. The element equivalent to the MERS-RBD helix α3 exhibits characteristics of a 3
          <sub>
           10
          </sub>
          helix in HKU4-RBD and is therefore labeled as η′. The external subdomain is highlighted by enclosure with a red box. The two deletions in HKU5-RBD are marked with blue lines. The Arabic numerals 1–4 indicate cysteine residues that pair to form disulfide bonds. See also
          <xref ref-type="sec" rid="app3">
           Figure S3
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0065">
       Thus, we prepared the individual Fc fusion RBD proteins and tested their binding avidities to human hepatoma Huh7 cells (CD26-expressing) via flow cytometry. Consistent with previous reports (
       <xref ref-type="bibr" rid="bib32">
        Raj et al., 2013
       </xref>
       ), Huh7 cells express abundant hCD26 protein on their membrane surface (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       A). MERS-RBD, as a natural viral ligand of hCD26, avidly binds to Huh7 cells. HKU4-RBD, but not HKU5-RBD, also bound to Huh7 cells (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       B). Compared to MERS-RBD, however, an evidently smaller fluorescence shift was observed for HKU4-RBD, indicating a lower binding potency than MERS-RBD. An hCD26-specific antibody rather than an isocontrol immunoglobulin G (IgG) blocked the Huh7 surface attachment by HKU4-RBD (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       C). The observed Huh7 binding was also inhibited by the soluble ectodomain protein of hCD26, but not by the extracellular fragment of the SARS-CoV receptor hACE2 (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       D). We also utilized the hCD26-negative BHK cell line in the binding assay. As expected, surface binding to BHK cells could only be observed for HKU4-RBD and MERS-RBD after transfection of the cells with an hCD26-expressing plasmid (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       E–2H). Taken together, these results clearly demonstrated that BatCoV HKU4, unlike its close relative BatCoV HKU5, is capable of binding to hCD26 via the spike-RBD region.
       <fig id="fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Characterization of Binding between HKU4-RBD and hCD26 by Flow Cytometry
         </p>
         <p>
          (A) Huh7 cells stained with an anti-hCD26 antibody.
         </p>
         <p>
          (B) Huh7 cells stained with MERS-RBD, HKU4-EBD, or HKU5-RBD.
         </p>
         <p>
          (C) Huh7 cells stained with HKU4-RBD in the presence of an anti-hCD26 antibody or an isocontrol antibody.
         </p>
         <p>
          (D) Huh7 cells stained with HKU4-RBD in the presence of hCD26 (hCD26-ecto) or hACE2 (hACE2-ecto) ectodomain protein.
         </p>
         <p>
          (E) BHK cells stained with an anti-hCD26 antibody.
         </p>
         <p>
          (F) BHK cells stained with MERS-RBD, HKU4-RBD, or HKU5-RBD.
         </p>
         <p>
          (G) hCD26-transfected BHK cells stained with an anti-hCD26 antibody.
         </p>
         <p>
          (H) hCD26-transfected BHK cells stained with MERS-RBD, HKU4-RBD, or HKU5-RBD.
         </p>
        </caption>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec2.2">
      <title>
       The Interaction between HKU4-RBD and hCD26 Is Specific but of Low Affinity
      </title>
      <p id="p0070">
       We next set out to characterize the interaction between HKU4-RBD and hCD26 using real-time biophysical binding assays. The proteins prepared from insect cells were purified to homogeneity (
       <xref ref-type="sec" rid="app3">
        Figure S1
       </xref>
       , available online) and subjected to SPR experiments. As assay controls, MERS-RBD and SARS-RBD were found to bind potently to their respective canonical receptors (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       A and 3B). HKU4-RBD interacted with hCD26, but not with hACE2 (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       C and 3D). However, in contrast to the control pairs showing slow on and off rates, the Biacore binding profile between HKU4-RBD and hCD26 revealed fast association/dissociation kinetics. The equilibrium dissociation constant (K
       <sub>
        D
       </sub>
       ) of HKU4-RBD binding to hCD26 was calculated to be 35.7 μM (
       <xref ref-type="fig" rid="fig3">
        Figures 3
       </xref>
       C and
       <xref ref-type="sec" rid="app3">
        S2
       </xref>
       ), which is approximately three orders of magnitude lower than that of MERS-RBD to hCD26 (
       <xref ref-type="bibr" rid="bib28">
        Lu et al., 2013
       </xref>
       ). Though HKU5-RBD behaved similarly to its HKU4 homolog protein by gel filtration (
       <xref ref-type="sec" rid="app3">
        Figure S1
       </xref>
       ), no hCD26 binding was observed (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       E), which is consistent with our flow cytometric assays (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       B and 2F).
       <fig id="fig3">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Specific Interaction between HKU4-RBD and hCD26 Characterized by SPR
         </p>
         <p>
          (A–H) The indicated wild-type or mutant RBD proteins were immobilized on the chip and tested for binding with gradient concentrations of hCD26 or hACE2. The binding profiles are shown.
         </p>
         <p>
          (A) hCD26 binding to MERS-RBD. (B) hACE2 binding to SARS-RBD. (C) hCD26 binding to HKU4-RBD. (D) hACE2 binding to HKU4-RBD. (E) hCD26 binding to HKU5-RBD. (F) hCD26 binding to HKU4-RBD-K506A. (G) hCD26 binding to HKU4-RBD-E541A. (H) hCD26 binding to HKU4-RBD-SKL, a triple mutant of S540W, K547R, and L558W. The dissociation constants were calculated to be 35.7 and 0.42 μM for the hCD26/HKU4-RBD and hCD26/HKU4-RBD-SKL pairs, respectively, and &gt;400 μM for the hCD26/HKU4-RBD-K506A and hCD26/HKU4-RBD-E541A pairs. See also
          <xref ref-type="sec" rid="app3">
           Figures S1
          </xref>
          and
          <xref ref-type="sec" rid="app3">
           S2
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec2.3">
      <title>
       Cell Infection of BatCoV HKU4 Pseudoviruses Is Mediated by hCD26
      </title>
      <p id="p0075">
       With evidence of binding between HKU4-RBD and hCD26, we then tested the potential of this human surface molecule to function as a receptor for BatCoV HKU4. Lentiviral particles pseudotyped with either the BatCoV HKU4 or the MERS-CoV S were individually prepared in 293T cells. The successful incorporation of the viral S protein into the pseudovirus envelope was ascertained by western blotting using a monoclonal antibody recognizing a FLAG epitope engineered at the S C terminus (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       A). In accordance with a previous report (
       <xref ref-type="bibr" rid="bib9">
        Gierer et al., 2013
       </xref>
       ), the majority of the MERS-CoV S protein was proteolytically cleaved (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       A). In marked contrast, however, BatCoV HKU4 S remained largely intact (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       A), displaying a pattern similar to that of SARS-CoV (
       <xref ref-type="bibr" rid="bib30">
        Moore et al., 2004
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        Simmons et al., 2004
       </xref>
       ).
       <fig id="fig4">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          Huh7 Infection by Lentiviral Particles Pseudotyped with BatCoV HKU4 S
         </p>
         <p>
          (A) Proteolytic processing of the embedded BatCoV HKU4 S by trypsin. The HKU4 pseudovirus was treated with trypsin at the indicated concentrations and characterized with an antibody recognizing a FLAG epitope engineered at the S C terminus. The untreated MERS pseudovirus was included as a reference control.
         </p>
         <p>
          (B) A Huh7 cell infection assay with the indicated pseudoviruses.
         </p>
         <p>
          (C) An antibody blocking assay using HKU4 pseudoviruses treated with 10 μg/ml trypsin and an anti-hCD26 antibody. The recorded fluorescence intensities were plotted as histograms, and the error bars represent ± SD for triplicate experiments.
         </p>
        </caption>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0080">
       The viral infection mediated by BatCoV HKU4 S was then tested in Huh7 cells. With a pseudotyped vector encoding luciferase, the infection efficiency was determined by quantifying luciferase activities in the cell lysates. As a positive control, pseudoparticles bearing the MERS-CoV S protein robustly infected Huh7 cells, showing an ∼400-fold increase in the luciferase signal as compared to particles bearing no S protein. However, no evident cell infection was observed for the BatCoV HKU4 pseudoviruses (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       B).
      </p>
      <p id="p0085">
       According to previous studies on other coronaviruses (reviewed in
       <xref ref-type="bibr" rid="bib37">
        Simmons et al., 2013
       </xref>
       ), proteolytic separation of the S protein into functional S1 and S2 subunits by host cell proteases is a prerequisite to subsequent membrane fusion. Noting the inefficient S proteolysis in the BatCoV HKU4 pseudoviruses above, we hypothesized that in vitro treatment of the virus particles with proteases such as trypsin might activate the S protein, enabling viral entry into the cells upon receptor recognition. Therefore, the harvested BatCoV HKU4 pseudovirus particles were treated with various concentrations of trypsin (2.5–40 μg/ml), incubated with fetal bovine serum to inactivate the trypsin, and then used to infect Huh7 cells. Proteolysis of the S protein was observed in a concentration-dependent manner for the pseudoviruses (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       A). Accordingly, significant increases (&gt;150-fold) in the luciferase activity were recorded for pseudoviruses pretreated with 10, 20, and 40 μg/ml of trypsin, demonstrating successful entry into the cells (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       B). Then, pseudoviruses digested with 10 μg/ml trypsin were used in the subsequent antibody blocking assays. As expected, a concentration-dependent inhibition of cell infection was observed using the hCD26 antibody that specifically blocked the Huh7 surface attachment of HKU4-RBD (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       C). Therefore, we provided direct evidence that pseudoviruses bearing BatCoV HKU4 S infect human cells via hCD26 recognition.
      </p>
     </sec>
     <sec id="sec2.4">
      <title>
       Complex Structure between HKU4-RBD and hCD26
      </title>
      <p id="p0090">
       We further used cocrystallography to study the molecular basis of binding between HKU4-RBD and hCD26. The two purified proteins were mixed in vitro to allow the formation of heterocomplexes, and we managed to solve the structure at a resolution of 2.6 Å (
       <xref ref-type="sec" rid="app3">
        Table S1
       </xref>
       ). In the crystallographic asymmetric unit, HKU4-RBD and hCD26 were observed to form two 1:1 binding complexes that are related by a two-fold axis (
       <xref ref-type="fig" rid="fig5">
        Figure 5
       </xref>
       A). These two complexes are of essentially the same structure, showing a root-mean-square deviation (rmsd) of ∼0.18 Å for all Cα pairs. For hCD26, clear electron densities could be traced for 727 amino acids from R40 to P766. As observed in previous reports (
       <xref ref-type="bibr" rid="bib4">
        Engel et al., 2003
       </xref>
       ), this human enzyme folds into two structural domains: an α/β hydrolase domain and an eight-bladed β-propeller domain. hCD26 utilizes its propeller blades IV and V to recognize HKU4-RBD (
       <xref ref-type="fig" rid="fig5">
        Figures 5
       </xref>
       A and 5B). The two hCD26 molecules in the asymmetric unit were assembled into a dimer in the structure, with each protomer engaging one HKU4-RBD via its propeller. This leads to an overall U-shaped structure very similar to that observed for the MERS-RBD/hCD26 complex (
       <xref ref-type="bibr" rid="bib28">
        Lu et al., 2013
       </xref>
       ).
       <fig id="fig5">
        <label>
         Figure 5
        </label>
        <caption>
         <p>
          The Complex Structure of HKU4-RBD Bound to hCD26
         </p>
         <p>
          (A) The overall structure. The two 1:1 complexes related by a two-fold axis (vertical arrow) are shown in cartoon and surface representations, respectively. The core and external subdomains of HKU4-RBD and the β-propeller and hydrolase domains of hCD26 are individually labeled and highlighted in orange, cyan, magenta, and green, respectively. The propeller blades (I–VIII) and the protein N/C termini are marked.
         </p>
         <p>
          (B) A magnified view of the HKU4-RBD structure and the ligand/receptor interface. The secondary structure elements are specified by ESPript and labeled for the viral ligand. Yellow sticks marked with Arabic numbers indicate disulfide bonds. For the receptor, only propeller blades IV and V that engage HKU4-RBD are shown, using a surface representation.
         </p>
         <p>
          (C–E) The important contact sites are marked with boxed letters A–E and are further delineated for interaction details as follows. (C) A solid network of H bond and salt bridge interactions. (D) A small patch of hydrophobic interactions. (E) Extra H bond contacts contributed by a carbohydrate moiety linked to hCD26 N229. The residues involved and the carbohydrates referred to are shown and labeled. See also
          <xref ref-type="sec" rid="app3">
           Tables S1
          </xref>
          and
          <xref ref-type="sec" rid="app3">
           S2
          </xref>
          .
         </p>
        </caption>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0095">
       In the complex structure, HKU4-RBD contains 208 consecutive density-traceable residues, spanning T386 to L593. The folded structure comprises a core subdomain located distally from the engaging hCD26 and an external subdomain recognizing blades IV and V of the receptor propeller (
       <xref ref-type="fig" rid="fig5">
        Figure 5
       </xref>
       B). The core subdomain involves a five-stranded β sheet (β1, β3, β4, β5, and β10) forming a “nucleus” in the center, several helices (α helices α2 and α4, and 3
       <sub>
        10
       </sub>
       helices η1, η′, and η2) decorating the center sheet on the exterior, and three disulfide bonds (C388/C412, C430/C483, and C442/C590) stabilizing the subdomain structure in the interior. The N and C termini are in close proximity, extending away from the bound receptor. The external subdomain is a strand-dominated structure with four anti-parallel β strands (β6–β9) and exposes a flat sheet-face for receptor engagement. An extra disulfide bond (C507/C531) located in this external region links helix η3 to strand β6 (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       B and
       <xref ref-type="fig" rid="fig5">
        5
       </xref>
       B).
      </p>
      <p id="p0100">
       As expected, this BatCoV HKU4 viral ligand exhibits significant structural homology to its MERS-CoV homolog, in agreement with the &gt;50% sequence identity between the two molecules (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       ). Superimposition of the HKU4-RBD structure onto a previously reported MERS-RBD structure (Protein Data Bank [PDB]:
       <ext-link ext-link-type="uri" id="intref0010" xlink:href="pdb:4KQZ">
        4KQZ
       </ext-link>
       ) revealed an rmsd of ∼1.1 Å for 194 equivalent Cα atoms. In comparison to MERS-RBD, the majority of the secondary structure elements are well preserved in HKU4-RBD. The latter, however, lacks an α helix (α1) and two small strands (β2 and β11) in its core subdomain and is devoid of a 3
       <sub>
        10
       </sub>
       helix (η4) in the external subdomain. In addition, the helix preceding strand β3 exhibits characteristics of a 3
       <sub>
        10
       </sub>
       helix (η′) in HKU4-RBD, rather than being α-helical (α3) as in MERS-RBD (
       <xref ref-type="fig" rid="fig1">
        Figures 1
       </xref>
       and
       <xref ref-type="sec" rid="app3">
        S3
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec2.5">
      <title>
       Atomic Details at the Binding Interface between HKU4-RBD and hCD26
      </title>
      <p id="p0105">
       In the complex structure, large surface areas (968.7 Å
       <sup>
        2
       </sup>
       in HKU4-RBD and 1,033.9 Å
       <sup>
        2
       </sup>
       in hCD26) are buried by the two binding entities. Therefore, we scrutinized this extended buried surface to identify key amino acids involved in complex formation. Residues located within the van der Waals (vdw) contact distance (4.5 Å resolution cutoff) between HKU4-RBD and hCD26 were selected (
       <xref ref-type="sec" rid="app3">
        Table S2
       </xref>
       ), and a series of hydrophilic amino acids located along the interface were found to form a solid network of H bond and salt bridge interactions (
       <xref ref-type="fig" rid="fig5">
        Figures 5
       </xref>
       B and 5C). These strong polar contacts include the HKU4-RBD residue K506 interacting with the receptor amino acids T288 and A289, N514 and Q515 with R317, D516 with Y322, E541 and D542 with K267, and K547 with I295 (
       <xref ref-type="fig" rid="fig5">
        Figure 5
       </xref>
       C). In addition, several residues (such as Y460 located in helix η2 of the RBD core subdomain) were further shown to contribute to the receptor binding by providing multiple vdw contacts (
       <xref ref-type="sec" rid="app3">
        Table S2
       </xref>
       ). It is notable that K506 and E541 of the viral ligand afforded both side-chain H bond and multi-vdw interactions in this network (
       <xref ref-type="sec" rid="app3">
        Table S2
       </xref>
       ). Thus, these residues were individually mutated to alanine, and the resultant HKU4-RBD mutants were tested for receptor binding using SPR assays. The calculated K
       <sub>
        D
       </sub>
       s for the two mutants binding to hCD26 were &gt;400 μM, which is an ∼10-fold decrease in binding affinity compared to that of the wild-type protein (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       F, 2G, and
       <xref ref-type="sec" rid="app3">
        S2
       </xref>
       ), demonstrating their important roles in receptor recognition. Interestingly, these two amino acids are conserved between HKU4-RBD and MERS-RBD (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       B) and are also involved in the binding of the MERS-CoV ligand to hCD26 (
       <xref ref-type="bibr" rid="bib28">
        Lu et al., 2013
       </xref>
       ).
      </p>
      <p id="p0110">
       In addition to the aforementioned contact network, extra HKU4-RBD/hCD26 interactions involve a small hydrophobic patch (
       <xref ref-type="fig" rid="fig5">
        Figure 5
       </xref>
       D) and a sugar-mediated engagement (
       <xref ref-type="fig" rid="fig5">
        Figure 5
       </xref>
       E). The former is located in the proximity to a bulged hCD26 helix, which packs amino acids A291, L294, and I295 against RBD residues L510 and I560; the latter consists of a carbohydrate moiety linked to hCD26 N229 and amino acids E541 and Q544 in HKU4-RBD, which together form two H bonds.
      </p>
     </sec>
     <sec id="sec2.6">
      <title>
       Variant Amino Acid Interaction Details with hCD26 between HKU4-RBD and MERS-RBD
      </title>
      <p id="p0115">
       Overall, the HKU4-RBD/hCD26 structure solved in this study is very similar to the previously reported structure of MERS-RBD bound to hCD26. The two complex structures can be superimposed onto each other well, except for two interstrand loops (the β6/β7 and β8/β9 loops) in the RBD, which are distinctly oriented between the two viral ligands (
       <xref ref-type="fig" rid="fig6">
        Figure 6
       </xref>
       A). Despite variance in sequence, HKU4-RBD and MERS-RBD engage the same IV and V blades of the hCD26 β-propeller, demonstrating an overall similar recognition mode for hCD26 between BatCoV HKU4 and MERS-CoV.
       <fig id="fig6">
        <label>
         Figure 6
        </label>
        <caption>
         <p>
          Comparison of the HKU4-RBD/hCD26 and MERS-RBD/hCD26 Pairs for Their Binding Modes and the Interaction Details
         </p>
         <p>
          (A) Overall similar receptor binding mode between HKU4-RBD and MERS-RBD. Superimposition of the structure of HKU4-RBD (cyan) bound to hCD26 (green) and a complex structure of MERS-RBD (orange) with hCD26 (magenta). The loops exhibiting variant conformations are highlighted.
         </p>
         <p>
          (B) A magnified view of the ligand/receptor (RBD in cartoon and hCD26 in surface) interface in the two binding pairs. The elements located within the vdw contact distance from the receptor are highlighted for the η2-α4 region (gray) in the core subdomain, and the β6-β7 (tint), β8 (red), and β9 (blue) strands in the external subdomain. Top: the HKU4-RBD/hCD26 structure. Bottom: the MERS-RBD/hCD26 structure.
         </p>
         <p>
          (C) Better hCD26 adaptation in MERS-RBD than in HKU4-RBD. For each element specified in (B), the amino acid sequences were aligned between HKU4-RBD and MERS-RBD. The number pairs listed above the sequence highlight the differences in vdw contacts. For clarity, only those providing ≥10 intermolecule contacts are labeled. The S540/W535, K547/R542, and L558/W553 pairs showing the most contact differences are marked with red boxes.
         </p>
        </caption>
        <graphic xlink:href="gr6_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0120">
       We next compared the receptor binding details between the two viruses by characterizing the vdw contacts for each RBD residue along the binding interface. In both HKU4-RBD and MERS-RBD, a limited number of intermolecule contacts are contributed by the core subdomain residues, such as those located in the η2 (e.g., HKU4-Y460 and MERS-D455) and α4 (e.g., HKU4-N468 and MERS-P463) helices. These amino acids are adapted for hCD26 in HKU4-RBD slightly better than for that in MERS-RBD. For example, both HKU4-Y460 and HKU4-N468 provide more vdw contacts than the equivalent residues in MERS-RBD (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       B and 6C).
      </p>
      <p id="p0125">
       In contrast to the core subdomain, with only limited contributions to hCD26 engagement, the majority of the ligand/receptor intermolecule contacts are provided by the amino acids located in the RBD external subdomain. Most HKU4 residues in this region contact hCD26 less efficiently than the corresponding MERS-RBD amino acids. Among these, the S540/W535 and K547/R542 pairs in the β8 strand and the L558/W553 pair in the β9 strand are most evident, each showing ∼20–30 contact differences (
       <xref ref-type="fig" rid="fig6">
        Figures 6
       </xref>
       B and 6C). Reminiscent of the low binding affinity of HKU4-RBD to hCD26, these three residues in HKU4-RBD were mutated to the MERS-RBD amino acids, and the resultant mutant protein was tested for receptor binding by SPR. The calculated dissociation constant for this triple mutant was 0.42 μM, indicating that its binding affinity is ∼100-fold greater than that of the wild-type parental protein. In addition, the mutation also shifted the binding kinetics from a fast-on/fast-off mode, as observed for the wild-type HKU4-RBD, to a slow-on/slow-off mode, as observed for the MERS-RBD (
       <xref ref-type="fig" rid="fig2">
        Figures 2
       </xref>
       H and
       <xref ref-type="sec" rid="app3">
        S2
       </xref>
       ). We believe that the resultant introduction of extra vdw contacts and hydrophobic interactions by substituting these three residues in HKU4-RBD with more hydrophobic amino acids (e.g., tryptophan) led to the change in the binding kinetics. A similar phenomenon of altered K
       <sub>
        on
       </sub>
       and/or K
       <sub>
        off
       </sub>
       rates resulting from changes in hydrophobic interaction has also previously been observed in other protein interactions (
       <xref ref-type="bibr" rid="bib41">
        Weihofen et al., 2004
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      Discussion
     </title>
     <p id="p0130">
      Entry into susceptible host cells is the first step in the virus life cycle, and each entry process starts with receptor recognition. Identification of the cellular receptors for a virus is therefore a key question in viral pathogenesis studies. The BatCoVs HKU4 and HKU5 represent two important bat-derived coronaviruses closely related to MERS-CoV (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       van Boheemen et al., 2012
      </xref>
      ). In this study, we performed a functional assay to identify potential receptors for these viruses. We found that HKU4-RBD, a protein domain spanning residues 372–611 of the BatCoV HKU4 S, but not the equivalent S region of BatCoV HKU5, binds to hCD26. In addition, the complex structure of HKU4-RBD bound to hCD26 was solved, demonstrating a receptor recognition mode similar to that observed for MERS-RBD, though with variant amino acid interaction details and a low binding affinity. We further showed that lentivirus particles pseudotyped with BatCoV HKU4 S could infect Huh7 cells via engagement of hCD26. Taken together, we provide the comprehensive data showing that hCD26 is also a functional receptor for the bat-derived HKU4 coronavirus. In support of this, a similar study of the functional reactivity of BatCoV HKU4 S for hCD26 was recently reported online (
      <xref ref-type="bibr" rid="bib52">
       Yang et al., 2014
      </xref>
      ) during the revision of our manuscript.
     </p>
     <p id="p0135">
      Coronavirus S proteins are among the typical class I membrane fusion proteins (
      <xref ref-type="bibr" rid="bib6">
       Gao, 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       Harrison, 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib50">
       Xu et al., 2004a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib51">
       Xu et al., 2004b
      </xref>
      ). Activation of the subsequent membrane fusion process requires, in most cases, proteolysis of the fusion proteins by host cell proteases. This proteolytic process either occurs during or after maturation of the viruses, such as with murine hepatitis virus (MHV) (
      <xref ref-type="bibr" rid="bib5">
       Frana et al., 1985
      </xref>
      ) and MERS-CoV (
      <xref ref-type="bibr" rid="bib9">
       Gierer et al., 2013
      </xref>
      ), or occurs during viral entry, such as with SARS-CoV (
      <xref ref-type="bibr" rid="bib37">
       Simmons et al., 2013
      </xref>
      ). When we analyzed the lentivirus particles, the pseudotyped BatCoV HKU4 S was predominantly uncleaved. Accordingly, we initially were unable to observe any infection of Huh7 cells by the HKU4 pseudoviruses. However, by mimicking the maturation process of MERS-CoV, we showed that treatment of the pseudoviruses with trypsin enabled hCD26-mediated Huh7 infection. These results demonstrated that engagement of a receptor by, and proteolytic activation of, the envelope S protein remain two prerequisite factors for BatCoV HKU4 infection, as with other coronaviruses (
      <xref ref-type="bibr" rid="bib37">
       Simmons et al., 2013
      </xref>
      ). By identifying hCD26 as a functional receptor for BatCoV HKU4, the spatiotemporal processing of its S protein to allow subsequent membrane fusion remains an unresolved issue that should be further explored in the future.
     </p>
     <p id="p0140">
      Our results should also shed light on virus isolation. Since the first identification of the full-length HKU4 genome in bats in 2006 (
      <xref ref-type="bibr" rid="bib45">
       Woo et al., 2006
      </xref>
      ), culturing of the viruses has been unsuccessful. Further trials should consider cell lines expressing hCD26 but displaying variant proteases (e.g., cathepsin L, furin/furin-like proteases, HAT, and TMPRSS2) that are commonly involved in the processing of coronavirus spikes (
      <xref ref-type="bibr" rid="bib37">
       Simmons et al., 2013
      </xref>
      ). Alternatively, including small amounts of trypsin during viral culturing may facilitate the viral infection and thereby progeny virus production.
     </p>
     <p id="p0145">
      The previous SARS epidemic and the recent emergence of MERS-CoV in the Middle East serve as a constant reminder of the importance of identifying potential newly emerging coronaviruses in their natural animal reservoirs. Bats are natural reservoirs of many alphaCoVs and betaCoVs, which provide viral genes for the genesis of newly emerging coronaviruses with interspecies transmission potential. Phylogenetic dating suggests three suspected interspecies jumps of animal betaCoVs into humans, two of which (the SARS-CoV and MERS-CoV) are very likely of bat origin (
      <xref ref-type="bibr" rid="bib8">
       Ge et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       Ithete et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib26">
       Li et al., 2005b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib29">
       Memish et al., 2013
      </xref>
      ) and were circulating in bats before they “jumped” to an intermediate host (e.g., civets for SARS-CoV and dromedary camels for MERS-CoV) and/or to humans (
      <xref ref-type="bibr" rid="bib8">
       Ge et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib13">
       Guan et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       Haagmans et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib35">
       Reusken et al., 2013
      </xref>
      ). A recent study demonstrates the circulation of BatCoV HKU4 in bats in the past years (
      <xref ref-type="bibr" rid="bib23">
       Lau et al., 2013
      </xref>
      ). With the data in this study, we found that BatCoV HKU4 has evolved to utilize hCD26 as a functional receptor and therefore gained one of the key factors sufficing for interspecies transmission and human infection. This highlights the necessity for a surveillance program to monitor HKU4 circulation in bats. Special attention should be paid to virus variants incorporating mutations in S that would increase their affinity for hCD26 and/or confer susceptibility to host protease cleavage.
     </p>
     <p id="p0150">
      The complex structure presented in this study makes BatCoV HKU4 the sixth coronavirus in the
      <italic>
       Coronaviridae
      </italic>
      family for which the receptor-recognition mode has been elucidated with complex structures, in addition to SARS-CoV (
      <xref ref-type="bibr" rid="bib25">
       Li et al., 2005a
      </xref>
      ), MERS-CoV (
      <xref ref-type="bibr" rid="bib28">
       Lu et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       Wang et al., 2013
      </xref>
      ), MHV (
      <xref ref-type="bibr" rid="bib31">
       Peng et al., 2011
      </xref>
      ), NL63 (
      <xref ref-type="bibr" rid="bib49">
       Wu et al., 2009
      </xref>
      ), and porcine respiratory coronavirus (
      <xref ref-type="bibr" rid="bib33">
       Reguera et al., 2012
      </xref>
      ). Among these, BatCoV HKU4 likely represents a coronavirus suboptimized for receptor adaptation, displaying micromolar affinity for hCD26. Compared to MERS-CoV, which recognizes the same hCD26 molecule as a receptor (
      <xref ref-type="bibr" rid="bib32">
       Raj et al., 2013
      </xref>
      ), HKU4-RBD and MERS-RBD form similar structures and engage hCD26 via similar binding modes. Nevertheless, the two viral ligands exhibit a difference in receptor binding affinity of three orders of magnitude. We noted that in the RBM region predominating the ligand binding interface with the receptor, the majority of the interface residues in MERS-RBD contribute more vdw contacts than the equivalent amino acids in HKU4-RBD. This demonstrates a much better adaptation to hCD26 for MERS-CoV than for BatCoV HKU4, which was further supported by our mutagenesis data. We therefore presented the molecular basis for the observed affinity variance and a structural explanation for the suboptimized hCD26 binding by BatCoV HKU4. This weak binding also raises the possibility for the presence of other high-affinity receptors for BatCoV HKU4. Nevertheless, the physical interaction between HKU4-RBD and hCD26 seems to favor a scenario in which BatCoV HKU4 has evolved to adapt to the human receptor. In this sense, we cannot rule out the possibility that this bat-derived virus has been exposed, at some stage, to humans or human tissues.
     </p>
     <p id="p0155">
      Though with slight differences, the BatCoVs HKU4 and HKU5 exhibit similar sequence identities to MERS-CoV in the RBD region (54.4% versus 52.9%). The marked difference between the HKU4-RBD and HKU5-RBD relative to MERS-RBD, however, lies in two sequence deletions in the HKU5-RBD. Both deletions are located in the external subdomain and in two regions corresponding to the scaffold strands β7 and β8 in the MERS/HKU4-RBD structure. The deletions would therefore alter the fold of HKU5-RBM and abolish its interaction with hCD26. Similar amino acid deletions that exclude the viral ligand from interacting with hACE2 have also been recorded for diverse SARS-like coronaviruses identified in bats (
      <xref ref-type="bibr" rid="bib34">
       Ren et al., 2008
      </xref>
      ). An intact full-length external subdomain is likely a prerequisite to maintain binding capacity for hCD26 or hACE2, in addition to preserving key interacting residues, such as K506 and E541 in HKU4-RBD.
     </p>
    </sec>
    <sec id="sec4">
     <title>
      Experimental Procedures
     </title>
     <sec id="sec4.1">
      <title>
       Gene Construction and Protein Expression
      </title>
      <p id="p0160">
       The coding sequences for target proteins were separately cloned into the EcoRI and
       <italic>
        Xho
       </italic>
       I restriction sites of pFastBac1 vector for baculovirus expression (Bac-to-Bac baculovirus expression system, Invitrogen). For each protein, an N-terminal gp67 signal peptide and a C-terminal hexa-His were added to facilitate protein secretion and purification. Sf9 cells were used to package and amplify the baculovirus, and High5 cells were used to express the proteins, which were purified by nickel affinity chromatography and gel filtration. The proteins were then used for crystallization and SPR experiments.
      </p>
      <p id="p0165">
       To prepare the Fc chimeric proteins, the fragments were fused 5′-terminally to a fragment coding for mouse Fc domain and ligated into the pCAGGS expression vector via the EcoRI and
       <italic>
        Xho
       </italic>
       I restriction sites. All fusion proteins were linked to the signal peptide of the MERS-CoV S protein. The proteins were transiently expressed in human embryonic kidney 293T (HEK293T) cells and purified by Protein A affinity chromatography and gel filtration. The purified proteins were then used for fluorescence-activated cell sorting (FACS) experiments (see
       <xref ref-type="sec" rid="app3">
        Supplemental Experimental Procedures
       </xref>
       for detailed information).
      </p>
     </sec>
     <sec id="sec4.2">
      <title>
       Crystallization, Data Collection, and Structure Determination
      </title>
      <p id="p0170">
       For protein crystallization, monomeric HKU4-RBD was mixed with hCD26 at a 1:1 stoichiometry and crystallized by the sitting-drop vapor diffusion method at 4°C at 15 mg/ml in a buffer consisting of 0.1 M sodium citrate (pH 5.5) and 15% PEG 6000. Diffraction data were collected with cryoprotected (in a reservoir solution containing 20% [v/v] glycerol) crystals at the Shanghai Synchrotron Radiation Facility (SSRF) BL17U. The complex structure was solved by molecular replacement using the structure of MERS-RBD/hCD26 (PDB:
       <ext-link ext-link-type="uri" id="intref0015" xlink:href="pdb:4KR0">
        4KR0
       </ext-link>
       ) as the search model. For details, see
       <xref ref-type="sec" rid="app3">
        Supplemental Experimental Procedures
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec4.3">
      <title>
       Binding Assays
      </title>
      <p id="p0175">
       Protein interactions were tested using both SPR analysis and FACS experiments. For the SPR assays, all proteins were exchanged into a buffer consisting of 10 mM HEPES (pH 7.4), 150 mM NaCl, and 0.005% v/v Tween 20. The indicated RBD proteins were immobilized onto CM5 chips and analyzed for real-time binding by flowing through gradient concentrations of hCD26 or hACE2.
      </p>
      <p id="p0180">
       For the cell sorting analysis, Huh7 or hCD26-transfected BHK cells were stained with different RBD-Fc fusion proteins and analyzed by flow cytometry. For the binding-block assay, Huh7 cells were incubated with an antibody (anti-hCD26 or anti-Flag; Sigma) or with the purified ectodomain protein (hCD26 or hACE2) before the addition of HKU4-RBD-mFc, then the cells were analyzed by cell sorting (for details, see
       <xref ref-type="sec" rid="app3">
        Supplemental Experimental Procedures
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec4.4">
      <title>
       Pseudovirus Infection
      </title>
      <p id="p0185">
       BatCoV HKU4 pseudovirus particles were produced in HEK293T cells using a previously described method (
       <xref ref-type="bibr" rid="bib7">
        Gao et al., 2013
       </xref>
       ). For the pseudovirus infection, the virus particles were first treated with trypsin and then used to infect Huh7 cells in the presence or absence of the anti-hCD26 antibody. The luciferase activity was determined 48 hr postinfection using a GloMax 96 Microplate luminometer (Promega) (for details, see
       <xref ref-type="sec" rid="app3">
        Supplemental Experimental Procedures
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <title>
      Author Contributions
     </title>
     <p id="p0190">
      G.F.G. and G.L. initiated and coordinated the project. G.F.G., G.L., Q.W., and J.Y. designed the experiments. Q.W. conducted the experiments with help from Y.Y., Y.X., P.H., Y.W., W.J., and Y.L. J.Q. solved the structure. J.W. and A.I. provided the reagents and helped with manuscript writing. P.C.Y.W. and K.-Y.Y. helped with the data analysis and manuscript writing. Q.W., G.L., J.Y., and G.F.G. analyzed the data. G.L., Q.W., and G.F.G. wrote the manuscript.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Aarons
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Langrish
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hoschler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <volume>
         17
        </volume>
        <year>
         2012
        </year>
        <fpage>
         20290
        </fpage>
        <pub-id pub-id-type="pmid">
         23078800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation id="sref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         40
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1721
        </fpage>
        <lpage>
         1729
        </lpage>
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gelfi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sjöström
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Norén
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         357
        </volume>
        <year>
         1992
        </year>
        <fpage>
         417
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="pmid">
         1350661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation id="sref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Engel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wermann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Heiser
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Kiefersauer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Huber
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bode
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Demuth
          </surname>
          <given-names>
           H.U.
          </given-names>
         </name>
         <name>
          <surname>
           Brandstetter
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         100
        </volume>
        <year>
         2003
        </year>
        <fpage>
         5063
        </fpage>
        <lpage>
         5068
        </lpage>
        <pub-id pub-id-type="pmid">
         12690074
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frana
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Behnke
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Sturman
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         56
        </volume>
        <year>
         1985
        </year>
        <fpage>
         912
        </fpage>
        <lpage>
         920
        </lpage>
        <pub-id pub-id-type="pmid">
         2999444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation id="sref6" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Peptide Inhibitors Targeting Virus-Cell Fusion in Class I Enveloped Viruses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Torrence
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
        </person-group>
        <source>
         Combating the Threat of Pandemic Influenza: Drug Discovery Approaches
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         John Wiley &amp; Sons
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         226
        </fpage>
        <lpage>
         246
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         13134
        </fpage>
        <lpage>
         13140
        </lpage>
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation id="sref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         503
        </volume>
        <year>
         2013
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation id="sref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaup
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Krämer-Kühl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welsch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         5502
        </fpage>
        <lpage>
         5511
        </lpage>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation id="sref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorrell
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gysbers
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           McCaughan
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes
        </article-title>
        <source>
         Scand. J. Immunol.
        </source>
        <volume>
         54
        </volume>
        <year>
         2001
        </year>
        <fpage>
         249
        </fpage>
        <lpage>
         264
        </lpage>
        <pub-id pub-id-type="pmid">
         11555388
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorse
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           T.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Vitale
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Nichol
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         199
        </volume>
        <year>
         2009
        </year>
        <fpage>
         847
        </fpage>
        <lpage>
         857
        </lpage>
        <pub-id pub-id-type="pmid">
         19239338
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gouet
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Courcelle
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Stuart
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Métoz
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ESPript: analysis of multiple sequence alignments in PostScript
        </article-title>
        <source>
         Bioinformatics
        </source>
        <volume>
         15
        </volume>
        <year>
         1999
        </year>
        <fpage>
         305
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         10320398
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <volume>
         302
        </volume>
        <year>
         2003
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral membrane fusion
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         15
        </volume>
        <year>
         2008
        </year>
        <fpage>
         690
        </fpage>
        <lpage>
         698
        </lpage>
        <pub-id pub-id-type="pmid">
         18596815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         102
        </volume>
        <year>
         2005
        </year>
        <fpage>
         7988
        </fpage>
        <lpage>
         7993
        </lpage>
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Stoffberg
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1697
        </fpage>
        <lpage>
         1699
        </lpage>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jean
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Quach
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Semret
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severity and outcome associated with human coronavirus OC43 infections among children
        </article-title>
        <source>
         Pediatr. Infect. Dis. J.
        </source>
        <volume>
         32
        </volume>
        <year>
         2013
        </year>
        <fpage>
         325
        </fpage>
        <lpage>
         329
        </lpage>
        <pub-id pub-id-type="pmid">
         23337903
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jevšnik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Uršič
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zigon
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Lusa
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Krivec
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Petrovec
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease
        </article-title>
        <source>
         BMC Infect. Dis.
        </source>
        <volume>
         12
        </volume>
        <year>
         2012
        </year>
        <fpage>
         365
        </fpage>
        <pub-id pub-id-type="pmid">
         23256846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation id="sref20" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           King
          </surname>
          <given-names>
           A.M.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Carstens
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses
        </chapter-title>
        <year>
         2012
        </year>
        <publisher-name>
         Elsevier Academic Press
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation id="sref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <collab>
          SARS Working Group
         </collab>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation id="sref22" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviridae
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Howley
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         Lippincott Williams &amp; Wilkins
        </publisher-name>
        <publisher-loc>
         Philadelphia, PA
        </publisher-loc>
        <fpage>
         1305
        </fpage>
        <lpage>
         1335
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         8638
        </fpage>
        <lpage>
         8650
        </lpage>
        <pub-id pub-id-type="pmid">
         23720729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases
        </article-title>
        <source>
         Protein Cell
        </source>
        <volume>
         3
        </volume>
        <year>
         2012
        </year>
        <fpage>
         803
        </fpage>
        <lpage>
         805
        </lpage>
        <pub-id pub-id-type="pmid">
         23143870
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         500
        </volume>
        <year>
         2013
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Durosinloun
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Asmari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1819
        </fpage>
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dorfman
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Coderre
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <year>
         2004
        </year>
        <fpage>
         10628
        </fpage>
        <lpage>
         10635
        </lpage>
        <pub-id pub-id-type="pmid">
         15367630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         108
        </volume>
        <year>
         2011
        </year>
        <fpage>
         10696
        </fpage>
        <lpage>
         10701
        </lpage>
        <pub-id pub-id-type="pmid">
         21670291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           J.A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reguera
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Santiago
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Mudgal
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ordoño
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Casasnovas
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         8
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e1002859
        </fpage>
        <pub-id pub-id-type="pmid">
         22876187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1899
        </fpage>
        <lpage>
         1907
        </lpage>
        <pub-id pub-id-type="pmid">
         18077725
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits-De Vries
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Reeves
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rennekamp
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Amberg
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Piefer
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         4240
        </fpage>
        <lpage>
         4245
        </lpage>
        <pub-id pub-id-type="pmid">
         15010527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation id="sref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zmora
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <volume>
         100
        </volume>
        <year>
         2013
        </year>
        <fpage>
         605
        </fpage>
        <lpage>
         614
        </lpage>
        <pub-id pub-id-type="pmid">
         24121034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Filipski
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MEGA6: Molecular Evolutionary Genetics Analysis version 6.0
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <volume>
         30
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2725
        </fpage>
        <lpage>
         2729
        </lpage>
        <pub-id pub-id-type="pmid">
         24132122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Graaf
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans
        </article-title>
        <source>
         MBio
        </source>
        <volume>
         3
        </volume>
        <year>
         2012
        </year>
        <comment>
         e00473–e12
        </comment>
       </element-citation>
      </ref>
      <ref id="bib40">
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weihofen
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Reutter
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Saenger
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         43330
        </fpage>
        <lpage>
         43335
        </lpage>
        <pub-id pub-id-type="pmid">
         15213224
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <element-citation id="sref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wevers
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recently discovered human coronaviruses
        </article-title>
        <source>
         Clin. Lab. Med.
        </source>
        <volume>
         29
        </volume>
        <year>
         2009
        </year>
        <fpage>
         715
        </fpage>
        <lpage>
         724
        </lpage>
        <pub-id pub-id-type="pmid">
         19892230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <mixed-citation id="oref1" publication-type="other">
        WHO (2004). Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS).
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.who.int/csr/sars/country/en/">
         http://www.who.int/csr/sars/country/en/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib44">
       <mixed-citation id="oref2" publication-type="other">
        WHO (2014). Middle East respiratory syndrome coronavirus (MERS-CoV) – update.
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="http://www.who.int/csr/don/2014_06_16_mers/en/">
         http://www.who.int/csr/don/2014_06_16_mers/en/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib45">
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular diversity of coronaviruses in bats
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         351
        </volume>
        <year>
         2006
        </year>
        <fpage>
         180
        </fpage>
        <lpage>
         187
        </lpage>
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1574
        </fpage>
        <lpage>
         1585
        </lpage>
        <pub-id pub-id-type="pmid">
         17121802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Dyrting
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         908
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         18971277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <year>
         2012
        </year>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         106
        </volume>
        <year>
         2009
        </year>
        <fpage>
         19970
        </fpage>
        <lpage>
         19974
        </lpage>
        <pub-id pub-id-type="pmid">
         19901337
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         30514
        </fpage>
        <lpage>
         30522
        </lpage>
        <pub-id pub-id-type="pmid">
         15123674
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         49414
        </fpage>
        <lpage>
         49419
        </lpage>
        <pub-id pub-id-type="pmid">
         15345712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <comment>
         in press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib53">
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeager
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ashmun
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           R.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cardellichio
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           L.H.
          </given-names>
         </name>
         <name>
          <surname>
           Look
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human aminopeptidase N is a receptor for human coronavirus 229E
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         357
        </volume>
        <year>
         1992
        </year>
        <fpage>
         420
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="pmid">
         1350662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="app1">
      <title>
       Accession Numbers
      </title>
      <p id="p0200">
       The atomic coordinate of the HKU4-RBD/hCD26 complex has been deposited in the Protein Data Bank with the PDB code
       <ext-link ext-link-type="uri" id="intref0020" xlink:href="pdb:4QZV">
        4QZV
       </ext-link>
       .
      </p>
     </sec>
     <sec id="app3" sec-type="supplementary-material">
      <title>
       Supplemental Information
      </title>
      <p id="p0210">
       <supplementary-material content-type="local-data" id="mmc1">
        <caption>
         <title>
          Document S1. Supplemental Experimental Procedures, Figures S1–S3, and Tables S1 and S2
         </title>
        </caption>
        <media xlink:href="mmc1.pdf">
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="mmc2">
        <caption>
         <title>
          Document S2. Article plus Supplemental Information
         </title>
        </caption>
        <media xlink:href="mmc2.pdf">
        </media>
       </supplementary-material>
      </p>
     </sec>
     <ack id="ack0010">
      <title>
       Acknowledgments
      </title>
      <p>
       This work was supported by the National Natural Science Foundation of China (NSFC, Grant No. 81290342), the China National Grand S&amp;T Special Project (No. 2014ZX10004-001-006), and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDB08020100). We thank the staff at the Shanghai Synchrotron Radiation Facility (SSRF) and Tong Zhao at the Institute of Microbiology, Chinese Academy of Sciences for support. G.F.G. is a leading principal investigator of the NSFC Innovative Research Group (Grant No. 81321063).
      </p>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="app2">
       <p id="p0205">
        Supplemental Information includes Supplemental Experimental Procedures, three figures, and two tables and can be found with this article online at
        <ext-link ext-link-type="doi" id="intref0025" xlink:href="10.1016/j.chom.2014.08.009">
         http://dx.doi.org/10.1016/j.chom.2014.08.009
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Clin Pathol
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jclinpath
      </journal-id>
      <journal-title>
       Journal of Clinical Pathology
      </journal-title>
      <issn pub-type="ppub">
       0021-9746
      </issn>
      <issn pub-type="epub">
       1472-4146
      </issn>
      <publisher>
       <publisher-name>
        Copyright 2005 Journal of Clinical Pathology
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15735160
      </article-id>
      <article-id pub-id-type="pmc">
       1770583
      </article-id>
      <article-id pub-id-type="publisher-id">
       0580276
      </article-id>
      <article-id pub-id-type="doi">
       10.1136/jcp.2004.016592
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Original Articles
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          S C C
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          J K C
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          K C
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lo
         </surname>
         <given-names>
          E S F
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tsang
         </surname>
         <given-names>
          D N C
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China
      </aff>
      <author-notes>
       <fn>
        <p>
         Correspondence to: Dr S C C Wong Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China;
         <email>
          cesar@clo.cuhk.edu.hk
         </email>
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        3
       </month>
       <year>
        2005
       </year>
      </pub-date>
      <volume>
       58
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       276
      </fpage>
      <lpage>
       280
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         9
        </month>
        <year>
         2004
        </year>
       </date>
      </history>
      <copyright-statement>
       Copyright © Copyright 2005 Journal of Clinical Pathology
      </copyright-statement>
      <copyright-year>
       2005
      </copyright-year>
      <abstract>
       <p>
        <bold>
         Aims:
        </bold>
        To develop a quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) for severe acute respiratory syndrome coronavirus (SARS-CoV) detection and explore the potential of using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as an internal control to exclude false negative results.
       </p>
       <p>
        <bold>
         Methods:
        </bold>
        SARS-CoV and GAPDH mRNA were both measured in 26 specimens from 16 patients with SARS, 40 follow up specimens from the same batch of patients, and appropriate control subjects. The relation between SARS positivity and GAPDH mRNA concentration was investigated using the χ
        <sup>
         2
        </sup>
        test. Increasing the sensitivity for SARS-CoV and GAPDH mRNA detection was investigated in follow up specimens in which SARS-CoV and GAPDH mRNA were not detected initially.
       </p>
       <p>
        <bold>
         Results:
        </bold>
        Varying amounts of SARS-CoV were found in the 26 SARS-CoV positive specimens and SARS-CoV was not detected in the 40 follow up specimens and controls. In addition, concentrations of GAPDH mRNA were significantly different between the patients with SARS, follow up specimens, and healthy controls (Kruskal-Wallis test, p&lt;0.05). Moreover, GAPDH mRNA concentrations were highly correlated with SARS-CoV positivity (χ
        <sup>
         2
        </sup>
        = 5.43; p&lt;0.05). Finally, SARS-CoV and GAPDH mRNA were both detected in three follow up urine specimens that were initially negative when the amount of cDNA used was increased from 5 μl to 10 and 15 μl.
       </p>
       <p>
        <bold>
         Conclusions:
        </bold>
        This Q-RT-PCR assay can be used to detect SARS-CoV. Moreover, GAPDH mRNA may be useful to rule out false negative results in SARS-CoV detection, and the current extraction method for urine may not be sensitive enough to detect low titres of SARS-CoV.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jvi
      </journal-id>
      <journal-id journal-id-type="pmc">
       jvi
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVI
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-538X
      </issn>
      <issn pub-type="epub">
       1098-5514
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23785207
      </article-id>
      <article-id pub-id-type="pmc">
       3754068
      </article-id>
      <article-id pub-id-type="publisher-id">
       01277-13
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/JVI.01277-13
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Virus-Cell Interactions
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mou
         </surname>
         <given-names>
          Huihui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raj
         </surname>
         <given-names>
          V. Stalin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          van Kuppeveld
         </surname>
         <given-names>
          Frank J. M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rottier
         </surname>
         <given-names>
          Peter J. M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          Bart L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Bosch
         </surname>
         <given-names>
          Berend Jan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
        <label>
         a
        </label>
       </aff>
       <aff id="aff2">
        Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
        <label>
         b
        </label>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Berend Jan Bosch,
        <email>
         b.j.bosch@uu.nl
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        8
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       87
      </volume>
      <issue>
       16
      </issue>
      <fpage>
       9379
      </fpage>
      <lpage>
       9383
      </lpage>
      <history>
       <date date-type="received">
        <day>
         10
        </day>
        <month>
         5
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="accepted">
        <day>
         11
        </day>
        <month>
         6
        </month>
        <year>
         2013
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2013, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2013
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri xlink:href="zjv01613009379.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        The spike (S) protein of the recently emerged human Middle East respiratory syndrome coronavirus (MERS-CoV) mediates infection by binding to the cellular receptor dipeptidyl peptidase 4 (DPP4). Here we mapped the receptor binding domain in the S protein to a 231-amino-acid fragment (residues 358 to 588) by evaluating the interaction of spike truncation variants with receptor-expressing cells and soluble DPP4. Antibodies to this domain—much less so those to the preceding N-terminal region—efficiently neutralize MERS-CoV infection.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Chem
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Chem
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       clinchem
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Chemistry
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0009-9147
      </issn>
      <issn pub-type="epub">
       1530-8561
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       16423906
      </article-id>
      <article-id pub-id-type="pmc">
       7108167
      </article-id>
      <article-id pub-id-type="doi">
       10.1373/clinchem.2005.061689
      </article-id>
      <article-id pub-id-type="publisher-id">
       061689_clinchem0421
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Proteomics and Protein Markers
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pang
         </surname>
         <given-names>
          Ronald TK
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff2">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Poon
         </surname>
         <given-names>
          Terence CW
         </given-names>
        </name>
        <xref ref-type="corresp" rid="C1">
        </xref>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff2">
        </xref>
        <email>
         tcwpoon@cuhk.edu.hk
        </email>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          KC Allen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff3">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          Nelson LS
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chiu
         </surname>
         <given-names>
          Rossa WK
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff3">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tong
         </surname>
         <given-names>
          Yu-Kwan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff3">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Ronald MY
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chim
         </surname>
         <given-names>
          Stephen SC
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ngai
         </surname>
         <given-names>
          Sai M
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sung
         </surname>
         <given-names>
          Joseph JY
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff2">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lo
         </surname>
         <given-names>
          YM Dennis
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
        </xref>
        <xref ref-type="aff" rid="aff3">
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        1
       </label>
       <institution>
        Centre for Emerging Infectious Diseases
       </institution>
       , and Departments of
      </aff>
      <aff id="aff2">
       <label>
        2
       </label>
       <institution>
        Medicine and Therapeutics
       </institution>
       ,
      </aff>
      <aff id="aff3">
       <label>
        3
       </label>
       <institution>
        Chemical Pathology, and Biology
       </institution>
       , The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong SAR
      </aff>
      <author-notes>
       <corresp id="C1">
        Address correspondence to this author at: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR. Fax 852-2648-8842; e-mail
        <email>
         tcwpoon@cuhk.edu.hk
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        3
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <pub-date iso-8601-date="2006-03-01" pub-type="epub">
       <day>
        01
       </day>
       <month>
        3
       </month>
       <year>
        2006
       </year>
      </pub-date>
      <volume>
       52
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       421
      </fpage>
      <lpage>
       429
      </lpage>
      <permissions>
       <copyright-statement>
        © 2006 The American Association for Clinical Chemistry
       </copyright-statement>
       <copyright-year>
        2006
       </copyright-year>
       <license license-type="publisher-standard" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">
        <license-p>
         This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (
         <ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model">
          https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
         </ext-link>
         )
        </license-p>
       </license>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="clinchem0421.pdf">
      </self-uri>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        <italic>
         Background:
        </italic>
        Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a new coronavirus strain, SARS-CoV. Specific proteomic patterns might be present in serum in response to the infection and could be useful for early detection of the disease.
       </p>
       <p>
        <italic>
         Methods:
        </italic>
        Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we profiled and compared serum proteins of 39 patients with early-stage SARS infection and 39 non-SARS patients who were suspected cases during the SARS outbreak period. Proteomic patterns associated with SARS were identified by bioinformatic and biostatistical analyses. Features of interest were then purified and identified by tandem mass spectrometry.
       </p>
       <p>
        <italic>
         Results:
        </italic>
        Twenty proteomic features were significantly different between the 2 groups. Fifteen were increased in the SARS group, and 5 were decreased. Their concentrations were correlated with 2 or more clinical and/or biochemical variables. Two were correlated with the SARS-CoV viral load. Hierarchical clustering analysis showed that a majority of the SARS patients (95%) had similar serum proteomic profiles and identified 2 subgroups with poor prognosis. ROC curve analysis identified individual features as potential biomarkers for SARS diagnosis (areas under ROC curves, 0.733–0.995). ROC curve areas were largest for an N-terminal fragment of complement C3c α chain (
        <italic>
         m/z
        </italic>
        28 119) and an internal fragment of fibrinogen α-E chain (
        <italic>
         m/z
        </italic>
        5908). Immunoglobulin κ light chain (
        <italic>
         m/z
        </italic>
        24 505) positively correlated with viral load.
       </p>
       <p>
        <italic>
         Conclusions:
        </italic>
        Specific proteomic fingerprints in the sera of adult SARS patients could be used to identify SARS cases early during onset with high specificity and sensitivity.
       </p>
      </abstract>
     </article-meta>
    </front>
    <p>
     The outbreak of severe acute respiratory syndrome (SARS)
     <xref ref-type="fn" rid="FN1">
      1
     </xref>
     has affected 32 countries and regions. SARS has infected more than 8000 people and killed more than 700 (
     <xref ref-type="bibr" rid="R1">
      1
     </xref>
     ). Since the outbreak, many efforts have been made to understand the nature of the disease. The causative agent for SARS was identified to be a human SARS coronavirus (SARS-CoV) (
     <xref ref-type="bibr" rid="R2">
      2
     </xref>
     )(
     <xref ref-type="bibr" rid="R3">
      3
     </xref>
     )(
     <xref ref-type="bibr" rid="R4">
      4
     </xref>
     ). High fever, dry cough, myalgia, and lymphopenia were the most distinctive characteristic symptoms seen in patients with SARS. The SARS-CoV has a RNA genome of 30 Kb encoding the replicase, spike glycoprotein, envelop protein, membrane protein, and nucleocapsid (
     <xref ref-type="bibr" rid="R2">
      2
     </xref>
     )(
     <xref ref-type="bibr" rid="R3">
      3
     </xref>
     )(
     <xref ref-type="bibr" rid="R4">
      4
     </xref>
     ). Early diagnosis is necessary to prevent the spread of the disease through isolation of infected patients. Diagnostic tests to detect the presence of either SARS antibody or SARS-CoV RNA have been developed (
     <xref ref-type="bibr" rid="R5">
      5
     </xref>
     )(
     <xref ref-type="bibr" rid="R6">
      6
     </xref>
     ). Quantitative real-time viral RNA reverse transcription-PCR assays allow the detection of SARS-CoV within the first week of illness, whereas antibody tests are reliable around 20 days after disease onset (
     <xref ref-type="bibr" rid="R5">
      5
     </xref>
     )(
     <xref ref-type="bibr" rid="R6">
      6
     </xref>
     ).
    </p>
    <p>
     Recently, advances in proteomics have provided new strategies to identify biomarkers and therapeutic targets and to study the pathology of diseases. Surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology is a proteomic tool that has been applied to the discovery of diagnostic proteomic fingerprints for various diseases, including cancer and infectious diseases (
     <xref ref-type="bibr" rid="R7">
      7
     </xref>
     )(
     <xref ref-type="bibr" rid="R8">
      8
     </xref>
     )(
     <xref ref-type="bibr" rid="R9">
      9
     </xref>
     ). Recent studies have shown that this technology could also be used to identify potential biomarkers for early diagnosis of SARS (
     <xref ref-type="bibr" rid="R7">
      7
     </xref>
     )(
     <xref ref-type="bibr" rid="R10">
      10
     </xref>
     )(
     <xref ref-type="bibr" rid="R11">
      11
     </xref>
     ). In these studies, the control cases were either healthy persons or persons with non-SARS viral infections. Unfortunately, the degree of similarity of the symptoms between the SARS and control groups and the time point of blood collection were not considered in these studies. From the perspective of infectious disease diagnosis, one is not trying to differentiate healthy persons from infected patients, but rather is trying to identify the disease causing the symptoms in patients presenting with similar symptoms (
     <xref ref-type="bibr" rid="R12">
      12
     </xref>
     ).
    </p>
    <p>
     Bearing in mind the above issues, in the present study we attempted to profile and compare the serum proteomes between SARS patients and non-SARS patients. The non-SARS patients were those who had symptoms similar to those in SARS patients. They were admitted to the same hospital as the SARS patients and were later shown to be negative for SARS-CoV infection. Furthermore, for both SARS and non-SARS patients, sera were collected within 1 week after fever onset.
    </p>
    <sec id="sec1">
     <title>
      Materials and Methods
     </title>
     <sec id="sec2">
      <title>
       patient materials
      </title>
      <p>
       The SARS group included 13 males and 26 females (mean age, 42 years; range, 21–88 years); the non-SARS group included 18 males and 21 females (mean age, 44.4 years; range, 20–88 years). The serum samples from both SARS and non-SARS groups represented the first time point after hospitalization (3–7 days after onset of fever); no medications, including steroids, ribavirin, traditional Chinese medicine, or intravenous immunoglobulins, had been given to the above patients before blood collection. All of the SARS cases were positive in the anti-SARS-CoV IgG antibody serology test. Anti-SARS-CoV IgG antibody was detected by an indirect immunofluorescence assay using Vero cells that were infected with a strain of CoV (GenBank accession no. AY278554) isolated from a patient with SARS. Both the sensitivity and the specificity of this serology test for SARS were 100%.
      </p>
      <p>
       The serum SARS-CoV RNA test was performed on 31 patients, and 22 of them (71%) showed detectable SARS-CoV RNA in their serum. For the control group, the 39 non-SARS patients (21 with bacterial pneumonia, 1 with aspiratory pneumonia, 2 with acute pulmonary edema, 2 with upper respiratory tract infection, 2 with influenza, 1 with acute bronchitis, 1 with bronchiectasis, 1 with secondary lung cancer, 1 with gastrointestinal bleeding, 1 with acute cholangitis, 1 with infectious mononucleosis, 1 with viral gastroenteritis, 1 with liver abscess, 1 with peritonitis and end stage renal failure, 1 with cellulites, and 1 with thalamic hemorrhage) were those who had symptoms similar to those for the SARS patients. They were admitted to the same hospital as the SARS patients and were later shown to be negative for SARS-CoV antibody by a serology test after at least 6 weeks of the onset of symptoms. All biochemical information was collected from the same blood samples. All samples were stored as aliquots at −70 °C until ProteinChip array profiling analysis was performed.
      </p>
     </sec>
     <sec id="sec3">
      <title>
       serum proteomic profiling
      </title>
      <p>
       In the SELDI ProteinChip analysis, the serum samples from the diseased and control groups were randomized, and the investigator was blinded to their identity. The SELDI ProteinChip analysis was performed as described previously (
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       )(
       <xref ref-type="bibr" rid="R10">
        10
       </xref>
       )(
       <xref ref-type="bibr" rid="R13">
        13
       </xref>
       ). For each set of binding conditions, samples were analyzed in duplicate. Serum samples (2 μL) were denatured by addition of 4 μL of U9 buffer (9 mol/L urea, 20 g/L CHAPS, 50 mmol/L Tris-HCl, pH 9.0) and incubated on ice for 20 min. Denatured serum samples were diluted with 34 μL of T4 (50 mmol/L sodium acetate, 1 mL/L Triton X-100, pH 4.0) or T9 (10 mmol/L Tris, 1 mL/L Triton X-100, pH 9.0) binding buffer, respectively, to give a final dilution of 20-fold. CM10 ProteinChip arrays (Ciphergen Biosystems) were used in this study. After dilution, 5 μL of the diluted sample was applied to a preequilibrated ProteinChip array in duplicate in a bioprocessor and incubated with shaking for 90 min at room temperature. After incubation, the ProteinChip arrays were washed 5 times with the same binding buffer and rinsed twice with deionized water. After air-drying, sinapinic acid matrix in 500 mL/L acetonitrile–5 mL/L trifluoroacetic acid was added to each array. The ProteinChip arrays were read on the ProteinChip PBS II reader of a ProteinChip Biomarker System (Ciphergen Biosystems) to determine the masses and intensities of all peaks over the range
       <italic>
        m/z
       </italic>
       1000 to 250 000. For each box (12 pieces containing 96 assay spots) of ProteinChip arrays, 1 array (8 assay spots) was used for calibration. Mixtures of peptide/protein calibrators [angiotensin (
       <italic>
        m/z
       </italic>
       1296.51), corticotropin (clip 1–17;
       <italic>
        m/z
       </italic>
       2093.46), corticotropin (clip 18–39;
       <italic>
        m/z
       </italic>
       2465.72), doubly charged horse apomyoglobin (
       <italic>
        m/z
       </italic>
       8475.8),
       <italic>
        Escherichia coli
       </italic>
       thioredoxin (
       <italic>
        m/z
       </italic>
       11 673.5), horse apomyoglobin (
       <italic>
        m/z
       </italic>
       16 951.6), bovine serum albumin (
       <italic>
        m/z
       </italic>
       66 430), and bovine serum albumin dimer (
       <italic>
        m/z
       </italic>
       132 861); Applied Biosystems Ltd.] were added to all 8 assay spots of the calibration array. Intensities of peaks between
       <italic>
        m/z
       </italic>
       1000 and 20 000 were obtained at a laser setting of 183 and a optimized range of
       <italic>
        m/z
       </italic>
       1000 to 20 000; intensities of peaks between
       <italic>
        m/z
       </italic>
       20 000 and 250 000 were obtained at a laser setting of 188 and a optimized range of
       <italic>
        m/z
       </italic>
       20 000 to 150 000. The spectra were smoothed, baseline-subtracted, and externally calibrated. The common peaks among the SELDI mass spectra were identified and quantified by use of Biomarker Wizard software (Ciphergen Biosystems). The peak intensities were normalized with the total ion current and, subsequently, with the total peak intensities. Before data mining, the normalized peak intensities of the duplicate measurements were averaged and log
       <sub>
        2
       </sub>
       -transformed. The intraassay CVs of the normalized intensities of various peaks were &lt;15%.
      </p>
     </sec>
     <sec id="sec4">
      <title>
       bioinformatic analysis
      </title>
      <p>
       To identify proteomic features associated only with disease, we used 2 criteria: (
       <italic>
        a
       </italic>
       ) the normalized peak intensities had to be significantly higher/lower in SARS patients than in non-SARS individuals; and (
       <italic>
        b
       </italic>
       ) the normalized peak intensities had to correlate with 2 or more clinical/biochemical variables, indicating their biological meaningfulness.
      </p>
      <p>
       The Significance Analysis of Microarray (SAM) algorithm (Stanford University) (
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       )(
       <xref ref-type="bibr" rid="R10">
        10
       </xref>
       )(
       <xref ref-type="bibr" rid="R13">
        13
       </xref>
       ) was used to identify proteomic features with concentrations significantly different between the SARS and non-SARS patient groups. During SAM analysis, “two classed, unpaired data” were selected as the data type, and 5000 permutations were performed. The false significant discovery rate was set to zero to avoid the identification of falsely significant proteomic features caused by multiple comparisons. Correlations between the differential proteomic features and various clinical/biochemical features were examined by the Spearman rank-order correlation test.
      </p>
      <p>
       The significant differential proteomic features correlated with various clinical/biochemical correlations were subjected to two-way hierarchical clustering analysis, as described previously (
       <xref ref-type="bibr" rid="R8">
        8
       </xref>
       ). Before clustering analysis, the data of each proteomic feature were subjected to zero-mean unit-variance normalization. The processed proteomic data and the serum samples were subjected to two-way hierarchical clustering analysis by the Cluster and TreeView (
       <xref ref-type="bibr" rid="R14">
        14
       </xref>
       ). Spearman rank correlation was used to calculate the distance, and complete linkage clustering was performed.
      </p>
     </sec>
     <sec id="sec5">
      <title>
       protein purification
      </title>
      <p>
       For protein identification, proteins corresponding to the SEDLI peaks were purified by cation-exchange chromatography with the use of CM10 ceramic beads (BioSepra) under binding conditions similar to those for CM10 ProteinChip arrays. Briefly, pooled serum samples were first denatured with U9 buffer and diluted with T4 or T9 sample binding buffer, respectively. After incubation for 120 min and subsequent washing, the bound proteins were eluted from the CM10 ceramic beads with 1 mol/L NaCl solution. C
       <sub>
        18
       </sub>
       ZipTips were used to desalt the eluted proteins according to the manufacturer’s instructions (Millipore). The desalted protein preparations were spotted on the gold-coated ProteinChip arrays and examined with the ProteinChip reader to confirm that the purified proteins had the same masses as the targeted SEDLI proteomic features. After confirmation, the purified proteins were resolved by 2-dimensional gel electrophoresis in the absence of reducing agents. Proteins on gels were visualized by either colloidal blue (Invitrogentrade;) or silver staining (GE Healthcare). The gel images were then digitized with a densitometer and analyzed by the PDQuest gel analysis software (Ver. 7.3.0; Bio-Rad). Protein spots with masses matched with the differential proteomic features were excised and subjected to mass spectrometric (MS) analysis.
      </p>
     </sec>
     <sec id="sec6">
      <title>
       protein identification by tandem ms
      </title>
      <p>
       Protein spots of interests were removed from the gel and subjected to trypsin digestion as described previously (
       <xref ref-type="bibr" rid="R15">
        15
       </xref>
       ). The trypsin digests were then extracted and subjected to tandem MS (MS/MS) analysis in the ABI 4700 system (Applied Biosystems). Trypsin peaks, possible keratin contamination, and matrix cluster peaks were excluded from subsequent collision-induced dissociation. The MS/MS spectra were then processed with Data Explorer software (Ver. 4.4; Applied Biosystems). The spectra were subjected to gaussian smoothing with a filter width of 5 points, and the baselines were corrected with default settings. Peaks were detected based on a signal-to-noise threshold of 15. The fragment masses and intensities of each MS/MS mass spectrum were subjected to an online Mascot MS/MS ion search (
       <ext-link ext-link-type="uri" xlink:href="http://www.matrixscience.com/">
        http://www.matrixscience.com/
       </ext-link>
       ) to obtain the protein identities. For the search parameters, the maximum allowed missed cleavage in trypsin digestion was 1; partial oxidation of methionine, phosphorylation of serine/threonine/tyrosine, and iodoacetamide modification of cysteine residues were selected. The error tolerance values of the parent peptides and the MS/MS ion masses were 0.1 and 0.3 Da, respectively. A protein identification result was considered significant when the MS/MS ion profile matched a known protein in the NCBInr (2005/06/01) database with a
       <italic>
        P
       </italic>
       value &lt;0.05. For each identified protein, an accession number in the UniProt protein database (Ver. 48.0) was reported when available.
      </p>
     </sec>
    </sec>
    <sec id="sec7">
     <title>
      Results
     </title>
     <sec id="sec8">
      <title>
       differential serum proteomic features in sars patients
      </title>
      <p>
       More than 800 common proteomic features were identified and compared between the SARS and non-SARS patient groups. Using SAM at a median false discovery rate of zero, we identified 107 proteomic features that were significantly differentially expressed between the 2 groups. Fifty-two were increased and 55 were decreased in the SARS group.
      </p>
      <p>
       To avoid identification of falsely significant proteomic features caused by systematic bias, we considered only 20 differential proteomic features (Fig. 1
       <xref ref-type="fig" rid="F1">
       </xref>
       and Table 1
       <xref ref-type="table" rid="T1">
       </xref>
       ) that were significantly correlated with at least 2 biochemical/clinical variables as SARS-specific (Table 2
       <xref ref-type="table" rid="T2">
       </xref>
       ). These potential biomarkers were found to be significantly associated with SARS-CoV viral load (2 correlated with SARS-CoV RNA), acute-phase reaction [10 correlated with C-reactive protein (CRP)], lung damage [12 correlated with lactate dehydrogenase (LD)], liver function (15 correlated with albumin and/or total protein), immune response (11 correlated with neutrophil count; 3 correlated with total leukocyte count), and age (3 correlated), respectively. Thus, these biomarkers could reflect different physiologic conditions of the body after infection with SARS-CoV.
      </p>
     </sec>
     <sec id="sec9">
      <title>
       differentiation of sars by two-way hierarchical clustering analysis of serum proteomic fingerprints
      </title>
      <p>
       In the dendrogram (Fig. 2
       <xref ref-type="fig" rid="F2">
       </xref>
       ), majority of SARS cases (95%) were grouped under 4 clusters. There were significantly more cases with poor prognosis [required treatment in the intensive care unit (ICU) and/or supplemental oxygen during treatment] in SARS clusters 2 and 3.
      </p>
     </sec>
     <sec id="sec10">
      <title>
       diagnostic values of individual proteomic features
      </title>
      <p>
       The areas under the ROC curves for most of the SARS-specific proteomic features were between 0.733 and 0.995. The 2 biomarkers at
       <italic>
        m/z
       </italic>
       28 119 and 5908 gave the largest ROC curve areas. For the biomarker at
       <italic>
        m/z
       </italic>
       28 119, the ROC curve area was 0.987 (95% confidence interval, 0.966–1.007; Fig. 3A
       <xref ref-type="fig" rid="F3">
       </xref>
       ). At 97% specificity, the sensitivity was 97%. For the biomarker at
       <italic>
        m/z
       </italic>
       5908, the ROC curve area of 1/peak intensity was 0.995 (95% confidence interval, 0.985–1.004; Fig. 3B
       <xref ref-type="fig" rid="F3">
       </xref>
       ). At 95% specificity, the sensitivity was 100%.
      </p>
     </sec>
     <sec id="sec11">
      <title>
       protein identities of the potential biomarkers
      </title>
      <p>
       Attempts were made to purify and identify the 2 biomarkers with the highest diagnostic values and the 2 biomarkers correlated with viral load. The CM10 ceramic beads captured proteomic features similar to those of the CM10 ProteinChip array. The proteins eluted from the CM10 ceramic beads were separated and concentrated as protein spots by 2-dimensional gel electrophoresis. We successfully identified the protein spots with masses corresponding to the proteomic features with
       <italic>
        m/z
       </italic>
       values of 5908, 24 505, and 28 119, which were internal fragment of fibrinogen α-E chain, immunoglobulin κ light chain, and N-terminal fragment of complement C3c α-chain, respectively (Fig. 4
       <xref ref-type="fig" rid="F4">
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec12">
     <title>
      Discussion
     </title>
     <p>
      This study demonstrates that the SELDI ProteinChip technology can identify serum proteins or protein fragments that are differentially regulated in adult SARS patients. To avoid identification of falsely significant differential proteomic features (
      <xref ref-type="bibr" rid="R16">
       16
      </xref>
      ), we used a data-mining strategy similar to that used in our previous studies (
      <xref ref-type="bibr" rid="R10">
       10
      </xref>
      )(
      <xref ref-type="bibr" rid="R13">
       13
      </xref>
      ). We considered only the differential proteomic features that were correlated with at least 2 biochemical/clinical features considered SARS-specific. This strategy was adopted to ensure that the identified disease-specific proteomic features had biological meaning and were not the product of systematic bias. We successfully identified potential biomarkers reflecting various physiologic or pathologic responses of the body to SARS infection, including acute-phase reaction (
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      )(
      <xref ref-type="bibr" rid="R17">
       17
      </xref>
      ), lung damage (
      <xref ref-type="bibr" rid="R18">
       18
      </xref>
      )(
      <xref ref-type="bibr" rid="R19">
       19
      </xref>
      )(
      <xref ref-type="bibr" rid="R20">
       20
      </xref>
      ), impairment of liver function (
      <xref ref-type="bibr" rid="R21">
       21
      </xref>
      )(
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
      )(
      <xref ref-type="bibr" rid="R23">
       23
      </xref>
      ), neutrophil activation (
      <xref ref-type="bibr" rid="R24">
       24
      </xref>
      )(
      <xref ref-type="bibr" rid="R25">
       25
      </xref>
      )(
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      ), and viral load (
      <xref ref-type="bibr" rid="R5">
       5
      </xref>
      )(
      <xref ref-type="bibr" rid="R10">
       10
      </xref>
      )(
      <xref ref-type="bibr" rid="R27">
       27
      </xref>
      )(
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
      ).
     </p>
     <p>
      The most sensitive marker, the proteomic feature at
      <italic>
       m/z
      </italic>
      5908, which was negatively correlated with neutrophil count and with the largest chest radiographic changes, was found to be an internal fragment of fibrinogen α-E chain. On the one hand, we previously reported that a high neutrophil count was a risk factor associated with clinical deterioration in SARS (
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      ). On the other hand, intravascular fibrin deposition has been observed in SARS patients (
      <xref ref-type="bibr" rid="R29">
       29
      </xref>
      ). Vascular fibrin thrombi are often associated with pulmonary infarcts. Specific interactions between neutrophils and fibrin thrombi are well recognized (
      <xref ref-type="bibr" rid="R30">
       30
      </xref>
      ). In addition, neutrophils produce a neutral peptide–generating protease that can cleave fibrinogen into peptide fragments (
      <xref ref-type="bibr" rid="R31">
       31
      </xref>
      ). It is possible that fibrinogen and/or its fragments are involved in the pathophysiologic mechanism linking neutrophil activation and lung damage.
     </p>
     <p>
      The next most sensitive biomarker is the proteomic feature at
      <italic>
       m/z
      </italic>
      28 119. This feature was identified as the N-terminal fragment of complement C3c α-chain. Complement 3 (C3), which is composed of an α chain (
      <italic>
       M
      </italic>
      <sub>
       r
      </sub>
      115 000) and a β chain (
      <italic>
       M
      </italic>
      <sub>
       r
      </sub>
      75 000), is the central molecule in complement systems comprising the classic, alternative, or lectin pathways. On activation and subsequent inactivation of C3, several physiologic protein fragments, such as C3c, are produced. When examined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, C3c separates into a β-chain (
      <italic>
       M
      </italic>
      <sub>
       r
      </sub>
      75 000) and 2 fragments of α-chain (
      <italic>
       M
      </italic>
      <sub>
       r
      </sub>
      27 000 N-terminal fragment and
      <italic>
       M
      </italic>
      <sub>
       r
      </sub>
      43 000 C-terminal fragment) (
      <xref ref-type="bibr" rid="R32">
       32
      </xref>
      ). The presence of free C3c α-chain N-terminal fragment in the blood circulation might be the result of degradation of C3c. In the SARS patients, the concentration of this C3c fragment was positively correlated with CRP, suggesting its positive association with the acute-phase reaction and with the activation of the complement system. It is worth nothing that this C3c fragment contains a binding domain for complement receptor type 1 (
      <xref ref-type="bibr" rid="R33">
       33
      </xref>
      ). Activation of complement receptor type 1 enhances phagocytosis of the neutrophils (
      <xref ref-type="bibr" rid="R34">
       34
      </xref>
      ) and activates B-cell differentiation (
      <xref ref-type="bibr" rid="R35">
       35
      </xref>
      )(
      <xref ref-type="bibr" rid="R36">
       36
      </xref>
      ). To date, information about the activation of the complement pathway in SARS patients has been limited. Liao et al. (
      <xref ref-type="bibr" rid="R17">
       17
      </xref>
      ) reported that there was no significant difference in C3 concentrations between SARS and control patients. Another group demonstrated that SARS-CoV could trigger complement activation through the lectin pathway (
      <xref ref-type="bibr" rid="R37">
       37
      </xref>
      ). The biological relevance of C3 in SARS remains unknown.
     </p>
     <p>
      The proteomic feature at
      <italic>
       m/z
      </italic>
      24 505, which was increased in SARS patients and was positively correlated with viral load, was found to be immunoglobulin κ light chain. This finding is consistent with our recent finding of anti-SARS-CoV IgG in 93% of SARS cases at the time of sampling. IgG was first detected on day 4 of illness (
      <xref ref-type="bibr" rid="R38">
       38
      </xref>
      ). Higher IgG concentrations were detected in patients with poor outcome (i.e., requiring supplemental oxygen for hypoxia or treatment in the ICU).
     </p>
     <p>
      Aside from using individual differential proteomic features as biomarkers, one could combine all of the differential features to form a SARS-specific fingerprint. The SARS-specific fingerprint not only could differentiate SARS from non-SARS diseases with similar symptoms, but also could be useful in identifying patients with poor prognosis. The prognostic capability could be explained by the fact that the identified differential proteomic features were correlated with clinical and biochemical features having prognostic values, including viral load (
      <xref ref-type="bibr" rid="R27">
       27
      </xref>
      )(
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
      ), neutrophil counts (
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      ), LD (
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      )(
      <xref ref-type="bibr" rid="R39">
       39
      </xref>
      )(
      <xref ref-type="bibr" rid="R40">
       40
      </xref>
      )(
      <xref ref-type="bibr" rid="R41">
       41
      </xref>
      ), and age (
      <xref ref-type="bibr" rid="R40">
       40
      </xref>
      )(
      <xref ref-type="bibr" rid="R41">
       41
      </xref>
      ).
     </p>
     <p>
      Previously, 2 research teams, using the SELDI ProteinChip technology, reported potential biomarkers in the sera of adult SARS patients (
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      )(
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      ). In the present study, the intensity of the proteomic feature at
      <italic>
       m/z
      </italic>
      7769 was significantly lower in SARS patients (Mann–Whitney test,
      <italic>
       P
      </italic>
      &lt;0.001); in their study, Yip et al. (
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      ) also reported that it is significantly lower in SARS patients (Mann–Whitney test,
      <italic>
       P
      </italic>
      = 4.9 × 10
      <sup>
       −8
      </sup>
      ). Except for this proteomic feature, the SARS-associated proteomic features in these other studies were different from our findings. These differences might be attributable to different selection criteria for the controls. In the previous studies, the control cases were either healthy persons or persons with viral infections from other clinics. The extent of similarities of symptoms between the SARS and control groups and the time point of blood collection were not considered. In the present study, the control group comprised suspected SARS patients who were admitted to the same hospital as the SARS patients but were later shown to be negative for SARS-CoV infection. The symptoms in the SARS and control groups and the time point of blood collection were very similar. The biomarkers identified in the present study may thus have an advantage in an actual diagnostic setting compared with those identified in the previous studies.
     </p>
     <p>
      The difference in the findings reported by Yip et al. (
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      ) and the present study could be also attributable to the use of different profiling methodologies. In their study, Yip et al. (
      <xref ref-type="bibr" rid="R7">
       7
      </xref>
      ) used a comprehensive profiling approach. After being denatured with urea and detergent, the serum proteins were first fractionated with anion-exchange beads to give 6 fractions, which were later analyzed with copper ProteinChip arrays and weak cation-exchange CM10 ProteinChip arrays. Use of the comprehensive profiling approach would increase the chance of identification of more potential protein markers (
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      ). In the present study, we analyzed the serum proteins directly after purification with only CM10 ProteinChip arrays at 2 different binding conditions (pH 4 and pH 9). We chose the CM10 ProteinChip arrays (previously called WCX2) because Kang et al. (
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      ) showed that this chip type gives the best profiling result when analyzing serum samples from SARS patients by a direct binding approach (
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      ). Although the direct binding approach might lead to the discovery of fewer biomarkers, such direct binding assays have higher potential to be modified for use as a clinical assay that can be used even when the protein identities of the disease-specific SELDI peaks are not known.
     </p>
     <p>
      The most commonly used assays for detecting SARS are based on the detection of viral RNA (
      <xref ref-type="bibr" rid="R6">
       6
      </xref>
      ) or antibodies against the SARS-CoV (
      <xref ref-type="bibr" rid="R5">
       5
      </xref>
      ). Detection of viral RNA is useful in the early phase of the disease, whereas the serology test for antibodies against SARS-CoV is useful from 21 days onward. The current study has demonstrated that within the first week after onset of fever, similar to viral RNA concentration, the serum proteome contains both diagnostic and prognostic information. The SELDI ProteinChip assay could be used for first-line detection of SARS, followed by the quantitative viral RNA assay for confirmation. Once the disease is confirmed, the treatment strategy could be adjusted according to the prognosis based on the SELDI ProteinChip profiling result and the viral RNA concentration.
     </p>
     <p>
      In conclusion, we have demonstrated that disease-specific proteomic fingerprints are present in the sera of adult SARS patients. They could be used to identify SARS cases during the early stage of the disease with high specificity and sensitivity. These markers may provide information about the patient’s physiologic status as well as prognostic information. The 2 proteomic features having the highest diagnostic value were the N-terminal fragment of complement C3c α-chain and an internal fragment of fibrinogen α-E chain. The proteomic feature (
      <italic>
       m/z
      </italic>
      24 505) positively correlated with viral load was identified as immunoglobulin κ light chain.
     </p>
    </sec>
    <sec id="sec13">
     <title>
     </title>
     <p>
      <fig id="F1" orientation="portrait" position="float">
       <label>
        Figure 1.
       </label>
       <caption>
        <p>
         Two representative mass spectra of serum samples in the SARS and non-SARS groups, respectively.
        </p>
        <p>
         (
         <italic>
          A
         </italic>
         ), proteomic feature
         <italic>
          m/z
         </italic>
         28 119 was specific to SARS cases, whereas proteomic feature
         <italic>
          m/z
         </italic>
         7769 (
         <italic>
          B
         </italic>
         ) was specific to the non-SARS control group.
        </p>
       </caption>
       <graphic xlink:href="zcy0030678440001">
       </graphic>
      </fig>
      <table-wrap id="T1" orientation="portrait" position="float">
       <label>
        Table 1.
       </label>
       <caption>
        <p>
         Summary of the proteomic features differentially expressed between the SARS and non-SARS control groups.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="2" valign="bottom">
           Mean (minimum–maximum)
           <italic>
            m/z
           </italic>
          </th>
          <th align="center" colspan="1" rowspan="2" valign="bottom">
           Area under ROC curve
           <sup>
            1
           </sup>
           (95% confidence interval)
          </th>
          <th align="center" colspan="2" rowspan="1" valign="bottom">
           Mean (SD) intensity of proteomic feature relative to total sum of proteomic features, %
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
          </th>
         </tr>
         <tr>
          <th align="left" colspan="1" rowspan="1" valign="bottom">
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           Non-SARS control
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           SARS cases
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4154 (4149–4159)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.867 (0.781–0.953)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.145 (0.102)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.534 (0.586)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4303 (4300–4309)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.914 (0.842–0.985)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.110 (0.115)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.397 (0.204)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4469 (4466–4475)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.898 (0.828–0.968)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.230 (0.130)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.664 (0.359)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4482 (4476–4489)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.819 (0.723–0.915)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.102 (0.079)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.245 (0.184)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4680 (4676–4683)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.802 (0.702–0.903)
           <sup>
            2
           </sup>
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.153 (0.075)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.087 (0.034)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5908 (5903–5915)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.995 (0.985–0.996)
           <sup>
            2
           </sup>
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           1.895 (0.716)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.255 (0.244)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6634 (6626–6643)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.745 (0.636–0.854)
           <sup>
            2
           </sup>
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.276 (0.144)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.167 (0.091)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7769 (7761–7776)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.733 (0.621–0.846)
           <sup>
            2
           </sup>
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.058 (0.054)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.027 (0.019)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8606 (8600–8612)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.923 (0.859–0.988)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.239 (0.298)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           1.054 (0.570)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8619 (8613–8623)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.923 (0.861–0.985)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.148 (0.178)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.670 (0.424)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8635 (8630–8641)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.915 (0.851–0.979)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.074 (0.072)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.331 (0.227)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8814 (8808–8820)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.850 (0.764–0.935)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.013 (0.020)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.060 (0.051)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8831 (8827–8836)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.835 (0.741–0.929)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.015 (0.017)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.049 (0.036)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8865 (8856–8874)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.762 (0.656–0.868)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.100 (0.071)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.170 (0.076)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8937 (8930–8946)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.901 (0.833–0.970)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.604 (0.335)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           1.612 (0.755)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8956 (8946–8968)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.925 (0.868–0.982)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.277 (0.168)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.869 (0.455)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           17 878 (17 860–17 902)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.846 (0.759–0.934)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.005 (0.004)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.014 (0.009)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           24 505 (24 465–24 553)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.733 (0.621–0.845)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           1.598 (0.828)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           2.302 (0.988)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           28 119 (28 064–28 171)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.987 (0.966–1.007)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.787 (0.496)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           3.904 (1.370)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           88 637 (88 474–88 736)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.851 (0.766–0.936)
           <sup>
            <italic>
             b
            </italic>
           </sup>
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           1.300 (0.316)
          </td>
          <td align="char" char="." colspan="1" rowspan="1" valign="top">
           0.920 (0.207)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="fn_1">
         <label>
          1
         </label>
         <p>
          <italic>
           P
          </italic>
          &lt;0.0005 for all.
         </p>
        </fn>
        <fn id="fn_2">
         <label>
          2
         </label>
         <p>
          Area under the ROC curve was calculated for 1/peak intensity.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="T2" orientation="portrait" position="float">
       <label>
        Table 2.
       </label>
       <caption>
        <p>
         Summary of the differentially expressed proteomic features and their correlations to various clinical/biochemical features.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           Feature,
           <italic>
            m/z
           </italic>
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           Concentration in SARS vs non-SARS control
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           Clinical/Biochemical features
           <sup>
            1
           </sup>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4154
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Age (
           <italic>
            r
           </italic>
           = 0.344;
           <italic>
            P
           </italic>
           = 0.035); neutrophil count (
           <italic>
            r
           </italic>
           = 0.395;
           <italic>
            P
           </italic>
           = 0.016)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4303
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.045;
           <italic>
            P
           </italic>
           = 0.005); LD (
           <italic>
            r
           </italic>
           = 0.495;
           <italic>
            P
           </italic>
           = 0.003); total protein (
           <italic>
            r
           </italic>
           = −0.325;
           <italic>
            P
           </italic>
           = 0.046); albumin (
           <italic>
            r
           </italic>
           = −0.332;
           <italic>
            P
           </italic>
           = 0.042)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4469
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LD (
           <italic>
            r
           </italic>
           = 0.417;
           <italic>
            P
           </italic>
           = 0.013); CRP (
           <italic>
            r
           </italic>
           = 0.513;
           <italic>
            P
           </italic>
           = 0.003); total protein (
           <italic>
            r
           </italic>
           = −0.383;
           <italic>
            P
           </italic>
           = 0.018); albumin (
           <italic>
            r
           </italic>
           = −0.451;
           <italic>
            P
           </italic>
           = 0.004)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4482
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.353;
           <italic>
            P
           </italic>
           = 0.032); LD (
           <italic>
            r
           </italic>
           = 0.463;
           <italic>
            P
           </italic>
           = 0.005); CRP (
           <italic>
            r
           </italic>
           = 0.600; &lt;0.0005); total protein (
           <italic>
            r
           </italic>
           = −0.358;
           <italic>
            P
           </italic>
           = 0.027); albumin (
           <italic>
            r
           </italic>
           = −0.339;
           <italic>
            P
           </italic>
           = 0.037)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           4680
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Viral load (
           <italic>
            r
           </italic>
           = −0.374;
           <italic>
            P
           </italic>
           = 0.042); bilirubin (
           <italic>
            r
           </italic>
           = −0.403;
           <italic>
            P
           </italic>
           = 0.012)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           5908
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = −0.39;
           <italic>
            P
           </italic>
           = 0.017); total leukocyte count (
           <italic>
            r
           </italic>
           = −0.373;
           <italic>
            P
           </italic>
           = 0.023); largest change in chest x-ray (
           <italic>
            r
           </italic>
           = −0.377;
           <italic>
            P
           </italic>
           = 0.04)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           6634
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           CRP (
           <italic>
            r
           </italic>
           = −0.384;
           <italic>
            P
           </italic>
           = 0.033); total protein (
           <italic>
            r
           </italic>
           = 0.402;
           <italic>
            P
           </italic>
           = 0.012); albumin (
           <italic>
            r
           </italic>
           = 0.388;
           <italic>
            P
           </italic>
           = 0.016)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           7769
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Bilirubin count (
           <italic>
            r
           </italic>
           = −0.405;
           <italic>
            P
           </italic>
           = 0.012); LD (
           <italic>
            r
           </italic>
           = −0.374;
           <italic>
            P
           </italic>
           = 0.027)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8606
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.364;
           <italic>
            P
           </italic>
           = 0.027); LD (
           <italic>
            r
           </italic>
           = 0.539;
           <italic>
            P
           </italic>
           = 0.001); CRP (
           <italic>
            r
           </italic>
           = 0.425;
           <italic>
            P
           </italic>
           = 0.017); age (
           <italic>
            r
           </italic>
           = 0.321;
           <italic>
            P
           </italic>
           = 0.049); total protein (
           <italic>
            r
           </italic>
           = −0.432;
           <italic>
            P
           </italic>
           = 0.007); albumin (
           <italic>
            r
           </italic>
           = −0.446;
           <italic>
            P
           </italic>
           = 0.017)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8619
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.394;
           <italic>
            P
           </italic>
           = 0.016); LD (
           <italic>
            r
           </italic>
           = 0.511;
           <italic>
            P
           </italic>
           = 0.002); CRP (
           <italic>
            r
           </italic>
           = 0.445;
           <italic>
            P
           </italic>
           = 0.012); age (
           <italic>
            r
           </italic>
           = 0.362;
           <italic>
            P
           </italic>
           = 0.026); total protein (
           <italic>
            r
           </italic>
           = −0.437;
           <italic>
            P
           </italic>
           = 0.006); albumin (
           <italic>
            r
           </italic>
           = −0.440;
           <italic>
            P
           </italic>
           = 0.006)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8635
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.408;
           <italic>
            P
           </italic>
           = 0.012); LD (
           <italic>
            r
           </italic>
           = 0.509;
           <italic>
            P
           </italic>
           = 0.002); CRP (
           <italic>
            r
           </italic>
           = 0.484;
           <italic>
            P
           </italic>
           = 0.006); total protein (
           <italic>
            r
           </italic>
           = −0.472;
           <italic>
            P
           </italic>
           = 0.003); albumin (
           <italic>
            r
           </italic>
           = −0.459;
           <italic>
            P
           </italic>
           = 0.004)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8814
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.391;
           <italic>
            P
           </italic>
           = 0.017); LD (
           <italic>
            r
           </italic>
           = 0.510;
           <italic>
            P
           </italic>
           = 0.002); albumin (
           <italic>
            r
           </italic>
           = −0.335;
           <italic>
            P
           </italic>
           = 0.04)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8831
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.339;
           <italic>
            P
           </italic>
           = 0.040); LD (
           <italic>
            r
           </italic>
           = 0.483;
           <italic>
            P
           </italic>
           = 0.003); CRP (
           <italic>
            r
           </italic>
           = 0.379;
           <italic>
            P
           </italic>
           = 0.036); total protein (
           <italic>
            r
           </italic>
           = −0.333;
           <italic>
            P
           </italic>
           = 0.041); albumin (
           <italic>
            r
           </italic>
           = −0.360;
           <italic>
            P
           </italic>
           = 0.027)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8865
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.383;
           <italic>
            P
           </italic>
           = 0.019); total leukocyte count (
           <italic>
            r
           </italic>
           = 0.330;
           <italic>
            P
           </italic>
           = 0.046)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8937
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LD (
           <italic>
            r
           </italic>
           = 0.448;
           <italic>
            P
           </italic>
           = 0.007); CRP (
           <italic>
            r
           </italic>
           = 0.521;
           <italic>
            P
           </italic>
           = 0.003); total protein (
           <italic>
            r
           </italic>
           = −0.415;
           <italic>
            P
           </italic>
           = 0.010); albumin (
           <italic>
            r
           </italic>
           = −0.459;
           <italic>
            P
           </italic>
           = 0.004)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           8956
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LD (
           <italic>
            r
           </italic>
           = 0.465;
           <italic>
            P
           </italic>
           = 0.005); CRP (
           <italic>
            r
           </italic>
           = 0.623; &lt;0.0005); total protein (
           <italic>
            r
           </italic>
           = −0.459;
           <italic>
            P
           </italic>
           = 0.004); albumin (
           <italic>
            r
           </italic>
           = −0.500;
           <italic>
            P
           </italic>
           = 0.001)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           17 878
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutrophil count (
           <italic>
            r
           </italic>
           = 0.584; &lt;0.0005); total leukocyte count (
           <italic>
            r
           </italic>
           = 0.373;
           <italic>
            P
           </italic>
           = 0.023); LD (
           <italic>
            r
           </italic>
           = 0.694; &lt;0.0005); CRP (
           <italic>
            r
           </italic>
           = 0.502;
           <italic>
            P
           </italic>
           = 0.004); total protein (
           <italic>
            r
           </italic>
           = −0.434;
           <italic>
            P
           </italic>
           = 0.006); albumin (
           <italic>
            r
           </italic>
           = −0.481;
           <italic>
            P
           </italic>
           = 0.002)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           24 505
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Viral load (
           <italic>
            r
           </italic>
           = 0.467;
           <italic>
            P
           </italic>
           = 0.0009); total protein (
           <italic>
            r
           </italic>
           = −0.481;
           <italic>
            P
           </italic>
           = 0.002); albumin (
           <italic>
            r
           </italic>
           = −0.488;
           <italic>
            P
           </italic>
           = 0.002)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           28 119
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Higher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LD (
           <italic>
            r
           </italic>
           = 0.375;
           <italic>
            P
           </italic>
           = 0.038); CRP (
           <italic>
            r
           </italic>
           = 0.375;
           <italic>
            P
           </italic>
           = 0.038); total protein (
           <italic>
            r
           </italic>
           = −0.375;
           <italic>
            P
           </italic>
           = 0.020); albumin (
           <italic>
            r
           </italic>
           = −0.416;
           <italic>
            P
           </italic>
           = 0.009)
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           88 637
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lower
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Total protein (
           <italic>
            r
           </italic>
           = 0.348;
           <italic>
            P
           </italic>
           = 0.032); initial change in chest x-ray (
           <italic>
            r
           </italic>
           = −0.394;
           <italic>
            P
           </italic>
           = 0.031)
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="fn_3">
         <label>
          1
         </label>
         <p>
          Correlations between various biochemical/clinical features and proteomic features were calculated by Spearman rank-order correlation test as stated in the
          <italic>
           Materials and Methods
          </italic>
          .
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <fig id="F2" orientation="portrait" position="float">
       <label>
        Figure 2.
       </label>
       <caption>
        <p>
         Two-way hierarchical clustering analysis (complete linkage) of the serum proteomic features among the SARS cases (case number starting with s) and non-SARS control cases (case numbers not starting with s).
        </p>
        <p>
         The intensity of the
         <italic>
          red
         </italic>
         or
         <italic>
          green
         </italic>
         color indicates that the relative protein concentration is higher than or lower than the mean value, respectively. The
         <italic>
          column labels
         </italic>
         indicate the individual cases; the
         <italic>
          row labels
         </italic>
         indicate the differential proteomic features found in the serum samples.
         <italic>
          I
         </italic>
         , case required care in the ICU;
         <italic>
          O
         </italic>
         , case required supplemental oxygen.
        </p>
       </caption>
       <graphic xlink:href="zcy0030678440002">
       </graphic>
      </fig>
      <fig id="F3" orientation="portrait" position="float">
       <label>
        Figure 3.
       </label>
       <caption>
        <p>
         ROC curves of proteomic features at
         <italic>
          m/z
         </italic>
         28 119 (
         <italic>
          A
         </italic>
         ) and 5908 (
         <italic>
          B
         </italic>
         ) for differentiating the SARS cases from the non-SARS control cases.
        </p>
        <p>
         <italic>
          AUC
         </italic>
         , area under the curve.
        </p>
       </caption>
       <graphic xlink:href="zcy0030678440003">
       </graphic>
      </fig>
      <fig id="F4" orientation="portrait" position="float">
       <label>
        Figure 4.
       </label>
       <caption>
        <p>
         MS/MS identification of the representative biomarkers.
        </p>
        <p>
         (
         <italic>
          A
         </italic>
         ), MS/MS spectrum of one of the tryptic peptides from biomarker
         <italic>
          m/z
         </italic>
         24 505; (
         <italic>
          B
         </italic>
         ), MS/MS spectrum of one of the tryptic peptides from biomarker
         <italic>
          m/z
         </italic>
         28 119. Amino acids in
         <italic>
          bold
         </italic>
         indicate y-series or b-series fragment ions identified from the spectra. Positions of the amino acids are indicated according to the b-series ions. (
         <italic>
          C
         </italic>
         ), summary of the MS/MS matching, the Mowse score, and the required score for significant matching (
         <italic>
          P
         </italic>
         &lt;0.05).
        </p>
       </caption>
       <graphic xlink:href="zcy0030678440004">
       </graphic>
      </fig>
      <fn id="FN1">
       <label>
        1
       </label>
       <p>
        Nonstandard abbreviations: SARS, severe acute respiratory syndrome; CoV, coronavirus; SELDI, surface-enhanced laser desorption/ionization; SAM, Significant Analysis of Microarray; MS/MS, tandem mass spectrometry; CRP, C-reactive protein; LD, lactate dehydrogenase; and ICU, intensive care unit.
       </p>
      </fn>
     </p>
    </sec>
    <back>
     <ack id="A01">
      <p>
       The project team is supported by the Research Fund for the Control of Infectious Diseases (RFCID) from the Health, Welfare and Food Bureau of the Hong Kong SAR Government.
      </p>
     </ack>
     <ref-list id="R01">
      <ref id="R1">
       <label>
        1
       </label>
       <mixed-citation publication-type="journal">
        World Health Organization. WHO issues consensus document on the epidemiology of SARS.
        <source>
         Wkly Epidemiol Rec
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         78
        </volume>
        :
        <fpage>
         373
        </fpage>
        -375.
        <pub-id pub-id-type="pmid">
         14601330
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2
       </label>
       <mixed-citation publication-type="journal">
        Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The genome sequence of the SARS-associated coronavirus.
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1399
        </fpage>
        -1404.
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome.
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1394
        </fpage>
        -1399.
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        Tsui SK, Chim SS, Lo YM, . Chinese University of Hong Kong Molecular SRG. Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome.
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         349
        </volume>
        :
        <fpage>
         187
        </fpage>
        -188.
        <pub-id pub-id-type="pmid">
         12853594
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5
       </label>
       <mixed-citation publication-type="journal">
        Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1767
        </fpage>
        -1772.
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        Ng EK, Hui DS, Chan KC, Hung EC, Chiu RW, Lee N, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome.
        <source>
         Clin Chem
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         49
        </volume>
        :
        <fpage>
         1976
        </fpage>
        -1980.
        <pub-id pub-id-type="pmid">
         14633867
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        Yip TT, Chan JW, Cho WC, Wang Z, Kwan TL, Law SC, et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia.
        <source>
         Clin Chem
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         47
        </fpage>
        -55.
        <pub-id pub-id-type="pmid">
         15364884
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes.
        <source>
         Clin Chem
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         49
        </volume>
        :
        <fpage>
         752
        </fpage>
        -760.
        <pub-id pub-id-type="pmid">
         12709366
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9
       </label>
       <mixed-citation publication-type="journal">
        Gravett MG, Novy MJ, Rosenfeld RG, Reddy AP, Jacob T, Turner M, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers.
        <source>
         JAMA
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         292
        </volume>
        :
        <fpage>
         462
        </fpage>
        -469.
        <pub-id pub-id-type="pmid">
         15280344
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        Poon TC, Chan KC, Ng PC, Chiu RW, Ang IL, Tong YK, et al. Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load.
        <source>
         Clin Chem
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         50
        </volume>
        :
        <fpage>
         1452
        </fpage>
        -1455.
        <pub-id pub-id-type="pmid">
         15178653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome.
        <source>
         Clin Chem
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         56
        </fpage>
        -64.
        <pub-id pub-id-type="pmid">
         15550479
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        Mazzulli T, Low DE, Poutanen SM. Proteomics and severe acute respiratory syndrome (SARS): emerging technology meets emerging pathogen.
        <source>
         Clin Chem
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         6
        </fpage>
        -7.
        <pub-id pub-id-type="pmid">
         15613703
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study.
        <source>
         Clin Chem
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         51
        </volume>
        :
        <fpage>
         328
        </fpage>
        -335.
        <pub-id pub-id-type="pmid">
         15590748
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns.
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1998
        </year>
        ;
        <volume>
         95
        </volume>
        :
        <fpage>
         14863
        </fpage>
        -14868.
        <pub-id pub-id-type="pmid">
         9843981
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        Pang RT, Poon TC, Wong N, Lai PB, Wong NL, Chan CM, et al. Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line.
        <source>
         Clin Proteomics
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         1
        </volume>
        :
        <fpage>
         313
        </fpage>
        -332.
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?.
        <source>
         Clin Chem
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         49
        </volume>
        :
        <fpage>
         1272
        </fpage>
        -1275.
        <pub-id pub-id-type="pmid">
         12881441
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        Liao WJ, Li YM, Chen T, He WQ, Lin YP, Li N. Determination of serum acute phase reaction protein in patients with severe acute respiratory syndrome.
        <source>
         Zhonghua Yu Fang Yi Xue Za Zhi
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         38
        </volume>
        :
        <fpage>
         92
        </fpage>
        -93.
        <pub-id pub-id-type="pmid">
         15061914
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18
       </label>
       <mixed-citation publication-type="journal">
        Shieh WJ, Hsiao CH, Paddock CD, Guarner J, Goldsmith CS, Tatti K, et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan.
        <source>
         Hum Pathol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         303
        </fpage>
        -309.
        <pub-id pub-id-type="pmid">
         15791576
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS).
        <source>
         J Clin Pathol
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         57
        </volume>
        :
        <fpage>
         260
        </fpage>
        -265.
        <pub-id pub-id-type="pmid">
         14990596
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20
       </label>
       <mixed-citation publication-type="journal">
        Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore.
        <source>
         Hum Pathol
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         743
        </fpage>
        -748.
        <pub-id pub-id-type="pmid">
         14506633
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21
       </label>
       <mixed-citation publication-type="journal">
        Guan YJ, Tang XP, Yin CB, Yi ZQ. Study on the damage of liver in patients with SARS.
        <source>
         Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         267
        </fpage>
        -270.
        <pub-id pub-id-type="pmid">
         15132787
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22
       </label>
       <mixed-citation publication-type="journal">
        Chan HL, Kwan AC, To KF, Lai ST, Chan PK, Leung WK, et al. Clinical significance of hepatic derangement in severe acute respiratory syndrome.
        <source>
         World J Gastroenterol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         2148
        </fpage>
        -2153.
        <pub-id pub-id-type="pmid">
         15810082
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23
       </label>
       <mixed-citation publication-type="journal">
        Yang Z, Xu M, Yi JQ, Jia WD. Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome.
        <source>
         Hepatobiliary Pancreat Dis Int
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         60
        </fpage>
        -63.
        <pub-id pub-id-type="pmid">
         15730921
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24
       </label>
       <mixed-citation publication-type="journal">
        Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         136
        </volume>
        :
        <fpage>
         95
        </fpage>
        -103.
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25
       </label>
       <mixed-citation publication-type="journal">
        Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon-γ-related cytokine storm in SARS patients.
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         75
        </volume>
        :
        <fpage>
         185
        </fpage>
        -194.
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26
       </label>
       <mixed-citation publication-type="journal">
        Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong.
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1986
        </fpage>
        -1994.
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27
       </label>
       <mixed-citation publication-type="journal">
        Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, et al. Viral loads in clinical specimens and SARS manifestations.
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1550
        </fpage>
        -1557.
        <pub-id pub-id-type="pmid">
         15498155
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28
       </label>
       <mixed-citation publication-type="journal">
        Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, et al. Initial viral load and the outcomes of SARS.
        <source>
         CMAJ
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         171
        </volume>
        :
        <fpage>
         1349
        </fpage>
        -1352.
        <pub-id pub-id-type="pmid">
         15557587
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29
       </label>
       <mixed-citation publication-type="journal">
        Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto.
        <source>
         Mod Pathol
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         1
        </fpage>
        -10.
        <pub-id pub-id-type="pmid">
         15272286
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30
       </label>
       <mixed-citation publication-type="journal">
        Loike JD, Sodeik B, Cao L, Leucona S, Weitz JI, Detmers PA, et al. CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the Aα chain of fibrinogen.
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1991
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         1044
        </fpage>
        -1048.
        <pub-id pub-id-type="pmid">
         1671533
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31
       </label>
       <mixed-citation publication-type="journal">
        Wintroub BU, Coblyn JS, Kaempfer CE, Austen KF. Cleavage of fibrinogen by the human neutrophil neutral peptide-generating protease.
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1980
        </year>
        ;
        <volume>
         77
        </volume>
        :
        <fpage>
         5448
        </fpage>
        -5452.
        <pub-id pub-id-type="pmid">
         7001479
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32
       </label>
       <mixed-citation publication-type="journal">
        Davis AE, 3rd, Harrison RA. Structural characterization of factor I mediated cleavage of the third component of complement.
        <source>
         Biochemistry
        </source>
        <year>
         1982
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         5745
        </fpage>
        -5749.
        <pub-id pub-id-type="pmid">
         6217832
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33
       </label>
       <mixed-citation publication-type="journal">
        Becherer JD, Lambris JD. Identification of the C3b receptor-binding domain in third component of complement.
        <source>
         J Biol Chem
        </source>
        <year>
         1988
        </year>
        ;
        <volume>
         263
        </volume>
        :
        <fpage>
         14586
        </fpage>
        -14591.
        <pub-id pub-id-type="pmid">
         2971659
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34
       </label>
       <mixed-citation publication-type="journal">
        Ehlenberger AG, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis.
        <source>
         J Exp Med
        </source>
        <year>
         1977
        </year>
        ;
        <volume>
         145
        </volume>
        :
        <fpage>
         357
        </fpage>
        -371.
        <pub-id pub-id-type="pmid">
         833545
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35
       </label>
       <mixed-citation publication-type="journal">
        Weiss L, Delfraissy JF, Vazquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation.
        <source>
         J Immunol
        </source>
        <year>
         1987
        </year>
        ;
        <volume>
         138
        </volume>
        :
        <fpage>
         2988
        </fpage>
        -2993.
        <pub-id pub-id-type="pmid">
         2952731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36
       </label>
       <mixed-citation publication-type="journal">
        Daha MR, Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies.
        <source>
         J Immunol
        </source>
        <year>
         1984
        </year>
        ;
        <volume>
         132
        </volume>
        :
        <fpage>
         1197
        </fpage>
        -1201.
        <pub-id pub-id-type="pmid">
         6229578
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37
       </label>
       <mixed-citation publication-type="journal">
        Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection.
        <source>
         J Infect Dis
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         191
        </volume>
        :
        <fpage>
         1697
        </fpage>
        -1704.
        <pub-id pub-id-type="pmid">
         15838797
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38
       </label>
       <mixed-citation publication-type="journal">
        Lee N, Chan PK, Ip M, Wong E, Ho J, Ho C, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome.
        <source>
         J Clin Virol
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         35
        </volume>
        :
        <fpage>
         179
        </fpage>
        -184.
        <pub-id pub-id-type="pmid">
         16112612
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39
       </label>
       <mixed-citation publication-type="journal">
        Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong.
        <source>
         Ann Intern Med
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         139
        </volume>
        :
        <fpage>
         715
        </fpage>
        -723.
        <pub-id pub-id-type="pmid">
         14597455
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40
       </label>
       <mixed-citation publication-type="journal">
        Tsui PT, Kwok ML, Yuen H, Lai ST. Severe acute respiratory syndrome: clinical outcome and prognostic correlates.
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2003
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         1064
        </fpage>
        -1069.
        <pub-id pub-id-type="pmid">
         14519241
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R41">
       <label>
        41
       </label>
       <mixed-citation publication-type="journal">
        Chen CY, Lee CH, Liu CY, Wang JH, Wang LM, Perng RP. Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome.
        <source>
         J Chin Med Assoc
        </source>
        <year>
         2005
        </year>
        ;
        <volume>
         68
        </volume>
        :
        <fpage>
         4
        </fpage>
        -10.
        <pub-id pub-id-type="pmid">
         15742856
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Virology
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Virology
      </journal-id>
      <journal-title-group>
       <journal-title>
        Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0042-6822
      </issn>
      <issn pub-type="epub">
       1096-0341
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28432925
      </article-id>
      <article-id pub-id-type="pmc">
       7111649
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0042-6822(17)30124-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.virol.2017.04.016
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Structure of the S1 subunit C-terminal domain from bat-derived coronavirus HKU5 spike protein
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Xue
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Qi
         </surname>
         <given-names>
          Jianxun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          Hao
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Qihui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0020">
         d
        </xref>
        <xref ref-type="aff" rid="aff0025">
         e
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Yanfang
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0030">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Ying
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0025">
         e
        </xref>
        <xref ref-type="aff" rid="aff0030">
         f
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0035">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Guangwen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0035">
         g
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0040">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0040">
         h
        </xref>
        <xref ref-type="aff" rid="aff0045">
         i
        </xref>
        <xref ref-type="aff" rid="aff0050">
         j
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0045">
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Yi
         </given-names>
        </name>
        <email>
         shiyi@im.ac.cn
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
        <xref ref-type="aff" rid="aff0025">
         e
        </xref>
        <xref ref-type="aff" rid="aff0055">
         k
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0050">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          George F.
         </given-names>
        </name>
        <email>
         gaof@im.ac.cn
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
        <xref ref-type="aff" rid="aff0015">
         c
        </xref>
        <xref ref-type="aff" rid="aff0025">
         e
        </xref>
        <xref ref-type="aff" rid="aff0050">
         j
        </xref>
        <xref ref-type="aff" rid="aff0055">
         k
        </xref>
        <xref ref-type="aff" rid="aff0060">
         l
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        a
       </label>
       CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff0010">
       <label>
        b
       </label>
       University of Chinese Academy of Sciences, Beijing 100049, China
      </aff>
      <aff id="aff0015">
       <label>
        c
       </label>
       Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff0020">
       <label>
        d
       </label>
       CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff0025">
       <label>
        e
       </label>
       Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen 518112, China
      </aff>
      <aff id="aff0030">
       <label>
        f
       </label>
       School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China
      </aff>
      <aff id="aff0035">
       <label>
        g
       </label>
       West China Hospital Emergency Department (WCHED), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, China
      </aff>
      <aff id="aff0040">
       <label>
        h
       </label>
       State Key Laboratory for Emerging Infectious Diseases, The University of Hong Kong, Pokfulam 999077, Hong Kong Special Administration Region
      </aff>
      <aff id="aff0045">
       <label>
        i
       </label>
       Department of Microbiology, The University of Hong Kong, Pokfulam 999077, Hong Kong Special Administration Region
      </aff>
      <aff id="aff0050">
       <label>
        j
       </label>
       Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310003, China
      </aff>
      <aff id="aff0055">
       <label>
        <sup>
         k
        </sup>
       </label>
       Center for Influenza Research and Early-warning (CASCIRE), Chinese Academy of Sciences, Beijing 100101, China
      </aff>
      <aff id="aff0060">
       <label>
        <sup>
         l
        </sup>
       </label>
       National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Corresponding authors at: CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
        <email>
         shiyi@im.ac.cn
        </email>
        <email>
         gaof@im.ac.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        19
       </day>
       <month>
        4
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        7
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        4
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       507
      </volume>
      <fpage>
       101
      </fpage>
      <lpage>
       109
      </lpage>
      <history>
       <date date-type="received">
        <day>
         12
        </day>
        <month>
         3
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         10
        </day>
        <month>
         4
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         15
        </day>
        <month>
         4
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 Elsevier Inc.
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0010">
       <p>
        Accumulating evidence indicates that MERS-CoV originated from bat coronaviruses (BatCoVs). Previously, we demonstrated that both MERS-CoV and BatCoV HKU4 use CD26 as a receptor, but how the BatCoVs evolved to bind CD26 is an intriguing question. Here, we solved the crystal structure of the S1 subunit C-terminal domain of HKU5 (HKU5-CTD), another BatCoV that is phylogenetically related to MERS-CoV but cannot bind to CD26. We observed that the conserved core subdomain and those of other betacoronaviruses (betaCoVs) have a similar topology of the external subdomain, indicating the same ancestor of lineage C betaCoVs. However, two deletions in two respective loops located in HKU5-CTD result in conformational variations in CD26-binding interface and are responsible for the non-binding of HKU5-CTD to CD26. Combined with sequence variation in the HKU5-CTD receptor binding interface, we propose the necessity for surveilling the mutation in BatCoV HKU5 spike protein in case of bat-to-human interspecies transmission.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="ab0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="li0005" list-type="simple">
         <list-item id="u0005">
          <label>
           •
          </label>
          <p id="p0005">
           Structure of the S1 subunit C-terminal domain (CTD) from bat-derived coronavirus HKU5 spike protein at 2.1 Å.
          </p>
         </list-item>
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           Identification of features of HKU5-CTD that response to non-binding to CD26.
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           Variations in the HKU5-CTD receptor binding interface indicate the need for surveillance.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="keys0005">
       <title>
        Keywords
       </title>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        BatCoV HKU5
       </kwd>
       <kwd>
        CTD
       </kwd>
       <kwd>
        Crystal structure
       </kwd>
       <kwd>
        Evolution
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0020">
      Coronaviruses (CoVs) are spherical enveloped viruses with single positive-strand RNA genomes of ~30 kb in length, which is the largest among RNA viruses (
      <xref ref-type="bibr" rid="bib35">
       Saif, 1993
      </xref>
      ). CoVs are divided into four genera: alpha-, beta-, gamma-, and deltaCoVs (
      <xref ref-type="bibr" rid="bib13">
       de Groot et al., 2013
      </xref>
      ). BetaCoVs are further subdivided into four lineages/subgroups: A, B, C, and D (
      <xref ref-type="bibr" rid="bib6">
       Chan et al., 2015
      </xref>
      ). To date, both alpha- and betaCoVs are found to infect humans (
      <xref ref-type="bibr" rid="bib25">
       Lu et al., 2015
      </xref>
      ), causing subclinical or very mild symptoms and accounting for 10–15% of common colds (
      <xref ref-type="bibr" rid="bib14">
       Heikkinen and Jarvinen, 2003
      </xref>
      ). In addition, CoVs can also be life-threatening and have pandemic potential. The epidemic of severe acute respiratory syndrome coronavirus (SARS-CoV), which belongs to lineage B of the betaCoVs, originated in southern China in 2002 and spread to 28 countries, infecting over 8000 and leading to almost 800 related deaths (
      <xref ref-type="bibr" rid="bib40">
       WHO, 2004
      </xref>
      ). The outbreak of MERS-CoV, a member of the lineage C betaCoVs (
      <xref ref-type="bibr" rid="bib7">
       Cotten et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib48">
       Zaki et al., 2012
      </xref>
      ), has caused 1832 laboratory-confirmed cases since 2012, including 651 related deaths as of Nov. 28, 2016 (
      <xref ref-type="bibr" rid="bib41">
       WHO, 2016
      </xref>
      ). Unlike the SARS-CoV, which suddenly disappeared after a massive global disease control effort, especially in China, the number of MERS-CoV infections is still on the rise.
     </p>
     <p id="p0025">
      Mounting evidence indicates that CoVs circulating in bats (BatCoVs) are the gene sources of alphaCoVs and betaCoVs (
      <xref ref-type="bibr" rid="bib23">
       Li et al., 2005b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       Woo et al., 2012
      </xref>
      ), including SARS-CoV (
      <xref ref-type="bibr" rid="bib12">
       Ge et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib20">
       Lau et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib23">
       Li et al., 2005b
      </xref>
      ). The data also underscore that bats are the likely natural reservoir for MERS-CoV (
      <xref ref-type="bibr" rid="bib3">
       Annan et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       Ithete et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       Memish et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Wang et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Yang et al., 2014
      </xref>
      ). For instance, viral gene fragments identical or quite similar to those of MERS-CoV have been reported in bats (
      <xref ref-type="bibr" rid="bib3">
       Annan et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib17">
       Ithete et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       Memish et al., 2013
      </xref>
      ). Moreover, parallel studies from our group and others show that BatCoV HKU4, grouped in lineage C with MERS-CoV, can also use human CD26 (hCD26; the receptor of MERS-CoV) for viral entry (
      <xref ref-type="bibr" rid="bib39">
       Wang et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib46">
       Yang et al., 2014
      </xref>
      ). In other words, two members in lineage C use the same human receptor. One has caused a human infection epidemic (MERS-CoV), and the other can utilize the same receptor (BatCoV HKU4) and has potential to infect humans. This highlights the necessity of surveillance for lineage C betaCoVs, including BatCoV HKU5, which was first sequenced in 2006 in Japanese pipistrelles (
      <italic>
       Pipistrellus abramus
      </italic>
      ) (
      <xref ref-type="bibr" rid="bib43">
       Woo et al., 2006
      </xref>
      ) and is circulating in bats (
      <xref ref-type="bibr" rid="bib21">
       Lau et al., 2013
      </xref>
      ). Whether the virus has the potential to bypass the bat-human barrier needs to be evaluated.
     </p>
     <p id="p0030">
      CoV infections initiate with the virus binding to the host receptor. The envelope-interspersed trimeric spike (S) protein plays a pivotal role in this process. S is further divided into two parts: S1, responsible for receptor binding, and S2, which initiates fusion (
      <xref ref-type="bibr" rid="bib4">
       Belouzard et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       Dai et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib18">
       Kielian and Rey, 2006
      </xref>
      ). S1 contains two relatively independent structures named the N-terminal domain (NTD) and C-terminal domain (CTD) based on their position. Most betaCoVs use the CTD as the receptor-binding domain (RBD/CTD) except mouse hepatitis virus (MHV), which uses the NTD to bind the cellular receptor carcinoembryonic-antigen-related cell-adhesion molecule 1 (CEACAM1) (
      <xref ref-type="bibr" rid="bib8">
       Dai et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       Du et al., 2009
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       Li et al., 2005a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       Lu et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       Peng et al., 2011
      </xref>
      ). Two of the RBD/CTDs in lineage C betaCoVs (MERS-RBD/CTD and HKU4-RBD/CTD) bind to the same human receptor CD26 (hCD26) to initiate infection, and the two domains share high sequences identities (55%) in addition to high structural similarities, with a root mean square deviation (rmsd) of 1.114 (193 Cα) (
      <xref ref-type="bibr" rid="bib24">
       Lu et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Wang et al., 2014
      </xref>
      ). Despite the similar sequence identities between HKU5-CTD and MERS-RBD/CTD (54%) or HKU4-RBD/CTD (57%), no detectable binding was found between HKU5-CTD and hCD26. The structural basis for this variation remains to be elucidated.
     </p>
     <p id="p0035">
      In this study, we determined the structure of HKU5-CTD. Similar to other solved structures, HKU5-CTD contains two subdomains: the core subdomain homologous to other CTDs in betaCoVs and the external subdomain, which resembles MERS-RBD/CTD and HKU4-RBD/CTD, indicating conservation of the external domain in lineage C. However, two deletions in HKU5-CTD lead to structural shifts in the hCD26-interaction interface and thereby result in its inability to bind this receptor. Our results suggest that the characteristic insertions in βc4 and βc5 among different lineages in betaCoVs result in different receptor engagement, thereby contributing for potential interspecies transmission.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Results
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       Overall structure of the HKU5-CTD
      </title>
      <p id="p0040">
       We first characterized the S protein of BatCoV HKU5 through bioinformatics analysis. BatCoV HKU5 S is composed of 1352 amino acids and exhibits typical features of CoVs S protein, including the predicted hydrophobic residue-rich HR1 and HR2 motifs and a similar concentration of hydrophobic amino acids to SARS-CoV fusion peptide (FP), internal fusion peptide (IFP), and pre transmembrane domain (PTM) (
       <xref ref-type="bibr" rid="bib11">
        Gao et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        Mahajan and Bhattacharjya, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib45">
        Xu et al., 2004
       </xref>
       ,
       <xref ref-type="bibr" rid="bib49">
        Zhu et al., 2004
       </xref>
       ). Like MERS-CoV S protein, a furin-like protease recognition motif is predicted at position R745/A746 (S1/S2), which separates the S1 and S2 subunits (
       <xref ref-type="bibr" rid="bib29">
        Millet and Whittaker, 2014
       </xref>
       ). In addition, a second furin cleavage site can be found at R884/S885, which resembles S2′ in the MERS-CoV S protein (
       <xref ref-type="bibr" rid="bib29">
        Millet and Whittaker, 2014
       </xref>
       ), indicating that the priming process of BatCoV HKU5 S in human cells probably occur in the same way like MERS-CoV (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       A). Because most betaCoVs use their CTD to bind their respective receptors, we next focused on the evolutionary relationships of the CTDs. Consistent with the phylogenetic relationships, HKU5-CTD, HKU4-RBD/CTD, and MERS-RBD/CTD are grouped in one branch representing lineage C, while HKU1-CTD and MHV-CTD cluster together in lineage A. HKU9-CTD, a member in lineage D, is phylogenetically more related to SARS-RBD/CTD, which belongs to lineage B (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       B).
       <fig id="f0005">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          <bold>
           Sequence features of HKU5-CTD.
          </bold>
          (A) Schematic representation of BatCoV HKU5 S. The indicated domain elements were defined through pairwise sequence alignments or bioinformatics analyses. The signal peptides (SP), transmembrane domain (TM), and heptad repeats 1 and 2 (HR1 and HR2, respectively) were predicted with the SignalP 4.0 server, TMHMM server, and Learncoil-VMF program, respectively, while the NTD, RBD, and fusion peptides (FP, IFP, and PTM) were deduced by alignment with the N-terminal galectin-like domain of murine hepatitis virus S, MERS-RBD/CTD, and SARS-CoV S, respectively. The S1/S2 and S2′ sites potentially cleaved by furin-like proteases were predicted using the ProP 1.0 server. (B) Phylogenetic tree generated using MEGA with the indicated RBD/CTD sequences. (C) Structure-based sequence alignment. The secondary structure elements are defined based on an ESPript algorithm and are labeled as in
          <xref ref-type="fig" rid="f0010">
           Fig. 2
          </xref>
          . The arrows and spiral line indicate strands and helices, respectively. The conserved cysteine residues that form four disulfide bonds in the structures are marked with Arabic numerals 1–4. The beta strands in the core-center, the elements in the core-peripheral, and the structures in the external domains are marked with c, p, and the character with prime, respectively. The blue triangle and green star represent the key amino acids for binding hCD26 in MERS-RBD/CTD and HKU4-RBD/CTD, respectively, while the yellow rhombus indicates two glycosylation sites in HKU5-CTD.
         </p>
        </caption>
        <alt-text id="at0005">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0045">
       The HKU5-CTD was then purified, crystallized and the structure was successfully determined at a resolution of 2.1 Å, with clear electron densities tracing from Q389 to Q586. The structure, solved through the molecular replacement method, contains a single molecule in the crystallographic asymmetric unit, with an
       <italic>
        R
       </italic>
       <sub>
        work
       </sub>
       of 0.2160 and an
       <italic>
        R
       </italic>
       <sub>
        free
       </sub>
       of 0.2585 (
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       ). Like the other solved CTD structures of betaCoVs (
       <xref ref-type="bibr" rid="bib15">
        Huang et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        Kirchdoerfer et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        Li et al., 2005a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        Lu et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib37">
        Walls et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        Wang et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        Wang et al., 2014
       </xref>
       ), HKU5-CTD folds into two discrete subdomains, the core and the external (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ). The core subdomain contains a five-stranded antiparallel scaffold center (core-center), which is decorated by five helices (α or 3
       <sub>
        10
       </sub>
       ) and two small strands (βp1 and βp2) on the exterior. Three pairs of disulfide bonds help to stabilize the scaffold, namely C391-C415 and C445-C583, located in the peripheral region of the core subdomain (core-peripheral), and C433-C486 in the core-center, linking βc2 and βc4. Notably, two antiparallel β strands, one of which is located in the C-terminus and the other forming the disulfide bond with the N-terminus, help to make keep two termini in proximity. In addition, traceable electron densities can be observed for two glycosylated modifications at N418 and N495, which form two protrusions at the core-peripheral region (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ).
       <table-wrap id="t0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Data collection and refinement statistics.
         </p>
        </caption>
        <alt-text id="at0035">
         Table 1.
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
           </th>
           <th>
            HKU5 CTD
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            <bold>
             Data collection
            </bold>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Wavelength (Å)
           </td>
           <td>
            0.97915
           </td>
          </tr>
          <tr>
           <td>
            Space group
           </td>
           <td>
            P 21
           </td>
          </tr>
          <tr>
           <td>
            Cell dimensions
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             a
            </italic>
            ,
            <italic>
             b
            </italic>
            ,
            <italic>
             c
            </italic>
            (Å)
           </td>
           <td>
            49.612, 212.659, 87.943
           </td>
          </tr>
          <tr>
           <td>
            α, β, γ (deg)
           </td>
           <td>
            90.000, 94.756, 90.000
           </td>
          </tr>
          <tr>
           <td>
            Resolution (Å)
           </td>
           <td>
            50.00–2.10 (2.18–2.10)
            <xref ref-type="table-fn" rid="tbl1fna">
             a
            </xref>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             R
            </italic>
            <sub>
             merge
            </sub>
           </td>
           <td>
            0.104 (1.038)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             R
            </italic>
            <sub>
             p.i.m.
            </sub>
           </td>
           <td>
            0.052 (0.527)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             I
            </italic>
            / σ
            <italic>
             I
            </italic>
           </td>
           <td>
            15.355 (1.645)
           </td>
          </tr>
          <tr>
           <td>
            CC
            <sub>
             1/2
            </sub>
           </td>
           <td>
            0.998 (0.801)
           </td>
          </tr>
          <tr>
           <td>
            Completeness (%)
           </td>
           <td>
            99.9 (99.9)
           </td>
          </tr>
          <tr>
           <td>
            Redundancy
           </td>
           <td>
            5.0 (4.8)
           </td>
          </tr>
          <tr>
           <td colspan="2">
           </td>
          </tr>
          <tr>
           <td>
            <bold>
             Refinement
            </bold>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Resolution (Å)
           </td>
           <td>
            37.80–2.10
           </td>
          </tr>
          <tr>
           <td>
            No. reflections
           </td>
           <td>
            104555
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             R
            </italic>
            <sub>
             work
            </sub>
            /
            <italic>
             R
            </italic>
            <sub>
             free
            </sub>
           </td>
           <td>
            0.2160/0.2585
           </td>
          </tr>
          <tr>
           <td>
            No. atoms
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Protein
           </td>
           <td>
            11032
           </td>
          </tr>
          <tr>
           <td>
            Ligand/ion
           </td>
           <td>
            0
           </td>
          </tr>
          <tr>
           <td>
            Water
           </td>
           <td>
            527
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             B
            </italic>
            -factors
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Protein
           </td>
           <td>
            52.9
           </td>
          </tr>
          <tr>
           <td>
            Ligand/ion
           </td>
           <td>
            –
           </td>
          </tr>
          <tr>
           <td>
            Water
           </td>
           <td>
            45.2
           </td>
          </tr>
          <tr>
           <td>
            R.m.s. deviations
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Bond lengths (Å)
           </td>
           <td>
            0.006
           </td>
          </tr>
          <tr>
           <td>
            Bond angles (deg)
           </td>
           <td>
            1.062
           </td>
          </tr>
          <tr>
           <td>
            Ramachandran plot
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            Favored (%)
           </td>
           <td>
            95.73
           </td>
          </tr>
          <tr>
           <td>
            Allowed (%)
           </td>
           <td>
            3.44
           </td>
          </tr>
          <tr>
           <td>
            Outliers (%)
           </td>
           <td>
            0.83
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tbl1fna">
          <label>
           a
          </label>
          <p id="ntp0005">
           Values in parentheses are for highest-resolution shell.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
       <fig id="f0010">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          <bold>
           Crystal structure of the HKU5-CTD.
          </bold>
          The core and external subdomains are colored orange and magenta, respectively. The core subdomain is further divided into a center region (core-center) and a peripheral region (core-peripheral). The core-center strands and helices are labeled βc1-βc5 and H1-H5, respectively, while the core-peripheral strands are marked βp1 and βp2. The glycan-moieties are displayed in sticks and marked in the left panel. The disulfide bonds are presented in spheres and labeled in the right panel. Both N- and C-terminus are indicated with the arrows. To depict the structure clearly, cartoon structures inside the transparent surface are presented at two angles.
         </p>
        </caption>
        <alt-text id="at0010">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0050">
       The external subdomain of HKU5-CTD extends out of βc4 in the core-center, sequentially folds into two antiparallel β strands (β1′ and β2′), an α helix (H1′), and another two antiparallel β strands (β3′ and β4′), and finally proceed into βc5. Between β1′ and H1′, a pair of disulfide bonds (C511-C532) is formed to stabilize the external structure (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ).
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       Conserved core subdomain and variable external subdomain for betaCoVs S protein
      </title>
      <p id="p0055">
       To date, seven structures of CTDs covering all four lineages of betaCoVs have been solved. They are HKU1-CTD and MHV-CTD, belonging to lineage A (
       <xref ref-type="bibr" rid="bib19">
        Kirchdoerfer et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib37">
        Walls et al., 2016
       </xref>
       ), MERS-RBD/CTD (
       <xref ref-type="bibr" rid="bib24">
        Lu et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        Wang et al., 2013
       </xref>
       ), HKU4-RBD/CTD (
       <xref ref-type="bibr" rid="bib39">
        Wang et al., 2014
       </xref>
       ), and HKU5-CTD grouped in lineage C (reported here), and SARS-RBD/CTD (
       <xref ref-type="bibr" rid="bib22">
        F. Li et al., 2005
       </xref>
       ) and HKU9-CTD (
       <xref ref-type="bibr" rid="bib15">
        Huang et al., 2016
       </xref>
       ) representing lineages B and D, respectively. All seven betaCoV CTD structures display a conserved core subdomain, with five antiparallel beta strands and a conserved disulfide bond between βc2 and βc4 (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ).
       <fig id="f0015">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          <bold>
           Topological diagrams of CTDs in betaCoVs.
          </bold>
          Structural and topological comparison of available betaCoV CTD structures. Seven structures, including those of MHV-CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0005" xlink:href="pdb:3CJL">
           3CJL
          </ext-link>
          ), HKU1-CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0010" xlink:href="pdb:5I08">
           5I08
          </ext-link>
          ), SARS-RBD/CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0015" xlink:href="pdb:2GHV">
           2GHV
          </ext-link>
          ), HKU5-CTD, HKU4-RBD/CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0020" xlink:href="pdb:4QZV">
           4QZV
          </ext-link>
          ), MERS-RBD/CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0025" xlink:href="pdb:4KQZ">
           4KQZ
          </ext-link>
          ), and HKU9-CTD (PDB code:
          <ext-link ext-link-type="uri" id="ir0030" xlink:href="pdb:5GYQ">
           5GYQ
          </ext-link>
          ) were oriented similarly and are presented as cartoons in parallel. The conserved disulfide bonds are labeled in red lines, while the non-conserved ones are displayed with lines in accordance with the color of indicated external subdomain. Arrows and cylinders represent the strands and helices, respectively.
         </p>
        </caption>
        <alt-text id="at0015">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0060">
       Despite the different combinations of α helices and β strands, the orientations of the secondary structures are conserved among CTDs in the core-peripheral region. In addition, two highly conserved disulfide bonds exist. One is formed between the N-terminus and the loop/β strand extended from βc1, and the other links the C-terminus and the loop/β strand proceeding to βc3. Thus, through the two disulfide bonds, both termini are brought into close proximity (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ). Although in the SARS-RBD/CTD electron density at the C-terminus is not clear enough to determine the structures (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       C), two conserved cysteines are present, indicating the probability of disulfide bond formation (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       C).
      </p>
      <p id="p0065">
       Opposite to the conserved core subdomain, the external subdomain varies considerably among different lineages. In lineage A, the external subdomain of MHV-CTD, which was obtained by density-guided homology modelling due to its large flexibility and poor quality of the density in this region, consists of four β strands and three small helices (PDB code:
       <ext-link ext-link-type="uri" id="ir0035" xlink:href="pdb:3CJL">
        3CJL
       </ext-link>
       ) (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       A). HKU1-CTD is comprised of a large, variable loop with three inlaid β strands (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       B). The absence of clear secondary structure from residues C476-F572 indicates the flexibility of this region (PDB code:
       <ext-link ext-link-type="uri" id="ir0040" xlink:href="pdb:5I08">
        5I08
       </ext-link>
       ). In lineage C, three CTDs show similar external folds, with rmsd ranging from 0.962 (HKU5-CTD
       <italic>
        vs.
       </italic>
       MERS-RBD/CTD (PDB code:
       <ext-link ext-link-type="uri" id="ir0045" xlink:href="pdb:4KQZ">
        4KQZ
       </ext-link>
       )) to 1.178 (HKU5-CTD
       <italic>
        vs.
       </italic>
       HKU4-RBD/CTD (PDB code:
       <ext-link ext-link-type="uri" id="ir0050" xlink:href="pdb:4QZV">
        4QZV
       </ext-link>
       )). All external subdomains are strand-dominated structures with four anti-parallel β strands and expose a flat strand-face that is stabilized by a conserved disulfide bond (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       D-F). In lineage B, the SARS-RBD/CTD is dominated by a disulfide bond-stabilized flexible loop that connects two small β strands (PDB code:
       <ext-link ext-link-type="uri" id="ir0055" xlink:href="pdb:2GHV">
        2GHV
       </ext-link>
       ) (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       C). In BatCoV HKU9, representing lineage D, the external subdomain only contains one large helix in this region (PDB code:
       <ext-link ext-link-type="uri" id="ir0060" xlink:href="pdb:5GYQ">
        5GYQ
       </ext-link>
       ) (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       G).
      </p>
      <p id="p0070">
       Although their external subdomain structures differ, all CTDs in betaCoVs extend out from βc4 and proceed back to the core subdomain through βc5 (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ), indicating that during evolution, different insertions in this region resulted in the different structures of the CTDs. This, then, led to different receptor usage if the CTD is utilized as the RBD.
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       Structural basis for HKU5-CTD not binding to CD26
      </title>
      <p id="p0075">
       Both MERS-RBD/CTD and HKU4-RBD/CTD bind to hCD26 to initiate infection. In addition, the structure of the HKU5-CTD displays a similar topology to the two RBD/CTDs in lineage C. Thus, we assayed for binding between HKU5-CTD and hCD26. However, consistent with previous results, no binding was detected, either by fluorescence-activated cell sorting (FACS) or surface plasmon resonance (SPR) (
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ).
       <fig id="f0020">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          <bold>
           Characterization of HKU5-CTD by FACS and SPR.
          </bold>
          (A) Huh7 cells were stained with MERS-RBD/CTD (green), HKU4-RBD/CTD (orange), and HKU5-CTD (red), respectively. (B-D) BHK21 cells transfected with hCD26 (BHK-hCD26) were stained with MERS-RBD/CTD (B), HKU4-RBD/CTD (C), and HKU5-CTD (D), respectively. (E-F) The indicated protein was immobilized on a CM5 chip, and a gradient concentration of hCD26 was flowed through the chip. The RUs were recorded. (E) hCD26 binding to HKU5-CTD. (F) hCD26 binding to MERS-RBD/CTD. (G) hCD26 binding to HKU4-RBD/CTD. (H) The saturation profile for HKU4-RBD/CTD binding to hCD26.
         </p>
        </caption>
        <alt-text id="at0020">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0080">
       According to the two solved complex structures, four concentrations of residues in MERS-RBD/CTD and HKU4-RBD/CTD are involved in binding to hCD26. These residues located in four beta strands and two loops (β1′/β2′ loop and β3′/β4′ loop) in the external subdomain as well as H4 and H5 (for MERS-RBD/CTD) or H5 and H6 (for HKU4-RBD/CTD) positioned in the core subdomain and the loop connecting the two helices (
       <xref ref-type="fig" rid="f0005">
        Figs. 1
       </xref>
       C,
       <xref ref-type="fig" rid="f0015">
        3
       </xref>
       E and
       <xref ref-type="fig" rid="f0015">
        3
       </xref>
       F). However, half of these regions (β1′/β2′ loop and β3′) have deletions in HKU5-CTD (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       C). Due to these deletions, the orientations of two loops (marked 1 and 2, respectively, in
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       D-F) in HKU5-CTD vary compared to MERS-RBD/CTD and HKU4-RBD/CTD, which leads to conformational shifts in HKU5-CTD at the hCD26-binding interface (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       A and E). The β1′/β2′ loop in both MERS-RBD/CTD and HKU4-RBD/CTD inserts into the groove formed by two helices on the side and β strands on the bottom (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       B and F). Sixty-five (328 in total) and 49 (214 in total) van der Waals contacts, including 5 (16 in total) and 4 (13 in total) hydrogen bonds, are formed in MERS-RBD/CTD/hCD26 and HKU4-RBD/CTD/hCD26, respectively. In contrast, this loop in HKU5-CTD is tilted away by ~6 and 9 Å (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       B and F) compared to MERS-RBD/CTD and HKU4-RBD/CTD, respectively, which results in the loss of binding to hCD26 at this region.
       <fig id="f0025">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          <bold>
           Structural basis for the lack of binding between HKU5-CTD and hCD26
          </bold>
          . Superimposition of the structures of HKU5-CTD and hCD26 binding-MERS-RBD/CTD (A-D) or HKU4-RBD/CTD (E-H). The variations in the receptor binding interface of HKU5-CTD compared with MERS-RBD/CTD or HKU4-RBD/CTD are allocated with B-D and F-H and further delineated in B-D and F-H for detailed structural shifts, respectively. The conserved core subdomains in HKU5-CTD, MERS-RBD/CTD, and HKU4-RBD/CTD are colored in grey, while the external subdomains of the three proteins are marked with orange, cyan, and wheat, respectively. The magenta represents hCD26.
         </p>
        </caption>
        <alt-text id="at0025">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0085">
       Moreover, a six-residue deletion in β3′ causes large discrepancies in the assemblies of β3′, β4′ and their connecting loop, compared with MERS-RBD/CTD and HKU4-RBD/CTD (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       D-F). In β3′ of both hCD26-binding RBD/CTDs, the side chains of Y540 and R542 face the receptor, conferring a strong hydrophilic interaction between the ligand and the receptor. In contrast, in HKU5-CTD, the orientation of β3′ is opposite. In addition, Y544 in HKU5-CTD likely sterically clashes Q286, which further pushes HKU5 away from hCD26 (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       C and G). In the other beta strand of β4′, both MERS-RBD/CTD and HKU4-RBD/CTD form a large hydrophobic interaction patch with hCD26. In HKU5-CTD, aside from the shift of the β3′/β4′ loop away from the receptor, the deletion of hydrophobic residues (
       <italic>
        e.g.
       </italic>
       , W535) compared to MERS-RBD/CTD (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       D) and the substitution of hydrophilic residues (
       <italic>
        e.g.
       </italic>
       , T553 and T555) instead of hydrophobic ones (I560 and V562 in HKU4-RBD/CTD) (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       H) likely inhibit HKU5-CTD binding to hCD26. In total, the conformational variations between HKU5-CTD and hCD26-binding RBD/CTDs explain the lack of hCD26 binding by HKU5-CTD. However, various deletions in HKU5-CTD loop 1 are present in nature (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       ), and might contribute to evolve for receptor binding.
       <fig id="f0030">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          <bold>
           CTDs of HKU5 show diversities.
          </bold>
          All referred sequences in HKU5 CTD regions were analyzed by alignment. The two black boxes indicate the sequences of loops 1 and 2 marked in
          <xref ref-type="fig" rid="f0015">
           Fig. 3
          </xref>
          C.
         </p>
        </caption>
        <alt-text id="at0030">
         Fig. 6
        </alt-text>
        <graphic xlink:href="gr6_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="s0030">
     <label>
      3
     </label>
     <title>
      Discussion
     </title>
     <p id="p0090">
      In this study, we solved the crystal structure of HKU5-CTD, which represents the seventh structure of a CTD belonging to a betaCoV. Like the other six CTDs (
      <xref ref-type="bibr" rid="bib15">
       Huang et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib19">
       Kirchdoerfer et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       Li et al., 2005a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       Lu et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib33">
       Peng et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       Walls et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       Wang et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Wang et al., 2014
      </xref>
      ), there are two subdomains in HKU5-CTD, the core and the external. Despite the low residue conservation among CTDs (pair-to-pair amino acid identity ranging from 17.2% to 58.7%) and the core subdomains (pair-to-pair amino acid identity ranging from 16.6% to 66.7%) in the four lineages, the topology of the latter ones are highly conserved, with five anti-parallel β strands constituting the core-center and the same orientation of secondary elements in the core-peripheral (
      <xref ref-type="fig" rid="f0015">
       Fig. 3
      </xref>
      ). This includes the same region of MHV, which uses the NTD of S1 to bind the receptor.
     </p>
     <p id="p0095">
      However, the external subdomains vary considerably among lineages. In lineage A, the MHV-CTD contains several β strands and inlaid helices, while the HKU1-CTD is comprised of loops and three small β strands. However, approximately 100 amino acids (C476-F572) are unclear at this region, likely due to their flexibility. SARS-RBD/CTD, in lineage B is dominated by loops, which are stabilized by a disulfide bond and two anti-parallel β strands. Most CTD structures solved to date are in lineage C, and all three CTDs (MERS-RBD/CTD, HKU4-RBD/CTD, and HKU5-CTD) display conserved structures with β strand-forming platforms decorated with helices. In addition, a disulfide bond is conserved among CTDs in lineage C in the external subdomain. HKU9-CTD, a member of lineage D, is comprised of a helix that is clamped with loops. Although different structures and topologies exist among lineages, all external subdomains extend out from βc4 and proceed back to βc5 (
      <xref ref-type="fig" rid="f0015">
       Fig. 3
      </xref>
      ), indicating that different insertions between βc4/βc5 during betaCoV evolution have conferred the betaCoVs with different properties, such as receptor usage, and thereby led to the parallel evolution of lineages.
     </p>
     <p id="p0100">
      The ligand–receptor interaction is a key factor determining the tissue tropism and host range of CoVs. For SARS-CoV, MERS-CoV, and BatCoV HKU4, the receptors are clear, and the complex structures demonstrate that the receptor mainly binds to the varied external subdomains of CTDs. Neutralizing antibodies against HCoV HKU1 bind to the HKU1-CTD, not the HKU1-NTD (
      <xref ref-type="bibr" rid="bib34">
       Qian et al., 2015
      </xref>
      ), indicating that the CTD in HCoV HKU1 is most likely to be the RBD, though the protein receptor has yet to be identified (
      <xref ref-type="bibr" rid="bib5">
       Chan et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       Huang et al., 2015
      </xref>
      ). HKU9-CTD does not bind to ACE2 or hCD26 (
      <xref ref-type="bibr" rid="bib15">
       Huang et al., 2016
      </xref>
      ). In our study, we found that although HKU5-CTD displays a similar structure and topology to MERS-RBD/CTD and HKU4-RBD/CTD, detailed structural analysis revealed variations at the hCD26-binding interface, which results in the loss of binding to this receptor. Thus, subtle distinctions in external subdomains could determine different receptor usage.
     </p>
     <p id="p0105">
      In addition to receptor binding, the priming process, which involves host proteases to liberate S2 and the fusion peptides from the otherwise covalently-linked S1 subunit, is another key factor affecting cell tropism and the entry route of CoVs. A two-step activation mechanism has been proposed for MERS-CoV entry (
      <xref ref-type="bibr" rid="bib29">
       Millet and Whittaker, 2014
      </xref>
      ). During the secretion of S protein, the proteolysis at S1/S2 occurs in the endoplasmic reticulum (ER)-Golgi compartments where furin is localized, while during virus entry into target cells, S2′ is cleaved. The same proteolysis in S1/S2 and S2′ is also essential for SARS-CoV infection, except that due to the lack of a furin-recognition site at S1/S2, SARS-CoV S remains uncleaved after biosynthesis and a diverse array of proteases are involved in this process (
      <xref ref-type="bibr" rid="bib30">
       Millet and Whittaker, 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib36">
       Simmons et al., 2011
      </xref>
      ). In contrast, although BatCoV HKU4 can utilize hCD26 as a receptor, the proteolysis is stuck due to the lack of a protease site. Treatment of pseudovirus particles containing BatCoV HKU4 S protein with trypsin or importing the furin-recognition site into S protein enables the particles to infect hCD26-expressing cells (
      <xref ref-type="bibr" rid="bib39">
       Wang et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       Yang et al., 2015
      </xref>
      ), indicating the BatCoV HKU4 is less adapted to human cells. However, in the BatCoV HKU5 S protein, both furin-recognition sites are present, as in MERS-CoV. Accordingly, BatCoV HKU5 S is predicted to be cleaved at S1/S2 after biosynthesis and at S2′ during virus entry. Furin is a ubiquitous proteinase and expressed in nearly all cells lines. The presence of the two furin-recognition sites indicates that the priming process of BatCoV HKU5 is ready to occur.
     </p>
     <p id="p0110">
      BatCoV HKU5 has been circulating in bats (
      <xref ref-type="bibr" rid="bib21">
       Lau et al., 2013
      </xref>
      ). In an epidemiology study over a 7-year period (April 2005 to August 2012), 25% of alimentary specimens of Japanese pipistrelle bats (
      <italic>
       Pipistrellus abramus
      </italic>
      ) collected from 13 locations in Hong Kong were positive for this virus (
      <xref ref-type="bibr" rid="bib21">
       Lau et al., 2013
      </xref>
      ), indicating that it might target gastro-intestinal tissues. However, BatCoV HKU5 virus has not been isolated and cultured successfully, which is an obstacle to virus transmission research. The problem is largely due to a lack of suitable cell lines for BatCoV HKU5 virus. The emerging but puzzling question is whether this virus could infect humans or not.
     </p>
     <p id="p0115">
      An infectious clone of BatCoV HKU5 containing the ectodomain from the SARS-CoV S protein was constructed through reverse genetics and synthetic-genome design, and the recombinant virus replicates efficiently in cell culture and in young and aged mice (
      <xref ref-type="bibr" rid="bib2">
       Agnihothram et al., 2014
      </xref>
      ). In addition, the key proteins for virus replication, such as the 3C-like protease, polymerase, and exonuclease of BatCoV HKU5 display high amino acid sequence similarity to those in MERS-CoV, indicating that once the genome of BatCoV HKU5 is released into host cells, genome replication, virus particle assembly, and release can readily occur. Therefore, the receptor would be the last barrier for BatCoV HKU5 to infect humans. Our data show that BatCoV HKU5-CTD does not use hCD26 as a receptor, though it folds into a very similar structure as MERS-RBD/CTD and HKU4-RBD/CTD. In other words, the cellular receptor of BatCoV HKU5 is still a mystery that requires further study.
     </p>
     <p id="p0120">
      Evolutionally, BatCoV HKU5 S protein is more diverse than BatCoV HKU4 S protein (
      <xref ref-type="bibr" rid="bib21">
       Lau et al., 2013
      </xref>
      ), and various deletions in loop 1 (
      <xref ref-type="fig" rid="f0015">
       Fig. 3
      </xref>
      D and
      <xref ref-type="fig" rid="f0030">
       Fig. 6
      </xref>
      ) have been sequenced. This indicates that BatCoV HKU5 is able to generate variants to occupy new ecological niches and might acquire the ability to bind to hCD26 by accumulating mutations and ultimately cause human respiratory infections like MERS-CoV and SARS-CoV. Accordingly, it is very important to perform long-lasting surveillance of BatCoV HKU5 evolution, especially the variety of S protein in the event that the virus breaks the inter-species and/or inter-tissue transmission barriers.
     </p>
    </sec>
    <sec id="s0035">
     <label>
      4
     </label>
     <title>
      Materials and methods
     </title>
     <sec id="s0040">
      <label>
       4.1
      </label>
      <title>
       Gene construction, protein expression, and purification
      </title>
      <p id="p0125">
       The coding region for HKU5-CTD (Q389-Q586) with a 6×His-tag at its C-terminus was cloned into the
       <italic>
        Eco
       </italic>
       RI and
       <italic>
        Xho
       </italic>
       I sites of pFastBac. HKU5-CTD, MERS-RBD/CTD, HKU4-RBD/CTD, and hCD26 were expressed and purified as previously reported (
       <xref ref-type="bibr" rid="bib24">
        Lu et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        Wang et al., 2014
       </xref>
       ). Briefly, the proteins were expressed in baculovirus-infected Hi5 cells. After 48 h of culturing, the supernatants were collected and purified through a 5 mL HisTrap HP column (GE Healthcare). The bound protein was eluted by a gradient of imidazole. Fractions containing the target protein as determined by SDS-PAGE were pooled and further subjected to gel filtration using a Superdex
       <sup>
        ®
       </sup>
       75 column (GE Healthcare) in a buffer composed of 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl.
      </p>
      <p id="p0130">
       The Fc fusion protein used for cell staining was purified following a previously published method (
       <xref ref-type="bibr" rid="bib24">
        Lu et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib39">
        Wang et al., 2014
       </xref>
       ). In brief, the plasmid containing the target gene was transfected into HEK293T cells. After 3 and 7 d of culturing, the supernatants containing secreted protein were pooled and subjected to HiTrap ProteinA chromatography (5 mL, GE Healthcare). Protein was eluted with 0.1 M sodium citrate (pH 4.5) and further purified by gel filtration. The protein was finally buffer-exchanged into PBS, concentrated to ~1 mg/mL, and stored at −80 °C before further usage.
      </p>
     </sec>
     <sec id="s0045">
      <label>
       4.2
      </label>
      <title>
       Crystallization, data collection, and structure determination
      </title>
      <p id="p0135">
       The HKU5-CTD protein expressed in Hi5 cells was crystallized by sitting drop vapor diffusion at 18 °C. Diffractable crystals were obtained in a condition consisting of 0.2 M potassium thiocyanate and 20% (w/v) polyethylene glycol 3350 with a protein concentration of 15 mg/mL. Crystals were cryoprotected in reservoir solution containing 20% (v/v) glycerol and flash-frozen in liquid nitrogen. Diffraction data were collected at Shanghai Synchrotron Radiation Facility (SSRF) BL17U and processed with HKL2000 (
       <xref ref-type="bibr" rid="bib32">
        Otwinowski and Minor, 1997
       </xref>
       ).
      </p>
      <p id="p0140">
       The HKU5-CTD structure was solved by the molecular replacement method using Phaser (
       <xref ref-type="bibr" rid="bib27">
        McCoy et al., 2007
       </xref>
       ) from the CCP4 program suite (
       <xref ref-type="bibr" rid="bib42">
        Winn et al., 2011
       </xref>
       ) with the structure of HKU4-RBD/CTD (PDB:
       <ext-link ext-link-type="uri" id="ir0065" xlink:href="pdb:5GJ4">
        5GJ4
       </ext-link>
       ) as the search model. Initial restrained rigid-body refinement and manual model building were performed using REFMAC5 (
       <xref ref-type="bibr" rid="bib31">
        Murshudov et al., 2011
       </xref>
       ) and COOT (
       <xref ref-type="bibr" rid="bib9">
        Debreczeni and Emsley, 2012
       </xref>
       ), respectively. Further refinement was performed using Phenix (
       <xref ref-type="bibr" rid="bib1">
        Adams et al., 2010
       </xref>
       ). Final statistics for data collection and structure refinement are represented in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       . Atomic coordinates and structure factors have been deposited in the Protein Data Bank with accession code 5XGR.
      </p>
     </sec>
     <sec id="s0050">
      <label>
       4.3
      </label>
      <title>
       SPR analysis
      </title>
      <p id="p0145">
       The BIAcore experiments were performed at 25 °C using a BIAcore 3000 machine with CM5 chips (GE Healthcare). All proteins used in the experiment were expressed in insect cells. After purification, the protein was exchanged into PBS (pH7.4) containing 0.005% (v/v) Tween 20. The MERS-RBD/CTD, HKU4-RBD/CTD, and HKU5-CTD proteins were immobilized on the chip at ~1000 response units (RUs), respectively. Gradient concentrations of hCD26 (ranging from 0.195 to 200 μM) were then injected at 30 μL/min. After each cycle, the sensor surface was re-generated using 7 μL of 10 mM NaOH. Measurements from the reference flow cell (immobilized with BSA) were subtracted from experimental values. The binding kinetics were analyzed with BIAevaluation Version 4.1 software using the 1:1 Langumuir binding and/or the steady state affinity models.
      </p>
     </sec>
     <sec id="s0055">
      <label>
       4.4
      </label>
      <title>
       Flow cytometry assay
      </title>
      <p id="p0150">
       Human hepatocellular carcinoma Huh7 or BHK-21 cells transfected with hCD26 (BHK-hCD26) were used for the binding test. Cells were stained with mouse Fc-fusion proteins, including MERS-RBD/CTD, HKU4-RBD/CTD, and HKU5-CTD, expressed using HEK 293T cells. BHK-21 cells were transfected with hCD26-containing plasmids 24 h before staining. Huh7 and BHK-hCD26 were suspended in PBS and incubated with individual proteins at 4 °C for 30 min, then washed and further incubated at 4 °C for another 30 min with an anti-mIgG/PE antibody. After washing, the cells were analyzed using a BD FACSCalibur. The data were processed with FlowJo software.
      </p>
     </sec>
    </sec>
    <back>
     <ref-list id="bibliog0005">
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation id="sbref1" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Afonine
          </surname>
          <given-names>
           P.V.
          </given-names>
         </name>
         <name>
          <surname>
           Bunkoczi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           I.W.
          </given-names>
         </name>
         <name>
          <surname>
           Echols
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Headd
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kapral
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Grosse-Kunstleve
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           McCoy
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Moriarty
          </surname>
          <given-names>
           N.W.
          </given-names>
         </name>
         <name>
          <surname>
           Oeffner
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Terwilliger
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zwart
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         PHENIX: a comprehensive Python-based system for macromolecular structure solution
        </chapter-title>
        <series>
         Acta Crystallogr. Sect. D, Biol. Crystallogr.
        </series>
        <volume>
         66
        </volume>
        <year>
         2010
        </year>
        <fpage>
         213
        </fpage>
        <lpage>
         221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation id="sbref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Huynh
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tomar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
         <name>
          <surname>
           Osswald
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Whitmore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gopal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ghosh
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Barica
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mouse model for betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant
        </article-title>
        <source>
         mBio
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e00047-14
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation id="sbref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Annan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baldwin
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Klose
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Owusu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nkrumah
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           Badu
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Anti
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Agbenyega
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkodie
          </surname>
          <given-names>
           Y.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kalko
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lina
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Godlevska
          </surname>
          <given-names>
           E.V.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Seebens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gloza-Rausch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vallo
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tschapka
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         456
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         23622767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation id="sbref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Licitra
          </surname>
          <given-names>
           B.N.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of coronavirus cell entry mediated by the viral spike protein
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         4
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1011
        </fpage>
        <lpage>
         1033
        </lpage>
        <pub-id pub-id-type="pmid">
         22816037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation id="sbref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carcinoembryonic antigen-related cell adhesion molecule 5 is an important surface attachment factor that facilitates entry of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         90
        </volume>
        <year>
         2016
        </year>
        <fpage>
         9114
        </fpage>
        <lpage>
         9127
        </lpage>
        <pub-id pub-id-type="pmid">
         27489282
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation id="sbref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         28
        </volume>
        <year>
         2015
        </year>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation id="sbref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Palser
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Petrova
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Pybus
          </surname>
          <given-names>
           O.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rambaut
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pillay
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Nastouli
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         736
        </fpage>
        <lpage>
         742B
        </lpage>
        <pub-id pub-id-type="pmid">
         23693015
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation id="sbref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dai
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of antibody-mediated neutralization and protection against flavivirus
        </article-title>
        <source>
         IUBMB Life
        </source>
        <volume>
         68
        </volume>
        <year>
         2016
        </year>
        <fpage>
         783
        </fpage>
        <lpage>
         791
        </lpage>
        <pub-id pub-id-type="pmid">
         27604155
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation id="sbref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Debreczeni
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Emsley
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Handling ligands with Coot
        </article-title>
        <source>
         Acta Crystallogr. Sect. D., Biol. Crystallogr.
        </source>
        <volume>
         68
        </volume>
        <year>
         2012
        </year>
        <fpage>
         425
        </fpage>
        <lpage>
         430
        </lpage>
        <pub-id pub-id-type="pmid">
         22505262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV - a target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation id="sbref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         13134
        </fpage>
        <lpage>
         13140
        </lpage>
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation id="sbref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.-L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         503
        </volume>
        <year>
         2013
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation id="sbref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         7790
        </fpage>
        <lpage>
         7792
        </lpage>
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation id="sbref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heikkinen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jarvinen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The common cold
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         51
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="pmid">
         12517470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation id="sbref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Putative receptor binding domain of bat-derived coronavirus HKU9 spike protein: evolution of betacoronavirus receptor binding motifs
        </article-title>
        <source>
         Biochemistry
        </source>
        <volume>
         55
        </volume>
        <year>
         2016
        </year>
        <fpage>
         5977
        </fpage>
        <lpage>
         5988
        </lpage>
        <pub-id pub-id-type="pmid">
         27696819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation id="sbref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Milewska
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Golda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.K.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         7202
        </fpage>
        <lpage>
         7213
        </lpage>
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation id="sbref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           N.L.
          </given-names>
         </name>
         <name>
          <surname>
           Stoffberg
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cottontail
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Richards
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schoeman
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1697
        </fpage>
        <lpage>
         1699
        </lpage>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation id="sbref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kielian
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus membrane-fusion proteins: more than one way to make a hairpin
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="pmid">
         16357862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation id="sbref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kirchdoerfer
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Cottrell
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pre-fusion structure of a human coronavirus spike protein
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <year>
         2016
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         121
        </lpage>
        <pub-id pub-id-type="pmid">
         26935699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         102
        </volume>
        <year>
         2005
        </year>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation id="sbref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         8638
        </fpage>
        <lpage>
         8650
        </lpage>
        <pub-id pub-id-type="pmid">
         23720729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation id="sbref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation id="sbref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McEachern
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eaton
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation id="sbref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         500
        </volume>
        <year>
         2013
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation id="sbref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         23
        </volume>
        <year>
         2015
        </year>
        <fpage>
         468
        </fpage>
        <lpage>
         478
        </lpage>
        <pub-id pub-id-type="pmid">
         26206723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation id="sbref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahajan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bhattacharjya
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         NMR structures and localization of the potential fusion peptides and the pre-transmembrane region of SARS-CoV: implications in membrane fusion
        </article-title>
        <source>
         Biochim. Biophys. Acta
        </source>
        <volume>
         1848
        </volume>
        <year>
         2015
        </year>
        <fpage>
         721
        </fpage>
        <lpage>
         730
        </lpage>
        <pub-id pub-id-type="pmid">
         25475644
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation id="sbref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCoy
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Grosse-Kunstleve
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Winn
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Storoni
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phaser crystallographic software
        </article-title>
        <source>
         J. Appl. Crystallogr
        </source>
        <volume>
         40
        </volume>
        <year>
         2007
        </year>
        <fpage>
         658
        </fpage>
        <lpage>
         674
        </lpage>
        <pub-id pub-id-type="pmid">
         19461840
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation id="sbref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Durosinloun
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Asmari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Islam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1819
        </fpage>
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation id="sbref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         111
        </volume>
        <year>
         2014
        </year>
        <fpage>
         15214
        </fpage>
        <lpage>
         15219
        </lpage>
        <pub-id pub-id-type="pmid">
         25288733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell proteases: critical determinants of coronavirus tropism and pathogenesis
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         202
        </volume>
        <year>
         2015
        </year>
        <fpage>
         120
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         25445340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation id="sbref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
         <name>
          <surname>
           Skubak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lebedev
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pannu
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Steiner
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Winn
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vagin
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         REFMAC5 for the refinement of macromolecular crystal structures
        </article-title>
        <source>
         Acta Crystallogr. Sect. D., Biol. Crystallogr.
        </source>
        <volume>
         67
        </volume>
        <year>
         2011
        </year>
        <fpage>
         355
        </fpage>
        <lpage>
         367
        </lpage>
        <pub-id pub-id-type="pmid">
         21460454
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation id="sbref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otwinowski
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Minor
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Processing of X-ray diffraction data collected in oscillation mode
        </article-title>
        <source>
         Method Enzymol.
        </source>
        <volume>
         276
        </volume>
        <year>
         1997
        </year>
        <fpage>
         307
        </fpage>
        <lpage>
         326
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation id="sbref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         108
        </volume>
        <year>
         2011
        </year>
        <fpage>
         10696
        </fpage>
        <lpage>
         10701
        </lpage>
        <pub-id pub-id-type="pmid">
         21670291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation id="sbref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Goes
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Osborne
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Castano
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Dominguez
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         8816
        </fpage>
        <lpage>
         8827
        </lpage>
        <pub-id pub-id-type="pmid">
         26085157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation id="sbref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus immunogens
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         37
        </volume>
        <year>
         1993
        </year>
        <fpage>
         285
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="pmid">
         8116187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation id="sbref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Chaipan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agudelo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rennekamp
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         413
        </volume>
        <year>
         2011
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="pmid">
         21435673
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation id="sbref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Frenz
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           DiMaio
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rey
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         531
        </volume>
        <year>
         2016
        </year>
        <fpage>
         114
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="pmid">
         26855426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation id="sbref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Arledge
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation id="sbref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Iwamoto
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         16
        </volume>
        <year>
         2014
        </year>
        <fpage>
         328
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <mixed-citation id="othref0005" publication-type="other">
        WHO, 2004. Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS).
        <ext-link ext-link-type="uri" id="ir0070" xlink:href="http://www.who.int/csr/sars/country/en/">
         〈http://www.who.int/csr/sars/country/en/〉
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib41">
       <mixed-citation id="othref0010" publication-type="other">
        WHO, 2016. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – Update.
        <ext-link ext-link-type="uri" id="ir0075" xlink:href="http://www.who.int/csr/don/7-january-2016-mers-oman/en/">
         〈http://www.who.int/csr/don/7-january-2016-mers-oman/en/〉
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib42">
       <element-citation id="sbref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Winn
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Ballard
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cowtan
          </surname>
          <given-names>
           K.D.
          </given-names>
         </name>
         <name>
          <surname>
           Dodson
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Emsley
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Keegan
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Krissinel
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Leslie
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           McCoy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McNicholas
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Murshudov
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
         <name>
          <surname>
           Pannu
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Potterton
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Powell
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vagin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of the CCP4 suite and current developments
        </article-title>
        <source>
         Acta Crystallogr. Sect. D., Biol. Crystallogr.
        </source>
        <volume>
         67
        </volume>
        <year>
         2011
        </year>
        <fpage>
         235
        </fpage>
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="pmid">
         21460441
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <element-citation id="sbref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular diversity of coronaviruses in bats
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         351
        </volume>
        <year>
         2006
        </year>
        <fpage>
         180
        </fpage>
        <lpage>
         187
        </lpage>
        <pub-id pub-id-type="pmid">
         16647731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <element-citation id="sbref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <year>
         2012
        </year>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <element-citation id="sbref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <volume>
         279
        </volume>
        <year>
         2004
        </year>
        <fpage>
         49414
        </fpage>
        <lpage>
         49419
        </lpage>
        <pub-id pub-id-type="pmid">
         15345712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation id="sbref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <volume>
         111
        </volume>
        <year>
         2014
        </year>
        <fpage>
         12516
        </fpage>
        <lpage>
         12521
        </lpage>
        <pub-id pub-id-type="pmid">
         25114257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation id="sbref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         9119
        </fpage>
        <lpage>
         9123
        </lpage>
        <pub-id pub-id-type="pmid">
         26063432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <element-citation id="sbref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <element-citation id="sbref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cole
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           J.I.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors
        </article-title>
        <source>
         Biochem. Biophys. Res. Co.
        </source>
        <volume>
         319
        </volume>
        <year>
         2004
        </year>
        <fpage>
         283
        </fpage>
        <lpage>
         288
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by the
       <funding-source id="gs1">
        National Natural Science Foundation of China
       </funding-source>
       (NSFC, Grants 81461168030 and 31502078), the Key Research and Development Program of
       <funding-source id="gs2">
        Ministry of Science and Technology of China
       </funding-source>
       (MOST, Grant 2016YFC1200300) and the
       <funding-source id="gs3">
        China National Grand S&amp;T Special Project
       </funding-source>
       (Grant 2014ZX10004-001-006). G. L. is supported in part by
       <funding-source id="gs4">
        NSFC
       </funding-source>
       (Grant 81522026 and 31400154) and the
       <funding-source id="gs5">
        Sichuan Outstanding Youth Science &amp; Technology Funding
       </funding-source>
       (Grant No: 2016JQ0001). Y.S. is supported by the Excellent Young Scientist Program of the
       <funding-source id="gs6">
        Chinese Academy of Sciences
       </funding-source>
       (CAS) and the
       <funding-source id="gs7">
        Youth Innovation Promotion Association CAS
       </funding-source>
       (2015078). H.S. is supported by the
       <funding-source id="gs8">
        Youth Innovation Promotion Association CAS
       </funding-source>
       (2017117). K.Y. Y. is partly supported by the
       <funding-source id="gs9">
        NSFC/RGC Joint Research Scheme
       </funding-source>
       (N_HKU728/14) and the Theme-Based Research Scheme (T11/707/15) of the
       <funding-source id="gs10">
        Research Grants Council
       </funding-source>
       , Hong Kong Special Administrative Region. G.F.G. is a leading principle investigator of the
       <funding-source id="gs11">
        NSFC Innovative Research Group
       </funding-source>
       (Grant 81621091).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Vet J
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Vet. J
      </journal-id>
      <journal-title-group>
       <journal-title>
        Veterinary Journal (London, England : 1997)
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1090-0233
      </issn>
      <issn pub-type="epub">
       1532-2971
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Science Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       14623149
      </article-id>
      <article-id pub-id-type="pmc">
       7128346
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1090-0233(03)00055-8
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S1090-0233(03)00055-8
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Changes in some acute phase protein and immunoglobulin concentrations in cats affected by feline infectious peritonitis or exposed to feline coronavirus infection
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Giordano
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        <email>
         alessia.giordano@unimi.it
        </email>
        <xref ref-type="corresp" rid="COR1">
         ∗
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Spagnolo
         </surname>
         <given-names>
          V.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Colombo
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Paltrinieri
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <aff>
       Dipartimento di Patologia Animale, Igiene e Sanità Pubblica Veterinaria, Sezione di Patologia Generale Veterinaria e Parassitologia – Università degli Studi di Milano Via Celoria 10, 20133, Milano, Italy
      </aff>
      <author-notes>
       <corresp id="COR1">
        <label>
         ∗
        </label>
        Corresponding author. Fax: +39-02-50318095
        <email>
         alessia.giordano@unimi.it
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        26
       </day>
       <month>
        4
       </month>
       <year>
        2003
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        4
       </month>
       <year>
        2003
       </year>
      </pub-date>
      <volume>
       167
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       38
      </fpage>
      <lpage>
       44
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2003
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2003 Elsevier Science Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2003
       </copyright-year>
       <copyright-holder>
        Elsevier Science Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The possible role of some acute phase proteins (APPs) and immunoglobulins in both the pathogenesis and diagnosis of feline infectious peritonitis (FIP) has been investigated. Serum protein electrophoresis and the concentration of haptoglobin (Hp), serum amyloid A (SAA), α
        <sub>
         1
        </sub>
        -acid glycoprotein (AGP), IgG and IgM were evaluated in cats exposed to feline coronavirus (FCoV) and in cats with FIP. The highest concentration of APPs was detected in affected cats, confirming the role of these proteins in supporting a clinical diagnosis of FIP. Repeated samplings from both FIP affected and FCoV-exposed cats showed that when FIP appeared in the group, all the cats had increased APP levels. This increase persisted only in cats that developed FIP (in spite of a decrease in α
        <sub>
         2
        </sub>
        -globulins) but it was only transient in FCoV-exposed cats, in which a long lasting increase in α
        <sub>
         2
        </sub>
        -globulins was observed. These results suggest that changes in the electrophoretic motility of APPs or APPs other than Hp, SAA and AGP might be involved in the pathogenesis of FIP or in protecting cats from the disease.
       </p>
      </abstract>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Previous studies on serum from cats with experimentally induced feline infectious peritonitis (FIP) have shown an early increase in α-globulins, mainly due to acute phase proteins (APPs) such as haptoglobin (Hp) and α
      <sub>
       1
      </sub>
      -acid glycoprotein (AGP), followed by increases in γ-globulins, reflecting the production of antibodies against the feline coronavirus (FCoV) which is responsible for the disease (
      <xref ref-type="bibr" rid="BIB15">
       Stoddart et al., 1988
      </xref>
      ). The balance between these two globulin fractions, together with the degree of lymphopenia, seem to influence the development of lesions (
      <xref ref-type="bibr" rid="BIB12">
       Paltrinieri et al., 2001
      </xref>
      ).
     </p>
     <p>
      No reports about possible changes of APPs in cats resistant to the infection are available. Furthermore, although the electrophoretic changes strongly support a clinical diagnosis of FIP, they can also be found, under certain environmental or pathophysiological conditions, in cats without FIP (
      <xref ref-type="bibr" rid="BIB7">
       Kristensen and Barsanti, 1977
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB6">
       Kaneko, 1997
      </xref>
      ). The detection of protein markers would be very useful in the diagnosis of FIPV infection as has already been demonstrated for AGP (
      <xref ref-type="bibr" rid="BIB2">
       Duthie et al., 1997
      </xref>
      ). Moreover, changes in APPs in FCoV-exposed cats that do not develop the disease, might also be used as a marker for resistance to FIP.
     </p>
     <p>
      In the present study, the concentration of some APPs such as Hp, AGP and serum amyloid A (SAA) have been evaluated in cats exposed to FCoV infection and in cats affected by FIP. The aim was to investigate the possible role of these proteins in the pathogenesis and diagnosis of FIP or in protecting cats living with FCoV shedders from the disease. IgG and IgM, were also studied in order to check the protein composition of the different globulin fractions.
     </p>
    </sec>
    <sec>
     <label>
      2
     </label>
     <title>
      Materials and methods
     </title>
     <p>
      This study used on 82 blood samples collected from 67 pet cats (
      <xref ref-type="table" rid="TBL1">
       Table 1
      </xref>
      ) grouped as follows:
      <table-wrap id="TBL1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Breed, sex, age and FCoV serology results of the examined cats
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th colspan="5">
           Group 1: Controls
          </th>
          <th colspan="5">
           Group 2: FcoV-exposed cats
          </th>
          <th colspan="5">
           Group 3: Cats with FIP
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           No.
          </td>
          <td>
           Breed
          </td>
          <td>
           Sex
          </td>
          <td>
           Age
          </td>
          <td>
           FS
          </td>
          <td>
           No.
          </td>
          <td>
           Breed
          </td>
          <td>
           Sex
          </td>
          <td>
           Age
          </td>
          <td>
           FS
          </td>
          <td>
           No.
          </td>
          <td>
           Breed
          </td>
          <td>
           Sex
          </td>
          <td>
           Age
          </td>
          <td>
           FS
          </td>
         </tr>
         <tr>
          <td colspan="15">
           <hr/>
          </td>
         </tr>
         <tr>
          <td align="char">
           1
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           11 y
          </td>
          <td>
           +
          </td>
          <td>
           25
           <xref ref-type="table-fn" rid="TBLFN1">
            *
           </xref>
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           3 y
          </td>
          <td>
           −
          </td>
          <td>
           36
          </td>
          <td>
           Balines
          </td>
          <td>
           M
          </td>
          <td>
           4 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           2
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           12 m
          </td>
          <td>
           −
          </td>
          <td>
           26
           <xref ref-type="table-fn" rid="TBLFN1">
            *
           </xref>
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           2 y
          </td>
          <td>
           +
          </td>
          <td>
           37
          </td>
          <td>
           DSH
          </td>
          <td>
           SF
          </td>
          <td>
           7 y
          </td>
          <td>
           −
          </td>
         </tr>
         <tr>
          <td align="char">
           3
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           9 m
          </td>
          <td>
           +
          </td>
          <td>
           27
           <xref ref-type="table-fn" rid="TBLFN1">
            *
           </xref>
          </td>
          <td>
           Exotic
          </td>
          <td>
           M
          </td>
          <td>
           3 y
          </td>
          <td>
           −
          </td>
          <td>
           38
          </td>
          <td>
           Persian
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           4
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           12 y
          </td>
          <td>
           −
          </td>
          <td>
           28
           <xref ref-type="table-fn" rid="TBLFN1">
            *
           </xref>
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           5 y
          </td>
          <td>
           −
          </td>
          <td>
           39
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           5
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           8 y
          </td>
          <td>
           +
          </td>
          <td>
           29
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           3 y
          </td>
          <td>
           −
          </td>
          <td>
           40
          </td>
          <td>
           Persian
          </td>
          <td>
           unk
          </td>
          <td>
           10 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           6
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           8 y
          </td>
          <td>
           −
          </td>
          <td>
           30
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           12 m
          </td>
          <td>
           +
          </td>
          <td>
           41
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           10 y
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           7
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           6 y
          </td>
          <td>
           −
          </td>
          <td>
           31
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           18 m
          </td>
          <td>
           +
          </td>
          <td>
           42
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           13 y
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           8
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           12 m
          </td>
          <td>
           −
          </td>
          <td>
           32
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           4 y
          </td>
          <td>
           −
          </td>
          <td>
           43
          </td>
          <td>
           DSH
          </td>
          <td>
           nM
          </td>
          <td>
           5 y
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           9
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           13 y
          </td>
          <td>
           −
          </td>
          <td>
           33
          </td>
          <td>
           Siamese
          </td>
          <td>
           F
          </td>
          <td>
           18 m
          </td>
          <td>
           −
          </td>
          <td>
           44
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           15 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           10
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           9 y
          </td>
          <td>
           −
          </td>
          <td>
           34
          </td>
          <td>
           Oriental
          </td>
          <td>
           F
          </td>
          <td>
           18 m
          </td>
          <td>
           +
          </td>
          <td>
           45
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           11
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           11 y
          </td>
          <td>
           +
          </td>
          <td>
           35
          </td>
          <td>
           Oriental
          </td>
          <td>
           M
          </td>
          <td>
           18 m
          </td>
          <td>
           −
          </td>
          <td>
           46
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           12
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           3 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           47
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           12 y
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           13
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           4 y
          </td>
          <td>
           +
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           48
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           7 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           14
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           5 y
          </td>
          <td>
           +
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           49
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           12 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           15
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           12 m
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           50
          </td>
          <td>
           Persian
          </td>
          <td>
           M
          </td>
          <td>
           unk
          </td>
          <td>
           −
          </td>
         </tr>
         <tr>
          <td align="char">
           16
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           9 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           51
           <xref ref-type="table-fn" rid="TBLFN2">
            **
           </xref>
          </td>
          <td>
           Persian
          </td>
          <td>
           F
          </td>
          <td>
           12 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           17
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           8 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           52
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           6 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           18
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           3 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           53
          </td>
          <td>
           Siames
          </td>
          <td>
           M
          </td>
          <td>
           3 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           19
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           2 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           54
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           20
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           2 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           55
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           10 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           21
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           12 m
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           56
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           22
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           2 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           57
           <xref ref-type="table-fn" rid="TBLFN3">
            ***
           </xref>
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           7 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           23
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           5 y
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           58
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td align="char">
           24
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           9 m
          </td>
          <td>
           −
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           59
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           60
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           12 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           61
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           −
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           62
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           unk
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           63
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           8 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           64
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           7 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           65
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           7 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           66
          </td>
          <td>
           DSH
          </td>
          <td>
           M
          </td>
          <td>
           7 m
          </td>
          <td>
           +
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           67
          </td>
          <td>
           DSH
          </td>
          <td>
           F
          </td>
          <td>
           8 m
          </td>
          <td>
           +
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          FS=FCoV serology; +=positive; −=negative; DSH=domestic shorthair; unk=unknown; M=male; nM=neutered male; F=female; sF=spayed female.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN1">
         <label>
          *
         </label>
         <p>
          Sampled also 28, 53 and 83 days after the basal sampling.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN2">
         <label>
          **
         </label>
         <p>
          Sampled also 28 and 53 days after the basal sampling.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN3">
         <label>
          ***
         </label>
         <p>
          Sampled also 40 days after the basal sampling.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p>
      <italic>
       Group 1—Controls
      </italic>
      : 24 non-SPF (specific pathogen free) cats without any clinical signs of disease, selected from single-cat environments (
      <italic>
       n
      </italic>
      =7) or from catteries with no clinical cases of FIP recorded in the previous five years (
      <italic>
       n
      </italic>
      =17).
     </p>
     <p>
      <italic>
       Group 2—FCoV-exposed cats:
      </italic>
      11 cats without clinical signs of FIP, selected from three catteries in which recent cases (1–6 months before the study) of FIP had been diagnosed. In one of these, five non-symptomatic cats were sampled: one (cat No. 51) developed a wet FIP 28 days later and results from this animal were not considered in group 2 and the cat was placed in group 3 and sampled also on days 28 (
      <italic>
       T
      </italic>
      <sub>
       28
      </sub>
      ) and 53 (
      <italic>
       T
      </italic>
      <sub>
       53
      </sub>
      ) after the basal sampling (
      <italic>
       T
      </italic>
      <sub>
       0
      </sub>
      ). The four non-symptomatic cats (Nos. 25–28) remained in group 2 and were also sampled at
      <italic>
       T
      </italic>
      <sub>
       28
      </sub>
      ,
      <italic>
       T
      </italic>
      <sub>
       53
      </sub>
      and
      <italic>
       T
      </italic>
      <sub>
       83
      </sub>
      .
     </p>
     <p>
      <italic>
       Group 3—FIP affected cats:
      </italic>
      32 cats with spontaneously occurring FIP (25 wet and seven dry forms), diagnosed by necropsy, histology and/or by the detection of FCoV in the effusion using a direct immunofluorescence test (
      <xref ref-type="bibr" rid="BIB11">
       Paltrinieri et al., 1999
      </xref>
      ). Cats No. 51 and 57 were also sampled 25 and 40 days after the onset of the symptoms, respectively. Blood (3 mL) was taken from the jugular vein and serum was obtained by centrifugation. Total proteins were measured by a discrete analyzer (EOS-BRAVO, Hospitex) using the biuret colorimetric method. Serum protein eletrophoresis was performed as previously described (
      <xref ref-type="bibr" rid="BIB12">
       Paltrinieri et al., 2001
      </xref>
      ).
     </p>
     <p>
      Serology for feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) was tested using commercially available ELISA kits (IDEXX). On 18 samples (four from group 2 and 14 from group 3) FCoV-serology was performed in our laboratory, using an Indirect Fluorescence Assay (IFA) (VMRD). As suggested by the producer of the kit, cats with antibody titres higher than 1:400 were considered positives. The other 49 cats were already classified as FCoV-positive or negative by the referring veterinarians, based on results obtained using different semiquantitative in-clinic ELISA kits.
     </p>
     <p>
      Radial immunodiffusion (RID) kits were used to measure immunoglobulins (Ig) G and M (VET-RID, Bethyl Lab) and AGP (Cardiotech Services), according to the manufacturer’s instructions. The concentration of SAA was determined using an ELISA kit (Tridelta Development) based on the method described by
      <xref ref-type="bibr" rid="BIB9">
       McDonald et al. (1991)
      </xref>
      . Hp was measured using a kit (Tridelta Development) based on haemoglobin (Hb) binding method (
      <xref ref-type="bibr" rid="BIB3">
       Eckersall et al., 1999
      </xref>
      ). IgG, IgM, SAA, AGP and Hp were determined on 38, 38, 64, 77 and 82 samples, respectively (see
      <xref ref-type="table" rid="TBL2">
       Table 2
      </xref>
      ,
      <xref ref-type="table" rid="TBL3">
       Table 3
      </xref>
      ,
      <xref ref-type="table" rid="TBL4">
       Table 4
      </xref>
      ).
      <table-wrap id="TBL2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Mean values (± SD) recorded in the three groups of cats
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th rowspan="2">
           Controls (C) (
           <italic>
            n
           </italic>
           =24)
          </th>
          <th rowspan="2">
           FCoV-exposed (FE) (
           <italic>
            n
           </italic>
           =11)
          </th>
          <th rowspan="2">
           FIP(F) (
           <italic>
            n
           </italic>
           =32)
          </th>
          <th rowspan="2">
           ANOVA
          </th>
          <th colspan="3">
           Tukey HSD test
           <hr/>
          </th>
          <th rowspan="2">
           Reference values
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
           *
          </th>
          <th>
           **
          </th>
          <th>
           ***
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Total proteins (g/dL)
          </td>
          <td>
           7.69±0.83
          </td>
          <td>
           7.86±0.67
          </td>
          <td>
           8.27±1.49
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           5.4–7.8
           <xref ref-type="table-fn" rid="TBLFN4">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           A/G ratio
          </td>
          <td>
           1.03±0.24
          </td>
          <td>
           0.97±0.32
          </td>
          <td>
           0.47±0.25
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C,FE
          </td>
          <td>
           0.45–1.19
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Albumins (g/dL)
          </td>
          <td>
           3.83±0.57
          </td>
          <td>
           3.91±0.99
          </td>
          <td>
           2.43±0.46
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C, FE
          </td>
          <td>
           2.1–3.3
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Globulins (g/dL)
          </td>
          <td>
           3.86±0.74
          </td>
          <td>
           4.29±1.21
          </td>
          <td>
           5.85±1.57
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
           F vs. FE
          </td>
          <td>
           F vs. C
          </td>
          <td>
           2.6–5.1
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            1
           </sub>
           -Globulins (g/dL)
          </td>
          <td>
           0.55±0.34
          </td>
          <td>
           0.64±0.26
          </td>
          <td>
           0.53±0.28
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           0.2–1.1
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            2
           </sub>
           -Globulins (g/dL)
          </td>
          <td>
           0.71±0.33
          </td>
          <td>
           0.54±0.21
          </td>
          <td>
           1.16±0.43
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C, FE
          </td>
          <td>
           0.4–0.9
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           β-Globulins (g/dL)
          </td>
          <td>
           0.76±0.18
          </td>
          <td>
           0.82±0.39
          </td>
          <td>
           1.09±0.51
          </td>
          <td>
           **
          </td>
          <td>
          </td>
          <td>
           F vs. C
          </td>
          <td>
          </td>
          <td>
           0.9–1.9
           <xref ref-type="table-fn" rid="TBLFN2">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           γ-Globulins (g/dL)
          </td>
          <td>
           1.84±0.57
          </td>
          <td>
           2.29±0.87
          </td>
          <td>
           3.07±1.41
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C
          </td>
          <td>
           2.5–4.1
           <xref ref-type="table-fn" rid="TBLFN5">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Serum amyloid A (μg/mL)
          </td>
          <td>
           10.21±8.32 (
           <italic>
            n
           </italic>
           =17)
          </td>
          <td>
           7.92±7.12 (
           <italic>
            n
           </italic>
           =7)
          </td>
          <td>
           82.88±50.23 (
           <italic>
            n
           </italic>
           =26)
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C, FE
          </td>
          <td>
           16.6±11.4
           <xref ref-type="table-fn" rid="TBLFN6">
            c
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Haptoglobin (mg/mL)
          </td>
          <td>
           1.30±0.64
          </td>
          <td>
           1.80±0.83
          </td>
          <td>
           2.13±0.73
          </td>
          <td>
           ***
          </td>
          <td>
           F vs. FE
          </td>
          <td>
          </td>
          <td>
           F vs. C
          </td>
          <td>
           0.04–3.84
           <xref ref-type="table-fn" rid="TBLFN7">
            d
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            1
           </sub>
           -Acid glycoprotein (mg/mL)
          </td>
          <td>
           1.20±0.62 (
           <italic>
            n
           </italic>
           =22)
          </td>
          <td>
           1.19±0.49 (
           <italic>
            n
           </italic>
           =11)
          </td>
          <td>
           2.72±1.46 (
           <italic>
            n
           </italic>
           =29)
          </td>
          <td>
           ***
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           F vs. C, FE
          </td>
          <td>
           0.1–0.48
           <xref ref-type="table-fn" rid="TBLFN3">
            d
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Immunoglobulin G (g/dL)
          </td>
          <td>
           1.73±1.8 (
           <italic>
            n
           </italic>
           =7)
          </td>
          <td>
           n.d.
          </td>
          <td>
           2.25±3.09 (
           <italic>
            n
           </italic>
           =30)
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           0.4–2.00
           <xref ref-type="table-fn" rid="TBLFN8">
            e
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Immunoglobulin M (g/dL)
          </td>
          <td>
           0.63±0.63 (
           <italic>
            n
           </italic>
           =7)
          </td>
          <td>
           n.d.
          </td>
          <td>
           0.36±0.31 (
           <italic>
            n
           </italic>
           =30)
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
          </td>
          <td>
           0.03–0.15
           <xref ref-type="table-fn" rid="TBLFN4">
            e
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          *
          <italic>
           P
          </italic>
          &lt;0.05; **
          <italic>
           P
          </italic>
          &lt;0.01; ***
          <italic>
           P
          </italic>
          &lt;0.001; n.d.=not determined; n.s.=not significant.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN4">
         <label>
          a
         </label>
         <p>
          From
          <xref ref-type="bibr" rid="BIB6">
           Kaneko (1997)
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN5">
         <label>
          b
         </label>
         <p>
          From
          <xref ref-type="bibr" rid="BIB7">
           Kristensen and Barsanti (1977)
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN6">
         <label>
          c
         </label>
         <p>
          From
          <xref ref-type="bibr" rid="BIB5">
           Kajikawa et al. (1999)
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN7">
         <label>
          d
         </label>
         <p>
          From
          <xref ref-type="bibr" rid="BIB2">
           Duthie et al. (1997)
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN8">
         <label>
          e
         </label>
         <p>
          From
          <xref ref-type="bibr" rid="BIB16">
           Tizard (2000)
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="TBL3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Results of the cats with FIP repeatedly sampled during the course of the disease
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th colspan="3">
           Cat No. 51
           <hr/>
          </th>
          <th colspan="2">
           Cat No. 57
           <hr/>
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            0
           </sub>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            28
           </sub>
           <xref ref-type="table-fn" rid="TBLFN9">
            a
           </xref>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            53
           </sub>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            0
           </sub>
           <xref ref-type="table-fn" rid="TBLFN5">
            a
           </xref>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            40
           </sub>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Total proteins (g/dL)
          </td>
          <td align="char">
           9.1
          </td>
          <td align="char">
           7.6
          </td>
          <td align="char">
           9.8
          </td>
          <td align="char">
           9.8
          </td>
          <td align="char">
           12.0
          </td>
         </tr>
         <tr>
          <td>
           A/G ratio
          </td>
          <td align="char">
           0.38
          </td>
          <td align="char">
           0.41
          </td>
          <td align="char">
           0.38
          </td>
          <td align="char">
           0.50
          </td>
          <td align="char">
           0.18
          </td>
         </tr>
         <tr>
          <td>
           Albumins (g/dL)
          </td>
          <td align="char">
           2.50
          </td>
          <td align="char">
           2.20
          </td>
          <td align="char">
           2.70
          </td>
          <td align="char">
           3.25
          </td>
          <td align="char">
           1.81
          </td>
         </tr>
         <tr>
          <td>
           Globulins (g/dL)
          </td>
          <td align="char">
           6.60
          </td>
          <td align="char">
           5.40
          </td>
          <td align="char">
           7.10
          </td>
          <td align="char">
           6.55
          </td>
          <td align="char">
           10.19
          </td>
         </tr>
         <tr>
          <td>
           α1-Globulins (g/dL)
          </td>
          <td align="char">
           0.34
          </td>
          <td align="char">
           0.24
          </td>
          <td align="char">
           0.16
          </td>
          <td align="char">
           0.56
          </td>
          <td align="char">
           0.52
          </td>
         </tr>
         <tr>
          <td>
           α2-Globulins (g/dL)
          </td>
          <td align="char">
           1.05
          </td>
          <td align="char">
           0.65
          </td>
          <td align="char">
           0.30
          </td>
          <td align="char">
           1.36
          </td>
          <td align="char">
           0.86
          </td>
         </tr>
         <tr>
          <td>
           β-Globulins (g/dL)
          </td>
          <td align="char">
           0.77
          </td>
          <td align="char">
           0.86
          </td>
          <td align="char">
           1.14
          </td>
          <td align="char">
           1.41
          </td>
          <td align="char">
           1.15
          </td>
         </tr>
         <tr>
          <td>
           γ-Globulins (g/dL)
          </td>
          <td align="char">
           4.44
          </td>
          <td align="char">
           3.64
          </td>
          <td align="char">
           5.50
          </td>
          <td align="char">
           3.21
          </td>
          <td align="char">
           7.66
          </td>
         </tr>
         <tr>
          <td>
           Serum amyloid A (μg/mL)
          </td>
          <td align="char">
           56.97
          </td>
          <td align="char">
           119.93
          </td>
          <td>
           n.d.
          </td>
          <td align="char">
           120.22
          </td>
          <td align="char">
           122.05
          </td>
         </tr>
         <tr>
          <td>
           Haptoglobin (mg/mL)
          </td>
          <td align="char">
           2.23
          </td>
          <td align="char">
           2.27
          </td>
          <td align="char">
           1.41
          </td>
          <td align="char">
           2.56
          </td>
          <td align="char">
           2.10
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            1
           </sub>
           -Acid glycoprotein (mg/mL)
          </td>
          <td align="char">
           4.06
          </td>
          <td align="char">
           3.12
          </td>
          <td align="char">
           1.65
          </td>
          <td align="char">
           2.68
          </td>
          <td align="char">
           5.41
          </td>
         </tr>
         <tr>
          <td>
           Immunoglobulin G (g/dL)
          </td>
          <td>
           n.d.
          </td>
          <td>
           n.d.
          </td>
          <td>
           n.d.
          </td>
          <td align="char">
           2.089
          </td>
          <td align="char">
           5.67
          </td>
         </tr>
         <tr>
          <td>
           Immunoglobulin M (g/dL)
          </td>
          <td>
           n.d.
          </td>
          <td>
           n.d.
          </td>
          <td>
           n.d.
          </td>
          <td align="char">
           1.21
          </td>
          <td align="char">
           0.74
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          n.d.=not determined;
          <italic>
           T
          </italic>
          <sub>
           0
          </sub>
          =first sample;
          <italic>
           T
          </italic>
          <sub>
           28
          </sub>
          ,
          <italic>
           T
          </italic>
          <sub>
           40
          </sub>
          ,
          <italic>
           T
          </italic>
          <sub>
           53
          </sub>
          =28,40 and 53 days after
          <italic>
           T
          </italic>
          <sub>
           0
          </sub>
          , respectively.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN9">
         <label>
          a
         </label>
         <p>
          Appearance of the symptoms.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="TBL4" position="float">
       <label>
        Table 4
       </label>
       <caption>
        <p>
         Results of the four FCoV-exposed cats repeatedly sampled
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            0
           </sub>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            28
           </sub>
           <xref ref-type="table-fn" rid="TBLFN10">
            a
           </xref>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            53
           </sub>
          </th>
          <th>
           <italic>
            T
           </italic>
           <sub>
            83
           </sub>
          </th>
          <th>
           ANOVA
          </th>
          <th>
           Tukey HSD Test
           <hr/>
          </th>
          <th>
           <hr/>
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
          </th>
          <th>
          </th>
          <th>
          </th>
          <th>
          </th>
          <th>
          </th>
          <th>
           *
          </th>
          <th>
           **
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Total proteins (g/dL)
          </td>
          <td>
           8.18±0.43
          </td>
          <td>
           7.45±0.44
          </td>
          <td>
           6.53±0.32
          </td>
          <td>
           7.45±0.54
          </td>
          <td>
           **
          </td>
          <td>
           <italic>
            T
           </italic>
           <sub>
            53
           </sub>
           vs.
           <italic>
            T
           </italic>
           <sub>
            28
           </sub>
           ,
           <italic>
            T
           </italic>
           <sub>
            83
           </sub>
          </td>
          <td>
           <italic>
            T
           </italic>
           <sub>
            53
           </sub>
           vs.
           <italic>
            T
           </italic>
           <sub>
            0
           </sub>
          </td>
         </tr>
         <tr>
          <td>
           A/G ratio
          </td>
          <td>
           1.07±0.19
          </td>
          <td>
           1.03±0.26
          </td>
          <td>
           0.86±0.23
          </td>
          <td>
           0.77±0.07
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           Albumins (g/dL)
          </td>
          <td>
           4.65±1.06
          </td>
          <td>
           3.73±0.45
          </td>
          <td>
           2.96±0.36
          </td>
          <td>
           3.23±0.07
          </td>
          <td>
           *
          </td>
          <td>
           <italic>
            T
           </italic>
           <sub>
            0
           </sub>
           vs.
           <italic>
            T
           </italic>
           <sub>
            53
           </sub>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           Globulins (g/dL)
          </td>
          <td>
           4.46±1.34
          </td>
          <td>
           3.72±0.54
          </td>
          <td>
           3.56±0.55
          </td>
          <td>
           4.22±0.49
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            1
           </sub>
           -Globulins (g/dL)
          </td>
          <td>
           0.45±0.16
          </td>
          <td>
           0.44±0.17
          </td>
          <td>
           0.29±0.06
          </td>
          <td>
           0.49±0.41
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            2
           </sub>
           -Globulins (g/dL)
          </td>
          <td>
           0.42±0.18
          </td>
          <td>
           0.45±0.05
          </td>
          <td>
           0.51±0.20
          </td>
          <td>
           0.64±0.16
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           β-Globulins (g/dL)
          </td>
          <td>
           1.02±0.61
          </td>
          <td>
           0.64±0.08
          </td>
          <td>
           0.71±0.26
          </td>
          <td>
           0.67±0.23
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           γ-Globulin (g/dL)
          </td>
          <td>
           2.30±0.37
          </td>
          <td>
           2.19±0.40
          </td>
          <td>
           2.06±0.31
          </td>
          <td>
           2.41±0.17
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           Serum amyloid A (μg/mL)
          </td>
          <td>
           4.97±0.74
          </td>
          <td>
           31.8±0.97
          </td>
          <td>
           15.5±0.87
          </td>
          <td>
           6.83±0.46
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           Haptoglobin (mg/mL)
          </td>
          <td>
           0.95±0.74
          </td>
          <td>
           1.20±0.97
          </td>
          <td>
           1.29±0.87
          </td>
          <td>
           1.27±0.46
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
         <tr>
          <td>
           α
           <sub>
            1
           </sub>
           -Acid glycoprotein (mg/mL)
          </td>
          <td>
           0.97±0.37
          </td>
          <td>
           1.10±0.48
          </td>
          <td>
           0.76±0.38
          </td>
          <td>
           0.92±0.44
          </td>
          <td>
           n.s.
          </td>
          <td>
          </td>
          <td>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          *
          <italic>
           P
          </italic>
          &lt;0.05; **
          <italic>
           P
          </italic>
          &lt;0.01;
          <italic>
           T
          </italic>
          <sub>
           0
          </sub>
          =first sample; T28, T53, T83=28,53 and 83 days after
          <italic>
           T
          </italic>
          <sub>
           0
          </sub>
          , respectively; n.s., not significant.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="TBLFN10">
         <label>
          a
         </label>
         <p>
          Appearance of the symptoms in another cat of the group.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p>
      Statistical analysis used specific software (Statsoft). Results from the three groups were compared with each other using an one-way ANOVA followed by the honest significant differences (HSD) Tukey test. If a normality test showed that data did not have a normal distribution, the non-parametric Kruskal Wallis test was used. ANOVA for repeated measurements or the corresponding non-parametric Friedmann tests were used to compare data obtained in repeated samplings. The percentages of positivity for FCoV in the three groups were compared using the chi-squared test.
     </p>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <p>
      All cats were FIV- and FeLV-negative, while FCoV-positive cats were present in all groups. The percentage of positive animals was higher (
      <italic>
       P
      </italic>
      &lt;0.001) in cats with FIP (90.6%) than in other groups (group 1: 25%; group 2: 36.4%).
     </p>
     <p>
      Results from FCoV-exposed cats did not significantly differ from those of controls, whereas cats with FIP had increased total globulins and globulin fractions, except for α
      <sub>
       1
      </sub>
      -globulins, and increased APPs (
      <xref ref-type="table" rid="TBL2">
       Table 2
      </xref>
      ). However, β- and γ-globulins were higher compared to controls, but not to FCoV-exposed cats. The results from cats with wet FIP were not significantly different from those obtained in cats with dry FIP.
     </p>
     <p>
      After the appearance of clinical symptoms, α
      <sub>
       1
      </sub>
      -, α
      <sub>
       2
      </sub>
      -globulins and Hp decreased, while γ-globulins increased in both the cats with FIP (
      <xref ref-type="table" rid="TBL3">
       Table 3
      </xref>
      ). β-Globulins and AGP were however different in these two cats and SAA did not change in the single cat in which it was measured. Total proteins and albumins significantly decreased at
      <italic>
       T
      </italic>
      <sub>
       53
      </sub>
      in FcoV-exposed cats (
      <xref ref-type="table" rid="TBL4">
       Table 4
      </xref>
      ). No other significant changes were detectable, in spite of an increase of mean values of α
      <sub>
       2
      </sub>
      -globulin from
      <italic>
       T
      </italic>
      <sub>
       0
      </sub>
      to
      <italic>
       T
      </italic>
      <sub>
       83
      </sub>
      and of the APPs at
      <italic>
       T
      </italic>
      <sub>
       28
      </sub>
      and/or a
      <italic>
       T
      </italic>
      <sub>
       53
      </sub>
      . In fact after the onset of the disease in the group, transient increases of the APPs were detected in all four cats, but in different samplings (
      <xref ref-type="fig" rid="FIG1">
       Fig. 1
      </xref>
      ,
      <xref ref-type="fig" rid="FIG2">
       Fig. 2
      </xref>
      ,
      <xref ref-type="fig" rid="FIG3">
       Fig. 3
      </xref>
      ).
      <fig id="FIG1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Serum amyloid A concentrations (μg/mL) in the four samples from FCoV-exposed cats.
        </p>
       </caption>
       <graphic xlink:href="gr1">
       </graphic>
      </fig>
      <fig id="FIG2">
       <label>
        Fig. 2
       </label>
       <caption>
        <p>
         Haptoglobin concentrations (mg/mL) in the four samples from FCoV-exposed cats.
        </p>
       </caption>
       <graphic xlink:href="gr2">
       </graphic>
      </fig>
      <fig id="FIG3">
       <label>
        Fig. 3
       </label>
       <caption>
        <p>
         α
         <sub>
          1
         </sub>
         -Acid glycoprotein concentrations (mg/mL) in the four samples FCoV-exposed cats.
        </p>
       </caption>
       <graphic xlink:href="gr3">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p>
      Cats with anti-FCoVs antibodies were present in both controls and cats classified as “FCoV exposed”, probably because most of them came from multicat environments, where fluctuating antibody titres could be found (
      <xref ref-type="bibr" rid="BIB13">
       Pedersen, 1995
      </xref>
      ). Nevertheless we considered separately these two groups due to their different incidences of FIP: in fact, although individual cats with clinical disease are not more likely to shed the virus than cats without FIP, the prevalence of FCoV shedding is higher in catteries with a high incidence of clinical cases of FIP (
      <xref ref-type="bibr" rid="BIB4">
       Foley et al., 1997
      </xref>
      ). In contrast, the percentage of seropositivity was higher in cats that developed the disease, in agreement with previous findings (
      <xref ref-type="bibr" rid="BIB13">
       Pedersen, 1995
      </xref>
      ).
     </p>
     <p>
      Results from our controls were within reference ranges (
      <xref ref-type="bibr" rid="BIB2">
       Duthie et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB5">
       Kajikawa et al., 1999
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB6">
       Kaneko, 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB16">
       Tizard, 2000
      </xref>
      ), except for IgM and AGP. Mean AGP values were slightly higher than those reported by
      <xref ref-type="bibr" rid="BIB2">
       Duthie et al. (1997)
      </xref>
      , but that study was undertaken on SPF cats, while we used cats from multicat environments, where a variety of antigenic stimuli can induce changes in serum proteins even in the absence of clinical signs (
      <xref ref-type="bibr" rid="BIB7">
       Kristensen and Barsanti, 1977
      </xref>
      ). IgG and IgM levels showed a high standard deviation, due to cat No. 1 (2 and 5.7 g/dL, respectively) which did not show any clinical symptoms.
     </p>
     <p>
      No statistically significant differences were detected between FCoV-exposed cats and controls, most likely due to the high individual variability of group 2. Compared to controls, cats with FIP shared the typical electrophoretic changes (
      <xref ref-type="bibr" rid="BIB14">
       Sparkes et al., 1991
      </xref>
      ), and increased APP levels. In particular, a 10-fold increase of SAA was detectable, thus confirming its role as an APP in cats (
      <xref ref-type="bibr" rid="BIB5">
       Kajikawa et al., 1999
      </xref>
      ). Although no cats with diseases other than FIP were included in this study, the high SAA concentration detected in sick cats suggests that this protein might also be a marker of FIP, as has been reported for Hp and AGP (
      <xref ref-type="bibr" rid="BIB2">
       Duthie et al., 1997
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB15">
       Stoddart et al., 1988
      </xref>
      ). It is interesting to note that the APPs were particularly high at
      <italic>
       T
      </italic>
      <sub>
       0
      </sub>
      in cat No. 51, suggesting that an inflammatory reaction was already occurring before the appearance of the symptoms (
      <xref ref-type="bibr" rid="BIB5">
       Kajikawa et al., 1999
      </xref>
      ). Furthermore, cats with FIP had high IgG levels, most likely due to antibody production, but low IgM concentrations probably reflecting the fact that most of the cats were at an advanced stage of disease: in fact, β-globulins, where IgM migrate, increase only in cases of FIP with recent lesions (
      <xref ref-type="bibr" rid="BIB12">
       Paltrinieri et al., 2001
      </xref>
      ). Unfortunately it was not possible to repeat the sampling in the two cats with FIP which were not euthanasized after the diagnosis. The behaviour of β-globulins and of APPs was different in the two cats probably depending on the different clinical forms or on the different times of sampling: in experimentally induced FIP, Hp decreases during the first 20 days post-infection, then increases (
      <xref ref-type="bibr" rid="BIB15">
       Stoddart et al., 1988
      </xref>
      ).
     </p>
     <p>
      When a clinical form of FIP appeared in a cattery, however, all cats of the group shared a transient increase of SAA and Hp and strong fluctuations of AGP. These changes were not statistically significant because they did not simultaneously occur in the different cats. Nevertheless, they suggest the presence of an acute phase reaction also in cats that did not develop the disease, maybe as a consequence of the spread of mutated FCoVs in the cattery.
     </p>
     <p>
      IgG and IgM levels were quantitatively lower than the corresponding electrophoretic band (γ- and β-globulins, respectively), in particular in cats with FIP. Non-Ig proteins with γ-motility have been already reported (
      <xref ref-type="bibr" rid="BIB10">
       Paltrinieri et al., 1998
      </xref>
      ). Although APPs with β-motility (e.g., transferrin or CRP) might account for the increase of β-globulins recorded in FCoV-exposed cats, one could speculate that the electrophoretic motility of some APPs might change during FIP, as occurs in humans, maybe due to changes in their glycosylation pattern (Mackiewicz and
      <xref ref-type="bibr" rid="BIB8">
       Mackiewicz, 1995
      </xref>
      ;
      <xref ref-type="bibr" rid="BIB1">
       Ducret et al., 1996
      </xref>
      ). This hypothesis is supported by the finding that AGP concentration was often higher than the total amount of α
      <sub>
       1
      </sub>
      -globulins, where AGP should migrate. Moreover the decrease of α
      <sub>
       2
      </sub>
      -globulins, observed in both the cats with FIP during the course of the disease, is not due to a quantitatively similar decrease of APPs. SAA concentration was too low (μg/mL) to influence the total α
      <sub>
       2
      </sub>
      -globulin concentration, but changes of Hp levels should induce changes in the corresponding electrophoretic band. In contrast, the decrease of α
      <sub>
       2
      </sub>
      -globulins in cats with FIP was higher than that of Hp, probably due to the decrease of some other “negative APP” (
      <xref ref-type="bibr" rid="BIB6">
       Kaneko, 1997
      </xref>
      ) or to changes of electrophoretic motility of APPs. The behaviour of α
      <sub>
       2
      </sub>
      -globulins needs to be further investigated because it might play a crucial role in the pathogenesis of the disease. This fraction decreased during FIP, but slightly increased in FCoV-exposed cats.
     </p>
     <p>
      In conclusion, this study confirms the possible diagnostic role for APPs in FIP. After the onset of a clinical form of FIP, the concentration of APPs increased in all the exposed cats in the cattery. These changes were transient in cats that did not develop FIP, but persisted in one cat that developed the clinical form of the disease. Furthermore, α
      <sub>
       2
      </sub>
      -globulins increased in FCoV-exposed cats, but decreased in cats that developed the disease. Further studies on APPs might allow us to understand better the pathogenesis and possible mechanisms of resistance or susceptibility to FIP.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="BIB1">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ducret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bruun
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Bures
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Marhaug
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Husby
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Aebersold
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry
        </article-title>
        <source>
         Electrophoresis
        </source>
        <volume>
         17
        </volume>
        <year>
         1996
        </year>
        <fpage>
         866
        </fpage>
        <lpage>
         876
        </lpage>
        <pub-id pub-id-type="pmid">
         8783012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB2">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Duthie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Eckersall
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Addie
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Jarret
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Value of α1-acid glycoprotein in the diagnosis of feline infectious peritonitis
        </article-title>
        <source>
         The Veterinary Record
        </source>
        <volume>
         141
        </volume>
        <year>
         1997
        </year>
        <fpage>
         299
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         9330474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB3">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckersall
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Duthie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Safi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Moffatt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Horadagoda
          </surname>
          <given-names>
           N.U.
          </given-names>
         </name>
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Parton
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Bennett
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fitzpatrick
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An automated biochemical assay for haptoglobin: prevention of interference from albumin
        </article-title>
        <source>
         Comparative Haematology International
        </source>
        <volume>
         9
        </volume>
        <year>
         1999
        </year>
        <fpage>
         117
        </fpage>
        <lpage>
         124
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB4">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Foley
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Poland
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Carlson
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus
        </article-title>
        <source>
         Journal of American Veterinary Medical Association
        </source>
        <volume>
         210
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1313
        </fpage>
        <lpage>
         1318
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB5">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kajikawa
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Furuta
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Onishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tajima
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sugii
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changes in concentrations of serum amyloid A protein, α1-acid glycoprotein, haptoglobin, and C-reactive protein in feline sera due to induced inflammation and surgery
        </article-title>
        <source>
         Veterinary Immunology and Immunopathology
        </source>
        <volume>
         68
        </volume>
        <year>
         1999
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         10231954
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB6">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaneko
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Serum proteins and the dysproteinemias
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Kaneko
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Harvey
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bruss
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <source>
         Clinical biochemistry of Domestic Animals
        </source>
        <edition>
         fifth ed.
        </edition>
        <year>
         1997
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <fpage>
         117
        </fpage>
        <lpage>
         138
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB7">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kristensen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Barsanti
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of serum proteins in clinically normal pet and colony cats, using agarose electrophoresis
        </article-title>
        <source>
         American Journal of Veterinary Research
        </source>
        <volume>
         38
        </volume>
        <year>
         1977
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="pmid">
         66888
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB8">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackiewicz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mackiewicz
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer
        </article-title>
        <source>
         Glycoconjugate Journal
        </source>
        <volume>
         12
        </volume>
        <year>
         1995
        </year>
        <fpage>
         241
        </fpage>
        <lpage>
         247
        </lpage>
        <pub-id pub-id-type="pmid">
         7496138
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB9">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           T.L.
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A monoclonal antibody sandwich immunoassay for serum amyloid A (Saa) protein
        </article-title>
        <source>
         Journal of Immunological Methods
        </source>
        <volume>
         144
        </volume>
        <year>
         1991
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="pmid">
         1720442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB10">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paltrinieri
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cammarata Parodi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cammarata
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Comazzi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Some aspects of humoral and cellular immunity in naturally occurring feline infectious peritonitis
        </article-title>
        <source>
         Veterinary Immunology and Immunopathology
        </source>
        <volume>
         65
        </volume>
        <year>
         1998
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="pmid">
         9839875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB11">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paltrinieri
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cammarata Parodi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cammarata
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vivo diagnosis of feline infectious peritonitis by comparison of protein content, cytology, and direct immunofluorescence test on peritoneal and pleureal effusions
        </article-title>
        <source>
         Journal of Veterinary Diagnostic Investigation
        </source>
        <volume>
         11
        </volume>
        <year>
         1999
        </year>
        <fpage>
         358
        </fpage>
        <lpage>
         361
        </lpage>
        <pub-id pub-id-type="pmid">
         10424653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB12">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paltrinieri
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Grieco
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Comazzi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cammarata Parodi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory profiles in cats with different pathological and immunohistochemical findings due to feline infectious peritonitis (FIP)
        </article-title>
        <source>
         Journal of Feline Medicine and Surgery
        </source>
        <volume>
         3
        </volume>
        <year>
         2001
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         159
        </lpage>
        <pub-id pub-id-type="pmid">
         11876632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB13">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The history and interpretation of feline coronavirus serology
        </article-title>
        <source>
         Feline Practice
        </source>
        <volume>
         23
        </volume>
        <year>
         1995
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         51
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB14">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sparkes
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Gruffydd-Jones
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Harbour
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feline infectious peritonitis: a review of clinical pathological changes in 65 cases, and a critical assessment of their diagnostic value
        </article-title>
        <source>
         The Veterinary Record
        </source>
        <volume>
         129
        </volume>
        <year>
         1991
        </year>
        <fpage>
         209
        </fpage>
        <lpage>
         212
        </lpage>
        <pub-id pub-id-type="pmid">
         1949515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB15">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stoddart
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Whicher
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Harbour
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cats inoculated with feline infectious peritonitis virus exhibit a biphasic acute phase plasma protein response
        </article-title>
        <source>
         The Veterinary Record
        </source>
        <volume>
         123
        </volume>
        <year>
         1988
        </year>
        <fpage>
         621
        </fpage>
        <lpage>
         624
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB16">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tizard
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <source>
         Veterinary Immunology. An Introduction
        </source>
        <edition>
         sixth ed.
        </edition>
        <year>
         2000
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         139
        </fpage>
        <lpage>
         148
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by the Italian fund M.U.R.S.T., ex-60%. The authors are very grateful to Dr. Fabrizio Ceciliani and to Dr. Stefano Comazzi for their support.
      </p>
     </ack>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>